PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Fields, BA; Malchiodi, EL; Li, HM; Ysern, X; Stauffacher, CV; Schlievert, PM; Karjalainen, K; Mariuzza, RA				Fields, BA; Malchiodi, EL; Li, HM; Ysern, X; Stauffacher, CV; Schlievert, PM; Karjalainen, K; Mariuzza, RA			Crystal structure of a T-cell receptor beta-chain complexed with a superantigen	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; ANTIGEN RECEPTOR; BINDING; MHC	SUPERANTIGENS (SAgs) are viral or bacterial proteins that act as potent T-cell stimulants and have been implicated in a number of human diseases, including toxic shock syndrome(1,2), diabetes mellitus(3) and multiple sclerosis(4). The interaction of SAgs with the T-cell receptor (TCR) and major histocompatibility complex (MHC) proteins results in the stimulation of a disproportionately large fraction of the T-cell population(2). We report here the crystal structures of the beta-chain of a TCR complexed with the Staphylococcus aureus enterotoxins C2 and C3 (SEC2, SEC3). These enterotoxins, which cause both toxic shock and food poisoning, bind in an identical way to the TCR beta-chain. The complementarity-determining region 2 (CDR2) of the beta-chain and, to lesser extents, CDR1 and hypervariable region 4 (HV4), bind in a cleft between the two domains of the SAgs. Thus, there is considerable overlap between the SAg-binding site and the peptide/MHC-binding sites of the TCR. A model of a TCR-SAg-MHC complex constructed from the crystal structures of (1) the beta-chain-SEC3 complex, (2) a complex between staphylococcal enterotoxin B (SEB) and an MHC molecule(5), and (3) a TCR V alpha domain(6), reveals that the SAg acts as a wedge between the TCR and MHC to displace the antigenic peptide away from the TCR combining site. In this way, the SAg is able to circumvent the normal mechanism for T-cell activation by specific peptide/MHC complexes.	UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR ADV RES BIOTECHNOL, ROCKVILLE, MD 20850 USA; UNIV BUENOS AIRES, FAC FARM & BIOQUIM,CATEDRA IMMUNOL,CONICET, INST ESTUDIOS INMUNIDAD HUMORAL, RA-1113 BUENOS AIRES, DF, ARGENTINA; US FDA, CTR DRUG EVALUAT & RES, ROCKVILLE, MD 20857 USA; PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; UNIV MINNESOTA, SCH MED, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA; BASEL INST IMMUNOL, CH-4005 BASEL, SWITZERLAND	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; US Food & Drug Administration (FDA); Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Minnesota System; University of Minnesota Twin Cities			Karjalainen, Klaus/A-2206-2011; Li, Hongmin/ABI-2439-2020	Li, Hongmin/0000-0002-8684-5308; Malchiodi, Emilio/0000-0001-7501-3330; Schlievert, Patrick/0000-0001-8314-9369; Fields, Barry/0000-0003-0628-1328				Arden Bernhard, 1995, Immunogenetics, V42, P455; Bentley GA, 1996, ANNU REV IMMUNOL, V14, P563, DOI 10.1146/annurev.immunol.14.1.563; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BLOMSTERHAUTAMAA DA, 1988, METHOD ENZYMOL, V165, P37; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; DECKHUT AM, 1994, J EXP MED, V180, P1931, DOI 10.1084/jem.180.5.1931; DERINGER JR, IN PRESS MOL MICROBI; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FREMONDT DH, 1996, J SCIE, V272, P1001; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FUREY W, IN PRESS METHODS ENZ; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; HOFFMANN ML, 1994, INFECT IMMUN, V62, P3396, DOI 10.1128/IAI.62.8.3396-3407.1994; Hong SC, 1996, J EXP MED, V183, P1437, DOI 10.1084/jem.183.4.1437; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; LABRECQUE N, 1994, J EXP MED, V180, P1921, DOI 10.1084/jem.180.5.1921; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MALCHIODI EL, 1995, J EXP MED, V182, P1833, DOI 10.1084/jem.182.6.1833; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAPAGEORGIOU AC, 1995, STRUCTURE, V3, P769, DOI 10.1016/S0969-2126(01)00212-X; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; WEBB SR, 1994, CURR OPIN IMMUNOL, V6, P467, DOI 10.1016/0952-7915(94)90129-5; WOODLAND DL, 1993, IMMUNOL TODAY, V14, P208, DOI 10.1016/0167-5699(93)90164-G	31	250	263	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	1996	384	6605					188	192		10.1038/384188a0	http://dx.doi.org/10.1038/384188a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906797				2022-12-28	WOS:A1996VT33600071
J	Hempel, CM; Vincent, P; Adams, SR; Tsien, RY; Selverston, AI				Hempel, CM; Vincent, P; Adams, SR; Tsien, RY; Selverston, AI			Spatio-temporal dynamics of cyclic AMP signals in an intact neural circuit	NATURE			English	Article							LOBSTER STOMATOGASTRIC GANGLION; PROTEIN KINASE-A; AMINERGIC MODULATION; PYLORIC CIRCUIT; NEURONS; CAMP; ORGANIZATION; OCTOPAMINE; PROCTOLIN; PATTERN	THE functional properties of neuronal networks can be reconfigured by a variety of modulatory neurotransmitters, which may alter the excitable properties of neurons or the strengths of synaptic connections. Many of these neuromodulators act via the intracellular second messenger cyclic AMP, but their effects on the spatial distribution of cAMP concentration have never been examined in an intact neural circuit. We therefore used the cAMP-indicator dye FICRhR (refs 1, 2) to investigate the effect of several neuromodulators (octopamine, dopamine, acetylcholine, serotonin and proctolin) on cAMP distribution in identified neurons of the lobster stomatogastric ganglion (STG). When added to the bath solution, each of these neuromodulators produced a unique pattern of cAMP transients among the different neurons of the STG. Electrical stimulation of neurons innervating the STG causes synaptic release of endogenous modulators, leading within a few seconds to local increases of cAMP in fine neurite branches, the site where many modulators are thought to act(3,4). After prolonged stimulation, cAMP diffuses from the site of production to throughout the neuritic tree and eventually to the cell body. Diffusion of cAMP may explain how transient localized inputs to a neuron can produce long-range effects such as long-term changes in gene expression.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Hempel, CM (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.		Vincent, Pierre/A-1055-2012	Vincent, Pierre/0000-0002-8479-1908				Adams S.R., 1993, FLUORESCENT PROBES B, P133; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALBERINI CM, 1995, ANN NY ACAD SCI, V758, P261, DOI 10.1111/j.1749-6632.1995.tb24833.x; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAL T, 1987, J NEUROSCI, P3019; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; FLAMM RE, 1986, J NEUROPHYSIOL, V55, P866, DOI 10.1152/jn.1986.55.5.866; FLAMM RE, 1987, J NEUROPHYSIOL, V58, P1370, DOI 10.1152/jn.1987.58.6.1370; FLAMM RE, 1986, J NEUROPHYSIOL, V55, P847, DOI 10.1152/jn.1986.55.5.847; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Harris-Warrick Ronald M., 1992, P87; Hartline Daniel K., 1992, P31; HEINZEL HG, 1988, J NEUROPHYSIOL, V59, P551, DOI 10.1152/jn.1988.59.2.551; HOOPER SL, 1987, J NEUROSCI, V7, P2097; Johnson Bruce R., 1992, P1; KING DG, 1976, J NEUROCYTOL, V5, P239, DOI 10.1007/BF01181658; MAYNARD DM, 1975, J COMP PHYSIOL, V100, P161, DOI 10.1007/BF00613967; RUSSELL DF, 1979, BRAIN RES, V177, P598, DOI 10.1016/0006-8993(79)90480-3; Tsien Roger Y., 1995, P459; Tsien Roger Y., 1993, Trends in Cell Biology, V3, P242, DOI 10.1016/0962-8924(93)90124-J	20	127	129	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	1996	384	6605					166	169		10.1038/384166a0	http://dx.doi.org/10.1038/384166a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906791				2022-12-28	WOS:A1996VT33600065
J	Broach, JR; Thorner, J				Broach, JR; Thorner, J			High-throughput screening for drug discovery	NATURE			English	Article							PHEROMONE RESPONSE PATHWAY; YEAST; RECEPTOR; EXPRESSION; LIGANDS		CADUS PHARMACEUT INC,TARRYTOWN,NY 10591; UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Broach, JR (corresponding author), PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544, USA.		THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Broach, James/0000-0003-1197-0312				BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Cheng LZ, 1996, NAT BIOTECHNOL, V14, P606, DOI 10.1038/nbt0596-606; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; KEE BI, 1996, J BIOL CHEM, V271, P2343; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; MANFREDI J, IN PRESS MOL CELL BI; MATHIS G, 1993, CLIN CHEM, V39, P1953; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; ONEIL KT, 1995, CURR OPIN STRUC BIOL, V5, P443, DOI 10.1016/0959-440X(95)80027-1; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; OZENBERGER BA, 1995, MOL ENDOCRINOL, V9, P1321, DOI 10.1210/me.9.10.1321; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; SupertiFurga G, 1996, NAT BIOTECHNOL, V14, P600, DOI 10.1038/nbt0596-600; TANG WM, 1995, MOL BIOL CELL, V6, P1231, DOI 10.1091/mbc.6.9.1231; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; UDENFRIEND S, 1987, ANAL BIOCHEM, V161, P494, DOI 10.1016/0003-2697(87)90479-9; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213	23	218	258	3	61	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604		S			14	16						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR392	8895594				2022-12-28	WOS:A1996VR39200005
J	Rosbash, M				Rosbash, M			Mixed mechanisms in yeast Pre-mRNA splicing?	CELL			English	Review							RNA				Rosbash, M (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,DEPT BIOL,WALTHAM,MA 02254, USA.							APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; Moore M., 1993, RNA WORLD, P303; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; TAM WY, 1996, SCIENCE, V273, P1824; TAM WY, 1966, CELL, V84, P801; VANDERVEEN R, 1987, EMBO J, V6, P3827, DOI 10.1002/j.1460-2075.1987.tb02719.x	14	3	3	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					357	359		10.1016/S0092-8674(00)81355-0	http://dx.doi.org/10.1016/S0092-8674(00)81355-0			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898188	Bronze			2022-12-28	WOS:A1996VQ46600001
J	Weber, DA; Evavold, BD; Jensen, PE				Weber, DA; Evavold, BD; Jensen, PE			Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM	SCIENCE			English	Article							CLASS-II MHC; ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; HISTOCOMPATIBILITY MOLECULES; BINDING; CLIP; TRANSPORT; LIGANDS; HLA-DR3; RELEASE	Human leukocyte antigen (HLA)-DM is a critical participant in antigen presentation that catalyzes the release of class II-associated invariant chain-derived peptides (CLIP) from newly synthesized class II histocompatibility molecules, freeing the peptide-binding site for acquisition of antigenic peptides. The mechanism for the selective release of CLIP but not other peptides is unknown. DM was found to enhance the rate of peptide dissociation to an extent directly proportional to the intrinsic rate of peptide dissociation from HLA-DR, regardless of peptide sequence. Thus, CLIP is rapidly released in the presence of DM, because its intrinsic rate of dissociation is relatively high. In antigen presentation, DM has the potential to markedly enhance the rate of peptide exchange, favoring the presentation of peptides with slower intrinsic rates of dissociation.	EMORY UNIV,SCH MED,DEPT PATHOL & LAB MED,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,ATLANTA,GA 30322	Emory University; Emory University				Evavold, Brian/0000-0002-3561-3494	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033614, R21AI030554, R01AI033614, R01AI030554] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30554, AI33614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GELUK A, 1994, J IMMUNOL, V152, P5742; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; KROPSHOFER H, 1995, SCIENCE, V270, P1357, DOI 10.1126/science.270.5240.1357; MALCHEREK G, 1994, J IMMUNOL, V153, P1141; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; WITT SN, 1991, P NATL ACAD SCI USA, V88, P8164, DOI 10.1073/pnas.88.18.8164	20	251	258	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					618	620		10.1126/science.274.5287.618	http://dx.doi.org/10.1126/science.274.5287.618			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849454				2022-12-28	WOS:A1996VN91900052
J	Zhou, QA; Sharp, PA				Zhou, QA; Sharp, PA			Tat-SF1: Cofactor for stimulation of transcriptional elongation by HIV-1 Tat	SCIENCE			English	Article							RNA-POLYMERASE-II; TUMOR-SUPPRESSOR PROTEIN; LONG TERMINAL REPEAT; ACTIVATION DOMAIN; TRANS-ACTIVATION; GENE-EXPRESSION; BINDING PROTEIN; SEQUENCE; FUSION; TRANSLOCATION	Tat may stimulate transcriptional elongation by recruitment of a complex containing Tat-SF1 and a kinase to the human immunodeficiency virus-type 1 (HIV-1) promoter through a Tat-TAR interaction. A complementary DNA for the cellular activity, Tat-SF1, has been isolated. This factor is required for Tat trans-activation and is a substrate of an associated cellular kinase, Cotransfection with the complementary DNA for Tat-SF1 specifically modulates Tat activation. Tat-SF1 contains two RNA recognition motifs and a highly acidic carboxyl-terminal half. It is distantly related to EWS and FUS/TLS, members of a family of putative transcription factors with RNA recognition motifs that are associated with sarcomas.	MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034277, R01GM034277] Funding Source: NIH RePORTER; NCI NIH HHS [CA14051] Funding Source: Medline; NIAID NIH HHS [AI32486] Funding Source: Medline; NIGMS NIH HHS [GM34277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BLAIR WS, 1996, EMBO J, V15, P101; Blau J, 1996, MOL CELL BIOL, V16, P2044; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; CULLEN BR, 1994, INFECT AGENT DIS, V3, P68; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Frankel AD, 1992, CURR OPIN GENET DEV, V2, P293, DOI 10.1016/S0959-437X(05)80287-4; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KARN J, 1992, TRENDS GENET, V8, P365, DOI 10.1016/0168-9525(92)90284-B; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Liu S., UNPUB; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TILEY LS, 1990, VIROLOGY, V178, P560, DOI 10.1016/0042-6822(90)90354-T; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	46	140	146	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	1996	274	5287					605	610		10.1126/science.274.5287.605	http://dx.doi.org/10.1126/science.274.5287.605			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849451				2022-12-28	WOS:A1996VN91900049
J	Gerber, MA; Shapiro, ED; Burke, GS; Parcells, VJ; Bell, GL				Gerber, MA; Shapiro, ED; Burke, GS; Parcells, VJ; Bell, GL			Lyme disease in children in southeastern Connecticut	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD; BORRELIOSIS; MANIFESTATIONS; SERODIAGNOSIS; DOXYCYCLINE; FEATURES; ASSAY; AREA	Background Although the incidence of Lyme disease is highest in children, there are few prospective data on the clinical manifestations and outcomes in children. Methods We conducted a prospective, longitudinal, community-based cohort study of children with newly diagnosed Lyme disease in an area of Connecticut in which the disease is highly endemic. We obtained clinical and demographic information and performed serial antibody tests and follow-up evaluations. Results Over a period of 20 months, 201 consecutive patients were enrolled; their median age was 7 years (range, 1 to 21). The initial clinical manifestations of Lyme disease were a single erythema migrans lesion in 66 percent, multiple erythema migrans lesions in 23 percent, arthritis in 6 percent, facial-nerve palsy in 3 percent, aseptic meningitis in 2 percent, and carditis in 0.5 percent. At presentation, 37 percent of the patients with a single erythema migrans lesion and 89 percent of those with multiple erythema migrans lesions had antibodies against Borrelia burgdorferi. All but 3 of the 201 patients were treated for two to four weeks with conventional antimicrobial therapy, which was adminis tered orally in 96 percent. All had prompt clinical responses, After four weeks, 94 percent were completely asymptomatic (including the two patients whose parents had refused to allow antimicrobial treatment), At follow-up a mean of 25.4 months later, none of the patients had evidence of either chronic or recurrent Lyme disease. Six patients subsequently had a new episode of erythema migrans. Conclusions About 90 percent of children with Lyme disease present with erythema migrans, which is an early stage of the disease. The prognosis is excellent for those with early Lyme disease who are treated promptly with conventional courses of antimicrobial agents. (C) 1996, Massachusetts Medical Society.	YALE UNIV, SCH MED, DEPT PEDIAT, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, CHILDRENS CLIN RES CTR, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University	Gerber, MA (corresponding author), UNIV CONNECTICUT, SCH MED, CONNECTICUT CHILDRENS MED CTR, DEPT PEDIAT, 282 WASHINGTON ST, HARTFORD, CT 06106 USA.							ADAMS WV, 1994, PEDIATRICS, V94, P185; AGUEROROSENFELD ME, 1993, J CLIN MICROBIOL, V31, P3090, DOI 10.1128/JCM.31.12.3090-3095.1993; BERGLUND J, 1995, NEW ENGL J MED, V333, P1319, DOI 10.1056/NEJM199511163332004; CHRISTEN HJ, 1990, ACTA PAEDIATR SCAND, V79, P1219; CHRISTEN HJ, 1993, ACTA PAEDIATR, V82, P1; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1994, CLIN EXP RHEUMATOL, V12, pS49; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; EICHENFIELD AH, 1986, J PEDIATR-US, V109, P753, DOI 10.1016/S0022-3476(86)80688-6; FEDER HM, 1995, J INFECT DIS, V171, P1371, DOI 10.1093/infdis/171.5.1371; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; JORBECK HJA, 1987, ACTA PAEDIATR SCAND, V76, P228, DOI 10.1111/j.1651-2227.1987.tb10452.x; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; Kramer M.S., 1988, CLIN EPIDEMIOLOGY BI; MAGNARELLI LA, 1988, AM J EPIDEMIOL, V127, P818, DOI 10.1093/oxfordjournals.aje.a114864; MARKOWITZ M, 1968, PEDIATRICS, V41, P151; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; PETERSEN LR, 1989, YALE J BIOL MED, V62, P253; SALAZAR JC, 1993, J PEDIATR-US, V122, P591, DOI 10.1016/S0022-3476(05)83541-3; Siegel S., 1988, NONPARAMETRIC STAT B; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; Tukey J, 1991, STAT SCI, V6, P100, DOI DOI 10.1214/SS/1177011945; WEBER K, 1986, INFECTION, V14, P32, DOI 10.1007/BF01644807; WILLIAMS CL, 1990, PEDIATR INFECT DIS J, V9, P10, DOI 10.1097/00006454-199001000-00003; [No title captured]; [No title captured]	29	228	232	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1270	1274		10.1056/NEJM199610243351703	http://dx.doi.org/10.1056/NEJM199610243351703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857006				2022-12-28	WOS:A1996VN59400003
J	Stiegler, G				Stiegler, G			Germans learn to bet on biotech	NATURE			English	Article																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					744	744		10.1038/383744a0	http://dx.doi.org/10.1038/383744a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878492	Bronze			2022-12-28	WOS:A1996VN91800064
J	McNamee, D				McNamee, D			Different kind of drug-company freebie	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1048	1048		10.1016/S0140-6736(05)64413-3	http://dx.doi.org/10.1016/S0140-6736(05)64413-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874454				2022-12-28	WOS:A1996VM88600007
J	Chan, SSY; Zheng, H; Su, MW; Wilk, R; Killeen, MT; Hedgecock, EM; Culotti, JG				Chan, SSY; Zheng, H; Su, MW; Wilk, R; Killeen, MT; Hedgecock, EM; Culotti, JG			UNC-40, a C-elegans homolog of DCC (Deleted in Colorectal Cancer), is required in motile cells responding to UNC-6 netrin cues	CELL			English	Article							PIONEER AXON MIGRATIONS; CAENORHABDITIS-ELEGANS; IMMUNOGLOBULIN SUPERFAMILY; NEURONAL DIFFERENTIATION; POINT MUTATIONS; NERVOUS-SYSTEM; GENE-PRODUCT; GUIDES CELL; GUIDANCE; EXPRESSION	UNC-6 netrin, a laminin-related protein secreted from neuroglia and neurons along the ventral midline, orients migrating cells and pioneering growth cones on the nematode epidermis. UNC-5, a cell surface protein expressed on motile cells and pioneer axons, orients movements away from UNC-6 sources. UNC-40, a homolog of the cell surface proteins DCC (Deleted in Colorectal Cancer) and neogenin, is also expressed on motile cells and pioneer neurons. UNC-40 acts cell autonomously to orient movement toward UNC-6 sources. For cells coexpressing UNC-5, it helps orient movement away from UNC-6 sources. Finally, UNC-40 helps determine the dorsoventral position of cells undergoing purely longitudinal migrations. Together with the recent report that DCC is a netrin receptor in vertebrates, our results suggest that UNC-40 is a component of UNC-6 receptors on motile cells.	UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	University of Toronto; Johns Hopkins University	Chan, SSY (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,600 UNIV AVE,TORONTO,ON M5G 1X5,CANADA.		Culotti, Joseph/G-6467-2013; Killeen, Marie/C-1131-2012	Killeen, Marie/0000-0001-9404-4845; Culotti, Joseph/0000-0001-6325-4612	NINDS NIH HHS [NS26295] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026295, R01NS026295] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; Burden-Gulley Susan M., 1995, Seminars in Developmental Biology, V6, P79, DOI 10.1016/S1044-5781(06)80017-4; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; CULOTTI JG, 1994, CURR OPIN GENET DEV, V4, P587, DOI 10.1016/0959-437X(94)90077-G; CUNNINGHAM BA, 1995, CURR OPIN CELL BIOL, V7, P628, DOI 10.1016/0955-0674(95)80103-0; DURBIN RM, 1987, THESIS U CAMBRIDGE E; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEDRICK L, 1992, COLD SPRING HARB SYM, V57, P345, DOI 10.1101/SQB.1992.057.01.039; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Maniatis T., 1982, MOL CLONING; Mello C, 1995, METHOD CELL BIOL, P452; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; Wadsworth William G., 1992, Current Opinion in Neurobiology, V2, P36, DOI 10.1016/0959-4388(92)90159-I; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Zinn Kai, 1993, Seminars in Cell Biology, V4, P397, DOI 10.1006/scel.1993.1047	39	389	402	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					187	195		10.1016/S0092-8674(00)81337-9	http://dx.doi.org/10.1016/S0092-8674(00)81337-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861903	hybrid			2022-12-28	WOS:A1996VN40300007
J	Draper, BW; Mello, CC; Bowerman, B; Hardin, J; Priess, JR				Draper, BW; Mello, CC; Bowerman, B; Hardin, J; Priess, JR			MEX-3 is a KH domain protein that regulates blastomere identity in early C-elegans embryos	CELL			English	Article							FRAGILE-X SYNDROME; CAENORHABDITIS-ELEGANS; RNA-BINDING; MESSENGER-RNA; CYTOPLASMIC LOCALIZATION; CLEAVAGE SPINDLE; GENE; ENCODES; FMR1; SKN-1	After the first division of the C. elegans embryo, the posterior blastomere can produce numerous muscles while the anterior blastomere cannot. We show here that maternal-effect lethal mutations in the gene mex-3 cause descendants of the anterior blastomere to produce muscles by a pattern of development similar to that of a descendant of the wild-type posterior blastomere. mex-3 encodes a probable RNA-binding protein that is distributed unequally in early embryos and that is a component of germline-specific granules called P granules. We propose that MEX-3 contributes to anterior-posterior asymmetry by regulating one or more mRNAs involved in specifying the fate of the posterior blastomere.	UNIV WASHINGTON,DEPT ZOOL,SEATTLE,WA 98195; UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706; HOWARD HUGHES MED INST,SEATTLE,WA	University of Washington; University of Washington Seattle; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute	Draper, BW (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98109, USA.			Draper, Bruce W/0000-0002-4397-7749				ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CHENG NN, 1995, GENETICS, V139, P549; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Harlow E., 1988, ANTIBODIES LAB MANUA; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HUTTER H, 1994, DEVELOPMENT, V120, P2051; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; LIU K, 1995, J MOL BIOL, V247, P547, DOI 10.1016/S0022-2836(05)80136-6; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; Mickey KM, 1996, DEVELOPMENT, V122, P1791; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; MORI I, 1988, GENETICS, V120, P397; MORTON DG, 1992, GENETICS, V130, P771; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; Schnabel R, 1996, MECH DEVELOP, V54, P133, DOI 10.1016/0925-4773(95)00466-1; Schnabel R, 1996, BIOESSAYS, V18, P591, DOI 10.1002/bies.950180711; SCHNABEL R, 1994, SCIENCE, V263, P1449, DOI 10.1126/science.8128230; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; URLAUB H, 1995, EMBO J, V14, P4578, DOI 10.1002/j.1460-2075.1995.tb00137.x; WARING DA, 1991, NATURE, V350, P712, DOI 10.1038/350712a0	45	213	235	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					205	216		10.1016/S0092-8674(00)81339-2	http://dx.doi.org/10.1016/S0092-8674(00)81339-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861905	Bronze			2022-12-28	WOS:A1996VN40300009
J	Holtschke, T; Lohler, J; Kanno, Y; Fehr, T; Giese, N; Rosenbauer, F; Lou, J; Knobeloch, KP; Gabriele, L; Waring, JF; Bachmann, MF; Zinkernagel, RM; Morse, HC; Ozato, K; Horak, I				Holtschke, T; Lohler, J; Kanno, Y; Fehr, T; Giese, N; Rosenbauer, F; Lou, J; Knobeloch, KP; Gabriele, L; Waring, JF; Bachmann, MF; Zinkernagel, RM; Morse, HC; Ozato, K; Horak, I			Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene	CELL			English	Article							INTERFERON REGULATORY FACTOR; SEQUENCE-BINDING-PROTEIN; FACTOR FAMILY; T-CELLS; HEMATOPOIETIC-CELLS; FACTOR-II; GAMMA; ALPHA; IFN; TRANSCRIPTION	Interferon consensus sequence binding protein (ICSBP) is a transcription factor of the interferon (IFN) regulatory factor (IRF) family. Mice with a null mutation of ICSBP exhibit two prominent phenotypes related to previously described activities of the IRF family. The fi rst is enhanced susceptibility to virus infections associated with impaired production of IFN gamma. The second is deregulated hematopoiesis in both ICSBP-/- and ICSBP+/- mice that manifests as a syndrome similar to human chronic myelogenous leukemia. The chronic period of the disease progresses to a fatal beast crisis characterized by a clonal expansion of undifferentiated cells. Normal mice injected with cells from mice in blast crisis developed acute leukemia within 6 weeks of transfer. These results suggest a novel role for ICSBP in regulating the proliferation and differentiation of hematopoietic progenitor cells.	UNIV WURZBURG,INST VIROL & IMMUNBIOL,D-8700 WURZBURG,GERMANY; UNIV HAMBURG,HEINRICH PETTE INST,HAMBURG,GERMANY; NICHHD,NATL INST HLTH,LAB MOL GROWTH REGULAT,BETHESDA,MD 20205; UNIV ZURICH,INST EXPT IMMUNOL,CH-8091 ZURICH,SWITZERLAND; NIAID,NATL INST HLTH,IMMUNOPATHOL LAB,BETHESDA,MD 20205; RES INST MOL PHARM,DEPT MOL GENET,D-12207 BERLIN,GERMANY	University of Wurzburg; Heinrich Pette Institute; University of Hamburg; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Zurich; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Kanno, Yuka/B-5802-2013; Fehr, Thomas/AFQ-9308-2022; Gabriele, Lucia/J-8335-2016	Kanno, Yuka/0000-0001-5668-9319; Fehr, Thomas/0000-0003-1668-1800; Gabriele, Lucia/0000-0002-1483-866X; Morse, Herbert/0000-0002-9331-3705				ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRIGGERS PH, 1992, NUCLEIC ACIDS RES, V20, P2533, DOI 10.1093/nar/20.10.2533; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; Giese NA, 1996, IMMUNOLOGY, V87, P467, DOI 10.1046/j.1365-2567.1996.492569.x; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nelson N, 1996, J IMMUNOL, V156, P3711; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Thornton AM, 1996, P NATL ACAD SCI USA, V93, P383, DOI 10.1073/pnas.93.1.383; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WEISSMAN IL, 1994, IMMUNITY, V1, P529, DOI 10.1016/1074-7613(94)90042-6; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; ZINKERNAGEL RM, 1986, J EXP MED, V164, P1057	41	530	539	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					307	317		10.1016/S0092-8674(00)81348-3	http://dx.doi.org/10.1016/S0092-8674(00)81348-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861914	Bronze			2022-12-28	WOS:A1996VN40300018
J	Nakamura, Y; Ito, K; Isaksson, LA				Nakamura, Y; Ito, K; Isaksson, LA			Emerging understanding of translation termination	CELL			English	Review							RELEASE FACTOR; IN-VIVO; STOP		UNIV STOCKHOLM,DEPT MICROBIOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University	Nakamura, Y (corresponding author), UNIV TOKYO,INST MED SCI,DEPT TUMOR BIOL,MINATO KU,4-6-1 SHIROKANEDAI,TOKYO 108,JAPAN.			Ito, Koichi/0000-0002-2042-405X				Bjornsson A, 1996, EMBO J, V15, P1696, DOI 10.1002/j.1460-2075.1996.tb00515.x; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; GOLDSTEIN JL, 1970, P NATL ACAD SCI USA, V67, P537, DOI 10.1073/pnas.67.2.537; HIRASHIM.A, 1970, BIOCHEM BIOPH RES CO, V41, P877, DOI 10.1016/0006-291X(70)90165-8; Ito K, 1996, P NATL ACAD SCI USA, V93, P5443, DOI 10.1073/pnas.93.11.5443; JANOSI L, 1994, P NATL ACAD SCI USA, V91, P4249, DOI 10.1073/pnas.91.10.4249; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; Matsumura K, 1996, J MOL BIOL, V258, P588, DOI 10.1006/jmbi.1996.0271; Nakamura Y, 1995, BIOCHEM CELL BIOL, V73, P1113, DOI 10.1139/o95-120; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; OFVERSTEDT LG, 1994, CELL, V79, P629, DOI 10.1016/0092-8674(94)90548-7; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; POOLE ES, 1995, EMBO J, V14, P151, DOI 10.1002/j.1460-2075.1995.tb06985.x; STANSFIELD I, 1994, CURR GENET, V25, P385, DOI 10.1007/BF00351776; TATE WP, 1992, BIOCHEMISTRY-US, V31, P2443, DOI 10.1021/bi00124a001; Tate WP, 1996, PROG NUCLEIC ACID RE, V52, P293, DOI 10.1016/S0079-6603(08)60970-8; Yarus M, 1992, TRANSFER RNA PROTEIN, P319; Zhang SP, 1996, J MOL BIOL, V261, P98, DOI 10.1006/jmbi.1996.0444; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	20	146	152	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					147	150		10.1016/S0092-8674(00)81331-8	http://dx.doi.org/10.1016/S0092-8674(00)81331-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861897	Bronze			2022-12-28	WOS:A1996VN40300001
J	Parker, G; Jenkins, S				Parker, G; Jenkins, S			Hepatitis B and admission to medical school: An audit of British medical school policy	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Parker, G (corresponding author), UNIV MANCHESTER, SCH EPIDEMIOL & HLTH SCI, CTR OCCUPAT HLTH, MANCHESTER M13 9PT, LANCS, ENGLAND.							*COMM VIC CHANC PR, 1994, FITN PRACT MED DENT; GERLICH WH, 1994, LANCET, V343, P1572, DOI 10.1016/S0140-6736(94)92974-2; LEVER AM, 1994, BRIT MED J, V308, P870, DOI 10.1136/bmj.308.6933.870; POLAND GA, 1994, LANCET, V343, P1162, DOI 10.1016/S0140-6736(94)90267-4; *UK HLTH DEP ADV G, 1993, PROT HLTH CAR WORK P	5	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	1996	313	7061					856	857						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870573				2022-12-28	WOS:A1996VL55900023
J	Krauskopf, A; Blackburn, EH				Krauskopf, A; Blackburn, EH			Control of telomere growth by interactions of RAP1 with the most distal telomeric repeats	NATURE			English	Article							KLUYVEROMYCES-LACTIS; FUNCTIONAL-ANALYSIS; BINDING-PROTEIN; YEAST TELOMERES; SILENCERS; DOMAIN; END	TELOMERES, the specialized DNA-protein structures at the ends of eukaryotic chromosomes, are required for chromosomal stability and integrity(1-3). Regulation of the overall length of the telomeric DNA repeat tract is likely to be a key requirement for its various biological roles. We have studied telomere length regulation in the yeast Kluyveromyces lactis, which has long (25 base pairs) homogeneous telomeric repeat units(4) that make it highly suitable for telomere studies. In the related Saccharomyces cerevisiae, the DNA-sequence-specific duplex-binding protein RAP1 is a component of the telomeric complex(5-9). Here we show that the phenotypic severity of previously described telomerase RNA (ter1) mutations(10) is directly proportional to the loss of RAP1 binding to mutated telomeric repeats. Using a carboxy-terminal-tail mutant of K. lactis RAP1, we also show that, unexpectedly, RAP1 interaction with the most terminal telomeric repeats is crucial for telomere length control.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								BERMAN J, 1986, P NATL ACAD SCI USA, V83, P3713, DOI 10.1073/pnas.83.11.3713; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHEN XJ, 1994, MOL CELL BIOL, V14, P4501, DOI 10.1128/MCB.14.7.4501; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; FANG G, 1995, TELOMERES, P69; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; LARSON GP, 1994, GENE, V150, P35, DOI 10.1016/0378-1119(94)90854-0; LIU C, 1994, GENETICS, V138, P1025; MCEACHERN MJ, 1994, P NATL ACAD SCI USA, V91, P3453, DOI 10.1073/pnas.91.8.3453; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	19	147	149	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					354	357		10.1038/383354a0	http://dx.doi.org/10.1038/383354a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848051				2022-12-28	WOS:A1996VJ43900050
J	Fang, J; Madhavan, S; Alderman, MH				Fang, J; Madhavan, S; Alderman, MH			The association between birthplace and mortality from cardiovascular causes among black and white residents of New York City	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; HYPERTENSIVE VETERANS; STROKE; MEN; ENGLAND	Background Life expectancy is shorter and mortality from cardiovascular disease higher among blacks than among whites in the United States. We studied whether place of birth was associated with mortality from cardiovascular causes among non-Hispanic black and white residents of New York City. Methods We linked mortality records from 1988 through 1992 with 1990 U.S. Census data for New York City. Mortality data for blacks born in the U.S. South and Northeast and in the Caribbean were compared with those for whites born in the Northeast. Results Among blacks, the rates of overall mortality and mortality from cardiovascular causes exceeded those among whites, Among persons born in the Northeast, the rates of death from cardiovascular disease for white men (285 per 100,000), as compared with black men (299), and for white women (155), as compared with black women (165), were similar. However, Southern-born black men and women both had mortality from cardiovascular disease that was substantially higher than that of their counterparts born in the Northeast, and Caribbean-born blacks had rates substantially lower than their Northeastern-born counterparts. The differences among the groups in the rates of death from coronary heart disease were greater than those for death due to stroke or hypertension. In each category defined by age and sex, Caribbean-born blacks had significantly lower rates of death from coronary heart disease than did whites. Black men who were 25 to 44 years of age and were born in the South had a rate of death from coronary heart disease that was 30 percent higher than that of Northeastern-born blacks, and four times that of Caribbean-born blacks of the same sex and age. Conclusions The higher rate of mortality from cardiovascular causes among blacks, as compared with whites, in New York City masks substantial variation among blacks based on their place of birth. (C) 1996. Massachusetts Medical Society.			Fang, J (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.							BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BEADENKOPF WG, 1963, J CHRON DIS, V16, P249, DOI 10.1016/0021-9681(63)90030-4; BERENSON GS, 1984, AM HEART J, V108, P672, DOI 10.1016/0002-8703(84)90654-9; BORHANI NO, 1965, AM J PUBLIC HEALTH N, V55, P673, DOI 10.2105/AJPH.55.5.673; Browne CM, 1996, CIRCULATION, V93, P16; *BUR CENS, 1993, 1990 CENS POP HOUS P; Bureau of the Census, 1992, 1990 CENS POP GEN PO; Cooper R S, 1993, Ann Epidemiol, V3, P137; CRUICKSHANK JK, 1980, BRIT MED J, V281, P1108, DOI 10.1136/bmj.281.6248.1108; GERBER LM, 1980, HUM BIOL, V52, P269; GERBER LM, 1980, MED ANTHROPOL, V4, P307; Gillum R F, 1991, Cardiovasc Clin, V21, P3; GREENBERG M, 1992, INT J EPIDEMIOL, V21, P324, DOI 10.1093/ije/21.2.324; GURALNICK L, 1966, J CHRON DIS, V19, P979, DOI 10.1016/0021-9681(66)90031-2; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12, P87; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KOCHANEK KD, 1995, MON VITAL STAT REP S, V43; KURTZKE JF, 1969, GEOGRAPHIC DISTRIBUT, P29; Lemann Nicholas, 1991, PROMISED LAND GREAT; Mason J O, 1993, Ann Epidemiol, V3, P120; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; MILLER JP, 1994, HYPERTENSION, V23, P431, DOI 10.1161/01.HYP.23.4.431; *NAT CTR HLTH STAT, 1990, MON VIT STAT REP S2, V40; *NAT CTR HLTH STAT, 1994, DHHS PUBL, V2; PERRY HM, 1994, J HYPERTENS, V12, P315; ROBERTSON TL, 1977, AM J CARDIOL, V39, P244, DOI 10.1016/S0002-9149(77)80198-7; ROCCELLA EJ, 1989, CLIN CARDIOLOGY, V0012; TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7	28	176	177	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1996	335	21					1545	1551		10.1056/NEJM199611213352101	http://dx.doi.org/10.1056/NEJM199611213352101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT341	8900086	Bronze			2022-12-28	WOS:A1996VT34100001
J	Lumsden, A; Krumlauf, R				Lumsden, A; Krumlauf, R			Patterning the vertebrate neuraxis	SCIENCE			English	Review							CHICK-EMBRYO HINDBRAIN; CENTRAL-NERVOUS-SYSTEM; ZINC-FINGER GENE; RETINOIC ACID; RHOMBOMERE BOUNDARIES; LINEAGE RESTRICTIONS; SEGMENTATION MUTANT; ANTERO-POSTERIOR; MOUSE HINDBRAIN; HOMEOBOX GENES	Neuraxial patterning is a continuous process that extends over a protracted period of development. During gastrulation a crude anteroposterior pattern, detectable by molecular markers, is conferred on the neuroectoderm by signals from the endomesoderm that are largely inseparable from those of neural induction itself. This coarse-grained pattern is subsequently reinforced and refined by diverse, locally acting mechanisms. Segmentation and long-range signaling from organizing centers are prominent among the emerging principles governing regional pattern.	NATL INST MED RES,DIV DEV NEUROBIOL,LONDON NW17 1AA,ENGLAND	MRC National Institute for Medical Research	Lumsden, A (corresponding author), UNITED MED & DENT SCH,GUYS HOSP,DEPT DEV NEUROBIOL,MRC,BRAIN DEV PROGRAMME,LONDON SE1 9RT,ENGLAND.		Krumlauf, Robb/AAH-5012-2019; Lumsden, Andrew/C-5146-2009	Krumlauf, Robb/0000-0001-9102-7927; 				ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; ALEXANDRED, 1996, DEVELOPMENT, V122, P735; ALTABA ARI, 1994, TRENDS NEUROSCI, V17, P233, DOI 10.1016/0166-2236(94)90006-X; ANG SL, 1993, DEVELOPMENT, V118, P139; ANG SL, 1996, DEVELOPMENT, V122, P247; BALLYCUIF L, 1995, MECH DEVELOP, V49, P49, DOI 10.1016/0925-4773(94)00301-3; Bang AG, 1996, CURR OPIN NEUROBIOL, V6, P25, DOI 10.1016/S0959-4388(96)80005-5; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BIRGBAUER E, 1994, DEVELOPMENT, V120, P1347; BLUMBERG B, IN PRESS DEVELOPMENT; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10056, DOI 10.1073/pnas.89.21.10056; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CLARKE JDW, 1993, DEVELOPMENT, V118, P151; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Cox WG, 1995, DEVELOPMENT, V121, P4349; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EISEN JS, 1991, NEURON, V6, P767, DOI 10.1016/0896-6273(91)90173-W; EISEN JS, 1991, SCIENCE, V252, P567; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FORTIN G, 1995, J PHYSIOL-LONDON, V486, P735, DOI 10.1113/jphysiol.1995.sp020849; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; GLOVER J, 1991, J NEUROBIOL, V22, P352; Golden JA, 1996, DEVELOPMENT, V122, P65; Gotz M, 1996, NEURON, V16, P551, DOI 10.1016/S0896-6273(00)80074-4; GRAPINBOTTON A, 1995, DEVELOPMENT, V121, P2707; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HARLAND RM, IN PRESS NEURONAL DE; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HEYMAN I, 1993, DEV DYNAM, V198, P241, DOI 10.1002/aja.1001980402; HEYMAN I, 1995, DEV DYNAM, V204, P301, DOI 10.1002/aja.1002040308; HILL J, 1995, MECH DEVELOP, V50, P3, DOI 10.1016/0925-4773(94)00321-D; Itasaki N, 1996, NEURON, V16, P55, DOI 10.1016/S0896-6273(00)80023-9; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; JACOBSON CO, 1964, ZOOL BIDR UPPS, V36, P73; Jacobson M., 1991, DEV NEUROBIOLOGY; JESSELL TM, 1996, NEURONAL DEV; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; KEYNES RJ, 1984, NATURE, V310, P786, DOI 10.1038/310786a0; KRAUSS S, 1992, NATURE, V360, P87, DOI 10.1038/360087a0; Kroll KL, 1996, DEVELOPMENT, V122, P3173; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Logan C, 1996, CURR BIOL, V6, P1006, DOI 10.1016/S0960-9822(02)00645-0; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Lumsden A, 1996, SEMIN CELL DEV BIOL, V7, P169, DOI 10.1006/scdb.1996.0023; Maden M, 1996, CURR BIOL, V6, P417, DOI 10.1016/S0960-9822(02)00509-2; MAHMOOD R, 1995, DEVELOPMENT, V121, P1399; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARIN F, 1995, EUR J NEUROSCI, V7, P1714, DOI 10.1111/j.1460-9568.1995.tb00693.x; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MARTINEZ S, 1992, DEVELOPMENT, V116, P1069; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; MCKAY IJ, 1994, DEVELOPMENT, V120, P2199; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; Millet S, 1996, DEVELOPMENT, V122, P3785; NEWMAN SA, 1993, BIOESSAYS, V15, P277, DOI 10.1002/bies.950150409; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; NODEN DM, 1988, DEVELOPMENT, V103, P121; Nonchev S, 1996, DEVELOPMENT, V122, P543; Papalopulu N, 1996, DEVELOPMENT, V122, P3409; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SIMEONE A, 1995, MECH DEVELOP, V51, P83, DOI 10.1016/0925-4773(95)96241-M; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SIMON H, 1995, CURR BIOL, V5, P205, DOI 10.1016/S0960-9822(95)00041-8; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; Song DL, 1996, DEVELOPMENT, V122, P627; Spemann H., 1938, EMBRYONIC DEV INDUCT; STERN CD, 1991, DEVELOPMENT, V113, P239; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; Wingate RJT, 1996, DEVELOPMENT, V122, P2143; Xu QL, 1995, DEVELOPMENT, V121, P4005; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; ZHANG MB, 1994, DEVELOPMENT, V120, P2431; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	101	896	915	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1109	1115		10.1126/science.274.5290.1109	http://dx.doi.org/10.1126/science.274.5290.1109			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895453				2022-12-28	WOS:A1996VT33500029
J	Garrett, HE; Dennis, EW; DeBakey, ME				Garrett, HE; Dennis, EW; DeBakey, ME			Aortocoronary bypass with saphenous vein graft - Seven-year follow-up (Reprinted from JAMA, vol 223, pg 792-794, 1973)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint								A 42-year-old man had extensive occlusive disease of the coronary artery and angina pectoris. An autogenous saphenous vein bypass from the ascending aorta to the anterior descending coronary artery was performed on Nov 23, 1964. The patient suffered an asymptomatic anterior myocardial infarction during operation but made an uncomplicated recovery, Seven years after the operation, the graft functions with normal left ventricular hemodynamics, while the occlusive process has produced obstruction of the left main coronary artery and almost complete occlusion of the right coronary artery. To our knowledge, this is the first successful case of a saphenous vein-coronary artery bypass with the longest follow-up of a functioning coronary vein bypass graft.										EFFLER DB, 1971, J THORAC CARDIOV SUR, V62, P503, DOI 10.1016/S0022-5223(19)42019-9; GARRETT HE, 1973, JAMA-J AM MED ASSOC, V223, P792, DOI 10.1001/jama.223.7.792; JOHNSON WD, 1970, J THORAC CARDIOV SUR, V59, P128, DOI 10.1016/S0022-5223(19)42520-8; KEELAN MH, 1971, J LAB CLIN MED, V78, P802; MITCHEL BF, 1970, J THORAC CARDIOV SUR, V60, P457, DOI 10.1016/S0022-5223(19)42326-X; MUNDTH ED, 1971, SURGERY, V70, P78; REUT GJ, 1971, J THORAC CARDIOVASC, V62, P511; SELZER A, 1971, AM J CARDIOL, V28, P490, DOI 10.1016/0002-9149(71)90017-8; SPENCER FC, 1971, ANN SURG, V173, P1029, DOI 10.1097/00000658-197106010-00022; Urschel H C Jr, 1970, Ann Thorac Surg, V10, P119	10	5	6	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1517	&		10.1001/jama.276.18.1517	http://dx.doi.org/10.1001/jama.276.18.1517			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ774	8903266				2022-12-28	WOS:A1996VQ77400038
J	Nathan, DM				Nathan, DM			Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY AMPUTATION; NEPHROPATHY; RETINOPATHY; PREVALENCE; MELLITUS; PEOPLE; CARE; POPULATION; TECHNOLOGY; IDDM	Objective.-To examine the cost-effectiveness of alternative approaches to the management of insulin-dependent diabetes mellitus (IDDM). Design.-A Monte Carlo simulation model was developed to estimate the lifetime benefits and costs of conventional and intensive insulin therapy. Data were collected as part of the Diabetes Control and Complications Trial (DCCT) and supplemented with data from other clinical trials and epidemiologic studies. Setting.-Twenty-nine academic medical centers. Patients.-Persons with IDDM in the United States who meet demographic and clinical eligibility criteria for enrollment in the DCCT. Interventions.-Conventional vs intensive diabetes management. Results.-Approximately 120 000 persons with IDDM in the United States meet DCCT eligibility criteria. implementing intensive rather than conventional therapy in this population would result in a gain of 920 000 years of sight, 691 000 years free from end-stage renal disease, 678 000 years free from lower extremity amputation, and 611 000 years of life at an additional cost of $4.0 billion over the lifetime of the population. The incremental cost per year of life gained is $28 661. Conclusions.-Over a lifetime, DCCT-defined intensive therapy reduces complications, improves quality of life, and can be expected to increase length of life. From a health care system perspective, intensive therapy is well within the range of cost-effectiveness considered to represent a good value.			Nathan, DM (corresponding author), MASSACHUSETTS GEN HOSP, DIABET UNIT BULFINCH 408, 32 FRUIT ST, BUL 405, BOSTON, MA 02114 USA.		Hramiak, Irene/G-3305-2011; Zinman, Bernard/E-7266-2013					ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], 1994, Diabetes Care, V17, P616; BLANKENSHIP GW, 1991, OPHTHALMOLOGY, V98, P125; BOJESTIG M, 1994, NEW ENGL J MED, V330, P15, DOI 10.1056/NEJM199401063300103; CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062; DASBACH EJ, 1992, MED DECIS MAKING, V12, P4; DCCT Res Grp, 1986, DIABETES, V35, P530; DCCT Res Grp, 1990, DIABETES CARE, V13, P427; Deckerf T., 1987, SCAND ACTUAR J, V1, P19; DIABET CONTROL COMPLICATIONS TRIAL RES GRP, 1995, DIABETES CARE, V18, P1468; Diabet Control Complications Trial Res Grp, 1996, DIABETES CARE, V19, P195; Drummond M, 1992, Pharmacoeconomics, V2, P1, DOI 10.2165/00019053-199202010-00001; DYCK PJ, 1993, NEUROLOGY, V43, P817, DOI 10.1212/WNL.43.4.817; EASTMAN RC, 1993, DIABETES CARE, V16, P1095, DOI 10.2337/diacare.16.8.1095; ECKMAN MH, 1995, JAMA-J AM MED ASSOC, V273, P712, DOI 10.1001/jama.273.9.712; Haddix A, 1996, PREVENTION EFFECTIVE; HUMPHREY LL, 1994, ARCH INTERN MED, V154, P885, DOI 10.1001/archinte.154.8.885; JAVITT JC, 1991, OPHTHALMOLOGY, V98, P1565; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909; JAVITT JC, 1995, DIABETES AM; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KLEIN R, 1995, OPHTHALMOLOGY, V102, P7; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1995, ARCH INTERN MED, V155, P745, DOI 10.1001/archinte.155.7.745; KOOPMANSCHAP MA, 1993, PHARMACOECONOMICS, V4, P446, DOI 10.2165/00019053-199304060-00006; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LAWRENCE WF, 1995, AM J KIDNEY DIS, V25, P701, DOI 10.1016/0272-6386(95)90545-6; LIBMAN I, 1993, DIABETES CARE, V16, P841, DOI 10.2337/diacare.16.5.841; MOGENSEN CE, 1983, DIABETES, V32, P64, DOI 10.2337/diab.32.2.S64; MOSS SE, 1992, ARCH INTERN MED, V152, P610, DOI 10.1001/archinte.152.3.610; *NIH, 1995, USRDS 1995 ANN DAT R; *NIH, 1993, USRDS 1993 ANN DAT R, P14; ORCHARD TJ, 1990, DIABETES, V39, P1116, DOI 10.2337/diabetes.39.9.1116; *PALL CORP, 1994, RISK RISK AN MOD SOF; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, pA809, DOI 10.1210/jcem.78.4.8157701; RUSSELL LB, 1986, IS PREVENTION BETTER, P36; SHAMOON H, 1995, ARCH OPHTHALMOL-CHIC, V113, P36; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, pS111; Songer TJ, 1995, DIABETES AM; The Diabetes Control and Complications Trial Research Group, 1993, DCCT MAN OP; US Bureau of the Census, 1995, STAT ABSTR US; WARRAM JH, 1996, J AM SOC NEPHROL, V7, P1; 1995, DIABETES CARE, V18, P261	49	371	374	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1409	1415						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892716				2022-12-28	WOS:A1996VQ46400027
J	Kannus, P; Palvanen, M; Niemi, S; Parkkari, J; Jarvinen, M; Vuori, I				Kannus, P; Palvanen, M; Niemi, S; Parkkari, J; Jarvinen, M; Vuori, I			Increasing number and incidence of osteoporotic fractures of the proximal humerus in elderly people	BRITISH MEDICAL JOURNAL			English	Article									TAMPERE UNIV HOSP,DEPT SURG,TAMPERE,FINLAND	Tampere University; Tampere University Hospital	Kannus, P (corresponding author), UKK INST HLTH PROMOT RES,ACCID & TRAUMA RES CTR,POB 30,FIN-33501 TAMPERE,FINLAND.							Aro S, 1990, Duodecim, V106, P1443; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; KANNUS P, 1995, LANCET, V346, P50, DOI 10.1016/S0140-6736(95)92679-8; LUTHJE P, 1995, ACTA ORTHOP SCAND, V66, P245; Salmela R, 1987, SAIRAALA, V49, P480	5	81	85	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1051	1052						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898596				2022-12-28	WOS:A1996VP74200026
J	Aitchison, JD; Blobel, G; Rout, MP				Aitchison, JD; Blobel, G; Rout, MP			Kap104p: A karyopherin involved in the nuclear transport of messenger RNA binding proteins	SCIENCE			English	Article							PORE COMPLEX; IMPORT SUBSTRATE; SACCHAROMYCES-CEREVISIAE; LOCALIZATION SEQUENCES; CYTOSOLIC FACTORS; MEDIATED BINDING; EXPORT PATHWAY; U SNRNPS; HNRNP A1; YEAST	A cytosolic yeast karyopherin, Kap104p, was isolated and shown to function in the nuclear import of a specific class of proteins. The protein bound directly to repeat-containing nucleoporins and to a cytosolic pool of two nuclear messenger RNA (mRNA) binding proteins, Nab2p and Nab4p, Depletion of Kap104p resulted in a rapid shift of Nab2p from the nucleus to the cytoplasm without affecting the localization of other nuclear proteins tested, This finding suggests that the major function of Kap104p lies in returning mRNA binding proteins to the nucleus after mRNA export.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University			Rout, Michael/Y-7090-2018	Rout, Michael/0000-0003-2010-706X				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1995, J CELL BIOL, V131, P1659, DOI 10.1083/jcb.131.6.1659; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BONIFACI N, COMMUNICATION; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CHOW TYK, 1992, J CELL SCI, V101, P709; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Henry M, 1996, GENETICS, V142, P103; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAEL WM, 1995, CELL, V83, P415; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; ROUT MP, UNPUB; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	57	275	278	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	1996	274	5287					624	627		10.1126/science.274.5287.624	http://dx.doi.org/10.1126/science.274.5287.624			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849456				2022-12-28	WOS:A1996VN91900054
J	Holland, SJ; Gale, NW; Mbamalu, G; Yancopoulos, GD; Henkemeyer, M; Pawson, T				Holland, SJ; Gale, NW; Mbamalu, G; Yancopoulos, GD; Henkemeyer, M; Pawson, T			Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands	NATURE			English	Article							PROTEIN-TYROSINE KINASES; CLONING; DOMAIN; BRAIN; CELLS; CEK5	RECEPTOR tyrosine kinases of the EPH class have been implicated in the control of axon guidance and fasciculation(1-7), in regulating cell migration(8), and in defining compartments in the developing embryo(9-11). Efficient activation of EPH receptors generally requires that their ligands be anchored to thr cell surface, either through a transmembrane (TM) region or a glycosyl phosphatidylinositol (GPI) group(12). These observations have suggested that EPH receptors can transduce signals initiated by direct cell-cell interaction. Genetic analysis of Nuk, a murine EPH receptor that binds TM ligands, has raised the possibility that these ligands might themselves have a signalling function(6). Consistent with this, the three known TM ligands have a highly conserved cytoplasmic region, with multiple potential sites for tyrosine phosphorylation(12-17). Here we show that challenging cells that express the TM ligands Elk-L or Htk-L with the clustered ectodomain of Nuk induces phosphorylation of the ligands on tyrosine, a process that can be mimicked both in vitro and in vivo by an activated Src tyrosine kinase. Co-culture of cells expressing a TM ligand with cells expressing Nuk leads to tyrosine phosphorylation of both the ligand and Nuk. These results suggest that the TM ligands are associated with a tyrosine kinase, and are inducibly phosphorylated upon binding Nuk in a fashion reminiscent of cytokine receptors(18). Furthermore, we show that TM ligands, as well as Nuk are phosphorylated on tyrosine in mouse embryos, indicating that this is a physiological process. EPH receptors and their TM ligands therefore mediate bidirectional cell signalling.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOL BIOL & CANC,TORONTO,ON M5G 1X5,CANADA; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10804; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Regeneron; University of Toronto			Pawson, Tony J/E-4578-2013	Henkemeyer, Mark/0000-0002-7525-1061				BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BRMABILLA R, 1995, EMBO J, V14, P3116; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LIU XQ, 1993, ONCOGENE, V8, P1119; NELSON P, 1976, P NATL ACAD SCI USA, V73, P123, DOI 10.1073/pnas.73.1.123; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; Owens T, 1996, CURR BIOL, V6, P32, DOI 10.1016/S0960-9822(02)00415-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005	29	448	462	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					722	725		10.1038/383722a0	http://dx.doi.org/10.1038/383722a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878483	Green Submitted			2022-12-28	WOS:A1996VN91800055
J	Cappelleri, JC; Ioannidis, JPA; Schmid, CH; deFerranti, SD; Aubert, M; Chalmers, TC; Lau, J				Cappelleri, JC; Ioannidis, JPA; Schmid, CH; deFerranti, SD; Aubert, M; Chalmers, TC; Lau, J			Large trials vs meta-analysis of smaller trials - How do their results compare?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED TRIALS; HEART-FAILURE; METAANALYSIS; MAGNESIUM; MORTALITY; SUPPLEMENTATION; MANAGEMENT; PREVENTION; INHIBITORS	Objective.-To evaluate the results of large clinical trials vs the pooled resu Data Identification.-Meta-analyses with at least 1 ''large'' study were identified from the Cochrane Pregnancy and Childbirth Database and from MEDLINE (1966-1995), Study Selection.-We used a sample size approach to select 79 meta-analyses with at least 1 large study of 1000 or more patients. We used a statistical power approach to select 61 meta-analyses with at least 1 large study based on statistical power considerations, Data Extraction.-The outcome of interest for each meta-analysis was the primary one stated in the orginal publication or, when not clearly specified, was decided on clinically. Data Synthesis.-By random effects calculations, we found agreement between large and smaller trials in 90% of the meta-analyses selected by the sample size approach and in 82% of the meta-analyses selected by the statistical power approach. Twice as many disagreements appeared when the variability among large studies and among smaller studies was not considered (ie, fixed effects calculations), Of the 15 disagreements between results of large and smaller trials using the random effects model, plausible explanations were identified in 10 meta-analyses: 5 with differences in the control rate of events between large and smaller trials, 4 with specific protocol or study differences, and 1 with potential publication bias, Two other disagreements were not clinically important, and tentative reasons could be identified for 2 of the remaining 3 disagreements, Conclusions.-Results of smaller studies are usually compatible with the results of large studies, but discrepancies do occur even when the diversity among both large studies and smaller studies is considered. Clinically important differences without a potential explanation are extremely uncommon, Future research should further examine sources of heterogeneity between the results of large and smaller trials.	TUFTS UNIV NEW ENGLAND MED CTR, DIV CLIN CARE RES, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DIV GEOG MED & INFECT DIS, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, BIOSTAT RES CTR, DEPT MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts Medical Center; Tufts Medical Center			Schmid, Christopher H./J-2398-2014; Ioannidis, John P. A./G-9836-2011	Schmid, Christopher H./0000-0002-0855-5313; 	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008532, R01HS007782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007389] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS08532, R01 HS07782] Funding Source: Medline; NIAID NIH HHS [T32 AI07389] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE O, 1995, NEW ENGL J MED, V333, P1444; ABRAMSON JH, 1994, MAKING SENSE DATA SE, P319; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1994, BMJ, V308, P235; [Anonymous], 1994, BMJ, V308, P159; [Anonymous], 1992, Lancet, V339, P1; ANTMAN EM, 1995, AM J CARDIOL, V75, P391, DOI 10.1016/S0002-9149(99)80561-X; BARNETT HJM, 1995, NEW ENGL J MED, V332, P238, DOI 10.1056/NEJM199501263320408; BASINSKI A, 1991, J CLIN EPIDEMIOL, V44, P1085, DOI 10.1016/0895-4356(91)90011-W; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; BOISSEL JP, 1993, J CARDIOVASC PHARM, V22, P356, DOI 10.1097/00005344-199309000-00003; BORZAK S, 1995, ANN INTERN MED, V123, P873, DOI 10.7326/0003-4819-123-11-199512010-00010; CAPPELLERI JC, 1995, ONLINE J CURR C 0314; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COLLINS R, 1995, LANCET, V345, P669; COX DR, 1989, ANAL BINARY DATA, P19; Dean A. G., 1990, EPI INFO VERSION 5 W; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DOMANSKI MJ, 1994, AM J CARDIOL, V74, P395, DOI 10.1016/0002-9149(94)90411-1; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; ENKIN MW, 1994, PREGNANCY CHILDBIRTH; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FLOURNOY N, 1995, LANCET, V345, P741, DOI 10.1016/S0140-6736(95)90632-0; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GLASZIOU PP, 1993, BMJ-BRIT MED J, V306, P366, DOI 10.1136/bmj.306.6874.366; GONSER M, 1995, LANCET, V345, P1304, DOI 10.1016/S0140-6736(95)90949-4; HALLIDAY HL, 1995, BIOL NEONATE, V67, P32; Hedges L.V., 1994, HDB RES SYNTHESIS; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; JOVELL AJ, 1993, ONLINE J CURR C 0605; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LAU J, 1994, CLIN RES, V42, pA290; LAU J, 1995, META ANAL VERSION 0; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LUMLEY T, 1995, LANCET, V346, P576, DOI 10.1016/S0140-6736(95)91413-7; *MATHS INC, 1995, MATHC PLUS 6 0; McIntosh MW, 1996, STAT MED, V15, P1713, DOI 10.1002/(SICI)1097-0258(19960830)15:16<1713::AID-SIM331>3.0.CO;2-D; MORRIS JL, 1995, CAN J CARDIOL, V11, pB5; NAYLOR CD, 1990, JAMA-J AM MED ASSOC, V264, P697, DOI 10.1001/jama.264.6.697; NONY P, 1994, EUR J CLIN PHARMACOL, V46, P191, DOI 10.1007/BF00192547; PETO R, 1993, ANN NY ACAD SCI, V703, P314, DOI 10.1111/j.1749-6632.1993.tb26369.x; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; Raudenbush S. W., 1994, HDB RES SYNTHESIS, P301, DOI DOI 10.1111/ACPS.12078; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P177; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; SACKETT DL, 1993, ANN NY ACAD SCI, V703, P25, DOI 10.1111/j.1749-6632.1993.tb26331.x; *SAS I INC, 1994, SAS SYST WIND VERS 6; SCHMID CH, 1995, CONTROL CLIN TRIALS, V16, pS66; SINCLAIR JC, 1994, J CLIN EPIDEMIOL, V47, P881, DOI 10.1016/0895-4356(94)90191-0; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; *STAT SCI INC, 1993, S PLUS US MAN VERS 3; Thompson S G, 1993, Stat Methods Med Res, V2, P173, DOI 10.1177/096228029300200205; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0; WOODS KL, 1995, LANCET, V346, P611, DOI 10.1016/S0140-6736(95)91440-4; YUSUF S, 1995, BRIT MED J, V310, P751, DOI 10.1136/bmj.310.6982.751; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; [No title captured]	62	298	304	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1332	1338		10.1001/jama.276.16.1332	http://dx.doi.org/10.1001/jama.276.16.1332			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM825	8861993				2022-12-28	WOS:A1996VM82500037
J	Fowles, JB; Weiner, JP; Knutson, D; Fowler, E; Tucker, AM; Ireland, M				Fowles, JB; Weiner, JP; Knutson, D; Fowler, E; Tucker, AM; Ireland, M			Taking health status into account when setting capitation rates - A comparison of risk-adjustment methods	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CASE-MIX ADJUSTMENT; SURVEY SF-36; MANAGED-CARE; PHYSICIANS; RELIABILITY; POPULATION; VALIDITY; QUALITY; GROWTH; APPLES	Objective.-To compare performance of different health status measures for risk Design.-Cross-sectional study. Health status measures derived from 1 year were used to predict resources for that year and the next, Setting.-Group-network health maintenance organization in Minnesota. Participants.-Sample of 18- to 64-year-old (n=3825) and elderly (aged greater than or equal to 65 years; n=1955) members enrolled in a network-model health maintenance organization in Minnesota. Main Outcome Measures.-Total expenditures in the year concurrent with the health status survey (July 1991 through June 1992) and total expenditures in the year following the survey (July 1992 through June 1993). Results.-Capitation adjustment based on demographic measures performed least well, Both self-reported health status measures and diagnoses predicted future expenditures twice as well as demographics, When predicting costs for groups of patients rather than individuals, the demographic model worked well for average groups but tended to overpredict healthier groups and underpredict sicker groups. Ambulatory Care Groups based on diagnoses performed better than self-reported health status both in the retrospective models and across healthier and sicker groups, Conclusions.-Without risk adjustment, capitation rates are likely to overpay or underpay physicians for certain patient groups. II. is possible to improve prediction using health status measures for risk adjustment. When selection bias is suspected and administrative data are available, we recommend a risk-adjustment method based on diagnostic information, If diagnostic data are not available, we recommend a system based on simple self-reported measures, such as chronic conditions, rather than complex functional status measures.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, HLTH SERV RES & DEV CTR, BALTIMORE, MD USA	Johns Hopkins University	Fowles, JB (corresponding author), HLTH SYST MINNESOTA, INST RES & EDUC, HLTH RES CTR, 3800 PK NICOLLET BLVD, MINNEAPOLIS, MN 55416 USA.							*A F HIGG INC, 1996, NAT SURV EMPL SPONS; EMMONS DW, 1993, PHYSICIAN MARKETPLAC; Epstein A M, 1988, Health Care Financ Rev, V10, P51; FOWLES JB, 1994, 93G07 NIC MED FDN; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; *GROUP HLTH ASS AM, 1995, NAT DIR HMS 1995 ED; GRUBER LR, 1988, HEALTH AFFAIR, V7, P197, DOI 10.1377/hlthaff.7.3.197; HOLOHAN J, 1995, HEALTH AFFAIR, V14, P199, DOI 10.1377/hlthaff.14.1.199; Hornbrook M C, 1991, Adv Health Econ Health Serv Res, V12, P111; Iezzoni L. I., 1994, RISK ADJUSTMENT MEAS, P29; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1167, DOI 10.1056/NEJM199410273311719; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; NEFF JM, 1995, JAMA-J AM MED ASSOC, V274, P1866, DOI 10.1001/jama.274.23.1866; Newhouse J P, 1989, Health Care Financ Rev, V10, P41; NEWHOUSE JP, 1994, HEALTH AFFAIR, V13, P132, DOI 10.1377/hlthaff.13.1.132; *PHYS PAYM REV COM, 1994, ANN REP C; ROBINSON JC, 1991, INQUIRY-J HEALTH CAR, V28, P107; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; SALEMSCHATZ S, 1994, JAMA-J AM MED ASSOC, V272, P871, DOI 10.1001/jama.272.11.871; Shewry S, 1996, HEALTH AFFAIR, V15, P171, DOI 10.1377/hlthaff.15.1.171; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Wallack S S, 1991, Health Care Financ Rev Annu Suppl, P27; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 1993, SF36 HLTH SURVEY MAN; Weiner JP, 1996, HEALTH CARE FINANC R, V17, P77; WEINER JP, 1995, JAMA-J AM MED ASSOC, V273, P1503, DOI 10.1001/jama.273.19.1503; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WELCH HG, 1995, JAMA-J AM MED ASSOC, V273, P772, DOI 10.1001/jama.273.10.772; Wetzell S, 1996, Minn Med, V79, P15; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510	34	108	109	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1316	1321		10.1001/jama.276.16.1316	http://dx.doi.org/10.1001/jama.276.16.1316			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VM825	8861990				2022-12-28	WOS:A1996VM82500034
J	Witzig, R				Witzig, R			The medicalization of race: Scientific legitimization of a flawed social construct	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ETHNICITY	The term ''race'' has many definitions, ranging from a family unit to a species, but in common and medical usage, defining ''race'' has meant separating Homo sapiens into three to six groups. This division of Homo sapiens into race taxons started in the 18th century, when the sciences of genetics and evolutionary biology were not yet invented. These disciplines have since shown that human race taxonomy has no scientific basis. Race categories are social constructs, that is, concepts created from prevailing social perceptions without scientific evidence. Despite modern proof that race is arbitrary biological fiction, racial taxons are still used widely in medical teaching, practice, and research. Human diversity is inconsistently taught in medical schools and erratically presented in medical texts. Race taxons have been ''medicalized''; that is, race groupings have been legitimized by their use in medical literature and practice as acceptable descriptive labels that are integral to the proper diagnosis and treatment of disease in humans. Assumptions about disease that are made because a race has been assigned can result in important negative consequences for individual patients and inaccurate genetic inferences for populations. In contrast, ethnicity is a concept that incorporates social, religious, linguistic, dietary, and other variables to identify individual persons and populations. Ethnicity may be able to impart clinical clues to diagnosis if the clinician taking the history is well informed and open minded. Ethnic boundaries are dynamic and imprecise, and a strict methodical approach to ethnicity that is equal to the approach required for the study of other variables is necessary if the concept of ethnicity is to be clinically useful.										ASHE A, 1993, DAYS GRACE, P139; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P656, DOI 10.1056/NEJM199308263290912; BATES B, 1991, GUIDE PHYSICAL EXAMI, P5; BEGLEY S, 1996, NEWSWEEK        0213, P67; BENDYSHE T, 1865, ANTHR TREATISES JF B, V99, P269; BOAS F, 1964, MANS MOST DANGEROUS, P321; BOAS F, 1938, MIND PRIMITIVE MAN, P255; CALDWELL SH, 1995, ANN INTERN MED, V122, P614, DOI 10.7326/0003-4819-122-8-199504150-00010; CARMELI Y, 1993, CLIN INFECT DIS, V16, P213, DOI 10.1093/clind/16.2.213; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CROMIE WJ, 1990, HARVARD GAZETTE 0223, P11; CRUICKSHANK JK, 1989, ETHNIC FACTORS HLTH; DELP MH, 1975, MAJORS PHYSICAL DIAG, P44; Diamond J., 1994, DISCOVER, P82; Duster Troy, 1990, BACKDOOR TO EUGENICS; GELEHRTER TD, 1990, PRINCIPLES MED GENET; GENNARO AR, 1984, BLACKISTONS GOULD ME, P1146; GLANZE WD, 1994, MOSBY MED ENCY, P657; GREENBERGER NJ, 1993, HIST TAKING PHYSICAL; HAHN RA, 1992, JAMA-J AM MED ASSOC, V267, P268, DOI 10.1001/jama.267.2.268; HAHN RA, 1992, JAMA-J AM MED ASSOC, V267, P259, DOI 10.1001/jama.267.2.259; HALL TS, 1951, SOURCE BOOK ANIMAL B, P31; Harris Marvin, 1970, AFROAMERICAN ANTHR, P75; HORNE G, 1993, COVERTACTION Q, V43, P29; Hubbard R., 1993, EXPLODING GENE MYTH; HUTH EJ, 1995, ANN INTERN MED, V122, P619, DOI 10.7326/0003-4819-122-8-199504150-00012; Hutt MSR, 1986, GEOGRAPHY NONINFECTI; HUXLEY JS, 1936, WE EUROPEANS, P82; KING JC, 1981, BIOL RACE, P70; KING RA, 1992, GENETIC BASIS COMMON; KING RK, 1995, AM MED WOMENS ASS J, V10, P55; LEARY W, 1990, NY TIMES        0925, pC10; LEARY W, 1990, NY TIMES        0925, pC1; MALASANOS L, 1986, HLTH ASSESSMENT, P36; MCKENZIE KJ, 1994, BRIT MED J, V309, P286, DOI 10.1136/bmj.309.6950.286; Mckusick V.A., 1994, MENDELIAN INHERITANC; MORGANTHAU T, 1995, NEWSWEEK        0213, P62; MUNRO J, 1990, MACLEODS CLIN EXAMIN; POLEDNAK AP, 1989, RACIAL ETHNIC DIFFER, P1; PUTSCH SA, 1990, CLIN METHODS HIST PH, P1057; RENSBERGER B, 1990, CONT PERSPECTIVES, P67; Rogers J.A., 1980, NATURE KNOWS NO COLO; ROSE S, 1984, NOT OUR GENES BIOL I, P119; SAPIRA JD, 1990, ART SCI BEDSIDE DIAG, P48; SEIDEL HM, 1995, MOSBYS GUIDE PHYSICA, P36; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; SEYMOURSMITH C, 1986, MACMILLAN DICT ANTHR, P238; SIMPSON JA, 1989, OXFORD ENGLISH DICT, V13, P69; SMULIAN AG, 1993, J INFECT DIS, V167, P1243, DOI 10.1093/infdis/167.5.1243; THOMAS CL, 1993, TABERS CYCLOPEDIC ME, P646; THOMPSON MW, 1994, THOMPSON THOMPSON GE, P144; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; Trowell HC, 1981, W DIS THEIR EMERGENC; VONLINNE C, 1956, SYSTEMA NATURAE PHOT, P20; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; 1993, MMWR-MORBID MORTAL W, V42, P220; 1990, STEDMANS MED DICT, P1306	57	227	228	3	38	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					675	679		10.7326/0003-4819-125-8-199610150-00008	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM889	8849153				2022-12-28	WOS:A1996VM88900010
J	Zein, NN; Rakela, J; Krawitt, EL; Reddy, KR; Tominaga, T; Persing, DH; Therneau, TM; Gross, JB; Poterucha, JJ; Gossard, AA; Jeffers, LJ; Schiff, ER				Zein, NN; Rakela, J; Krawitt, EL; Reddy, KR; Tominaga, T; Persing, DH; Therneau, TM; Gross, JB; Poterucha, JJ; Gossard, AA; Jeffers, LJ; Schiff, ER			Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis C; interferons; genotype; outcome assessment (health care); liver cirrhosis	NON-B-HEPATITIS; CHRONIC NON-A; POLYMERASE CHAIN-REACTION; RECIPIENTS; DISEASE; RNA; HOMOLOGY; SEQUENCE; SEVERITY; REGIONS	Objective: To study 1) the geographic distribution and clinical significance of hepatitis C virus (HCV) genotypes in the United States and 2) the influence of HCV genotypes on response to interferon therapy. Design: Hepatitis C virus genotype was determined in 179 stored serum samples obtained from patients who were positive for antibody to HCV and for HCV RNA by using polymerase chain reaction. Setting: Tertiary referral centers in four geographic regions of the United States. Patients: Patients who visited medical centers in the Midwest (50 patients), Northeast (42 patients), Southeast (35 patients), and West (52 patients). Measurements: Chaotropic lysis and isopropanol precipitation were used to extract RNA from serum. Polymerase chain reaction was done on the NS5 region and was followed by automated direct sequencing and genotyping of desalted amplification products. Results: 104 patients (58%) had subtype 1a; 38 (21%)had subtype 1b; 4 (2%) had subtype 2a; 23 (13%) had subtype 2b; 8 (5%) had subtype 3a; and 2 (1%) had subtype 4a. Examination of the known risk factors for acquiring HCV showed no association between genotype and mode of acquisition (blood transfusion, injection drug use, employment at a health care facility) or histologic findings at presentation (mild active hepatitis, moderately active hepatitis, or cirrhosis). Sixty-eight percent of patients with genotype 1a, 80% of patients with genotype 1b, and 37% of patients with genotype 2a or 2b had severe hepatitis. Thirteen of 46 (28%) patients with genotype 1a and 4 of 15 (26%) patients with genotype 1b had a complete biochemical response after 6 months of interferon therapy. In contrast, 10 of 14 (71%) patients with genotype 2a or 2b had a complete response to interferon therapy. Five of: 39 (13%) patients with genotype 1a, 1 of 14 (7%) patients with genotype 1b, and 2 of 11 (18%) patients with genotype 2a or 2b had a sustained biochemical response. Conclusions: In the United States, HCV genotypes 1a and 1b are the predominant genotypes in patients with ch ron ic hepatitis C. Genotype is not correlated with mode of virus acquisition or with histologic findings at presentation. Patients with HCV genotype 1a or 1b had more severe liver disease and lower rates of response to interferon therapy than did patients with HCV genotype 2a or 2b. These findings may have implications for predicting outcome and selecting patients for interferon treatment.	MAYO CLIN, ROCHESTER, MN 55905 USA; UNIV VERMONT, BURLINGTON, VT 05405 USA; UNIV MIAMI, MIAMI, FL 33101 USA	Mayo Clinic; University of Vermont; University of Miami					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032403, P01AI030548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041497] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32403, AI 30548] Funding Source: Medline; NIAMS NIH HHS [AR 41497] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; CHAYAMA K, 1993, GASTROENTEROL JPN, V28, P45, DOI 10.1007/BF02989204; CHEN PJ, 1992, VIROLOGY, V188, P102, DOI 10.1016/0042-6822(92)90739-C; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DELISSE AM, 1991, J HEPATOL, V13, pS20, DOI 10.1016/0168-8278(91)90017-6; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DUSHEIKO G, 1994, HEPATOLOGY, V19, P13, DOI 10.1016/0270-9139(94)90046-9; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; GORDON FD, 1995, GASTROENTEROLOGY, V108, pA1074; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HIJIKATA M, 1991, BIOCHEM BIOPH RES CO, V175, P220, DOI 10.1016/S0006-291X(05)81223-9; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; KARINO Y, 1991, GASTROENTEROL JPN, V26, P234; KATO N, 1991, BIOCHEM BIOPH RES CO, V181, P279, DOI 10.1016/S0006-291X(05)81414-7; LI JS, 1991, GENE, V105, P167; LIJS, 1991, J HEPATOL S4, V13, pS33; LIN R, 1991, AUST NZ J MED, V21, P387, DOI 10.1111/j.1445-5994.1991.tb04715.x; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; POL S, 1995, GASTROENTEROLOGY, V108, P581, DOI 10.1016/0016-5085(95)90088-8; POZZATO G, 1991, LANCET, V338, P509, DOI 10.1016/0140-6736(91)90578-D; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; TAKADA N, 1993, GASTROENTEROL JPN, V28, P268; WEILAND O, 1993, SCAND J INFECT DIS, V25, P25, DOI 10.3109/00365549309169665; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203; ZEIN NN, 1995, MAYO CLIN PROC, V70, P449, DOI 10.4065/70.5.449; ZEIN NN, 1995, GASTROENTEROLOGY, V108, pA1208; ZEIN NN, 1995, J LIVER TRANSPLANT S, V6, P354; ZEIN NN, 1995, SEMIN GASTROINTEST D, V1, P46	31	319	331	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					634	+		10.7326/0003-4819-125-8-199610150-00002	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM889	8849147				2022-12-28	WOS:A1996VM88900004
J	Boise, LH; Thompson, CB				Boise, LH; Thompson, CB			Hierarchical control of lymphocyte survival	SCIENCE			English	Editorial Material							HUMAN B-LYMPHOCYTES; BCL-2-DEFICIENT MICE; APOPTOSIS; CELL; CTLA-4; EXPRESSION; LIGAND		UNIV CHICAGO,DEPT MOL GENET,HOWARD HUGHES MED INST,GWEN KNAPP CTR LUPUS IMMUNOL RES,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CELL BIOL,HOWARD HUGHES MED INST,GWEN KNAPP CTR LUPUS IMMUNOL RES,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Boise, LH (corresponding author), UNIV CHICAGO,DEPT MED,HOWARD HUGHES MED INST,GWEN KNAPP CTR LUPUS IMMUNOL RES,CHICAGO,IL 60637, USA.		Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOISE LH, 1995, P NATL ACAD SCI USA, V92, P5491, DOI 10.1073/pnas.92.12.5491; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; ILLERA VA, 1993, J IMMUNOL, V151, P2965; Kehry MR, 1996, J IMMUNOL, V156, P2345; KOSCO MH, 1992, J IMMUNOL, V148, P2331; Lagresle C, 1996, J EXP MED, V183, P1377, DOI 10.1084/jem.183.4.1377; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NAKAYAMA KI, 1995, J EXP MED, V182, P1101, DOI 10.1084/jem.182.4.1101; PARIJS LV, 1996, IMMUNITY, V4, P321; Radvanyi LG, 1996, J IMMUNOL, V156, P1788; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHATTNER EJ, 1995, J EXP MED, V182, P1557, DOI 10.1084/jem.182.5.1557; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	29	107	108	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					67	68		10.1126/science.274.5284.67	http://dx.doi.org/10.1126/science.274.5284.67			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8848725				2022-12-28	WOS:A1996VK74800046
J	Dikstein, R; Zhou, S; Tjian, R				Dikstein, R; Zhou, S; Tjian, R			Human TAF(parallel to)105 is a cell type-specific TFIID subunit related to hTAF(parallel to)130	CELL			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; BASAL TRANSCRIPTION; MOLECULAR-CLONING; COMPLEX; COACTIVATORS; PROMOTER; INTERACTS; GENE	We previously characterized Drosophila and human TAF subunits that make up the core TFIID complex found in all cells. Here, we report that differentiated B cells contain a novel substoichiometric TAF of 105 kDa not found associated with TFIID isolated from other cell types. The cDNA encoding hTAF(II)105 reveals a highly conserved C-terminal domain shared by hTAF(II)130 and dTAF(II)110, while the N-terminal coactivator domain has diverged significantly. All cells tested express TAF(II)105 mRNA, but only B cells contain significant levels of protein associated with TFIID. Transient overexpression of hTAF(II)105 selectively squelches the transcription of some genes in B cells. These properties suggest that TAF(II)105 is a cell type-specific subunit of TFIID that may be responsible for mediating transcription by a subset of activators in B cells.			Dikstein, R (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.							ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; LUO Y, 1995, MOL CELL BIOL, V15, P4115; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	37	153	158	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					137	146		10.1016/S0092-8674(00)81330-6	http://dx.doi.org/10.1016/S0092-8674(00)81330-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858156	Bronze			2022-12-28	WOS:A1996VL69500016
J	Milot, E; Strouboulis, J; Trimborn, T; Wijgerde, M; deBoer, E; Langeveld, A; TanUn, K; Vergeer, W; Yannoutsos, N; Grosveld, F; Fraser, P				Milot, E; Strouboulis, J; Trimborn, T; Wijgerde, M; deBoer, E; Langeveld, A; TanUn, K; Vergeer, W; Yannoutsos, N; Grosveld, F; Fraser, P			Heterochromatin effects on the frequency and duration of LCR-mediated gene transcription	CELL			English	Article							BETA-GLOBIN LOCUS; DOMINANT CONTROL REGION; HIGH-LEVEL EXPRESSION; TRANSGENIC MICE; HYPERSENSITIVE SITE; DEVELOPMENTAL REGULATION; ACTIVATION REGION; REPLICATION; ELEMENT; DNA	Locus control regions (LCRs) are responsible for initiating and maintaining a stable tissue-specific open chromatin structure of a locus. In transgenic mice, LCRs confer high level expression on linked genes independent of position in the mouse genome. Here we show that an incomplete LCR loses this property when integrated into heterochromatic regions. Two disruption mechanisms were observed. One is classical position-effect variegation, resulting in continuous transcription in a clonal subpopulation of cells. The other is a novel mechanism resulting in intermittent gene transcription in all cells. We conclude that only a complete LCR fully overcomes heterochromatin silencing and that it controls the level of transcription by ensuring activity in all cells at all times rather than directly controlling the rate of transcription.	NATL INST MED RES,DEPT GENE STRUCT & EXPRESS,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	Milot, E (corresponding author), ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL,CTR MED GENET,NL-3000 DR ROTTERDAM,NETHERLANDS.		Fraser, Peter/B-7549-2009; Strouboulis, John/U-4459-2019	Strouboulis, John/0000-0002-6133-2872; Fraser, Peter/0000-0002-0041-1227				ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; CURTIN PT, 1989, P NATL ACAD SCI USA, V86, P7082, DOI 10.1073/pnas.86.18.7082; EISSENBERG JC, 1995, CHROMATIN STRUCTURE, P147; ELLIOTT JI, 1995, EMBO J, V14, P575, DOI 10.1002/j.1460-2075.1995.tb07033.x; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; FLERING S, 1995, GENE DEV, V9, P2203; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; HANSCOMBE O, 1989, GENE DEV, V3, P1572, DOI 10.1101/gad.3.10.1572; HEINTZ E, 1928, WISS BOTANIK, V69, P762; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; Hug BA, 1996, MOL CELL BIOL, V16, P2906; John B, 1979, Int Rev Cytol, V58, P1, DOI 10.1016/S0074-7696(08)61473-4; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KLOUSSIS D, 1983, NATURE, V306, P662; KULOZIK AE, 1991, J CLIN INVEST, V87, P2142, DOI 10.1172/JCI115246; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; Milot E, 1996, TRENDS GENET, V12, P123, DOI 10.1016/0168-9525(96)30019-X; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; MULDER MP, 1995, HUM GENET, V96, P133, DOI 10.1007/BF00207368; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PILLUS L, 1995, CHROMATIN STRUCTURE, P123; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SCHEDL P, 1995, CHROMATIN STRUCTURE, P174; STROUBOULIS J, 1992, NUCLEIC ACIDS RES, V20, P6109, DOI 10.1093/nar/20.22.6109; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; ZAFARANA G, 1995, P 9 C HEM SWITCH 199, P39	42	279	289	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					105	114		10.1016/S0092-8674(00)81327-6	http://dx.doi.org/10.1016/S0092-8674(00)81327-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858153	Green Published, Bronze			2022-12-28	WOS:A1996VL69500013
J	Cooper, RF; Fanselow, JB; Weber, JKR; Merkley, DR; Poker, DB				Cooper, RF; Fanselow, JB; Weber, JKR; Merkley, DR; Poker, DB			Dynamics of oxidation of a Fe2+-bearing aluminosilicate (Basaltic) melt	SCIENCE			English	Article							OXYGEN DIFFUSION; CHEMICAL DIFFUSION; SOLID-SOLUTIONS; TEMPERATURES; OLIVINE	Rutherford backscattering spectroscopy (RBS) and microscopy demonstrate that the similar to 1400 degrees C oxidation of levitated droplets of a natural Fe2+-bearing aluminosilicate (basalt) melt occurs by chemical diffusion of Fe2+ and Ca2+ to the free surface of the droplet; internal oxidation of the melt results from the required counterflux of electron holes. Diffusion of an oxygen species is not required. Oxidation causes the droplets to go subsolidus; magnetite (Fe3O4) forms at the oxidation-solidification front with a morphology suggestive of a Liesegang-band nucleation process.	INTERSON INC,NORTHBROOK,IL 60062; OAK RIDGE NATL LAB,OAK RIDGE,TN 37831; UNIV WISCONSIN,DEPT GEOL & GEOPHYS,MADISON,WI 53706	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Wisconsin System; University of Wisconsin Madison	Cooper, RF (corresponding author), UNIV WISCONSIN,DEPT MAT SCI & ENGN,1500 ENGN DR,MADISON,WI 53706, USA.							CANIL D, 1990, GEOCHIM COSMOCHIM AC, V54, P2947, DOI 10.1016/0016-7037(90)90112-X; COOK GB, 1990, J NON-CRYST SOLIDS, V120, P207, DOI 10.1016/0022-3093(90)90205-Z; Cooper RF, 1996, GEOCHIM COSMOCHIM AC, V60, P3253, DOI 10.1016/0016-7037(96)00160-3; DOOLITTLE LR, 1985, NUCL INSTRUM METH B, V9, P344, DOI 10.1016/0168-583X(85)90762-1; DUNN T, 1982, GEOCHIM COSMOCHIM AC, V46, P2293, DOI 10.1016/0016-7037(82)90202-2; DUNN T, 1983, GEOCHIM COSMOCHIM AC, V47, P1923, DOI 10.1016/0016-7037(83)90209-0; GROVE TL, 1981, CONTRIB MINERAL PETR, V78, P298; HESS PC, 1989, ORIGINS IGNEOUS ROCK, pCH5; KOHLSTEDT DL, 1987, CONTRIB MINERAL PETR, V95, P226, DOI 10.1007/BF00381272; KOHLSTEDT DL, 1976, SCIENCE, V191, P1045, DOI 10.1126/science.191.4231.1045; Muan A., 1965, PHASE EQUILIBRIA OXI; MYERS J, 1983, CONTRIB MINERAL PETR, V82, P75, DOI 10.1007/BF00371177; RICOULT DL, 1986, BER BUNSEN PHYS CHEM, V90, P135, DOI 10.1002/bbpc.19860900209; ROEDER PL, 1966, AM J SCI, V264, P428, DOI 10.2475/ajs.264.6.428; SCHMALZRIED H, 1983, BER BUNSEN PHYS CHEM, V87, P551, DOI 10.1002/bbpc.19830870702; SCHMALZRIED H, 1984, BER BUNSEN PHYS CHEM, V88, P1186, DOI 10.1002/bbpc.198400046; SCHMALZRIED H, 1981, SOLID STATE REACTION, pCH8; SCHREIBER HD, 1986, PHYS CHEM GLASSES, V27, P152; WAGNER C, 1950, J COLL SCI IMP U TOK, V5, P85, DOI 10.1016/0095-8522(50)90008-0; WASON JT, 1985, METEORITES THEIR REC, pCH7; WATSON EB, 1981, EARTH PLANET SC LETT, V52, P291, DOI 10.1016/0012-821X(81)90184-9; WEBER JKR, 1994, REV SCI INSTRUM, V65, P456, DOI 10.1063/1.1145157; WENDLANDT RF, 1991, CONTRIB MINERAL PETR, V108, P463, DOI 10.1007/BF00303450; WU T, 1988, J AM CERAM SOC, V71, P540, DOI 10.1111/j.1151-2916.1988.tb05917.x; ZARZYCKI J, 1991, GLASSES VITREOUS STA, pCH11; Ziegler J.F., 1985, STOPPING RANGE IONS	26	46	46	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1173	1176		10.1126/science.274.5290.1173	http://dx.doi.org/10.1126/science.274.5290.1173			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895462				2022-12-28	WOS:A1996VT33500048
J	Kang, HK; Bullman, TA				Kang, HK; Bullman, TA			Mortality among US veterans of the Persian Gulf War	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; VIETNAM VETERANS; DESERT-STORM; SYMPTOMS; COHORT; DEATH	Background Since the 1990-1991 Persian Gulf War, there has been persistent concern that U.S. war veterans may have had adverse health consequences, including higher-than-normal mortality. Methods We conducted a retrospective cohort study of postwar mortality according to cause among 695,516 Gulf War veterans and 746,291 other veterans. ans. The follow-up continued through September 1993. A stratified, multivariate analysis (with Cox proportional-hazards models) controlled for branch of service, type of unit, age, sex, and race in comparing the two groups. We used standardized mortality ratios to compare the groups of veterans with the general population of the United States. Results Among the Gulf War veterans, there was a small but significant excess of deaths as compared with the veterans who did not serve in the Persian Gulf (adjusted rate ratio, 1.09; 95 percent confidence interval, 1.01 to 1.16). The excess deaths were mainly caused by accidents (1.25; 1.13 to 1.39) rather than disease (0.88; 0.77 to 1.02). The corresponding rate ratios among 49,919 female veterans of the Gulf War were 1.32 (0.95 to 1.83) for death from all causes, 1.83 (1.02 to 3.28) for accidental death, and 0.89 (0.45 to 1.78) for death from disease. In both groups of veterans the mortality rates were significantly lower overall than those in the general population. The adjusted standardized mortality ratios were 0.44 (95 percent confidence interval, 0.42 to 0.47) for Gulf War veterans and 0.38 (0.36 to 0.40) for other veterans. Conclusions Among veterans of the Persian Gulf War, there was a significantly higher mortality rate than among veterans deployed elsewhere, but most of the increase was due to accidents rather than disease, a finding consistent with patterns of postwar mortality among veterans of previous wars. (C) 1996, Massachusetts Medical Society.			Kang, HK (corresponding author), DEPT VET AFFAIRS,ENVIRONM EPIDEMIOL SERV 135,1120 20TH ST NW,WASHINGTON,DC 20036, USA.							[Anonymous], 1995, Arch Intern Med, V155, P262; BOICE JD, 1991, O E SYSTEM OBSERVED; BULLMAN TA, 1994, J NERV MENT DIS, V182, P604, DOI 10.1097/00005053-199411000-00002; CARD JJ, 1987, J CLIN PSYCHOL, V43, P6, DOI 10.1002/1097-4679(198701)43:1<6::AID-JCLP2270430103>3.0.CO;2-X; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P1559, DOI 10.1001/jama.271.20.1559; *CTR DIS CONTR VIE, 1987, JAMA-J AM MED ASSOC, V257, P790; ENGEL CC, 1993, J NERV MENT DIS, V181, P683, DOI 10.1097/00005053-199311000-00006; Kulka R.A., 1990, TRAUMA VIETNAM WAR G; *NAT I HLTH TECHN, 1994, JAMA-J AM MED ASSOC, V272, P391; NICOLSON GL, 1995, INT J OCCUP MED TOX, V4, P365; Page WF, 1996, ANN EPIDEMIOL, V6, P102, DOI 10.1016/1047-2797(95)00126-3; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; ROTHBERG JM, 1990, JAMA-J AM MED ASSOC, V264, P2241, DOI 10.1001/jama.264.17.2241; *SAS STAT SOFTW, 1991, P217 SAS I STAT SOFT; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; SOUTHWICK SM, 1995, AM J PSYCHIAT, V152, P1150; THOMAS TL, 1991, AM J EPIDEMIOL, V134, P973, DOI 10.1093/oxfordjournals.aje.a116182; Watanabe Kevin K., 1995, Annals of Epidemiology, V5, P407, DOI 10.1016/1047-2797(95)00039-A; WOLFE J, 1993, J SOC ISSUES, V49, P15, DOI 10.1111/j.1540-4560.1993.tb01179.x; World Health Organization, 1977, INT CLASS DIS, V1; Writer JV, 1996, JAMA-J AM MED ASSOC, V275, P118, DOI 10.1001/jama.275.2.118	21	250	251	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1498	1504		10.1056/NEJM199611143352006	http://dx.doi.org/10.1056/NEJM199611143352006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT340	8890102				2022-12-28	WOS:A1996VT34000006
J	Cauley, JA; Lucas, FL; Kuller, LH; Vogt, MT; Browner, WS; Cummings, SR				Cauley, JA; Lucas, FL; Kuller, LH; Vogt, MT; Browner, WS; Cummings, SR			Bone mineral density and risk of breast cancer in older women - The study of osteoporotic fractures	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN REPLACEMENT THERAPY; SERUM SEX-HORMONES; POSTMENOPAUSAL WOMEN; ELDERLY WOMEN; ENDOMETRIAL CANCER; MENSTRUAL FACTORS; HIP-FRACTURES; REDUCED RISK; MASS; AGE	Objective.-To test the hypothesis that bone mineral density (BMD) is associated with the risk of developing breast cancer in older women. Design.-Prospective cohort study with mean (SD) follow-up of 3.2 (1.6) years. Setting.-Four clinical centers, one each located in the following areas: Baltimore, Md; Minneapolis, Minn; Portland, Ore; and the Monongahela Valley in Pennsylvania. Participants.-A total of 6854 nonblack women who were 65 years of age or older and enrolled in the Study of Osteoporotic Fractures. Measurements.-Radius and calcaneus BMD by single photon absorptiometry at baseline; hip and spine BMD by dual-energy x-ray absorptiometry 2 years later. Main Outcome Measure.-Breast cancer confirmed by medical record review. Results.-A total of 97 women developed breast cancer. In the multivariate model, adjusting for age, the degree of obesity, and other important covariates, the risk of breast cancer was about 30% to 50% higher per 1 SD increase in BMD (relative risk, distal radius BMD=1.50; 95% confidence interval, 1.16-1.95), The age-adjusted incidence rate of breast cancer per 1000 person-years among women in the lowest quartile of distal radius BMD was 2.46, compared with 5.99 among women with the highest BMD. Women with BMD above the 25th percentile were at 2.0 to 2.5 times increased risk of breast cancer compared with women below the 25th percentile. Results were consistent across all BMD sites. Conclusions.-Bone mineral density predicts the risk of breast cancer in older women. The magnitude of the association is similar to that observed between BMD and all fractures. Our findings suggest a link between 2 of the most common conditions affecting a woman's health, Identifying a common denominator for these conditions should substantially improve our understanding of their etiology and prevention.	UNIV PITTSBURGH, SCH MED, DEPT ORTHOPED SURG, PITTSBURGH, PA 15261 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOSTAT & EPIDEMIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94143 USA; MAINE MED CTR, HLTH SERV RES, PORTLAND, ME 04102 USA; VET AFFAIRS MED CTR, DEPT MED, GEN INTERNAL MED SECT, SAN FRANCISCO, CA 94121 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Maine Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Cauley, JA (corresponding author), UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, 130 DESOTO ST, CRABTREE HALL A524, PITTSBURGH, PA 15261 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05407, AG05394] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMI HO, 1990, AM J EPIDEMIOL, V132, P877, DOI 10.1093/oxfordjournals.aje.a115730; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; BERG RL, 1990, 2ND 50 YEARS PROMOTI, P76; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BLACK DM, 1992, J BONE MINER RES, V7, P633; BRINTON LA, 1988, CANCER INVEST, V6, P245, DOI 10.3109/07357908809080645; BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; BULBROOK RD, 1986, ANN NY ACAD SCI, V464, P378, DOI 10.1111/j.1749-6632.1986.tb16017.x; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CAULEY JA, 1994, AM J EPIDEMIOL, V139, P1035, DOI 10.1093/oxfordjournals.aje.a116943; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; CAULEY JA, 1991, AM J EPIDEMIOL, V133, P50, DOI 10.1093/oxfordjournals.aje.a115801; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; CULLEN KJ, 1991, CANCER RES, V51, P4978; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DESTAVOLA BL, 1993, CANCER CAUSE CONTROL, V4, P331, DOI 10.1007/BF00051335; ELLIS MJC, 1994, BREAST CANCER RES TR, V31, P249, DOI 10.1007/BF00666158; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FOX KM, 1993, J BONE MINER RES, V8, P901; GARLAND CF, 1992, AM J EPIDEMIOL, V135, P1220, DOI 10.1093/oxfordjournals.aje.a116228; HELZLSOUER KJ, 1994, CANCER DETECT PREV, V18, P79; JONNAVITHULA S, 1993, OBSTET GYNECOL, V81, P669; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112; KVALE G, 1988, CANCER-AM CANCER SOC, V62, P1625, DOI 10.1002/1097-0142(19881015)62:8<1625::AID-CNCR2820620828>3.0.CO;2-K; LINDSAY R, 1993, AM J MED, V95, pS37, DOI 10.1016/0002-9343(93)90380-8; Lohman T. G., 1998, ANTROPOMETRIC STANDA; LONGCOPE C, 1984, MATURITAS, V6, P309, DOI 10.1016/0378-5122(84)90002-1; LOOKER AC, 1995, J BONE MINER RES, V10, P796; MILLER BA, 1993, NIH PUBLICATION; MOORE JW, 1986, INT J CANCER, V38, P625, DOI 10.1002/ijc.2910380502; Muir C.S., 1987, CANC INCIDENCE 5 CON; MURPHY LC, 1994, BREAST CANCER RES TR, V31, P61, DOI 10.1007/BF00689677; NEGRI E, 1988, AM J EPIDEMIOL, V128, P1207, DOI 10.1093/oxfordjournals.aje.a115075; NIELSEN HE, 1985, ACTA RADIOL ONCOL, V24, P247, DOI 10.3109/02841868509134395; NILAS L, 1987, J CLIN ENDOCR METAB, V65, P697, DOI 10.1210/jcem-65-4-697; OLSSON H, 1992, AM J EPIDEMIOL, V136, P422, DOI 10.1093/oxfordjournals.aje.a116515; PERSSON I, 1994, CANCER CAUSE CONTROL, V5, P523, DOI 10.1007/BF01831380; PERSSON I, 1992, INT J EPIDEMIOL, V21, P636, DOI 10.1093/ije/21.4.636; RAUTALAHTI M, 1993, EUR J EPIDEMIOL, V9, P17, DOI 10.1007/BF00463085; Salamone LM, 1996, ARCH INTERN MED, V156, P1293, DOI 10.1001/archinte.156.12.1293; SCHMID C, 1993, J INTERN MED, V234, P535, DOI 10.1111/j.1365-2796.1993.tb01011.x; STEIGER P, 1992, J BONE MINER RES, V7, P625; STREWLER GJ, 1990, WESTERN J MED, V153, P635; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; UTZ JP, 1987, J CHRON DIS, V40, P105, DOI 10.1016/0021-9681(87)90061-0; VANDAELE PLA, 1995, ANN INTERN MED, V122, P409, DOI 10.7326/0003-4819-122-6-199503150-00002; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WYSOWSKI DK, 1987, AM J EPIDEMIOL, V125, P791, DOI 10.1093/oxfordjournals.aje.a114596	50	285	288	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1404	1408		10.1001/jama.276.17.1404	http://dx.doi.org/10.1001/jama.276.17.1404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892715				2022-12-28	WOS:A1996VQ46400026
J	Perseghin, G; Price, TB; Petersen, KF; Roden, M; Cline, GW; Gerow, K; Rothman, DL; Shulman, GI				Perseghin, G; Price, TB; Petersen, KF; Roden, M; Cline, GW; Gerow, K; Rothman, DL; Shulman, GI			Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; RAT SKELETAL-MUSCLE; 1ST-DEGREE RELATIVES; PHYSICAL-ACTIVITY; INCREASED RISK; SINGLE BOUT; MEN; SENSITIVITY; METABOLISM; SYNTHASE	Background Insulin resistance in the offspring of parents with non-insulin-dependent diabetes mellitus (NIDDM) is the best predictor of development of the disease and probably plays an important part in its pathogenesis. We studied the mechanism and degree to which exercise training improves insulin sensitivity in these subjects. Methods Ten adult children of parents with NIDDM and eight normal subjects were studied before starting an aerobic exercise-training program, after one session of exercise, and after six weeks of exercise. Insulin sensitivity was measured by the hyperglycemic-hyperinsulinemic clamp technique combined with indirect calorimetry, and the rate of glycogen synthesis in muscle and the intramuscular glucose-6-phosphate concentration were measured by carbon-13 and phosphorus-31 nuclear magnetic resonance spectroscopy, respectively. Results During the base-line study, the mean (+/-SE) rate of muscle glycogen synthesis was 63+/-9 percent lower in the offspring of diabetic parents than in the normal subjects (P<0.001). The mean value increased 69+/-10 percent (P=0.04) and 62+/-11 percent (P=0.04) after the first exercise session and 102+/-11 percent (P=0.02) and 97+/-9 percent (P=0.008) after six weeks of exercise training in the offspring and the normal subjects, respectively. The increment in glucose-6-phosphate during hyperglycemic-hyperinsulinemic clamping was lower in the offspring than in the normal subjects (0.039+/-0.013 vs. 0.089+/-0.009 mol per liter, P=0.005), reflecting reduced glucose transport-phosphorylation, but this increment was normal in the offspring after the first exercise session and after exercise training. Basal and stimulated insulin secretion was higher in the offspring than the normal subjects and was not altered by the exercise training program. Conclusions Exercise increases insulin sensitivity in both normal subjects and the insulin-resistant offspring of diabetic parents because of a twofold increase in insulin-stimulated glycogen synthesis in muscle, due to an increase in insulin-stimulated glucose transport-phosphorylation. (C) 1996, Massachusetts Medical society.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06520	Yale University			Shulman, Gerald I./P-7176-2019; Roden, Michael/AAD-3843-2019	Shulman, Gerald I./0000-0003-1529-5668; PERSEGHIN, Gianluca/0000-0002-3024-0457	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK049230] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-00125] Funding Source: Medline; NIDDK NIH HHS [P30 DK-45735, R01 DK-49230] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN P, 1977, J PHYSIOL-LONDON, V270, P677, DOI 10.1113/jphysiol.1977.sp011975; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BECKNIELSEN H, 1994, J CLIN INVEST, V94, P1714, DOI 10.1172/JCI117518; BOGARDUS C, 1984, DIABETES, V33, P311, DOI 10.2337/diabetes.33.4.311; DEFRONZO RA, 1987, DIABETES, V36, P1379, DOI 10.2337/diabetes.36.12.1379; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEVLIN JT, 1987, DIABETES, V36, P434, DOI 10.2337/diabetes.36.4.434; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; EBELING P, 1993, J CLIN INVEST, V92, P1623, DOI 10.1172/JCI116747; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; GOODYEAR LJ, 1992, DIABETES, V41, P1091, DOI 10.2337/diabetes.41.9.1091; GOODYEAR LJ, 1990, J APPL PHYSIOL, V68, P193, DOI 10.1152/jappl.1990.68.1.193; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOTHERNIELSEN O, 1989, ACTA ENDOCRINOL-COP, V120, P257, DOI 10.1530/acta.0.1200257; HOUMARD JA, 1991, AM J PHYSIOL, V261, pE437, DOI 10.1152/ajpendo.1991.261.4.E437; KOBBERLING J, 1971, DIABETOLOGIA, V7, P46, DOI 10.1007/BF02346253; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; Lusk G, 1924, J BIOL CHEM, V59, P41; MIKINES KJ, 1989, J APPL PHYSIOL, V66, P704, DOI 10.1152/jappl.1989.66.2.704; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; OSHIDA Y, 1989, J APPL PHYSIOL, V66, P2206, DOI 10.1152/jappl.1989.66.5.2206; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; SCHALINJANTTI C, 1992, DIABETES, V41, P598, DOI 10.2337/diabetes.41.5.598; SEGAL KR, 1991, J APPL PHYSIOL, V71, P2402, DOI 10.1152/jappl.1991.71.6.2402; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; TONINO RP, 1989, AM J PHYSIOL, V256, pE352, DOI 10.1152/ajpendo.1989.256.3.E352; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WIDEN EIM, 1992, DIABETES, V41, P354, DOI 10.2337/diabetes.41.3.354; WOLFE RR, 1992, RADIOACTIVE STABLE I, P49	32	486	504	2	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1996	335	18					1357	1362		10.1056/NEJM199610313351804	http://dx.doi.org/10.1056/NEJM199610313351804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP484	8857019				2022-12-28	WOS:A1996VP48400004
J	Cruysberg, JRM; Boers, GHJ; Trijbels, JMF; Deutman, AF				Cruysberg, JRM; Boers, GHJ; Trijbels, JMF; Deutman, AF			Delay in diagnosis of homocystinuria: Retrospective study of consecutive patients	BRITISH MEDICAL JOURNAL			English	Article							SYNTHASE DEFICIENCY; CYSTATHIONINE	Objective-To assess the causes for delay in the diagnosis of homocystinuria. Design-Clinical and laboratory data were collected from patients diagnosed as having homocystinuria due to cystathionine synthase deficiency, with special reference to the ages at which the patients had their first major signs of the disease, ectopia lentis was established, and homocystinuria was diagnosed. Setting-University hospital in the Netherlands. Subjects-34 patients (18 males) in whom homocystinuria due to cystathionine synthase deficiency was diagnosed in the period 1970-94. Results-Among 34 consecutively detected homocystinuria patients the mean age at diagnosis of homocystinuria was 24 (range 1-61) years. Despite frequent ocular manifestations, serious complications in the vascular, skeletal, and central nervous systems, and repeated examinations performed in these patients by clinicians of various disciplines, there was a mean delay of 11 (0-43) years between the first major signs of the disease (at mean age 13 (1-40) years) and the ultimate diagnosis of homocystinuria. Even when ectopia lentis was diagnosed (in 26 (76%) patients, mean age 18 (1-50) years), this did not lead to adequate biochemical analysis for homocystinuria at the time of detection, causing a mean diagnostic delay of 8 (0-24) years in these patients. Conclusions-Three factors should have precipitated the diagnosis of homocystinuria: early recognition that unusual myopia (high, very high, abnormal progressive, or at young age) was caused by subluxation of the ocular lenses; awareness that the occurrence of myopia combined with systemic complications (''myopia plus'') might be due to homocystinuria; and appropriate biochemical investigations carried out in patients with ectopia lentis and in their siblings.			Cruysberg, JRM (corresponding author), UNIV NIJMEGEN HOSP,POB 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.		Cruysberg, Johannes R. M./D-4313-2009	Cruysberg, Johannes R. M./0000-0002-5330-0774				APPLEGARTH DA, 1995, EUR J PEDIATR, V154, P589, DOI 10.1007/BF02074844; BLIKA S, 1982, ACTA OPHTHALMOL, V60, P894; BOERS GHJ, 1983, METABOLISM, V32, P390, DOI 10.1016/0026-0495(83)90049-5; BOERS GHJ, 1984, NETH J MED, V27, P206; BOERS GHJ, 1985, HUM GENET, V69, P164, DOI 10.1007/BF00293290; BOERS GHJ, 1986, CLIN RES SERIES, V3; BRENTON D P, 1972, Journal of Bone and Joint Surgery British Volume, V54, P277; CARSON NAJ, 1962, ARCH DIS CHILD, V37, P505, DOI 10.1136/adc.37.195.505; Cernea P, 1972, Ann Ocul (Paris), V205, P167; CROSS HE, 1973, AM J OPHTHALMOL, V75, P405, DOI 10.1016/0002-9394(73)91149-5; CROXATTO JO, 1986, OPHTHALMOLOGICA, V193, P23, DOI 10.1159/000309674; CULLOM RD, 1995, SURV OPHTHALMOL, V40, P217, DOI 10.1016/S0039-6257(95)80028-X; GARSTON JB, 1970, BRIT J OPHTHALMOL, V54, P248, DOI 10.1136/bjo.54.4.248; GERRITSEN T, 1962, BIOCHEM BIOPH RES CO, V9, P493, DOI 10.1016/0006-291X(62)90114-6; HINDLE NW, 1969, CAN J OPHTHALMOLOGY, V4, P128; JARRETT WH, 1967, ARCH OPHTHALMOL-CHIC, V78, P289, DOI 10.1001/archopht.1967.00980030291006; JOHNSTON SS, 1968, BRIT J OPHTHALMOL, V52, P251, DOI 10.1136/bjo.52.3.251; LEUENBERGER S, 1983, KLIN MONATSBL AUGENH, V182, P457, DOI 10.1055/s-2008-1054821; MATTHAUS W, 1984, KLIN MONATSBL AUGENH, V185, P253, DOI 10.1055/s-2008-1054609; MATTHAUS W, 1976, OPHTHALMOLOGICA, V173, P111, DOI 10.1159/000307862; MCKUSICK VA, 1972, HERITABLE DISORDERS, P224; Mohindra I, 1981, DOC OPHTHALMOL PROC, V28, P17; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MUDD SH, 1985, AM J HUM GENET, V37, P1; MURPHREE AL, 1984, SURV OPHTHALMOL, V28, P357; Neetens A, 1980, Bull Soc Belge Ophtalmol, V191, P29; PEYMAN GA, 1979, BRIT J OPHTHALMOL, V63, P771, DOI 10.1136/bjo.63.11.771; SCHOONDERWALDT HC, 1981, CLIN NEUROL NEUROSUR, V83, P153, DOI 10.1016/0303-8467(81)90017-2; SORSBY A, 1960, BRIT MED J, V1, P1394, DOI 10.1136/bmj.1.5183.1394; SORSBY A, 1962, VISION RES, V2, P309, DOI 10.1016/0042-6989(62)90039-1; SPAETH GL, 1967, PEDIATRICS, V40, P586; SPAETH GL, 1984, SURV OPHTHALMOL, V29, P230, DOI 10.1016/0039-6257(84)90213-3; Spaeth GL, 1996, J PEDIAT OPHTHALMOL, V3, P42; WALSH FB, 1969, CLIN NEUROOPHTHALMOL, V1, P782	34	46	47	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1037	1040						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898592				2022-12-28	WOS:A1996VP74200021
J	Takahashi, T; Forsythe, ID; Tsujimoto, T; BarnesDavies, M; Onodera, K				Takahashi, T; Forsythe, ID; Tsujimoto, T; BarnesDavies, M; Onodera, K			Presynaptic calcium current modulation by a metabotropic glutamate receptor	SCIENCE			English	Article							SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; TRANSMITTER RELEASE; RAT HIPPOCAMPUS; CHANNELS; SLICES; INFLUX; BRAIN; INHIBITION; SYNAPSES	Metabotropic glutamate receptors (mGluRs) regulate transmitter release at mammalian central synapses. However, because oi the difficulty of recording from mammalian presynaptic terminals, the mechanism underlying mGluR-mediated presynaptic inhibition is not known. Here, simultaneous recordings from a giant presynaptic terminal, the calyx of Held, and its postsynaptic target in the medial nucleus of the trapezoid body were obtained in rat brainstem slices. Agonists of mGluRs suppressed a high voltage-activated P/Q-type calcium conductance in the presynaptic terminal, thereby inhibiting transmitter release at this glutamatergic synapse. Because several forms of presynaptic modulation and plasticity are mediated by mGluRs, this identification of a target ion channel is a first step toward elucidation of their molecular mechanism.	UNIV LEICESTER,DEPT CELL PHYSIOL & PHARMACOL,ION CHANNEL GRP,LEICESTER LE1 9HN,LEICS,ENGLAND	University of Leicester	Takahashi, T (corresponding author), UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROPHYSIOL,TOKYO 113,JAPAN.		Takahashi, Tomoyuki/G-5951-2015	Takahashi, Tomoyuki/0000-0002-8771-7666	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; AUGUSTINE GJ, 1986, J PHYSIOL-LONDON, V381, P619, DOI 10.1113/jphysiol.1986.sp016347; BAMESDAVIES M, 1995, J PHYSIOL-LONDON, V488, P387; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; Borst JGG, 1995, J PHYSIOL-LONDON, V489, P825, DOI 10.1113/jphysiol.1995.sp021095; Dittman JS, 1996, J NEUROSCI, V16, P1623; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FORSYTHE ID, 1993, P ROY SOC B-BIOL SCI, V251, P143, DOI 10.1098/rspb.1993.0021; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; FORSYTHE ID, 1994, J PHYSIOL-LONDON, V479, P381, DOI 10.1113/jphysiol.1994.sp020303; FU WM, 1991, NEURON, V6, P837, DOI 10.1016/0896-6273(91)90179-4; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; HORI Y, 1996, J PHYSIOL-LONDON, V492, P967; KATZ B, 1967, J PHYSIOL-LONDON, V192, P407, DOI 10.1113/jphysiol.1967.sp008307; KAWAI N, 1980, J PHYSIOL-LONDON, V305, P73, DOI 10.1113/jphysiol.1980.sp013350; Kobayashi K, 1996, SCIENCE, V273, P648, DOI 10.1126/science.273.5275.648; LLANO I, 1995, J PHYSIOL-LONDON, V486, P163, DOI 10.1113/jphysiol.1995.sp020800; LOVINGER DM, 1993, J NEUROPHYSIOL, V69, P1236, DOI 10.1152/jn.1993.69.4.1236; MARTIN AR, 1963, J PHYSIOL-LONDON, V168, P443, DOI 10.1113/jphysiol.1963.sp007202; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402; PONCER JC, 1995, J PHYSIOL-LONDON, V485, P121, DOI 10.1113/jphysiol.1995.sp020717; SAHARA Y, 1993, J NEUROSCI, V13, P3041; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SIVARAMAKRISHNAN S, 1995, J NEUROSCI, V15, P6576; SLADECZEK F, 1993, P ROY SOC B-BIOL SCI, V253, P297, DOI 10.1098/rspb.1993.0117; STANLEY EF, 1991, J NEUROSCI, V11, P985; SWARTZ KJ, 1992, J NEUROSCI, V12, P458; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TAKAHASHI T, 1992, J PHYSIOL-LONDON, V446, pP549; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2; WU LG, 1995, J PHYSIOL-LONDON, V485, P649, DOI 10.1113/jphysiol.1995.sp020759; YAWO H, 1993, J PHYSIOL-LONDON, V460, P153, DOI 10.1113/jphysiol.1993.sp019464; Yokoi M, 1996, SCIENCE, V273, P645, DOI 10.1126/science.273.5275.645; YOSHINO M, 1995, BRAIN RES, V695, P179, DOI 10.1016/0006-8993(95)00743-A	39	333	337	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					594	597		10.1126/science.274.5287.594	http://dx.doi.org/10.1126/science.274.5287.594			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849448				2022-12-28	WOS:A1996VN91900046
J	Wingrove, JA; Gober, JW				Wingrove, JA; Gober, JW			Identification of an asymmetrically localized sensor histidine kinase responsible for temporally and spatially regulated transcription	SCIENCE			English	Article							CAULOBACTER-CRESCENTUS; BACTERIAL CHEMORECEPTOR; SIGNAL-TRANSDUCTION; FLAGELLAR GENES; CELL; PROTEIN; FLBD; ACTIVATOR; DIVISION; DIFFERENTIATION	Caulobacter crescentus undergoes asymmetric cell division, resulting in a stalked cell and a motile swarmer cell. The genes encoding external components of the flagellum are expressed in the swarmer compartment of the predivisional cell through the localized activation of the transcription factor FlbD. The mechanisms responsible for the temporal and spatial activation of FlbD were determined through identification of FlbE, a histidine kinase required for FlbD activity. FlbE is asymmetrically distributed in the predivisional cell. It is located at the pole of the stalked compartment and at the site of cell division in the swarmer compartment. These findings suggest that FlbE and FlbD are activated in response to a morphological change in the cell resulting from cell division events.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM-07104, GM48417] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BENSON AK, 1994, RES MICROBIOL, V145, P420, DOI 10.1016/0923-2508(94)90090-6; BENSON AK, 1994, P NATL ACAD SCI USA, V91, P4989, DOI 10.1073/pnas.91.11.4989; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CONTRERAS I, 1978, J BACTERIOL, V135, P1130, DOI 10.1128/JB.135.3.1130-1136.1978; DUNCAN L, 1995, SCIENCE, V270, P641, DOI 10.1126/science.270.5236.641; GOBER JW, 1992, MOL BIOL CELL, V3, P913, DOI 10.1091/mbc.3.8.913; GOBER JW, 1995, MICROBIOL REV, V59, P31, DOI 10.1128/MMBR.59.1.31-47.1995; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; Jenal U, 1996, EMBO J, V15, P2393, DOI 10.1002/j.1460-2075.1996.tb00597.x; KOSHLAND DE, 1951, J AM CHEM SOC, V74, P2286; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MADDOCK JR, 1993, SCIENCE, V259, P1717; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POINDEXTER JS, 1964, BACTERIOL REV, V28, P231, DOI 10.1128/MMBR.28.3.231-295.1964; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; RAMAKRISHNAN G, 1990, P NATL ACAD SCI USA, V87, P2369, DOI 10.1073/pnas.87.6.2369; RAMAKRISHNAN G, 1994, J BACTERIOL, V176, P7587, DOI 10.1128/JB.176.24.7587-7600.1994; SCHWEIZER HP, 1992, MOL MICROBIOL, V6, P1195, DOI 10.1111/j.1365-2958.1992.tb01558.x; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; WINGROVE JA, 1994, GENE DEV, V8, P1839, DOI 10.1101/gad.8.15.1839; WINGROVE JA, 1993, GENE DEV, V7, P1979, DOI 10.1101/gad.7.10.1979; WINGROVE JA, UNPUB; WU JG, 1995, J BACTERIOL, V177, P3241, DOI 10.1128/jb.177.11.3241-3250.1995	33	36	37	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					597	601		10.1126/science.274.5287.597	http://dx.doi.org/10.1126/science.274.5287.597			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849449				2022-12-28	WOS:A1996VN91900047
J	Siegel, JE; Weinstein, MC; Russell, LB; Gold, MR				Siegel, JE; Weinstein, MC; Russell, LB; Gold, MR			Recommendations for reporting cost-effectiveness analyses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH	Objective.-This article, the third in a 3-part series, describes recommendations for the reporting of cost-effective analyses (CEAs) intended to improve the quality and accessibility of CEA reports. Participants.-The Panel on Cost-Effectiveness in Health and Medicine, a nonfederal panel with expertise in CEA, clinical medicine, ethics, and health outcomes measurement, convened by the US Public Health Service. Evidence.-The panel reviewed the theoretical foundations of CEA, current practices, alternative methods, published critiques of CEAs, and criticisms of general CEA methods and reporting practices. Consensus Process.-The panel developed recommendations through 21/2 years of discussions. Comments on preliminary drafts were solicited from federal government methodologists, health agency officials, and academic methodologists. Conclusions.-These recommendations are proposed to enhance the transparency of study methods, assist analysts in providing complete information, and facilitate the presentation of comparable cost-effectiveness results across studies. Adherence to reporting conventions and attention to providing information required to understand and interpret study results will improve the relevance and accessibility of CEAs.	US PHS,OFF DIS PREVENT & HLTH PROMOT,WASHINGTON,DC 20201; HARVARD UNIV,SCH PUBL HLTH,DEPT MATERNAL & CHILD HLTH,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; RUTGERS STATE UNIV,INST HLTH HLTH CARE POLICY & AGING RES,NEW BRUNSWICK,NJ 08903	United States Public Health Service; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Rutgers State University New Brunswick								ADAMS ME, 1992, MED CARE, V30, P231, DOI 10.1097/00005650-199203000-00005; Canadian Coordinating Office for Health Technology Assessment, 1994, GUID EC EV PHARM CAN, V1st; CANTOR SB, 1994, MED DECIS MAKING, V14, P259, DOI 10.1177/0272989X9401400308; *COMM DEP HUM SERV, 1995, GUID PHARM IND PREP; Gold MR, 1996, COST EFFECTIVENESS H; Henry D, 1992, Pharmacoeconomics, V1, P54, DOI 10.2165/00019053-199201010-00010; MASON J, 1995, HEALTH ECON, V4, P85, DOI 10.1002/hec.4730040202; *OFF TECHN ASS, 1980, IMPL COST EFF AN MED; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SHEPARD DS, 1979, PUBLIC HEALTH REP, V94, P535; Torrance G W, 1972, Health Serv Res, V7, P118; Torrance GW, 1987, METHODS EC EVALUATIO; UDVARHELYI S, 1992, ANN INTERN MED, V116, P238; Weinstein M C, 1990, Int J Technol Assess Health Care, V6, P93; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; 1995, ANN INTERN MED, V122, P60	17	1259	1265	2	81	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1339	1341		10.1001/jama.276.16.1339	http://dx.doi.org/10.1001/jama.276.16.1339			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM825	8861994				2022-12-28	WOS:A1996VM82500038
J	Arnott, SJ; Cunningham, D; Gallagher, J; Gray, R; Hardcastle, J; Houghton, J; James, RD; Lennon, TA; Meadows, HM; Mossman, J; Northover, JMA; Morgan, DAL; Plowman, PN; Slevin, M				Arnott, SJ; Cunningham, D; Gallagher, J; Gray, R; Hardcastle, J; Houghton, J; James, RD; Lennon, TA; Meadows, HM; Mossman, J; Northover, JMA; Morgan, DAL; Plowman, PN; Slevin, M			Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin	LANCET			English	Article							SQUAMOUS-CELL CARCINOMA; CANAL CARCINOMA; RADIATION; CHEMOTHERAPY; THERAPY; MANAGEMENT; ANUS	Background Non-surgical management of anal cancer by radiotherapy alone or combined with chemotherapy has, in uncontrolled studies, yielded similar local tumour control and survival rates to surgery. However, whether the addition of chemotherapy improves outcome without adding to morbidity is not known. Our trial was designed to compare combined modality therapy (CMT) with radiotherapy alone in patients with epidermoid anal cancer. Methods From 856 patients considered for entry to our multicentre trial, 585 patients were randomised to receive initially either 45 Gy radiotherapy in twenty or twenty-five fractions over 4-5 weeks (290 patients) or the same regimen of radiotherapy combined with 5-fluorouracil (1000 mg/m(2) for 4 days or 750 mg/m(2) for 5 days) by continuous infusion during the first and the final weeks of radiotherapy and mitomycin (12 mg/m(2)) on day 1 of the first course (295 patients). We assessed clinical response 6 weeks after initial treatment: good responders were recommended for boost radiotherapy and poor responders for salvage surgery. The main endpoint was local-failure rate (greater than or equal to 6 weeks after initial treatment); secondary endpoints were overall and cause-specific survival. Analysis was by intention-to-treat. Findings In the radiotherapy and CMT arms, respectively, five and three were ineligible, and six and nine died 6 weeks after initial treatment. After a median follow-up of 42 months (interquartile range 28-62), 164 of 279 (59%) radiotherapy patients had a local failure compared with 101 of 283 (36%) CMT patients. This gave a 46% reduction in the risk of local failure in the patients receiving CMT (relative risk 0.54, 95% CI 0.42-0.69, p<0.0001). The risk of death from anal cancer was also reduced in the CMT arm (0.71, 0.53-0.95, p=0.02). There was no overall survival advantage (0.86, 0.67-1.11, p=0.25). Early morbidity was significantly more frequent in the CMT arm (p=0.03), but late morbidity occurred at similar rates. Interpretation Our trial shows that the standard treatment for most patients with epidermoid anal cancer should be a combination of radiotherapy and infused 5-fluorouracil and mitomycin, with surgery reserved for those who fail on this regimen.	ST MARKS HOSP,IMPERIAL CANC RES FUND,COLORECTAL CANC UNIT,HARROW HA1 3UJ,MIDDX,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON,ENGLAND; ROYAL MARSDEN HOSP,LONDON,ENGLAND; CRC,CLIN TRIALS CTR,LONDON,ENGLAND; CLIN TRIAL SERV UNIT,OXFORD,ENGLAND; UNIV NOTTINGHAM HOSP,NOTTINGHAM,ENGLAND; CHRISTIE HOSP,MANCHESTER,LANCS,ENGLAND; UKCCCR,LONDON,ENGLAND; CITY HOSP NOTTINGHAM,NOTTINGHAM,ENGLAND	Imperial College London; University of London; Queen Mary University London; Royal Marsden NHS Foundation Trust; University of Oxford; University of Nottingham; Christie NHS Foundation Trust; Christie Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital				Gray, Richard/0000-0003-4440-574X; Cunningham, David/0000-0001-5158-1069; Morgan, David/0000-0002-2291-1740				ALTMAN DG, 1995, BRIT J CANCER, V72, P511, DOI 10.1038/bjc.1995.364; BOMAN BM, 1984, CANCER-AM CANCER SOC, V54, P114, DOI 10.1002/1097-0142(19840701)54:1<114::AID-CNCR2820540124>3.0.CO;2-P; CORTESE AF, 1975, CANCER, V36, P1869, DOI 10.1002/1097-0142(197511)36:5<1869::AID-CNCR2820360544>3.0.CO;2-2; CUMMINGS B, 1984, CANCER-AM CANCER SOC, V54, P2062, DOI 10.1002/1097-0142(19841115)54:10<2062::AID-CNCR2820541004>3.0.CO;2-T; CUMMINGS BJ, 1993, INT J RADIAT ONCOL, V27, P173, DOI 10.1016/0360-3016(93)90436-Y; CUMMINGS BJ, 1982, CANCER TREAT REV, V9, P125, DOI 10.1016/S0305-7372(82)80013-3; DIXON WJ, 1985, BMDP STATISTICAL SOF; DOBROWSKY W, 1992, INT J RADIAT ONCOL, V22, P875, DOI 10.1016/0360-3016(92)90782-D; FLAM MS, 1995, P AN M AM SOC CLIN, V14, P191; GABRIEL W., 1940, PROC ROY SOC MED, V34, P139; GERARD JP, 1991, LYON CHIR, V87, P74; GREEN JP, 1980, AM J SURG, V140, P151, DOI 10.1016/0002-9610(80)90432-8; GREENALL MJ, 1985, SURG GYNECOL OBSTET, V161, P509; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; JAMES RD, 1985, BRIT J SURG, V72, P282, DOI 10.1002/bjs.1800720411; JENSEN S, 1987, DIS COLON RECTUM, V31, P273; MADDEN MV, 1981, BRIT J SURG, V68, P287, DOI 10.1002/bjs.1800680420; NIGRO N, 1974, DIS COLON RECTUM, V15, P354; NIGRO ND, 1983, CANCER, V51, P1826, DOI 10.1002/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L; NIGRO ND, 1984, DIS COLON RECTUM, V27, P763, DOI 10.1007/BF02553933; PAPILLON J, 1983, CANCER, V51, P1830, DOI 10.1002/1097-0142(19830515)51:10<1830::AID-CNCR2820511013>3.0.CO;2-Z; PAPILLON J, 1987, DIS COLON RECTUM, V30, P324, DOI 10.1007/BF02555448; PAPILLON J, 1982, RECTAL ANAL CANCERS; PINTOR MP, 1989, BRIT J SURG, V76, P806, DOI 10.1002/bjs.1800760814; RICH TA, 1993, RADIOTHER ONCOL, V27, P209, DOI 10.1016/0167-8140(93)90076-K; ROELOFSON F, 1955, P AM SOC CLIN ONCOL, V14, P194; SPIESSL B, 1985, UICC TNM ATLAS ILLUS; TANNOCK IF, 1989, RADIOTHER ONCOL, V16, P83, DOI 10.1016/0167-8140(89)90025-X	28	772	788	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1049	1054						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874455				2022-12-28	WOS:A1996VM88600008
J	Bhattacharya, S; Eckner, R; Grossman, S; Oldread, E; Arany, Z; DAndrea, A; Livingston, DM				Bhattacharya, S; Eckner, R; Grossman, S; Oldread, E; Arany, Z; DAndrea, A; Livingston, DM			Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; TRANSFORMATION; INHIBITION; REPRESSION; INDUCTION; PATHWAYS; ONCOGENE; PROMOTER	THE transcription factor ISGF3 transduces interferon (IFN)-alpha signals and activates the transcription of cellular antiviral defence genes(1,2). Adenovirus EIA blocks the IFN-alpha response, allowing unhindered viral replication(3-5). ISGF3 consists of Stat1, Stat2 and p48. Here we show that p300 and/or CBP (CREB-binding protein), which are transcription adaptors targeted by E1A, interact specifically with Stat2, Binding occurs between the first cysteine-histidine-rich region of p300/CBP and the carboxy terminal segment of Stat2, a domain essential for ISGF3 function(6). We find that this domain of Stat2 has transactivation potential, which correlates with its binding to p300/CBP, Moreover, E1A represses Stat2 transactivation and IFN-alpha-activated transcription by inhibiting p300/CBP function, This provides a new mechanism for inhibition of the IFN-alpha-activated antiviral response by ELA, and supports the view that E1A binding to p300/CBP has functional significance for adenovirus replication in its natural host.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Bhattacharya, Shoumo/F-4127-2010	Bhattacharya, Shoumo/0000-0002-5571-0478				ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BAYLEY ST, 1994, INT J ONCOL, V5, P425; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANDOLFO S, 1995, PHARMACOL THERAPEUT, V65, P415, DOI 10.1016/0163-7258(95)98599-L; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LUNDBLAD JR, 1995, NATURE, V374, P81; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459	29	406	414	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					344	347		10.1038/383344a0	http://dx.doi.org/10.1038/383344a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848048				2022-12-28	WOS:A1996VJ43900047
J	Yel, L; Minegishi, Y; CoustanSmith, E; Buckley, RH; Trubel, H; Pachman, LM; Kitchingman, GR; Campana, D; Rohrer, J; Conley, ME				Yel, L; Minegishi, Y; CoustanSmith, E; Buckley, RH; Trubel, H; Pachman, LM; Kitchingman, GR; Campana, D; Rohrer, J; Conley, ME			Mutations in the mu heavy-chain gene in patients with agammaglobulinemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; BRUTONS TYROSINE KINASE; SWITCH RECOMBINATION; B-LYMPHOCYTES; IMMUNOGLOBULIN; DNA; DEFICIENT; SEQUENCE; REGIONS; CELLS	Background Most patients with congenital hypogammaglobulinemia and absent B cells are males with X-linked agammaglobulinemia, which is caused by mutations in the gene for Bruton's tyrosine kinase (Btk); however, there are females with a similar disorder who do not have mutations in this gene. We studied two families with autosomal recessive defects in B-cell development and patients with presumed X-linked agammaglobulinemia who did not have mutations in Btk. Methods A series of candidate genes that encode proteins involved in B-cell signal-transduction pathways were analyzed by linkage studies and mutation screening. Results Four different mutations were identified in the mu heavy-chain gene on chromosome 14. In one family, there was a homozygous 75-to-100-kb deletion that included D-region genes, J-region genes, and the mu constant-region gene. In a second family, there was a homozygous base-pair substitution in the alternative splice site of the mu heavy-chain gene. This mutation would inhibit production of the membrane form of the mu chain and produce an amino acid substitution in the secreted form. In additions, a patient previously thought to have X-linked agammaglobulinemia was found to have an amino acid substitution on one chromosome at an invariant cysteine that is required for the intrachain disulfide bond and, on the other chromosome, a large deletion that included the immunoglobulin locus. Conclusions Defects in the mu heavy-chain gene are a cause of agammaglobulinemia in humans. This implies that an intact membrane-bound mu chain is essential for B-cell development. (C) 1996, Massachusetts Medical Society.	ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT VIROL, MEMPHIS, TN 38105 USA; DUKE UNIV, SCH MED, DEPT PEDIAT, DURHAM, NC USA; UNIV MAINZ, DEPT PEDIAT, D-6500 MAINZ, GERMANY; NORTHWESTERN UNIV, SCH MED, DEPT PEDIAT, CHICAGO, IL 60611 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Duke University; Johannes Gutenberg University of Mainz; Northwestern University; University of Tennessee System; University of Tennessee Health Science Center			Buckley, Rebecca/AAB-1578-2019; Pachman, Lauren/AAZ-6061-2021	Pachman, Lauren/0000-0001-8117-574X	NATIONAL CANCER INSTITUTE [R01CA058297, P01CA020180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI025129, R01AI025129] Funding Source: NIH RePORTER; NCI NIH HHS [CA58297, P01 CA20180] Funding Source: Medline; NIAID NIH HHS [AI25129] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BEALE D, 1976, Q REV BIOPHYS, V9, P135, DOI 10.1017/S0033583500002390; BENGER JC, 1989, AM J HUM GENET, V45, P606; BENGER JC, 1991, GENOMICS, V9, P614, DOI 10.1016/0888-7543(91)90354-H; BORZILLO GV, 1987, J IMMUNOL, V139, P1326; BORZILLO GV, 1988, J IMMUNOL, V141, P3625; BRADLEY LAD, 1994, HUM MOL GENET, V3, P79, DOI 10.1093/hmg/3.1.79; BUBB MO, 1978, IMMUNOLOGY, V34, P449; Burrows P D, 1990, Semin Immunol, V2, P189; CAMPANA D, 1990, J IMMUNOL, V145, P1675; CARTER M, 1991, LEUKEMIA, V5, P668; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; CONLEY ME, 1985, J IMMUNOL, V134, P3070; CONLEY ME, 1992, J CLIN IMMUNOL, V12, P139, DOI 10.1007/BF00918144; CONLEY ME, 1994, HUM MOL GENET, V3, P1751, DOI 10.1093/hmg/3.10.1751; DELAMORENA M, 1995, EUR J IMMUNOL, V25, P809, DOI 10.1002/eji.1830250327; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; FRIEDLANDER RM, 1990, NUCLEIC ACIDS RES, V18, P4278, DOI 10.1093/nar/18.14.4278; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HA HJ, 1994, J IMMUNOL, V152, P5749; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HOFFMAN T, 1977, CLIN IMMUNOL IMMUNOP, V7, P364, DOI 10.1016/0090-1229(77)90070-8; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; JIN H, 1995, HUM MOL GENET, V4, P693, DOI 10.1093/hmg/4.4.693; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KU G, 1994, IMMUNOGENETICS, V40, P300, DOI 10.1007/BF00189976; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; MIGONE N, 1983, P NATL ACAD SCI-BIOL, V80, P467, DOI 10.1073/pnas.80.2.467; MILATOVICH A, 1994, MAMM GENOME, V5, P211, DOI 10.1007/BF00360547; NAGAOKA H, 1994, GENOMICS, V22, P189, DOI 10.1006/geno.1994.1360; PUTNAM FW, 1973, SCIENCE, V182, P287, DOI 10.1126/science.182.4109.287; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Satterthwaite A, 1996, ANNU REV IMMUNOL, V14, P131, DOI 10.1146/annurev.immunol.14.1.131; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V364, P362, DOI 10.1038/364362a0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VORECHOVSKY I, 1995, HUM MOL GENET, V4, P51, DOI 10.1093/hmg/4.1.51; WICKER LS, 1986, CURR TOP MICROBIOL, V124, P87	44	169	178	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1486	1493		10.1056/NEJM199611143352003	http://dx.doi.org/10.1056/NEJM199611143352003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT340	8890099				2022-12-28	WOS:A1996VT34000003
J	EmmertBuck, MR; Bonner, RF; Smith, PD; Chuaqui, RF; Zhuang, ZP; Goldstein, SR; Weiss, RA; Liotta, LA				EmmertBuck, MR; Bonner, RF; Smith, PD; Chuaqui, RF; Zhuang, ZP; Goldstein, SR; Weiss, RA; Liotta, LA			Laser capture microdissection	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; GENE-EXPRESSION; CLONAL ANALYSIS; ALLELIC LOSS; BREAST; CARCINOMAS; LESIONS; TISSUE	Laser capture microdissection (LCM) under direct microscopic visualization permits rapid one-step procurement of selected human cell populations from a section of complex, heterogeneous tissue. In this technique, a transparent thermoplastic film (ethylene vinyl acetate polymer) is applied to the surface of the tissue section on a standard glass histopathology slide; a carbon dioxide laser pulse then specifically activates the film above the cells of interest. Strong focal adhesion allows selective procurement of the targeted cells. Multiple examples of LCM transfer and tissue analysis, including polymerase chain reaction amplification of DNA and RNA, and enzyme recovery from transferred tissue are demonstrated.	NCI,PATHOL LAB,BETHESDA,MD 20892; NIH,BIOMED ENGN & INSTRUMENTAT PROGRAM,NATL CTR RES RESOURCES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA			Bonner, Robert F/C-6783-2015; Bonner, Robert/GQO-9087-2022					Abbott A, 1996, NATURE, V379, P392; BONNER RF, UNPUB; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; MCNEAL JE, 1986, HUM PATHOL, V17, P64, DOI 10.1016/S0046-8177(86)80156-3; MEYERS SM, 1983, OPHTHALMOLOGY, V90, P563; NOGUCHI S, 1994, CANCER RES, V54, P1849; NOWAK R, 1995, SCIENCE, V270, P368, DOI 10.1126/science.270.5235.368; OCONNELL P, 1994, BREAST CANCER RES TR, V32, P5, DOI 10.1007/BF00666201; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; PARK TW, 1995, CANCER RES, V55, P4793; RADFORD DM, 1993, CANCER RES, V53, P2947; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHIBATA D, 1992, AM J PATHOL, V141, P539; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WALSH JT, 1988, LASER SURG MED, V8, P108, DOI 10.1002/lsm.1900080204; ZHUANG ZP, 1995, CANCER RES, V55, P467; ZHUANG ZP, 1995, AM J PATHOL, V146, P620	20	1934	2099	7	188	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					998	1001		10.1126/science.274.5289.998	http://dx.doi.org/10.1126/science.274.5289.998			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875945				2022-12-28	WOS:A1996VR79200054
J	Sanguinetti, MC; Curran, ME; Zou, A; Shen, J; Spector, PS; Atkinson, DL; Keating, MT				Sanguinetti, MC; Curran, ME; Zou, A; Shen, J; Spector, PS; Atkinson, DL; Keating, MT			Coassembly of K(v)LQT1 and minK (IsK) proteins to form cardiac I-Ks potassium channel	NATURE			English	Article							DEPENDENT OUTWARD CURRENT; PIG VENTRICULAR MYOCYTES; GUINEA-PIG; DELAYED RECTIFIER; K+; MUTATIONS; ARRHYTHMIA; BLOCK	THE slowly activating delayed-rectifier K+ current, I-Ks, modulates the repolarization or cardiac action potentials. The molecular structure of the I-Ks, channel is not known, but physiological data indicate that one component of the I-Ks channel is minK (refs 1-6), a 130-amino-acid protein with a single putative transmembrane domain(7). The size and structure of this protein is such that it is unlikely that minK alone forms functional channels(8,9). We have previously used positional cloning techniques to define a new putative K+-channel gene, KVLQT1(10). Mutations in this gene cause long-QT syndrome, an inherited disorder that increases the risk of sudden death from cardiac arrhythmias. Here se show that KVLQT1 encodes a K+ channel with biophysical properties unlike other known cardiac currents. We considered that K(v)LQT1 might coassemble with another subunit to form functional channels in cardiac myocytes. Coexpression of K(v)LQT1 with minK induced a current that was almost identical to cardiac I-Ks. Therefore, K(v)LQT1 is the subunit that coassembles with minK to form I-Ks channels and I-Ks dysfunction is a cause of cardiac arrhythmia.	UNIV UTAH,ECCLES PROGRAM HUMAN MOL BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Sanguinetti, MC (corresponding author), UNIV UTAH,DEPT MED,DIV CARDIOL,SALT LAKE CITY,UT 84112, USA.		Sanguinetti, Michael/AAN-2615-2020					ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; BALSER JR, 1990, J GEN PHYSIOL, V96, P835, DOI 10.1085/jgp.96.4.835; BALSER JR, 1991, CIRC RES, V69, P519, DOI 10.1161/01.RES.69.2.519; BUSCH AE, 1992, SCIENCE, V255, P1705, DOI 10.1126/science.1553557; CUI J, 1994, J GEN PHYSIOL, V104, P87, DOI 10.1085/jgp.104.1.87; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HAUSDORFF SF, 1991, BIOCHEMISTRY-US, V30, P3341, DOI 10.1021/bi00227a025; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; Li GR, 1996, CIRC RES, V78, P689, DOI 10.1161/01.RES.78.4.689; MATSUURA H, 1987, PFLUG ARCH EUR J PHY, V410, P596, DOI 10.1007/BF00581319; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17	22	1409	1465	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					80	83		10.1038/384080a0	http://dx.doi.org/10.1038/384080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900283				2022-12-28	WOS:A1996VR21900059
J	Delbanco, TL; Baughman, RD				Delbanco, TL; Baughman, RD			A 61-year-old man with psoriasis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PALMOPLANTAR PUSTULOSIS; METHOTREXATE THERAPY; CYCLOSPORINE		DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, HANOVER, NH 03756 USA	Dartmouth College								ABEL EA, 1986, J AM ACAD DERMATOL, V15, P1007, DOI 10.1016/S0190-9622(86)70265-X; ABEL EA, 1990, INT J DERMATOL, V29, P640, DOI 10.1111/j.1365-4362.1990.tb02586.x; BAUGHMAN R, 1971, ARCH DERMATOL, V103, P599, DOI 10.1001/archderm.103.6.599; CHRISTENSENSZALANSKI JJJ, 1984, MED DECIS MAKING, V4, P47, DOI 10.1177/0272989X8400400108; ELDER JT, 1994, ARCH DERMATOL, V130, P216, DOI 10.1001/archderm.130.2.216; ESGLEYESRIBOT T, 1994, J AM ACAD DERMATOL, V30, P581, DOI 10.1016/S0190-9622(94)70066-4; FARBER EM, 1994, CUTIS, V53, P21; GINSBURG IH, 1989, J AM ACAD DERMATOL, V20, P53, DOI 10.1016/S0190-9622(89)70007-4; Ginsburg IH, 1996, CUTIS, V57, P323; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; Grossman RM, 1996, ARCH DERMATOL, V132, P623, DOI 10.1001/archderm.132.6.623; Gupta MA, 1996, J AM ACAD DERMATOL, V34, P1030, DOI 10.1016/S0190-9622(96)90284-4; JEFFES EWB, 1995, J INVEST DERMATOL, V104, P183, DOI 10.1111/1523-1747.ep12612745; JEGASOTHY BV, 1992, ARCH DERMATOL, V128, P781, DOI 10.1001/archderm.128.6.781; KRAGBALLE K, 1989, ARCH DERMATOL, V125, P1647, DOI 10.1001/archderm.125.12.1647; LEUNG DYM, 1995, J INVEST DERMATOL, V105, pS37, DOI 10.1111/1523-1747.ep12315250; MARTIN MF, 1994, MAYO CLIN PROC, V69, P191, DOI 10.1016/S0025-6196(12)61049-0; OCONNOR GT, 1989, ARCH DERMATOL, V125, P1209, DOI 10.1001/archderm.125.9.1209; ODOHERTY CJ, 1985, BRIT MED J, V291, P861, DOI 10.1136/bmj.291.6499.861; PARRISH JA, 1974, NEW ENGL J MED, V291, P1207, DOI 10.1056/NEJM197412052912301; Rappersberger K, 1996, J INVEST DERMATOL, V106, P701, DOI 10.1111/1523-1747.ep12345542; REITAMO S, 1993, ARCH DERMATOL, V129, P1273, DOI 10.1001/archderm.129.10.1273; ROENIGK HH, 1988, J AM ACAD DERMATOL, V19, P145, DOI 10.1016/S0190-9622(88)80237-8; SANDER HM, 1993, J AM ACAD DERMATOL, V28, P422, DOI 10.1016/0190-9622(93)70062-X; Smith JB, 1996, J AM ACAD DERMATOL, V34, P717; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; STERN RS, 1994, CANCER-AM CANCER SOC, V73, P2759, DOI 10.1002/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; Weinstein GD, 1996, J INVEST DERMATOL, V106, P589, DOI 10.1111/1523-1747.ep12345035; WEINSTEIN GD, 1993, THERAPY MODERATE SEV; WENTZELL JM, 1987, ARCH DERMATOL, V123, P163, DOI 10.1001/archderm.123.2.163; WHYTE HJ, 1964, ARCH DERMATOL, V89, P350, DOI 10.1001/archderm.1964.01590270036008; Zachariae R, 1996, J AM ACAD DERMATOL, V34, P1008, DOI 10.1016/S0190-9622(96)90280-7; ZUG KA, 1995, ARCH DERMATOL, V131, P561, DOI 10.1001/archderm.131.5.561	34	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1421	1428						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892718				2022-12-28	WOS:A1996VQ46400029
J	Gallinari, P; Jiricny, J				Gallinari, P; Jiricny, J			A new class of uracil-DNA glycosylases related to human thymine-DNA glycosylase	NATURE			English	Article							ESCHERICHIA-COLI; NUCLEAR EXTRACTS; G.T MISPAIRS; HUMAN-CELLS; HELA-CELLS; INSECTS; DROSOPHILA; MUTATIONS; REPAIR; GENE	MISPAIRS in DNA of guanine with uracil and thymine can arise as a result of deamination of cytosine and 5-methylcytosine, respectively. In humans such mispairs are removed by thymine-DNA glycosylase (TDG)(1-3). By deleting the carboxy and amino termini of this enzyme we have identified a core region capable of processing G/U but not G/T mispairs. We have further identified two bacterial proteins with strong sequence homology to this core and shown that the homologue from Escherichia coli (dsUDG) can remove uracil from G/U mispairs. This enzyme is likely to act as a back-up to the highly efficient and abundant enzyme uracil-DNA glycosylase (UDG) which is found in most organisms. Pupating insects have been reported to lack UDG activity(4), but we have identified an enzyme similar to dsUDG in cell lines from three different insect species. These data imply the existence of a family of double-strand-specific uracil-DNA glycosylases which, although they are subservient to UDG in mast organisms, may constitute the first line of defence against the mutagenic effects of cytosine deamination in insects.	IST RIC BIOL MOL P ANGELETTI,I-00040 POMEZIA,ITALY	Merck & Company			Gallinari, Paola/ABE-8238-2021					AUSUBEL FM, 1995, CURR PROT MOL BIOL; Deutsch W. A., 1995, Insect Molecular Biology, V4, P1, DOI 10.1111/j.1365-2583.1995.tb00001.x; DUDLEY B, 1992, J BIOL CHEM, V267, P11964; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; DUNCAN BK, 1985, J BACTERIOL, V164, P689, DOI 10.1128/JB.164.2.689-695.1985; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORGAN AR, 1989, J BIOL CHEM, V264, P9911; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Sawa R., 1995, NATURE, V373, P487; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; TOMLIN NV, 1989, INT REV CYTOL, P125; VARSHNEY U, 1989, NUCLEIC ACIDS RES, V17, P813, DOI 10.1093/nar/17.2.813; WANG Z, 1989, J BIOL CHEM, V264, P1163; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	18	179	182	2	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					735	738		10.1038/383735a0	http://dx.doi.org/10.1038/383735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878487				2022-12-28	WOS:A1996VN91800059
J	Gilbert, MJ; Riddell, SR; Plachter, B; Greenberg, PD				Gilbert, MJ; Riddell, SR; Plachter, B; Greenberg, PD			Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product	NATURE			English	Article							CYTOTOXIC T-LYMPHOCYTES; KINASE-ACTIVITY; INFECTED-CELLS; PROTEIN PP65; VIRUS; EXPRESSION; CHAINS; IDENTIFICATION; TRANSCRIPTION; MOLECULES	RECOGNITION of virus-infected cells by CD8(+) cytotoxic T lymphocytes requires that the viral proteins be processed into peptides, the derived peptides transported into the endoplasmic reticulum and inserted into the binding groove of a major histocompatability complex class I molecule, and the antigenic complex exported to the cell surface(1). However, viral pathogens can disrupt this process and interfere with immune recognition(1-4). These mechanisms may be vital to large viruses such as human cytomegalovirus (CMV), which causes persistent infection despite producing over 200 potentially antigenic proteins during the sequential immediate-early, early and late phases of viral gene expression(5,6). Products of CMV early-phase gene expression can globally block class I presentation(7-10) and prevent recognition of infected cells by cytotoxic T lymphocytes, but an essential viral transcription factor, the 72K principal immediate-early protein, is abundantly expressed before this blockade. However, only a few host CD8(+) cytotoxic T lymphocytes specific for immediate-early protein are present in seropositive individuals, and these lyse CMV-infected cells poorly(11). Here we demonstrate selective abrogation of immediate-early peptide presentation by a CMV matrix protein with associated kinase activity and suggest that modification of a viral protein can result in limiting access to the processing machinery and evasion of cytotoxic-T-cell recognition.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98104; UNIV ERLANGEN NURNBERG,INST KLIN & MOL VIROL,D-91054 ERLANGEN,GERMANY	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Erlangen Nuremberg	Gilbert, MJ (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; BRITT WJ, 1986, J VIROL, V59, P185, DOI 10.1128/JVI.59.1.185-188.1986; DEMARCHI JM, 1980, J VIROL, V35, P277, DOI 10.1128/JVI.35.2.277-286.1980; FALK K, 1993, IMMUNOGENETICS, V38, P161, DOI 10.1007/BF00190906; GAVIN MA, 1993, J IMMUNOL, V151, P3971; GILBERT MJ, 1993, J VIROL, V67, P3461, DOI 10.1128/JVI.67.6.3461-3469.1993; GOODING LR, 1992, CELL, V71, P5; JAHN G, 1987, J GEN VIROL, V68, P1327, DOI 10.1099/0022-1317-68-5-1327; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; MACH M, 1989, J GEN VIROL, V70, P3117, DOI 10.1099/0022-1317-70-12-3117; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; MCLAUGHLINTAYLOR E, 1994, J MED VIROL, V43, P103, DOI 10.1002/jmv.1890430119; MURRAY N, 1992, CURR OPIN IMMUNOL, V4, P401, DOI 10.1016/S0952-7915(06)80030-0; PARKER KC, 1994, J IMMUNOL, V152, P163; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; RIDDELL SR, 1991, J IMMUNOL, V146, P2795; RUGER B, 1987, J VIROL, V61, P446; SCHMOLKE S, 1995, J VIROL, V69, P5959, DOI 10.1128/JVI.69.10.5959-5968.1995; SCHMOLKE S, 1995, J VIROL, V69, P1071, DOI 10.1128/JVI.69.2.1071-1078.1995; SOMOGYI T, 1990, VIROLOGY, V174, P276, DOI 10.1016/0042-6822(90)90075-3; STENBERG RM, 1990, J VIROL, V64, P1556, DOI 10.1128/JVI.64.4.1556-1565.1990; STINSKI MF, 1983, J VIROL, V46, P1; STINSKI MF, 1978, J VIROL, V26, P686, DOI 10.1128/JVI.26.3.686-701.1978; WARREN AP, 1994, J VIROL, V68, P2822, DOI 10.1128/JVI.68.5.2822-2829.1994; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	26	221	230	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					720	722		10.1038/383720a0	http://dx.doi.org/10.1038/383720a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878482				2022-12-28	WOS:A1996VN91800054
J	Mann, RS; AbuShaar, M				Mann, RS; AbuShaar, M			Nuclear import of the homeodomain protein Extradenticle in response to Wg and Dpp signalling	NATURE			English	Article							HOMEOTIC GENE-EXPRESSION; VISCERAL MESODERM; DROSOPHILA EMBRYOS; PATTERN-FORMATION; LIMB DEVELOPMENT; DISTAL-LESS; GERM LAYERS; MIDGUT; ULTRABITHORAX; WINGLESS	IN Drosophila, Decapentaplegic (Dpp)(1) and Wingless (Wg)(2) are two secreted signalling proteins of the transforming growth factor (TGF)-beta and Wnt families, respectively. Although both are often required during development, only a few downstream components of these signalling pathways have been described. Here we present evidence that in the embryonic midgut both signalling pathways control the subcellular localization of the homeodomain protein encoded by the extradenticle (exd) gene. Exd protein is predominantly nuclear in endoderm cells close to Dpp- and Wg-secreting cells of the, visceral mesoderm, but is in the cytoplasm in more distant endoderm cells. Both dpp and log are required for the nuclear localization of Exd in the endoderm.	COLUMBIA UNIV,COLL PHYS & SURG,INTEGRATED PROGRAM CELLULAR MOL & BIOPHYS STUDIES,NEW YORK,NY 10032	Columbia University	Mann, RS (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOL BIOPHYS,630 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058575] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHAN SK, 1996, EMBO J, V15, P2477; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; GELBART WM, 1989, DEVELOPMENT, V107, P65; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GRILLI M, 1993, INT REV CYTOL, V143, P1; HOFFMANN FM, 1987, GENE DEV, V1, P615, DOI 10.1101/gad.1.6.615; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; LEE KJ, 1991, EMBO J, V10, P817, DOI 10.1002/j.1460-2075.1991.tb08014.x; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; Poulson D. F., 1950, BIOL DROSOPHILA; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1; REUTER R, 1990, DEVELOPMENT, V110, P1031; RUSHLOW C, 1992, BIOESSAYS, V14, P89, DOI 10.1002/bies.950140204; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TEPASS U, 1994, DEVELOPMENT, V120, P579; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; XU T, 1993, DEVELOPMENT, V117, P1223	30	109	109	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					630	633		10.1038/383630a0	http://dx.doi.org/10.1038/383630a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857540				2022-12-28	WOS:A1996VM75500056
J	Basu, S; Senior, R; Dore, C; Lahiri, A				Basu, S; Senior, R; Dore, C; Lahiri, A			Value of thallium-201 imaging in detecting adverse cardiac events after myocardial infarction and thrombolysis: A follow up of 100 consecutive patients	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROGNOSTIC VALUE; JEOPARDIZED MYOCARDIUM; RISK STRATIFICATION; SCINTIGRAPHY; TETROFOSMIN; ANGIOGRAPHY; THERAPY; TRIAL; SOON	Objective-To determine the prognostic role of thallium-201 imaging compared with that of exercise electrocardiography in patients with acute myocardial infarction treated by thrombolysis. Design-Patients who remained free of adverse cardiac events six weeks after myocardial infarction had stress and rest Tl-201 imaging and exercise electrocardiography and were followed up for 8-32 months. Adverse cardiac events (death, reinfarction, unstable angina, and congestive heart failure) were documented. Setting-Large district general hospital, Middlesex. Subjects-100 consecutive male and female patients who were stable six weeks after thrombolysis for myocardial infarction. Main outcome measures-Prediction of occurrence of adverse cardiac events after myocardial infarction by exercise cardiography and Tl-201 myocardial perfusion imaging. Results-Reversible ischaemia on Tl-201 imaging predicted adverse cardiac events in 33 out of 37 patients with such events during follow up (hazard ratio 8.1 (95% confidence interval 2.7 to 23.8), P<0.001). Exercise electrocardiography showed reversible ischaemia in 33 patients, of whom 13 had subsequent events, and failed to predict events in 24 patients (hazard ratio 1.1 (0.56 to 2.2), P = 0.8). Conclusion-Tl-201 imaging is a sensitive predictor of subsequent adverse cardiac events in patients who have received thrombolysis after acute myocardial infarction, whereas exercise electrocardiography fails to predict outcome.	NORTHWICK PK HOSP & CLIN RES CTR, DEPT CARDIAC RES, HARROW HA1 3UJ, MIDDX, ENGLAND; INST MED RES, HARROW HA1 3UJ, MIDDX, ENGLAND; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, MED STAT UNIT, LONDON, ENGLAND	Imperial College London; MRC National Institute for Medical Research; Imperial College London			Dore, Caroline J/J-4716-2012	Dore, Caroline J/0000-0001-9796-4970				[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; BASU S, 1993, BRIT HEART J, V69, P61; BROWN KA, 1990, AM J CARDIOL, V65, P160, DOI 10.1016/0002-9149(90)90078-F; DAVIDSON DM, 1980, CIRCULATION, V61, P236, DOI 10.1161/01.CIR.61.2.236; ELLESTAD MH, 1969, CIRCULATION, V39, P517, DOI 10.1161/01.CIR.39.4.517; FEIT F, 1990, J AM COLL CARDIOL, V16, P1529, DOI 10.1016/0735-1097(90)90295-Z; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; GIBSON RS, 1981, AM J CARDIOL, V47, P1010, DOI 10.1016/0002-9149(81)90206-X; HUNG J, 1984, AM J CARDIOL, V53, P1221, DOI 10.1016/0002-9149(84)90068-7; JAIN A, 1990, AM J CARDIOL, V66, P551, DOI 10.1016/0002-9149(90)90480-O; JAIN D, 1990, AM J CARDIOL, V65, P154, DOI 10.1016/0002-9149(90)90077-E; LEPPO JA, 1984, NEW ENGL J MED, V310, P1014, DOI 10.1056/NEJM198404193101603; McMurray J., 1993, European Heart Journal, V14, P133; NORRIS RM, 1970, LANCET, V2, P485; PEEL AAF, 1962, BRIT HEART J, V24, P745; SCHELBERT HR, 1976, AM J CARDIOL, V38, P407, DOI 10.1016/0002-9149(76)90455-0; SENIOR R, 1995, BRIT HEART J, V74, P358; SENIOR R, 1995, J NUCL CARDIOL, V2, P296, DOI 10.1016/S1071-3581(05)80073-X; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; SRIDHARA B, 1994, J NUCL CARDIOL, V1, P138, DOI 10.1007/BF02984085; STARLING MR, 1980, AM J CARDIOL, V46, P909, DOI 10.1016/0002-9149(80)90344-6; STEVENSON R, 1993, BRIT HEART J, V70, P415; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; TILKEMEIER PL, 1990, AM J CARDIOL, V66, P1203, DOI 10.1016/0002-9149(90)91100-K; TURNER JD, 1980, CIRCULATION, V61, P729, DOI 10.1161/01.CIR.61.4.729; WELD FM, 1981, CIRCULATION, V64, P306, DOI 10.1161/01.CIR.64.2.306; ZARET BL, 1995, CIRCULATION, V91, P313, DOI 10.1161/01.CIR.91.2.313; 1993, LANCET, V339, P753	29	26	26	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	1996	313	7061					844	848						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870569				2022-12-28	WOS:A1996VL55900019
J	Jorm, CM; Stamford, JA; Strunin, L				Jorm, CM; Stamford, JA; Strunin, L			Doctor in the lab: What is it Like for a doctor to work with scientists?	BRITISH MEDICAL JOURNAL			English	Article								As clinical academic medical departments strive to improve the quality of their research, clinicians and scientists are forced into closer liaison. In many cases, clinical departments now have research laboratories directed by ''basic scientists'' but often staffed, in part at least, by doctors. To someone who has not worked in one, these laboratories may seem uncompromising and forbidding work environments. This article presents a ''case report'' written from the viewpoints of the doctor, the scientist, and the professor.	ROYAL LONDON HOSP,ANAESTHET UNIT,LONDON HOSP,COLL MED,LONDON E1 1BB,ENGLAND	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London									0	1	1	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					867	869						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870579				2022-12-28	WOS:A1996VL55900031
J	Sonke, GS; Beaglehole, R; Stewart, AW; Jackson, R; Stewart, FM				Sonke, GS; Beaglehole, R; Stewart, AW; Jackson, R; Stewart, FM			Sex differences in case fatality before and after admission to hospital after acute cardiac events: Analysis of community based coronary heart disease register	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; MORTALITY; PROGNOSIS; COUNTRIES; GENDER; WOMEN	Objective-To determine whether the reported higher case fatality in hospital after an acute cardiac event in women can be explained by sex differences in mortality before admission and in baseline risk factors. Design-Analyses of data from a community based coronary heart disease register. Setting-Auckland region, New Zealand. Subjects-5106 patients aged 25-64 years with an acute cardiac event leading to coronary death or definite myocardial infarction within 28 days of onset, occurring between 1986 and 1992. Main outcome measures-Case fatality before admission, 28 day case fatality for patients in hospital, and total case fatality after an acute cardiac event. Results-Despite a more unfavourable risk profile women tended to have lower case fatality before admission than men (crude odds ratio 0.88; 95% confidence interval 0.75 to 1.02). Adjustment for age, Living arrangements, smoking, medical history, and treatment increased the effect of sex (0.72; 0.60 to 0.86). After admission to hospital, women had a higher case fatality than men (1.76; 1.43 to 2.17), but after adjustment for confounders this was reduced to 1.18 (0.89 to 1.58). Total case fatality 28 days after an acute cardiac event showed no significant difference between men and women (0.85; 0.70 to 1.02). Conclusions-The higher case fatality after an acute cardiac event in women admitted to hospital is largely explained by differences in Living status, history, and medical treatment and is balanced by a lower case fatality before admission.	UNIV AUCKLAND,FAC MED & HLTH SCI,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND; AUCKLAND HOSP,DEPT MED,AUCKLAND,NEW ZEALAND	University of Auckland; Auckland City Hospital				Sonke, Gabe/0000-0001-8088-9628; Jackson, Rod/0000-0001-5914-6934				Brett Kate M., 1995, Annals of Epidemiology, V5, P25, DOI 10.1016/1047-2797(94)00037-T; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; DEMIROVIC J, 1995, AM J CARDIOL, V75, P1096, DOI 10.1016/S0002-9149(99)80737-1; JACKSON R, 1990, INT J EPIDEMIOL, V19, P279, DOI 10.1093/ije/19.2.279; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KARLSON BW, 1994, AM HEART J, V128, P477, DOI 10.1016/0002-8703(94)90620-3; LOWEL H, 1993, CIRCULATION, V88, P2524, DOI 10.1161/01.CIR.88.6.2524; MARRUGAT J, 1994, J CLIN EPIDEMIOL, V47, P111, DOI 10.1016/0895-4356(94)90016-7; Moser D K, 1993, Prog Cardiovasc Nurs, V8, P6; Prineas R., 1982, MINNESOTA CODE MANUA; *SAS I, 1994, SAS SOFTW REL 6 10; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; WILKINSON P, 1994, BRIT MED J, V309, P566, DOI 10.1136/bmj.309.6954.566	14	70	72	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					853	855						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870571				2022-12-28	WOS:A1996VL55900021
J	DeCock, KM; Binkin, NJ; Zuber, PLF; Tappero, JW; Castro, KG				DeCock, KM; Binkin, NJ; Zuber, PLF; Tappero, JW; Castro, KG			Research issues involving HIV-associated tuberculosis in resource-poor countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; CALMETTE-GUERIN IMMUNIZATION; DIRECTLY OBSERVED THERAPY; PULMONARY TUBERCULOSIS; COTE-DIVOIRE; MYCOBACTERIUM-TUBERCULOSIS; INFECTED PATIENTS; ANTITUBERCULOSIS DRUGS; ACTIVE TUBERCULOSIS	Each year, there are an estimated 8 million new cases of tuberculosis (TB) and 3 million deaths due to TB, most of which occur in resource-poor countries. Tuberculosis incidence is increasing rapidly in countries with high rates of human immunodeficiency virus (HIV) infection, and despite the availability of effective interventions, many TB programs are failing to cope with the increased TB caseload. This report highlights gaps in current understanding of the interaction between TB and HIV that contribute to failure of optimal TB management and control; we focus on the diagnosis of TB, its epidemiology and transmission, preventive strategies, and programmatic issues in the integration of HIV and TB services. Research into how best to apply existing knowledge will be at least as important as searching for new knowledge, The global control of TB will also require increased resources, greater political commitment, and stronger international public health leadership.	CTR DIS CONTROL & PREVENT, NATL CTR HIV STD TB PREVENT, DIV TB ELIMINATION, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA	DeCock, KM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				ABOUYA L, 1995, TUBERCLE LUNG DIS, V76, P436, DOI 10.1016/0962-8479(95)90011-X; ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; BARRY M, 1988, NEW ENGL J MED, V319, P1083, DOI 10.1056/NEJM198810203191609; BAYER R, 1995, LANCET, V345, P1545, DOI 10.1016/S0140-6736(95)91090-5; BESNARD M, 1993, PEDIATR INFECT DIS J, V12, P993, DOI 10.1097/00006454-199312000-00006; BRAUN MM, 1992, AIDS, V6, P1327, DOI 10.1097/00002030-199211000-00014; BRAUN MM, 1992, PEDIATR INFECT DIS J, V11, P220, DOI 10.1097/00006454-199203000-00010; BRINDLE RJ, 1993, AIDS, V7, P1469, DOI 10.1097/00002030-199311000-00010; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Cantwell MF, 1996, TUBERCLE LUNG DIS, V77, P220, DOI 10.1016/S0962-8479(96)90004-0; CANTWELL MF, IN PRESS TUBER LUNG; CASTRO KG, 1993, INFECT CONT HOSP EP, V14, P65, DOI 10.2307/30147162; CHINTU C, 1993, PEDIATR INFECT DIS J, V12, P499, DOI 10.1097/00006454-199306000-00008; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1995, LANCET, V346, P675, DOI 10.1016/S0140-6736(95)92284-9; DECOCK KM, 1994, JAMA-J AM MED ASSOC, V272, P481, DOI 10.1001/jama.272.6.481; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DECOCK KM, 1995, LANCET, V345, P873, DOI 10.1016/S0140-6736(95)90003-9; DECOCK KM, 1995, LANCET, V345, P833, DOI 10.1016/S0140-6736(95)92967-3; DIPERRI G, 1993, INFECT CONT HOSP EP, V14, P67, DOI 10.2307/30147163; DIPERRI G, 1989, LANCET, V2, P1502; ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1; ELLIOTT AM, 1993, TUBERCLE LUNG DIS, V74, P191, DOI 10.1016/0962-8479(93)90010-U; ENARSON DA, 1994, TUBERCULOSIS GUIDE L; FINE PEM, 1995, CLIN INFECT DIS, V20, P11, DOI 10.1093/clinids/20.1.11; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GANGADHARAM PRJ, 1994, TUBERCLE LUNG DIS, V75, P241, DOI 10.1016/0962-8479(94)90127-9; GEBRE N, 1995, T ROY SOC TROP MED H, V89, P191, DOI 10.1016/0035-9203(95)90491-3; GITHUI W, 1992, TUBERCLE LUNG DIS, V73, P203, DOI 10.1016/0962-8479(92)90087-Z; GREENBERG AE, 1995, AIDS, V9, P1251, DOI 10.1097/00002030-199511000-00006; GROSSET J, 1995, TUBERCLE LUNG DIS, V76, P183, DOI 10.1016/S0962-8479(05)80001-2; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; KASSIM S, 1995, AIDS, V9, P1185, DOI 10.1097/00002030-199510000-00011; LALLEMANTLECOEUR S, 1991, AIDS, V5, P195, DOI 10.1097/00002030-199102000-00010; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; LUCAS SB, 1994, TUBERCLE LUNG DIS, V75, P301, DOI 10.1016/0962-8479(94)90137-6; LUCS SB, 1996, BRIT MED J, V312, P335; MARTIN DJ, 1995, J ACQ IMMUN DEF SYND, V8, P386; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P663; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; NUNN P, 1994, TUBERCLE LUNG DIS, V75, P163, DOI 10.1016/0962-8479(94)90001-9; NUNN P, 1991, LANCET, V337, P627; OBRIEN RJ, 1995, AIDS, V9, P665, DOI 10.1097/00002030-199507000-00001; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; POZNIAK AL, 1992, AIDS, V6, P809, DOI 10.1097/00002030-199208000-00007; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RICKMAN TW, 1980, J CLIN MICROBIOL, V11, P618, DOI 10.1128/JCM.11.6.618-620.1980; RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9; SACEANU CA, 1993, J CLIN MICROBIOL, V31, P2371, DOI 10.1128/JCM.31.9.2371-2374.1993; SASSANMOROKRO M, 1994, T ROY SOC TROP MED H, V88, P178, DOI 10.1016/0035-9203(94)90285-2; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SMITH PJ, 1995, C GLOB LUNG HLTH 199; STANFORD JL, 1991, LANCET, V338, P557, DOI 10.1016/0140-6736(91)91113-9; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; VARELDZIS BP, 1993, WHO PUBLICATION; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; Wilkinson D, 1996, AM J PUBLIC HEALTH, V86, P1094, DOI 10.2105/AJPH.86.8_Pt_1.1094; World Bank, 1993, INV HLTH WORLD DEV R; World Health Organization, 1993, TREATM TUB GUID NAT; 1994, TUBER LUNG DIS, V75, P94; 1987, WKLY EPIDEMIOL REC, V62, P297; 1993, MMWR-MORBID MORTAL W, V42, P961	81	19	20	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1502	1507		10.1001/jama.276.18.1502	http://dx.doi.org/10.1001/jama.276.18.1502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ774	8903262				2022-12-28	WOS:A1996VQ77400033
J	Kramer, MS; Joseph, KS				Kramer, MS; Joseph, KS			Enigma of fetal infant-origins hypothesis	LANCET			English	Editorial Material							BLOOD-PRESSURE; BIRTH-WEIGHT; ADULT LIFE; ADOLESCENCE; DISEASE; TERM		MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MONTREAL, PQ H3A 1A2, CANADA; LAB CTR DIS CONTROL, BUR REPROD & CHILD HLTH, OTTAWA, ON K1A 0L2, CANADA	McGill University	Kramer, MS (corresponding author), MCGILL UNIV, DEPT PAEDIAT, MONTREAL, PQ H3A 1A2, CANADA.			Joseph, K.S./0000-0003-2317-5607				BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; HIGGINS M, 1980, AM J EPIDEMIOL, V111, P142, DOI 10.1093/oxfordjournals.aje.a112882; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; LUCAS A, 1994, BRIT MED J, V309, P304, DOI 10.1136/bmj.309.6950.304; MATTHES JWA, 1994, BMJ-BRIT MED J, V308, P1074, DOI 10.1136/bmj.308.6936.1074; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; THOM TJ, 1989, INT J EPIDEMIOL, V18, pS20; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423	9	77	78	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	1996	348	9037					1254	1255		10.1016/S0140-6736(05)65750-9	http://dx.doi.org/10.1016/S0140-6736(05)65750-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909372				2022-12-28	WOS:A1996VR55500002
J	Haase, AT; Henry, K; Zupancic, M; Sedgewick, G; Faust, RA; Melroe, H; Cavert, W; Gebhard, K; Staskus, K; Zhang, ZQ; Dailey, PJ; Balfour, HH; Erice, A; Perelson, AS				Haase, AT; Henry, K; Zupancic, M; Sedgewick, G; Faust, RA; Melroe, H; Cavert, W; Gebhard, K; Staskus, K; Zhang, ZQ; Dailey, PJ; Balfour, HH; Erice, A; Perelson, AS			Quantitative image analysis of HIV-1 infection in lymphoid tissue	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FOLLICULAR DENDRITIC CELLS; INSITU HYBRIDIZATION; T-CELLS; REPLICATION; LATENCY; TYPE-1; RNA; LYMPHOCYTES; EXPRESSION	Tracking human immunodeficiency virus-type 1 (HIV-1) infection at the cellular level in tissue reservoirs provides opportunities to better understand the pathogenesis of infection and to rationally design and monitor therapy. A quantitative technique was developed to determine viral burden in two important cellular compartments in lymphoid tissues. Image analysis and in situ hybridization were combined to show that in the presymptomatic stages of infection there is a large, relatively stable pool of virions on the surfaces of follicular dendritic cells and a smaller pool of productively infected cells. Despite evidence of constraints on HIV-1 replication in the infected cell population in lymphoid tissues, estimates of the numbers of these cells and the virus they could produce are consistent with the quantities of virus that have been detected in the bloodstream. The cellular Sources of virus production and storage in lymphoid tissues can now be studied with this approach over the course of infection and treatment.	UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455; ST PAUL RAMSEY MED CTR,HIV PROGRAM,ST PAUL,MN 55101; UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT OTOLARYNGOL,MINNEAPOLIS,MN 55455; CHIRON CORP,EMERYVILLE,CA 94608; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545	University of Minnesota System; University of Minnesota Twin Cities; Saint Paul Ramsey Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Novartis; University of Minnesota System; University of Minnesota Twin Cities; United States Department of Energy (DOE); Los Alamos National Laboratory	Haase, AT (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MICROBIOL,MINNEAPOLIS,MN 55455, USA.		Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002	NCRR NIH HHS [RR 06555] Funding Source: Medline; NIAID NIH HHS [AI 28246, AI 27661] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027661, R37AI028246] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; DUAN LX, 1994, VIROLOGY, V199, P474, DOI 10.1006/viro.1994.1148; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Faust RA, 1996, OTOLARYNG HEAD NECK, V114, P593, DOI 10.1016/S0194-5998(96)70252-8; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GARCIABLANCO MA, 1991, SCIENCE, V254, P815, DOI 10.1126/science.1658933; HAASE AT, 1982, VIROLOGY, V119, P399, DOI 10.1016/0042-6822(82)90099-X; Haase AT, 1987, IN SITU HYBRIDIZATIO, P197; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; LYDYARD P, 1989, IMMUNOLOGY; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; NUOVO GJ, 1994, AM J PATHOL, V144, P659; NUOVO GJ, 1994, AM J PATHOL, V144, P40; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PENG HR, 1995, VIROLOGY, V206, P16, DOI 10.1016/S0042-6822(95)80015-8; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; ROGERS AW, 1979, TECHNIQUES AUTORADIO, P102; SCHMITZ J, 1994, J IMMUNOL, V153, P1352; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; SPIEGEL H, 1992, AM J PATHOL, V140, P15; TENNERRACZ K, 1988, AIDS, V2, P299, DOI 10.1097/00002030-198808000-00010; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1991, J VIROL, V65, P5921, DOI 10.1128/JVI.65.11.5921-5927.1991; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	39	497	503	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					985	989		10.1126/science.274.5289.985	http://dx.doi.org/10.1126/science.274.5289.985			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875941				2022-12-28	WOS:A1996VR79200050
J	Barley, V				Barley, V			Time for reappraisal of ovarian ablation in early breast cancer	LANCET			English	Editorial Material							ADJUVANT				Barley, V (corresponding author), BRISTOL ONCOL CTR,BRISTOL BS2 8ED,AVON,ENGLAND.							Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Brunt A M, 1994, Clin Oncol (R Coll Radiol), V6, P209, DOI 10.1016/S0936-6555(05)80287-0; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; PATERSON R, 1959, J Fac Radiol, V10, P130, DOI 10.1016/S0368-2242(59)80037-3; PERREN TJ, 1995, BRIT J CANCER, V71, P1142, DOI 10.1038/bjc.1995.223; RICHARDS MA, 1990, J CLIN ONCOL, V8, P2032, DOI 10.1200/JCO.1990.8.12.2032; VALAGUSSA P, 1996, RECENT RESULTS CANC, V140, pCH8; 1992, LANCET, V339, P95; 1985, LANCET, V1, P836; 1992, LANCET, V339, P71	10	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1184	1184		10.1016/S0140-6736(05)65474-8	http://dx.doi.org/10.1016/S0140-6736(05)65474-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898029				2022-12-28	WOS:A1996VQ46700002
J	Grellier, L; Mutimer, D; Ahmed, M; Brown, D; Burroughs, AK; Rolles, K; McMaster, P; Beranek, P; Kennedy, F; Kibbler, H; McPhillips, P; Elias, E; Dusheiko, G				Grellier, L; Mutimer, D; Ahmed, M; Brown, D; Burroughs, AK; Rolles, K; McMaster, P; Beranek, P; Kennedy, F; Kibbler, H; McPhillips, P; Elias, E; Dusheiko, G			Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis	LANCET			English	Article							VIRUS-INFECTION; SURFACE-ANTIGEN; REPLICATION; RECURRENCE	Background Orthotopic liver transplantation in patients positive for hepatitis B virus (HBV) DNA is associated with a high reinfection rate, even with hepatitis B immunoglobulin (HBIG) prophylaxis. Nucleoside analogues that inhibit hepatitis B replication in patients with chronic hepatitis B could prevent reinfection after transplantation. The aim of this study was to analyse the efficacy and safety of prophylaxis both before and after transplantation with the nucleoside analogue lamivudine, without HBIG, in patients undergoing liver transplantation. Methods 17 HBsAg-positive patients with decompensated cirrhosis and previous evidence of viral replication were enrolled. 12 were HBV-DNA-positive by a signal amplification assay. Patients were treated with oral lamivudine (100 mg daily) for at least 4 weeks before transplantation and followed up for 18-90 weeks after transplantation. Findings HBV DNA became undetectable in serum before transplantation in all HBV-DNA-positive patients. Four died before transplantation from complications of cirrhosis; one patient was withdrawn from the study because of a cerebrovascular accident. The remaining 12 patients underwent transplantation. Two patients died after transplantation (one at 3 days and one [suicide] at 20 weeks). HBV DNA reappeared in one patient with histological evidence of recurrent hepatitis (72 weeks). By week 24 the nine remaining patients had lost HBsAg and remained negative for HBV DNA. Interpretation Lamivudine treatment may prove useful in preventing recurrence of hepatitis B after liver transplantation. The effect on survival of patients after transplantation remains to be assessed.	UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT MED,LONDON NW3 2QG,ENGLAND; QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; GLAXO WELLCOME RES & DEV LTD,GREENFORD,MIDDX,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Birmingham; GlaxoSmithKline			Dusheiko, Geoffrey M/C-7677-2010; Burroughs, Andrew K/C-5645-2009	Burroughs, Andrew K/0000-0001-6527-457X				BISMUTH H, 1989, EUR J GASTROEN HEPAT, V1, P79; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHAZOUILLERES O, 1994, LANCET, V343, P142, DOI 10.1016/S0140-6736(94)90934-2; DELAMATA M, 1995, HEPATOLOGY, V22, pA95; DEMAN RA, 1995, AASLD SINGL TOP S LI, P10; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; Duvoux C., 1995, Hepatology, V22, p325A; FERAY C, 1990, TRANSPLANTATION, V49, P1155, DOI 10.1097/00007890-199006000-00025; FLOWERS M, 1994, TRANSPLANTATION, V58, P183; GOY JJ, 1989, LANCET, V1, P1446; ILAN Y, 1993, HEPATOLOGY, V18, P256; KRUGER M, 1995, HEPATOLOGY, V22, pA449; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; LOWELL JA, 1995, LANCET, V345, P1084, DOI 10.1016/S0140-6736(95)90819-6; MARCELLIN P, 1994, HEPATOLOGY, V19, P6, DOI 10.1002/hep.1840190103; MCMILLAN JS, 1995, HEPATOLOGY, V22, P36, DOI 10.1016/0270-9139(95)90350-X; MULLER R, 1994, J HEPATOL, V21, P1140, DOI 10.1016/S0168-8278(05)80632-4; OGATA N, 1993, P NATL ACAD SCI USA, V90, P3014, DOI 10.1073/pnas.90.7.3014; OGRADY JG, 1992, J HEPATOL, V14, P104, DOI 10.1016/0168-8278(92)90138-F; SAMUEL D, 1993, NEW ENGL J MED, V329, P1842, DOI 10.1056/NEJM199312163292503; SIMPSON DM, 1993, NEUROLOGY, V43, P971, DOI 10.1212/WNL.43.5.971; SINGH N, 1995, TRANSPLANTATION, V59, P1629; VANTHIEL DH, 1992, DIGEST DIS SCI, V37, P1245, DOI 10.1007/BF01296567; WRIGHT TL, 1992, LANCET, V339, P952, DOI 10.1016/0140-6736(92)91530-L	25	348	357	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1212	1215		10.1016/S0140-6736(96)04444-3	http://dx.doi.org/10.1016/S0140-6736(96)04444-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898039				2022-12-28	WOS:A1996VQ46700013
J	Mouallem, M; Matetzky, S; Raichlin, E; Farfel, Z				Mouallem, M; Matetzky, S; Raichlin, E; Farfel, Z			A man with a prosthetic valve, anaemia, fever, and splenomegaly	LANCET			English	Article											Mouallem, M (corresponding author), TEL AVIV UNIV,SHEBA MED CTR,DEPT MED E,IL-52621 TEL HASHOMER,ISRAEL.		Raichlin, Eugenia/AAX-8421-2021					BABIOR BM, 1994, HARRISONS PRINCIPLES, P1726; CABOT RC, 1908, OSLERS MODERN MED, V4, P612; DAVIDSON S, 1957, BRIT MED J, V1, P141; HALL CA, 1965, ANN INTERN MED, V63, P951, DOI 10.7326/0003-4819-63-6-951; MCKEE LC, 1979, SOUTHERN MED J, V72, P1423, DOI 10.1097/00007611-197911000-00023	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1216	1216		10.1016/S0140-6736(96)07608-8	http://dx.doi.org/10.1016/S0140-6736(96)07608-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898040				2022-12-28	WOS:A1996VQ46700014
J	Gaudet, R; Bohm, A; Sigler, PB				Gaudet, R; Bohm, A; Sigler, PB			Crystal structure at 2.4 angstrom resolution of the complex of transducin beta gamma and its regulator, phosducin	CELL			English	Article							G-PROTEIN; ALPHA-SUBUNIT; BINDING; KINASE; PHOSPHORYLATION; THIOREDOXIN; ACTIVATION; ALGORITHM; MECHANISM; MODULATOR	The crystal structure of transducin's py subunits complexed with phosducin, which regulates G(t) beta gamma activity, has been solved to 2.4 Angstrom resolution. Phosducin has two domains that wrap around G(t) beta gamma to form an extensive interface. The N-terminal domain binds loops on the ''top'' G(t) beta surface, overlapping the G(t) alpha binding surface, explaining how phosducin blocks G(t) beta gamma's interaction with G(t) alpha. The C-terminal domain shows structural homology to thioredoxin and binds the outer strands of G(t) beta's seventh and first blades in a manner likely to disrupt G(t) beta gamma's normal orientation relative to the membrane and receptor. Phosducin's Ser-73, which when phosphorylated inhibits phosducin's function, points away from G(t) beta gamma, toward a large flexible loop. Thus phosphorylation is not likely to affect the interface directly, but rather indirectly through an induced conformational change.	YALE UNIV,HOWARD HUGHES MED INST,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Howard Hughes Medical Institute; Yale University			Gaudet, Rachelle/I-4133-2014; Gaudet, Rachelle/Y-3985-2019	Gaudet, Rachelle/0000-0002-9177-054X; Gaudet, Rachelle/0000-0002-9177-054X	NIGMS NIH HHS [GM22324] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022324] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AraIwata F, 1996, OPHTHALMIC GENET, V17, P3, DOI 10.3109/13816819609057863; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BIGAY J, 1994, METHOD ENZYMOL, V237, P449; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; CROMER DT, 1981, ACTA CRYSTALLOGR A, V37, P267, DOI 10.1107/S0567739481000600; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HAWES BE, 1994, J BIOL CHEM, V269, P29825; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE RH, 1990, EXP EYE RES, V51, P325, DOI 10.1016/0014-4835(90)90029-T; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LOLLEY RN, 1990, FASEB J, V4, P3001, DOI 10.1096/fasebj.4.12.1697545; MANSERGH FC, 1994, HUM MOL GENET, V3, P2077; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; MITTAL R, 1994, BIOCHEMISTRY-US, V33, P10178, DOI 10.1021/bi00199a046; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAGHROEHL K, 1995, J NEUROSCI, V15, P6475; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REIG JA, 1990, J BIOL CHEM, V265, P5816; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Tanaka H, 1996, BIOCHEM BIOPH RES CO, V223, P587, DOI 10.1006/bbrc.1996.0939; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	49	265	271	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					577	588		10.1016/S0092-8674(00)81376-8	http://dx.doi.org/10.1016/S0092-8674(00)81376-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898209	hybrid			2022-12-28	WOS:A1996VQ46600022
J	Shahani, A				Shahani, A			Models can be powerful tools for making decisions about effective and efficient health care : Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material											Shahani, A (corresponding author), UNIV SOUTHAMPTON,FAC MATH STUDIES,INST MODELLING HEALTHCARE,SOUTHAMPTON SO17 1BJ,HANTS,ENGLAND.							SHAHANI AK, 1994, MODELING THE AIDS EPIDEMIC: PLANNING, POLICY, AND PREDICTION, P179; SHAHANI AK, 1994, J OPER RES SOC, V45, P916, DOI 10.1038/sj/jors/0450807; SHAHANI AK, 1996, GO WITH FLOW, P179	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1057	1057						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898600				2022-12-28	WOS:A1996VP74200030
J	Pruss, D; Bartholomew, B; Persinger, J; Hayes, J; Arents, G; Moudrianakis, EN; Wolffe, AP				Pruss, D; Bartholomew, B; Persinger, J; Hayes, J; Arents, G; Moudrianakis, EN; Wolffe, AP			An asymmetric model for the nucleosome: A binding site for linker histones inside the DNA gyres	SCIENCE			English	Article							POSITIONED NUCLEOSOMES; CHROMATIN STRUCTURE; CRYSTAL-STRUCTURE; GLOBULAR DOMAIN; MMTV PROMOTER; RNA GENE; TRANSCRIPTION; OCTAMER; CORE; H5	Histone-DNA contacts within a nucleosome influence the function of trans-acting factors and the molecular machines required to activate the transcription process, The internal architecture of a positioned nucleosome has now been probed with the use of photoactivatable cross-linking reagents to determine the placement of histones along the DNA molecule. A model for the nucleosome is proposed in which the winged-helix domain of the linker histone is asymmetrically located inside the gyres of DNA that also wrap around the core histones. This domain extends the path of the protein superhelix to one side of the core particle.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892; SO ILLINOIS UNIV,SCH MED,DEPT MED BIOCHEM,CARBONDALE,IL 62901; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Southern Illinois University System; Southern Illinois University; University of Rochester; Johns Hopkins University								ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BOULIKAS T, 1980, P NATL ACAD SCI-BIOL, V77, P127, DOI 10.1073/pnas.77.1.127; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; GRUNSTEIN M, 1995, J CELL SCI S, V19, P29; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; KORNBERG RD, 1974, SCIENCE, V184, P865, DOI 10.1126/science.184.4139.865; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; LENNARD AC, 1985, EMBO J, V4, P3455, DOI 10.1002/j.1460-2075.1985.tb04104.x; LI Q, 1995, MOL CELL BIOL, V15, P4375; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Nightingale KP, 1996, J BIOL CHEM, V271, P7090, DOI 10.1074/jbc.271.12.7090; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RICHMOND TJ, 1993, COLD SPRING HARB SYM, V58, P265, DOI 10.1101/SQB.1993.058.01.031; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; van Holde K.E., 1988, CHROMATIN; YANEVA J, 1995, P NATL ACAD SCI USA, V92, P7060, DOI 10.1073/pnas.92.15.7060	41	156	160	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					614	617		10.1126/science.274.5287.614	http://dx.doi.org/10.1126/science.274.5287.614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849453				2022-12-28	WOS:A1996VN91900051
J	Janowski, BA; Willy, PJ; Devi, TR; Falck, JR; Mangelsdorf, DJ				Janowski, BA; Willy, PJ; Devi, TR; Falck, JR; Mangelsdorf, DJ			An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha	NATURE			English	Article							THYROID-HORMONE RECEPTOR; 9-CIS RETINOIC ACID; HETERODIMER FORMATION; RESPONSE PATHWAY; CO-REPRESSOR; ERB-A; IDENTIFICATION; SUPERFAMILY; ACTIVATION; EXPRESSION	CHOLESTEROL and its oxysterol congeners are important constitutents of cell membranes and function as intermediates in several crucial biosynthetic pathways. These compounds autoregulate their metabolic fate by end-product repression and activation of downstream catabolism(1). Although end-product repression by oxysterols is relatively well understood(2), the mechanism by which these compounds act as positive transcription signalling molecules is unknown. Here we identify a specific group of endogenous oxysterols that activate transcription through the nuclear receptor LXR alpha. Transactivation of LXR alpha by oxysterols occurs at concentrations at which these compounds exist in vivo. The most potent activators also serve as intermediary substrates in the rate-limiting steps of three important metabolic pathways: steroid hormone biosynthesis, bile acid synthesis, and conversion of lanosterol to cholesterol. Our results demonstrate the existence of a nuclear receptor signalling pathway for oxysterols and suggest that LXR alpha may be important as a sensor of cholesterol metabolites.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Mangelsdorf, David/0000-0002-4355-0796; Falck, John/0000-0002-9219-7845				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BYSKOV AG, 1995, NATURE, V374, P559, DOI 10.1038/374559a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DHAR AK, 1973, J NEUROCHEM, V21, P51, DOI 10.1111/j.1471-4159.1973.tb04224.x; DIXON R, 1970, BIOCHEM BIOPH RES CO, V40, P161, DOI 10.1016/0006-291X(70)91060-0; DOLLE RE, 1989, J AM CHEM SOC, V111, P278, DOI 10.1021/ja00183a042; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HARMON MA, 1995, P NATL ACAD SCI USA, V92, P6157, DOI 10.1073/pnas.92.13.6157; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; IKEKAWA N, 1985, STEROLS BILE ACIDS, P199; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JAVITT NB, 1981, J BIOL CHEM, V256, P2644; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MORISAKI M, 1977, CHEM PHARM BULL, V25, P2576; ONATE SA, 1995, SCIENCE, V270, P1354; RUSSELL DW, 1992, CARDIOVASC DRUG THER, V6, P103, DOI 10.1007/BF00054556; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	31	1413	1468	2	61	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					728	731		10.1038/383728a0	http://dx.doi.org/10.1038/383728a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878485				2022-12-28	WOS:A1996VN91800057
J	Joutel, A; Corpechot, C; Ducros, A; Vahedi, K; Chabriat, H; Mouton, P; Alamowitch, S; Domenga, V; Cecillion, M; Marechal, E; Maciazek, J; Vayssiere, C; Cruaud, C; Cabanis, EA; Ruchoux, MM; Weissenbach, J; Bach, JF; Bousser, MG; TournierLasserve, E				Joutel, A; Corpechot, C; Ducros, A; Vahedi, K; Chabriat, H; Mouton, P; Alamowitch, S; Domenga, V; Cecillion, M; Marechal, E; Maciazek, J; Vayssiere, C; Cruaud, C; Cabanis, EA; Ruchoux, MM; Weissenbach, J; Bach, JF; Bousser, MG; TournierLasserve, E			Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia	NATURE			English	Article							ALZHEIMERS-DISEASE; GENE-PRODUCT; C-ELEGANS; DROSOPHILA; LEUKOENCEPHALOPATHY; RECEPTOR; REPEATS; LOCUS; PROTEINS; HOMOLOG	STROKE is the third leading cause of death, and vascular dementia the second cause of dementia after Alzheimer's disease. CADASIL (for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) causes a type of stroke and dementia whose key features include recurrent subcortical ischaemic events and vascular dementia and which is associated with diffuse white-matter abnormalities on neuroimaging(1,2). Pathological examination reveals multiple small, deep cerebral infarcts, a leukoencephalopathy, and a non-atherosclerotic, non-amyloid angiopathy involving mainly the small cerebral arteries(3). Severe alterations of vascular smooth-muscle cells are evident on ultrastructural analysis(4). We have previously mapped the mutant gene to chromosome 19 (ref. 5). Here we report the characterization of the human Notch3 gene which we mapped to the CADASIL critical region. We have identified mutations in CADASIL patients that cause serious disruption of this gene, indicating that Notch3 could be the defective protein in CADASIL patients.	UNIV PARIS 05,INSERM,U25,F-75730 PARIS,FRANCE; HOP ST ANTOINE,SERV NEUROL,F-75012 PARIS,FRANCE; GENETHON,F-91000 EVRY,FRANCE; CHNO XV XX,F-75571 PARIS,FRANCE; CH&U LILLE,SERV NEUROPATHOL,F-59000 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHNO des Quinze-Vingts; UDICE-French Research Universities; Sorbonne Universite; Universite de Lille - ISITE; CHU Lille			Joutel, Anne/K-5601-2017; Tournier-Lasserve, Elisabeth/N-7134-2017; DUCROS, Anne/D-1899-2010; Chabriat, Hugues/G-5699-2010	Joutel, Anne/0000-0003-3963-3860; Tournier-Lasserve, Elisabeth/0000-0002-3039-1677; DUCROS, Anne/0000-0001-5560-5013; Chabriat, Hugues/0000-0001-8436-6074; Dichgans, Martin/0000-0002-0654-387X; Cruaud, Corinne/0000-0002-4752-7278				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BAUDRIMONT M, 1993, STROKE, V24, P122, DOI 10.1161/01.STR.24.1.122; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; BUROKER NE, 1987, HUM GENET, V76, P90; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5; Ducros A, 1996, AM J HUM GENET, V58, P171; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; LARSSON C, 1994, GENOMICS, V24, P253, DOI 10.1006/geno.1994.1613; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROMMENS JM, 1993, HUM MOL GENET, V2, P901, DOI 10.1093/hmg/2.7.901; RUCHOUX MM, 1995, NEUROPATHOL, V89, P500; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TOURNIERLASSERVE E, 1991, STROKE, V22, P1297, DOI 10.1161/01.STR.22.10.1297; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	30	1513	1599	2	73	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					707	710		10.1038/383707a0	http://dx.doi.org/10.1038/383707a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878478				2022-12-28	WOS:A1996VN91800050
J	Koskinen, SVP; Martelin, TP; Valkonen, T				Koskinen, SVP; Martelin, TP; Valkonen, T			Socioeconomic differences in mortality among diabetic people in Finland: Five year follow up	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL-CLASS; MELLITUS	Objective-To compare socioeconomic differences in mortality (by cause of death) among diabetic people with those in the rest of the population. Design-Five year follow up of mortality in the population of Finland, comparing people with diabetes and those without diabetes. Setting-Finland. Subjects-All residents of Finland aged 30 to 74 included in the 1980 census. Subjects were classified as diabetic (230 000 person years) or other (12 400 000 person years) according to whether they were exempted from charges for medication for diabetes, During 1981-5 there were 114 058 deaths, of which 11 215 were in people with diabetes. Main outcome measures-Age standardised mortality by sex, social class, and cause of death for the diabetic and non-diabetic populations. Results-No significant social class differences in mortality were found among women with diabetes. Among diabetic men there was a slight increasing trend in mortality from the upper white collar group to the unskilled blue collar workers but it was much less steep than that of non-diabetic men. Conclusions-Among people with diabetes in Finland the quality of treatment and compliance with treatment probably do not vary by socioeconomic status. Health education for diabetic people seems to be effective in all socioeconomic strata; in people from the lower strata this leads to greater changes because their health behaviour was originally less good.	UNIV HELSINKI,DEPT SOCIOL,POPULAT RES UNIT,FIN-00014 HELSINKI,FINLAND	University of Helsinki								AARVA P, 1995, J SOCIAL MED, V32, P103; Aitkin M., 1980, Applied Statistics, V29, P156, DOI 10.2307/2986301; AUVINEN A, 1995, AM J EPIDEMIOL, V142, P1089, DOI 10.1093/oxfordjournals.aje.a117562; Dahlgren G., 1992, POLICIES STRATEGIES; DORMAN JS, 1985, DIABETES CARE, V8, P54, DOI 10.2337/diacare.8.1.S54; HAKKINEN U, 1992, 20 NAT AG WELF HLTH; KESKIMAKI I, 1995, SOC SCI MED, V41, P425, DOI 10.1016/0277-9536(94)00339-U; KOSKENVUO M, 1981, J EPIDEMIOL COMMUN H, V35, P192, DOI 10.1136/jech.35.3.192; KOSKINEN S, 1994, SOC SCI MED, V38, P1385, DOI 10.1016/0277-9536(94)90276-3; LAAKSO M, 1991, AM J EPIDEMIOL, V133, P850, DOI 10.1093/oxfordjournals.aje.a115965; Matsushima M, 1996, DIABETOLOGIA, V39, P710; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; NYMAN K, 1993, PUBLICATIONS SOCIA M, V88; PAYNE CD, 1985, GLIM SYSTEM RELEASE; PILL R, 1995, J EPIDEMIOL COMMUN H, V49, P28, DOI 10.1136/jech.49.1.28; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; RICHMOND RL, 1993, ADDICTION, V88, P1127, DOI 10.1111/j.1360-0443.1993.tb02132.x; TOWNSEND P, 1988, INEQUALITIES HLTH HL; Valkonen T, 1992, Int J Health Sci, V3, P157; VALKONEN T, 1990, SOCIOECONOMIC MORTAL; VALKONEN T, 1993, POPULATION, P1; 1993, NEW ENGL J MED, V329, P977; [No title captured]	23	47	47	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					975	978						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VN916	8892417	Green Published			2022-12-28	WOS:A1996VN91600021
J	Kelsey, MC; Kouloumas, GA; Lamport, PA; Davis, CL				Kelsey, MC; Kouloumas, GA; Lamport, PA; Davis, CL			Relation between general practitioners' prescribing of antibacterial drugs and their use of laboratory tests	BRITISH MEDICAL JOURNAL			English	Article									CAMDEN & ISLINGTON FAMILY HLTH SERV AUTHOR,LONDON NW1 TLJ,ENGLAND		Kelsey, MC (corresponding author), WHITTINGTON HOSP,DEPT MICROBIOL,LONDON N19 5NF,ENGLAND.							BUYS H, 1994, BRIT MED J, V308, P690, DOI 10.1136/bmj.308.6930.690; *JONT FORM COMM, 1994, BRIT NAT FORM, V23; POWELL HR, 1987, ARCH DIS CHILD, V62, P138, DOI 10.1136/adc.62.2.138; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; 1991, J R COLL PHYSICIANS, V25, P36	5	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					922	922						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876098				2022-12-28	WOS:A1996VM75400030
J	Malik, T				Malik, T			United States of America - Academic institutions and primary care	LANCET			English	Article											Malik, T (corresponding author), CUNY MT SINAI SCH MED,INTERNAL MED ASSOCIATES,MADISON AVE & 101 ST,NEW YORK,NY 10029, USA.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					1004	1005						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855862				2022-12-28	WOS:A1996VM02700018
J	Bjorck, S; Kromer, B; Johnsen, S; Bennike, O; Hammarlund, D; Lemdahl, G; Possnert, G; Rasmussen, TL; Wohlfarth, B; Hammer, CU; Spurk, M				Bjorck, S; Kromer, B; Johnsen, S; Bennike, O; Hammarlund, D; Lemdahl, G; Possnert, G; Rasmussen, TL; Wohlfarth, B; Hammer, CU; Spurk, M			Synchronized terrestrial-atmospheric deglacial records around the North Atlantic	SCIENCE			English	Article							GLACIAL-INTERGLACIAL TRANSITION; HIGH-RESOLUTION RECORD; YOUNGER DRYAS EVENT; ICE-CORE; THERMOHALINE CIRCULATION; ENVIRONMENTAL HISTORY; CLIMATIC OSCILLATIONS; HOLOCENE BOUNDARY; OCEAN CIRCULATION; CARBON-DIOXIDE	On the basis of synchronization of three carbon-14 (C-14)-dated lacustrine sequences from Sweden With tree ring and ice core records, the absolute age of the Younger Dryas-Preboreal climatic shift was determined to be 11,450 to 11,390 +/- 80 years before the present. A 150-year-long cooling in the early Preboreal, associated with rising Delta(14)C values, is evident in all records and indicates an ocean ventilation change. This cooling is similar to earlier deglacial coolings, and box-model calculations suggest that they all may have been the result of increased freshwater forcing that inhibited the strength of the North Atlantic heat conveyor, although the Younger Dryas may have begun as an anomalous meltwater event.	HEIDELBERG ACAD SCI,D-69120 HEIDELBERG,GERMANY; NIELS BOHR INST,DEPT GEOPHYS,DK-2100 COPENHAGEN O,DENMARK; UNIV ICELAND,INST SCI,IS-107 REYKJAVIK,ICELAND; GEUS,DK-2400 COPENHAGEN,DENMARK; LUND UNIV,DEPT QUATERNARY GEOL,S-22363 LUND,SWEDEN; UNIV UPPSALA,TANDEM LAB,S-75121 UPPSALA,SWEDEN; NIELS BOHR INST,DEPT GEOPHYS,DK-2100 COPENHAGEN O,DENMARK; UNIV HOHENHEIM,INST BOT,D-70593 STUTTGART,GERMANY	University of Copenhagen; Niels Bohr Institute; University of Iceland; Geological Survey Of Denmark & Greenland; Lund University; Uppsala University; University of Copenhagen; Niels Bohr Institute; University Hohenheim	Bjorck, S (corresponding author), UNIV COPENHAGEN,INST GEOL,OSTER VOLDGADE 10,DK-1350 COPENHAGEN K,DENMARK.		Hammarlund, Dan/B-9698-2008; Bennike, Ole/G-7070-2018	Bennike, Ole/0000-0002-5486-9946; Hammarlund, Dan/0000-0001-7147-8173				ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; AMMANN B, 1989, BOREAS, V18, P109, DOI 10.1111/j.1502-3885.1989.tb00381.x; ANDREWS JT, 1994, QUATERNARY RES, V41, P26, DOI 10.1006/qres.1994.1003; ATKINSON TC, 1987, NATURE, V325, P587, DOI 10.1038/325587a0; Bard E, 1996, NATURE, V382, P241, DOI 10.1038/382241a0; BARD E, 1994, EARTH PLANET SC LETT, V126, P275, DOI 10.1016/0012-821X(94)90112-0; BARNOLA JM, 1991, TELLUS B, V43, P83, DOI 10.1034/j.1600-0889.1991.t01-1-00002.x; BECKER B, 1991, NATURE, V353, P647, DOI 10.1038/353647a0; BECKER B, 1993, COMMUNICATION; BECKER B, 1993, RADIOCARBON, V35, P210; Beerling DJ, 1995, J QUATERNARY SCI, V10, P379, DOI 10.1002/jqs.3390100407; Behre K.-E., 1966, EISZEITALTER GEGENWA, V17, P69; Behre KE, 1978, PETERMANN GEOGR MITT, V122, P97; BERGLUND BE, 1966, OPERA BOT, V12, P180; BIRKS HH, 1994, J QUATERNARY SCI, V9, P133, DOI 10.1002/jqs.3390090207; Birks HH, 1996, QUATERNARY RES, V45, P119, DOI 10.1006/qres.1996.0014; BIRKS HH, UNPUB; BJORCK S, 1995, QUATERN INT, V27, P19, DOI 10.1016/1040-6182(94)00057-C; BJORCK S, 1992, BOREAS, V21, P15; BJORCK S, 1984, GEOL FOREN STOCK FOR, V106, P81; BJORCK S, 1987, QUATERNARY RES, V28, P1, DOI 10.1016/0033-5894(87)90030-5; BJORCK S, UNPUB; BJORCK S, 1981, FOSSILS STRATA, V14, P93; BLUNIER T, 1995, NATURE, V374, P46, DOI 10.1038/374046a0; BODEN P, UNPUB; BOHNCKE S, 1988, BOREAS, V17, P403; BOYLE EA, 1987, NATURE, V330, P35, DOI 10.1038/330035a0; BROECKER WS, 1989, NATURE, V341, P318, DOI 10.1038/341318a0; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; BROECKER WS, 1990, CLIM DYNAM, V6, P265; BRUNNBERG L, 1995, QUATEMARIA STOCKHOLM, V2; CATO I, 1987, SVERIGES GEOLOGISKA, V68, P55; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; COOPE R, 1995, J QUATERNARY SCI, V10, P391; CWYNAR LC, 1989, QUATERNARY RES, V31, P377, DOI 10.1016/0033-5894(89)90044-6; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; de Vernal A, 1996, NATURE, V381, P774, DOI 10.1038/381774a0; DIGERFELDT G, 1971, Geologiska Foreningens i Stockholm Forhandlingar, V93, P601; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; Eicher U., 1980, MITTEILUNGEN NATURFO, V37, P65; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; FENTON MM, 1983, GEOLOGICAL ASS CANAD, V26, P49; FUHRER K, 1993, ATMOS ENVIRON A-GEN, V27, P1873, DOI 10.1016/0960-1686(93)90292-7; Funder S, 1996, B GEOL SOC DENMARK, V42, P137; GOSLAR T, 1995, NATURE, V377, P414, DOI 10.1038/377414a0; GRONVOLD K, 1995, EARTH PLANET SC LETT, V135, P149, DOI 10.1016/0012-821X(95)00145-3; HALLIDASON H, 1995, GEOLOGY, V23, P1059; HAMMARLUND D, 1994, THESIS, V31; HAMMARLUND D, UNPUB; Hammarlund D, 1994, GFF, V116, P235, DOI 10.1080/11035899409546189; HAMMER CU, 1986, RADIOCARBON, V28, P284, DOI 10.1017/S0033822200007384; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; INGOLFSSON O, 1994, J QUATERNARY SCI, V9, P147, DOI 10.1002/jqs.3390090208; Ingolfsson O., 1988, Geologiska Foreningens i Stockholm Forhandlingar, V110, P293; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; JOHNSEN SJ, 1995, TELLUS B, V47, P624, DOI 10.1034/j.1600-0889.47.issue5.9.x; JOHNSEN SJ, 1992, MEDDELELSER GRONLAND, V29, P22; Karpuz NK, 1992, PALEOCEANOGRAPHY, V7, P499, DOI 10.1029/92PA01651; KAUFMAN DS, 1993, GEOLOGY, V21, P1063, DOI 10.1130/0091-7613(1993)021<1063:AEHKIS>2.3.CO;2; KROMER B, 1993, RADIOCARBON, V35, P125, DOI 10.1017/S0033822200013862; KROMER B, UNPUB; LEHMAN SJ, 1992, NATURE, V356, P767; LEUENBERGER M, 1992, NATURE, V357, P488, DOI 10.1038/357488a0; LEUSCHNER H, UNPUB; LEVESQUE AJ, 1993, NATURE, V361, P623, DOI 10.1038/361623a0; LOTTER AF, 1992, J QUATERNARY SCI, V7, P187; LOWE JJ, 1994, J QUATERNARY SCI, V9, P185, DOI 10.1002/jqs.3390090215; LUNDQVIST J, 1988, BOREAS, V17, P301; MAGNY M, 1995, GEOGR PHYS QUATERN, V49, P401, DOI 10.7202/033062ar; MANABE S, 1995, NATURE, V378, P165, DOI 10.1038/378165a0; MAYEWSKI PA, 1994, SCIENCE, V263, P1747, DOI 10.1126/science.263.5154.1747; MAYEWSKI PA, 1993, SCIENCE, V261, P195, DOI 10.1126/science.261.5118.195; OESCHGER H, 1975, TELLUS, V27, P168, DOI 10.1111/j.2153-3490.1975.tb01671.x; PAUS A, 1989, REV PALAEOBOT PALYNO, V61, P177, DOI 10.1016/0034-6667(89)90032-8; RAHMSTORF S, 1995, NATURE, V378, P145, DOI 10.1038/378145a0; RASMUSSEN TL, IN PRESS GEOLOGY; RODRIGUES CG, 1994, QUATERNARY SCI REV, V13, P923, DOI 10.1016/0277-3791(94)90009-4; ROOTH C, 1982, PROG OCEANOGR, V11, P131, DOI 10.1016/0079-6611(82)90006-4; SARNTHEIN M, 1995, PALEOCEANOGRAPHY, V10, P1063, DOI 10.1029/95PA01453; SIEGENTHALER U, 1993, NATURE, V365, P119, DOI 10.1038/365119a0; SORENSEN R, 1979, BOREAS, V8, P241; STOCKER TF, IN PRESS PALEOCEANOG; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Stuiver M., 1993, HOLOCENE, V3, P289, DOI DOI 10.1177/095968369300300401; Teller J.T., 1983, GLACIAL LAKE AGASSIZ, V26, P261; VEUM T, 1992, NATURE, V356, P783, DOI 10.1038/356783a0; VORREN KD, 1986, NORSK GEOL TIDSSKR, V66, P135; WHITE JWC, 1994, NATURE, V367, P153, DOI 10.1038/367153a0; WOHLFARTH B, 1993, BOREAS, V22, P113; WOHLFARTH B, UNPUB	91	444	450	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1155	1160		10.1126/science.274.5290.1155	http://dx.doi.org/10.1126/science.274.5290.1155			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895457				2022-12-28	WOS:A1996VT33500043
J	Zachariae, W; Shin, TH; Galova, M; Obermaier, B; Nasmyth, K				Zachariae, W; Shin, TH; Galova, M; Obermaier, B; Nasmyth, K			Identification of subunits of the anaphase-promoting complex of Saccharomyces cerevisiae	SCIENCE			English	Article							CELL-CYCLE CONTROL; ASPERGILLUS-NIDULANS; BUDDING YEAST; S-PHASE; MITOSIS; PROTEIN; GENE; DESTRUCTION; PROTEOLYSIS; TRANSITION	Entry into anaphase and proteolysis of B-type cyclins depend on a complex containing the tetratricopeptide repeat proteins Cdc16p, Cdc23p, and Cdc27p. This particle, called the anaphase-promoting complex (APC) or cyclosome, functions as a cell cycle-regulated ubiquitin-protein ligase. Two additional subunits of the budding yeast APC were identified: The largest subunit, encoded by the APC1 gene, is conserved between fungi and vertebrates and shows similarity to BIMEp from Aspergillus nidulans. A small heat-inducible subunit is encoded by the CDC26 gene. The yeast APC is a 36S particle that contains at least seven different proteins.	RES INST MOL PATHOL, A-1030 VIENNA, AUSTRIA; MEDIGENE GMBH, D-82152 MARTINSRIED, GERMANY	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Nasmyth, Kim/0000-0001-7030-4403				AKARI H, 1992, MOL GEN GENET, V231, P329; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; CIECHANOVER A, 1994, CELL, V79, P113; CIOSK R, UNPUB; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JAMES SW, 1995, J CELL SCI, V108, P3485; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MURRAY AW, 1989, NATURE, V339, P503; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; ODONNELL KL, 1991, J CELL SCI, V99, P711; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIN TJ, UNPUB; STARBORG M, 1994, J BIOL CHEM, V269, P24133; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; ZACHARIAE W, UNPUB	32	235	238	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1996	274	5290					1201	1204		10.1126/science.274.5290.1201	http://dx.doi.org/10.1126/science.274.5290.1201			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895471				2022-12-28	WOS:A1996VT33500057
J	Garboczi, DN; Ghosh, P; Utz, U; Fan, QR; Biddison, WE; Wiley, DC				Garboczi, DN; Ghosh, P; Utz, U; Fan, QR; Biddison, WE; Wiley, DC			Structure of the complex between human T-cell receptor, viral peptide and HLA-A2	NATURE			English	Article							ANTIGEN-BINDING SITE; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; MHC COMPLEXES; CLASS-I; HISTOCOMPATIBILITY ANTIGEN; RECOGNITION; LYMPHOCYTES; MOLECULES; ANTIBODY	Recognition by a T-cell antigen receptor (TCR) of peptide complexed with a major histocompatibility complex (MHC) molecule occurs through variable loops in the TCR structure which bury almost all the available peptide and a much larger area of the MHC molecule. The TCR fits diagonally across the MHC peptide-binding site in a surface feature common to all class I and class II MHC molecules, providing evidence that the nature of binding is general, A broadly applicable binding mode has implications for the mechanism of repertoire selection and the magnitude of alloreactions.	HARVARD UNIV, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA; INST RECH CLIN MONTREAL, IMMUNOL LAB, MONTREAL, PQ H2W 1R7, CANADA; NINCDS, MOL IMMUNOL SECT, NEUROIMMUNOL BRANCH, NIH, BETHESDA, MD 20892 USA	Harvard University; Harvard University; Howard Hughes Medical Institute; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								Arden Bernhard, 1995, Immunogenetics, V42, P455; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bentley GA, 1996, ANNU REV IMMUNOL, V14, P563, DOI 10.1146/annurev.immunol.14.1.563; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; ELOVAARA I, 1993, J EXP MED, V177, P1567, DOI 10.1084/jem.177.6.1567; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GARBOCZI DN, IN PRESS J IMMUNOL; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Hedrick Stephen M., 1993, P383; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; JANEWAY CA, 1989, COLD SH Q B, V54, P657; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JERNE N K, 1971, European Journal of Immunology, V1, P1, DOI 10.1002/eji.1830010102; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kabat EA, 1991, SEQUENCES PROTEINS I; KATZ DH, 1973, P NATL ACAD SCI USA, V70, P2624, DOI 10.1073/pnas.70.9.2624; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; ROMAN GC, 1988, LANCET, V1, P651; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; SantAngelo DB, 1996, IMMUNITY, V4, P367, DOI 10.1016/S1074-7613(00)80250-2; SHEVACH EM, 1973, J EXP MED, V138, P1213, DOI 10.1084/jem.138.5.1213; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SUN R, 1995, IMMUNITY, V3, P573, DOI 10.1016/1074-7613(95)90128-0; Utz U, 1996, J VIROL, V70, P843, DOI 10.1128/JVI.70.2.843-851.1996; Vasmatzis G, 1996, J MOL BIOL, V261, P72, DOI 10.1006/jmbi.1996.0442; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WILSON IA, 1993, STRUCTURE, V3, P113; WILSON IA, 1996, 55 FOR IMM, P73; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	53	873	913	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	1996	384	6605					134	141		10.1038/384134a0	http://dx.doi.org/10.1038/384134a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906788				2022-12-28	WOS:A1996VT33600056
J	Schobel, HP; Fischer, T; Heuszer, K; Geiger, H; Schmieder, RE				Schobel, HP; Fischer, T; Heuszer, K; Geiger, H; Schmieder, RE			Preeclampsia - A state of sympathetic overactivity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY-INDUCED HYPERTENSION; NITRIC-OXIDE; HUMANS; NORADRENALINE; RESPONSES; NERVES	Background Preeclampsia is characterized by a marked increase in peripheral vascular resistance leading to an increase in blood pressure, but the triggering mechanisms are unclear. Methods To determine whether augmented sympathetic vasoconstrictor activity may be an important mechanism in mediating the increase in vasomotor tone, we measured postganglionic sympathetic-nerve activity in the blood vessels of skeletal muscle by means of intraneural microelectrodes in nine women with preeclampsia, eight normotensive pregnant women, six normotensive nonpregnant women, and seven nonpregnant women with hypertension, both at rest and during noninvasive cardiovascular-reflex testing (with the Valsalva maneuver and the cold presser test). Results The mean (+/-SE) rate of sympathetic nerve activity in the normotensive pregnant women (10+/-1 bursts per minute) was not significantly different from that in normotensive nonpregnant women (12+/-2 bursts per minute) or hypertensive nonpregnant women (15+/-3 bursts per minute). In contrast, the rate of sympathetic-nerve activity in the patients with preeclampsia (33+/-3 bursts per minute) was more than three times as high as that in the normotensive pregnant women (P<0.05) and more than twice as high as in the group of nonpregnant women with hypertension (P<0.05). Hemodynamic and sympathetic-nerve responses to both reflex tests did not differ significantly among the four groups. Six patients with preeclampsia were studied again after delivery; mean sympathetic-nerve activity at that time had decreased significantly from the value during pregnancy (from 36+/-4 to 13+/-2 bursts per minute, P<0.01), as had mean arterial pressure (from 118+/-3 to 96+/-1 mm Hg, P<0.01). Conclusions Preeclampsia is a state of sympathetic overactivity, which reverts to normal after delivery. Our data indicate that the increases in peripheral vascular resistance and blood pressure that characterize this disorder are mediated, at least in part, by a substantial increase in sympathetic vasoconstrictor activity. (C) 1996 Massachusetts Medical Society.	UNIV ERLANGEN NURNBERG,DEPT OBSTET & GYNECOL,D-91054 ERLANGEN,GERMANY	University of Erlangen Nuremberg	Schobel, HP (corresponding author), UNIV ERLANGEN NURNBERG,MED KLIN 4,DEPT INTERNAL MED,KRANKENHAUSSTR 12,D-91054 ERLANGEN,GERMANY.		Fischer, Thorsten/F-6341-2013	Fischer, Thorsten/0000-0002-9371-4672				BARTON JR, 1992, AM J OBSTET GYNECOL, V167, P931, DOI 10.1016/S0002-9378(12)80014-7; CAMERON IT, 1993, HYPERTENS PREGNANCY, V12, P85, DOI 10.3109/10641959309031055; CASTREN O, 1973, INT J GYNECOL OBSTET, V11, P236; CONRAD KP, 1993, FASEB J, V7, P566, DOI 10.1096/fasebj.7.6.7682524; CUNNINGHAM FG, 1992, NEW ENGL J MED, V326, P927; Cunningham FG, 1989, WILLIAMS OBSTET, V18th, P653; CURTIS NE, 1995, HYPERTENS PREGNANCY, V14, P339, DOI 10.3109/10641959509015680; DAVEY DA, 1986, CLIN EXP HYPERTENS B, V5, P97, DOI 10.3109/10641958609023478; DAVEY DA, 1981, BRIT J OBSTET GYNAEC, V88, P611, DOI 10.1111/j.1471-0528.1981.tb01217.x; DELIUS W, 1972, ACTA PHYSIOL SCAND, V84, P82, DOI 10.1111/j.1748-1716.1972.tb05158.x; EKHOLM EMK, 1994, HYPERTENS PREGNANCY, V13, P253, DOI 10.3109/10641959409072227; FOLKOW B, 1983, HYPERTENSION, V5, P399, DOI 10.1161/01.HYP.5.4.399; KAUNITZ AM, 1985, OBSTET GYNECOL, V65, P605; LEVIN AB, 1966, AM J CARDIOL, V18, P90, DOI 10.1016/0002-9149(66)90200-1; MARK AL, 1985, CIRC RES, V57, P461, DOI 10.1161/01.RES.57.3.461; NISELL H, 1985, AM J OBSTET GYNECOL, V152, P554, DOI 10.1016/0002-9378(85)90623-4; PASSLOER HJ, 1991, Z GEBURTSH PERINATOL, V195, P137; ROBERTS JM, 1993, LANCET, V342, P504; SCHOBEL HP, 1992, CIRC RES, V70, P172, DOI 10.1161/01.RES.70.1.172; SELIGMAN SP, 1994, AM J OBSTET GYNECOL, V171, P944, DOI 10.1016/S0002-9378(94)70064-8; TUNBRIDGE RDG, 1981, BRIT J OBSTET GYNAEC, V88, P105, DOI 10.1111/j.1471-0528.1981.tb00950.x; VALLBO AB, 1979, PHYSIOL REV, V59, P919, DOI 10.1152/physrev.1979.59.4.919; VICTOR RG, 1987, HYPERTENSION, V9, P429, DOI 10.1161/01.HYP.9.5.429; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; ZUSPAN FP, 1979, J REPROD MED, V23, P143	25	409	421	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1480	1485		10.1056/NEJM199611143352002	http://dx.doi.org/10.1056/NEJM199611143352002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT340	8890098				2022-12-28	WOS:A1996VT34000002
J	Smith, JM; Szathmary, E				Smith, JM; Szathmary, E			On the likelihood of habitable worlds	NATURE			English	Editorial Material									COLLEGIUM BUDAPEST,H-1014 BUDAPEST,HUNGARY		Smith, JM (corresponding author), UNIV SUSSEX,SCH BIOL SCI,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.		Szathmáry, Eörs/A-5007-2011; Szathmary, Eors/AAS-1202-2021	Szathmary, Eors/0000-0001-5227-2997				Barrow J., 1998, ANTHROPIC COSMOLOGIC; Carter B, 1974, CONFRONTATION COSMOL; HENDERSON LJ, 1913, FITNESS ENV; SMOLIN L, 1992, CLASSICAL QUANT GRAV, V9, P173, DOI 10.1088/0264-9381/9/1/016	4	6	6	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					107	107		10.1038/384107a0	http://dx.doi.org/10.1038/384107a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906778				2022-12-28	WOS:A1996VT33600029
J	Rouse, DJ; Owen, J; Goldenberg, RL; Cliver, SP				Rouse, DJ; Owen, J; Goldenberg, RL; Cliver, SP			The effectiveness and costs of elective cesarean delivery for fetal macrosomia diagnosed by ultrasound	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHOULDER DYSTOCIA; RISK-FACTORS; BIRTH TRAUMA; SONOGRAPHIC DIAGNOSIS; DIABETIC PREGNANCIES; TERM; MANAGEMENT; SECTION; WEIGHT; LABOR	Objective.-To quantitate the potential effectiveness and monetary costs of a policy of elective cesarean delivery for fetal macrosomia diagnosed by ultrasound. Design.-A decision analytic model was constructed to compare 3 policies: (1) management without ultrasound; (2) ultrasound and elective cesarean delivery for estimated fetal weight of 4000 g or more (4000-g policy); and (3) ultrasound and elective cesarean delivery for estimated fetal weight of 4500 g or more (4500-g policy). The impact of maternal diabetes was analyzed separately. Probability data used in the decision analytic model were summarized from the literature and supplemented with unpublished data from the Collaborative Trial of Preterm Birth Prevention. Costs were estimated from the literature, regional reimbursements, and clinical practice data. Main Outcome Measures.-Rates of shoulder dystocia and permanent brachial plexus injury, and both the number of additional cesarean births and monetary costs per permanent brachial plexus injury averted. Results.-In the baseline analysis for nondiabetic women, the ultrasound policies increased both the cesarean delivery rate and costs, while decreasing the rate of shoulder dystocia and brachial plexus injury. For each permanent brachial plexus injury prevented by the 4500-g policy, 3695 cesarean deliveries were performed at an additional cost of $8.7 million, vs 2345 cesarean deliveries and $4.9 million with the 4000-g policy. in the baseline analysis for diabetic women, with all 3 policies, rates of cesarean delivery, shoulder dystocia and brachial plexus injury, and total costs were higher than for nondiabetic women. However, more favorable ratios for both cesarean deliveries and cost per permanent injury avoided were observed: 443 deliveries and $930 000, respectively, with the 4500-g policy, and 489 deliveries and $880 000, respectively, with the 4000-g policy. Sensitivity analysis confirmed the general robustness of these findings. Conclusions.-For the 97% of pregnant women who are not diabetic, a policy of elective cesarean delivery for ultrasonographically diagnosed fetal macrosomia is medically and economically unsound. In pregnancies complicated by diabetes, such a policy appears to be more tenable, although the merits of such an approach are debatable.			Rouse, DJ (corresponding author), UNIV ALABAMA, DEPT OBSTET & GYNECOL, CTR OBSTET RES, DIV MATERNAL FETAL MED, 618 S 20TH 457 OHB, BIRMINGHAM, AL 35233 USA.				BHP HRSA HHS [DHHS 290-92-0055] Funding Source: Medline	BHP HRSA HHS		ACKER DB, 1988, OBSTET GYNECOL, V71, P389; ACKER DB, 1985, OBSTET GYNECOL, V66, P762; *AM COLL OBST GYN, 1991, FET MAT ASS PRIOR EL, P98; *AM COLL OBST GYN, 1991, AM COLL OBST GYN TEC, V159; BENEDETTI TJ, 1978, OBSTET GYNECOL, V52, P526; BENSON CB, 1987, AM J OBSTET GYNECOL, V156, P441, DOI 10.1016/0002-9378(87)90303-6; BOCHNER CJ, 1987, AM J OBSTET GYNECOL, V157, P703, DOI 10.1016/S0002-9378(87)80033-9; BOOME RS, 1988, J BONE JOINT SURG BR, V70, P571, DOI 10.1302/0301-620X.70B4.3403599; BOYD ME, 1983, OBSTET GYNECOL, V61, P715; BROWN KLB, 1984, CLIN PLAST SURG, V11, P181; CHERVENAK JL, 1989, AM J OBSTET GYNECOL, V161, P753, DOI 10.1016/0002-9378(89)90395-5; CLARKE SC, 1995, BIRTH-ISS PERINAT C, V22, P63, DOI 10.1111/j.1523-536X.1995.tb00561.x; COMBS CA, 1993, OBSTET GYNECOL, V81, P492; DELPAPA EH, 1991, OBSTET GYNECOL, V78, P340; DENNIS J, 1989, AM J OBSTET GYNECOL, V161, P213, DOI 10.1016/0002-9378(89)90269-X; DEPP R, 1993, AM J OBSTET GYNECOL, V169, P352; DETER RL, 1985, J CLIN ULTRASOUND, V13, P519, DOI 10.1002/1097-0096(199010)13:8<519::AID-JCU1870130802>3.0.CO;2-L; *DIV QUAL ASS, 1995, NAT PRACT DAT BANK R; FEE SC, 1990, AM J OBSTET GYNECOL, V162, P802, DOI 10.1016/0002-9378(90)91014-4; GILBERT A, 1991, CLIN ORTHOP RELAT R, P39; GOLDITCH IM, 1978, OBSTET GYNECOL, V52, P26; GONIK B, 1991, AM J PERINAT, V8, P31, DOI 10.1055/s-2007-999334; GORDON M, 1973, AM J OBSTET GYNECOL, V117, P51, DOI 10.1016/0002-9378(73)90727-8; GROSS SJ, 1987, AM J OBSTET GYNECOL, V156, P334, DOI 10.1016/0002-9378(87)90278-X; GROSS TL, 1987, AM J OBSTET GYNECOL, V156, P1408, DOI 10.1016/0002-9378(87)90008-1; HARDY AE, 1981, J BONE JOINT SURG BR, V63, P98, DOI 10.1302/0301-620X.63B1.7204481; *HLTH CAR CONS AM, 1995, PHYS FEE COD GUID, P508; JENNETT RJ, 1992, AM J OBSTET GYNECOL, V166, P1673, DOI 10.1016/0002-9378(92)91555-O; KELLER JD, 1991, AM J OBSTET GYNECOL, V165, P928, DOI 10.1016/0002-9378(91)90441-S; LANDON MB, 1991, OBSTET NORMAL PROBLE, P1215; LANGER O, 1991, AM J OBSTET GYNECOL, V165, P831, DOI 10.1016/0002-9378(91)90424-P; LEVINE AB, 1992, OBSTET GYNECOL, V79, P55; LEVINE MG, 1984, OBSTET GYNECOL, V63, P792; LEWIS DF, 1995, AM J OBSTET GYNECOL, V172, P1369, DOI 10.1016/0002-9378(95)90464-6; LIPSCOMB KR, 1995, OBSTET GYNECOL, V85, P558, DOI 10.1016/0029-7844(95)00005-C; MCFARLAND LV, 1986, OBSTET GYNECOL, V68, P784; MCLAREN RA, 1995, OBSTET GYNECOL, V85, P565, DOI 10.1016/0029-7844(94)00454-L; MINTZ MC, 1989, AM J PERINAT, V6, P240, DOI 10.1055/s-2007-999585; MODANLOU HD, 1980, OBSTET GYNECOL, V55, P420; MORRISON JC, 1992, SURG GYNECOL OBSTET, V175, P515; MORRISON JJ, 1995, BRIT J OBSTET GYNAEC, V102, P101, DOI 10.1111/j.1471-0528.1995.tb09060.x; MUSHINSKI M, 1994, AVERAGE CHARGES UNCO; NADAS S, 1992, EUR J PEDIATR SURG, V2, P165, DOI 10.1055/s-2008-1063431; NOCON JJ, 1993, AM J OBSTET GYNECOL, V168, P1732, DOI 10.1016/0002-9378(93)90684-B; PARKS DG, 1978, OBSTET GYNECOL, V52, P407; PARRISH KM, 1994, JAMA-J AM MED ASSOC, V271, P443, DOI 10.1001/jama.271.6.443; PEDERSEN JF, 1992, BRIT J OBSTET GYNAEC, V99, P475, DOI 10.1111/j.1471-0528.1992.tb13784.x; POLLACK RN, 1992, AM J OBSTET GYNECOL, V167, P7, DOI 10.1016/S0002-9378(11)91615-9; RANDOLPH AG, 1993, JAMA-J AM MED ASSOC, V270, P77, DOI 10.1001/jama.270.1.77; ROSSAVIK IK, 1993, SOUTHERN MED J, V86, P1129, DOI 10.1097/00007611-199310000-00010; SANDMIRE HF, 1988, INT J GYNECOL OBSTET, V26, P65, DOI 10.1016/0020-7292(88)90198-1; SANDMIRE HF, 1993, OBSTET GYNECOL, V82, P860; SARNO AP, 1991, MIL MED, V156, P55, DOI 10.1093/milmed/156.2.55; SPECHT EE, 1975, CLIN ORTHOP RELAT R, V110, P32; SPELLACY WN, 1985, OBSTET GYNECOL, V66, P158; TURNPENNY PD, 1993, BRIT J OBSTET GYNAEC, V100, P338, DOI 10.1111/j.1471-0528.1993.tb12976.x	56	275	282	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1480	1486		10.1001/jama.276.18.1480	http://dx.doi.org/10.1001/jama.276.18.1480			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ774	8903259				2022-12-28	WOS:A1996VQ77400030
J	Bromann, K; Felix, C; Brune, H; Harbich, W; Monot, R; Buttet, J; Kern, K				Bromann, K; Felix, C; Brune, H; Harbich, W; Monot, R; Buttet, J; Kern, K			Controlled deposition of size-selected silver nanoclusters	SCIENCE			English	Article							SURFACE; CLUSTERS; DIFFUSION; GROWTH; FRAGMENTATION; PHOTOEMISSION; ADSORPTION; PT(111); AR	Variable-temperature scanning tunneling microscopy was used to study the effect of kinetic cluster energy and rare-gas buffer layers on the deposition process of size-selected silver nanoclusters on a platinum(111) surface. Clusters with impact energies of less than or equal to 1 electron volt per atom could be landed nondestructively on the bare substrate, whereas at higher kinetic energies fragmentation and substrate damage were observed. Clusters with elevated impact energy could be soft-landed via an argon buffer layer on the platinum substrate, which efficiently dissipated the kinetic energy. Nondestructive cluster deposition represents a promising method to produce monodispersed nanostructures at surfaces.	ECOLE POLYTECH FED LAUSANNE, INST PHYS EXPT, CH-1015 LAUSANNE, SWITZERLAND	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne			Brune, Harald/E-7284-2017	Brune, Harald/0000-0003-4459-3111; Felix, Christian/0000-0002-0719-8916				AVOURIS P, 1995, ACCOUNTS CHEM RES, V28, P95, DOI 10.1021/ar00051a002; AVOURIS P, 1993, ATOMIC NANOMETER SCA; BARDOTTI L, 1995, PHYS REV LETT, V74, P4694, DOI 10.1103/PhysRevLett.74.4694; BARTELT MC, 1992, PHYS REV B, V46, P12675, DOI 10.1103/PhysRevB.46.12675; BRUNE H, 1995, THIN SOLID FILMS, V264, P230, DOI 10.1016/0040-6090(94)05821-0; BRUNE H, 1994, NATURE, V369, P469, DOI 10.1038/369469a0; BRUNE H, 1994, PHYS REV LETT, V73, P1955, DOI 10.1103/PhysRevLett.73.1955; CHENG HP, 1994, J PHYS CHEM-US, V98, P3527, DOI 10.1021/j100064a040; CHENG HP, 1993, SCIENCE, V260, P1304, DOI 10.1126/science.260.5112.1304; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; EBERHARDT W, 1990, PHYS REV LETT, V64, P780, DOI 10.1103/PhysRevLett.64.780; FEDRIGO S, 1993, PHYS REV B, V47, P10706, DOI 10.1103/PhysRevB.47.10706; Francis GM, 1996, J CHEM SOC DALTON, P665, DOI 10.1039/dt9960000665; HARBICH W, 1991, MAT RES SOC S, V208, P369; JACOBSEN KW, 1987, PHYS REV B, V35, P7423, DOI 10.1103/PhysRevB.35.7423; JOHN PMS, 1992, PHYS REV LETT, V69, P1467; KUK Y, 1989, PHYS REV B, V39, P11168, DOI 10.1103/PhysRevB.39.11168; RODER H, 1993, PHYS REV LETT, V71, P2086, DOI 10.1103/PhysRevLett.71.2086; RODER H, 1994, PHYS REV LETT, V73, P2143, DOI 10.1103/PhysRevLett.73.2143; RODER H, 1993, NATURE, V366, P141, DOI 10.1038/366141a0; ROY HV, 1994, PHYS REV B, V49, P5611, DOI 10.1103/PhysRevB.49.5611; TERSOFF J, 1995, PHYS REV LETT, V74, P434, DOI 10.1103/PhysRevLett.74.434; UNGURIS J, 1981, SURF SCI, V109, P522, DOI 10.1016/0039-6028(81)90425-8; VANDONI G, 1994, CHEM PHYS LETT, V229, P51, DOI 10.1016/0009-2614(94)01046-3; YAMADA I, 1989, APPL SURF SCI, V43, P23, DOI 10.1016/0169-4332(89)90185-2; ZEPPENFELD P, 1992, PHYS REV B, V45, P5179, DOI 10.1103/PhysRevB.45.5179	26	277	283	0	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					956	958		10.1126/science.274.5289.956	http://dx.doi.org/10.1126/science.274.5289.956			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875931				2022-12-28	WOS:A1996VR79200040
J	Ling, LH; EnriquezSarano, M; Seward, JB; Tajik, AJ; Schaff, HV; Bailey, KR; Frye, RL				Ling, LH; EnriquezSarano, M; Seward, JB; Tajik, AJ; Schaff, HV; Bailey, KR; Frye, RL			Clinical outcome of mitral regurgitation due to flail leaflet	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TWO-DIMENSIONAL ECHOCARDIOGRAPHY; VENTRICULAR EJECTION FRACTION; RUPTURED CHORDAE-TENDINEAE; NATURAL-HISTORY; VALVE REPLACEMENT; TREATED PATIENTS; PERFORMANCE; PREDICTION; VALIDATION; SURVIVAL	Background Mitral regurgitation due to flail leaflet is difficult to manage, because it is frequently asymptomatic yet carries a high risk of left ventricular dysfunction and because the natural history of the condition is poorly defined. Methods We obtained clinical follow-up data through 1994-1995 in 229 patients with isolated mitral regurgitation due to flail leaflet; this condition was first diagnosed by echocardiography between 1980 and 1989. Results The 86 patients who were treated medically had a mortality rate significantly higher than expected (6.3 percent yearly, P = 0.016 for the comparison with the expected rate in the U.S. population according to the 1990 census). independent determinants of mortality were an older age, the presence of symptoms, and a lower ejection fraction. Patients who were even transiently in New York Heart Association functional class III or IV had a high mortality rate (34 percent yearly), but the rate was also notable (4.1 percent yearly) among those in class I or ii. At 10 years, the mean (+/-SE) rates of heart failure, atrial fibrillation, and death or surgery were 63+/-8, 30+/-12, and 90+/-3 percent, respectively. In a multivariate analysis, surgical correction of mitral regurgitation (performed in 143 patients) was associated with a reduced mortality rate (hazard ratio, 0.29; 95 percent confidence interval, 0.15 to 0.56; P<0.001). Conclusions When treated medically, mitral regurgitation due to flail leaflet is associated with excess mortality and high morbidity. Surgery is almost unavoidable within 10 years after the diagnosis and appears to be associated with an improved prognosis; this finding suggests that surgery should be considered early in the course of the disease. (C)1996, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN,DIV CARDIOVASC DIS & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,CARDIOVASC SURG SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic				Schaff, Hartzell/0000-0003-0994-027X; Ling, Lieng H./0000-0001-6063-8530				ABBASI AS, 1980, CIRCULATION, V61, P143, DOI 10.1161/01.CIR.61.1.143; ACAR J, 1991, EUR HEART J, V12, P52, DOI 10.1093/eurheartj/12.suppl_B.52; BARLOW JB, 1987, PERSPECTIVES MITRAL, P113; BAXLEY WA, 1973, CIRCULATION, V48, P1288, DOI 10.1161/01.CIR.48.6.1288; BERGERON GA, 1986, AM J MED, V81, P333, DOI 10.1016/0002-9343(86)90273-1; BURWASH IG, 1992, AM J CARDIOL, V70, P774, DOI 10.1016/0002-9149(92)90558-G; CARABELLO BA, 1988, MOD CONC CARDIOV DIS, V57, P53; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DELAHAYE JP, 1991, EUR HEART J, V12, P5, DOI 10.1093/eurheartj/12.suppl_B.5; DEPACE NL, 1983, AM J CARDIOL, V52, P789, DOI 10.1016/0002-9149(83)90416-2; ELLIS LB, 1969, AM HEART J, V78, P406, DOI 10.1016/0002-8703(69)90047-7; EMOND M, 1994, CIRCULATION, V90, P2645, DOI 10.1161/01.CIR.90.6.2645; ENRIQUEZSARANO M, 1995, CIRCULATION, V91, P1022, DOI 10.1161/01.CIR.91.4.1022; ENRIQUEZSARANO M, 1994, J AM COLL CARDIOL, V24, P1536, DOI 10.1016/0735-1097(94)90151-1; ENRIQUEZSARANO M, 1994, CIRCULATION, V90, P830, DOI 10.1161/01.CIR.90.2.830; ENRIQUEZSARANO M, 1994, J AM COLL CARDIOL, V23, P443, DOI 10.1016/0735-1097(94)90432-4; GALLOWAY AC, 1988, CIRCULATION, V78, P97; GEHL LG, 1982, AM J CARDIOL, V49, P33, DOI 10.1016/0002-9149(82)90274-0; GRENADIER E, 1985, EUR HEART J, V6, P1006, DOI 10.1093/oxfordjournals.eurheartj.a061803; HAMMERMEISTER KE, 1978, CIRCULATION, V57, P341, DOI 10.1161/01.CIR.57.2.341; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; HOCHREITER C, 1986, CIRCULATION, V73, P900, DOI 10.1161/01.CIR.73.5.900; HORSTKOTTE D, 1983, Z KARDIOL, V72, P494; JHAVERI S, 1960, CIRCULATION, V22, P39, DOI 10.1161/01.CIR.22.1.39; KOLIBASH AJ, 1986, AM J CARDIOL, V58, P762, DOI 10.1016/0002-9149(86)90352-8; LUXEREAU P, 1991, EUR HEART J, V12, P2, DOI 10.1093/eurheartj/12.suppl_B.2; MINTZ GS, 1978, CIRCULATION, V57, P244, DOI 10.1161/01.CIR.57.2.244; MINTZ GS, 1980, AM J CARDIOL, V45, P253, DOI 10.1016/0002-9149(80)90643-8; MUNOZ S, 1975, AM J CARDIOL, V35, P234, DOI 10.1016/0002-9149(75)90007-7; OLIVEIRA DBG, 1983, BRIT HEART J, V50, P312; OLSON LJ, 1987, MAYO CLIN PROC, V62, P22, DOI 10.1016/S0025-6196(12)61522-5; PEARSON AC, 1990, J AM COLL CARDIOL, V16, P232, DOI 10.1016/0735-1097(90)90483-6; PHILLIPS HR, 1981, AM J CARDIOL, V48, P647, DOI 10.1016/0002-9149(81)90142-9; QUINONES MA, 1981, CIRCULATION, V64, P744, DOI 10.1161/01.CIR.64.4.744; RAMANATHAN KB, 1984, J AM COLL CARDIOL, V3, P1412, DOI 10.1016/S0735-1097(84)80279-X; RAPAPORT E, 1975, AM J CARDIOL, V35, P221, DOI 10.1016/0002-9149(75)90005-3; REICHEK N, 1982, CIRCULATION, V65, P99, DOI 10.1161/01.CIR.65.1.99; REN JF, 1985, AM HEART J, V109, P435, DOI 10.1016/0002-8703(85)90544-7; RICH S, 1982, AM HEART J, V104, P603, DOI 10.1016/0002-8703(82)90233-2; ROBERTS WC, 1966, CIRCULATION, V33, P58; ROSEN SE, 1994, AM J CARDIOL, V74, P374, DOI 10.1016/0002-9149(94)90406-5; ROZICH JD, 1992, CIRCULATION, V86, P1718, DOI 10.1161/01.CIR.86.6.1718; SANDERS CA, 1967, NEW ENGL J MED, V276, P943, DOI 10.1056/NEJM196704272761702; SANDERS CA, 1965, CIRCULATION, V31, P506, DOI 10.1161/01.CIR.31.4.506; SELZER A, 1972, MEDICINE, V51, P337, DOI 10.1097/00005792-197209000-00001; TAJIK AJ, 1978, MAYO CLIN PROC, V53, P271; VAZIRI SM, 1994, CIRCULATION, V89, P724, DOI 10.1161/01.CIR.89.2.724; WILSON MG, 1957, CIRCULATION, V16, P700, DOI 10.1161/01.CIR.16.5.700	48	444	453	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1417	1423		10.1056/NEJM199611073351902	http://dx.doi.org/10.1056/NEJM199611073351902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT339	8875918	Bronze			2022-12-28	WOS:A1996VT33900002
J	Feinberg, MB				Feinberg, MB			Lessons from and about AIDS ...	LANCET			English	Editorial Material											Feinberg, MB (corresponding author), NIH,OFF AIDS RES,BETHESDA,MD 20892, USA.							Coates TJ, 1996, LANCET, V348, P1143, DOI 10.1016/S0140-6736(96)02307-0; DCRUZGROTE, 1996, LANCET, V348, P1071; Feinberg MB, 1996, LANCET, V348, P239, DOI 10.1016/S0140-6736(96)06231-9; Haynes BF, 1996, LANCET, V348, P933, DOI 10.1016/S0140-6736(96)09339-7; Kirby M, 1996, LANCET, V348, P1217, DOI 10.1016/S0140-6736(96)05468-2; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1188	1188		10.1016/S0140-6736(05)65479-7	http://dx.doi.org/10.1016/S0140-6736(05)65479-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898034				2022-12-28	WOS:A1996VQ46700007
J	Harper, PS				Harper, PS			Naming of syndromes and unethical activities: The case of Hallervorden and Spatz	LANCET			English	Editorial Material											Harper, PS (corresponding author), UNIV WALES COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							ADAMS JH, 1992, GREENFIELDS NEUROPAT, P857; Beighton P., 1986, MAN SYNDROME; ELEJALDE BR, 1979, CLIN GENET, V16, P1; FIRKIN BG, 1987, DICT MED EPONYMS, P214; Hallervorden J, 1922, Z GESAMTE NEUROL PSY, V79, P254, DOI 10.1007/BF02878455; JABLONSKI S, 1991, JABLONSKIS DICT SYND; Leiber Bernfried, 1957, WORTERBUCH KLINISCHE; Muller-Hill B., 1988, MURDEROUS SCI; Peiffer J, 1991, BRAIN PATHOL, V1, P125, DOI 10.1111/j.1750-3639.1991.tb00649.x; Spatz H, 1966, Nervenarzt, V37, P477; VANBOGAERT L, 1967, J NEUROL SCI, V5, P190, DOI 10.1016/0022-510X(67)90018-4	11	48	48	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1224	1225		10.1016/S0140-6736(96)05222-1	http://dx.doi.org/10.1016/S0140-6736(96)05222-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898043				2022-12-28	WOS:A1996VQ46700017
J	Merdes, A; Ramyar, K; Vechio, JD; Cleveland, DW				Merdes, A; Ramyar, K; Vechio, JD; Cleveland, DW			A complex of NuMA and cytoplasmic dynein is essential for mitotic spindle assembly	CELL			English	Article							MONOCLONAL-ANTIBODIES; APPARATUS PROTEIN; SPN ANTIGEN; PTK2 CELLS; MICROTUBULES; ORGANIZATION; CENTROSOME; EXTRACTS; MITOSIS; MOTOR	NuMA is a nuclear protein during interphase but redistributes to the spindle poles early in mitosis. To investigate its role during spindle formation, we tested spindle assembly in frog egg extracts from which NuMA was immunodepleted. Immunodepletion revealed that NuMA forms a complex with cytoplasmic dynein and dynactin. The depleted extracts failed to assemble normal mitotic spindles, producing, instead, chromatin-associated irregular arrays of microtubules lacking characteristic spindle poles. A subdomain of the NuMA tail was shown to induce microtubule aster formation by mediating microtubule bundling. Our findings suggest that NuMA forms bifunctional complexes with cytoplasmic dynein and dynactin that can tether microtubules at the spindle poles and that are essential for mitotic spindle pole assembly and stabilization.	UNIV CALIF SAN DIEGO,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	University of California System; University of California San Diego; Johns Hopkins University	Merdes, A (corresponding author), UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,LA JOLLA,CA 92093, USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029513, R01GM029513] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29513] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; COMPTON DA, 1995, J CELL SCI, V108, P621; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GOUNARI F, 1993, J CELL BIOL, V121, P847, DOI 10.1083/jcb.121.4.847; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; KALLAJOKI M, 1991, EMBO J, V10, P3351, DOI 10.1002/j.1460-2075.1991.tb04899.x; KALLAJOKI M, 1992, J CELL SCI, V102, P91; KALLAJOKI M, 1993, J CELL SCI, V104, P139; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAEKAWA T, 1991, EUR J CELL BIOL, V54, P255; MASTRONARDE DN, 1993, J CELL BIOL, V123, P1475, DOI 10.1083/jcb.123.6.1475; Matthies HJG, 1996, J CELL BIOL, V134, P455, DOI 10.1083/jcb.134.2.455; MAZIA D, 1987, INT REV CYTOL, V100, P49; McNally FJ, 1996, J CELL SCI, V109, P561; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; NICKLAS RB, 1989, J CELL SCI, V94, P415; NICLAS J, 1996, J CELL BIOL, V133, P558; Saredi A, 1996, J CELL SCI, V109, P619; SAWIN KE, 1992, J CELL SCI, V101, P303; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TANG TK, 1994, J CELL SCI, V107, P1389; TANG TK, 1993, J CELL SCI, V104, P249; TOUSSON A, 1991, J CELL BIOL, V112, P427, DOI 10.1083/jcb.112.3.427; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303; YANG CH, 1992, MOL BIOL CELL, V3, P1259, DOI 10.1091/mbc.3.11.1259	43	456	462	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					447	458		10.1016/S0092-8674(00)81365-3	http://dx.doi.org/10.1016/S0092-8674(00)81365-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898198	hybrid			2022-12-28	WOS:A1996VQ46600011
J	NoirotGros, MF; Ehrlich, SD				NoirotGros, MF; Ehrlich, SD			Change of a catalytic reaction carried out by a DNA replication protein	SCIENCE			English	Article							ACTIVE-SITE TYROSINE; STRAND TRANSFER; TOPOISOMERASE; MUTAGENESIS; MECHANISM	The RepA protein of plasmid pC194 initiates and terminates rolling circle replication. At initiation, it forms a 5'-phosphotyrosyl DNA link, whereas at termination, a glutamate residue directs hydrolytic cleavage of the newly synthesized origin, and the resulting 5'-hydroxyl group undergoes transesterification with the phosphotyrosine link. The protein is thus released from DNA, and the termination is uncoupled from reinitiation of replication. Replacement of the glulamate with tyrosine in RepA altered this mechanism, so that termination occurred by two successive transesterifications and became coupled to reinitiation. This result suggests that various enzymes involved in DNA cleavage and rejoining may have similar mechanistic and evolutionary roots.	INRA,F-78352 JOUY EN JOSAS,FRANCE	INRAE; UDICE-French Research Universities; Universite Paris Saclay			Noirot-Gros, Marie-Françoise/AAY-1001-2021; Ehrlich, S./Y-2423-2019; noirot-gros, marie-francoise/C-5051-2011	Ehrlich, S./0000-0002-7563-4046; 				ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; GROS MF, 1989, EMBO J, V8, P2711, DOI 10.1002/j.1460-2075.1989.tb08412.x; HANAI R, 1993, J BIOL CHEM, V268, P23830; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; NOIROTGROS MF, 1994, EMBO J, V13, P4412, DOI 10.1002/j.1460-2075.1994.tb06761.x; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; RASOOLY A, 1993, SCIENCE, V262, P1048, DOI 10.1126/science.8235621; REED RR, 1984, COLD SPRING HARB SYM, V49, P245, DOI 10.1101/SQB.1984.049.01.028; ROTH MJ, 1984, J BIOL CHEM, V259, P556	12	22	23	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					777	780		10.1126/science.274.5288.777	http://dx.doi.org/10.1126/science.274.5288.777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864116				2022-12-28	WOS:A1996VQ14500041
J	Rucker, J; Samson, M; Doranz, BJ; Libert, F; Berson, JF; Yi, YJ; Smyth, RJ; Collman, RG; Broder, CC; Vassart, G; Doms, RW; Parmentier, M				Rucker, J; Samson, M; Doranz, BJ; Libert, F; Berson, JF; Yi, YJ; Smyth, RJ; Collman, RG; Broder, CC; Vassart, G; Doms, RW; Parmentier, M			Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; CD4-MEDIATED FUSION; MOLECULAR-CLONING; INFECTION; TYPE-1; CELLS; IDENTIFICATION; PROGRESSION; EXPRESSION	Macrophage-tropic (M-tropic) HIV-1 strains use the beta-chemokine receptor CCR5, but not CCR2b, as a cofactor for membrane fusion and infection, while the dual-tropic strain 89.6 uses both. CCR5/2b chimeras and mutants were used to map regions of CCR5 important for cofactor function and specificity. M-tropic strains required either the amino-terminal domain or the first extracellular loop of CCR5. A CCR2b chimera containing the first 20 N-terminal residues of CCR5 supported M-tropic envelope protein fusion. Aminoterminal truncations of CCR5/CCR2b chimeras indicated that residues 2-5 are important for M-tropic viruses, while 89.6 is dependent on residues 6-9. The identification of multiple functionally important regions in CCR5, coupled with differences in how CCR5 is used by M- and dual-tropic viruses, suggests that interactions between HIV-1 and entry cofactors are conformationally complex.	UNIV PENN,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; FREE UNIV BRUSSELS,IRIBHN,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,SERV GENET MED,B-1070 BRUSSELS,BELGIUM; UNIFORMED SERV UNIV HLTH SCI,DEPT IMMUNOL & MICROBIOL,BETHESDA,MD 20814	University of Pennsylvania; University of Pennsylvania; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Uniformed Services University of the Health Sciences - USA			Samson, Michel/F-8356-2013; Broder, Christopher/E-1169-2013	Parmentier, Marc/0000-0001-8081-4685	NIAID NIH HHS [AI-35383, AI-38225] Funding Source: Medline; NINDS NIH HHS [NS-27405] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035383, R01AI038225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS027405, P01NS027405] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; ALEXANDER WA, 1992, J VIROL, V66, P2934, DOI 10.1128/JVI.66.5.2934-2942.1992; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; ASJO B, 1986, LANCET, V2, P660; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; Earl P, 1991, CURRENT PROTOCOLS MO; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRANCI C, 1995, J IMMUNOL, V154, P6511; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LustiNarasimhan M, 1996, J BIOL CHEM, V271, P3148, DOI 10.1074/jbc.271.6.3148; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; Zhao-Hai Lu, 1995, Journal of Biological Chemistry, V270, P26239	41	273	296	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					437	446		10.1016/S0092-8674(00)81364-1	http://dx.doi.org/10.1016/S0092-8674(00)81364-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898197	hybrid			2022-12-28	WOS:A1996VQ46600010
J	Conconi, A; Smerdon, MJ; Howe, GA; Ryan, CA				Conconi, A; Smerdon, MJ; Howe, GA; Ryan, CA			The octadecanoid signalling pathway in plants mediates a response to ultraviolet radiation	NATURE			English	Article							PROTEINASE INHIBITOR-I; GENE-EXPRESSION; TOMATO LEAVES; VIRUS-INFECTION; B RADIATION; ACID; ACTIVATION; INDUCTION; DAMAGE; CELLS	MANY plant genes that respond to environmental and developmental changes are regulated by jasmonic acid, which is derived from linolenic acid via the octadecanoid pathway(1). Linolenic acid is an important fatty-acid constituent of membranes in most plant species and its intracellular levels increase in response to certain signals. Here we report that irradiation of tomato leaves with ultraviolet light induces the expression of several plant defensive genes that are normally activated through the octadecanoid pathway after wounding(2). The response to ultraviolet light is blocked by an inhibitor of the octadecanoid pathway and it does not occur in a tomato mutant defective in this pathway. The ultraviolet irradiation maximally induces the defence genes at levels where cyclobutane pyrimidine dimer formation, an indicator of DNA damage, is less than 0.2 dimers per gene. Our evidence indicates that this plant defence response to certain wavelengths of ultraviolet radiation requires the activation of the octadecanoid defence signalling pathway.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164	Washington State University; Washington State University			Howe, Gregg A/N-1887-2014	Howe, Gregg A/0000-0002-9218-979X				BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; COHEN D, 1993, PHOTOCHEM PHOTOBIOL, V57, P383, DOI 10.1111/j.1751-1097.1993.tb02306.x; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; GOLD WG, 1983, PHYSIOL PLANTARUM, V58, P435, DOI 10.1111/j.1399-3054.1983.tb04205.x; GORDON LK, 1982, RADIAT RES, V89, P99, DOI 10.2307/3575688; GRAHAM JS, 1986, PLANTA, V169, P399, DOI 10.1007/BF00392137; GRAHAM JS, 1985, J BIOL CHEM, V260, P6561; GREEN R, 1995, PLANT CELL, V7, P203, DOI 10.1105/tpc.7.2.203; HAWK JLM, 1983, J INVEST DERMATOL, V80, P496, DOI 10.1111/1523-1747.ep12535038; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HILDMANN T, 1992, PLANT CELL, V4, P1157, DOI 10.1105/tpc.4.9.1157; HOWE GA, IN PRESS PLANT CELL; JONES JS, 1991, NUCLEIC ACIDS RES, V19, P893, DOI 10.1093/nar/19.4.893; LEE JS, 1986, P NATL ACAD SCI USA, V83, P7277, DOI 10.1073/pnas.83.19.7277; MITCHELL DL, 1992, NUCLEIC ACIDS RES, V20, P225, DOI 10.1093/nar/20.2.225; MITCHELL DL, 1991, PHOTOCHEM PHOTOBIOL, V54, P741, DOI 10.1111/j.1751-1097.1991.tb02084.x; MURAD AO, 1995, J BIOL CHEM, V270, P3949, DOI 10.1074/jbc.270.8.3949; PENACORTES H, 1993, PLANTA, V191, P123, DOI 10.1007/BF00240903; QUAITE FE, 1992, NATURE, V358, P576, DOI 10.1038/358576a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; REINBOTHE S, 1994, PLANT CELL, V6, P1197, DOI 10.1105/tpc.6.9.1197; SCHALLER A, 1995, PLANT CELL, V7, P1893, DOI 10.1105/tpc.7.11.1893; SHENG YH, 1995, CURR EYE RES, V14, P341, DOI 10.3109/02713689508999931; STAPLETON AE, 1992, PLANT CELL, V4, P1353, DOI 10.1105/tpc.4.11.1353; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984	30	183	203	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					826	829		10.1038/383826a0	http://dx.doi.org/10.1038/383826a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893008				2022-12-28	WOS:A1996VQ14400064
J	Snowden, JA; Biggs, JC; Brooks, PM				Snowden, JA; Biggs, JC; Brooks, PM			Autologous blood stem cell transplantation for autoimmune diseases	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; RHEUMATOID-ARTHRITIS; ANTIBODY		ST VINCENTS HOSP,MED PROFESSORIAL UNIT,SYDNEY,NSW 2110,AUSTRALIA	St Vincents Hospital Sydney	Snowden, JA (corresponding author), ST VINCENTS HOSP,DEPT HAEMATOL,SYDNEY,NSW 2110,AUSTRALIA.			SNOWDEN, JOHN/0000-0001-6819-3476				ATKINSON K, 1995, AUST NZ J MED, V25, P483, DOI 10.1111/j.1445-5994.1995.tb01492.x; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; HAMILTON JA, 1995, BAILLIERE CLIN RHEUM, V9, P673; MARKENSON JA, 1991, SEMIN ARTHRITIS RHEU, V21, P4, DOI 10.1016/0049-0172(91)90046-3; MARMONT AM, 1994, STEM CELLS, V12, P125, DOI 10.1002/stem.5530120119; MIYAHARA H, 1993, CLIN IMMUNOL IMMUNOP, V69, P69, DOI 10.1006/clin.1993.1151; MKENDRY RJR, 1996, ARTHRITIS RHEUM, V39, P1246; Tyndall A, 1996, ANN RHEUM DIS, V55, P149, DOI 10.1136/ard.55.3.149; VIDARSSON B, 1995, AM J MED, V98, P589, DOI 10.1016/S0002-9343(99)80019-9; WILSKE KR, 1993, RHEUM DIS CLIN N AM, V19, P153	10	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1112	1113		10.1016/S0140-6736(05)65267-1	http://dx.doi.org/10.1016/S0140-6736(05)65267-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888160				2022-12-28	WOS:A1996VP10600004
J	Shaheen, SO; Aaby, P; Hall, AJ; Barker, DJP; Heyes, CB; Shiell, AW; Goudiaby, A				Shaheen, SO; Aaby, P; Hall, AJ; Barker, DJP; Heyes, CB; Shiell, AW; Goudiaby, A			Cell mediated immunity after measles in Guinea-Bissau: Historical cohort study	BRITISH MEDICAL JOURNAL			English	Article							T-LYMPHOCYTE SUBSETS; CHILD-MORTALITY; WEST-AFRICA; DELAYED-HYPERSENSITIVITY; BANGLADESHI CHILDREN; PERUVIAN CHILDREN; VACCINE EFFICACY; COMMUNITY; IMMUNIZATION; TRANSMISSION	Objective-To investigate whether children who have had measles have reduced general cell mediated immunity three years later compared with vaccinated children who have not had measles. Design-Historical cohort study. Setting-Bissau, Guinea-Bissau. Subjects-391 children aged 3-13 years who were living in Bissau during a measles epidemic in 1991 and still lived there. These included 131 primary cases and 139 secondary cases from the epidemic and 121 vaccinated controls with no history of measles. Main outcome measures-General cell mediated immunity assessed by measurement of delayed type hypersensitivity skin responses to seven recall antigens. Anergy was defined as a lack of response to all antigens. Results-82 out of 268 cases of measles (31%) were anergic compared with 20 of the 121 vaccinated controls (17%) (odds ratio adjusted for potential confounding variables 2.2 (95% confidence interval 1.2 to 4.0); P = 0.009), The prevalence of anergy was higher in secondary cases (33% (46/138)) than in primary cases (28% (36/130)), although this difference was not significant, Anergy was more common in the rainy season (unadjusted prevalence 31% (91/291)) than in the dry season (11% (11/98)) (adjusted odds ratio 4.8 (2.2 to 10.3)). This seasonal increase occurred predominantly in the cases of measles. Conclusions-Reduced general cell mediated immunity may contribute to the higher long term mortality in children who have had measles compared with recipients of standard measles vaccine and to the higher child mortality in the rainy season in west Africa.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,DK-2300 COPENHAGEN,DENMARK; UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND; MINIST PUBL HLTH,BISSAU,GUINEA BISSAU	University of Southampton; Aarhus University; Statens Serum Institut; University of London; London School of Hygiene & Tropical Medicine				Aaby, Peter/0000-0001-8331-1389	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AABY P, 1993, BRIT MED J, V307, P1308, DOI 10.1136/bmj.307.6915.1308; AABY P, 1989, PEDIATR INFECT DIS J, V8, P197; AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043; AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; Aaby P, 1996, AM J EPIDEMIOL, V143, P1035, DOI 10.1093/oxfordjournals.aje.a008667; AABY P, 1993, J PEDIATR-US, V122, P904, DOI 10.1016/S0022-3476(09)90015-4; Aaby P, 1996, PEDIATR INFECT DIS J, V15, P39, DOI 10.1097/00006454-199601000-00009; AABY P, 1985, MED HYPOTHESES, V18, P93, DOI 10.1016/0306-9877(85)90042-8; AABY P, 1988, REV INFECT DIS, V10, P474; AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X; AKINWOLERE O A O, 1988, African Journal of Medicine and Medical Sciences, V17, P47; BAQUI AH, 1993, AM J EPIDEMIOL, V137, P355, DOI 10.1093/oxfordjournals.aje.a116682; BLACK RE, 1989, PEDIATR INFECT DIS J, V8, P210; CHANDRA RK, 1977, BIOL NEONATE, V31, P15; CORRIEL RN, 1985, AM J DIS CHILD, V139, P141, DOI 10.1001/archpedi.1985.02140040039022; FERGUSON AC, 1978, J PEDIATR-US, V93, P52, DOI 10.1016/S0022-3476(78)80599-X; FOULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; GADNER MJ, 1989, STAT CONFIDENCE; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; GORDIN FM, 1994, J INFECT DIS, V169, P893, DOI 10.1093/infdis/169.4.893; GREENWOOD BM, 1972, LANCET, V1, P169; HARLAND PSE, 1965, LANCET, V2, P719; HULL HF, 1983, LANCET, V1, P972; KAUFFMAN CA, 1976, INFECT IMMUN, V13, P78, DOI 10.1128/IAI.13.1.78-83.1976; KIPPS A, 1996, S AFR MED J, V40, P104; KNIKER WT, 1985, AM J DIS CHILD, V139, P840, DOI 10.1001/archpedi.1985.02140100102044; KNIKER WT, 1979, ANN ALLERGY, V43, P73; KOSTER FT, 1987, AM J CLIN NUTR, V46, P115, DOI 10.1093/ajcn/46.1.115; LEON ME, 1993, J INFECT DIS, V168, P1097, DOI 10.1093/infdis/168.5.1097; LISSE I, IN PRESS J PEDIAT; LISSE IM, 1994, T ROY SOC TROP MED H, V88, P709, DOI 10.1016/0035-9203(94)90242-9; LISSE IM, 1994, PEDIATR INFECT DIS J, V13, P109, DOI 10.1097/00006454-199402000-00006; MOLBAK K, 1992, T ROY SOC TROP MED H, V86, P216, DOI 10.1016/0035-9203(92)90580-6; PABST HF, 1989, LANCET, V1, P295, DOI 10.1016/S0140-6736(89)91307-X; POULSEN AG, 1989, LANCET, V1, P827, DOI 10.1016/S0140-6736(89)92281-2; POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941; SALMERON G, 1983, AM J MED, V75, P19, DOI 10.1016/0002-9343(83)91266-4; SCHLESINGER JJ, 1977, LANCET, V2, P529; SEMBA RD, 1993, LANCET, V341, P5, DOI 10.1016/0140-6736(93)92478-C; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Smedman L, 1983, Ann Trop Paediatr, V3, P169; SMITH SM, 1987, J NUTR, V117, P857, DOI 10.1093/jn/117.5.857; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; TAMASHIRO VG, 1987, PEDIATR INFECT DIS J, V6, P451, DOI 10.1097/00006454-198705000-00007; von Pirquet C, 1908, DEUT MED WOCHENSCHR, V34, P1297; WHITTLE HC, 1973, ARCH DIS CHILD, V48, P753, DOI 10.1136/adc.48.10.753; 1994, LANCET, V344, P174	47	59	59	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					969	974						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892416	Green Published			2022-12-28	WOS:A1996VN91600020
J	Hunter, CP; Kenyon, C				Hunter, CP; Kenyon, C			Spatial and temporal controls target pal-1 blastomere-specification activity to a single blastomere lineage in C-elegans embryos	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA BODY PATTERN; 3' UNTRANSLATED REGION; MESSENGER-RNA; HOMEOBOX GENE; TRANSLATIONAL REGULATION; CELLULAR INTERACTIONS; PROTEIN GRADIENT; MATERNAL GENES; CAUDAL GENE	The early asymmetric cleavages of Caenorhabditis elegans embryos produce blastomeres with distinct developmental potentials. Here, we show that the caudal-like homeodomain protein PAL-1 is required to specify the somatic identity of one posterior blastomere in the 4 cell embryo. We find that pal-1 activity is sequentially restricted to this blastomere. First, at the 4 cell stage, it is translated only in the two posterior blastomeres. Then, its function is restricted to one of these blastomeres. This second targeting step is dependent on the activities of the posteriorly localized SKN-1 and asymmetrically segregated PIE-1 proteins. We propose that the segregation of PIE-1, combined with the temporal decay of SKN-1, targets pal-1 activity to this posterior lineage, thus coupling the regulation of this conserved posterior patterning gene to asymmetric cell cleavages.			Hunter, CP (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037053] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37053] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; Ahringer J, 1996, GENE DEV, V10, P1120, DOI 10.1101/gad.10.9.1120; BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; BORING L, 1993, MECH DEVELOP, V42, P97, DOI 10.1016/0925-4773(93)90102-4; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FRUMKIN A, 1991, DEVELOPMENT, V112, P207; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HUTTER H, 1995, DEVELOPMENT, V121, P1559; HUTTER H, 1994, DEVELOPMENT, V120, P2051; JOLY JS, 1992, DIFFERENTIATION, V50, P75, DOI 10.1111/j.1432-0436.1992.tb00488.x; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; Miller DM, 1995, METHOD CELL BIOL, V48, P365; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MOSKOWITZ IPG, 1994, DEVELOPMENT, V120, P3325; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SCHULZ C, 1995, DEVELOPMENT, V121, P1023; SCHULZ C, 1994, DEVELOPMENT, V120, P3043; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; Seydoux G, 1995, METHOD CELL BIOL, V48, P323; STJOHNSTON D, 1992, CELL, V68, P201; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SURDEJ P, 1994, ANNU REV GENET, V28, P263; WARING DA, 1991, NATURE, V350, P712, DOI 10.1038/350712a0; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WOOD WB, 1994, TRENDS GENET, V10, P49, DOI 10.1016/0168-9525(94)90148-1; XU X, 1994, DEVELOPMENT, V120, P277; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381	52	175	186	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					217	226		10.1016/S0092-8674(00)81340-9	http://dx.doi.org/10.1016/S0092-8674(00)81340-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861906	Bronze			2022-12-28	WOS:A1996VN40300010
J	Rowles, A; Chong, JPJ; Brown, L; Howell, M; Evan, GI; Blow, JJ				Rowles, A; Chong, JPJ; Brown, L; Howell, M; Evan, GI; Blow, JJ			Interaction between the origin recognition complex and the replication licensing system in Xenopus	CELL			English	Article							CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; CELL-CYCLE; EGG EXTRACTS; CHROMOSOMAL REPLICATION; NUCLEAR-ENVELOPE; PURIFIED DNA; YEAST; INITIATION; PROTEIN	The origin recognition complex (ORC) binds to origins of replication in budding yeast. We have cloned a Xenopus homolog of the largest ORC polypeptide (XORC1). Immunodepletion of XOrc1 from Xenopus egg extracts blocks the initiation of DNA replication. We have purified Xenopus ORC, consisting of a protein complex similar to yeast ORC. In Xenopus egg extracts, ORC associates with chromatin throughout G1 and S phases. RLF-M, a component of the replication licensing system, also associates with chromatin early in the cell cycle but dissociates during S phase. We show that the assembly of RLF-M onto chromatin is dependent on the presence of chromatin-bound ORC, leading to sequential assembly of initiation proteins onto replication origins during the cell cycle.	IMPERIAL CANC RES FUND, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	Rowles, A (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND.		Chong, James/AAC-4957-2019; Blow, J. Julian/B-3977-2009	Blow, J. Julian/0000-0002-9524-5849; Chong, James/0000-0001-9447-7421; Howell, Michael/0000-0003-0912-0079				BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; CHEVALIER S, 1995, J CELL SCI, V108, P1831; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOLAN A, 1992, J GEN VIROL, V73, P971, DOI 10.1099/0022-1317-73-4-971; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; Harlow E., 1988, ANTIBODIES LAB MANUA; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; LASKEY RA, 1993, PHILOS T ROY SOC B, V339, P263, DOI 10.1098/rstb.1993.0024; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; MAINE GT, 1984, GENETICS, V106, P365; MAITI AK, 1992, J MOL BIOL, V224, P545, DOI 10.1016/0022-2836(92)90543-S; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SINHA P, 1986, J MOL BIOL, V192, P805, DOI 10.1016/0022-2836(86)90030-6; Strausfeld UP, 1996, J CELL SCI, V109, P1555; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	60	222	225	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1996	87	2					287	296		10.1016/S0092-8674(00)81346-X	http://dx.doi.org/10.1016/S0092-8674(00)81346-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861912	Bronze			2022-12-28	WOS:A1996VN40300016
J	Kamada, K; Horiuchi, T; Ohsumi, K; Shimamoto, N; Morikawa, K				Kamada, K; Horiuchi, T; Ohsumi, K; Shimamoto, N; Morikawa, K			Structure of a replication-terminator protein complexed with DNA	NATURE			English	Article							RIBOSOMAL-RNA GENES; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; ANTIGEN HELICASE; BINDING-PROTEIN; FORK MOVEMENT; SEQUENCE; INVITRO; IDENTIFICATION	The crystal structure of the Escherichia coli replication-terminator protein (Tus) bound to terminus-site (Ter) DNA has been determined at 2.7 Angstrom resolution. The Tus protein folds into a previously undescribed architecture divided into two domains by a central basic cleft. This cleft accommodates locally deformed B-form Ter DNA and makes extensive contacts with the major groove, mainly through two interdomain beta-strands. The unusual structural features of this complex may explain how the replication fork is halted in only one direction.	PROT ENGN RES INST,BIOMOL ENGN RES INST,SUITA,OSAKA 565,JAPAN; NATL INST GENET,MISHIMA,SHIZUOKA 411,JAPAN; GRAD UNIV ADV STUDIES,DEPT MOL BIOMECH,OKAZAKI,AICHI 444,JAPAN; NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN; GRAD UNIV ADV STUDIES,DEPT GENET,MISHIMA,SHIZUOKA 411,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan			Shimamoto, Nobuo/AAJ-4999-2020; Kamada, Katsuhiko/M-3666-2017	Shimamoto, Nobuo/0000-0001-7579-0084; Kamada, Katsuhiko/0000-0001-8523-3417				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BABCOCK MS, 1993, J BIOMOL STRUCT DYN, V11, P597, DOI 10.1080/07391102.1993.10508018; BAKER TA, 1995, CELL, V80, P521, DOI 10.1016/0092-8674(95)90504-9; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUSSIERE DE, 1995, CELL, V80, P651; DUGGAN LJ, 1995, J BIOL CHEM, V270, P28049; FRANKS AH, 1995, MOL MICROBIOL, V17, P13, DOI 10.1111/j.1365-2958.1995.mmi_17010013.x; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HERNANDEZ P, 1988, EMBO J, V7, P303, DOI 10.1002/j.1460-2075.1988.tb02813.x; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; HORIUCHI T, 1995, J BACTERIOL, V177, P783, DOI 10.1128/jb.177.3.783-791.1995; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamada K, 1996, PROTEINS, V24, P402; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MARUYAMA M, 1983, J MOL BIOL, V167, P757, DOI 10.1016/S0022-2836(83)80109-0; NATARAJAN S, 1993, CELL, V72, P113, DOI 10.1016/0092-8674(93)90055-U; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OLIS DL, 1985, NATURE, V313, P762; OTWINOWSKI Z, 1994, MACEDENZO MANUAL; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SKOLKOTAS A, 1994, J BIOL CHEM, V269, P20446; SKOLKOTAS A, 1995, J BIOL CHEM, V270, P30941; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SWINDELLS MB, 1995, TRENDS BIOCHEM SCI, V20, P300, DOI 10.1016/S0968-0004(00)89055-6; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WEISS AS, 1984, J MOL BIOL, V179, P745, DOI 10.1016/0022-2836(84)90165-7; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; YOUNG PA, 1994, J MOL BIOL, V240, P275, DOI 10.1006/jmbi.1994.1444	41	92	96	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					598	603		10.1038/383598a0	http://dx.doi.org/10.1038/383598a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857533				2022-12-28	WOS:A1996VM75500045
J	Weinstein, MC; Siegel, JE; Gold, MR; Kamlet, MS; Russell, LB				Weinstein, MC; Siegel, JE; Gold, MR; Kamlet, MS; Russell, LB			Recommendations of the panel on cost-effectiveness in health and medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOCIAL PREFERENCES; STATES	Objective.-To develop consensus-based recommendations for the conduct of cost-effectiveness analysis (CEA), This article, the second in a 3-part series, describes the basis for recommendations constituting the reference case analysis, the set of practices developed to guide CEAs that inform societal resource allocation decisions, and the content of these recommendations. Participants.-The Panel on Cost-Effectiveness in Health and Medicine, a nonfederal panel with expertise in CEA, clinical medicine, ethics, and health outcomes measurement, was convened by the US Public Health Service (PHS). Evidence.-The panel reviewed the theoretical foundations of CEA, current practices, and alternative methods used in analyses, Recommendations were developed on the basis of theory where possible, but tempered by ethical and pragmatic considerations, as well as the needs of users. Consensus Process.-The panel developed recommendations through 2 1/2 years of discussions, Comments on preliminary drafts prepared by panel working groups were solicited from federal government methodologists, health agency officials, and academic methodologists. Conclusions.-The panel's methodological recommendations address (1) components belonging in the numerator and denominator of a cost-effectiveness (C/E) ratio; (2) measuring resource use in the numerator of a C/E ratio; (3) valuing health consequences in the denominator of a C/E ratio; (4) estimating effectiveness of interventions; (5) incorporating time preference and discounting; and (6) handling uncertainty, Recommendations are subject to the ''rule of reason,'' balancing the burden engendered by a practice with its importance to a study, If researchers follow a standard set of methods in CEA, the quality and comparability of studies, and their ultimate utility, can be much improved.	US PHS,OFF DIS PREVENT & HLTH PROMOT,WASHINGTON,DC 20201; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT MATERNAL & CHILD HLTH,BOSTON,MA 02115; CARNEGIE MELLON UNIV,HEINZ SCH,PITTSBURGH,PA 15213; RUTGERS STATE UNIV,INST HLTH HLTH CARE POLICY & AGING RES,NEW BRUNSWICK,NJ 08903	United States Public Health Service; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Carnegie Mellon University; Rutgers State University New Brunswick								ERICKSON P, 1995, DEP HLTH HUMAN SERV; GARBER AM, IN PRESS J HLTH EC; Gold MR, 1996, COST EFFECTIVENESS H; KAPLAN RM, 1988, HEALTH SERV RES, V23, P203; KOOPMANSCHAP MA, 1995, J HEALTH ECON, V14, P171, DOI 10.1016/0167-6296(94)00044-5; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; MELTZER DO, IN PRESS J HLTH EC; NEWHOUSE JP, 1992, J ECON PERSPECT, V6, P3, DOI 10.1257/jep.6.3.3; NORD E, 1992, SOC SCI MED, V34, P559, DOI 10.1016/0277-9536(92)90211-8; Patrick D. L., 1993, HLTH STATUS HLTH POL; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Russell LB., 1986, IS PREVENTION BETTER; SIEGEL JE, IN PRESS JAMA; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; TORRANCE GW, 1976, SOCIO ECON PLAN SCI, V10, P129, DOI 10.1016/0038-0121(76)90036-7; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; Torrance GW, 1987, METHODS EC EVALUATIO; UDVARHELYI S, 1992, ANN INTERN MED, V116, P238; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WEINSTEIN MC, 1976, HYPERTENSION POLICY; 1990, HLTH POLICY, V16, P199	23	1999	2009	3	114	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1253	1258		10.1001/jama.276.15.1253	http://dx.doi.org/10.1001/jama.276.15.1253			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VL691	8849754				2022-12-28	WOS:A1996VL69100035
J	Doyle, L				Doyle, L			Antenatal phenobarbitone and neonatal outcome	LANCET			English	Editorial Material											Doyle, L (corresponding author), ROYAL HOSP WOMEN,DEPT OBSTET & GYNAECOL,CARLTON,VIC 3053,AUSTRALIA.		Doyle, Lex/AAJ-5205-2021	Doyle, Lex/0000-0002-7667-7312				Horbar Jeffrey D., 1992, P562; MENT LR, 1994, PEDIATRICS, V93, P543; NELSON KB, 1995, PEDIATRICS, V95, P263; Shankaran S, 1996, PEDIATRICS, V97, P644; Shankaran S, 1996, PEDIATRICS, V97, P649; Shankaran Seetha, 1996, Pediatric Research, V39, p245A	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					975	976		10.1016/S0140-6736(05)64922-7	http://dx.doi.org/10.1016/S0140-6736(05)64922-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855850				2022-12-28	WOS:A1996VM02700006
J	Rasio, FA; Ford, EB				Rasio, FA; Ford, EB			Dynamical instabilities and the formation of extrasolar planetary systems	SCIENCE			English	Article							OUTER PLANETS; EVOLUTION	The existence of a dominant massive planet, Jupiter, in our solar system, although perhaps essential for long-term dynamical stability and the development of life, may not be typical of planetary systems that form around other stars. In a system containing two Jupiter-like planets, the possibility exists that a dynamical instability will develop. Computer simulations suggest that in many cases this instability leads to the ejection of one planet while the other is left in a smaller, eccentric orbit. In extreme cases, the eccentric orbit has a small enough periastron distance that it may circularize at an orbital period as short as a few days through tidal dissipation. This may explain the recently detected Jupiter-mass planets in very tight circular orbits and wider eccentric orb its around nearby stars.			Rasio, FA (corresponding author), MIT, DEPT PHYS, CAMBRIDGE, MA 02139 USA.		Ford, Eric B./AAB-5479-2019	Ford, Eric B./0000-0001-6545-639X; Rasio, Frederic/0000-0002-7132-418X				BOSS AP, 1995, SCIENCE, V267, P360, DOI 10.1126/science.267.5196.360; BOSS AP, 1996, LUNAR PLANET SCI, V27, P139; Butler RP, 1996, ASTROPHYS J, V464, pL153, DOI 10.1086/310102; Chambers JE, 1996, ICARUS, V119, P261, DOI 10.1006/icar.1996.0019; GLADMAN B, 1993, ICARUS, V106, P247, DOI 10.1006/icar.1993.1169; HUT P, 1981, ASTRON ASTROPHYS, V99, P126; IOANNOU PJ, 1993, ASTROPHYS J, V406, P266, DOI 10.1086/172438; Lin DNC, 1996, NATURE, V380, P606, DOI 10.1038/380606a0; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; Marcy GW, 1996, ASTROPHYS J, V464, pL147, DOI 10.1086/310096; MARDLING RA, 1995, ASTROPHYS J, V450, P732, DOI 10.1086/176179; QUINLAN GD, 1992, IAU SYMP, V152, P25; Rasio FA, 1996, ASTROPHYS J, V470, P1187, DOI 10.1086/177941; Schilling G, 1996, SCIENCE, V273, P429, DOI 10.1126/science.273.5274.429; Vetterling V., 1992, NUMERICAL RECIPES, V693, P59; WILLIAMS E, UNPUB	18	740	747	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	1996	274	5289					954	956		10.1126/science.274.5289.954	http://dx.doi.org/10.1126/science.274.5289.954			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875930				2022-12-28	WOS:A1996VR79200039
J	Speroff, L; Rowan, J; Symons, J; Genant, H; Wilborn, W				Speroff, L; Rowan, J; Symons, J; Genant, H; Wilborn, W			The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study) - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; OSTEOPOROSIS; FRACTURE; MASS; WITHDRAWAL; PREVENTION; BENEFITS; ACETATE; RISKS	Objective.-To compare the effect of continuous norethindrone acetate (NA)-ethinyl estradiol (EE(2)) combinations with matching unopposed EE(2) or placebo. Design.-A 2-year, double-blind, placebo-controlled, parallel-group clinical trial. Setting.-Outpatients at 65 centers. Patients.-Asymptomatic or mildly symptomatic women aged 40 years or older who had undergone the onset of spontaneous menopause within the last 5 years and who had an intact uterus. Interventions.-Patients were equally randomized to placebo or 1 of 8 treatment groups: 0.2 mg of NA and 1 mu g of EE(2); 0.5 mg of NA and 2.5 mu g of EE(2); 1 mg of NA and 5 mu g of EE(2); 1 mg of NA and 10 mu g of EE(2); 1 mu g of EE(2); 2.5 mu g of EE(2); 5 mu g of EE(2); or 10 mu g of EE(2). Primary Outcome Measures.-Bone mineral density (BMD) measured by quantitative computed tomography, serum lipids, and endometrial effects as assessed by rate of hyperplasia and proliferative status. Results.-Twelve hundred sixty-five patients entered the study, Bone mineral density increased significantly from baseline (P<.001) in the 1 mg NA-5 mu g EE(2) and the 1 mg NA-10 mu g EE(2) treatment groups at each annual assessment. Among the unopposed EE(2) groups, only the 10-mu g group had increased BMD above baseline, but also was accompanied by an unacceptably high rate of endometrial hyperplasia. The NA-EE(2) treatment groups had a significant linear dose-response trend for increasing BMD. Increased endometrial proliferation and hyperplasia occurred with increasing unopposed estrogen doses, The combination of NA and EE(2) effectively protected the endometrium against hyperplasia. The percentage of change in the ratio of high-density lipoprotein cholesterol to low-density lipoprotein cholesterol was positive for all treatment groups; The increase in triglyceride levels associated with EE(2) was attenuated with NA-EE(2) treatment. Conclusions.-Daily treatment with NA-EE(2) was well tolerated and protected the endometrium from EE(2)-induced proliferation and hyperplasia, The NA-EE(2) treatments produced a dose-related significant increase in BMD that was not present with unopposed EE(2)treatment. The overall effect of NA-EE(2) treatments on lipid measures was favorable.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,ANN ARBOR,MI 48105; OREGON HLTH SCI UNIV,DEPT OBSTET & GYNECOL,PORTLAND,OR 97201; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143; STRUCT RES CTR,MOBILE,AL	Pfizer; Oregon Health & Science University; University of California System; University of California San Francisco								ARCHER DF, 1994, OBSTET GYNECOL, V83, P686; BARENTSEN R, 1993, EUR J OBSTET GYN R B, V51, P203, DOI 10.1016/0028-2243(93)90036-C; BARRETTCONNOR E, 1992, ANNU REV MED, V43, P239, DOI 10.1146/annurev.med.43.1.239; BLUNT BA, 1993, J BONE MINER RES, V8, pS356; CHRISTIANSEN C, 1981, LANCET, V1, P459; DELIGDISCH L, 1993, MODERN PATHOL, V6, P94; DELVA MD, 1993, CAN FAM PHYSICIAN, V39, P2149; EIKEN P, 1995, MATURITAS, V22, P97, DOI 10.1016/0378-5122(95)00921-7; ESTILO MJ, 1991, J BONE MINER RES  S1, V6, pS335; ETTINGER B, 1994, MENOPAUSE, V1, P19; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; GENANT HK, 1989, AM J OBSTET GYNECOL, V161, P1842, DOI 10.1016/S0002-9378(89)80004-3; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; GLUER CC, 1993, OSTEOPOROSIS INT, V3, P227, DOI 10.1007/BF01623825; HAHN RG, 1984, J FAM PRACTICE, V18, P411; HANKEY BF, 1991, US DEP HHS PUBLICATI; HEMMINKI E, 1991, DICP ANN PHARMAC, V25, P418, DOI 10.1177/106002809102500416; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; JENSEN GF, 1982, CLIN ORTHOP RELAT R, V166, P75; KROGER H, 1995, J BONE MINER RES, V10, P302; LAFFERTY FW, 1994, AM J MED, V97, P66, DOI 10.1016/0002-9343(94)90050-7; LAVALJEANTET AM, 1993, J COMPUT ASSIST TOMO, V17, P915, DOI 10.1097/00004728-199311000-00012; LINDSAY R, 1992, OSTEOPOROSIS INT, V2, P267; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; RYAN PJ, 1992, BRIT J OBSTET GYNAEC, V99, P325, DOI 10.1111/j.1471-0528.1992.tb13732.x; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WILLIAMS SR, 1990, AM J OBSTET GYNECOL, V162, P438, DOI 10.1016/0002-9378(90)90402-S; WREN BG, 1991, MATURITAS, V13, P17, DOI 10.1016/0378-5122(91)90281-T; 1995, JAMA-J AM MED ASSOC, V273, P199; 1995, JAMA-J AM MED ASSOC, V274, P1676	31	204	212	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1397	1403		10.1001/jama.276.17.1397	http://dx.doi.org/10.1001/jama.276.17.1397			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892714				2022-12-28	WOS:A1996VQ46400025
J	White, NJ				White, NJ			Can amodiaquine be resurrected?	LANCET			English	Editorial Material											White, NJ (corresponding author), MAHIDOL UNIV,FAC TROP MED,BANGKOK 10400,THAILAND.		White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; 				PHILLIPSHOWARD PA, 1980, J ROY SOC MED, V83, P82; *WHO, 1993, 19 EXP COMM MAL	2	32	32	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1184	1185		10.1016/S0140-6736(05)65475-X	http://dx.doi.org/10.1016/S0140-6736(05)65475-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898030				2022-12-28	WOS:A1996VQ46700003
J	Ireton, K; Payrastre, B; Chap, H; Ogawa, W; Sakaue, H; Kasuga, M; Cossart, P				Ireton, K; Payrastre, B; Chap, H; Ogawa, W; Sakaue, H; Kasuga, M; Cossart, P			A role for phosphoinositide 3-kinase in bacterial invasion	SCIENCE			English	Article							LISTERIA-MONOCYTOGENES; EPITHELIAL-CELLS; DYNAMIN BINDS; PROTEIN; KINASE; INTERNALIN; PLATELETS; ENTRY	Listeria monocytogenes is a bacterial pathogen that invades cultured nonphagocytic cells. inhibitors and a dominant negative mutation were used to demonstrate that efficient entry requires the phosphoinositide (PI) 9-kinase p85 alpha-p110. Infection with L. monocytogenes caused rapid increases in cellular amounts of PI(3,4)P-2 and PI(3,4,5)P-3, indicating that invading bacteria stimulated PI 3-kinase activity. This stimulation required the bacterial protein In1B, host cell tyrosine phosphorylation, and association of p85 alpha with one or more tyrosine-phosphorylated proteins. This role for PI 3-kinase in bacterial entry may have parallels in some endocytic events.	INST PASTEUR,UNITE INTERACT BACTERIES CELLULES,F-75724 PARIS 15,FRANCE; HOP PURPAN,INSERM,U326,F-31059 TOULOUSE,FRANCE; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Kobe University			OGAWA, Wataru/AAQ-9586-2020; Sakaue, Hiroshi/ABE-2337-2021	Sakaue, Hiroshi/0000-0002-2468-2363; , Bernard/0000-0002-8693-0190				ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; Dramsi S, 1996, CURR TOP MICROBIOL, V209, P61; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; IRETON K, UNPUB; KASUGA M, UNPUB; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; TANG P, 1994, MOL BIOL CELL, V5, P455, DOI 10.1091/mbc.5.4.455; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VELGE P, 1994, MICROB PATHOGENESIS, V17, P37, DOI 10.1006/mpat.1994.1050; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	19	281	288	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					780	782		10.1126/science.274.5288.780	http://dx.doi.org/10.1126/science.274.5288.780			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864117				2022-12-28	WOS:A1996VQ14500042
J	Sidrauski, C; Cox, JS; Walter, P				Sidrauski, C; Cox, JS; Walter, P			tRNA ligase is required for regulated mRNA splicing in the unfolded protein response	CELL			English	Article							TRANSFER-RNA LIGASE; KAR2 BIP GENE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; RESIDENT PROTEINS; SHUTTLE VECTORS; MESSENGER-RNAS; YEAST; KINASE	The accumulation of unfolded proteins in the endoplasmic reticulum (ER) triggers an intracellular signaling pathway, the unfolded protein response (UPR), that leads to increased transcription of genes encoding ER-resident proteins. Transcriptional activation is mediated by a dedicated transcription factor, Hac1p, whose activity is controlled by regulated splicing of its mRNA. We have identified a mutation in tRNA ligase that disrupts the UPR in the yeast Saccharomyces cerevisiae. In this mutant, splicing of HAC1 mRNA, but not tRNA, is blocked. In contrast, HAC1 mRNA splicing is not impaired in cells that are blocked in spliceosome-mediated mRNA splicing. Furthermore, the splice junctions of HAC1 mRNA do not conform to the consensus sequences of other yeast pre-mRNAs. Our results suggest that the regulated splicing of HAC1 mRNA occurs by a novel pathway, involving tRNA ligase and bypassing the spliceosome.			Sidrauski, C (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; APOSTOL BL, 1991, NUCLEIC ACIDS RES, V19, P1853, DOI 10.1093/nar/19.8.1853; BEH CT, 1995, P NATL ACAD SCI USA, V92, P9820, DOI 10.1073/pnas.92.21.9820; BORK P, 1993, FEBS LETT, V334, P149, DOI 10.1016/0014-5793(93)81701-Z; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; LEE MG, 1984, EMBO J, V3, P2825, DOI 10.1002/j.1460-2075.1984.tb02215.x; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; SWEET DJ, 1993, CURR BIOL, V3, P622, DOI 10.1016/0960-9822(93)90014-F; TEEM JL, 1983, MOL GEN GENET, V192, P101, DOI 10.1007/BF00327653; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	37	337	350	1	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1996	87	3					405	413		10.1016/S0092-8674(00)81361-6	http://dx.doi.org/10.1016/S0092-8674(00)81361-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898194	Bronze			2022-12-28	WOS:A1996VQ46600007
J	Doherty, JF; Moody, AH; Wright, SG				Doherty, JF; Moody, AH; Wright, SG			Lesson of the week - Katayama fever: An acute manifestation of schistosomiasis	BRITISH MEDICAL JOURNAL			English	Article									HOSP TROP DIS,LONDON NW1 0PE,ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine								COOK GC, 1988, LANCET, V1, P127; Davis A., 1996, Manson's tropical diseases., P1413; Day JH, 1996, BRIT MED J, V313, P268, DOI 10.1136/bmj.313.7052.268; HARRIES AD, 1987, J INFECTION, V14, P159, DOI 10.1016/S0163-4453(87)92002-0; MCLAREN ML, 1981, T ROY SOC TROP MED H, V75, P72, DOI 10.1016/0035-9203(81)90014-6; VAZQUEZ ML, 1987, NEUROLOGY, V37, P1561, DOI 10.1212/WNL.37.9.1561; 1985, NEW ENGL J MED, V312, P1376	7	64	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1071	1072						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898604	Green Published			2022-12-28	WOS:A1996VP74200038
J	Zhang, K; Guo, B; Colarusso, P; Bernath, PF				Zhang, K; Guo, B; Colarusso, P; Bernath, PF			Far-infrared emission spectra of selected gas-phase PAHs: Spectroscopic fingerprints	SCIENCE			English	Article							AROMATIC HYDROCARBON CATIONS; MOLECULES; BANDS; TEMPERATURE; DUST; IDENTIFICATION; CORONENE; MATTER	The emission spectra of the gaseous polycyclic aromatic hydrocarbons (PAHs) naphthalene, chrysene, and pyrene were recorded in the far-infrared (far-IR) region. The vibrational bands that lie in the far IR are unique for each PAH molecule and allow discrimination among the three PAH molecules. The far-IR PAH spectra, therefore, may prove useful in the assignment of unidentified spectral features from astronomical objects.	UNIV ARIZONA, DEPT CHEM, TUCSON, AZ 85721 USA	University of Arizona	Zhang, K (corresponding author), UNIV WATERLOO, DEPT CHEM, CTR MOL BEAMS & LASER CHEM, OTTAWA, ON N2L 3G1, CANADA.		Bernath, Peter F/B-6567-2012	Bernath, Peter F/0000-0002-1255-396X				ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLAMANDOLA LJ, 1985, ASTROPHYS J, V290, pL25, DOI 10.1086/184435; BERNARD JP, 1989, ASTRON ASTROPHYS, V220, P245; Bernath PF, 1996, CHEM SOC REV, V25, P111, DOI 10.1039/cs9962500111; BERNATH PF, 1992, LECT NOTES PHYSICS, V407; BLANCO A, 1990, ASTROPHYS J, V364, P152, DOI 10.1086/169396; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; Cook DJ, 1996, NATURE, V380, P227, DOI 10.1038/380227a0; DESERT FX, 1995, ASTRON ASTROPHYS, V303, P223; HAHN JH, 1988, SCIENCE, V239, P1523, DOI 10.1126/science.239.4847.1523; HUDGINS DM, 1995, J PHYS CHEM-US, V99, P8978, DOI 10.1021/j100022a007; HUDGINS DM, 1994, J PHYS CHEM-US, V98, P4243, DOI 10.1021/j100067a008; JOBLIN C, 1994, ASTRON ASTROPHYS, V281, P923; JOBLIN C, 1995, ASTRON ASTROPHYS, V299, P835; KURTZ J, 1992, ASTRON ASTROPHYS, V255, pL1; Langhoff SR, 1996, J PHYS CHEM-US, V100, P2819, DOI 10.1021/jp952074g; LEGER A, 1984, ASTRON ASTROPHYS, V137, pL5; Moutou C, 1996, ASTRON ASTROPHYS, V310, P297; MULLIE F, 1987, TOP CURR CHEM, V139, P83; PUGET JL, 1989, ANNU REV ASTRON ASTR, V27, P161; SALAMA F, 1994, J CHEM PHYS, V101, P10252, DOI 10.1063/1.467905; SCHLEMMER S, 1994, SCIENCE, V265, P1686, DOI 10.1126/science.11539830; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; SZCZEPANSKI J, 1993, ASTROPHYS J, V414, P646, DOI 10.1086/173110	24	44	44	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	1996	274	5287					582	583		10.1126/science.274.5287.582	http://dx.doi.org/10.1126/science.274.5287.582			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849443				2022-12-28	WOS:A1996VN91900041
J	Bittl, JA				Bittl, JA			Medical progress: Advances in coronary angioplasty	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ATHERECTOMY TRIAL CAVEAT; BALLOON ANGIOPLASTY; ARTERY DISEASE; MYOCARDIAL-INFARCTION; RANDOMIZED TRIAL; INTRAVASCULAR ULTRASOUND; DIRECTIONAL ATHERECTOMY; BYPASS-SURGERY; ROTATIONAL ATHERECTOMY; FOLLOW-UP				Bittl, JA (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA.			Bittl, John/0000-0003-3254-5198				ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; Alderman EL, 1996, NEW ENGL J MED, V335, P217; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; AMBROSE JA, 1994, CIRCULATION, V90, P69, DOI 10.1161/01.CIR.90.1.69; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; [Anonymous], 1994, Circulation, V89, P1545; Appelman YEA, 1996, LANCET, V347, P79, DOI 10.1016/S0140-6736(96)90209-3; Appelman YEA, 1996, AM J CARDIOL, V78, P757, DOI 10.1016/S0002-9149(96)00416-X; Aronson D, 1996, J AM COLL CARDIOL, V27, P528, DOI 10.1016/0735-1097(95)00496-3; Baim Donald S., 1996, Journal of the American College of Cardiology, V27, p291A; BAUMBACH A, 1994, J AM COLL CARDIOL, V23, P1305, DOI 10.1016/0735-1097(94)90371-9; BITTL JA, 1995, NEW ENGL J MED, V333, P764, DOI 10.1056/NEJM199509213331204; BITTL JA, 1993, NEW ENGL J MED, V329, P273, DOI 10.1056/NEJM199307223290410; BITTL JA, 1993, J AM COLL CARDIOL, V21, P1158, DOI 10.1016/0735-1097(93)90240-2; Bittl JA, 1996, J AM COLL CARDIOL, V28, P368, DOI 10.1016/0735-1097(96)00183-0; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; CURRIER JW, 1995, J AM COLL CARDIOL, V25, P516, DOI 10.1016/0735-1097(95)98445-J; DECKELBAUM LI, 1995, J AM COLL CARDIOL, V26, P1264, DOI 10.1016/0735-1097(95)00330-4; DEMUINCK ED, 1994, AM J CARDIOL, V74, P1002, DOI 10.1016/0002-9149(94)90848-6; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DUSSAILLANT GR, 1995, J AM COLL CARDIOL, V26, P720, DOI 10.1016/0735-1097(95)00249-4; EISENBERG PR, 1992, J AM COLL CARDIOL, V19, P1065, DOI 10.1016/0735-1097(92)90296-Y; ELLIOTT JM, 1995, CIRCULATION, V91, P2158, DOI 10.1161/01.CIR.91.8.2158; ELLIS SG, 1995, J AM COLL CARDIOL, V25, P1137, DOI 10.1016/0735-1097(94)00541-W; Ellis SG, 1996, CIRCULATION, V93, P431, DOI 10.1161/01.CIR.93.3.431; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; GOLDBERG SL, 1995, J AM COLL CARDIOL, V26, P713, DOI 10.1016/0735-1097(95)00219-T; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; HARRINGTON RA, 1995, J AM COLL CARDIOL, V25, P1693, DOI 10.1016/0735-1097(95)00091-H; Hasdai D, 1996, J AM COLL CARDIOL, V28, P361, DOI 10.1016/0735-1097(96)00136-2; HIRSH J, 1994, CIRCULATION, V89, P1449, DOI 10.1161/01.CIR.89.3.1449; HOLMES DR, 1995, CIRCULATION, V91, P1966, DOI 10.1161/01.CIR.91.7.1966; Horrigan Mark C. G., 1996, Journal of the American College of Cardiology, V27, p55A; HUEB WA, 1995, J AM COLL CARDIOL, V26, P1600, DOI 10.1016/0735-1097(95)00384-3; Itoh Akira, 1996, Journal of the American College of Cardiology, V27, p277A; KAKUTA T, 1994, CIRCULATION, V89, P2809, DOI 10.1161/01.CIR.89.6.2809; Kimura T, 1996, NEW ENGL J MED, V334, P561, DOI 10.1056/NEJM199602293340903; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LEMAITRE DT, 1996, COWEN REPORT    0306, P1; LINCOFE AM, 1992, J AM COLL CARDIOL, V19, P926, DOI 10.1016/0735-1097(92)90272-O; LINCOFF AM, 1993, J AM COLL CARDIOL, V21, P866, DOI 10.1016/0735-1097(93)90341-W; LINCOFF AM, 1995, CIRCULATION, V92, P2905; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; Macaya C, 1996, J AM COLL CARDIOL, V27, P255, DOI 10.1016/0735-1097(95)00473-4; MACISAAC AI, 1995, J AM COLL CARDIOL, V26, P731, DOI 10.1016/0735-1097(95)00206-J; Mak KH, 1996, J AM COLL CARDIOL, V27, P494, DOI 10.1016/0735-1097(95)00466-1; MARMUR JD, 1994, J AM COLL CARDIOL, V24, P1484, DOI 10.1016/0735-1097(94)90144-9; MERINO A, 1994, J AM COLL CARDIOL, V24, P1091, DOI 10.1016/0735-1097(94)90875-3; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; MINTZ GS, 1995, CIRCULATION, V92, P3408, DOI 10.1161/01.CIR.92.12.3408; Mintz GS, 1996, J AM COLL CARDIOL, V27, P1678, DOI 10.1016/0735-1097(96)00083-6; MINTZ GS, 1995, J AM COLL CARDIOL, V25, P1479, DOI 10.1016/0735-1097(95)00088-L; Mintz GS, 1996, CIRCULATION, V94, P35, DOI 10.1161/01.CIR.94.1.35; Neumann FJ, 1996, J AM COLL CARDIOL, V27, P15, DOI 10.1016/0735-1097(95)00433-5; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PEDERSEN TR, 1994, LANCET, V344, P1383; PIANA RN, 1994, J AM COLL CARDIOL, V23, P1296, DOI 10.1016/0735-1097(94)90370-0; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; POPMA JJ, 1995, CHEST, V108, pS486, DOI 10.1378/chest.108.4_Supplement.486S; ROGERS C, 1995, CIRCULATION, V91, P2995, DOI 10.1161/01.CIR.91.12.2995; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; ROUBIN GS, 1988, CIRCULATION, V78, P557, DOI 10.1161/01.CIR.78.3.557; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAFIAN RD, 1993, CIRCULATION, V88, P961, DOI 10.1161/01.CIR.88.3.961; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Serruys P. W., 1996, Journal of the American College of Cardiology, V27, p152A; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; STRAUSS BH, 1994, CIRC RES, V75, P650, DOI 10.1161/01.RES.75.4.650; SUTTON JM, 1994, CIRCULATION, V89, P1126, DOI 10.1161/01.CIR.89.3.1126; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; TOPOL EJ, 1996, SCI SESS EUR SOC CAR; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; UREN NG, 1994, NEW ENGL J MED, V330, P1782, DOI 10.1056/NEJM199406233302503; VANDORMAEL M, 1994, CIRCULATION, V90, P213; VANLEEUWEN TG, 1993, CIRCULATION, V87, P1258, DOI 10.1161/01.CIR.87.4.1258; WEINTRAUB WS, 1994, NEW ENGL J MED, V331, P1331, DOI 10.1056/NEJM199411173312002; WHITE CJ, 1995, J AM COLL CARDIOL, V25, P1681, DOI 10.1016/0735-1097(95)00112-H; WOLFE MW, 1995, CIRCULATION, V92, P311, DOI 10.1161/01.CIR.92.3.311; WONG SC, 1995, J AM COLL CARDIOL, V26, P704, DOI 10.1016/0735-1097(95)00217-R; 1996, J AM COLL CARDIOL  S, V27, pA156	98	188	204	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1290	1302		10.1056/NEJM199610243351707	http://dx.doi.org/10.1056/NEJM199610243351707			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857010				2022-12-28	WOS:A1996VN59400007
J	Kaplan, SH; Sullivan, LM; Dukes, KA; Phillips, CF; Kelch, RP; Schaller, JG				Kaplan, SH; Sullivan, LM; Dukes, KA; Phillips, CF; Kelch, RP; Schaller, JG			Sex differences in academic advancement - Results of a national study of pediatricians	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNAL-MEDICINE; WOMEN PHYSICIANS; MEN FACULTY; ROLE MODELS; CAREER; RANK; DEPARTMENTS; RADIOLOGY; STUDENTS; SCIENCE	Background Although the numbers of women in in entry-level academic positions in have increased substantially in recent years, the proportion of women in senior faculty positions has not changed. We conducted a study to determine the contributions of background and training, academic productivity, distribution of work time, institutional support, career attitudes, and family responsibilities to sex differences in academic rank and salary among faculty members of academic pediatric departments. Methods We conducted a cross-sectional survey of all salaried physicians in 126 academic departments of pediatrics in the United States in January 1992. Of the 6441 questionnaires distributed, 4285 (67 percent) were returned. The sample was representative of U.S. pediatric faculty members. Multi variate models were used to relate academic rank and salary to 16 independent variables. Results Significantly fewer women than men achieved the rank of associate professor or higher. For both men and women, higher salaries and ranks were related to greater academic productivity (more publications and grants), more hours worked, more institutional support of research, greater overall career satisfaction, and fewer career problems. Less time spent in teaching and patient care was related to greater academic productivity for both sexes. Women in the low ranks were less academically productive and spent significantly more time in teaching and patient care than men in those ranks. Adjust ment for all independent variables eliminated sex differences in academic rank but not in salary. Conclusions Lower rates of academic productivity, more time spent in teaching and patient care and less time spent in research, less institutional support for research, and lower rates of specialization in highly paid subspecialties contributed to the lower ranks and salaries of female faculty members in pediatrics. (C) 1996, Massachusetts Medical Society.	TUFTS UNIV NEW ENGLAND MED CTR,FLOATING HOSP CHILDREN,DEPT PEDIAT,BOSTON,MA 02111; UNIV VERMONT,COLL MED,BURLINGTON,VT; UNIV IOWA,COLL MED,IOWA CITY,IA	Floating Hospital For Children; Tufts Medical Center; University of Vermont; University of Iowa	Kaplan, SH (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,PRIMARY CARE OUTCOMES RES INST,750 WASHINGTON ST,BOX 345,BOSTON,MA 02111, USA.			Sullivan, Lisa/0000-0003-0726-7149; Kaplan, Sherrie/0000-0002-8644-5849				*ASS AM MED COLL, 1991, AAMC FAC ROST SYST U; *ASS AM MED COLL, 1994, AAMC FAC ROST SYST U; BALDWIN DWC, 1991, WESTERN J MED, V155, P140; BEATY HN, 1986, ANN INTERN MED, V104, P90, DOI 10.7326/0003-4819-104-1-90; BELLAS ML, 1994, AM SOCIOL REV, V59, P807, DOI 10.2307/2096369; BICKEL J, 1988, NEW ENGL J MED, V319, P1579, DOI 10.1056/NEJM198812153192405; Calkins E V, 1992, J Am Med Womens Assoc (1972), V47, P58; CARR P, 1992, J GEN INTERN MED, V7, P418, DOI 10.1007/BF02599159; COLE JR, 1987, SCI AM, V256, P119, DOI 10.1038/scientificamerican0287-119; Cole JR., 1979, FAIR SCI WOMEN SCI C; DIAL TH, 1989, ACAD MED, V64, P198, DOI 10.1097/00001888-198904000-00007; FLACH DH, 1982, J MED EDUC, V57, P514; Grant L, 1988, J Am Med Womens Assoc (1972), V43, P109; GRANT L, 1988, J AM MED WOMEN ASSOC, V43, P115; GRAVES PL, 1985, JAMA-J AM MED ASSOC, V254, P781, DOI 10.1001/jama.254.6.781; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KOMAROMY M, 1993, NEW ENGL J MED, V328, P322, DOI 10.1056/NEJM199302043280507; KOSHLAND DE, 1988, SCIENCE, V239, P1473, DOI 10.1126/science.239.4847.1473; LANDAU C, 1986, J MED EDUC, V61, P654; LEVEY BA, 1990, ACAD MED, V65, P102, DOI 10.1097/00001888-199002000-00011; LEVINSON W, 1989, NEW ENGL J MED, V321, P1511, DOI 10.1056/NEJM198911303212205; LONG JS, 1993, AM SOCIOL REV, V58, P703, DOI 10.2307/2096282; LORBER J, 1983, J MED EDUC, V58, P447; MANDELBAUM DR, 1981, WORK MARRIAGE MOTHER; MARTIN SC, 1988, J HEALTH SOC BEHAV, V29, P333, DOI 10.2307/2136867; NEUMAYER L, 1993, ARCH SURG-CHICAGO, V128, P669; NICKERSON KG, 1990, JAMA-J AM MED ASSOC, V264, P1813, DOI 10.1001/jama.264.14.1813; Ochberg R L, 1989, J Am Med Womens Assoc (1972), V44, P123; Ramos S M, 1989, J Am Med Womens Assoc (1972), V44, P21; RELMAN AS, 1980, NEW ENGL J MED, V302, P1252, DOI 10.1056/NEJM198005293022209; RICHMAN JA, 1992, JAMA-J AM MED ASSOC, V267, P692, DOI 10.1001/jama.267.5.692; ROESKE NA, 1977, J MED EDUC, V52, P459; SCHALLER JG, 1991, J PEDIATR-US, V118, P314, DOI 10.1016/S0022-3476(05)80511-6; Schermerhorn G R, 1986, J Am Med Womens Assoc (1972), V41, P74; TESCH BJ, 1995, JAMA-J AM MED ASSOC, V273, P1022, DOI 10.1001/jama.273.13.1022; WALLIS LA, 1981, JAMA-J AM MED ASSOC, V246, P2350, DOI 10.1001/jama.246.20.2350; WHITLEY NO, 1987, INVEST RADIOL, V22, P431, DOI 10.1097/00004424-198705000-00015; WILKINSON CJ, 1986, ANESTHESIOLOGY, V64, P496, DOI 10.1097/00000542-198604000-00014; 1991, ANN INTERN MED, V114, P63	39	198	198	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1282	1289		10.1056/NEJM199610243351706	http://dx.doi.org/10.1056/NEJM199610243351706			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VN594	8857009				2022-12-28	WOS:A1996VN59400006
J	Blazeby, JM; Cooper, MJ				Blazeby, JM; Cooper, MJ			Is site of necrosis in acute pancreatitis a predictor of outcome?	LANCET			English	Editorial Material							COMPUTED-TOMOGRAPHY; CT				Blazeby, JM (corresponding author), ROYAL DEVON & EXETER HOSP,DEPT SURG,EXETER EX2 5DW,DEVON,ENGLAND.							BALTHAZAR EJ, 1985, RADIOLOGY, V156, P767, DOI 10.1148/radiology.156.3.4023241; BALTHAZAR EJ, 1990, RADIOLOGY, V174, P331, DOI 10.1148/radiology.174.2.2296641; Kemppainen E, 1996, BRIT J SURG, V83, P924, DOI 10.1002/bjs.1800830713; LUCAROTTI ME, 1993, BRIT J SURG, V80, P1393, DOI 10.1002/bjs.1800801112; VESENTINI S, 1993, BRIT J SURG, V80, P755, DOI 10.1002/bjs.1800800633	5	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1044	1044		10.1016/S0140-6736(05)64408-X	http://dx.doi.org/10.1016/S0140-6736(05)64408-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874449				2022-12-28	WOS:A1996VM88600002
J	Suhonen, JO; Peterson, DA; Ray, J; Gage, FH				Suhonen, JO; Peterson, DA; Ray, J; Gage, FH			Differentiation of adult hippocampus-derived progenitors into olfactory neurons in vivo	NATURE			English	Article							SUBVENTRICULAR ZONE; N-CAM; NERVOUS-SYSTEM; DENTATE GYRUS; CELLS; RAT; BRAIN; PRECURSORS; FOREBRAIN; ASTROCYTES	NEUROGENESIS continues throughout adulthood in discrete regions. Proliferative zones include the subependymal zone(1-4), from where progenitors migrate along the rostral migratory pathway to differentiate into neurons in the olfactory bulb(4), and the hippocampal subgranular zone, where they migrate and differentiate into granule neurons(5-7). Progenitors isolated from adult subependymal zone exhibit in vitro neurogenesis when stimulated with epidermals(8,9) or fibroblast growth factor(10). Cultured adult rat hippocampal progenitors (AHPs) grafted to adult rat hippocampus show site specific neuronal differentiation(11). Were we investigate determinants of multipotentiality in the adult central nervous system, by grafting AHPs into homotypic (hippocampus) or heterotypic (the rostral migratory pathway) neurogenic sites or a heterotypic, non-neurogenic site (the cerebellum). We found that grafts into neurogenic, but not non-neurogenic sites, showed neuronal differentiation. Furthermore, AHPs grafted in the rostral migratory pathway migrated into the olfactory bulb, differentiating into tyrosine-hydroxylase-positive neurons, a non-hippocampus phenotype. These results reveal that AHP populations can respond to persistent neuronal differentiation cues in the adult central nervous system.	SALK INST BIOL STUDIES, GENET LAB, LA JOLLA, CA 92037 USA	Salk Institute								ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BAYER SA, 1982, EXP BRAIN RES, V46, P315; Campbell K, 1995, NEURON, V15, P1259, DOI 10.1016/0896-6273(95)90006-3; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; EDELMAN GM, 1981, J SUPRAMOL STR CELL, V16, P259, DOI 10.1002/jsscb.1981.380160306; FISHELL G, 1995, DEVELOPMENT, V121, P803; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; GAO WQ, 1993, SCIENCE, V260, P367, DOI 10.1126/science.8469990; HALASZ N, 1977, BRAIN RES, V126, P455, DOI 10.1016/0006-8993(77)90597-2; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KEVERNE EB, 1995, CURR OPIN NEUROBIOL, V5, P482, DOI 10.1016/0959-4388(95)80009-3; LEVEY MS, 1991, J NEUROSCI, V11, P3556; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Menezes JRL, 1995, MOL CELL NEUROSCI, V6, P496, DOI 10.1006/mcne.1995.0002; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; ORourke NA, 1996, NEURON, V16, P1061, DOI 10.1016/S0896-6273(00)80130-0; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; ROUSSELOT P, 1995, J COMP NEUROL, V351, P51, DOI 10.1002/cne.903510106; SEKI T, 1991, NEUROSCI RES, V12, P503, DOI 10.1016/S0168-0102(09)80003-5; VICARIOABEJON C, 1995, J NEUROSCI, V15, P6351	30	491	533	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	1996	383	6601					624	627		10.1038/383624a0	http://dx.doi.org/10.1038/383624a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857538				2022-12-28	WOS:A1996VM75500054
J	Kerr, EA; Mittman, BS; Hays, RD; Leake, B; Brook, RH				Kerr, EA; Mittman, BS; Hays, RD; Leake, B; Brook, RH			Quality assurance in capitated physician groups - Where is the emphasis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Objective.-To describe quality assurance (QA) programs implemented by capitated physician groups; to measure their relative emphasis on monitoring of overuse compared with underuse and monitoring and improving preventive services compared with chronic disease care; and to examine how group characteristics influence QA activity. Design.-Cross-sectional questionnaire. Setting.-A large network-model health maintenance organization in California (133 contracting physician groups). Participants.-Ninety-four physician groups (71%) caring for 2.9 million capitated patients. Main outcome Measures.-Self-reported use of quality monitoring and improvement methods. Results.-All capitated physician groups conducted some QA, Groups' QA programs monitored areas subject to overuse, such as cesarean delivery and angioplasty rates, more than areas subject to underuse, such as childhood immunization rates and performance of retinal examinations for diabetic patients (64% vs 43%, P<.001). They monitored underuse of preventive services more than followup services for chronic diseases (54% vs 31%, P<.001), Groups also used reminders For preventive services more than they monitored follow-up services for chronic diseases (26% vs 15%, P<.01). Physician group characteristics independently associated with higher overall QA activity were greater number of years in existence, higher profitability, and capitated care penetration, Conclusion.-Capitation places a large share of responsibility for QA in the hands of physician groups, but not ail aspects of QA are being equally addressed, The emphasis on overuse may result from financial incentives inherent in capitation, while the focus on preventive services may stem from lack of adequate quality measurement tools for monitoring chronic disease care, Further research efforts should address how capitated physician groups might expand their QA programs to include monitoring of underuse, especially for patients with chronic disease.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; CTR STUDY HEALTHCARE PROVIDER BEHAV,SEPULVEDA VET AFFAIRS HLTH SERV,RES & DEV SERV,FIELD PROGRAM,SEPULVEDA,CA; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Hays, Ronald/D-5629-2013	Hays, Ronald/0000-0001-6697-907X				BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; CHASE D, 1994, J AMBULATORY CARE MA, V4, P15; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; ENTHOVEN AC, 1994, SOC SCI MED, V10, P1413; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; *JOINT COMM ACR HE, 1989, QUAL ASS MAN CAR ORG; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Lohr K.N., 1990, MEDICARE STRATEGY QU, V1; Mosier CI, 1943, PSYCHOMETRIKA, V8, P161, DOI 10.1007/BF02288700; *NAT COMM QUAL ASS, 1995, REP CARD PIL PROJ EX; SISK JE, 1990, INQUIRY-J HEALTH CAR, V27, P263; SIU AL, 1992, RAND PUBLICATION; WELCH WP, 1987, J HEALTH POLIT POLIC, V12, P723, DOI 10.1215/03616878-12-4-723; 1994, ANN INTERN MED, V120, P423	15	58	58	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1236	1239		10.1001/jama.276.15.1236	http://dx.doi.org/10.1001/jama.276.15.1236			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VL691	8849751				2022-12-28	WOS:A1996VL69100032
J	Lassen, NA				Lassen, NA			Epidemiologic assessment of the role of blood pressure in stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Lassen, NA (corresponding author), BISPEBJERG HOSP,DEPT CLIN PHYSIOL & NUCL MED,BISPEBJERG BAKKE 23,DK-2400 COPENHAGEN NV,DENMARK.							COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; GORELICK PB, 1994, STROKE, V25, P220, DOI 10.1161/01.STR.25.1.220; KANNEL WB, 1970, J AMER MED ASSOC, V214, P301, DOI 10.1001/jama.214.2.301; Menotti A, 1996, STROKE, V27, P381, DOI 10.1161/01.STR.27.3.381; 1967, JAMA-J AM MED ASSOC, V202, P116	5	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1279	1280						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL691	8849758				2022-12-28	WOS:A1996VL69100040
J	Dikshit, RK; Dikshit, N				Dikshit, RK; Dikshit, N			What information is available on request from drug advertisers in India?	BRITISH MEDICAL JOURNAL			English	Article									BJ MED COLL,DEPT PHYSIOL,AHMEDABAD 380016,GUJARAT,INDIA	B. J. Medical College & Civil Hospital, Ahmedabad	Dikshit, RK (corresponding author), BJ MED COLL,DEPT PHARMACOL,AHMEDABAD 380016,GUJARAT,INDIA.							BROWN EG, 1993, TEXT BOOK PHARM MED, P295; HERXHEIMER A, 1987, LANCET, V1, P31; 1992, WHO TECH REP SER, V825, P18	3	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					855	856						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870572				2022-12-28	WOS:A1996VL55900022
J	Coleman, TR; Carpenter, PB; Dunphy, WG				Coleman, TR; Carpenter, PB; Dunphy, WG			The Xenopus Cdc6 protein is essential for the initiation of a single round of DNA replication in cell-free extracts	CELL			English	Article							CYCLIN-DEPENDENT KINASES; EGG EXTRACTS; SACCHAROMYCES-CEREVISIAE; S-PHASE; FISSION YEAST; NEGATIVE REGULATION; LICENSING FACTOR; PURIFIED DNA; INVITRO; GENE	We have cloned a Xenopus Cdc6 homolog (Xcdc6) and characterized its role in DNA replication with Xenopus egg extracts. Immunodepletion of Xcdc6 abolishes chromosomal replication but not elongation on single-stranded DNA templates. Xcdc6 binds to chromatin at the beginning of interphase but disappears from chromatin upon initiation of replication. Immunodepletion studies indicate that binding of Xcdc6 to chromatin requires Xorc2, a component of the origin recognition complex. Moreover, Xmcm3 cannot bind to chromatin lacking Xcdc6, suggesting that Xorc2, Xcdc6, and Xmcm3 associate with the DNA sequentially. In postreplicative nuclei, Xcdc6 is associated with the nuclear envelope. These studies indicate that Xcdc6 is essential for initiation of replication in vertebrates and that interaction with the nuclear envelope may regulate its function.			Coleman, TR (corresponding author), CALTECH, HOWARD HUGHES MED INST, DIV BIOL 21676, PASADENA, CA 91125 USA.							ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BENAVENTE R, 1985, CELL, V41, P177, DOI 10.1016/0092-8674(85)90072-8; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BROWN JA, 1991, MOL CELL BIOL, V11, P5301, DOI 10.1128/MCB.11.10.5301; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Diffley JFX, 1995, YEAST, V11, P1651, DOI 10.1002/yea.320111608; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FANG F, 1993, J CELL SCI, V106, P983; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Jallepalli PV, 1996, GENE DEV, V10, P541, DOI 10.1101/gad.10.5.541; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KORNBLUTH S, 1992, MOL CELL BIOL, V12, P3216, DOI 10.1128/MCB.12.7.3216; KROHNE G, 1986, EXP CELL RES, V162, P1, DOI 10.1016/0014-4827(86)90421-0; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LISZIEWICZ J, 1988, NUCLEIC ACIDS RES, V16, P11507, DOI 10.1093/nar/16.24.11507; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; MILLS AD, 1989, J CELL SCI, V94, P471; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MuziFalconi F, 1996, CURR BIOL, V6, P229, DOI 10.1016/S0960-9822(02)00464-5; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; WANG TA, 1995, CURR OPIN CELL BIOL, V7, P414, DOI 10.1016/0955-0674(95)80098-0; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; ZHOU C, 1989, J BIOL CHEM, V264, P9022	56	337	341	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1996	87	1					53	63		10.1016/S0092-8674(00)81322-7	http://dx.doi.org/10.1016/S0092-8674(00)81322-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858148	Bronze			2022-12-28	WOS:A1996VL69500008
J	Sheikh, SP; Zvyaga, TA; Lichtarge, O; Sakmar, TP; Bourne, HR				Sheikh, SP; Zvyaga, TA; Lichtarge, O; Sakmar, TP; Bourne, HR			Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F	NATURE			English	Article							TRANSDUCIN INTERACTION; PROJECTION STRUCTURE; METARHODOPSIN-II; BOVINE RHODOPSIN; PROTEIN; SPECIFICITY; MUTATIONS; RECEPTOR; CELLS; FORM	A LARGE superfamily of receptors containing seven transmembrane (TRI) helices transmits hormonal and sensory signals across the plasma membrane to heterotrimeric G proteins at the cytoplasmic face of the membrane. To investigate how G-protein-coupled receptors work at the molecular level, we have engineered metal-ion-binding sites between TM helices to restrain activation-induced conformational change in specific locations. In rhodopsin, the photoreceptor of retinal rod cells, we substituted histidine residues for natural amino acids at the cytoplasmic ends of the TM helices C and F. The resulting mutant proteins were able to activate the visual G protein transducin in the absence but not in the presence of metal ions. These results indicate that the TM helices C and F are in close proximity and suggest that movements of these helices relative to one another are required for transducin activation. Thus a change in the orientations of TRI helices C and F is likely to be a key element in the mechanism for coupling binding of ligands (or isomerization of retinal) to the activation of G-protein-coupled receptors.	UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,DEPT MOL BIOL & BIOCHEM,NEW YORK,NY 10021	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Rockefeller University			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BOURNE HR, 1990, NATURE, V363, P274; CHAKRABATI P, 1991, PROTEIN ENG, V4, P57; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARRENS DL, IN PRESS SCIENCE; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P9478; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; MIN KC, 1993, J BIOL CHEM, V268, P9400; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WILLETT WS, 1995, BIOCHEMISTRY-US, V34, P2172, DOI 10.1021/bi00007a010; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0; ZVYAGA TA, 1994, BIOCHEMISTRY-US, V33, P9753, DOI 10.1021/bi00198a046; ZVYAGA TA, 1993, J BIOL CHEM, V268, P4661	29	384	386	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					347	350		10.1038/383347a0	http://dx.doi.org/10.1038/383347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848049				2022-12-28	WOS:A1996VJ43900048
J	Polymeropoulos, MH; Higgins, JJ; Golbe, LI; Johnson, WG; Ide, SE; DiIorio, G; Sanges, G; Stenroos, ES; Pho, LT; Schaffer, AA; Lazzarini, AM; Nussbaum, RL; Duvoisin, RC				Polymeropoulos, MH; Higgins, JJ; Golbe, LI; Johnson, WG; Ide, SE; DiIorio, G; Sanges, G; Stenroos, ES; Pho, LT; Schaffer, AA; Lazzarini, AM; Nussbaum, RL; Duvoisin, RC			Mapping of a gene for Parkinson's disease to chromosome 4q21-q23	SCIENCE			English	Article							MITOCHONDRIAL-DNA; COMPLEX; LINKAGE; HUMANS; DEFECT	Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 1 percent of the population over age 50. Recent studies have confirmed significant familial aggregation of PD and a large number of large multicase families have been documented. Genetic markers on chromosome 4q21-q23 were found to be linked to the PD phenotype in a large kindred with autosomal dominant PD, with a Z(max) = 6.00 for marker D4S2380. This finding will facilitate identification of the gene and research on the pathogenesis of PD.	NINCDS,CLIN NEUROGENET UNIT,MED NEUROL BRANCH,NIH,BETHESDA,MD 20892; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854; UNIV NAPLES 2,FAC MED,IST SCI NEUROL,NAPLES,ITALY	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); Rutgers State University New Brunswick; Rutgers State University Medical Center; Universita della Campania Vanvitelli	Polymeropoulos, MH (corresponding author), NIH,LAB GENET DIS RES,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892, USA.		Schaffer, Alejandro A/F-2902-2012; Schaffer, Alejandro/N-1222-2019					ARMSTRONG M, 1992, LANCET, V339, P1017, DOI 10.1016/0140-6736(92)90537-D; BELL GI, 1981, P NATL ACAD SCI USA, V78, P5979; CARREROVALENZUELA R, 1995, NEUROLOGY, V45, P1760, DOI 10.1212/WNL.45.9.1760; COTTINGHAM RW, 1984, AM J HUM GENET, V54, P252; DAVIS GC, 1979, PSYCHIAT RES, V1, P249, DOI 10.1016/0165-1781(79)90006-4; DUVOISIN RC, 1995, ANN NEUROL, V38, P355, DOI 10.1002/ana.410380303; Duvoisin RC, 1996, ADV NEUROL, V69, P33; FORNO LS, 1986, ADV NEUROL, V45, P35; GASSER T, 1994, ANN NEUROL, V36, P387, DOI 10.1002/ana.410360310; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; GIBB WRG, 1986, BRAIN, V1110, P1131; GOLBE LI, 1990, ANN NEUROL, V27, P276, DOI 10.1002/ana.410270309; GOLBE LI, 1992, MOV DIS, V7, P24; GOLBE LI, IN PRESS ANN NEUROL; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; GOWERS WR, 1893, MANUAL DIS NERVOUS S, P6366; GUPTA SK, 1995, COMPUT BIOMED RES, V28, P116, DOI 10.1006/cbmr.1995.1009; GYAPAY JM, 1994, NAT GENET, V7, P262; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; JAGER WAD, 1978, J NEUROL NEUROSUR PS, V23, P283; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LATHROP GM, 1984, P NATL ACAD SCI USA, V81, P3442; LAZZARINI AM, 1994, NEUROLOGY, V44, P499, DOI 10.1212/WNL.44.3_Part_1.499; LESTIENNE P, 1990, J NEUROCHEM, V55, P1810, DOI 10.1111/j.1471-4159.1990.tb04973.x; LYNCH T, 1994, NEUROLOGY, V44, P1878, DOI 10.1212/WNL.44.10.1878; MJONES HENRY, 1949, ACTA PSYCHIAT ET NEUROL [COPENHAGEN], V54, P1; Parkinson J, 1817, ESSAY SHAKING PALSY; POLYMEROPOULOS M, UNPUB; SANDY MS, 1993, MOVEMENT DISORD, V8, P74, DOI 10.1002/mds.870080114; SCHAPIRA AHV, 1990, MOVEMENT DISORD, V5, P294, DOI 10.1002/mds.870050406; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; TSUNEOKA Y, 1993, J BIOCHEM, V114, P263, DOI 10.1093/oxfordjournals.jbchem.a124164; VYAS I, 1986, J NEUROCHEM, V46, P1501, DOI 10.1111/j.1471-4159.1986.tb01768.x; WAKABAYASHI K, 1988, ACTA NEUROPATHOL, V76, P217, DOI 10.1007/BF00687767	34	572	614	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1197	1199		10.1126/science.274.5290.1197	http://dx.doi.org/10.1126/science.274.5290.1197			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895469	Green Submitted			2022-12-28	WOS:A1996VT33500055
J	Dronkers, NF				Dronkers, NF			A new brain region for coordinating speech articulation	NATURE			English	Article							SOMATOSENSORY AREA; STROKE PATIENTS; CT SCAN; INSULA; LOCALIZATION; VARIABILITY; COMPONENT; LANGUAGE; APRAXIA; APHEMIA	HUMAN speech requires complex planning and coordination of mouth and tongue movements, Certain types of brain injury can lead to a condition known as apraxia of speech, in which patients are impaired in their ability to coordinate speech movements but their ability to perceive speech sounds, including their own errors, is unaffected(1-3). The brain regions involved in coordinating speech, however, remain largely unknown, In this study, brain lesions of 25 stroke patients with a disorder in the motor planning of articulatory movements were compared with lesions of 19 patients without such deficits. A robust double dissociation was found between these two groups. All patients,vith articulatory planning deficits had lesions that included a discrete region of the left precentral gyrus of the insula, a cortical area beneath the frontal and temporal lobes. This area was completely spared in all patients without these articulation deficits. Thus this area seems to be specialized for the motor planning of speech.	UNIV CALIF DAVIS,DEPT NEUROL,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT LINGUIST,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis	Dronkers, NF (corresponding author), VA NO CALIF HLTH CARE SYST,150 MUIR RD 126S,MARTINEZ,CA 94553, USA.		Dronkers, Nina F/K-6312-2015					Augustine J R, 1985, Neurol Res, V7, P2; Blumstein S., 1991, ACQUIRED APHASIA, P151; BURTON H, 1993, SOMATOSENS MOT RES, V10, P297, DOI 10.3109/08990229309028839; CANIER M, 1990, AGRAMMATIC APHASIA C, P37; DAMASIO H, 1980, BRAIN, V103, P337, DOI 10.1093/brain/103.2.337; Darley FL, 1975, MOTOR SPEECH DISORDE; DEAMMOND SJ, 1976, STRUCTURE HUMAN BRAI; DRONKERS N, 1992, J CLIN EXPT NEUROPSY, V14, P52; FREY R T, 1987, Society for Neuroscience Abstracts, V13, P1266; HABIB M, 1995, NEUROPSYCHOLOGIA, V33, P327, DOI 10.1016/0028-3932(94)00108-2; HALPERN H, 1973, J SPEECH HEAR DISORD, V38, P162, DOI 10.1044/jshd.3802.162; JOHNS DF, 1970, J SPEECH HEAR RES, V13, P556, DOI 10.1044/jshr.1303.556; Kertesz A, 1984, APRAXIA SPEECH PHYSL, P73; Luria A.R., 1966, HIGHER CORTICAL FUNC, P3; MARIE P, 1906, SEM MED, V26, P241; Marquardt T. P., 1984, APRAXIA SPEECH PHYSL, P91; MAZZOCCHI F, 1979, CORTEX, V15, P627, DOI 10.1016/S0010-9452(79)80051-9; MESULAM MM, 1982, J COMP NEUROL, V212, P1, DOI 10.1002/cne.902120102; OJEMANN GA, 1978, BRAIN LANG, V6, P239, DOI 10.1016/0093-934X(78)90061-5; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; RUFF RL, 1981, NEUROLOGY, V31, P353, DOI 10.1212/WNL.31.3.353; SCHIFF HB, 1983, ARCH NEUROL-CHICAGO, V40, P720, DOI 10.1001/archneur.1983.04050110038005; SCHNEIDER RJ, 1993, BRAIN RES, V621, P116, DOI 10.1016/0006-8993(93)90305-7; Shankweiler D., 1966, CORTEX, V2, P277, DOI [10.1016/S0010-9452(66)80008-4, DOI 10.1016/S0010-9452(66)80008-4]; SQUARE PA, IN PRESS APRAXIA; Talairach J., 1988, COPLANAR STEREOTAXIC; TOGNOLA G, 1980, NEUROPSYCHOLOGIA, V18, P257, DOI 10.1016/0028-3932(80)90122-0; WERTZ RT, 1991, APRAXIA SPEECH DISOR	29	848	871	0	59	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					159	161		10.1038/384159a0	http://dx.doi.org/10.1038/384159a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VT336	8906789				2022-12-28	WOS:A1996VT33600063
J	Gartner, HV; Seidl, C; Luckenbach, C; Schumm, G; Seifried, E; Ritter, H; Bultmann, B				Gartner, HV; Seidl, C; Luckenbach, C; Schumm, G; Seifried, E; Ritter, H; Bultmann, B			Genetic analysis of a sarcoma accidentally transplanted from a patient to a surgeon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TETRANUCLEOTIDE REPEAT POLYMORPHISM; ANTIGENS; PURIFICATION; MOLECULES; CELLS; DNA		UNIV TUBINGEN,INST ANTHROPOL & HUMAN GENET,D-72076 TUBINGEN,GERMANY; RED CROSS BLOOD DONOR SERV,INST TRANSFUS MED & IMMUNOHEMATOL,FRANKFURT,GERMANY; GEN HOSP,INST PATHOL,HEILBRONN,GERMANY	Eberhard Karls University of Tubingen; Landstuhl Regional Medical Center	Gartner, HV (corresponding author), UNIV TUBINGEN,INST PATHOL,LIEBERMEISTERSTR 8,D-72076 TUBINGEN,GERMANY.							BEIN G, 1992, TISSUE ANTIGENS, V39, P68, DOI 10.1111/j.1399-0039.1992.tb01909.x; BOON T, 1992, ADV CANCER RES, V58, P177, DOI 10.1016/S0065-230X(08)60295-X; BOUSSIOTIS VA, 1994, CURR OPIN IMMUNOL, V6, P797, DOI 10.1016/0952-7915(94)90087-6; Colonna M, 1996, CURR OPIN IMMUNOL, V8, P101, DOI 10.1016/S0952-7915(96)80112-9; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GOODENOW RS, 1985, SCIENCE, V230, P777, DOI 10.1126/science.2997918; GUGEL EA, 1986, NEW ENGL J MED, V315, P1487; KLEIN J, 1986, NATURAL HIST MAJOR H; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Luckenbach C, 1996, ADV FOREN H, V6, P192; MARSH SGE, 1992, TISSUE ANTIGENS, V40, P229, DOI 10.1111/j.1399-0039.1992.tb02050.x; MCHUGH RS, 1995, P NATL ACAD SCI USA, V92, P8059, DOI 10.1073/pnas.92.17.8059; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOLLER P, 1992, CANCER SURV, V13, P101; NADLER SH, 1969, ARCH SURG-CHICAGO, V99, P376; POLYMEROPOULOS MH, 1992, NUCLEIC ACIDS RES, V20, P1432, DOI 10.1093/nar/20.6.1432; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P195, DOI 10.1093/nar/19.1.195; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P3753, DOI 10.1093/nar/19.13.3753; Rammensee HG, 1996, CURR OPIN IMMUNOL, V8, P49, DOI 10.1016/S0952-7915(96)80104-X; SCANLON EF, 1965, CANCER, V18, P782, DOI 10.1002/1097-0142(196506)18:6<782::AID-CNCR2820180616>3.0.CO;2-#; Schreiber Hans, 1993, P1143; SOUTHAM C M, 1958, Bull N Y Acad Med, V34, P416; SUTHANTHIRAN M, 1995, TRANSPLANT P, V27, P5; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; TRAVERS PJ, 1982, NIH PUBLICATION	25	52	54	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1494	1496		10.1056/NEJM199611143352004	http://dx.doi.org/10.1056/NEJM199611143352004			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT340	8890100				2022-12-28	WOS:A1996VT34000004
J	Takimoto, E; Ishida, J; Sugiyama, F; Horiguchi, H; Murakami, K; Fukamizu, A				Takimoto, E; Ishida, J; Sugiyama, F; Horiguchi, H; Murakami, K; Fukamizu, A			Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen	SCIENCE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; TRANSGENIC MICE; INACTIVE RENIN; BLOOD-PRESSURE; EXPRESSION; SYSTEM; GENES; PRORENIN; SEQUENCE; CDNA	Maternal hypertension is a common complication of pregnancy and its pathophysiology is poorly understood. This phenomenon was studied in an animal model by mating transgenic mice expressing components of the human renin-angiotensin system. When transgenic females expressing angiotensinogen were mated with transgenic males expressing renin, the pregnant females displayed a transient elevation of blood pressure in late pregnancy, due to secretion of placental human renin into the maternal circulation. Blood pressure returned to normal levels after delivery of the pup. Histopathologic examination revealed uniform enlargement of glomeruli associated with an increase in urinary protein excretion, myocardial hypertrophy, and necrosis and edema in the placenta. These mice may provide molecular insights into pregnancy-associated hypertension in humans.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,LAB ANIM RES CTR,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba			fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				BRAR HS, 1987, AM J OBSTET GYNECOL, V157, P363, DOI 10.1016/S0002-9378(87)80173-4; FUKAMIZU A, 1993, ARZNEIMITTEL-FORSCH, V43-1, P222; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; FUKAMIZU A, 1989, BIOCHEM BIOPH RES CO, V165, P826, DOI 10.1016/S0006-291X(89)80040-3; GRAVES SW, 1993, NAT GENET, V4, P7, DOI 10.1038/ng0593-7; HAGEMANN A, 1994, EXP CLIN ENDOCRINOL, V102, P252, DOI 10.1055/s-0029-1211289; HSUEH WA, 1982, J CLIN ENDOCR METAB, V54, P1010, DOI 10.1210/jcem-54-5-1010; IHARA Y, 1987, ENDOCRINOL JAPON, V34, P887; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; LENZ T, 1991, AM J PHYSIOL, V260, pE876, DOI 10.1152/ajpendo.1991.260.6.E876; LENZ T, 1989, J CLIN ENDOCR METAB, V69, P31, DOI 10.1210/jcem-69-1-31; LI Y, 1991, J HYPERTENS, V9, P1119; NADEN RP, 1981, J CLIN INVEST, V68, P468, DOI 10.1172/JCI110277; SEALEY JE, 1985, AM J OBSTET GYNECOL, V153, P514, DOI 10.1016/0002-9378(85)90464-8; SHAW KJ, 1989, J CLIN INVEST, V83, P2085, DOI 10.1172/JCI114121; SKINNER SL, 1993, RENIN ANGIOTENSIN SY; SYMONDS EM, 1968, NATURE, V217, P1152, DOI 10.1038/2171152a0; TAKAHASHI S, 1991, BIOCHEM BIOPH RES CO, V180, P1103, DOI 10.1016/S0006-291X(05)81180-5; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; WARD K, 1993, NAT GENET, V4, P114; WARREN AY, 1982, BRIT J OBSTET GYNAEC, V89, P628, DOI 10.1111/j.1471-0528.1982.tb04717.x; WILSON M, 1980, AM J MED, V68, P97, DOI 10.1016/0002-9343(80)90178-3	24	203	207	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					995	998		10.1126/science.274.5289.995	http://dx.doi.org/10.1126/science.274.5289.995			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875944				2022-12-28	WOS:A1996VR79200053
J	Weissman, JM; Sunkara, HB; Tse, AS; Asher, SA				Weissman, JM; Sunkara, HB; Tse, AS; Asher, SA			Thermally switchable periodicities and diffraction from mesoscopically ordered materials	SCIENCE			English	Article							CADMIUM-SULFIDE NANOCOMPOSITES; CRYSTALLINE COLLOIDAL ARRAYS; POLY(METHYL METHACRYLATE); N-ISOPROPYLACRYLAMIDE; SILICA; FILTER	Two switchable, mesoscopically periodic materials were created by combining crystalline colloidal array (CCA) self-assembly with the temperature-induced volume phase transition of poly(N-isopropylacrylamide) (PNIPAM). Body-centered-cubic CCAs of hydrated, swollen PNIPAM particles Bragg-diffract infrared, visible, and ultraviolet,light weakly, whereas arrays of compact shrunken particles diffract efficiently. A tunable diffracting array was also created by embedding a CCA of polystyrene spheres within a PNIPAM hydrogel that swells and contracts-with temperature; thus the array lattice constant varies with temperature, and the diffracted wavelength was thermally tunable across the entire visible spectrum. These materials may find applications in many areas of optics and materials science.	UNIV PITTSBURGH,DEPT CHEM,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								Asher S.A., 1986, Patent No. [US4632517A, 4632517]; Asher S.A., 1993, US Patent, Patent No. [5266238, 5266238 A]; Asher S.A., 1986, SPECTROSCOPY, V1, P26; ASHER SA, 1994, J AM CHEM SOC, V116, P4997, DOI 10.1021/ja00090a059; Asher SA, 1995, MATER RES SOC SYMP P, V374, P305; ASHER SA, 1986, Patent No. 4627689; ASHER SA, 1994, Patent No. 5281370; ASHER SA, 1992, NONLINEAR OPT 3, V1626, P238; ASHER SWA, 1995, Patent No. 5452123; CARLSON RJ, 1984, APPL SPECTROSC, V38, P297, DOI 10.1366/0003702844555548; CHANG SY, 1994, J AM CHEM SOC, V116, P6739, DOI 10.1021/ja00094a032; CHANG SY, 1994, MATER RES SOC SYMP P, V346, P875, DOI 10.1557/PROC-346-875; CLARK NA, 1979, NATURE, V281, P57, DOI 10.1038/281057a0; FLAUGH PL, 1984, APPL SPECTROSC, V38, P847, DOI 10.1366/0003702844554693; GOODWIN JW, 1980, J PHYS CHEM-US, V84, P1580, DOI 10.1021/j100449a029; HILTNER PA, 1969, J PHYS CHEM-US, V73, P2386, DOI 10.1021/j100727a049; HIROKAWA Y, 1984, J CHEM PHYS, V81, P6379, DOI 10.1063/1.447548; KAMENETZKY EA, 1994, SCIENCE, V263, P207, DOI 10.1126/science.263.5144.207; KESAVAMOORTHY R, 1992, J APPL PHYS, V71, P1116, DOI 10.1063/1.351275; KRIEGER IM, 1968, J AM CHEM SOC, V90, P3114, DOI 10.1021/ja01014a025; LUCK W, 1963, BERICH BUNSEN GESELL, V67, P75, DOI 10.1002/bbpc.19630670113; MCPHEE W, 1993, J COLLOID INTERF SCI, V156, P24, DOI 10.1006/jcis.1993.1075; PANKASEM S, 1994, LANGMUIR, V10, P3023, DOI 10.1021/la00021a027; PELTON RH, 1986, COLLOID SURFACE, V20, P247, DOI 10.1016/0166-6622(86)80274-8; PELTON RH, 1989, LANGMUIR, V5, P816, DOI 10.1021/la00087a040; RUNDQUIST PA, 1989, J CHEM PHYS, V91, P4932, DOI 10.1063/1.456734; SANDERS JV, 1964, NATURE, V204, P1151, DOI 10.1038/2041151a0; SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R; SPRY RJ, 1986, APPL SPECTROSC, V40, P782, DOI 10.1366/0003702864508403; SUNKARA HB, 1994, CHEM MATER, V6, P362, DOI 10.1021/cm00040a006; SUNKARA HB, 1995, ACS SYM SER, V585, P181; TSE AS, 1995, MACROMOLECULES, V28, P6533, DOI 10.1021/ma00123a021; van de Hulst H.C., 1981, LIGHT SCATTERING SMA; WU XS, 1992, J POLYM SCI POL CHEM, V30, P2121, DOI 10.1002/pola.1992.080301005	34	768	798	13	477	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					959	960		10.1126/science.274.5289.959	http://dx.doi.org/10.1126/science.274.5289.959			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875932				2022-12-28	WOS:A1996VR79200041
J	Blundell, TL				Blundell, TL			Structure-based drug design	NATURE			English	Article							BINDING-SITES; RECEPTOR; SEARCH; MOLECULES; GRAPHICS; PROGRAM; LUDI		UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,IMPERIAL CANC RES FUND,UNIT STRUCT MOL BIOL,LONDON WC1E 7HX,ENGLAND	Cancer Research UK; University of London; Birkbeck University London	Blundell, TL (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,TENNIS COURT RD,CAMBRIDGE CB2 1QW,ENGLAND.							ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BOHACEK RS, 1994, J AM CHEM SOC, V116, P5560, DOI 10.1021/ja00092a006; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P593, DOI 10.1007/BF00126217; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/bf00124387; BUSETTA B, 1983, J APPL CRYSTALLOGR, V16, P432, DOI 10.1107/S002188988301078X; CLORE M, 1995, PROG BIOPHYS MOL BIO, V62, P153; Cohen N C, 1995, Prog Drug Res, V45, P205; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; CRUCIANI G, 1994, J MOL GRAPHICS, V12, P116, DOI 10.1016/0263-7855(94)80076-6; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GOODSELL DS, 1989, J MOL GRAPHICS, V7, P41, DOI 10.1016/0263-7855(89)80055-4; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; LANGRIDGE R, 1981, SCIENCE, V211, P661, DOI 10.1126/science.7455704; LEACH AR, 1992, J COMPUT CHEM, V13, P730, DOI 10.1002/jcc.540130608; LEWIS RA, 1993, J MOL GRAPHICS, V10, P31; MIRANKER A, 1991, PROTEINS, V11, P29, DOI 10.1002/prot.340110104; PASTOR M, 1995, J MED CHEM, V38, P4637, DOI 10.1021/jm00023a003; PATTABIRAMAN N, 1985, J COMPUT CHEM, V6, P432, DOI 10.1002/jcc.540060510; PAYNE AWR, 1993, J MOL GRAPHICS, V11, P76; ROTSTEIN SH, 1993, J COMPUT AID MOL DES, V7, P23, DOI 10.1007/BF00141573; RUSINKO A, 1989, J CHEM INF COMP SCI, V29, P327; SALI A, 1990, TRENDS BIOCHEM SCI, V15, P235, DOI 10.1016/0968-0004(90)90036-B; SUSSMAN J, 1996, PROT DATABANK Q NEWS, V76; Tomioka N, 1987, J Comput Aided Mol Des, V1, P197, DOI 10.1007/BF01677044; WHITTLE PJ, 1994, ANNU REV BIOPH BIOM, V23, P349, DOI 10.1146/annurev.bb.23.060194.002025; WODAK SJ, 1978, J MOL BIOL, V124, P323, DOI 10.1016/0022-2836(78)90302-9; WUTHRICH K, 1993, CAHIERS FDN L JEANTE, V8, P1	31	169	183	0	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604		S			23	26						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR392	8895597				2022-12-28	WOS:A1996VR39200008
J	Cravatt, BF; Giang, DK; Mayfield, SP; Boger, DL; Lerner, RA; Gilula, NB				Cravatt, BF; Giang, DK; Mayfield, SP; Boger, DL; Lerner, RA; Gilula, NB			Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides	NATURE			English	Article							CANNABINOID RECEPTOR; NUCLEOTIDE-SEQUENCE; ANANDAMIDE; PURIFICATION; AMIDASE; GENE; IDENTIFICATION; MEMBRANE; PROTEINS; KETONES	ENDOGENOUS neuromodulatory molecules are commonly coupled to specific metabolic enzymes to ensure rapid signal inactivation, Thus, acetylcholine is hydrolysed by acetylcholine esterase(1) and tryptamine neurotransmitters like serotonin are degraded by monoamine oxidases(2). Previously, we reported the structure and sleep-inducing properties of cis-9-octadecenamide, a lipid isolated from the cerebrospinal fluid of sleep-deprived cats(3). cis-9-Octadecenamide, or oleamide, has since been shown to affect serotonergic systems(4) and block gap-junction communication in glial cells (our unpublished results). We also identified a membrane-bound enzyme activity that hydrolyses oleamide to its inactive acid, oleic acid(3). We now report the mechanism-based isolation, cloning and expression of this enzyme activity, originally named oleamide hydrolase(5), from rat liver plasma membranes. We also show that oleamide hydrolase converts anandamide, a fatty-acid amide identified as the endogenous ligand for the cannabinoid receptor(6), to arachidonic acid, indicating that oleamide hydrolase may serve as the general inactivating enzyme for a growing family of bioactive signalling molecules, the fatty-acid amides(6-8). Therefore we will hereafter refer to oleamide hydrolase as fatty-acid amide hydrolase, in recognition of the plurality of fatty-acid amides that the enzyme can accept as substrates.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92307 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92307 USA	Scripps Research Institute; Scripps Research Institute					NIDA NIH HHS [R01 DA015648] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABDELAAL YAI, 1986, SCIENCE, V233, P1073, DOI 10.1126/science.3738525; BOIVIN J, 1992, TETRAHEDRON LETT, V33, P1285, DOI 10.1016/S0040-4039(00)91602-2; CHANG TH, 1990, NUCLEIC ACIDS RES, V18, P7180, DOI 10.1093/nar/18.23.7180; CORRICK CM, 1987, GENE, V53, P63, DOI 10.1016/0378-1119(87)90093-X; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; Cravatt BF, 1996, J AM CHEM SOC, V118, P580, DOI 10.1021/ja9532345; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; ETTINGER RA, 1995, ARCH BIOCHEM BIOPHYS, V316, P14, DOI 10.1006/abbi.1995.1003; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; FALK MM, 1994, J CELL BIOL, V127, P343, DOI 10.1083/jcb.127.2.343; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; HuidobroToro JP, 1996, P NATL ACAD SCI USA, V93, P8078, DOI 10.1073/pnas.93.15.8078; IMPERIALI B, 1986, BIOCHEMISTRY-US, V25, P3760, DOI 10.1021/bi00361a005; KLEE H, 1984, P NATL ACAD SCI-BIOL, V81, P1728, DOI 10.1073/pnas.81.6.1728; MACPHEEQUIGLEY K, 1985, J BIOL CHEM, V260, P2185; Maurelli S, 1995, FEBS LETT, V377, P82, DOI 10.1016/0014-5793(95)01311-3; MAYAUX JF, 1990, J BACTERIOL, V172, P6764, DOI 10.1128/jb.172.12.6764-6773.1990; Patterson JE, 1996, J AM CHEM SOC, V118, P5938, DOI 10.1021/ja954064z; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SINGER TP, 1995, FASEB J, V9, P605, DOI 10.1096/fasebj.9.8.7768351; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823; WAKAMATSU K, 1990, BIOCHEM BIOPH RES CO, V168, P423, DOI 10.1016/0006-291X(90)92338-Z; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMADA T, 1985, P NATL ACAD SCI USA, V82, P6522, DOI 10.1073/pnas.82.19.6522	28	1659	1720	7	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1996	384	6604					83	87		10.1038/384083a0	http://dx.doi.org/10.1038/384083a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	VR219	8900284				2022-12-28	WOS:A1996VR21900060
J	Woods, KA; CamachoHubner, C; Savage, MO; Clark, AJL				Woods, KA; CamachoHubner, C; Savage, MO; Clark, AJL			Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FACTOR BINDING-PROTEINS; HORMONE-RECEPTOR; HUMAN-FETUS; IGF-I; SERUM; EXPRESSION; MUTATIONS; MICE; RADIOIMMUNOASSAY; INSENSITIVITY		ST BARTHOLOMEWS HOSP, DEPT CHEM ENDOCRINOL, LONDON EC1A 7BE, ENGLAND; ST BARTHOLOMEWS HOSP, DEPT ENDOCRINOL, LONDON EC1A 7BE, ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London								AMSELEM S, 1989, NEW ENGL J MED, V321, P989, DOI 10.1056/NEJM198910123211501; BAXTER RC, 1990, J CLIN ENDOCR METAB, V70, P1347, DOI 10.1210/jcem-70-5-1347; BECK KD, 1995, NEURON, V14, P717, DOI 10.1016/0896-6273(95)90216-3; BLUM WF, 1988, ACTA ENDOCRINOL-COP, V118, P374, DOI 10.1530/acta.0.1180374; BRISSENDEN JE, 1984, NATURE, V310, P781, DOI 10.1038/310781a0; CAMERON N, 1978, HUMAN GROWTH, V2, P35, DOI DOI 10.1007/978-1-4684-2622-9_3; CHEW SL, 1995, ENDOCRINOLOGY, V136, P1939, DOI 10.1210/en.136.5.1939; DERCOLE AJ, 1993, ANN NY ACAD SCI, V692, P149; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; GARGOSKY SE, 1993, J CLIN ENDOCR METAB, V77, P1683, DOI 10.1210/jc.77.6.1683; GIUDICE LC, 1995, J CLIN ENDOCR METAB, V80, P1548, DOI 10.1210/jc.80.5.1548; GLUCKMAN PD, 1995, J CLIN ENDOCR METAB, V80, P1047, DOI 10.1210/jc.80.4.1047; GLUCKMAN PD, 1992, J PEDIATR-US, V121, P920, DOI 10.1016/S0022-3476(05)80342-7; GODDARD AD, 1995, NEW ENGL J MED, V333, P1093, DOI 10.1056/NEJM199510263331701; HAN VKM, 1988, J CLIN ENDOCR METAB, V66, P422, DOI 10.1210/jcem-66-2-422; HARDOUIN S, 1989, J CLIN ENDOCR METAB, V69, P1291, DOI 10.1210/jcem-69-6-1291; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; ISAKSSON OGP, 1987, ENDOCR REV, V8, P426, DOI 10.1210/edrv-8-4-426; LASSARRE C, 1991, PEDIATR RES, V29, P219, DOI 10.1203/00006450-199103000-00001; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MORRELL DJ, 1989, J MOL ENDOCRINOL, V2, P201, DOI 10.1677/jme.0.0020201; NAEYE RL, 1987, HUM PATHOL, V18, P387, DOI 10.1016/S0046-8177(87)80170-3; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; ROSENFELD RG, 1994, ENDOCR REV, V15, P369, DOI 10.1210/er.15.3.369; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SAVAGE MO, 1993, J CLIN ENDOCR METAB, V77, P1465, DOI 10.1210/jc.77.6.1465; Trainer P.J., 1995, BARTS ENDOCRINE PROT; Wajnrajch MP, 1996, NAT GENET, V12, P88, DOI 10.1038/ng0196-88; WOODS KA, 1995, GENETIC MOL BIOL ASP, P453; ZAPF J, 1989, P NATL ACAD SCI USA, V86, P3813, DOI 10.1073/pnas.86.10.3813	31	817	840	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1996	335	18					1363	1367		10.1056/NEJM199610313351805	http://dx.doi.org/10.1056/NEJM199610313351805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP484	8857020	Bronze			2022-12-28	WOS:A1996VP48400005
J	Schipper, H; Turley, EA; Baum, M				Schipper, H; Turley, EA; Baum, M			A new biological framework for cancer research	LANCET			English	Editorial Material							HELICOBACTER-PYLORI; LYMPHOID-TISSUE; THERAPY		UNIV MANITOBA,WINNIPEG,MB,CANADA; UNIV COLL,LONDON,ENGLAND	University of Manitoba; University of London; University College London								BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; BAUM M, 1996, BREAST CANC CONTROVE, P61; Gleick James, 1988, CHAOS MAKING NEW SCI; Goldberger AL, 1996, LANCET, V347, P1312, DOI 10.1016/S0140-6736(96)90948-4; GOLDIE JH, 1984, CANCER RES, V44, P3643; Hall CL, 1995, J NEURO-ONCOL, V26, P221, DOI 10.1007/BF01052625; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; Israel L, 1996, J THEOR BIOL, V178, P375, DOI 10.1006/jtbi.1996.0033; LEVINE MD, 1994, EXS, V74, P157; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Miller WH, 1996, CANCER INVEST, V14, P142, DOI 10.3109/07357909609018889; NOBES CD, 1955, BIOCHEM SOC T, V23, P456; NORTON L, 1977, CANCER TREAT REP, V61, P1307; NORTON L, 1993, CANCER MED, P598; OLIVER RTD, 1995, LANCET, V346, P1506, DOI 10.1016/S0140-6736(95)92046-3; PAYNE CM, 1995, LEUKEMIA LYMPHOMA, V19, P43, DOI 10.3109/10428199509059662; Porter A., 1971, IEE centenary lectures, P135; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; SCHABEL FM, 1975, CANCER, V35, P15, DOI 10.1002/1097-0142(197501)35:1<15::AID-CNCR2820350104>3.0.CO;2-W; SCHIPPER H, 1995, J CLIN ONCOL, V13, P801, DOI 10.1200/JCO.1995.13.4.801; Schipper H, 1996, BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, P235; SCHIPPER H, 1993, CAN J ONCOL, V3, P207; SCHIPPER H, 1993, CAN J ONCOL, V3, P220; SHERRATT JA, 1992, P ROY SOC B-BIOL SCI, V248, P261, DOI 10.1098/rspb.1992.0071; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; SPORN MB, 1991, CANCER RES, V51, P6215; TAKAHASHI Y, 1995, J NATL CANCER I, V87, P1262; TROSKO J E, 1987, Molecular Toxicology, V1, P83; TROSKO JE, 1987, EUR J CANCER CLIN ON, V23, P599, DOI 10.1016/0277-5379(87)90252-5; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; 1993, LANCET, V341, P343	33	42	43	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1149	1151		10.1016/S0140-6736(96)06184-3	http://dx.doi.org/10.1016/S0140-6736(96)06184-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888171				2022-12-28	WOS:A1996VP10600015
J	Donelan, K; Blendon, RJ; Hill, CA; Hoffman, C; Rowland, D; Frankel, M; Altman, D				Donelan, K; Blendon, RJ; Hill, CA; Hoffman, C; Rowland, D; Frankel, M; Altman, D			Whatever happened to the health insurance crisis in the United States? Voices from a national survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								FOUR YEARS AGO, in the presidential campaign, in major medical journals and medical associations, in the media, and in civic groups, our nation was engaged in a great debate about the best way to provide health insurance coverage to all Americans. By contrast, these debates have been conspicuous spicuous their absence in this election year, The health system reform debate was marked by some controversy about whether there was a health insurance crisis at all.(1) On one side were those who said that most of the uninsured could get care when they needed it, a view that was expressed in a commentary in the Wall Street Journal in 1994 that noted that ''these [uninsured] citizens are not denied health care'' and only 1 in 5 uninsured (about 3% of the population) cannot obtain affordable insurance.(2) On the other side were those who claimed that many of the uninsured faced major barriers to needed health care serviccs and experienced health and economic consequences because of these barriers While the political urgency of these concerns has subsided, we know that gaps in insurance coverage remain for a sizable number of Americans-recent estimates indicate that approximately 40 million people in the United States were uninsured in 1994 (oral communication, B. Katherine Swartz, PhD, April 23, 1996, regarding unpublished data from analyses of March 1995 Current Population Survey); another 29 million are underinsured.(3) Reports of public opinion surveys hare noted that support for reform was driven in large part by anxieties about access to and cost of medical care among both insured and uninsured persons.(1-6) Prior research has documented decreased. access to health care services, and increased burdens of economic hardship, ill health, and mortality that the uninsured and underinsured experience.(7-9). In them midst of the heal system reform debate, media reports about this research were frequently augmented with vignettes illustrating the consequences of access and financial problems for individuals and families, While vignettes can add a valuable qualitative dimension to quantitative estimated of problem, they are not randomly selected and may illustrate extreme, rather than average, consequences. Verbatim responses are common in the development of sample surveys, but in larger-scale surveys, structured and coded responses are preferred to minimize cost and increase analytic power. Now that the politically charged health system reform debate has subsided, we return to the basic questions that marked that discussion. What problems do uninsured and insured people have in getting and paying for medical care in today's changing health care system? How man Americans are affected? How severe are their problems and their consequences? We sought to answer these questions by using a combination of quantitative measures of access to health care and personal qualitative accounts in a recent survey of Americans to determine who has experienced problems getting medical care and paying for it.	UNIV CHICAGO,NATL OPIN RES CTR,CHICAGO,IL 60637; HENRY J KAISER FAMILY FDN,MENLO PK,CA; CUNY,BARUCH COLL,DEPT STAT,NEW YORK,NY 10021	University of Chicago; City University of New York (CUNY) System; Baruch College (CUNY)	Donelan, K (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Donelan, Karen/R-6162-2019	Hill, Craig/0000-0002-0826-2019				BLENDON RJ, 1994, JAMA-J AM MED ASSOC, V271, P949, DOI 10.1001/jama.271.12.949; BLENDON RJ, 1991, STANFORD LAW POLICY, V3, P146; *HJ KAIS FAM FDN, 1993, HARR POLL; *HJ KAIS FAM FDN, 1994, 1004 HJ KAIS FAM FDN; *HJ KAIS FAM FDN C, 1992, HARR POLL; SHORT PF, 1995, JAMA-J AM MED ASSOC, V274, P1302; STELZER IM, 1994, WALL STREET J   0125, P12; SWARTZ K, 1994, JAMA-J AM MED ASSOC, V271, P64; Weissman JS., 1994, FALLING SAFETY NET I	9	50	50	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1346	1350		10.1001/jama.276.16.1346	http://dx.doi.org/10.1001/jama.276.16.1346			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM825	8861997				2022-12-28	WOS:A1996VM82500041
J	Laine, C; Davidoff, F; Lewis, CE; Nelson, EC; Nelson, E; Kessler, RC; Delbanco, TL				Laine, C; Davidoff, F; Lewis, CE; Nelson, EC; Nelson, E; Kessler, RC; Delbanco, TL			Important elements of outpatient care: A comparison of patients' and physicians' opinions	ANNALS OF INTERNAL MEDICINE			English	Article						quality of health care; ambulatory care; clinical competence; physician-patient relationships; patient education	MEDICAL-CARE; SATISFACTION; EMERGENCY	Objective: To compare patients' and physicians' opinions on the importance of discrete elements of health care as determinants of the quality of outpatient care. Design: Analysis of results of a mailed survey. Setting: Community-based internal medicine practices. Participants: 74 general internists and 814 patients randomly selected from the practices of these internists. Measures: 125 elements of care that covered nine domains were identified: physician clinical skill, physician interpersonal skill, support staff office environment, provision of information, patient involvement, nonfinancial access, finances, and coordination of care. Participants rated each element on its importance to high-quality care on a 4-point scale: 1 = not important; 2 = of medium importance; 3 = of high importance; and 4 = essential. Patients' and physicians' ratings were compared for individual elements of care and for elements aggregated into domains. Results: Survey response rates were 93% for physicians and 60% for patients. In an element-by-element comparison of ratings, ratings by the two groups differed substantially for 58% of the attributes. The most striking difference was seen in the domain of provision of information (median ratings, 3.56 for patients and 2.85 for physicians; P < 0.001). Ratings by the two groups also differed in the domains of clinical skill (3.75 for patients and 3.35 for physicians: P < 0.001), nonfinancial access (3.00 for patients and 2.87 for physicians; P < 0.001), and finances (3.00 for patients and 2.80 for physicians; P - 0.006). When relative rankings of the domains were compared, both groups agreed that clinical skill is most important; however, patients ranked provision of information second in importance whereas physicians ranked it sixth. Conclusions: Patients and physicians agreed that the most crucial element of outpatient care is clinical skill, but they disagreed about the relative importance of other aspects of care, particularly effective communication of health-related information. These differences in perception may influence the quality of interactions between physicians and patients.	AMER COLL PHYSICIANS, PHILADELPHIA, PA 19106 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, HLTH SCI CTR, DIV HLTH PROMOT & DIS PREVENT, LOS ANGELES, CA 90095 USA; DARTMOUTH HITCHCOCK MED CTR, LEBANON, NH 03756 USA; UNIV MICHIGAN, ANN ARBOR, MI 48109 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	American College of Physicians; University of California System; University of California Los Angeles; Dartmouth College; University of Michigan System; University of Michigan; Harvard University; Harvard Medical School	Laine, C (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, CTR RES MED EDUC & HLTH CARE, 1025 WALNUT ST, ROOM 119, PHILADELPHIA, PA 19107 USA.							Aharony L, 1993, Med Care Rev, V50, P49, DOI 10.1177/002570879305000104; BABBIE ER, 1989, PRACTICE SOCIAL RES; BAKER R, 1993, MEASUREMENT PATIENTS, P57; BURSCH B, 1993, ANN EMERG MED, V22, P586, DOI 10.1016/S0196-0644(05)81947-X; CARRHILL RA, 1992, J PUBLIC HEALTH MED, V14, P236; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; DELBANCO TL, 1992, ANN INTERN MED, V116, P414, DOI 10.7326/0003-4819-116-5-414; Donabedian A, 1992, Qual Health Care, V1, P247, DOI 10.1136/qshc.1.4.247; FLETCHER RH, 1983, MED CARE, V21, P234, DOI 10.1097/00005650-198302000-00010; GERTELS M, 1993, PATIENTS EYES; HALL JA, 1988, SOC SCI MED, V27, P935, DOI 10.1016/0277-9536(88)90284-5; KAPLAN SH, 1989, PROVIDING QUALITY CA, P25; KRISHEL S, 1993, ANN EMERG MED, V22, P568, DOI 10.1016/S0196-0644(05)81943-2; Linder-Pelz S, 1985, J Community Health, V10, P42, DOI 10.1007/BF01321358; Robbins J A, 1993, Fam Med, V25, P17; STEIN MD, 1993, MED CARE, V31, P182, DOI 10.1097/00005650-199302000-00008; Strasser S, 1993, Med Care Rev, V50, P219, DOI 10.1177/107755879305000205; VONKORFF M, 1994, ANN INTERN MED, V121, P187, DOI 10.7326/0003-4819-121-3-199408010-00005; WARE JE, 1975, MED CARE, V13, P669, DOI 10.1097/00005650-197508000-00006	19	203	206	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					640	+		10.7326/0003-4819-125-8-199610150-00003	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VM889	8849148				2022-12-28	WOS:A1996VM88900005
J	Fletcher, RH; Fletcher, SW				Fletcher, RH; Fletcher, SW			United States of America - Managed care and medical education	LANCET			English	Article									HARVARD PILGRIM HLTH CARE,BOSTON,MA 02215	Harvard Pilgrim Health Care	Fletcher, RH (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,SUITE 200,126 BROOKLINE AVE,BOSTON,MA 02215, USA.								0	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					1003	1004						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855861				2022-12-28	WOS:A1996VM02700017
J	Holohan, TV				Holohan, TV			United States of America - The federal role in health technology assessment	LANCET			English	Article											Holohan, TV (corresponding author), DEPT VET AFFAIRS,PATIENT CARE SERV 11,810 VERMONT AVE NW,WASHINGTON,DC 20420, USA.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					1006	1007						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855864				2022-12-28	WOS:A1996VM02700020
J	Vandenbroucke, JP; Helmerhorst, FM				Vandenbroucke, JP; Helmerhorst, FM			Risk of venous thrombosis with hormone-replacement therapy	LANCET			English	Editorial Material									LEIDEN UNIV HOSP,DEPT OBSTET GYNAECOL & REPROD MED,NL-2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	Vandenbroucke, JP (corresponding author), LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,NL-2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				[Anonymous], 1995, LANCET, V346, P1575; GOLDHABER SZ, 1994, HAEMOSTASIS THROMBOS, V2, P1327; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; SALZMAN EW, 1994, HEMOSTASIS THROMBOSI, P1275; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VANDENBROUCKE JP, 1996, GYNECOL ENDOCRINOL, V10, P5; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; 1996, BRIT MED J, V312, P473	8	41	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					972	972		10.1016/S0140-6736(05)64918-5	http://dx.doi.org/10.1016/S0140-6736(05)64918-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855846				2022-12-28	WOS:A1996VM02700002
J	Matthews, JNS; Altman, DG				Matthews, JNS; Altman, DG			Statistics notes - Interaction 3: How to examine heterogeneity	BRITISH MEDICAL JOURNAL			English	Article									IMPERIAL CANC RES FUND,MED STAT GRP,CTR STAT MED,INST HLTH SCI,OXFORD OX3 7LF,ENGLAND	University of Oxford	Matthews, JNS (corresponding author), UNIV NEWCASTLE,DEPT MED STAT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.		Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X				Altman DG, 1996, BRIT MED J, V313, P486; ALTMAN DG, 1991, PRACTICAL STAT MED R, P160; COCKBURN F, 1980, BRIT MED J, V281, P11, DOI 10.1136/bmj.281.6232.11; Matthews JNS, 1996, BRIT MED J, V313, P808; 1981, AM J OBSTET GYNECOL, V141, P276	5	71	71	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					862	862						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870577				2022-12-28	WOS:A1996VL55900028
J	Jain, C; Belasco, JG				Jain, C; Belasco, JG			A structural model for the HIV-1 Rev-RRE complex deduced from altered-specificity rev variants isolated by a rapid genetic strategy	CELL			English	Article							HOMEODOMAIN-DNA INTERACTIONS; CRYSTAL-STRUCTURE; TRANS-ACTIVATOR; MESSENGER-RNA; RESPONSIVE ELEMENT; OPERATOR COMPLEX; ESCHERICHIA-COLI; BINDING-ELEMENT; TARGET SEQUENCE; CLONED GENES	A broadly applicable genetic strategy was developed for investigating RNA-protein interactions and applied to the HIV-1 Rev protein. By rapidly screening thousands of Rev-RNA interactions in Escherichia coli, we isolated Rev suppressor mutations that alleviated the deleterious effect of mutations in RRE stem-loop IIB, the high affinity RNA-binding site for Rev. All of these suppressor mutations map to a single arginine-deficient face of a Rev alpha-helix, and some alter the binding specificity of the protein, providing genetic evidence for direct contacts between specific Rev amino acids and RNA nucleotides in the RNA complex of Rev. The spatial constraints suggested by these data have enabled us to model the structure of this complex.			Jain, C (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115, USA.		Jain, Chaitanya/ABA-4238-2021	Jain, Chaitanya/0000-0003-2429-0105				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Battiste JL, 1995, J BIOMOL NMR, V6, P375; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CADWELL RC, 1992, PCR METH APPL, V2, P28; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; GHOSH S, 1996, IN PRESS GENE; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; JAIN C, 1993, MOL MICROBIOL, V9, P233, DOI 10.1111/j.1365-2958.1993.tb01686.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LECLERC F, 1994, NAT STRUCT BIOL, V1, P293, DOI 10.1038/nsb0594-293; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MANDELGUTFREUND Y, 1995, J MOL BIOL, V253, P370, DOI 10.1006/jmbi.1995.0559; MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller J.H., 1972, EXPT MOL GENETICS; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6	42	84	87	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					115	125		10.1016/S0092-8674(00)81328-8	http://dx.doi.org/10.1016/S0092-8674(00)81328-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858154	Bronze			2022-12-28	WOS:A1996VL69500014
J	Ma, QF; Kintner, C; Anderson, DJ				Ma, QF; Kintner, C; Anderson, DJ			Identification of neurogenin, a vertebrate neuronal determination gene	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; CELL FATE SPECIFICATION; ACHAETE-SCUTE HOMOLOG-1; LOOP-HELIX PROTEIN; XENOPUS-EMBRYOS; NEURAL INDUCTION; PRONEURAL GENE; LATERAL INHIBITION; DROSOPHILA-HAIRY; ORGAN FORMATION	Several bHLH proteins are involved in vertebrate neurogenesis, but those controlling early stages of neuronal determination have not yet been identified. Here we describe a novel, NeuroD-related bHLH protein, NEUROGENIN, whose expression precedes that of NeuroD in both mouse and Xenopus. Expression of Xenopus NEUROGENIN-related-1 (X-NGNR-1) defines the three prospective territories of primary neurogenesis. Overexpression of X-NGNR-1 (or NEUROGENIN) induces ectopic neurogenesis and ectopic expression of XNeuroD mRNA. Endogenous X-ngnr-1 expression becomes restricted to subsets of cells by lateral inhibition, mediated by X-Delta-1 and X-Notch. The properties of X-NGNR-1 are thus analogous to those of the Drosophila proneural genes, suggesting that it functions as a vertebrate neuronal determination factor.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; SALK INST BIOL STUDIES,LA JOLLA,CA 92186	California Institute of Technology; Howard Hughes Medical Institute; Salk Institute	Ma, QF (corresponding author), CALTECH,DIV BIOL 21676,PASADENA,CA 91125, USA.							AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Amon A, 1996, CELL, V84, P651, DOI 10.1016/S0092-8674(00)81041-7; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BARTHOLOMA A, 1994, MECH DEVELOP, V48, P217, DOI 10.1016/0925-4773(94)90061-2; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BRAND M, 1993, DEVELOPMENT, V119, P1; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; Chitnis A, 1996, DEVELOPMENT, V122, P2295; CHITNIS AB, 1995, MOL CELL NEUROSCI, V6, P311, DOI 10.1006/mcne.1995.1024; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; FERREIRO B, 1994, DEVELOPMENT, V120, P3649; FERREIRO B, 1992, MECH DEVELOP, V40, P25; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GURDON JB, 1987, DEVELOPMENT, V99, P285; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; JAN YN, 1994, ANNU REV GENET, V28, P373, DOI 10.1146/annurev.ge.28.120194.002105; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, DEVELOPMENT, V119, P19; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOPAN R, 1994, DEVELOPMENT, V120, P2385; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kume H, 1996, BIOCHEM BIOPH RES CO, V219, P526, DOI 10.1006/bbrc.1996.0267; KUNISCH M, 1994, P NATL ACAD SCI USA, V91, P10139, DOI 10.1073/pnas.91.21.10139; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSCHWALD R, 1991, International Journal of Developmental Biology, V35, P399; Ramon y Cajal S, 1995, HISTOLOGY NERVOUS SY; SAITO T, 1995, MOL CELL NEUROSCI, V6, P280, DOI 10.1006/mcne.1995.1022; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SHIMIZU C, 1995, EUR J BIOCHEM, V229, P239, DOI 10.1111/j.1432-1033.1995.0239l.x; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; Wang YK, 1996, NATURE, V379, P823, DOI 10.1038/379823a0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	52	707	718	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					43	52		10.1016/S0092-8674(00)81321-5	http://dx.doi.org/10.1016/S0092-8674(00)81321-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858147	Bronze			2022-12-28	WOS:A1996VL69500007
J	Robertson, HD				Robertson, HD			How did replicating and coding RNAs first get together?	SCIENCE			English	Editorial Material											Robertson, HD (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,DEPT BIOCHEM,1300 YORK AVE,NEW YORK,NY 10021, USA.							BRANCH AD, 1989, SCIENCE, V243, P649, DOI 10.1126/science.2492676; BRANCH AD, 1984, SCIENCE, V223, P450, DOI 10.1126/science.6197756; Brazas R, 1996, SCIENCE, V274, P90, DOI 10.1126/science.274.5284.90; GESTELAND RF, 1993, RNA WORLD; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; Moore M., 1993, RNA WORLD, P303; ROBERTSON HD, 1992, CURR TOP MICROBIOL, V176, P213; SEMANCIK JS, 1987, VIROIDS VIROID LIKE	8	24	24	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					66	67		10.1126/science.274.5284.66	http://dx.doi.org/10.1126/science.274.5284.66			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8848724				2022-12-28	WOS:A1996VK74800045
J	Pearce, KF; Haefner, HK; Sarwar, SF; Nolan, TE				Pearce, KF; Haefner, HK; Sarwar, SF; Nolan, TE			Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVASIVE-CARCINOMA; INSITU; CANCER; NEED	Background Periodic, routine Papanicolaou smears of cells from the vagina are commonly examined in women who have undergone a hysterectomy for benign gynecologic disease. The benefits of this method of screening are not known. Methods We analyzed Papanicolaou smears obtained from the vaginal apex (cuff) in 6265 women at Charity Hospital in New Orleans between January 1, 1992, and December 31, 1994. Of the 10,595 vaginal smears, an estimated 9610 were obtained during follow-up examinations of 5682 women who had undergone hysterectomy for benign gynecologic disease. Results Among these 9610 vaginal smears, 104, from 79 women, were abnormal. The abnormal smears were categorized according to the findings, as follows: atypical squamous cells of undetermined significance, 52 (0.5 percent of all smears); low-grade squamous intraepithelial lesion, 44 (0.5 percent); high-grade squamous intraepithelial lesion, 6 (0.1 percent); and squamous-cell carcinoma, 2 (0.02 per cent). In five women, biopsies revealed vaginal intraepithelial neoplasia type I or II; there were no biopsy proved cases of vaginal cancer. The probability of an abnormal Papanicolaou smear in this group of women was 1.1 percent, and the positive predictive value of the Papanicolaou test for detecting vaginal cancer was 0 percent (95 percent confidence interval, 0 to 33 percent). Conclusions The prevalence of abnormal findings on cytopathological examination of vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease is extremely low. (C) 1996, Massachusetts Medical Society.	LOUISIANA STATE UNIV,MED CTR,DEPT OBSTET & GYNECOL,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,DEPT INTERNAL MED,NEW ORLEANS,LA; LOUISIANA STATE UNIV,MED CTR,DEPT PATHOL,NEW ORLEANS,LA 70112; UNIV MICHIGAN,DEPT OBSTET & GYNECOL,ANN ARBOR,MI 48109	Louisiana State University System; Louisiana State University System; Louisiana State University System; University of Michigan System; University of Michigan								AHO M, 1991, CANCER, V68, P195, DOI 10.1002/1097-0142(19910701)68:1<195::AID-CNCR2820680135>3.0.CO;2-L; *AM COLL OBST GYN, 1993, ACOG TECHN B, V183; American Cancer Society, 1991, PAP TEST; BELL J, 1984, OBSTET GYNECOL, V64, P699; BRINTON LA, 1990, GYNECOL ONCOL, V38, P49, DOI 10.1016/0090-8258(90)90010-I; CHRISTOPHERSON WM, 1969, CANCER-AM CANCER SOC, V24, P64, DOI 10.1002/1097-0142(196907)24:1<64::AID-CNCR2820240108>3.0.CO;2-Y; CHRISTOPHERSON WM, 1976, CANCER, V38, P1357, DOI 10.1002/1097-0142(197609)38:3<1357::AID-CNCR2820380340>3.0.CO;2-A; CRAMER DW, 1974, AM J OBSTET GYNECOL, V118, P443, DOI 10.1016/S0002-9378(16)33683-3; DICKINSON L, 1972, MAYO CLIN PROC, V47, P545; Fetters MD, 1996, JAMA-J AM MED ASSOC, V275, P940, DOI 10.1001/jama.275.12.940; FOLTZ AM, 1978, MILBANK FUND Q, V56, P426, DOI 10.2307/3349572; FUNNELL JD, 1963, SURG GYNECOL OBSTET, V117, P15; GALLUP DG, 1975, OBSTET GYNECOL, V46, P334; GALLUP DG, 1987, OBSTET GYNECOL, V69, P782; HANKINS CA, 1994, CAN MED ASSOC J, V150, P681; HUMMER WK, 1970, AM J OBSTET GYNECOL, V108, P1109, DOI 10.1016/0002-9378(70)90461-8; JIMERSON G K, 1976, Gynecologic Oncology, V4, P328, DOI 10.1016/0090-8258(76)90040-8; JOHNSTON GA, 1983, SURG GYNECOL OBSTET, V156, P34; Kurman RJ, 1994, BETHESDA SYSTEM REPO; Kvale K M, 1994, Wis Med J, V93, P275; MCINDOE WA, 1969, ACTA CYTOL, V13, P158; MILLER J, 1987, POSTGRAD MED, V82, P205; MILLER JM, 1987, POSTGRAD MED, V82, P200, DOI 10.1080/00325481.1987.11699908; OLIVER JA, 1979, AM J OBSTET GYNECOL, V134, P133, DOI 10.1016/0002-9378(79)90876-7; PISCITELLI JT, 1995, AM J OBSTET GYNECOL, V173, P424, DOI 10.1016/0002-9378(95)90262-7; RUTLEDGE F, 1967, AM J OBSTET GYNECOL, V97, P635, DOI 10.1016/0002-9378(67)90451-6; SCHIFFER MA, 1972, SURG GYNECOL OBSTET, V134, P653; STUART GCE, 1981, AM J OBSTET GYNECOL, V139, P311, DOI 10.1016/0002-9378(81)90016-8	28	81	84	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1996	335	21					1559	1562		10.1056/NEJM199611213352103	http://dx.doi.org/10.1056/NEJM199611213352103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT341	8900088				2022-12-28	WOS:A1996VT34100003
J	Gray, GC; Coate, BD; Anderson, CM; Kang, HK; Berg, SW; Wignall, FS; Knoke, JD; BarrettConnor, E				Gray, GC; Coate, BD; Anderson, CM; Kang, HK; Berg, SW; Wignall, FS; Knoke, JD; BarrettConnor, E			The postwar hospitalization experience of US veterans of the Persian Gulf War	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES-ARMY; NAVY PERSONNEL; DESERT-STORM; RECRUITS; HEALTH	Background Since the Persian Gulf War ended in 1991, many veterans of that conflict have reported diverse, unexplained symptoms. To evaluate the health of Gulf War veterans, we studied their postwar hospitalization experience and compared it with that of other military personnel serving at the same time who did not go to the Persian Gulf. Methods Using a retrospective cohort approach and data from Department of Defense hospitals, we studied hospitalizations of 547,076 veterans of the Gulf War who were serving in the Army, Navy, Marine Corps, and Air Force and 618,335 other veterans from the same era who did not serve in the Persian Gulf. Using multivariate logistic-regression models, we analyzed risk factors for hospitalization both overall and in 14 broad diagnostic categories during three periods from August 1991 through September 1993 (a total of 45 comparisons). Results After the war, the overall odds ratio for hospitalization of the Gulf War veterans was not higher than that of the other veterans, even after adjustment for selection effects related to deployment. In 16 of the 42 comparisons involving specific diagnoses, the risk of hospitalization among Gulf War veterans differed significantly from that among other veterans. Among these 16 comparisons, Gulf War veterans were at higher risk in 5: neoplasms (largely benign) during 1991, diseases of the genitourinary system during 1991, diseases of the blood and blood-forming organs (mostly forms of anemia) during 1992, and mental disorders during both 1992 and 1993. The differences were not consistent over time and could be accounted for by deferred care, postwar pregnancies, and postwar stress. Conclusions During the two years after the Persian Gulf War, there was no excess of unexplained hospitalization among Americans who remained on active duty after serving in that conflict. (C) 1996, Massachusetts Medical Society.	DEPT VET AFFAIRS,ENVIRONM EPIDEMIOL SERV,WASHINGTON,DC; USN,CTR ENVIRONM HLTH,NORFOLK,VA; NAVAL MED RES UNIT 2,JAKARTA,INDONESIA; UNIV CALIF SAN DIEGO,SCH MED,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093	United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); US Naval Medical Research Unit-2 (NAMRU-2); University of California System; University of California San Diego	Gray, GC (corresponding author), USN,HLTH RES CTR,DIV CLIN EPIDEMIOL,EMERGING ILLNESS RES TEAM,POB 85122,SAN DIEGO,CA 92186, USA.		Gray, Gregory C./ABF-1298-2020	Gray, Gregory/0000-0002-4628-5908				[Anonymous], 1995, Arch Intern Med, V155, P262; ARDAY DR, 1989, AM J PUBLIC HEALTH, V79, P471, DOI 10.2105/AJPH.79.4.471; BEST F, 1995, MED GULF WAR; BROWN D, 1994, WASHINGTON POST 0724; *C RES SERV, 1992, IR KUW CRIS CHRON EV; *COMM REV HLTH CON, 1995, HLTH CONS SERV PERS; COMSTOCK GW, 1974, AM REV RESPIR DIS, V110, P572; COTTON P, 1992, JAMA-J AM MED ASSOC, V268, P2619, DOI 10.1001/jama.268.19.2619; COWLEY G, 1994, NEWSWEEK        1024, P56; *DEF SCI BOARD, 1994, REP DEF SCI BOARD TA; DEFRAITES RF, 1992, INVESTIGATION SUSPEC; *DEP DEF, 1996, COMPR CLIN EV PROGR; *DHHS, 1989, DHHS PUBL; FLANDERS L, 1995, NATION          0123, P94; FRANCE D, 1994, REDBOOK          SEP, V114, P148; FUMENTO M, 1995, AM SPECTATOR     MAY, P28; GARLAND FC, 1990, AM J EPIDEMIOL, V132, P293, DOI 10.1093/oxfordjournals.aje.a115658; GRAY GC, 1990, PEDIATRICS, V86, P867; GRAY GC, 1994, AM J EPIDEMIOL, V139, P793, DOI 10.1093/oxfordjournals.aje.a117076; HELMKAMP JC, 1994, J OCCUP ENVIRON MED, V36, P609; HELMKAMP JC, 1992, MIL MED, V157, pA7, DOI 10.1093/milmed/157.3.A7; HOBFOLL SE, 1991, AM PSYCHOL, V146, P848; HOIBERG A, 1980, J OCCUP ENVIRON MED, V22, P685, DOI 10.1097/00043764-198010000-00017; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; HYAMS KC, 1995, CLIN INFECT DIS, V20, P1497, DOI 10.1093/clinids/20.6.1497; JEHL D, 1995, NY TIMES        0307, pA14; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; KANG HK, 1995, HLTH SURVEILLANCE PE; MILNER UB, 1994, JAMA-J AM MED ASSOC, V271, P1661; *NAT I HLTH TECHN, 1994, JAMA-J AM MED ASSOC, V272, P391; NELSON S, 1995, NAVY TIMES      0704, P10; NELSON S, 1995, ARMY TIMES      0619; *OFF ASS SECR DEF, 1991, OCC CONV MAN ENL OFF; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P144; STRETCH RH, 1995, MIL MED, V160, P131, DOI 10.1093/milmed/160.3.131; SUTKER PB, 1994, J TRAUMA STRESS, V71, P159; TIPPIT S, 1994, LADIES HOME J    JUN, V100, P148; Writer JV, 1996, JAMA-J AM MED ASSOC, V275, P118, DOI 10.1001/jama.275.2.118; 1995, MMWR-MORBID MORTAL W, V44, P443; 1991, FED REGISTER, V156, P2663; 1995, PERSIAN GULF REV, P5	41	137	139	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1505	1513		10.1056/NEJM199611143352007	http://dx.doi.org/10.1056/NEJM199611143352007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT340	8890103				2022-12-28	WOS:A1996VT34000007
J	Marigo, V; Davey, RA; Zuo, Y; Cunningham, JM; Tabin, CJ				Marigo, V; Davey, RA; Zuo, Y; Cunningham, JM; Tabin, CJ			Biochemical evidence that Patched is the Hedgehog receptor	NATURE			English	Article							TERMINAL CLEAVAGE PRODUCT; SONIC-HEDGEHOG; DROSOPHILA SEGMENT; GENE ENCODES; POLARITY; PROTEIN; INDUCTION; LOCALIZATION; EMBRYOS; SOMITE	THE protein Sonic hedgehog (Shh) is essential for a variety of patterning events during development. It is the signal from the notochord that induces ventral cell fate in the neural tube and somites(1,2), and is the polarizing signal for patterning of the anterior-posterior axis of the developing limb bud(3). Because of these and other inductive functions of Shh, it is important to understand how the Hedgehog (Hh) signal is received by the target cells. Here we describe binding studies using labelled Shh that strongly suggest that the Hh receptor is encoded by patched (ptc), a gene first identified in genetic screens in Drosophila(4).	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute			Marigo, Valeria/B-7947-2015	Marigo, Valeria/0000-0002-4428-2084; Davey, Robert/0000-0001-9168-2892	Telethon [TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BUMCROT DA, 1995, CURR BIOL, V5, P612, DOI 10.1016/S0960-9822(95)00123-0; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FORBES AJ, 1993, DEVELOPMENT, P115; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; Lumsden A, 1995, CURR BIOL, V5, P1347, DOI 10.1016/S0960-9822(95)00266-1; Marigo V, 1996, DEVELOPMENT, V122, P1225; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OPRESKO LK, 1990, J CELL BIOL, V111, P1661, DOI 10.1083/jcb.111.4.1661; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0	29	700	731	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	1996	384	6605					176	179		10.1038/384176a0	http://dx.doi.org/10.1038/384176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906794				2022-12-28	WOS:A1996VT33600068
J	Petsko, GA				Petsko, GA			For medicinal purposes	NATURE			English	Editorial Material											Petsko, GA (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254, USA.		Petsko, Gregory/AAO-7962-2020					Allen KN, 1996, J PHYS CHEM-US, V100, P2605, DOI 10.1021/jp952516o; Blundell TL, 1996, NATURE, V384, P23; Broach JR, 1996, NATURE, V384, P14; Hogan JC, 1996, NATURE, V384, P17; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; MATTEUCCI MD, 1996, NATURE S, V382, P20; Ringe D, 1995, CURR OPIN STRUC BIOL, V5, P825, DOI 10.1016/0959-440X(95)80017-4; Verdine GL, 1996, NATURE, V384, P11; VITALI J, 1992, J BIOL CHEM, V267, P17670	9	28	28	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604		S			7	9						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR392	8895592				2022-12-28	WOS:A1996VR39200003
J	Herxheimer, A				Herxheimer, A			Euthanasia and palliative care: A pseudoconflict?	LANCET			English	Editorial Material																		*HOUS LORDS, 1994, REP SEL COMM MED ETH, V1; World Health Organization, 1996, CANC PAIN REL	2	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1187	1188		10.1016/S0140-6736(05)65478-5	http://dx.doi.org/10.1016/S0140-6736(05)65478-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898033				2022-12-28	WOS:A1996VQ46700006
J	Chen, Y; Struhl, G				Chen, Y; Struhl, G			Dual roles for patched in sequestering and transducing hedgehog	CELL			English	Article							PROTEIN-KINASE-A; TERMINAL CLEAVAGE PRODUCT; TGF-BETA FAMILY; SIGNAL-TRANSDUCTION; DROSOPHILA EMBRYO; WINGLESS TRANSCRIPTION; GENETIC MOSAICS; SONIC HEDGEHOG; IMAGINAL DISKS; BODY PATTERN	Secreted proteins of the Hedgehog (Hh) family have diverse organizing roles in animal development. Recently, a serpentine protein Smoothened (Smo) has been proposed as a Hh receptor. Here, we present evidence that implicates another multiple-pass transmembrane protein, Patched (Ptc), in Hh reception and suggests a novel signal transduction mechanism in which Hh binds to Ptc, or a Ptc-Smo complex, and thereby induces Smo activity. Our results also show that Ptc limits the range of Hh action; we provide evidence that high levels of Ptc induced by Hh serve to sequester any free Hh and therefore create a barrier to its further movement.			Chen, Y (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT GENET & DEV,NEW YORK,NY 10032, USA.							Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CASANOVA J, 1995, GENE DEV, V9, P2539, DOI 10.1101/gad.9.20.2539; CASANOVA J, 1993, NATURE, V362, P152, DOI 10.1038/362152a0; CHOU TB, 1992, GENETICS, V131, P643; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Marigo V, 1996, DEVELOPMENT, V122, P1225; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1995, CURR OPIN NEUROBIOL, V6, P33; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; VANDENHEUVEL M, 1993, DEVELOPMENT, P105; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	51	729	770	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					553	563		10.1016/S0092-8674(00)81374-4	http://dx.doi.org/10.1016/S0092-8674(00)81374-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898207	hybrid			2022-12-28	WOS:A1996VQ46600020
J	Montgomery, RI; Warner, MS; Lum, BJ; Spear, PG				Montgomery, RI; Warner, MS; Lum, BJ; Spear, PG			Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family	CELL			English	Article							NECROSIS-FACTOR RECEPTOR; GROWTH-FACTOR RECEPTOR; GLYCOPROTEIN-D; HEPARAN-SULFATE; SYN PHENOTYPE; STRAIN KOS; TYPE-1; INFECTION; SEQUENCES; REPLICATION	We identified and cloned a cellular mediator of herpes simplex virus (HSV) entry. Hamster and swine cells resistant to viral entry became susceptible upon expression of a human cDNA encoding this protein, designated HVEM (for herpesvirus entry mediator). HVEM was shown to mediate the entry of several wild-type HSV strains of both serotypes. Anti-HVEM antibodies and a soluble hybrid protein containing the HVEM ectodomain inhibited HVEM-dependent infection but not virus binding to cells. Mutations in the HSV envelope glycoprotein go significantly reduced HVEM-mediated entry. The contribution of HVEM to HSV entry into human cells was demonstrable in activated T cells. HVEM, the first identified mediator of HSV entry, is a new member of the TNF/NGF receptor family.			Montgomery, RI (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.			Warner, Morgyn/0000-0002-4053-1610				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; BATTERSON W, 1983, J VIROL, V46, P371, DOI 10.1128/JVI.46.2.371-377.1983; BODDINGIUS J, 1987, J CUTAN PATHOL, V14, P165, DOI 10.1111/j.1600-0560.1987.tb00492.x; BRUNETTI CR, 1995, J VIROL, V69, P3517, DOI 10.1128/JVI.69.6.3517-3528.1995; CAL WH, 1988, J VIROL, V62, P2596, DOI 10.1128/JVI.62.8.2596-2604.1988; CAMPADELLIFIUME G, 1988, J VIROL, V62, P159, DOI 10.1128/JVI.62.1.159-167.1988; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEAN HJ, 1994, VIROLOGY, V199, P67, DOI 10.1006/viro.1994.1098; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FORRESTER A, 1992, J VIROL, V66, P341, DOI 10.1128/JVI.66.1.341-348.1992; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HIGHLANDER SL, 1987, J VIROL, V61, P3356, DOI 10.1128/JVI.61.11.3356-3364.1987; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOGGAN MD, 1959, AM J HYG, V70, P208, DOI 10.1093/oxfordjournals.aje.a120071; HUANG AS, 1964, P SOC EXP BIOL MED, V116, P863, DOI 10.3181/00379727-116-29392; JOHNSON RM, 1989, J VIROL, V63, P819, DOI 10.1128/JVI.63.2.819-827.1989; KANER RJ, 1990, SCIENCE, V248, P1410, DOI 10.1126/science.2162560; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KLUPP BG, 1994, J VIROL, V68, P3868, DOI 10.1128/JVI.68.6.3868-3878.1994; LIGAS MW, 1988, J VIROL, V62, P1486, DOI 10.1128/JVI.62.5.1486-1494.1988; LITTLE SP, 1981, VIROLOGY, V112, P686, DOI 10.1016/0042-6822(81)90314-7; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MANESS LM, 1994, NEUROSCI BIOBEHAV R, V18, P143, DOI 10.1016/0149-7634(94)90043-4; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MIRDA DP, 1992, J VIROL, V66, P448, DOI 10.1128/JVI.66.1.448-457.1992; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MUNK K., 1963, ARCH GES VIRUSFORSCH, V13, P529, DOI 10.1007/BF01267795; PELTON BK, 1977, IMMUNOLOGY, V32, P803; POGUEGEILE KL, 1987, VIROLOGY, V157, P67, DOI 10.1016/0042-6822(87)90314-X; RABIZADEH S, 1994, DEV NEUROSCI-BASEL, V16, P207, DOI 10.1159/000112108; RINALDO CR, 1978, J IMMUNOL, V120, P130; ROOP C, 1993, J VIROL, V67, P2285, DOI 10.1128/JVI.67.4.2285-2297.1993; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SARMIENTO M, 1979, J VIROL, V29, P1149, DOI 10.1128/JVI.29.3.1149-1158.1979; SHIEH MT, 1991, SCIENCE, V253, P208, DOI 10.1126/science.1649495; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPEAR PG, 1993, SEMIN VIROL, V4, P167, DOI 10.1006/smvy.1993.1012; SUBRAMANIAN G, 1994, J VIROL, V68, P5667, DOI 10.1128/JVI.68.9.5667-5676.1994; TEUTE H, 1983, INTERVIROLOGY, V20, P32, DOI 10.1159/000149371; WEISE K, 1987, J GEN VIROL, V68, P1909, DOI 10.1099/0022-1317-68-7-1909; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WITTELS M, 1991, VIRUS RES, V18, P271, DOI 10.1016/0168-1702(91)90024-P	54	964	1060	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1996	87	3					427	436		10.1016/S0092-8674(00)81363-X	http://dx.doi.org/10.1016/S0092-8674(00)81363-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898196	Bronze			2022-12-28	WOS:A1996VQ46600009
J	Tonks, NK; Neel, BG				Tonks, NK; Neel, BG			From form to function: Signaling by protein tyrosine phosphatases	CELL			English	Review							RECRUITMENT; ACTIVATION; DOMAIN	Tyrosine phosphorylation, controlled by the coordinated actions of protein tyrosine phosphatases (PTPs) and kinases (PTKs), is a critical control mechanism for numerous physiological processes, including growth, differentiation, metabolism, cell cycle regulation and cytoskeletal function. Originally, PTKs were believed to be the key enzymes controlling the dynamic process of tyrosine phosphorylation in vivo, with a small number of PTPs playing largely housekeeping roles. Unexpected structural diversity within a large family of PTPs called this idea into question. Approximately 75 PTPs have been identified, including both receptor-like and nontransmembrane enzymes, with genome sequencing data predicting the existence of similar to 500 human PTPs. These enzymes are characterized by the presence of a conserved catalytic domain of similar to 240 residues, containing the unique signature motif, [I/V]HCxAGxxR[S/T]G that defines this enzyme family (see accompanying minireview by Denu et al., 1996 [this issue of Cell]), fused, at either the N- or C-terminal ends, to a variety of noncatalytic, regulatory sequences. Now, several studies have illustrated subtleties of regulation and diversity of function for the PTPs which at least match those of the PTKs. Furthermore, PTPs can have both positive and negative effects on cellular signaling. This minireview discusses selected recent examples in which insights have been gained into the physiological function of PTP family members.	BETH ISRAEL HOSP,CANC BIOL PROGRAM,DIV HEMATOL ONCOL,DEPT MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center	Tonks, NK (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Neel, Benjamin/0000-0002-9589-585X				BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CYSTER JG, 1995, IMMUNITY, V2, P1; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; GARTON AJ, 1996, IN PRESS MOL CELL BI; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	20	477	496	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					365	368		10.1016/S0092-8674(00)81357-4	http://dx.doi.org/10.1016/S0092-8674(00)81357-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898190	Bronze			2022-12-28	WOS:A1996VQ46600003
J	Kiechl, S; Willeit, J; Poewe, W; Egger, G; Oberhollenzer, F; Muggeo, M; Bonora, E				Kiechl, S; Willeit, J; Poewe, W; Egger, G; Oberhollenzer, F; Muggeo, M; Bonora, E			Insulin sensitivity and regular alcohol consumption: Large, prospective, cross sectional population study (Bruneck study)	BRITISH MEDICAL JOURNAL			English	Article							SYNDROME SYNDROME-X; CAROTID ATHEROSCLEROSIS; HEALTHY POPULATION; GLUCOSE-TOLERANCE; RISK-FACTORS; RESISTANCE; ETHANOL; RAT; HYPERINSULINEMIA; METABOLISM	Objectives-To assess the relation between regular alcohol consumption and insulin sensitivity, and to estimate the importance of insulin in the association of alcohol with multiple vascular risk factors and cardiovascular disease. Design-Prospective and cross sectional study of a large randomly selected population sample. Setting-Part of the Bruneck study 1990-5 (Bolzano province, Italy). Subjects-820 healthy non-diabetic women and men aged 40-79 years. Main outcome measure-Concentrations of fasting and post-glucose insulin, cholesterol, apolipoproteins, triglycerides, Lp(a) lipoprotein, glucose, fibrinogen, and antithrombin III; blood pressure; insulin resistance estimated by the homeostasis model assessment. Results-Fasting insulin concentrations in those who did not drink alcohol and subjects reporting low (1-50 g/day), moderate (51-99 g/day), and heavy (greater than or equal to 100 g/day) alcohol intake were 12.4, 10.0, 8.7, and 7.1 mU/l (P<0.001). Likewise, post-glucose insulin concentrations and estimates for insulin resistance assessed by the homeostasis model assessment decreased significantly with increasing amounts of regular alcohol consumption. These trends were independent of sex, body mass index, physical activity, cigarette smoking, medication, and diet (P<0.001). Regular alcohol intake predicted multiple changes in vascular risk factors over a five year period including increased concentrations of high density lipoprotein cholesterol and apolipoprotein A I; higher blood pressure; and decreased concentration of antithrombin III. These associations were in part attributable to the decrease in insulin concentrations observed among alcohol consumers. Conclusions-Low to moderate amounts of alcohol, when taken on a regular basis, improve insulin sensitivity. Insulin is a potential intermediate component in the association between alcohol consumption and vascular risk factors (metabolic syndrome).	BRUNECK HOSP, DEPT INTERNAL MED, I-39031 BRUNICO, ITALY; OSPED CIVILE, DEPT ENDOCRINOL & METAB, I-37126 VERONA, ITALY		Kiechl, S (corresponding author), UNIV INNSBRUCK, DEPT NEUROL, ANICHST 35, A-6020 INNSBRUCK, AUSTRIA.		Bonora, Enzo/AAA-5300-2022	BONORA, Enzo/0000-0003-1074-5164				ALANKO T, 1984, RES ADV ALCOHOL DRUG; AVOGARO A, 1993, DIABETES METAB REV, V9, P129, DOI 10.1002/dmr.5610090205; BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45; BODEN G, 1993, DIABETES, V42, P28, DOI 10.2337/diabetes.42.1.28; CASEY CA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P96, DOI 10.1016/0167-4889(92)90032-7; FACCHINI F, 1994, DIABETES CARE, V17, P115, DOI 10.2337/diacare.17.2.115; FAWCETT J, 1993, AM J PHYSIOL, V264, pE420, DOI 10.1152/ajpendo.1993.264.3.E420; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; HAFFNER SM, 1994, ARTERIOSCLER THROMB, V14, P1430, DOI 10.1161/01.ATV.14.9.1430; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; HILL MA, 1987, BMDP USERS GUIDE; KIECHL S, 1994, STROKE, V25, P1593, DOI 10.1161/01.STR.25.8.1593; KIECHL S, 1994, NEUROEPIDEMIOLOGY, V13, P314, DOI 10.1159/000110397; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LAAKSO M, 1991, ARTERIOSCLER THROMB, V11, P1068, DOI 10.1161/01.ATV.11.4.1068; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MANOLIO TA, 1990, ARTERIOSCLEROSIS, V10, P430, DOI 10.1161/01.ATV.10.3.430; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190; METZ R, 1969, DIABETES, V18, P517, DOI 10.2337/diab.18.8.517; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; NORUSIS MJ, 1990, USERS GUIDE SPSS X V; PANDIT MK, 1993, ANN INTERN MED, V118, P529, DOI 10.7326/0003-4819-118-7-199304010-00008; PATEL DG, 1979, METABOLISM, V28, P85, DOI 10.1016/0026-0495(79)90173-2; PYORALA K, 1985, ACTA MED SCAND, P38; RAZAY G, 1992, BRIT MED J, V304, P80, DOI 10.1136/bmj.304.6819.80; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RUSSELL JC, 1989, ARTERIOSCLEROSIS, V9, P122, DOI 10.1161/01.ATV.9.1.122; SEVAK L, 1994, AM J CLIN NUTR, V59, P1069, DOI 10.1093/ajcn/59.5.1069; SINGH SP, 1988, ALCOHOL CLIN EXP RES, V12, P727, DOI 10.1111/j.1530-0277.1988.tb01335.x; TIENGO A, 1981, DIABETES, V30, P705, DOI 10.2337/diabetes.30.9.705; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; *WHO, 1985, WHO TECH REP SER, V727; WILLEIT J, 1993, ARTERIOSCLER THROMB, V13, P661, DOI 10.1161/01.ATV.13.5.661; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	36	265	270	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1040	1044						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898593				2022-12-28	WOS:A1996VP74200022
J	Verkasalo, PK; Pukkala, E; Kaprio, J; Heikkila, KV; Koskenvuo, M				Verkasalo, PK; Pukkala, E; Kaprio, J; Heikkila, KV; Koskenvuo, M			Magnetic fields of high voltage power Lines and risk of cancer in Finnish adults: Nationwide cohort study	BRITISH MEDICAL JOURNAL			English	Article							ELECTRIC UTILITY WORKERS; BREAST-CANCER; ELECTROMAGNETIC-FIELDS; TELECOMMUNICATIONS INDUSTRY; TRANSMISSION EQUIPMENT; OCCUPATIONAL EXPOSURE; MALIGNANT-MELANOMA; BRAIN CANCER; MORTALITY; LEUKEMIA	Objective-To investigate the risk of cancer in association with magnetic fields in Finnish adults Living close to high voltage power lines. Design-Nationwide cohort study. Subjects-383 700 people who Lived during 1970-89 within 500 metres of overhead power lines of 110-400 kV in a magnetic field calculated to be greater than or equal to 0.01 mu T. Study subjects were identified by record linkages of nationwide registers. Main outcome measures-Numbers of observed and expected cases of cancer, standardised incidence ratios, and incidence rate ratios adjusted for sex, age, calendar year, and social class-for example, by continuous cumulative exposure per 1 mu T year-with 95% confidence intervals from multiplicative models for all cancers combined and 21 selected types. Results-Altogether 8415 cases of cancer were observed (standardised incidence ratio 0.98; 95% confidence interval 0.96 to 1.00) in adults. All incidence rate ratios for both sexes combined were non-significant and between 0.91 and 1.11. Significant excesses were observed in multiple myeloma in men (incidence rate ratio 1.22) and in colon cancer in women (1.16). Conclusions-Typical residential magnetic fields generated by high voltage power lines do not seem to be related to the risk of overall cancer in adults. The previously suggested associations between extremely low frequency magnetic fields and tumours of the nervous system, lymphoma, and leukaemia in adults and breast cancer in women were not confirmed.	FINNISH CANC REGISTRY,INST STAT & EPIDEMIOL CANC RES,FIN-00170 HELSINKI,FINLAND; UNIV TURKU,DEPT PUBL HLTH,FIN-20520 TURKU,FINLAND	Finnish Cancer Registry; University of Turku	Verkasalo, PK (corresponding author), UNIV HELSINKI,DEPT PUBL HLTH,POB 41,FIN-00014 HELSINKI,FINLAND.		Kaprio, Jaakko/A-1820-2008; Heikkilä, Kauko/E-5578-2019	Kaprio, Jaakko/0000-0002-3716-2455; Heikkilä, Kauko/0000-0002-9256-8028				COLEMAN MP, 1989, BRIT J CANCER, V60, P793, DOI 10.1038/bjc.1989.362; DEGUIRE L, 1988, BRIT J IND MED, V45, P824; FEYCHTING M, 1994, EPIDEMIOLOGY, V5, P501; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467, DOI 10.1093/oxfordjournals.aje.a116881; FLODERUS B, 1993, CANCER CAUSE CONTROL, V4, P465, DOI 10.1007/BF00050866; GUENEL P, 1993, BRIT J IND MED, V50, P758; Gurney JG, 1996, AM J EPIDEMIOL, V143, P120; LOOMIS DP, 1994, J NATL CANCER I, V86, P921, DOI 10.1093/jnci/86.12.921; MCDOWALL ME, 1986, BRIT J CANCER, V53, P271, DOI 10.1038/bjc.1986.45; OLIN R, 1985, BRIT J IND MED, V42, P211; OLSEN JH, 1993, BRIT MED J, V307, P891, DOI 10.1136/bmj.307.6909.891; PHILLIPS JL, 1986, CANCER RES, V46, P239; PrestonMartin S, 1996, AM J EPIDEMIOL, V143, P105; PRESTONMARTIN S, 1988, BIOELECTROMAGNETICS, V9, P207, DOI 10.1002/bem.2250090302; Pukkala E, 1992, GEOGRAPHICAL ENV EPI, P125; Pukkala E, 1995, CONTRIBUTIONS EPIDEM, V7; ROCKLEY PF, 1994, INT J DERMATOL, V33, P398, DOI 10.1111/j.1365-4362.1994.tb04038.x; SAHL JD, 1993, EPIDEMIOLOGY, V4, P104, DOI 10.1097/00001648-199303000-00005; SAVITZ DA, 1995, AM J EPIDEMIOL, V141, P123, DOI 10.1093/oxfordjournals.aje.a117400; SAVITZ DA, 1994, BIOL EFFECTS ELECTRI, V2, P233; SCHREIBER GH, 1993, INT J EPIDEMIOL, V22, P9, DOI 10.1093/ije/22.1.9; SEVERSON RK, 1988, AM J EPIDEMIOL, V128, P10, DOI 10.1093/oxfordjournals.aje.a114932; SORAHAN T, 1985, BRIT J IND MED, V42, P546; STEVENS RG, 1993, ENVIRON HEALTH PERSP, V101, P93, DOI 10.2307/3431665; STEVENS RG, 1987, AM J EPIDEMIOL, V125, P556, DOI 10.1093/oxfordjournals.aje.a114569; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; THERIAULT G, 1994, AM J EPIDEMIOL, V139, P550, DOI 10.1093/oxfordjournals.aje.a117046; TYNES T, 1994, SCAND J WORK ENV HEA, V20, P339, DOI 10.5271/sjweh.1388; TYNES T, 1992, AM J EPIDEMIOL, V136, P81, DOI 10.1093/oxfordjournals.aje.a116423; VAGERO D, 1985, BRIT J IND MED, V42, P191; VAGERO D, 1983, BRIT J IND MED, V40, P188; Valjus J, 1995, BIOELECTROMAGNETICS, V16, P365, DOI 10.1002/bem.2250160604; VENA JE, 1994, AM J EPIDEMIOL, V140, P974, DOI 10.1093/oxfordjournals.aje.a117204; VENA JE, 1991, AM J EPIDEMIOL, V134, P180, DOI 10.1093/oxfordjournals.aje.a116070; VERKASALO P, 1994, BRIT MED J, V308, P1162; VERKASALO PK, 1993, BRIT MED J, V307, P895, DOI 10.1136/bmj.307.6909.895; VERREAULT R, 1990, AM J EPIDEMIOL, V131, P759, DOI 10.1093/oxfordjournals.aje.a115565; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WERTHEIMER N, 1982, INT J EPIDEMIOL, V11, P345, DOI 10.1093/ije/11.4.345; WERTHEIMER N, 1987, ANN NY ACAD SCI, V502, P43, DOI 10.1111/j.1749-6632.1987.tb37645.x; WHITEMAN D, 1994, CANCER CAUSE CONTROL, V5, P564, DOI 10.1007/BF01831385; YOUNGSON JHAM, 1991, BRIT J CANCER, V63, P977, DOI 10.1038/bjc.1991.214	42	72	74	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1047	1051						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898595	Green Published			2022-12-28	WOS:A1996VP74200025
J	Cavaille, J; Nicoloso, M; Bachellerie, JP				Cavaille, J; Nicoloso, M; Bachellerie, JP			Targeted ribose methylation of RNA in vivo directed by tailored antisense RNA guides	NATURE			English	Article							NUCLEOLIN GENE; MESSENGER-RNA; NUCLEAR-RNA; YEAST; LOCALIZATION; SEQUENCES; DUPLEXES; MOUSE	EUKARYOTIC ribosomal RNAs are post-transcriptionally modified by methylation at the ribose sugar of specific nucleotides(1). This takes place in the nucleolus and involves a family of small nucleolar RNAs (snoRNAs) with long regions (10-21 nucleotides) complementary to rRNA sequences spanning the methylation site(2-4)-a complementary snoRNA is required for methylation at a specific site(5). Here we show that altering the sequence of the snoRNA is sufficient to change the specificity of methylation. Mammalian cells transfected with a snoRNA engineered to be complementary to an arbitrary rRNA sequence direct the methylation of the predicted nucleotide in that sequence. We have further identified structural features, both of the guide and substrate RNA, required for methylation and have used these to design an exogenous transcript, devoid of rRNA sequence, that is site-specifically methylated when co-expressed with an appropriate guide snoRNA. Endogenous non-ribosomal RNA can thus be targeted, possibly providing a highly selective tool for the alteration of gene expression at the post-transcriptional level.	UNIV TOULOUSE 3, CNRS, LAB BIOL MOL EUCARYOTE, F-31062 TOULOUSE, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			cavaille, jerome/AAM-8047-2020	CAVAILLE, Jerome/0000-0003-2833-6836				Bachellerie JP, 1995, BIOCHEM CELL BIOL, V73, P835, DOI 10.1139/o95-091; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; BOURBON HM, 1990, GENE, V88, P187, DOI 10.1016/0378-1119(90)90031-L; BRANCH AD, 1989, METHOD ENZYMOL, V180, P130; CAAILLE J, 1996, BIOCHIMIE, V78, P443; CABOCHE M, 1977, EUR J BIOCHEM, V74, P19, DOI 10.1111/j.1432-1033.1977.tb11362.x; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; CATTANEO R, 1994, CURR BIOL, V4, P134, DOI 10.1016/S0960-9822(94)00030-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HADJIOLOVA KV, 1994, MOL CELL BIOL, V14, P4044, DOI 10.1128/MCB.14.6.4044; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1974, J MOL BIOL, V88, P133, DOI 10.1016/0022-2836(74)90299-X; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MILLER KS, 1984, J MOL BIOL, V177, P343, DOI 10.1016/0022-2836(84)90461-3; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NICOLOSO M, 1994, MOL CELL BIOL, V14, P5766, DOI 10.1128/MCB.14.9.5766; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; REIMER G, 1987, ARTHRITIS RHEUM, V30, P793, DOI 10.1002/art.1780300709; SCHNEITER R, 1995, MOL BIOL CELL, V6, P357, DOI 10.1091/mbc.6.4.357; STEITZ JA, 1995, SCIENCE, V270, P1626, DOI 10.1126/science.270.5242.1626; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; WARNER JR, 1966, J MOL BIOL, V19, P383, DOI 10.1016/S0022-2836(66)80012-8	30	275	307	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1996	383	6602					732	735		10.1038/383732a0	http://dx.doi.org/10.1038/383732a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878486				2022-12-28	WOS:A1996VN91800058
J	Lange, RA; Hillis, LD				Lange, RA; Hillis, LD			Thrombolysis - The preferred treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; PRIMARY ANGIOPLASTY; IMMEDIATE ANGIOPLASTY; CORONARY ANGIOPLASTY; THERAPY; REPERFUSION				Lange, RA (corresponding author), UNIV TEXAS, SW MED CTR, RM CS7102, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Lange, Richard/AAM-9594-2021					APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BERGER PB, 1994, AM J CARDIOL, V73, P231, DOI 10.1016/0002-9149(94)90225-9; BRODIE BR, 1995, BRIT HEART J, V73, P411; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; OKEEFE JH, 1993, AM J CARDIOL, V72, pG107, DOI 10.1016/0002-9149(93)90115-S; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; STONE GW, 1995, J AM COLL CARDIOL, V25, P370, DOI 10.1016/0735-1097(94)00367-Y; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	14	60	60	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1311	1312						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857013				2022-12-28	WOS:A1996VN59400010
J	Ward, M				Ward, M			Tough competition in Europe	NATURE			English	Article																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					742	744		10.1038/383742a0	http://dx.doi.org/10.1038/383742a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878490				2022-12-28	WOS:A1996VN91800062
J	Donohue, SM; Dufty, JMK; Kafkarkou, NA; Kirwan, R; Taberner, DA				Donohue, SM; Dufty, JMK; Kafkarkou, NA; Kirwan, R; Taberner, DA			Capillary testing in an anticoagulant clinic: Comparison of two methods	BRITISH MEDICAL JOURNAL			English	Article									N MIDDLESEX HOSP NHS TRUST,DEPT HAEMATOL,LONDON N18 1QX,ENGLAND; WITHINGTON HOSP,THROMBOSIS REFERENCE CTR,MANCHESTER M20 2LR,LANCS,ENGLAND									BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; HARPIN VA, 1983, ARCH DIS CHILD, V58, P226, DOI 10.1136/adc.58.3.226; POLLER L, 1993, J CLIN PATHOL, V46, P64, DOI 10.1136/jcp.46.1.64; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					982	982						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892419				2022-12-28	WOS:A1996VN91600025
J	Moore, JK; Haber, JE				Moore, JK; Haber, JE			Capture of retrotransposon DNA at the sites of chromosomal double-strand breaks	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; REVERSE TRANSCRIPTION; NUCLEOTIDE-SEQUENCE; TY ELEMENT; YEAST; RECOMBINATION; MECHANISMS; EVOLUTION; REPAIR; RNA	NON-HOMOLOGOUS repair of broken chromosomes in Saccharomyces cerevisiae san be studied at a defined location by expressing the site-specific HO endonuclease that cuts the mating-type (MAT) locus. When homologous recombination is prevented, most double-strand breaks are repaired by non-homologous end-joinings similar to those observed in mammalian cells. About 1% of non-homologous repair events were exceptional, having 'captured' approximately 100 base pairs of DNA within the HO cleavage site. In each case, the insertion came from yeast's retrotransposon Ty1 element. Four of the five contained the R-U5 region, which is the first part of Ty1 messenger RNA to be converted to complementary DNA. The capture of cDNA fragments at fhe sites of double-strand breaks may account for the way that pseudogenes and long and short interspersed sequences (LINES and SINES) have been inserted at many locations in the mammalian genome.	BRANDEIS UNIV,ROSENSTIEL CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University; Brandeis University			Wilson, Matthew H/K-3193-2013	Haber, James/0000-0002-1878-0610				BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1989, ANNU REV MICROBIOL, V43, P403, DOI 10.1146/annurev.micro.43.1.403; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; CHAPMAN KB, 1992, P NATL ACAD SCI USA, V89, P3236, DOI 10.1073/pnas.89.8.3236; CLARE J, 1985, P NATL ACAD SCI USA, V82, P2829, DOI 10.1073/pnas.82.9.2829; CONNOLLY B, 1988, MOL CELL BIOL, V8, P2342, DOI 10.1128/MCB.8.6.2342; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; ERREDE B, 1986, MOL CELL BIOL, V6, P1334, DOI 10.1128/MCB.6.4.1334; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HAUBER J, 1985, NUCLEIC ACIDS RES, V13, P2745, DOI 10.1093/nar/13.8.2745; JENSEN RE, 1984, COLD SPRING HARB SYM, V49, P97, DOI 10.1101/SQB.1984.049.01.013; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; MEZARD C, 1994, MOL CELL BIOL, V14, P1278, DOI 10.1128/MCB.14.2.1278; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; MULLER F, 1991, MOL GEN GENET, V226, P145, DOI 10.1007/BF00273598; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; Roth D., 1988, GENETIC RECOMBINATIO, P621; SHEN MR, 1991, J MOL EVOL, V33, P311; TENG SC, 1986, NATURE, V383, P641; VOYTAS DF, 1993, TRENDS GENET, V9, P421, DOI 10.1016/0168-9525(93)90105-Q; Yang J, 1996, NATURE, V381, P332, DOI 10.1038/381332a0	22	200	207	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					644	646		10.1038/383644a0	http://dx.doi.org/10.1038/383644a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857544				2022-12-28	WOS:A1996VM75500060
J	Sanson, B; White, P; Vincent, JP				Sanson, B; White, P; Vincent, JP			Uncoupling cadherin-based adhesion from wingless signalling in Drosophila	NATURE			English	Article							POLARITY GENE ARMADILLO; CELL-ADHESION; CYTOPLASMIC DOMAIN; BETA-CATENIN; PROTEIN; COMPLEX; INDUCTION; MOLECULE; HOMOLOG; REGION	THE Wnt genes encode secreted glycoproteins used in intercellular communication at multiple steps during development. Signalling by Wingless, the Drosophila Wnt-1 homologue, requires the activity of Armadillo(1,2), the homologue of vertebrate beta-catenin(3), which is a component of the cadherin/catenin complex at adherens junctions(4,5). The genetic link between wingless and armadillo suggests that cell fate specification and cell-cell adhesion might be controlled concurrently. For instance, in one extreme view, Wingless could specify cell fate entirely by modulating cell adhesion. Alternatively, it might signal independently of adherens junctions. To distinguish between these alternatives, we have expressed two polypeptides that have opposite effects on cadherin-dependent adhesion: full-length Drosophila E-cadherin and a dominant-negative truncated form. We found that overexpression of either construct mimics wingless phenotypes, thereby uncoupling changes in adhesion from signalling effects. We demonstrate that both constructs titrate Armadillo from a 'signalling' pool which is functionally distinct from the junctional pool.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Sanson, Benedicte/0000-0002-2782-4195				Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; ABERLE H, 1994, J CELL SCI, V107, P3655; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BENJUMEA FD, 1995, DEVELOPMENT, V121, P4215; BRAND AH, 1993, DEVELOPMENT, V118, P401; COUSO JP, 1994, DEVELOPMENT, V120, P621; DTNARDO S, 1988, NATURE, V332, P604; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Grawe F, 1996, DEVELOPMENT, V122, P951; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOORDEMEER J, 1994, NATURE, V387, P80; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1993, DEVELOPMENT, V118, P1191; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; Stappert J, 1993, Curr Opin Neurobiol, V3, P60, DOI 10.1016/0959-4388(93)90036-X; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659	30	313	316	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					627	630		10.1038/383627a0	http://dx.doi.org/10.1038/383627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857539				2022-12-28	WOS:A1996VM75500055
J	Fauci, AS				Fauci, AS			United States of America - Biomedical research in an era of unlimited aspirations and limited resources	LANCET			English	Article											Fauci, AS (corresponding author), NIAID,NIH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.								0	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					1002	1003						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855860				2022-12-28	WOS:A1996VM02700016
J	Tan, KH; Kilby, MD; Whittle, MJ; Beattie, BR; Booth, IW; Botting, BJ				Tan, KH; Kilby, MD; Whittle, MJ; Beattie, BR; Booth, IW; Botting, BJ			Congenital anterior abdominal wall defects in England and Wales 1987-93: Retrospective analysis of OPCS data	BRITISH MEDICAL JOURNAL			English	Article							OMPHALOMESENTERIC ARTERY; RISK-FACTORS; GASTROSCHISIS; MALFORMATIONS; OMPHALOCELE; NOTIFICATION; INTERRUPTION; MANAGEMENT; PREGNANCY	Objective-Analysis of incidence and characteristics of congenital abdominal wall defects, with special reference to the differences between the incidence of gastroschisis and exomphalos (omphalocele). Design-Retrospective analysis using data from the Office of Population Censuses and Surveys (recoded to differentiate exomphalos and gastroschisis) and the National Congenital Malformation Notification Scheme. Setting-England and Wales, 1987 to 1993. Results-1043 congenital anterior abdominal wall defects were notified within the seven year study period. Of these, 539 were classified as gastroschisis, 448 as exomphalos, 19 as ''prune belly syndrome,'' and 37 as ''unclassified'' Gastroschisis doubled in incidence from 0.65 in 1987 to 1.35 per 10 000 total births in 1991, with little further change; the incidence of exomphalos decreased from 1.13 to 0.77 per 10 000 births. The overall incidence of notified congenital abdominal wall defects was 2.15 per 10 000 total births. Gastroschisis was associated with a lower overall maternal age than exomphalos and with a significantly lower proportion of additional reported congenital malformations (5.0%) than in the cohort with exomphalos (27.4%) (odds ratio 0.14, 95% confidence interval 0.09 to 0.22; P<0.001). The sex ratio of the two cohorts was the same. The incidence of gastroschisis and exomphalos was higher in the northern regions of England than in the south east of the country. Conclusions-The national congenital malformation notification system showed an increasing trend in the incidence of fetuses born with gastroschisis and a progressive decreasing incidence of exomphalos in England and Wales between 1987 and 1993. Although the reasons for this are likely to be multifactorial, a true differential change seems likely. The observed increase in incidence Of gastroschisis relative to exomphalos and the differentiation in maternal age have implications for resource management within the NHS and warrant further epidemiological monitoring. Regional differences may be due to a dietary or environmental factor, which requires further study.	UNIV BIRMINGHAM,ACAD DEPT OBSTET,DIV FETAL MED,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND; UNIV WALES COLL CARDIFF,DEPT FETAL MED,CARDIFF CF4 4XN,S GLAM,WALES; UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; OFF NATL STAT,LONDON WC2B 6JP,ENGLAND	University of Birmingham; Cardiff University; University of Birmingham			FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Tan, Kok Hian/0000-0003-1945-0266				BAIRD PA, 1981, AM J HUM GENET, V33, P470; BALLANTYNE TW, 1904, MANUAL ANTENATAL PAT; BILL AH, 1969, PEDIAT SURG, P885; BIRCH D, 1986, SCHOOLGIRL PREGNANCI; *CAL DEP HLTH SERV, 1994, CAL BIRTH DEF MON PR; CALZOLARI E, 1993, TERATOLOGY, V48, P47; DOYLE PE, 1990, J EPIDEMIOL COMMUNIT, V45, P43; DUTTON SJ, 1991, J EPIDEMIOL COMMUN H, V45, P294, DOI 10.1136/jech.45.4.294; FRISANCHO AR, 1983, AM J CLIN NUTR, V38, P739, DOI 10.1093/ajcn/38.5.739; GIERUP J, 1979, Z KINDERCHIR, V28, P39; GOLDBAUM G, 1990, TERATOLOGY, V42, P397, DOI 10.1002/tera.1420420408; HEMMINKI K, 1982, J EPIDEMIOL COMMUN H, V36, P289, DOI 10.1136/jech.36.4.289; HOLLABAUGH RS, 1977, J PEDIATR SURG, V8, P263; HOYME HE, 1983, SEMIN PERINATOL, V7, P294; HOYME HE, 1981, J PEDIATR-US, V98, P228, DOI 10.1016/S0022-3476(81)80640-3; KIRK EP, 1983, AM J OBSTET GYNECOL, V146, P512, DOI 10.1016/0002-9378(83)90791-3; KNOX EG, 1984, J EPIDEMIOL COMMUN H, V38, P296, DOI 10.1136/jech.38.4.296; LAMBERT P, 1976, POPULATION TRENDS, V4, P4; LINDHAM S, 1981, ACTA PAEDIATR SCAND, V70, P55, DOI 10.1111/j.1651-2227.1981.tb07173.x; MARTINEZFRIAS ML, 1984, TERATOLOGY, V29, P377, DOI 10.1002/tera.1420290308; MAYER T, 1980, ANN SURG, V192, P783, DOI 10.1097/00000658-198012000-00015; MCALLISTER F, 1978, NEONATAL SURG, P308; MOORE TC, 1977, SURGERY, V82, P561; MOORE TC, 1963, ANN SURG, V158, P263, DOI 10.1097/00000658-196308000-00017; MOORE TC, 1953, SURGERY, V33, P112; MORROW RJ, 1993, PRENATAL DIAG, V13, P111, DOI 10.1002/pd.1970130205; *OFF POP CENS SURV, 1993, MORT STAT PER IN DH3, P9; *OFF POP CENS SURV, 1994, AB STAT NOT 1987 AB; *OFF POP CENS SURV, 1990, CONG MALF STAT 1 MB3; PARE A, 1634, WORKS FAMOUS CHIRURG, V24, P59; PAYNE JN, 1992, PUBLIC HEALTH, V106, P437, DOI 10.1016/S0033-3506(05)80458-5; RICHMAN PP, 1969, NEONATAL SURG, P245; ROEPER PJ, 1987, TERATOLOGY, V35, P203, DOI 10.1002/tera.1420350206; SWERDLOW AJ, 1988, J EPIDEMIOL COMMUN H, V42, P8, DOI 10.1136/jech.42.1.8; TORFS CP, 1994, TERATOLOGY, V50, P44, DOI 10.1002/tera.1420500107; WHITTLE MJ, 1989, PRENATAL DIAGNOSIS O, P65; 1991, LANCET, V338, P131	37	135	137	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					903	906						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876090				2022-12-28	WOS:A1996VM75400021
J	Weidner, KM; DiCesare, S; Sachs, M; Brinkmann, V; Behrens, J; Birchmeier, W				Weidner, KM; DiCesare, S; Sachs, M; Brinkmann, V; Behrens, J; Birchmeier, W			Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis	NATURE			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; MOTILITY; SIGNALS; INSULIN; CELLS	THE proteins Gab1 and the related DOS (for 'daughter of sevenless') each bind to substrates of tyrosine kinases like Grb2 or Corkscrew, and act in signalling pathways downstream of tyrosine kinase receptors(1-3). Here we show that Gab1 interacts directly with the c-met-encoded receptor tyrosine kinase but not ,vith a number of other tyrosine kinases from different subfamilies. A newly identified proline-rich domain of Gab1 is responsible for the binding of this protein to the tyrosine-phosphorylated bidentate docking site(4,5) in c-Met. Expression of Gab1 in epithelial cells is sufficient to induce the c-Met-specific activities(6-9), including branching morphogenesis. Thus we have discovered a new phosphotyrosine interaction domain in Gab1 and shown that Gab1 is the substrate of the c-Met receptor tyrosine kinase that mediates epithelial morphogenesis.	MAX DELBRUCK CTR MOL MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Brinkmann, Volker/A-6015-2009					Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRINKMANN V, 1995, J CELL BIOL, V131, P215; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Miller J.H., 1972, EXPT MOL GENETICS; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHU H, 1994, J BIOL CHEM, V269, P29943	25	489	501	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					173	176		10.1038/384173a0	http://dx.doi.org/10.1038/384173a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906793				2022-12-28	WOS:A1996VT33600067
J	Kakimoto, T				Kakimoto, T			CKI1, a histidine kinase homolog implicated in cytokinin signal transduction	SCIENCE			English	Article							2-COMPONENT REGULATORS; ADAPTIVE RESPONSES; GENE; TRANSFORMATION; PROTEIN; FAMILY; YEAST; ETR1	Although cytokinin plays a central role in plant development, little is known about cytokinin signal transduction. Five Arabidopsis thaliana mutants that exhibit typical cytokinin responses, including rapid cell division and shoot formation in tissue culture in the absence of exogenous cytokinin, were isolated by activation transferred DNA tagging. A gene, CKI1, which was tagged in four of the five mutants and induced typical cytokinin responses after introduction and overexpression in plants, was cloned. CKI1 encodes a protein similar to the two-component regulators. These results suggest that CKI1 is involved in cytokinin signal transduction, possibly as a cytokinin receptor.			Kakimoto, T (corresponding author), OSAKA UNIV,GRAD SCH SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.							AKAMA K, 1992, PLANT CELL REP, V12, P7, DOI 10.1007/BF00232413; BINNS AN, 1994, ANNU REV PLANT PHYS, V45, P173, DOI 10.1146/annurev.pp.45.060194.001133; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; HAYASHI H, 1992, SCIENCE, V258, P1350, DOI 10.1126/science.1455228; HORGAN R, 1984, ADV PLANT PHYSL, P53; HRABAK EM, 1992, J BACTERIOL, V174, P3011, DOI 10.1128/JB.174.9.3011-3020.1992; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; KONCZ C, 1994, PLANT MOL BIOL MANUA; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Meyerowitz E. M., 1992, Methods in Arabidopsis research., P100; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; OLA IM, 1993, SCIENCE, V262, P566; PERKINSON JS, 1992, ANNU REV GENET, V26, P71; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Wang N, 1996, EMBO J, V15, P3890, DOI 10.1002/j.1460-2075.1996.tb00763.x; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807	20	474	541	3	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					982	985		10.1126/science.274.5289.982	http://dx.doi.org/10.1126/science.274.5289.982			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875940				2022-12-28	WOS:A1996VR79200049
J	Munoz, E				Munoz, E			Patient-physician confidentiality on trial in Turkey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Munoz, E (corresponding author), AMER ASSOC ADVANCEMENT SCI,SCI & HUMAN RIGHTS PROGRAM,1200 NEW YORK AVE NW,WASHINGTON,DC 20005, USA.							Iacopino V, 1996, JAMA-J AM MED ASSOC, V276, P396, DOI 10.1001/jama.276.5.396; *US DEP STAT, 1995, COUNTR REP HUM RIGHT	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1375	1376		10.1001/jama.276.17.1375	http://dx.doi.org/10.1001/jama.276.17.1375			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892704				2022-12-28	WOS:A1996VQ46400008
J	Beg, AA; Baltimore, D				Beg, AA; Baltimore, D			An essential role for NF-kappa B in preventing TNF-alpha-induced cell death	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; MANGANOUS SUPEROXIDE-DISMUTASE; DNA-BINDING SUBUNIT; REL; INHIBITION; EXPRESSION; CLONING; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; STIMULATION	Studies on mice deficient in nuclear factor kappa B (NF-kappa B) subunits have shown that this transcription factor is important for lymphocyte responses to antigens and cylokine-inducible gene expression. In particular, the RelA (p65) subunit is required for induction of tumor necrosis factor-alpha (TNF-alpha)-dependent genes. Treatment of RelA-deficient (RelA(-/-)) mouse fibroblasts and macrophages with TNF-alpha resulted in a significant reduction in viability, whereas RelA(+/+) cells were unaffected. Cytotoxicity to both cell types was mediated by TNF receptor 1. Reintroduction of RelA into RelA(-/-) fibroblasts resulted in enhanced survival, demonstrating that the presence of RelA is required for protection from TNF-alpha. These results have implications for the treatment of inflammatory and proliferative diseases.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, UNPUB; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COICO R, 1994, CURRENT PROTOCOLS IM; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHSAWA T, 1989, DEV BIOL, V135, P459, DOI 10.1016/0012-1606(89)90194-2; OPLPARI AW, 1992, J BIOL CHEM, V267, P12424; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6	31	2781	2891	3	167	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					782	784		10.1126/science.274.5288.782	http://dx.doi.org/10.1126/science.274.5288.782			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864118				2022-12-28	WOS:A1996VQ14500043
J	Maina, F; Casagranda, F; Audero, E; Simeone, A; Comoglio, PM; Klein, R; Ponzetto, C				Maina, F; Casagranda, F; Audero, E; Simeone, A; Comoglio, PM; Klein, R; Ponzetto, C			Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development	CELL			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; EPITHELIAL-CELLS; TYROSINE KINASE; PROTOONCOGENE; MOTILITY; GENE; MICE; IDENTIFICATION; TRANSFORMATION	Hepatocyte growth factor (HGF) and its receptor, the Met tyrosine kinase, are determinants of placenta, liver, and muscle development. Here, we show that Met function in vivo requires signaling via two carboxyterminal tyrosines. Mutation of both residues in the mouse genome caused embryonal death, with placenta, liver, and limb muscle defects, mimicking the phenotype of met null mutants. In contrast, disrupting the consensus for Grb2 binding allowed development to proceed to term without affecting placenta and liver but caused a striking reduction in limb muscle coupled to a generalized deficit of secondary fibers. These data show that the requirements for Met signaling vary depending on the tissue and reveal a novel role for HGF/Met in late myogenesis.	UNIV TURIN, DEPT BIOMED SCI & ONCOL, I-10126 TURIN, ITALY; EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY; INT INST GENET & BIOPHYS, I-80125 NAPLES, ITALY; INST CANC RES, I-10060 CANDIOLO, TORINO, ITALY	University of Turin; European Molecular Biology Laboratory (EMBL); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Maina, Flavio/J-9962-2019; Simeone, Antonio/ABG-5269-2020; Klein, Ruediger/C-6147-2008	Maina, Flavio/0000-0001-6100-4695; Simeone, Antonio/0000-0003-2693-9836; Klein, Ruediger/0000-0002-3109-0163; Audero, Enrica/0000-0002-6138-244X; ponzetto, antonio/0000-0002-1551-3664; Comoglio, Paolo/0000-0002-7056-5328	Telethon [805] Funding Source: Medline	Telethon(Fondazione Telethon)		ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Haramis AG, 1995, DEVELOPMENT, V121, P4237; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HOGAN B, 1994, MANIPULATING MOUSE E, P325; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LYONS GE, 1992, SEM DEV BIOL, V3, P243; Matsumoto K, 1993, EXS, V65, P225; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; TAKEBAYASHI T, 1995, J CELL BIOL, V129, P1411, DOI 10.1083/jcb.129.5.1411; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Wachtler F., 1992, SEMIN DEV BIOL, V3, P217; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, J BIOL CHEM, V269, P29943	46	261	277	1	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1996	87	3					531	542		10.1016/S0092-8674(00)81372-0	http://dx.doi.org/10.1016/S0092-8674(00)81372-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898205	Bronze			2022-12-28	WOS:A1996VQ46600018
J	Hedges, REM; Jiang, ZX; Ramsey, CB; Cowey, A; Roberts, JDB; Somogyi, P				Hedges, REM; Jiang, ZX; Ramsey, CB; Cowey, A; Roberts, JDB; Somogyi, P			Imaging of radiocarbon labelled tracer molecules in neural tissue using accelerator mass spectrometry	NATURE			English	Article							GAMMA-AMINOBUTYRIC ACID; STRIATE CORTEX; VISUAL-CORTEX; GOLGI IMPREGNATION; NEURONS; H-3-GABA; MONKEY; CONNECTIONS; ANTISERA; SYSTEM	AUTORADIOGRAPHY is widely and successfully used to image the distribution of radiolabelled tracer molecules in biological samples. The method is, however, limited in resolution and sensitivity, especially for C-14. Here we describe a new method for imaging C-14-labelled tracers in sections of biological tissue. A highly focused beam of gallium ions bombards the tissue, which is eroded (sputtered) into constituent atoms, molecules and secondary ions. The C-14 ions are detected in the secondary beam by the most sensitive method available, namely accelerator mass spectrometry(1). The specimen is scanned pixel by pixel (1 x 2 mu m), generating an image in a manner analogous to scanning electron microscopy. The method can thus be regarded as a specialized form of scanning secondary ion mass spectrometry (SIMS), referred to here as SIAMS (ref. 2). We have used SIAMS to localize the neurotransmitter gamma-aminobutyric acid (GABA) in thin sections of cerebral cortex, and show that it can generate C-14 images that are much improved on C-14 autoradiography. A scan takes 10-20 min and reveals individual axons, neurons and glial cells at high sensitivity. In principle, the resolution could be increased by up to tenfold, and the method could be extended to some other nuclides.	DEPT EXPT PSYCHOL,OXFORD OX1 3UD,ENGLAND; MRC,ANAT NEUROPHARMACOL UNIT,DEPT PHARMACOL,OXFORD OX1 3TH,ENGLAND		Hedges, REM (corresponding author), RES LAB ARCHAEOL,RAIOCARBON ACCELERATOR UNIT,6 KEBLE RD,OXFORD OX1 3QJ,ENGLAND.		Ramsey, Christopher Bronk/A-3277-2012; Ramsey, Christopher Bronk/AAQ-2227-2021	Ramsey, Christopher Bronk/0000-0002-8641-9309; Ramsey, Christopher Bronk/0000-0002-8641-9309				BAKER JRJ, 1989, MICROSCOPY HDB, V18; CUENOD M, 1983, METHODS CHEM NEUROAN, P365; DUNCAN GE, 1990, METHODS NEUROSCIENCE, V3, P50; FREEMAN SPH, 1993, NUCL INSTRUM METH B, V93, P231; HEDGES REM, 1987, PHILOS T R SOC A, V323, P57, DOI 10.1098/rsta.1987.0072; HERTZ L, 1979, PROG NEUROBIOL, V13, P277, DOI 10.1016/0301-0082(79)90018-2; HODGSON AJ, 1985, J HISTOCHEM CYTOCHEM, V33, P229, DOI 10.1177/33.3.3973378; HOLDFELT T, 1972, EXP BRAIN RES, V14, P354; JIANG ZX, IN PRESS NUCL INST B; KISVARDAY ZF, 1987, J COMP NEUROL, V260, P1, DOI 10.1002/cne.902600102; LITHERLAND AE, 1987, PHILOS T R SOC A, V323, P5, DOI 10.1098/rsta.1987.0069; Martin D.L., 1976, GABA NERVOUS SYSTEM, P347; SOMOGYI P, 1985, J HISTOCHEM CYTOCHEM, V33, P240, DOI 10.1177/33.3.2579123; SOMOGYI P, 1983, P NATL ACAD SCI-BIOL, V80, P2385, DOI 10.1073/pnas.80.8.2385; SOMOGYI P, 1984, EXP BRAIN RES, V53, P295; SOMOGYI P, 1984, EXP BRAIN RES, V54, P45; SOMOGYI P, 1983, NEUROSCIENCE, V10, P261, DOI 10.1016/0306-4522(83)90133-1; SOMOGYI P, 1981, NATURE, V294, P761, DOI 10.1038/294761a0	18	8	8	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					823	826		10.1038/383823a0	http://dx.doi.org/10.1038/383823a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893007				2022-12-28	WOS:A1996VQ14400063
J	Morris, JS; Frith, CD; Perrett, DI; Rowland, D; Young, AW; Calder, AJ; Dolan, RJ				Morris, JS; Frith, CD; Perrett, DI; Rowland, D; Young, AW; Calder, AJ; Dolan, RJ			A differential neural response in the human amygdala to fearful and happy facial expressions	NATURE			English	Article							RHESUS-MONKEY; CONNECTIONS; IDENTITY; EMOTION; MULATTA; BRAIN	THE amygdala is thought to play a crucial role in emotional and social behaviour(1). Animal studies implicate the amygdala in both fear conditioning(2) and face perception(3). In humans, lesions of the amygdala can lead to selective deficits in the recognition of fearful facial expressions(4,5) and impaired fear conditioning(6,7), and direct electrical stimulation evokes fearful emotional responses(8). Here we report direct in vivo evidence of a differential neural response in the human amygdala to facial expressions of fear and happiness, Positron-emission tomography (PET) measures of neural activity were acquired while subjects viewed photographs of fearful or happy faces, varying systematically in emotional intensity, The neuronal response in the left amygdala was significantly greater to fearful as opposed to happy expressions, Furthermore, this response showed a significant interaction with the intensity of emotion (increasing with increasing fearfulness, decreasing with increasing happiness). The findings provide direct evidence that the human amygdala is engaged in processing the emotional salience of faces, with a specificity of response to fearful facial expressions.	WELLCOME DEPT COGNIT NEUROL, LONDON WC1N 3BG, ENGLAND; UNIV ST ANDREWS, SCH PSYCHOL, ST ANDREWS KY16 9JU, FIFE, SCOTLAND; MRC, APPL PSYCHOL UNIT, CAMBRIDGE CBE 2EF, ENGLAND; ROYAL FREE HOSP, LONDON NW3 2DF, ENGLAND; UCL HOSP, SCH MED, LONDON NW3 2DF, ENGLAND	University of London; University College London; University of St Andrews; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School			Morris, John/B-9190-2013; Young, Andy/G-2189-2011; Frith, Chris D/A-2171-2009; anand, amit/A-7222-2009; Tudusciuc, Oana/C-1339-2011	Young, Andy/0000-0002-1202-6297; Frith, Chris D/0000-0002-8665-0690; Dolan, Ray/0000-0001-9356-761X; Perrett, David/0000-0002-6025-0939	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADOLPHS R, 1995, J NEUROSCI, V15, P5879; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; AGGLETON JP, 1980, BRAIN RES, V190, P347, DOI 10.1016/0006-8993(80)90279-6; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Darwin C., 1965, EXPRESS EMOT MAN; Ekman P., 1976, PICTURES FACIAL AFFE; Ekman P., 1982, EMOTION HUMAN FACE; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; GEORGE MS, 1993, J NEUROPSYCH CLIN N, V5, P384; HALGREN E, 1978, BRAIN, V101, P83, DOI 10.1093/brain/101.1.83; HALGREN E, 1992, AMYGDALA NEUROBIOLOG, P190; Hamann SB, 1996, NATURE, V379, P497, DOI 10.1038/379497a0; HERZOG AG, 1976, BRAIN RES, V115, P57, DOI 10.1016/0006-8993(76)90822-2; IWAI E, 1987, J COMP NEUROL, V261, P362, DOI 10.1002/cne.902610304; Ketter TA, 1996, ARCH GEN PSYCHIAT, V53, P59; KING AS, 1979, EXP NEUROL, V66, P88; KLING A S, 1992, P353; Kluver H, 1939, ARCH NEURO PSYCHIATR, V42, P979; LABAR KS, 1995, J NEUROSCI, V15, P6846; LEDOUX JE, 1990, J NEUROSCI, V10, P1062; LEDOUX JE, 1993, BEHAV BRAIN RES, V58, P69, DOI 10.1016/0166-4328(93)90091-4; PERRETT DI, 1994, NATURE, V368, P239, DOI 10.1038/368239a0; PERRETT DI, 1989, J EXP BIOL, V146, P87; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; ROLLS E T, 1992, P143; Sergent J., 1994, VIS COGN, V1, P349, DOI [10.1080/13506289408402305, DOI 10.1080/13506289408402305]; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009; WORSLEY KJ, IN PRESS HUM BRAIN M	30	1455	1474	1	198	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					812	815		10.1038/383812a0	http://dx.doi.org/10.1038/383812a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893004	Green Submitted			2022-12-28	WOS:A1996VQ14400060
J	Brookes, JAS; HallCraggs, MA; Sams, VR; Lees, WR				Brookes, JAS; HallCraggs, MA; Sams, VR; Lees, WR			Non-invasive perinatal necropsy by magnetic resonance imaging	LANCET			English	Article							POSTMORTEM EXAMINATION; QUALITY	Background At present necropsy is done in less than 60% of cases of perinatal death in the UK, despite the value of the procedure to the bereaved parents and their doctors. This low rate reflects the difficulty in discussing the examination during the acute distress after the death of a baby, and the personal and religious objections of many parents to necropsy. We compared post-mortem magnetic resonance imaging (MRI) of the fetus with internal perinatal necropsy to assess whether MRI examination is a feasible option for the 40% of cases where consent for necropsy is not given or requested. Methods We examined 20 stillborn, miscarried, or aborted fetuses by MRI and necropsy. Scanning was done in a 1 . 5 T system, in accordance with our protocol, immediately before necropsy, The MRI and necropsy findings were compared to assess how much diagnostic information was obtained by each technique. Findings In eight of the 20 cases the two examinations were in total agreement about the abnormalities present. In eight cases the necropsy provided more detailed information than MRI examination, but in four cases the MRI information was more extensive than that obtained at necropsy. In two of the latter cases, abnormalities of the central nervous system were seen only on MRI, Thus, in 12 (60%) of the 20 cases studied, MRI had equivalent or better diagnostic sensitivity than internal necropsy examination; in 18 (90%) of the 20 cases the two examinations were of similar clinical significance. Interpretation MRI of the stillborn or aborted fetus provides non-invasive access to information previously available only from necropsy.	UCL, SCH MED, UNIV COLL LONDON HOSP GRP, DEPT HISTOPATHOL, LONDON W1N 8AA, ENGLAND	University of London; University College London; UCL Medical School	Brookes, JAS (corresponding author), MIDDLESEX HOSP, DEPT MED IMAGING, LONDON W1N 8AA, ENGLAND.			Hall-Craggs, Margaret/0000-0001-8734-4065				BECKWITH JB, 1989, PEDIATR CLIN N AM, V36, P29; CARTLIDGE PHT, 1995, BRIT MED J, V310, P155, DOI 10.1136/bmj.310.6973.155; CHISWICK M, 1995, BRIT MED J, V310, P141, DOI 10.1136/bmj.310.6973.141; CURRY CJR, 1992, PEDIATR CLIN N AM, V39, P160; DENG J, IN PRESS FETAL DIAGN; *DEP HLTH, 1993, REP NAT CONF ENQ PER; Ferguson MVJ, 1991, TXB FETAL ANDPERINAT, P843; Hagerstrand I, 1993, Qual Assur Health Care, V5, P295; HUSAIN AN, 1991, IARC SCI PUBL, V112, P151; KEELING JW, 1993, FETAL NEONATAL PATHO, P1; MCCARTHY SM, 1985, RADIOLOGY, V154, P427, DOI 10.1148/radiology.154.2.3966129; PORTER HJ, 1987, J CLIN PATHOL, V40, P180, DOI 10.1136/jcp.40.2.180; *RCOG, 1988, JOINT WORK PART ROYA; ROS PR, 1990, MAGN RESON IMAGING, V8, P303, DOI 10.1016/0730-725X(90)90103-9; *ROYAL COLL PATH, 1993, CE4SDI POSTM GUID; RUSHTON DI, 1994, BRIT J HOSP MED, V52, P450; RUSHTON DI, 1991, BRIT J OBSTET GYNAEC, V98, P624, DOI 10.1111/j.1471-0528.1991.tb13446.x; WIGGLESWORTH JS, 1991, BRIT J OBSTET GYNAEC, V98, P617, DOI 10.1111/j.1471-0528.1991.tb13444.x	18	122	129	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1139	1141		10.1016/S0140-6736(96)02287-8	http://dx.doi.org/10.1016/S0140-6736(96)02287-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888168				2022-12-28	WOS:A1996VP10600012
J	Simpson, GR; Schulz, TF; Whitby, D; Cook, PM; Boshoff, C; Rainbow, L; Howard, MR; Gao, SJ; Bohenzky, RA; Simmonds, P; Lee, C; deRuiter, A; Hatzakis, A; Tedder, RS; Weller, IVD; Weiss, RA; Moore, PS				Simpson, GR; Schulz, TF; Whitby, D; Cook, PM; Boshoff, C; Rainbow, L; Howard, MR; Gao, SJ; Bohenzky, RA; Simmonds, P; Lee, C; deRuiter, A; Hatzakis, A; Tedder, RS; Weller, IVD; Weiss, RA; Moore, PS			Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen	LANCET			English	Article							DNA-SEQUENCES; VIRUS; AIDS	Background Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8, may be the infectious cause of KS. Its prevalence in the general population, on the basis of detection of the virus genome, is controversial. To investigate the seroprevalence, we measured antibodies to a recombinant capsid-related (lytic cycle) KSHV antigen and a latent antigen complex. Methods We selected potentially immunoreactive capsid-related proteins of KSHV by expressing them as recombinant proteins and testing them in western blot assays. We used a truncated recombinant protein encoded by KSHV open reading frame 65 (orf 65) to develop a diagnostic enzyme-linked immunosorbent assay (ELISA) and tested sera from HIV-infected individuals with KS, HIV-uninfected patients with ''classic'' KS, other HIV risk groups, and blood donors. We also compared the antibody response to this capsid-related protein to the response to latent antigen(s) in an immunofluorescence assay. Findings 77/92 (84%) sera from KS patients reacted with the KSHV orf 65 protein and 84/103 (81 . 5%) reacted with KSHV latent antigen(s). The dominant immunogenic region of orf 65 is within the carboxyterminal 80 aminoacids, a region with little sequence similarity to the related Epstein-Barr virus, suggesting that orf 65 is a KSHV specific antigen. Only three sera from patients with haemophilia (1/84) or from intravenous drug users (2/63) had KSHV specific antibodies in the orf 65 assay whereas none of these sera reacted with latent antigen. Antibodies to KSHV were also infrequently found in UK and US blood donors by either assay (UK, 3/174 with orf 65 and 4/150 with latent antigen; US, 6/117 with orf 65 and 0/117 with latent antigen). They were more common among HIV-infected gay men without KS (5/16 by orf 65 ELISA, 10/33 by IFA), HIV-uninfected STD clinic attenders (14/166 by IFA), and Ugandan HIV-uninfected controls (6/17 by orf 65 ELISA, 9/17 by IFA). Antibody reactivity to the orf 65 protein (ELISA) and to latent antigen(s) (IFA) was concordant in 89% of 462 sera tested but reactive blood donor sera were discordant in both assays. Four AIDS-KS sera were unreactive in both assays. Interpretation The distribution of antibodies to both a capsid-related recombinant protein and latent antigen(s) of KSHV strongly supports the view that infection with this virus is largely confined to individuals with, or at increased risk for, KS. However, infection with KSHV does occur, rarely, in the general UK and US population and is more common in Uganda. Antibodies to latent antigen(s) or to orf 65 encoded capsid protein will not detect all cases of KSHV infection, and a combination of several antigens will probably be required for accurate screening and confirmatory assays.	UNIV LIVERPOOL, DEPT MED MICROBIOL & GENITOURINARY MED, LIVERPOOL L69 3GA, MERSEYSIDE, ENGLAND; CANC RES INST, VIROL LAB, LONDON, ENGLAND; UCL, SCH MED, DEPT VIROL, DIV PATHOL, LONDON W1N 8AA, ENGLAND; UCL, SCH MED, DEPT SEXUALLY TRANSMITTED DIS, DIV PATHOL, LONDON W1N 8AA, ENGLAND; COLUMBIA UNIV, DEPT PATHOL, NEW YORK, NY USA; UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND; ROYAL FREE HOSP, SCH MED, HAEMOPHILIA CTR, LONDON, ENGLAND; ST THOMAS HOSP, DEPT GENITOURINARY MED, LONDON SE1 7EH, ENGLAND; UNIV ATHENS, DEPT HYG & EPIDEMIOL, ATHENS, GREECE	University of Liverpool; University of London; Institute of Cancer Research - UK; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; Columbia University; University of Edinburgh; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Guy's & St Thomas' NHS Foundation Trust; National & Kapodistrian University of Athens			Moore, Patrick/GVR-8294-2022; Schulz, Thomas/AAA-1634-2019; Gao, Shou-Jiang/B-8641-2012; Moore, Patrick S./F-3960-2011	Moore, Patrick S./0000-0002-8132-858X; Simpson, Guy/0000-0003-0447-5436; Simmonds, Peter/0000-0002-7964-4700; Gao, Shou-Jiang/0000-0001-6194-1742; Tedder, Richard/0000-0002-9672-5721; Schulz, Thomas/0000-0001-8792-5345	PHS HHS [U64CCU210852] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADES AE, 1989, J EPIDEMIOL COMMUN H, V43, P53, DOI 10.1136/jech.43.1.53; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; ARCHIBALD CP, 1990, J ACQ IMMUN DEF SYND, V3, pS18; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER SURV, V10, P5; Bigoni B, 1996, J INFECT DIS, V173, P542, DOI 10.1093/infdis/173.3.542; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BOSHOFF C, 1995, LANCET, V345, P1043; Buonaguro FM, 1996, INT J CANCER, V65, P25, DOI 10.1002/(SICI)1097-0215(19960103)65:1&lt;25::AID-IJC5&gt;3.0.CO;2-3; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; CRAWFORD DH, 1995, CLIN VIROLOGY, P109; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; HORNEF MW, 1995, TRANSPLANTATION, V60, P474, DOI 10.1097/00007890-199509000-00013; HOWARD M, UNPUB DETECTION HUMA; JACOBSON LP, 1990, J ACQ IMMUN DEF SYND, V3, pS24; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; LEBBE C, 1995, LANCET, V345, P1180, DOI 10.1016/S0140-6736(95)91011-5; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; LI JJ, 1995, AIDS RES HUM RETROV, V11, pS98; LIN JC, 1995, LANCET, V346, P1601, DOI 10.1016/S0140-6736(95)91931-7; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, AIDS, V10, P175, DOI 10.1097/00002030-199602000-00007; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SCHULZ TF, 1995, NATURE, V373, P17, DOI 10.1038/373017a0; VANGRUNSVEN WMJ, 1993, J VIROL, V67, P3908, DOI 10.1128/JVI.67.7.3908-3916.1993; VANGRUNSVEN WMJ, 1994, J INFECT DIS, V170, P13, DOI 10.1093/infdis/170.1.13; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; WHITBY D, 1991, LANCET, V338, P1215, DOI 10.1016/0140-6736(91)92085-G	34	524	551	1	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1133	1138		10.1016/S0140-6736(96)07560-5	http://dx.doi.org/10.1016/S0140-6736(96)07560-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888167	hybrid			2022-12-28	WOS:A1996VP10600011
J	Adisesh, A; Parker, G				Adisesh, A; Parker, G			ABC of work related disorders - Working with an occupational health department	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,HLTH & SAFETY SERV,MANCHESTER M13 9PL,LANCS,ENGLAND; UNIV MANCHESTER,CTR OCCUPAT HLTH,MANCHESTER M13 9PL,LANCS,ENGLAND	University of Manchester; University of Manchester	Adisesh, A (corresponding author), WYTHENSHAWE HOSP,NW LUNG CTR,MANCHESTER M23 9LT,LANCS,ENGLAND.		Adisesh, Anil/AAK-7552-2020	Adisesh, Anil/0000-0002-4973-8474				BUNT K, 1993, 57 HSE; COX RAF, 1995, FITNESS WORK MED ASP; *FAC OCC MED ROYAL, 1993, GUID ETH OCC HLTH PH; *HLTH SAF EX, 1993, YOUR PAT THEIR WORK	4	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					999	1002						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892425				2022-12-28	WOS:A1996VN91600032
J	Daly, E; Vessey, MP; Hawkins, MN; Carson, JL; Gough, P; Marsh, S				Daly, E; Vessey, MP; Hawkins, MN; Carson, JL; Gough, P; Marsh, S			Risk of venous thromboembolism in users of hormone replacement therapy	LANCET			English	Article							ESTROGEN REPLACEMENT; ORAL-CONTRACEPTIVES; POSTMENOPAUSAL WOMEN; DISEASE	Background The association between current use of oral contraceptives and increased risk of venous thromboembolism (VTE) has been firmly established. Although data-sheets for hormone replacement therapy (HRT) carry similar warnings as regards VTE, evidence of an association is inconclusive. We carried out a hospital-based case-control study to investigate whether current use of HRT is associated with VTE. Methods We screened all women aged 45-64 years admitted to hospitals in the area of the Oxford Regional Health Authority with a suspected diagnosis of VTE between February, 1993, and December, 1994. We recruited 81 cases of idiopathic VTE and 146 hospital controls with disorders of eyes, skin, ears, respiratory and alimentary tracts, kidneys, bones, and joints, and trauma; controls were matched to cases for age-group and date and district of admission. To increase the study power, an additional 22 cases of idiopathic VTE and 32 hospital controls admitted before February, 1993, were recruited retrospectively. Participants were questioned about medical and gynaecological history, use of oral contraceptives and HRT, use of other drugs within the previous 3 months, and lifestyle and socioeconomic characteristics. Detailed diagnostic data were extracted from the notes of eligible cases. Matched analyses, adjusted for body-mass index, socioeconomic group, and history of varicose veins, were undertaken by conditional logistic regression. Findings 44 (42 . 7%) cases and 44 (24 . 7%) controls were current users of HRT, The adjusted odds ratio for VTE in current users of HRT compared with non-users (never-users and past users combined) was 3 . 5 (95% CI 1 . 8-7 . 0; p<0 . 001). No association was found with past use, and risk appeared to be highest among short-term current users (adjusted likelihood ratio test of trend in odds ratios across different durations of current use, p=0 . 011). Interpretation Current HRT use is associated with risk of VTE, The increased risk may be concentrated in new users. The number of extra cases appears to be only about one in 5000 users per year. These findings need to be weighed against the probable benefits of long-term treatment, including reductions in risks of osteoporotic fracture and coronary heart disease, and the probable modest increase in risk of breast cancer.	CHILDRENS CANC RES GRP,OXFORD,ENGLAND	University of Oxford	Daly, E (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.							[Anonymous], 1974, N Engl J Med, V290, P15; [Anonymous], 1995, LANCET, V346, P1575; Banks E, 1996, BRIT MED J, V312, P638; Breslow N.E., 1980, STAT METHODS CANC RE, P192; *BRIT MED ASS ROYA, 1995, BRIT NATL FORM, V28; COMPSTON JE, 1992, BRIT MED BULL, V48, P309, DOI 10.1093/oxfordjournals.bmb.a072549; Daly E, 1996, MATURITAS, V23, P247, DOI 10.1016/0378-5122(95)00978-7; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; *OPCS, 1995, 1993 BAS SUBP PR PP3; *OPCS, 1990, STAND OCC CLASS, V1; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; RCOG, 1995, REP RCOG WORK PART P; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; 1995, JAMA-J AM MED ASSOC, V273, P199	21	665	675	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					977	980		10.1016/S0140-6736(96)07113-9	http://dx.doi.org/10.1016/S0140-6736(96)07113-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855852				2022-12-28	WOS:A1996VM02700008
J	Davies, W				Davies, W			Assessing fitness for work	BRITISH MEDICAL JOURNAL			English	Article																		COX RAF, 1995, FITNESS WORK MED ASP; *DEP ED, 1993, 1393 DEP ED; *DEP SOC SEC BEN A, 1995, GUID REG MED PRACT I; *DVLA MED ADV BRAN, 1996, GLANC GUID CURR MED; *HLTH SAF EX, 1992, YOUR PAT THEIR WORK; *HLTH SAF EX, 1989, MS23 HLTH SAF EX; *HLTH SAF EX, 1982, MS20 HLTH SAF EX; TAYLOR J, 1995, MED ASPECTS FITNESS	8	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					934	938						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876103				2022-12-28	WOS:A1996VM75400036
J	Grodstein, F; Stampfer, MJ; Goldhaber, SZ; Manson, JE; Colditz, GA; Speizer, FE; Willett, WC; Hennekens, CH				Grodstein, F; Stampfer, MJ; Goldhaber, SZ; Manson, JE; Colditz, GA; Speizer, FE; Willett, WC; Hennekens, CH			Prospective study of exogenous hormones and risk of pulmonary embolism in women	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; ORAL-CONTRACEPTIVES; THROMBOEMBOLIC DISEASE; VENOUS THROMBOEMBOLISM; MENOPAUSAL WOMEN; PROGESTAGEN; COAGULATION; THROMBOSIS; SAFETY; DEATH	Background Current use of oral contraceptives (OCs) is a well-recognised risk factor for venous thrombosis and consequent pulmonary embolism (PE). Little is known about residual effects of past OC use. Furthermore, few epidemiological studies have assessed the relation between postmenopausal use of hormones and thrombotic disease. Methods in this prospective study information was obtained through questionnaires sent every 2 years (1976-92) to 112 593 women aged 30-55 in 1976, We excluded women with previously diagnosed cardiovascular disease or cancer in 1976 and at the beginning of each subsequent 2-year follow-up period. Findings From self-reports and medical records, we documented 123 cases of primary PE (no identified antecedent cancer, trauma, surgery, or immobilisation). Current users of postmenopausal hormones had an increased risk of primary PE (relative risk adjusted for multiple risk factors 2 . 1 [95% CI 1 . 2-3 . 8]). However, past use showed no relation to PE (1 . 3[0 . 7-2 . 4]). In current users of OCs the risk of primary PE was about twice that in non-users (2 . 2[0 . 8-5 . 9]), but this finding was based on only five cases who were current OC users. Users of OCs in the past had no increase in risk of PE (0 . 8[0 . 5-1 . 2]). These relations were consistent irrespective of cigarette-smoking status. Interpretation Primary PE was uncommon in this cohort. The risk was increased by current though not past use of postmenopausal hormones or OCs.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,181 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40935] Funding Source: Medline; NHLBI NIH HHS [HL 24074, HL 34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1974, N Engl J Med, V290, P15; [Anonymous], 1995, LANCET, V346, P1575; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; KOSTER T, 1995, J INTERN MED, V238, P31, DOI 10.1111/j.1365-2796.1995.tb00896.x; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; LOBO RA, 1992, AM J MED, V92, P283, DOI 10.1016/0002-9343(92)90078-P; MEADE TW, 1988, AM J OBSTET GYNECOL, V158, P1646, DOI 10.1016/0002-9378(88)90203-7; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; MELIS GB, 1988, MATURITAS S1, V10, P131; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NOTELOVITZ M, 1983, OBSTET GYNECOL, V62, P596; NOTELOVITZ M, 1984, OBSTET GYNECOL, V63, P621; PETTITI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150; POLLER L, 1977, BRIT MED J, V1, P935, DOI 10.1136/bmj.1.6066.935; QUINN DA, 1992, JAMA-J AM MED ASSOC, V268, P1689, DOI 10.1001/jama.268.13.1689; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; ROSENBERG L, 1985, JAMA-J AM MED ASSOC, V253, P2965, DOI 10.1001/jama.253.20.2965; *ROYAL COLL GEN PR, 1974, OR CONTR HLTH; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1993, CARDIOVASCULAR HLTH, P175; STAMPFER MJ, 1992, CIRCULATION, V86, P1; STANGEL JJ, 1977, OBSTET GYNECOL, V49, P314; VESSEY MP, 1968, BMJ-BRIT MED J, V2, P199, DOI 10.1136/bmj.2.5599.199; 1995, JAMA-J AM MED ASSOC, V273, P199; 1995, LANCET, V346, P1582	32	447	457	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					983	987		10.1016/S0140-6736(96)07308-4	http://dx.doi.org/10.1016/S0140-6736(96)07308-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855854				2022-12-28	WOS:A1996VM02700010
J	Malhotra, A; Severinova, E; Darst, SA				Malhotra, A; Severinova, E; Darst, SA			Crystal structure of a sigma(70) subunit fragment from E-coli RNA polymerase	CELL			English	Article							TRANSCRIPTION INITIATION-FACTOR; SINGLE-STRANDED REGIONS; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; 3-DIMENSIONAL STRUCTURE; SIGMA-70 SUBUNIT; AMINO-ACIDS; ANOMALOUS DIFFRACTION; PROMOTER RECOGNITION; GENETIC-EVIDENCE	The 2.6 Angstrom crystal structure of a fragment of the sigma(70) promoter specificity subunit of E. coli RNA polymerase is described. Residues involved in core RNA polymerase binding lie on one face of the structure. On the opposite face, aligned along one helix, are exposed residues that interact with the -10 consensus promoter element (the Pribnow box), including four aromatic residues involved in promoter melting. The structure suggests one way in which DNA interactions may be inhibited in the absence of RNA polymerase and provides a framework for the interpretation of a large number of genetic and biochemical analyses.			Malhotra, A (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Malhotra, Arun/A-3916-2008; Malhotra, Arun/Z-5140-2019	Malhotra, Arun/0000-0001-6656-7841; Malhotra, Arun/0000-0001-6656-7841				AHEARN JM, 1987, J BIOL CHEM, V262, P10695; AIYAR SE, 1994, BIOCHEMISTRY-US, V33, P11501, DOI 10.1021/bi00204a012; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BUCKLE M, 1989, BIOCHEMISTRY-US, V28, P4388, DOI 10.1021/bi00436a040; BUCKLE M, 1991, NUCLEIC ACIDS RES, V19, P833, DOI 10.1093/nar/19.4.833; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAN B, 1990, FEBS LETT, V267, P46, DOI 10.1016/0014-5793(90)80284-P; CHRISTIE GE, 1995, GENE, V162, P161, DOI 10.1016/0378-1119(95)00333-2; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Gross C., 1992, BACTERIAL SIGMA FACT; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HILTON MD, 1985, J BIOL CHEM, V260, P8121; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; JANG SH, 1991, J BIOL CHEM, V266, P22671; JONES CH, 1992, P NATL ACAD SCI USA, V89, P1958, DOI 10.1073/pnas.89.5.1958; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUANG YL, 1995, BIOCHEMISTRY-US, V34, P8465, DOI 10.1021/bi00026a030; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; LOSICK R, 1981, CELL, V25, P582, DOI 10.1016/0092-8674(81)90164-1; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PARK CS, 1980, NUCLEIC ACIDS RES, V8, P5895, DOI 10.1093/nar/8.23.5895; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RONG JC, 1994, J BACTERIOL, V176, P5218, DOI 10.1128/JB.176.17.5218-5224.1994; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHELDRICK GM, 1991, P CCP4 STUDY WEEKEND, P23; SHULER MF, 1995, J BACTERIOL, V177, P3687, DOI 10.1128/jb.177.13.3687-3694.1995; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SPASSKY A, 1988, EMBO J, V7, P1871, DOI 10.1002/j.1460-2075.1988.tb03020.x; STRAGIER P, 1985, FEBS LETT, V187, P11, DOI 10.1016/0014-5793(85)81203-5; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TATTI KM, 1991, J BACTERIOL, V173, P7828, DOI 10.1128/jb.173.24.7828-7833.1991; TINTUT Y, 1995, J BACTERIOL, V177, P5818, DOI 10.1128/jb.177.20.5818-5825.1995; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120; YONG K, 1990, ACTA CRYSTALLOGR A, V46, P41; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	73	267	273	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1996	87	1					127	136		10.1016/S0092-8674(00)81329-X	http://dx.doi.org/10.1016/S0092-8674(00)81329-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858155	Bronze			2022-12-28	WOS:A1996VL69500015
J	Middleton, RE; Pheasant, DJ; Miller, C				Middleton, RE; Pheasant, DJ; Miller, C			Homodimeric architecture of a CIC-type chloride ion channel	NATURE			English	Article							DOMINANT MYOTONIA-CONGENITA; TORPEDO ELECTROPLAX; ACETYLCHOLINE-RECEPTOR; THOMSEN	THE recent discovery of the ClC-family of anion-conducting channel proteins(1-3) has led to an appreciation of the central roles played by chloride ion channels in cellular functions, such as electrical behaviour of muscle(4-7) and nerve(8) and epithelial solute transport(9). Little is known, however, about molecular architecture or sequence-function relationships in these membrane proteins, In the single case of ClC-0, a voltage-gated 'muscle-type' chloride channel, the functional complex is known to be a homo-oligomer of a polypeptide of M(r) similar to 90,000, with no associated 'helper' subunits(10). The subunit stoichiometry of ClC-type channels is controversial, however, with either dimeric or tetrameric association suggested by different indirect experiments(10,11). Before a coherent molecular view of this new class of ion channels can emerge, the fundamental question of subunit composition must first be settled, We have examined hybrid ClC-0 channels constructed from functionally tagged subunits, and report here that ClC-0 is a homodimer containing two chloride-conduction pores.	BRANDEIS UNIV,HOWARD HUGHES MED INST,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Howard Hughes Medical Institute								ACKERMAN MJ, 1993, TRENDS CARDIOVAS MED, V3, P23, DOI 10.1016/1050-1738(93)90024-Z; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; HANKE W, 1983, J GEN PHYSIOL, V82, P25, DOI 10.1085/jgp.82.1.25; Hille B., 1992, IONIC CHANNELS EXCIT; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MAYER ML, 1985, J PHYSIOL-LONDON, V364, P217, DOI 10.1113/jphysiol.1985.sp015740; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; MILLER C, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P383; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; PALADE PT, 1977, J GEN PHYSIOL, V69, P879, DOI 10.1085/jgp.69.6.879; PUSCH M, 1994, PHYSIOL REV, V74, P813, DOI 10.1152/physrev.1994.74.4.813; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W	26	219	222	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					337	340		10.1038/383337a0	http://dx.doi.org/10.1038/383337a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848046				2022-12-28	WOS:A1996VJ43900045
J	Bodenheimer, T				Bodenheimer, T			The HMO backlash - Righteous or reactionary?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Bodenheimer, T (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94110, USA.							Dimmit B, 1996, Bus Health, V14, P42; Felsenthal E, 1996, WALL STREET J   1126, pB10; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FREUDENHEIM M, 1996, NY TIMES         MAY, P1; *GOV COMM, 1995, GREAT GOOD, P262; Kassirer JP, 1996, NEW ENGL J MED, V335, P433, DOI 10.1056/NEJM199608083350612; Keeler EB, 1996, JAMA-J AM MED ASSOC, V275, P1666, DOI 10.1001/jama.275.21.1666; LARSON E, 1996, TIME            0122, P44; LIGHT D, 1993, BRITAINS HLTH SYSTEM; LOPEZ L, 1996, STATE HLTH WATCH MAR, V3, P8; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MITKA M, 1996, AM MED NEWS     0205, V3, P23; PAGE L, 1996, AM MED NEWS     0909, P6; PEAR R, 1996, NY TIMES        0317, P1; ROSENTHAL E, 1996, NY TIMES        0115, P1; Swartz K, 1996, ANN INTERN MED, V124, P442, DOI 10.7326/0003-4819-124-4-199602150-00009; THORPE KE, 1995, HEALTH AFFAIR, V14, P254, DOI 10.1377/hlthaff.14.3.254; WINSLOW R, 1994, WALL STREET J   0906, P1; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510; 1996, NY TIMES        0615, P14; 1996, WASHINGTON POST 0102, pE3	21	92	92	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1996	335	21					1601	1604		10.1056/NEJM199611213352112	http://dx.doi.org/10.1056/NEJM199611213352112			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT341	8900097				2022-12-28	WOS:A1996VT34100012
J	Rosette, C; Karin, M				Rosette, C; Karin, M			Ultraviolet light and osmotic stress: Activation of the JNK cascade through multiple growth factor and cytokine receptors	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; C-JUN; PROTEIN-KINASES; UV; PHOSPHORYLATION; BINDING; DOMAIN; GENE; FOS; EXPRESSION	Exposure of mammalian cells to ultraviolet (UV) light or high osmolarity strongly activates the c-Jun amino-terminal protein kinase (JNK) cascade, causing induction of many target genes. Exposure to UV light or osmotic shock induced clustering and internalization of cell surface receptors for epidermal growth factor (EGF), tumor necrosis factor (TNF), and interleukin-1 (IL-1), Activation of the EGF and TNF receptors was also detected biochemically. Whereas activation of each receptor alone resulted in modest activation of JNK, coadministration of EGF, IL-1, and TNF resulted in a strong synergistic response equal to that caused by exposure to osmotic shock or UV light. Inhibition of clustering or receptor down-regulation attenuated both the osmotic shock and UV responses. Physical stresses may perturb the cell surface or alter receptor conformation, thereby subverting signaling pathways normally used by growth factors and cytokines.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego								ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BUSCHER M, 1988, ONCOGENE, V3, P301; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FISHER GJ, 1995, NATURE, V379, P353; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GORDEN P, 1978, P NATL ACAD SCI USA, V75, P5025, DOI 10.1073/pnas.75.10.5025; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOCH A, 1990, J EXP MED, V172, P1609; Krutmann J., 1995, J INVEST DERMATOL, V105, P675; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x	37	919	946	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1194	1197		10.1126/science.274.5290.1194	http://dx.doi.org/10.1126/science.274.5290.1194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895468				2022-12-28	WOS:A1996VT33500054
J	Buerhaus, PI; Staiger, DO				Buerhaus, PI; Staiger, DO			Managed care and the nurse workforce	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARKET	Objectives.-To identify recent national trends in the employment and earnings of nursing personnel and determine whether managed care is associated with changes in the employment and wage growth of nursing personnel. Design.-Retrospective analysis of trends in data on employment and earnings of nursing personnel based on monthly US Bureau of the Census Current Population Surveys between 1983 and 1994, and comparison of trends between states with high and low rates of enrollment in health maintenance organizations (HMOs). Population.-Registered nurses (RNs), licensed practical nurses (LPNs), and nurse aides/assistants, orderlies, and attendants (referred to collectively as aides) between the ages of 21 and 64 years. Outcome Measures.-Full- and part-time employment, unemployment, percentage of nursing personnel employed in key sectors of the nurse labor market, and inflation-adjusted hourly wages. Results.-From 1983 through 1994, there was strong overall growth in both RN employment (37%) and inflation-adjusted wages (22%). Beginning in the early 1990s, however, RNs experienced stagnant wages and a small but steady shift toward employment in lower-paying nonhospital settings, particularly in home health care, In states with high HMO enrollment, RN and LPN employment has grown more slowly since 1990, and the shift of RN employment out of the hospital was strongest. For aides and LPNs, the shift out of hospital employment occurred years before that of RNs and at a much greater rate, Since 1990 the employment of aides has grown rapidly in nursing homes and in home health care settings, whereas employment of LPNs has shifted primarily into physician offices and nursing homes. Overall, the movement toward nonhospital employment has had a modest negative impact on wages for all nursing personnel. Conclusions.-Managed care is associated with stower employment growth for RNs in hospitals and a shift toward employment in nonhospital settings, but its effect on earnings has been overshadowed by other forces impacting nurse wages.	HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138; NATL BUR ECON RES,CAMBRIDGE,MA 02138	Harvard University; National Bureau of Economic Research	Buerhaus, PI (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,NURSING RES INST,667 HUNTINGTON AVE,BOSTON,MA 02115, USA.							*ADV BOARD CO, 1995, GREAT GOOD REC AM PH; AIKEN LH, 1995, NURS OUTLOOK, V43, P201, DOI 10.1016/S0029-6554(05)80005-3; *AM HOSP ASS, 1996, AHA PROF US HOSP 199, V2; ANDERSON GF, 1996, HLTH AFF MILLWOOD, V15, P153; [Anonymous], 1995, REF HLTH CAR WORKF R; BUERHAUS P, IN PRESS NURS EC; BUERHAUS PI, 1995, NURS ECON, V13, P137; *BUR LAB STAT, 1995, EMPL WAG ANN AV 1994; COHANY SR, 1994, REVISIONS CURRENT PO, P13; GREINER A, 1995, COST QUALITY MATTERS, P3; HASSON J, 1995, USA TODAY       1220, pA5; *HLTH CAR ADV BOAR, 1994, REP CAP; IGLEHART JK, 1995, NEW ENGL J MED, V333, P1019, DOI 10.1056/NEJM199510123331525; LARSON PF, 1994, HLTH WORKFORCE ISSUE; MOSES EB, 1992, REGISTERED NURSE POP; Oaxaca R., 1973, INT ECON REV, V14, P693, DOI DOI 10.2307/2525981; OSTERWEIS M, 1996, US HLTH WORKFORCE PO; Pew Health Professions Commission, 1994, PRIM CAR WORKF 2000; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; *RW JOHNS FDN, 1995, COLL CAR COLL NURS W; *STAT CORP, 1993, STAT REF MAN REL 3 1, V2, P405; UHLMAN M, 1996, PHILADELPHIA IN 0320, pA1; UHLMAN M, 1996, PHILADELPHIA IN 0320, pA16; WUNDERLICH GS, 1996, NURSING STAFF HOSPIT; 1996, AM J NURS, V96, P71; 1994, INQUIRY, V3, P241; 1996, AM J NURS, V96, P62; 1996, AM J NURS, V96, P61; 1996, AM J NURS, V96, P65; 1996, AM J NURS, V96, P64	30	60	60	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1487	1493		10.1001/jama.276.18.1487	http://dx.doi.org/10.1001/jama.276.18.1487			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VQ774	8903260				2022-12-28	WOS:A1996VQ77400031
J	Chinnaiyan, AM; ORourke, K; Yu, GL; Lyons, RH; Garg, M; Duan, DR; Xing, L; Gentz, R; Ni, J; Dixit, VM				Chinnaiyan, AM; ORourke, K; Yu, GL; Lyons, RH; Garg, M; Duan, DR; Xing, L; Gentz, R; Ni, J; Dixit, VM			Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95	SCIENCE			English	Article							CELL-DEATH; FAS ANTIGEN; APOPTOSIS; PROTEIN; INTERACTS; FAMILY	Tumor necrosis factor receptor-1 (TNFR-1) and CD95 (also called Fas or APO-I) are cytokine receptors that engage the apoptosis pathway through a region of intracellular homology, designated the ''death domain.'' Another death domain-containing member of the TNFR family, death receptor 3 (DR3), was identified and was shown to induce both apoptosis and activation of nuclear factor kappa B. Expression of DR3 appears to be restricted to tissues enriched in lymphocytes. DR3 signal transduction is mediated by a complex of intracellular signaling molecules including TRADD, TRAF2, FADD, and FLICE. Thus, DR3 likely plays a role in regulating lymphocyte homeostasis.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-07863] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHINNAIYAN AM, UNPUB; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	31	514	589	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					990	992		10.1126/science.274.5289.990	http://dx.doi.org/10.1126/science.274.5289.990			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875942				2022-12-28	WOS:A1996VR79200051
J	Hogan, JC				Hogan, JC			Directed combinatorial chemistry	NATURE			English	Article							SOLID-PHASE SYNTHESIS; DRUG DISCOVERY; DIVERSITY				Hogan, JC (corresponding author), ARQULE,200 BOSTON AVE,MEDFORD,MA 02155, USA.							BUNIN BA, 1992, J AM CHEM SOC, V114, P10997, DOI 10.1021/ja00053a067; CAMPBELL DA, 1994, J ORG CHEM, V59, P658, DOI 10.1021/jo00082a027; CAMPBELL DA, 1992, J ORG CHEM, V57, P6331, DOI 10.1021/jo00049a051; CHO CY, 1993, SCIENCE, V261, P1303, DOI 10.1126/science.7689747; DEWITT SH, 1993, P NATL ACAD SCI USA, V90, P6909, DOI 10.1073/pnas.90.15.6909; EVANS BE, 1988, J MED CHEM, V31, P2235, DOI 10.1021/jm00120a002; FURKA A, INT J PEPT PROT RES; HAGIHARA M, 1992, J AM CHEM SOC, V114, P6568, DOI 10.1021/ja00042a052; Hermkens PHH, 1996, TETRAHEDRON, V52, P4527, DOI 10.1016/0040-4020(96)00216-5; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HOUGHTON RA, 1991, NATURE, V354, P64; MARTIN EJ, 1995, J MED CHEM, V38, P1431, DOI 10.1021/jm00009a003; PATEK M, 1995, TETRAHEDRON LETT, V36, P2227, DOI 10.1016/0040-4039(95)00261-A	14	49	57	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604		S			17	19						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR392	8895595				2022-12-28	WOS:A1996VR39200006
J	Hux, JE; Naylor, CD; Abdulla, A; Bartlett, G; Beanlands, DS; Bickerton, LM; Chisholm, R; Lozon, J; Goldbach, M; McKenzie, N; Kaminski, V; Monoghan, BJ; Morgan, CD; Pym, J; Scully, H; Schragge, BW; Swan, J				Hux, JE; Naylor, CD; Abdulla, A; Bartlett, G; Beanlands, DS; Bickerton, LM; Chisholm, R; Lozon, J; Goldbach, M; McKenzie, N; Kaminski, V; Monoghan, BJ; Morgan, CD; Pym, J; Scully, H; Schragge, BW; Swan, J			Are the marginal returns of coronary artery surgery smaller in high-rate areas?	LANCET			English	Article							BYPASS GRAFT-SURGERY; HEALTH-CARE SERVICES; NEW-YORK-STATE; UNSTABLE ANGINA; SURGICAL-TREATMENT; APPROPRIATENESS; CANADA; SURVIVAL; DISEASE; ONTARIO	Background Population-based rates of surgery vary within and between health-care systems, causing concern that case selection is less appropriate in high-rate areas. This inverse relationship has not been shown with appropriateness criteria generated by expert panels. We applied a trials-based measure of the potential survival benefit of coronary artery bypass graft surgery (CABG) to patients in a provincial registry, to determine the relationship between survival gains and rates of CABG. Methods We did a population-based retrospective review of linked registry and administrative datasets. 5058 patients in the linked datasets underwent isolated CABG in Ontario between April 1, 1992, and March 31, 1993. Potential survival benefit of surgery was scored with an algorithm derived from a published overview of trials comparing CABG to medical treatment, analysed by county and by referral regions. Findings Overall, case selection was appropriate whether assessed clinically (96 . 3% had either severe disease as judged on the coronary arteries affected or moderate to severe angina) or on the basis of survival benefit scores (94 . 0% predicted to obtain moderate or high benefit). There was significant variation in benefit scores across referral regions (p<0 . 001). Benefit scores correlated inversely with county surgical rate (r=-0 . 49, p<0 . 005) and the proportion of low-benefit cases increased with rates (r=0 . 50, p<0 . 005). Referral regions served by high-rate surgical centres had lower mean benefit scores. Interpretation Most patients undergoing CABG in Ontario are in the high-survival benefit category. Surgery is defensible for patients with low survival benefit on the grounds of symptom relief, but the proportion of cases with low benefit rises with higher local rates of surgery, The inverse relationship between surgery rates and appropriateness of case selection may be better understood as diminishing marginal returns for specific outcomes with rising local use of procedures.	UNIV TORONTO,DEPT MED,SUNNYBROOK UNIT,CLIN EPIDEMIOL & HLTH CARE RES PROGRAM,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT SURG,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT HLTH ADM,TORONTO,ON M5S 1A1,CANADA; SUDBURY MEM HOSP,SUDBURY,ON,CANADA; UNIV OTTAWA,INST HEART,OTTAWA,ON K1N 6N5,CANADA; ST MICHAELS HOSP,TORONTO,ON M5B 1W8,CANADA; LONDON HLTH SCI CTR,LONDON,ON,CANADA; W PK HOSP,TORONTO,ON,CANADA; SUNNYBROOK HLTH SCI CTR,TORONTO,ON M4N 3M5,CANADA; KINGSTON GEN HOSP,KINGSTON,ON K7L 2V7,CANADA; TORONTO HOSP,TORONTO,ON M5T 2S8,CANADA; HAMILTON CIV HOSP,GENERAL DIV,HAMILTON,ON,CANADA; SCARBOROUGH CENTENARY HLTH CTR,SCARBOROUGH,ON,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Ottawa; University of Ottawa; University of Ottawa Heart Institute; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; London Health Sciences Centre; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Queens University - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; McMaster University; Scarborough Hospital	Hux, JE (corresponding author), INST CLIN EVALUAT SCI,G-106,2075 BAYVIEW AVE,N YORK,ON M4N 3M5,CANADA.							ANDERSON GM, 1989, MED CARE, V27, P288, DOI 10.1097/00005650-198903000-00007; Black N, 1994, Int J Qual Health Care, V6, P231; Black N, 1995, INT J TECHNOL ASSESS, V11, P719; BROOK RH, 1988, LANCET, V1, P750; Cameron A, 1996, NEW ENGL J MED, V334, P216, DOI 10.1056/NEJM199601253340402; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; DAVIDSON G, 1993, HEALTH SERV RES, V28, P389; DAVIS KB, 1995, J AM COLL CARDIOL, V25, P1000, DOI 10.1016/0735-1097(94)00518-U; HICKS NR, 1994, BRIT MED J, V309, P730, DOI 10.1136/bmj.309.6956.730; HIGGINSON LAJ, 1994, CAN J CARDIOL, V10, P728; KAHAN JP, 1994, MED CARE, V32, P357, DOI 10.1097/00005650-199404000-00004; Leape L L, 1992, Qual Assur Health Care, V4, P151; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; LOOP FD, 1988, CLEV CLIN J MED, V55, P23, DOI 10.3949/ccjm.55.1.23; LUCHI RJ, 1987, NEW ENGL J MED, V316, P977, DOI 10.1056/NEJM198704163161603; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; NAYLOR CD, 1995, LANCET, V346, P1605, DOI 10.1016/S0140-6736(95)91934-1; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; PARISI AF, 1989, CIRCULATION, V80, P1176, DOI 10.1161/01.CIR.80.5.1176; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; SCOTT SM, 1988, CIRCULATION, V78, P113; *STAT CORP, STAT REF MANN REL 3, V2, P198; UGNAT AM, 1994, CAN MED ASSOC J, V151, P575; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	26	21	21	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1202	1207		10.1016/S0140-6736(96)04091-3	http://dx.doi.org/10.1016/S0140-6736(96)04091-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898037				2022-12-28	WOS:A1996VQ46700011
J	Farrens, DL; Altenbach, C; Yang, K; Hubbell, WL; Khorana, HG				Farrens, DL; Altenbach, C; Yang, K; Hubbell, WL; Khorana, HG			Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin	SCIENCE			English	Article							BOVINE RHODOPSIN; STRUCTURAL-CHANGES; AMINO-ACIDS; BACTERIORHODOPSIN; TRANSDUCIN; FLUORESCENCE; ARRANGEMENT; PHOTOCYCLE; MEMBRANE; RECEPTOR	Conformational changes are thought to underlie the activation of heterotrimeric GTP-binding protein (G protein)-coupled receptors. Such changes in rhodopsin were explored by construction of double cysteine mutants, each containing one cysteine at the cytoplasmic end of helix C and one cysteine at various positions in the cytoplasmic end of helix F. Magnetic dipolar interactions between spin labels attached to these residues revealed their proximity, and changes in their interaction upon rhodopsin light activation suggested a rigid body movement of helices relative to one another. Disulfide crosslinking of the helices prevented activation of transducin, which suggests the importance of this movement for activation of rhodopsin.	UNIV CALIF LOS ANGELES,JULES STEIN EYE INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT CHEM,LOS ANGELES,CA 90095; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL EYE INSTITUTE [R37EY005216, F32EY006465, R01EY005216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028289, R37GM028289] Funding Source: NIH RePORTER; NEI NIH HHS [EY06465, EY05216] Funding Source: Medline; NIGMS NIH HHS [GM28289] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; ALTENBACH C, IN PRESS BIOCHEMISTR; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BETH AH, 1984, J BIOL CHEM, V259, P9717; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; FARRENS DL, UNPUB; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; Hubbell Wayne L., 1995, Biophysical Journal, V68, pA21; Kamikubo H, 1996, P NATL ACAD SCI USA, V93, P1386, DOI 10.1073/pnas.93.4.1386; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; NAKANISHI K, 1995, BIOPHYS CHEM, V56, P13, DOI 10.1016/0301-4622(95)00010-U; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NAKAYAMA TA, 1989, THESIS MIT; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PAPPIN DJC, 1984, BIOCHEM J, V217, P605, DOI 10.1042/bj2170605; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; SHEIKH S, IN PRESS NATURE; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; STEINHOFF HJ, 1994, SCIENCE, V266, P105, DOI 10.1126/science.7939627; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUBRAMANIAM S, 1993, EMBO J, V12, P1; Thurmond Robin L., 1995, Biophysical Journal, V68, pA385; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; YANG K, IN PRESS BIOCHEMISTR	38	1074	1090	1	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					768	770		10.1126/science.274.5288.768	http://dx.doi.org/10.1126/science.274.5288.768			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864113				2022-12-28	WOS:A1996VQ14500038
J	Zhu, ZW; Thiele, DJ				Zhu, ZW; Thiele, DJ			A specialized nucleosome modulates transcription factor access to a C-glabrata metal responsive promoter	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; MICROCOCCAL NUCLEASE; GENE-EXPRESSION; CORE PARTICLE; DNA; MECHANISM; ELEMENTS; OXYGEN; SITES	The ability of DNA binding transcription factors to access cis-acting promoter elements is critical for transcriptional responses. We demonstrate that rapid transcriptional autoactivation by the Amt1 Cu metalloregulatory transcription factor from the opportunistic pathogenic yeast Candida glabrata is dependent on rapid metal-induced DNA binding to a single metal response element (MRE). In vivo footprinting and chromatin-mapping experiments demonstrate that the MRE and a homopolymeric (dA . dT) element adjacent to the MRE are packaged into a positioned nucleosome that exhibits homopolymeric (dA . dT)-dependent localized distortion. This distortion is critical for rapid Amt1 binding to the MRE, for Cu-dependent AMT1 gene transcription, and for C. glabrata cells to mount a rapid transcriptional response to Cu for normal metal detoxification. The AMT1 promoter represents a novel class of specialized nucleosomal structures that links rapid transcriptional responses to the biology of metal homeostasis.			Zhu, ZW (corresponding author), UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041840, F32GM017067] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41840, F32 GM17067] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERNARDI F, 1991, YEAST, V7, P547, DOI 10.1002/yea.320070603; COMPANY M, 1988, MOL CELL BIOL, V8, P2545, DOI 10.1128/MCB.8.6.2545; Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GANTER B, 1993, J MOL BIOL, V234, P975, DOI 10.1006/jmbi.1993.1652; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Koch KA, 1996, MOL CELL BIOL, V16, P724; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LU Q, 1995, EMBO J, V14, P4738, DOI 10.1002/j.1460-2075.1995.tb00155.x; MCGHEE JD, 1983, CELL, V32, P1205, DOI 10.1016/0092-8674(83)90303-3; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PEREZORTIN JE, 1987, NUCLEIC ACIDS RES, V15, P6937; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; PUHL HL, 1991, J MOL BIOL, V222, P1149, DOI 10.1016/0022-2836(91)90598-Z; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SABOVA L, 1993, EUR J BIOCHEM, V213, P547, DOI 10.1111/j.1432-1033.1993.tb17793.x; SHOPLAND LS, 1995, GENE DEV, V9, P2756, DOI 10.1101/gad.9.22.2756; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; ZHOU PB, 1993, GENE DEV, V7, P1824, DOI 10.1101/gad.7.9.1824; ZHOU PB, 1992, MOL CELL BIOL, V12, P3766, DOI 10.1128/MCB.12.9.3766; ZHU ZW, 1995, GENETIC RESPONSE TO METALS, P379; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	46	83	84	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					459	470		10.1016/S0092-8674(00)81366-5	http://dx.doi.org/10.1016/S0092-8674(00)81366-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898199	Bronze			2022-12-28	WOS:A1996VQ46600012
J	Mabey, D				Mabey, D			Importance of clinical trials in developing countries	LANCET			English	Editorial Material											Mabey, D (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.			Mabey, David/0000-0002-0031-8276				[Anonymous], 1972, LANCET, Vi, P1079; BLUESTONE CD, 1985, PEDIATR INFECT DIS J, V4, P607, DOI 10.1097/00006454-198511000-00001; DECOCK KM, 1995, BRIT MED J, V311, P860, DOI 10.1136/bmj.311.7009.860; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; WHITTLE HC, 1973, BMJ-BRIT MED J, V3, P379, DOI 10.1136/bmj.3.5876.379	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1113	1114		10.1016/S0140-6736(05)65268-3	http://dx.doi.org/10.1016/S0140-6736(05)65268-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888161				2022-12-28	WOS:A1996VP10600005
J	BenTovim, DI				BenTovim, DI			Is big still beautiful in Polynesia?	LANCET			English	Editorial Material							ADOLESCENT GIRLS; WEIGHT				BenTovim, DI (corresponding author), REPATRIAT GEN HOSP, DEPT PSYCHIAT, DAW PK, SA 5041, AUSTRALIA.							Craig PL, 1996, NEW ZEAL MED J, V109, P200; Hoek Hans Wijbrand, 1993, International Review of Psychiatry, V5, P61, DOI 10.3109/09540269309028295; KILLEN JD, 1994, INT J EAT DISORDER, V16, P227, DOI 10.1002/1098-108X(199411)16:3&lt;227::AID-EAT2260160303&gt;3.0.CO;2-L; KILLEN JD, 1993, INT J EAT DISORDER, V13, P369, DOI 10.1002/1098-108X(199305)13:4&lt;369::AID-EAT2260130405&gt;3.0.CO;2-0; Rodin J, 1984, Nebr Symp Motiv, V32, P267; STICE E, 1994, J ABNORM PSYCHOL, V103, P836, DOI 10.1037/0021-843X.103.4.836; WILKINSON JY, 1994, INT J OBESITY, V18, P602	7	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	1996	348	9034					1047	1048		10.1016/S0140-6736(05)64412-1	http://dx.doi.org/10.1016/S0140-6736(05)64412-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VM886	8874453				2022-12-28	WOS:A1996VM88600006
J	King, M; Elliott, C				King, M; Elliott, C			Averting a world food shortage: Tighten your belts for CAIRO II	BRITISH MEDICAL JOURNAL			English	Article								We are going to have to eat what the world will produce with all its failings, not what it could produce without them. Trends in global food production are therefore all important. These are now giving cause for anxiety, in that the rate of increase of global grain yields has been slowing seriously. Locally, the food security of some demographically trapped communities is so dire that, like China, they need one child families. The 1994 Cairo population conference (Cairo I) took future food supplies for granted and took no account of demographic entrapment: the conference should be recalled urgently as CAIRO II.	UNIV LEEDS,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds								ALEXANDRATOS N, 1996, WORLD AGR 2010 FAO S; Dyson T, 1996, POPULATION FOOD GLOB; *GOV MAL, 1993, SIT AN POV MAL; King M, 1996, NATL MED J INDIA, V9, P130; KING MH, 1995, HLTH POLICY PLANN, V100, P376; MCINTOSH CA, 1995, POPUL DEV REV, V21, P223, DOI 10.2307/2137493; Sen Gita, 1994, POPULATION POLICIES; 1996, FOOD OUTLOOK, V5, P3	8	6	6	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					995	997						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892423	Green Published			2022-12-28	WOS:A1996VN91600029
J	Bone, RC				Bone, RC			Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS)	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TUMOR-NECROSIS-FACTOR; PLACEBO-CONTROLLED TRIAL; GROWTH-FACTOR-BETA; IMMUNOSUPPRESSED TRAUMA PATIENTS; RESPIRATORY-DISTRESS SYNDROME; INTERLEUKIN-6 IL-6 PRODUCTION; MULTICENTER CLINICAL-TRIAL; HUMAN MONOCLONAL-ANTIBODY; GRAM-NEGATIVE BACTEREMIA; CRITICALLY ILL PATIENTS	Our current understanding of sepsis and multiple organ dysfunction needs to be revised, as the uniformly negative results of new therapies for these disorders suggest. Previous theories for the pathogenesis of these conditions are incomplete; reasons for this include the following. First, the surrogate models that have been used to study these disorders are not analogous to the clinical situation. Second, patients who have less severe manifestations of these diseases are often overlooked. And third, patients' preexisting conditions have not been taken into account. Considerable new evidence indicates that, in addition to a massive proinflammatory reaction, a compensatory antiinflammatory response contributes to the onset of these disorders. At a local site of injury or infection and during the initial appearance of pro- and anti-inflammatory mediators in the circulation, the beneficial effects of these mediators outweigh their harmful effects. Only when the balance between these two forces is lost do these mediators become harmful. Sequelae of an unbalanced systemic proinflammatory reaction include shock, transudation into organs, and defects in coagulation. An unbalanced systemic compensatory anti-inflammatory response can result in anergy and immunosuppression. The proinflammatory and anti-inflammatory forces may ultimately reinforce each other, creating a state of increasingly destructive immunologic dissonance.			Bone, RC (corresponding author), RUSH MED COLL, RUSH PRESBYTERIAN ST LUKES MED CTR, OFF DEAN, 600 S PAULINA, SUITE 202, CHICAGO, IL 60612 USA.							ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; ABRAHAM E, 1986, CRIT CARE MED, V14, P81, DOI 10.1097/00003246-198602000-00001; ABRAHAM E, 1991, CRIT CARE MED, V19, P613, DOI 10.1097/00003246-199105000-00007; ASHBAUGH DG, 1967, LANCET, V2, P319; BALK RA, 1988, CRIT CARE MED, V16, P1121, DOI 10.1097/00003246-198811000-00008; BAUE AE, 1975, ARCH SURG-CHICAGO, V110, P779; BAUMGARTNER JD, 1985, LANCET, V2, P59; BOBER LA, 1995, IMMUNOPHARMACOLOGY, V29, P111, DOI 10.1016/0162-3109(94)00050-P; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; BONE RC, 1996, JAMA-J AM MED ASSOC, V276, P7; BORDER JR, 1976, SURG CLIN N AM, V56, P1147; BROWDER W, 1990, ANN SURG, V211, P605; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; BRUNET F, 1995, AM J RESP CRIT CARE, V151, P1269; BRUSERUD O, 1995, LEUKEMIA RES, V19, P15, DOI 10.1016/0145-2126(94)00062-F; BURKE JF, 1963, ANN SURG, V158, P581, DOI 10.1097/00000658-196310000-00008; CALANDRA T, 1988, J INFECT DIS, V158, P312, DOI 10.1093/infdis/158.2.312; CANNON JG, 1992, CRIT CARE MED, V20, P1414, DOI 10.1097/00003246-199210000-00009; CHANTRY D, 1989, J IMMUNOL, V142, P4295; CHEADLE WG, 1989, IMMUNE CONSEQUENCES, P119; CHRISTOU NV, 1979, J SURG RES, V26, P355, DOI 10.1016/0022-4804(79)90020-9; CIPOLLE MD, 1993, CRIT CARE CLIN, V9, P261, DOI 10.1016/S0749-0704(18)30196-9; CLOWES GHA, 1968, ANN SURG, V167, P630, DOI 10.1097/00000658-196805000-00003; COMETTA A, 1992, NEW ENGL J MED, V327, P234; CONSTANTIAN MB, 1977, ANN SURG, V185, P73, DOI 10.1097/00000658-197701000-00012; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; DHAINAUT JFA, 1994, CRIT CARE MED, V22, P1720, DOI 10.1097/00003246-199422110-00005; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; DOFFERHOFF ASM, 1992, CRIT CARE MED, V20, P185, DOI 10.1097/00003246-199202000-00007; EISEMAN B, 1977, SURG GYNECOL OBSTET, V144, P323; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; FAIST E, 1992, SURGERY, V112, P562; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CJ, 1993, CRIT CARE MED, V21, P318, DOI 10.1097/00003246-199303000-00006; FORD HR, 1989, ARCH SURG-CHICAGO, V124, P1422; Freeman B.D., 1995, CURR OPIN CRIT CARE, V1, P349; FRY DE, 1980, ARCH SURG-CHICAGO, V115, P136; FUKUSHIMA R, 1994, CRIT CARE MED, V22, P114, DOI 10.1097/00003246-199401000-00022; GIBBONS RA, 1989, CLIN EXP IMMUNOL, V75, P371; GIRARDIN E, 1992, J INFECT DIS, V165, P695, DOI 10.1093/infdis/165.4.695; GOMEZJIMENEZ J, 1995, CRIT CARE MED, V23, P253, DOI 10.1097/00003246-199502000-00009; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HAIRE WD, 1995, JAMA-J AM MED ASSOC, V274, P1289, DOI 10.1001/jama.274.16.1289; HAMILTON G, 1992, SCAND J INFECT DIS, V24, P361, DOI 10.3109/00365549209061344; IBBOTSON GC, 1989, PROSTAG OTH LIPID M, V37, P237, DOI 10.1016/0090-6980(89)90060-9; KEOGH C, 1990, ARCH SURG-CHICAGO, V125, P79; KUPPER TS, 1986, SURGERY, V100, P409; LEHMANN AK, 1995, INFECT IMMUN, V63, P2109, DOI 10.1128/IAI.63.6.2109-2112.1995; LESER HG, 1991, GASTROENTEROLOGY, V101, P782, DOI 10.1016/0016-5085(91)90539-W; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LIVINGSTON DH, 1988, ARCH SURG-CHICAGO, V123, P1309; MALEFYT RD, 1991, J EXP MED, V174, P915; MARANO MA, 1990, SURG GYNECOL OBSTET, V170, P32; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001; MCCUTCHAN JA, 1983, SCHWEIZ MED WOCHEN S, V113, P40; MEDURI GU, 1995, CHEST, V108, P1303, DOI 10.1378/chest.108.5.1303; MILLERGRAZIANO CL, 1990, J TRAUMA, V30, pS86; MILLS CD, 1989, J CLIN IMMUNOL, V9, P139, DOI 10.1007/BF00916942; MIYAUCHI T, 1990, CIRCULATION, V81, P1874, DOI 10.1161/01.CIR.81.6.1874; Moore F A, 1993, New Horiz, V1, P538; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; NINNEMANN JL, 1982, J TRAUMA, V22, P837, DOI 10.1097/00005373-198210000-00006; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; PERL TM, 1995, JAMA-J AM MED ASSOC, V274, P338, DOI 10.1001/jama.274.4.338; PETRAK RA, 1989, CRIT CARE CLIN, V5, P303; PETTY TL, 1971, CHEST, V60, P233, DOI 10.1378/chest.60.3.233; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; PLATZER C, 1995, INT IMMUNOL, V7, P517, DOI 10.1093/intimm/7.4.517; POLK HC, 1977, SURGERY, V81, P310; POS O, 1990, CLIN EXP IMMUNOL, V82, P579; PUREN AJ, 1995, CHEST, V107, P1342, DOI 10.1378/chest.107.5.1342; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; REMICK DG, 1995, J CRIT CARE, V10, P198, DOI 10.1016/0883-9441(95)90011-X; RINALDO JE, 1990, AM J RESP CELL MOL, V3, P207, DOI 10.1165/ajrcmb/3.3.207; ROTHE G, 1988, NATURWISSENSCHAFTEN, V75, P354, DOI 10.1007/BF00368326; SAUDER DN, 1986, J INVEST DERMATOL, V87, P711, DOI 10.1111/1523-1747.ep12456681; SIGURDSSON GH, 1992, CRIT CARE MED, V20, P458, DOI 10.1097/00003246-199204000-00005; SKILLMAN JJ, 1969, ANN SURG, V170, P122, DOI 10.1097/00000658-196907000-00013; STEPHENS KE, 1988, AM REV RESPIR DIS, V137, P1364, DOI 10.1164/ajrccm/137.6.1364; STRIETER RM, 1993, CRIT CARE MED, V21, pS447, DOI 10.1097/00003246-199310001-00006; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; SYRBE U, 1994, SEPSIS CURRENT PERSP, P473; SZABO G, 1991, J CLIN IMMUNOL, V11, P326, DOI 10.1007/BF00918798; SZABO G, 1991, J CLIN IMMUNOL, V11, P336, DOI 10.1007/BF00918799; TILNEY NL, 1973, ANN SURG, V178, P117, DOI 10.1097/00000658-197308000-00001; TRACEY KJ, 1988, AM REV RESPIR DIS, V138, P1377, DOI 10.1164/ajrccm/138.6.1377; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; WAKEFIELD CH, 1993, BRIT J SURG, V80, P205, DOI 10.1002/bjs.1800800224; WANG P, 1992, SURGERY, V112, P451; WANG P, 1992, J SURG RES, V52, P364, DOI 10.1016/0022-4804(92)90117-I; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; ZUCKERMAN SH, 1989, INFECT IMMUN, V57, P3009, DOI 10.1128/IAI.57.10.3009-3013.1989	101	520	664	1	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					680	687		10.7326/0003-4819-125-8-199610150-00009	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM889	8849154				2022-12-28	WOS:A1996VM88900011
J	Raoult, D; Fournier, PE; Drancourt, M; Marrie, TJ; Etienne, J; Cosserat, J; Cacoub, P; Poinsignon, Y; Leclercq, P; Sefton, AM				Raoult, D; Fournier, PE; Drancourt, M; Marrie, TJ; Etienne, J; Cosserat, J; Cacoub, P; Poinsignon, Y; Leclercq, P; Sefton, AM			Diagnosis of 22 new cases of Bartonella endocarditis	ANNALS OF INTERNAL MEDICINE			English	Article						Bartonella infection; endocarditis, bacterial; Bartonella henselae; Bartonella quintana; alcoholism	CULTURE-NEGATIVE ENDOCARDITIS; HUMAN-IMMUNODEFICIENCY-VIRUS; CAT-SCRATCH DISEASE; ROCHALIMAEA-HENSELAE; BACILLARY ANGIOMATOSIS; INFECTIVE ENDOCARDITIS; TRENCH FEVER; SP-NOV; QUINTANA; IDENTIFICATION	Background: Bartonella species are emerging pathogens that are seldom reported as a cause of blood culture-negative endocarditis. Objective: To report the occurrence of, risk factors for, and clinical features of Bartonella endocarditis and to evaluate the diagnostic tools available for this condition. Design: Case series and comparison with past series. Setting: Multicenter international study in Halifax, Nova Scotia, Canada; Lyon, France; and Marseille, France. Patients: 22 patients from France, England, Canada, and South Africa were investigated for blood culture-negative endocarditis. Measurements: Titer of antibodies to Bartonella species by microimmunofluorescence assay, blood or vegetation culture, and amplification of Bartonella DNA from valvular tissue by polymerase chain reaction. Cross-adsorption was done for patients with antibodies to Chlamydia species. Results: 22 patients had definite endocarditis. Five were infected with B. quintana, 4 with B. henselae, and 13 with an undetermined Bartonella species. These cases were compared with the 11 previously reported cases. Of the patients with the newly reported cases, 19 had valvular surgery and 6 died. Nine were homeless, 11 were alcoholic, 4 owned cats, and 13 had preexisting valvular heart disease. Bartonella species caused 3% of the cases of endocarditis seen in the three study centers. The patients with these cases could have previously received a diagnosis of chlamydial endocarditis because of apparently high levels of cross-reacting antibodies to Chlamydia species. Conclusions: Bartonella species are an important cause of blood culture-negative endocarditis and can be identified by culture, serologic studies, or molecular biology techniques. Alcoholism and homelessness without previous valvular heart disease are risk factors for B. quintana infection but not for infection with other Bartonella species.	VICTORIA GEN HOSP, DEPT MED, DIV INFECT DIS, HALIFAX, NS 83H 2Y9, CANADA; HOP LOUIS PRADEL, BACTERIOL LAB, F-69500 LYON, FRANCE; CTR MED CHIRURG FOCH, SERV MED INTERNE, F-92151 SURESNES, FRANCE; GRP HOSP PITIE SALPETRIERE, SERV MED INTERNE, F-75651 PARIS 13, FRANCE; HOP ST LOUIS, SERV MED INTERNE & PATHOL VASC, F-75475 PARIS 10, FRANCE; CHU GRENOBLE, CLIN MED & MALAD INFECT, F-38043 GRENOBLE 09, FRANCE; UNIV LONDON LONDON HOSP, COLL MED, DEPT MED MICROBIOL, LONDON E1 2AD, ENGLAND	Dalhousie University; University of Victoria; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); University of London; University College London	Raoult, D (corresponding author), FAC MED MARSEILLE, CNRS, EPJ0054, UNITE RICKETTSIES, 27 BLVD JEAN MOULIN, F-13385 MARSEILLE 05, FRANCE.		ETIENNE, Jerome/C-5471-2014; Fournier, Pierre-Edouard/AAC-6155-2021; RAOULT, Didier/A-8434-2008	ETIENNE, Jerome/0000-0002-3348-3315; Fournier, Pierre-Edouard/0000-0001-8463-8885; RAOULT, Didier/0000-0002-0633-5974; Cacoub, Patrice/0000-0002-6727-4992				BIRTLES RJ, 1995, INT J SYST BACTERIOL, V45, P1, DOI 10.1099/00207713-45-1-1; COOPER MD, 1976, J INFECT DIS, V134, P605, DOI 10.1093/infdis/134.6.605; DALY JS, 1993, J CLIN MICROBIOL, V31, P872, DOI 10.1128/JCM.31.4.872-881.1993; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; DRANCOURT M, 1995, NEW ENGL J MED, V332, P419, DOI 10.1056/NEJM199502163320702; Drancourt M, 1996, LANCET, V347, P441, DOI 10.1016/S0140-6736(96)90012-4; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; ETIENNE J, 1992, EUR HEART J, V13, P1422, DOI 10.1093/oxfordjournals.eurheartj.a060077; HADFIELD TL, 1993, HUM PATHOL, V24, P1140, DOI 10.1016/0046-8177(93)90196-N; HOLMES AH, 1995, CLIN INFECT DIS, V21, P1004, DOI 10.1093/clinids/21.4.1004; JALAVA J, 1995, CLIN INFECT DIS, V21, P891, DOI 10.1093/clinids/21.4.891; JOBLET C, 1995, J CLIN MICROBIOL, V33, P1879, DOI 10.1128/JCM.33.7.1879-1883.1995; KNOBLOCH J, 1988, AM J TROP MED HYG, V39, P427, DOI 10.4269/ajtmh.1988.39.427; KOEHLER JE, 1993, CLIN INFECT DIS, V17, P612, DOI 10.1093/clinids/17.4.612; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; Mainardi J. L., 1996, Clin Microbiol Infect, V1, P275; MARRIE TJ, 1990, J INFECT DIS, V161, P127, DOI 10.1093/infdis/161.1.127; MAURIN M, 1993, J ANTIMICROB CHEMOTH, V32, P587, DOI 10.1093/jac/32.4.587; MAURIN M, 1994, J CLIN MICROBIOL, V32, P1166, DOI 10.1128/JCM.32.5.1166-1171.1994; MUSSO D, 1995, J ANTIMICROB CHEMOTH, V36, P101, DOI 10.1093/jac/36.1.101; PESANTI EL, 1979, AM J MED, V66, P43, DOI 10.1016/0002-9343(79)90480-7; RAOULT D, 1995, CLIN INFECT DIS, V20, P489, DOI 10.1093/clinids/20.3.489; RAOULT D, 1994, CLIN INFECT DIS, V19, P355, DOI 10.1093/clinids/19.2.355; RAOULT D, 1994, LANCET, V343, P977, DOI 10.1016/S0140-6736(94)90102-3; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; REGNERY RL, 1991, J BACTERIOL, V173, P1576, DOI 10.1128/jb.173.5.1576-1589.1991; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; RELMAN DA, 1995, NEW ENGL J MED, V332, P463, DOI 10.1056/NEJM199502163320710; ROUX V, 1995, J CLIN MICROBIOL, V33, P1573, DOI 10.1128/JCM.33.6.1573-1579.1995; SPACH DH, 1995, NEW ENGL J MED, V332, P424, DOI 10.1056/NEJM199502163320703; SPACH DH, 1995, CLIN INFECT DIS, V20, P1044, DOI 10.1093/clinids/20.4.1044; SPACH DH, 1993, J CLIN MICROBIOL, V31, P692, DOI 10.1128/JCM.31.3.692-694.1993; STEIN A, 1995, LANCET, V345, P450, DOI 10.1016/S0140-6736(95)90430-1; STEIN A, 1992, NUCLEIC ACIDS RES, V20, P5237, DOI 10.1093/nar/20.19.5237; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; TIERNO PM, 1995, AM J CLIN PATHOL, V104, P530; VANSCOY RE, 1982, MAYO CLIN PROC, V57, P149; WATANAKUNAKORN C, 1993, MEDICINE, V72, P90, DOI 10.1097/00005792-199303000-00003; WEISS E, 1975, APPL MICROBIOL, V30, P456, DOI 10.1128/AEM.30.3.456-463.1975; WONG MT, 1995, CLIN INFECT DIS, V21, P352, DOI 10.1093/clinids/21.2.352	41	271	281	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					646	+		10.7326/0003-4819-125-8-199610150-00004	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM889	8849149				2022-12-28	WOS:A1996VM88900006
J	Ashby, D				Ashby, D			Can iron supplementation improve cognitive functioning?	LANCET			English	Editorial Material									UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool	Ashby, D (corresponding author), UNIV LIVERPOOL,DEPT MATH SCI,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							BENTON D, 1988, LANCET, V1, P140; LEWIS JA, 1993, BRIT J CANCER, V68, P647, DOI 10.1038/bjc.1993.402; MURRAY GD, 1991, BRIT J SURG, V78, P777, DOI 10.1002/bjs.1800780704	3	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					973	973		10.1016/S0140-6736(05)64919-7	http://dx.doi.org/10.1016/S0140-6736(05)64919-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855847				2022-12-28	WOS:A1996VM02700003
J	Love, SM; Barsky, SH				Love, SM; Barsky, SH			Breast-duct endoscopy to study stages of cancerous breast disease	LANCET			English	Article							NIPPLE DISCHARGE	Background In breast-cancer research, we lack reproducible non-invasive access to breast tissue. Breast cancer is thought to start in the lining of the milk duct or lobule. We have had no direct access to this area other than in tissue removed surgically or by fine-needle aspiration. Our objective was to explore an intraductal approach to studying breast cancer and precancerous changes by duct cannulation and endoscopy. Methods In this pilot study, women in a university hospital were asked to participate. Nine patients with previously diagnosed ductal carcinoma-in-situ (DCIS) or invasive breast cancer who were about to undergo mastectomy under general anaesthesia agreed. After the patient was asleep but before the operation, we spent 15 minutes cannulating their ducts, obtaining washings, and attempting endoscopy. The ducts that had been cannulated were marked by instillation of dye or other materials, the nipple was sutured shut, and the mastectomy proceeded as planned. The mastectomy specimen underwent extensive histopathological examination. Findings We were successful in intraductal cannulation and endoscopy in seven of the nine patients, In five of the nine, we obtained epithelial cells in the washings. In one the cells were consistent with proliferative disease, in three there was atypical epithelium, and in one there was frank DCIS. With several different contrast materials injected into separate duct orifices, DCIS was confined to a single duct system. Interpretation We found that the intraductal approach is feasible for the study of the early changes of breast cancer. Technical difficulties include identification of the breast-duct orifices, determining the distensibility of the duct, and developing a reliable technique to obtain washings.	UNIV CALIF LOS ANGELES,DEPT SURG,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NCI NIH HHS [CA01351, CA40225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040225] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		FABIAN C, 1993, P AM ASSOC CANC RES, V34, pA1556; LVOE SM, 1992, 15 ANN SAN ANT BREAS; MAKITA M, 1991, BREAST CANCER RES TR, V18, P179, DOI 10.1007/BF01990034; OHTAKE T, 1995, CANCER, V76, P32, DOI 10.1002/1097-0142(19950701)76:1<32::AID-CNCR2820760106>3.0.CO;2-R; OKAZAKI A, 1991, JPN J CLIN ONCOL, V21, P188; Sartorius OW, 1977, BREAST CARCINOMA, P281; WRENSCH MR, 1991, AM J EPIDEMIOL, V135, P130	7	67	90	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					997	999		10.1016/S0140-6736(96)04145-1	http://dx.doi.org/10.1016/S0140-6736(96)04145-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855857				2022-12-28	WOS:A1996VM02700013
J	Smith, GD; Phillips, AN				Smith, GD; Phillips, AN			Passive smoking and health: Should we believe Philip Morris's ''experts''?	BRITISH MEDICAL JOURNAL			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; LUNG-CANCER; CORRELATED EXPOSURES; CIGARETTE-SMOKE; RISK; EPIDEMIOLOGY; INHALATION; BIAS		UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Smith, GD (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND.		Phillips, Andrew N/B-4427-2008; Davey Smith, George/A-7407-2013	Phillips, Andrew N/0000-0003-2384-4807; Davey Smith, George/0000-0002-1407-8314				BERO LA, 1994, JAMA-J AM MED ASSOC, V272, P133, DOI 10.1001/jama.272.2.133; Blair PS, 1996, BRIT MED J, V313, P195, DOI 10.1136/bmj.313.7051.195; Boffetta P, 1996, LANCET, V348, P410, DOI 10.1016/S0140-6736(05)65031-3; BORLAND R, 1990, AM J PUBLIC HEALTH, V80, P178, DOI 10.2105/AJPH.80.2.178; CHAPMAN S, 1990, INT J HLTH SERV, V20, P117; Charlton A, 1996, BRIT MED BULL, V52, P90, DOI 10.1093/oxfordjournals.bmb.a011535; Ciruzzi M., 1996, European Heart Journal, V17, P309; COOPER G, 1996, INDEPENDENT     0828, P3; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; *EUR WORK GRP, 1996, ENV TOB SMOK LUNG CA; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; Glantz S.A., 1996, CIGARETTE PAPERS; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; HECHT SS, 1993, NEW ENGL J MED, V329, P1543, DOI 10.1056/NEJM199311183292105; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; Howard G, 1996, BRIT MED BULL, V52, P143, DOI 10.1093/oxfordjournals.bmb.a011522; KULLER LH, 1991, PREV MED, V20, P638, DOI 10.1016/0091-7435(91)90060-H; Law MR, 1996, BRIT MED BULL, V52, P22, DOI 10.1093/oxfordjournals.bmb.a011528; Lee PN, 1996, STAT MED, V15, P581, DOI 10.1002/(SICI)1097-0258(19960330)15:6<581::AID-SIM182>3.0.CO;2-B; LEE PN, 1995, INT ARCH OCC ENV HEA, V67, P287, DOI 10.1007/BF00385642; LEE PN, 1987, HUM TOXICOL, V6, P517, DOI 10.1177/096032718700600612; LEE PN, 1992, ENV TOBACCO SMOKE MO; LEMARCHAND L, 1991, CANCER CAUSE CONTROL, V2, P11, DOI 10.1007/BF00052356; *OFF HLTH ENV ASS, 1992, RESP HLTH EFF PASS S; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PENN A, 1993, CIRCULATION, V88, P1820, DOI 10.1161/01.CIR.88.4.1820; PENN A, 1994, CIRCULATION, V90, P1363, DOI 10.1161/01.CIR.90.3.1363; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; Proctor RN, 1995, CANC WARS POLITICS S; RICHMOND C, 1996, OBSERVER        0818, P2; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; Smith GD, 1996, BMJ-BRIT MED J, V312, P1659, DOI 10.1136/bmj.312.7047.1659; SMITH GD, 1992, LANCET, V340, P709; Smith GD, 1996, BRIT MED J, V312, P1479, DOI 10.1136/bmj.312.7044.1479c; STRACHAN DP, 1989, BRIT MED J, V298, P1549, DOI 10.1136/bmj.298.6687.1549; TRICHOPOULOS D, 1992, JAMA-J AM MED ASSOC, V268, P1697, DOI 10.1001/jama.268.13.1697; WOLFF S, 1989, SCIENCE, V245, P575, DOI 10.1126/science.2762808; WOLFF S, 1989, SCIENCE, V245, P621; 1994, NEW ENGL J MED, V330, P1029	41	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					929	933						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876102				2022-12-28	WOS:A1996VM75400034
J	Dikic, I; Tokiwa, G; Lev, S; Courtneidge, SA; Schlessinger, J				Dikic, I; Tokiwa, G; Lev, S; Courtneidge, SA; Schlessinger, J			A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation	NATURE			English	Article							TYROSINE-KINASE; SIGNALING PATHWAY; BINDING; DOMAIN	THE mechanisms by which mitogenic G-protein-coupled receptors activate the MAP kinase signalling pathway are poorly understood. Candidate protein tyrosine kinases that link G-protein-coupled receptors with MAP kinase include Src family kinases(1), the epidermal growth factor receptor(2), Lyn and Syk(3). Here we show that lysophosphatidic acid (LPA) and bradykinin induce tyrosine phosphorylation of Pyk2 and complex formation between Pyk2 and activated Src. Moreover, tyrosine phosphorylation of Pyk2 Leads to binding of the SH2 domain of Src to tyrosine 402 of Pyk2 and activation of Src. Transient overexpression of a dominant interfering mutant of Pyk2 or the protein tyrosine kinase Csk reduces LPA- or bradykinin-induced activation of MAP kinase. LPA- or bradykinin-induced MAP kinase activation was also inhibited by overexpression of dominant interfering mutants of Grb2 and Sos. We propose that Pyk2 acts with Src to link G(i)- and G(q)-coupled receptors with Grb2 and Sos to activate the MAP kinase signalling pathway in PC12 cells.	NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; SUGEN INC,REDWOOD CITY,CA 94063	New York University			Dikic, Ivan/O-4650-2015; Lev, Sima/AAP-7880-2020	Dikic, Ivan/0000-0001-8156-9511; Lev, Sima/0000-0002-2108-3330				Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIU XQ, 1993, ONCOGENE, V8, P1119; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SONGYANG Z, 1993, CELL, V72, P76; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717	18	868	891	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					547	550		10.1038/383547a0	http://dx.doi.org/10.1038/383547a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849729				2022-12-28	WOS:A1996VL75500056
J	Briner, RB				Briner, RB			ABC of work related disorders - Absence from work	BRITISH MEDICAL JOURNAL			English	Article									GUYS & ST THOMAS HOSP,NHS TRUST,OCCUPAT HLTH SERV,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	Briner, RB (corresponding author), UNIV LONDON,BIRKBECK COLL,DEPT ORG PSYCHOL,LONDON WC1H 0PP,ENGLAND.							FITZGIBBONS D. E., 1992, RES PERSONNEL HUMAN, V10, P73; HODGSON JT, 1993, SELF REPORTED WORK R; Huczynski A. A., 1989, MANAGING EMPLOYEE AB; Johns G., 1987, CANADIAN READINGS PE, P324	4	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					874	877						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870582				2022-12-28	WOS:A1996VL55900035
J	Sabatini, BL; Regehr, WG				Sabatini, BL; Regehr, WG			Timing of neurotransmission at fast synapses in the mammalian brain	NATURE			English	Article							SQUID GIANT SYNAPSE; PRESYNAPTIC TERMINALS; CALCIUM TRANSIENTS; SENSORY NEURONS; PARALLEL FIBERS; TRANSMISSION; CURRENTS; FURA-2; RAT; EXOCYTOSIS	UNDERSTANDING the factors controlling synaptic delays has broad implications. On a systems level, the speed of synaptic transmission limits the communication rate between neurons and strongly influences local circuit dynamics(1,2). On a molecular level, the delay from presynaptic calcium entry to postsynaptic responses constrains the molecular mechanism of vesicle fusion(3). Previously it has not been possible to elucidate the determinants of synaptic delays in the mammalian central nervous system, where presynaptic terminals are small and difficult to study. We have developed a new approach to study timing at rat cerebellar synapses: we used optical techniques to measure voltage and calcium current simultaneously from presynaptic boutons while monitoring postsynaptic currents electrically(4-6). Here we report that the classic view that vesicle release is driven by calcium entry during action-potential repolarization(7) holds for these synapses at room temperature, but not at physiological temperatures, where postsynaptic responses commence just 150 mu s after the start of the presynaptic action potential. This brisk communication is a consequence of rapid calcium channel kinetics, which allow significant calcium entry during the upstroke of the presynaptic action potential, and extremely fast calcium-driven vesicle fusion, which lags behind calcium influx by 60 mu s.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								APPENTENG K, 1989, J PHYSIOL-LONDON, V417, P91, DOI 10.1113/jphysiol.1989.sp017792; Atluri PP, 1996, J NEUROSCI, V16, P5661; AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P163, DOI 10.1113/jphysiol.1985.sp015819; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; DELBONO O, 1993, J PHYSIOL-LONDON, V463, P689, DOI 10.1113/jphysiol.1993.sp019617; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HODGKIN AL, 1949, J PHYSIOL-LONDON, V109, P240, DOI 10.1113/jphysiol.1949.sp004388; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; Kandel E.R., 1991, PRINC NEUROSCI, V3rd ed.; KAO JPY, 1988, BIOPHYS J, V53, P635, DOI 10.1016/S0006-3495(88)83142-4; KOCSIS JD, 1983, J PHYSIOL-LONDON, V334, P225, DOI 10.1113/jphysiol.1983.sp014491; KONNERTH A, 1987, J PHYSIOL-LONDON, V393, P681, DOI 10.1113/jphysiol.1987.sp016848; LLINAS R, 1982, P NATL ACAD SCI-BIOL, V79, P2415, DOI 10.1073/pnas.79.7.2415; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; LOEW LM, 1985, BIOPHYS J, V47, P71, DOI 10.1016/S0006-3495(85)83878-9; MCALLISTERWILLIAMS RH, 1995, NEUROPHARMACOLOGY, V34, P1479, DOI 10.1016/0028-3908(95)00130-X; NEHER E, 1995, NEUROPHARMACOLOGY, V34, P1423, DOI 10.1016/0028-3908(95)00144-U; NOBILE M, 1990, PFLUG ARCH EUR J PHY, V415, P658, DOI 10.1007/BF02584002; OERTEL D, 1983, J NEUROSCI, V3, P2043; Palay S. L., 1974, CEREBELLAR CORTEX CY; PFRIEGER FW, 1992, J NEUROSCI, V12, P4347; REGEHR WG, 1991, J NEUROSCI METH, V37, P111, DOI 10.1016/0165-0270(91)90121-F; REGEHR WG, 1995, BIOPHYS J, V68, P2156, DOI 10.1016/S0006-3495(95)80398-X; SABATINI BL, 1995, NEUROPHARMACOLOGY, V34, P1453, DOI 10.1016/0028-3908(95)00129-T; SCHWEIZER FE, 1995, NEURON, V14, P689, DOI 10.1016/0896-6273(95)90213-9; Stratford KJ, 1996, NATURE, V382, P258, DOI 10.1038/382258a0; TAYLOR WR, 1988, J PHYSIOL-LONDON, V407, P405, DOI 10.1113/jphysiol.1988.sp017423; Wheeler DB, 1996, J NEUROSCI, V16, P2226; Zhao MD, 1996, BIOPHYS J, V70, P896, DOI 10.1016/S0006-3495(96)79633-9	30	290	297	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					170	172		10.1038/384170a0	http://dx.doi.org/10.1038/384170a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906792				2022-12-28	WOS:A1996VT33600066
J	Lindberg, FP; Bullard, DC; Caver, TE; Gresham, HD; Beaudet, AL; Brown, EJ				Lindberg, FP; Bullard, DC; Caver, TE; Gresham, HD; Beaudet, AL; Brown, EJ			Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice	SCIENCE			English	Article							INTEGRIN-ASSOCIATED PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; LEUKOCYTE RESPONSE INTEGRIN; GROWTH-FACTOR-BETA; LIGAND-BINDING; NEUTROPHILS; MODEL; CD47; PROTOONCOGENE; PHAGOCYTOSIS	Granulocyte [polymorphonuclear leucocyte (PMN)] migration to sites of infection and subsequent activation is essential for host defense. Gene-targeted mice deficient for integrin-associated protein (IAP, also termed CD47) succumbed to Escherichia coli peritonitis at inoccula survived by heterozygous littermates. In vivo, they had an early defect in PMN accumulation at the site of infection. In vitro, IAP(-/-) PMNs were deficient in beta(3) integrin-dependent ligand binding, activation oi an oxidative burst, and Fc receptor-mediated phagocytosis. Thus, IAP plays a key role in host defense by participating both in PMN migration in response to bacterial infection and in PMN activation at extravascular sites.	WASHINGTON UNIV, SCH MED, DEPT MOL MICROBIOL, ST LOUIS, MO 63110 USA; BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; UNIV MISSOURI, SCH MED, DEPT MOL MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA; HARRY S TRUMAN VET AFFAIRS MED CTR, RES SERV, COLUMBIA, MO 65201 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Washington University (WUSTL); Baylor College of Medicine; University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital; Baylor College of Medicine; Howard Hughes Medical Institute	Lindberg, FP (corresponding author), WASHINGTON UNIV, SCH MED, DEPT INFECT DIS, ST LOUIS, MO 63110 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032177, R37AI032177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32177] Funding Source: Medline; NIGMS NIH HHS [GM38330, GM15483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; BROWN EJ, 1993, BLOOD CELL BIOCH, V5, P279; BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; CROSS AS, 1989, J EXP MED, V169, P2021, DOI 10.1084/jem.169.6.2021; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GRESHAM HD, 1992, J BIOL CHEM, V267, P13895; GRESHAM HD, 1991, J IMMUNOL, V146, P3911; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; GRIFFIN JA, 1979, J EXP MED, V150, P653, DOI 10.1084/jem.150.3.653; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LINDBERG FP, 1994, J BIOL CHEM, V269, P1567; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LINDBERG FP, UNPUB; LOWRANCE JH, 1994, J EXP MED, V180, P1693, DOI 10.1084/jem.180.5.1693; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; REINHOLD MI, 1995, J CELL SCI, V108, P3419; SARMAN G, 1995, J INFECT DIS, V172, P1001, DOI 10.1093/infdis/172.4.1001; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	27	289	304	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	1996	274	5288					795	798		10.1126/science.274.5288.795	http://dx.doi.org/10.1126/science.274.5288.795			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864123				2022-12-28	WOS:A1996VQ14500048
J	Wang, CY; Mayo, MW; Baldwin, AS				Wang, CY; Mayo, MW; Baldwin, AS			TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappa B	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; GLUCOCORTICOID RECEPTOR; ALPHA PROTEOLYSIS; ACTIVATION; PHOSPHORYLATION; RADIATION; MECHANISM; CERAMIDE; CELLS	Many cells are resistant to stimuli that can induce apoptosis, but the mechanisms involved are not fully understood. The activation of the transcription factor nuclear factor-kappa B (NF-kappa B) by tumor necrosis factor (TNF), ionizing radiation, or daunorubicin (a cancer chemotherapeutic compound), was found to protect from cell killing. Inhibition of NF-kappa B nuclear translocation enhanced apoptotic killing by these reagents but not by apoptotic stimuli that do not activate NF-kappa B. These results provide a mechanism of cellular resistance to killing by some apoptotic reagents, offer insight into a new role for NF-kappa B, and have potential for improvement of the efficacy of cancer therapies.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH DENT,DEPT ENDODONT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [F32CA069790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098, R37AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [1F32-CA69790-01] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DEVITA VT, 1987, CANCER RES, V47, P5810; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRIMM S, 1996, J CELL BIOL, V134, P1; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHARTZMAN RA, 1993, ENDOCR REV, V14, P133; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; SLATER A, 1995, BIOCHEM J, V312, P844; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang C.-W., UNPUB; WU M, 1996, EMBO J, V15, P4662	49	2434	2554	2	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					784	787		10.1126/science.274.5288.784	http://dx.doi.org/10.1126/science.274.5288.784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864119	Green Submitted			2022-12-28	WOS:A1996VQ14500044
J	Kovacs, JA; Vogel, S; Albert, JM; Falloon, J; Davey, RT; Walker, RE; Polis, MA; Spooner, K; Metcalf, JA; Baseler, M; Fyfe, G; Lane, HC				Kovacs, JA; Vogel, S; Albert, JM; Falloon, J; Davey, RT; Walker, RE; Polis, MA; Spooner, K; Metcalf, JA; Baseler, M; Fyfe, G; Lane, HC			Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TYPE-1 INFECTION; HIV-1 PROTEASE; RITONAVIR; INHIBITOR; EFFICACY; PLASMA	Background Interleukin-2 is a cytokine that regulates the proliferation and differentiation of lymphocytes. In preliminary studies, intermittent infusions of interleukin-2 led to increases in CD4 counts in patients with human immunodeficiency virus (HIV) infection and more than 200 CD4 cells per cubic millimeter. We conducted a controlled study to evaluate the long-term effects of such therapy on both CD4 counts and the viral burden. Methods Sixty HIV-infected patients with base-line CD4 counts above 200 cells per cubic millimeter were randomly assigned to receive either interleukin-2 plus antiretroviral therapy (31 patients, 1 of whom was lost to follow-up) or antiretroviral therapy alone (29 patients). Interleukin-2 was administered every two months for six cycles of five days each, starting at a dosage of 18 million IU per day. Safety and immunologic and virologic measures were monitored monthly until four months after the last treatment cycle. Results In patients treated with interleukin-2, the mean (+/-SE) CD4 count increased from 428+/-25 cells per cubic millimeter at base line to 916+/-128 at month 12, whereas in the control group, the mean CD4 count decreased from 406+/-29 cells per cubic millimeter to 349+/-41 (P<0.001). There were no significant differences between the groups in serial measurements of the plasma HIV RNA or p24 antigen concentration during the 12 months of treatment. Constitutional symptoms (fever, malaise, and fatigue) and asymptomatic hyperbilirubinemia were the chief dose-limiting toxic effects of interleukin-2 therapy. Conclusions In patients with HIV infection and base-line CD4 counts above 200 cells per cubic millimeter, intermittent infusions of interleukin-2 produced substantial and sustained increases in CD4 counts with no associated increase in plasma HIV RNA levels. (C) 1996, Massachusetts Medical Society.	NIAID,CTR CLIN,DEPT CRIT CARE MED,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; NIAID,DIV AIDS,BETHESDA,MD 20892; SCI APPLICAT INT CORP,FREDERICK,MD; CHIRON CORP,EMERYVILLE,CA 94608	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Science Applications International Corporation (SAIC); Novartis			Albert, Jeffrey/P-7273-2019; Kovacs, Joseph/AAU-6105-2021	Albert, Jeffrey/0000-0003-2245-1745; Kovacs, Joseph/0000-0002-5191-9880; Polis, Michael/0000-0002-9151-2268				CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; Emery S, 1996, AIDS, V10 Suppl A, pS159, DOI 10.1097/00002030-199601001-00022; FALLOON J, 1995, 35 INT C ANT AG CHEM, P236; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LEDERMAN MM, 1995, ANN INTERN MED, V122, P218, DOI 10.7326/0003-4819-122-3-199502010-00010; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MASSARI F, 1995, 35 INT C ANT AG CHEM; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; SCHWARTZ DH, 1991, J ACQ IMMUN DEF SYND, V4, P11; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STEIN DS, 1993, CLIN INFECT DIS, V17, P749, DOI 10.1093/clinids/17.4.749; TEPPLER H, 1993, J INFECT DIS, V167, P291, DOI 10.1093/infdis/167.2.291; TEPPLER H, 1993, J EXP MED, V177, P483, DOI 10.1084/jem.177.2.483; URDEA MS, 1993, AIDS, V7, pS11, DOI 10.1097/00002030-199311002-00004; VASUDEVACHARI MB, 1993, J CLIN IMMUNOL, V13, P185, DOI 10.1007/BF00919971; 1994, MMWR-MORBID MORTAL W, V43, P1	24	373	385	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1996	335	18					1350	1356		10.1056/NEJM199610313351803	http://dx.doi.org/10.1056/NEJM199610313351803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP484	8857018				2022-12-28	WOS:A1996VP48400003
J	Duff, K; Eckman, C; Zehr, C; Yu, X; Prada, CM; Pereztur, J; Hutton, M; Buee, L; Harigaya, Y; Yager, D; Morgan, D; Gordon, MN; Holcomb, L; Refolo, L; Zenk, B; Hardy, J; Younkin, S				Duff, K; Eckman, C; Zehr, C; Yu, X; Prada, CM; Pereztur, J; Hutton, M; Buee, L; Harigaya, Y; Yager, D; Morgan, D; Gordon, MN; Holcomb, L; Refolo, L; Zenk, B; Hardy, J; Younkin, S			Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin 1	NATURE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; MISSENSE MUTATIONS; TRANSGENIC MICE; A-BETA; GENE; A-BETA-42(43)	MUTATIONS in the genes encoding amyloid-beta precursor protein (APP)(1), presenilin 1 (PS1)(2) and presenilin 2 (PS2)(3,4) are known to cause early-onset, autosomal dominant Alzheimer's disease. Studies of plasma and fibroblasts from subjects with these mutations have established that they all alter amyloid beta-protein (beta APP) processing, which normally leads to the secretion of amyloid-beta protein (relative molecular mass 4,000; M(r) 4K; similar to 90% A beta 1-40, similar to 10% A beta 1-42(43)), so that the extracellular concentration of A beta 42(43) is increased(5). This increase in A beta 42(43) is believed to be the critical change that initiates Alzheimer's disease pathogenesis because A beta 42(43) is deposited early and selectively in the senile plaques that are observed in the brains of patients with all forms of the disease. To establish that the presenilin mutations increase the amount of A beta 42(43) in the brain and to test whether presenilin mutations act as true (gain of function) dominants, we have now constructed mice expressing wild-type and mutant presenilin genes. Analysis of these mice showed that overexpression of mutant, but not wild-type, PS1 selectively increases brain A beta 42(43). These results indicate that the presenilin mutations probably cause Alzheimer's disease through a gain of deleterious function that increases the amount of A beta 42(43) in the brain.	MAYO CLIN JACKSONVILLE,JACKSONVILLE,FL 32224; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,TAMPA,FL 33612; INSERM,U422,F-50945 LILLE,FRANCE; UNIV S FLORIDA,ALZHEIMERS RES LAB,DEPT PHARMACOL,TAMPA,FL 33613	Mayo Clinic; State University System of Florida; University of South Florida; Institut National de la Sante et de la Recherche Medicale (Inserm); State University System of Florida; University of South Florida			Perez-Tur, Jordi/A-2143-2010; Gordon, Marcia N. N/K-2420-2012; BUEE, Luc/B-3126-2010; Morgan, David G/J-5989-2012; Hardy, John/C-2451-2009	Perez-Tur, Jordi/0000-0002-9111-1712; Gordon, Marcia N. N/0000-0002-4051-9283; BUEE, Luc/0000-0002-6261-4230; Hardy, John/0000-0002-3122-0423; Duff, Karen/0000-0002-6177-868X				BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HALTIA M, 1994, ANN NEUROL, V36, P362, DOI 10.1002/ana.410360307; HSIAO K, IN PRESS SCIENCE; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; ODAKA N, 1995, BIOCHEMISTRY-US, V34, P10272; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SUZUKI N, 1994, AM J PATHOL, V145, P452; SUZUKI N, 1994, SCIENCE, V264, P1335; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; 1995, NAT GENET, V11, P219	21	1282	1358	0	51	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					710	713		10.1038/383710a0	http://dx.doi.org/10.1038/383710a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878479				2022-12-28	WOS:A1996VN91800051
J	Grines, CL				Grines, CL			Primary angioplasty - The strategy of choice	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; INTRAVENOUS STREPTOKINASE; IMMEDIATE ANGIOPLASTY; THROMBOLYSIS				Grines, CL (corresponding author), WILLIAM BEAUMONT HOSP, DIV CARDIOL, 3601 W 13 MILE RD, ROYAL OAK, MI 48073 USA.							[Anonymous], 1994, Circulation, V90, P1631; BRODIE B, 1995, J AM COLL CARDIOL, V25, pA5; BRODIE BR, 1994, CIRCULATION, V90, P156, DOI 10.1161/01.CIR.90.1.156; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; ELLIS S, 1996, AM COLL CARD SCI SES; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	12	70	74	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1313	1316						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857014				2022-12-28	WOS:A1996VN59400011
J	Carson, JL				Carson, JL			Effect of anaemia and cardiovascular disease on surgical mortality and morbidity	LANCET			English	Article							CLASSIFICATION-SYSTEM; TRANSFUSION; BLOOD; SEVERITY; RISK	Background Guidelines have been offered on haemoglobin thresholds for blood transfusion in surgical patients. However, good evidence is lacking on the haemoglobin concentrations at which the risk of death or serious morbidity begins to rise and at which transfusion is indicated. Methods A retrospective cohort study was performed in 1958 patients, 18 years and older, who underwent surgery and declined blood tranfusion for religious reasons. The primary outcome was 30-day mortality and the secondary outcome was 30-day mortality or in-hospital 30-day morbidity. Cardiovascular disease was defined as a history of angina, myocardial infarction, congestive heart failure, or peripheral vascular disease. Findings The 30-day mortality was 3.2% (95% CI 2.4-4.0). The mortality was 1.3% (0.8-2.0) in patients with preoperative haemoglobin 12 g/dL or greater and 33.3% (18.6-51.0) in patients with preoperative haemoglobin less than 6 g/dL. The increase in risk of death associated with low preoperative haemoglobin was more pronounced in patients with cardiovascular disease than in patients without (interaction p<0.03). The effect of blood loss on mortality was larger in patients with low preoperative haemoglobin than in those with a higher preoperative haemoglobin (interaction p<0.001). The results were similar in analyses of postoperative haemoglobin and 30-day mortality or in-hospital morbidity. Interpretation A low preoperative haemoglobin or a substantial operative blood loss increases the risk of death or serious morbidity more in patients with cardiovascular disease than in those without. Decisions about transfusion should take account of cardiovascular status and operative blood loss as well as the haemoglobin concentration.	BROWN UNIV,SCH MED,DEPT MED,DIV GEN INTERNAL MED,PROVIDENCE,RI 02912; MEM HOSP RHODE ISL,PAWTUCKET,RI; UNIV PENN,SCH MED,DEPT MED,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR CLIN EPIDEMIOL & BIOSTAT,DEPT BIOSTAT & EPIDEMIOL,PHILADELPHIA,PA 19104; STATEN ISL UNIV HOSP,DEPT SURG,STATEN ISL,NY; RUTGERS STATE UNIV,DEPT STAT,PISCATAWAY,NJ 08855	Brown University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Northwell Health; Rutgers State University New Brunswick	Carson, JL (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MED,DIV GEN INTERNAL MED,NEW BRUNSWICK,NJ 08903, USA.							ANDERSON HT, 1978, SURGERY, V84, P8; BIRKMEYER J, 1993, TRANSFUSION, V33, P644; CARSON JL, 1988, LANCET, V1, P727; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COOPER N, 1974, SURGERY, V75, P508; COUNSELL CE, 1994, BMJ-BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677; CROW RS, 1989, AM J CARDIOL, V64, P454, DOI 10.1016/0002-9149(89)90420-7; DELANEY FM, 1995, CECLUXVF13395 EUR CO; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; FEINBERG SE, 1977, ANAL CROSS CLASSIFIE, P9; Geha A S, 1978, World J Surg, V2, P645; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HAGL S, 1977, BASIC RES CARDIOL, V72, P344, DOI 10.1007/BF02023594; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; LUNN JN, 1970, BRIT MED J, V3, P71, DOI 10.1136/bmj.3.5714.71; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Rawstron R E, 1970, Aust N Z J Surg, V39, P425, DOI 10.1111/j.1445-2197.1970.tb05389.x; *SAS I, 1988, SAS PROC GUID REL 6, P441; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393; WILKERSON DK, 1988, SURGERY, V103, P665; YOSHIKAWA H, 1973, AM J CARDIOL, V32, P670, DOI 10.1016/S0002-9149(73)80061-X; 1988, JAMA-J AM MED ASSOC, V260, P2700	27	659	684	0	23	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1055	1060		10.1016/S0140-6736(96)04330-9	http://dx.doi.org/10.1016/S0140-6736(96)04330-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874456	hybrid			2022-12-28	WOS:A1996VM88600009
J	Vaughan, CJ; Murphy, MB; Buckley, BM				Vaughan, CJ; Murphy, MB; Buckley, BM			Statins do more than just lower cholesterol	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE; HEART-DISEASE; IN-VITRO; HYPERCHOLESTEROLEMIA; PRAVASTATIN; SIMVASTATIN; LOVASTATIN; INHIBITION; CELLS; FLUVASTATIN		NATL UNIV IRELAND UNIV COLL CORK, DEPT PHARMACOL & THERAPEUT, CLIN SCI UNIT, CORK, IRELAND	University College Cork			Murphy, Michael B/A-1310-2011	Murphy, Michael/0000-0001-6722-7080				BADIMON JJ, 1991, ARTERIOSCLER THROMB, V11, P395, DOI 10.1161/01.ATV.11.2.395; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; BUCHWALD H, 1995, J AM COLL CARDIOL, V26, P351, DOI 10.1016/0735-1097(95)80006-3; DELACRETAZ E, 1993, HYPERTENSION, V22, P437; DIMINNO G, 1986, ARTERIOSCLEROSIS, V6, P203, DOI 10.1161/01.ATV.6.2.203; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; EICHSTADT HW, 1995, AM J CARDIOL, V76, pA122, DOI 10.1016/S0002-9149(05)80033-5; GERRITY RG, 1981, AM J PATHOL, V103, P181; GRANDALIANO G, 1993, KIDNEY INT, V44, P503, DOI 10.1038/ki.1993.274; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HIDAKA Y, 1992, ATHEROSCLEROSIS, V95, P87, DOI 10.1016/0021-9150(92)90179-K; KEIDAR S, 1994, BRIT J CLIN PHARMACO, V38, P513, DOI 10.1111/j.1365-2125.1994.tb04392.x; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; LACOSTE L, 1995, CIRCULATION, V92, P3172, DOI 10.1161/01.CIR.92.11.3172; MAYER J, 1992, ANN HEMATOL, V64, P196, DOI 10.1007/BF01696223; MCPHERSON R, 1993, J CLIN IMMUNOL, V13, P439, DOI 10.1007/BF00920019; MUNRO E, 1994, EUR J CLIN INVEST, V24, P766, DOI 10.1111/j.1365-2362.1994.tb01074.x; NOTARBARTOLO A, 1995, ARTERIOSCL THROM VAS, V15, P247, DOI 10.1161/01.ATV.15.2.247; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; ROGLER G, 1995, AM J CARDIOL, V76, pA114; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SANG KHLQ, 1995, ARTERIOSCL THROM VAS, V15, P759, DOI 10.1161/01.ATV.15.6.759; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STRAZNICKY NE, 1995, AM J CARDIOL, V75, P582, DOI 10.1016/S0002-9149(99)80621-3; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; VITA JA, 1992, CIRCULATION, V85, P1390, DOI 10.1161/01.CIR.85.4.1390; WADA H, 1993, AM J HEMATOL, V44, P112, DOI 10.1002/ajh.2830440208; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205	29	604	625	1	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	1996	348	9034					1079	1082		10.1016/S0140-6736(96)05190-2	http://dx.doi.org/10.1016/S0140-6736(96)05190-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874463				2022-12-28	WOS:A1996VM88600016
J	Love, RA; Parge, HE; Wickersham, JA; Hostomsky, Z; Habuka, N; Moomaw, EW; Adachi, T; Hostomska, Z				Love, RA; Parge, HE; Wickersham, JA; Hostomsky, Z; Habuka, N; Moomaw, EW; Adachi, T; Hostomska, Z			The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site	CELL			English	Article							GLUTATHIONE-S-TRANSFERASE; SERINE PROTEINASE; HUMAN RHINOVIRUS; HYDROGEN-BOND; NON-A; PROTEASE; POLYPROTEIN; CLEAVAGE; ORGANIZATION; RESOLUTION	During replication of hepatitis C virus (HCV), the final steps of polyprotein processing are performed by a viral proteinase located in the N-terminal one-third of nonstructural protein 3. The structure of NS3 proteinase from HCV BK strain was determined by X-ray crystallography at 2.4 Angstrom resolution. NS3P folds as a trypsinlike proteinase with two beta barrels and a catalytic triad of His-57, Asp-81, Ser-139. The structure has a substrate-binding site consistent with the cleavage specificity of the enzyme. Novel features include a structural zinc-binding site and a long N-terminus that interacts with neighboring molecules by binding to a hydrophobic surface patch.	AGOURON PHARMACEUT INC,SAN DIEGO,CA 92121; JAPAN TOBACCO INC,CENT PHARMACEUT RES INST,TAKATSUKI,OSAKA 569,JAPAN; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN	Pfizer; Japan Tobacco Inc.; University of Tsukuba				Moomaw, Ellen/0000-0002-2341-1676				ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; BARTENSCHLAGER R, 1995, J VIROL, V69, P198, DOI 10.1128/JVI.69.1.198-205.1995; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DSOUZA EDA, 1995, J GEN VIROL, V76, P1729, DOI 10.1099/0022-1317-76-7-1729; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; FUJINAGA M, 1985, J MOL BIOL, V183, P479; FUREY W, 1990, ACA M SUMM, V73; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; HAN DS, 1995, J GEN VIROL, V76, P985, DOI 10.1099/0022-1317-76-4-985; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Koch JO, 1996, VIROLOGY, V221, P54, DOI 10.1006/viro.1996.0352; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; LIN C, 1995, P NATL ACAD SCI USA, V92, P7622, DOI 10.1073/pnas.92.17.7622; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LIU SX, 1993, J AM CHEM SOC, V115, P7910, DOI 10.1021/ja00070a060; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; OTWINOWSKI Z, 1996, METHOD ENZYMOL, V276, P307; PIZZI E, 1994, P NATL ACAD SCI USA, V91, P888, DOI 10.1073/pnas.91.3.888; READ RJ, 1986, PROTEINASE INHIBITOR, P301; Schwabe JWR, 1994, STRUCT BIOL, V1, P345; SIMMONDS P, 1994, J GEN VIROL, V75, P1053, DOI 10.1099/0022-1317-75-5-1053; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SOMMERGRUBER W, 1994, VIROLOGY, V204, P815, DOI 10.1006/viro.1994.1599; Steinkuhler C, 1996, J BIOL CHEM, V271, P6367, DOI 10.1074/jbc.271.11.6367; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VANDOORN LJ, 1994, J MED VIROL, V43, P345, DOI 10.1002/jmv.1890430406; VOSS T, 1995, PROTEIN SCI, V4, P2526, DOI 10.1002/pro.5560041209; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YU SYF, 1992, VIROLOGY, V186, P725, DOI 10.1016/0042-6822(92)90039-R	51	466	495	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					331	342		10.1016/S0092-8674(00)81350-1	http://dx.doi.org/10.1016/S0092-8674(00)81350-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861916	Bronze			2022-12-28	WOS:A1996VN40300020
J	Rathmell, JC; Townsend, SE; Xu, JCC; Flavell, RA; Goodnow, CC				Rathmell, JC; Townsend, SE; Xu, JCC; Flavell, RA; Goodnow, CC			Expansion or elimination of B cells in vivo: Dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor	CELL			English	Article							X-LINKED IMMUNODEFICIENCY; PRESENT SELF ANTIGEN; HUMAN T-LYMPHOCYTES; HYPER-IGM SYNDROME; LYMPHOPROLIFERATIVE SYNDROME; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; CROSS-LINKING; UP-REGULATION; LIGAND	Signals from CD4(+) T cells induce two opposite fates in B cells: clonal proliferation of B cells that bind specifically to foreign antigens and clonal deletion of equivalent B cells that bind self-antigens. This B cell fate decision is determined by the concerted action of two surface proteins on activated T cells, CD40- and Fas-ligands (CD40L and Fast), whose effects are switched by signals from the B cell antigen receptor (BCR). Foreign antigens that stimulate the BCR acutely cause CD40L and Fast to promote clonal proliferation. CD40L and Fast trigger deletion, however, when the BCRs become desensitized by chronic stimulation with self-antigens or when BCRs have not bound an antigen. The need for both Fas and CD40L to correctly regulate self-reactive B cell fate may explain the severe autoantibody disorders in Fas- or CD40L-deficient children.	STANFORD UNIV,HOWARD HUGHES MED INST,DEPT IMMUNOL & MICROBIOL,STANFORD,CA 94305; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Yale University			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155	NIAID NIH HHS [P01 AI19512, P01 AI36535] Funding Source: Medline; NIAMS NIH HHS [P60 AR20610] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI036535, P01AI019512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020610] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; ACKERMAN BD, 1964, PEDIATRICS, V34, P211; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; Cyster JG, 1995, IMMUNITY, V3, P691, DOI 10.1016/1074-7613(95)90059-4; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; ERIS JM, 1994, P NATL ACAD SCI USA, V91, P4392, DOI 10.1073/pnas.91.10.4392; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Fulcher DA, 1996, J EXP MED, V183, P2313, DOI 10.1084/jem.183.5.2313; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; GOODNOW CC, 1990, SCIENCE, V248, P1373, DOI 10.1126/science.2356469; HINZ CF, 1963, NEW ENGL J MED, V269, P1329, DOI 10.1056/NEJM196312192692501; HO WY, 1994, J EXP MED, V179, P1539, DOI 10.1084/jem.179.5.1539; HOLLENBAUGH D, 1994, J CLIN INVEST, V94, P616, DOI 10.1172/JCI117377; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; JACOBSON BA, 1995, IMMUNITY, V3, P509, DOI 10.1016/1074-7613(95)90179-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KANOST D, 1994, EUR J IMMUNOL, V24, P1186, DOI 10.1002/eji.1830240527; KLAUS SJ, 1994, J IMMUNOL, V152, P5643; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; Lagresle C, 1996, J EXP MED, V183, P1377, DOI 10.1084/jem.183.4.1377; Lens SMA, 1996, J IMMUNOL, V156, P507; LENSCHOW DJ, 1994, J IMMUNOL, V153, P1990; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1995, IMMUNITY, V2, P239, DOI 10.1016/1074-7613(95)90048-9; MERINO R, 1995, J IMMUNOL, V155, P3830; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.iy.11.040193.001555; PUI CH, 1980, J PEDIATR-US, V97, P754, DOI 10.1016/S0022-3476(80)80258-7; RAMESH N, 1993, INT IMMUNOL, V5, P769, DOI 10.1093/intimm/5.7.769; RATHMELL JC, 1994, J IMMUNOL, V153, P2831; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROSEN FS, 1966, NEW ENGL J MED, V275, P769, DOI 10.1056/NEJM196610062751407; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; RUST S, 1993, NUCLEIC ACIDS RES, V21, P3623, DOI 10.1093/nar/21.16.3623; SANTOSARGUMEDO L, 1994, CELL IMMUNOL, V156, P272, DOI 10.1006/cimm.1994.1174; SCHATTNER EJ, 1995, J EXP MED, V182, P1557, DOI 10.1084/jem.182.5.1557; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; Wang JY, 1996, EUR J IMMUNOL, V26, P92, DOI 10.1002/eji.1830260114; WANG ZH, 1995, J IMMUNOL, V155, P3722; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	69	352	357	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					319	329		10.1016/S0092-8674(00)81349-5	http://dx.doi.org/10.1016/S0092-8674(00)81349-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861915	Bronze			2022-12-28	WOS:A1996VN40300019
J	Ferreira, PA; Nakayama, TA; Pak, WL; Travis, GH				Ferreira, PA; Nakayama, TA; Pak, WL; Travis, GH			Cyclophilin-related protein RanBP2 acts as chaperone for red/green opsin	NATURE			English	Article							CYCLOSPORINE-A BINDING; BOVINE RHODOPSIN; HOMOLOG NINAA; ACTIVE-SITE; DROSOPHILA; MEMBRANE; INTERACT; RAN/TC4; ENCODES; RETINA	CYCLOPHILINS are ubiquitous and abundant proteins that exhibit peptidyl prolyl cis-trans isomerization (PPlase) activity in vitro(1,2). Their functions in vivo, however, are not well understood. Two new retinal cyclophilin isoforms, types I and II, are highly expressed in cone photoreceptors of the vertebrate retina(3). Type-II cyclophilin is identical to RanBP2, a large protein that binds the GTPase Ran(4,5). Here we report that two contiguous domains in RanBP(2), Ran binding domain 4 (RBD4) and cyclophilin, act in concert as a chaperone for the opsin molecule of the red/green-sensitive visual pigment of a dichromatic vertebrate. In Drosophila, the cyclophilin NinaA(6,7) is expressed in all photoreceptors(8) and is required for the expression of only a subset of opsins(8,9). The molecular basis of these photoreceptor class-specific effects and the functions of NinaA and other cyclophilins in vivo remain unclear(10). Unlike NinaA, which forms a stable complex with opsin from retinular cells R1-6(11) we find that the cyclophilin domain of RanBP2 does not bind opsin directly; rather, it augments and stabilizes the interaction between red/green (R/G) opsin and the RBD4 domain. This involves a cyclophilin-mediated modification of R/G opsin, possibly involving proline isomerization. The RBD4-cyclophilin supradomain of RanBP2, therefore, is a form of vertebrate chaperone of defined substrate specificity, which may be involved in the processing and/or transport of long-wavelength opsin in cone photoreceptor cells.	UNIV TEXAS,SW MED CTR,PROGRAM NEUROSCI,DALLAS,TX 75235; UNIV CONNECTICUT,CTR HLTH,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Connecticut; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Ferreira, PA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PSYCHIAT,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Ferreira, Paulo/A-3893-2008; Travis, Gabriel Harvey/AIF-1062-2022; Ferreira, Paulo A/S-4209-2016	Travis, Gabriel Harvey/0000-0003-4020-9493; Ferreira, Paulo A/0000-0003-4585-1717				BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; FERREIRA PA, 1995, J BIOL CHEM, V270, P23179, DOI 10.1074/jbc.270.39.23179; Ferreira PA, 1995, DEGENERATIVE DISEASES OF THE RETINA, P263; FISHER G, 1989, NATURE, V337, P476; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KAMPS KMP, 1982, BIOCHIM BIOPHYS ACTA, V687, P296, DOI 10.1016/0005-2736(82)90558-2; KE HM, 1993, P NATL ACAD SCI USA, V90, P3324, DOI 10.1073/pnas.90.8.3324; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MOLDAY RS, 1987, J CELL BIOL, V105, P2598; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; REN MD, 1995, MOL CELL BIOL, V15, P2117; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Roepman R, 1996, HUM MOL GENET, V5, P827, DOI 10.1093/hmg/5.6.827; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEPHENSON RS, 1983, BIOL PHOTORECEPTION, P447; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; WALTER AE, 1986, INVEST OPHTH VIS SCI, V27, P1609; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	30	188	191	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					637	640		10.1038/383637a0	http://dx.doi.org/10.1038/383637a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857542				2022-12-28	WOS:A1996VM75500058
J	Hilton, C				Hilton, C			Collecting ethnic group data for inpatients: Is it useful?	BRITISH MEDICAL JOURNAL			English	Article							MINORITY GROUPS; ILLNESS; NURSES	Since April last year British hospitals have had to collect data on the ethnic group of every patient. Patients must categorise their own ethnic group using the categories of the 1991 census. Claire Hilton argues that such data collection is unhelpful and will not meet its stated aim of helping to provide equitable access to NHS services for all ethnic groups. Self categorisation is unreliable, and the number of ethnic groups available is inadequate, in particular for the white population. Additional data on the size of each ethnic group in the local population and on rates of illness in particular groups are necessary to assess whether services are being provided equitably, Moreover, ethnicity is a multidimensional concept, and information on patients' language and cultural and religious practices, as well as their place of origin, is necessary if services are to be culturally sensitive.			Hilton, C (corresponding author), MENTAL HLTH SERV SALFORD,ELDERLY SERV,MANCHESTER M25 3BL,LANCS,ENGLAND.							ADELSTEIN AM, 1989, ETHNIC FACTORS HLTH, P35; [Anonymous], 1989, OXFORD ENGLISH DICT; BAKER R, 1985, PSYCHOL PROBLEMS REF; BALARAJAN R, 1993, HLTH NATION ETHNICIT; BATES MS, 1993, PAIN, V52, P101, DOI 10.1016/0304-3959(93)90120-E; CHATURVEDI N, 1994, J EPIDEMIOL COMMUN H, V48, P107, DOI 10.1136/jech.48.2.107; Department of Health, 1992, PAT CHART; ESMAIL A, 1993, BRIT MED J, V306, P691, DOI 10.1136/bmj.306.6879.691; KING M, 1994, BMJ-BRIT MED J, V309, P1115, DOI 10.1136/bmj.309.6962.1115; KLEIN R, 1994, HLTH VISITOR, V67, P278; LEFF J, 1981, PSYCHIATRY GLOBE TRA; LITTLEWOOD R, 1988, BRIT MED J, V296, P950, DOI 10.1136/bmj.296.6627.950; LITTLEWOOD R, 1990, BRIT J PSYCHIAT, V156, P308, DOI 10.1192/bjp.156.3.308; MCALLISTER G, 1992, J ADV NURS, V17, P1447, DOI 10.1111/j.1365-2648.1992.tb02816.x; McKenzie K, 1996, BRIT MED J, V312, P1054; MCMANUS IC, 1995, BRIT MED J, V310, P496, DOI 10.1136/bmj.310.6978.496; MURPHY K, 1993, J ADV NURS, V18, P442, DOI 10.1046/j.1365-2648.1993.18030442.x; Neeleman J, 1994, Int J Soc Psychiatry, V40, P124, DOI 10.1177/002076409404000204; *NHS EX INF MAN GR, 1994, COLL ETHN GROUP DAT; NIMA C, 1995, NOT JUST BLACK WHITE, P9; PEARSON M, 1989, ETHNIC FACTORS HLTH, P71; RALEIGH VS, 1992, BRIT J PSYCHIAT, V161, P365, DOI 10.1192/bjp.161.3.365; RASHID A, 1992, BRIT J GEN PRACT, V42, P197; RODERICK PJ, 1994, BRIT MED J, V309, P1111, DOI 10.1136/bmj.309.6962.1111; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; THOMAS V, 1994, J ADV NURS, V20, P802, DOI 10.1046/j.1365-2648.1994.20050802.x; 1995, WEEKLY GLEANER  1011, P9; 1996, BRIT MED J, V312, P1094	28	18	18	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					923	925						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VM754	8876099				2022-12-28	WOS:A1996VM75400031
J	Williams, TN; Maitland, K; Bennett, S; Ganczakowski, M; Peto, TEA; Newbold, CI; Bowden, DK; Weatherall, DJ; Clegg, JB				Williams, TN; Maitland, K; Bennett, S; Ganczakowski, M; Peto, TEA; Newbold, CI; Bowden, DK; Weatherall, DJ; Clegg, JB			High incidence of malaria in alpha-thalassaemic children	NATURE			English	Article							PLASMODIUM-FALCIPARUM; NATURAL-SELECTION; BETA-THALASSEMIA; RED-CELLS; DEFICIENCY; SUSCEPTIBILITY; ERYTHROCYTES; HEMOGLOBIN; GENETICS; ANTIGENS	THE alpha(+)-thalassaemias are the commonest known human genetic disorders, affecting up to 80 per cent of some populations(1). Although there is good evidence from both epidemiological(2,3) and clinical(4) studies that these gene frequencies reflect selection by, and protection from, malaria, the mechanism is unknown. We have studied the epidemiology of malaria in childhood on the southwestern Pacific island of Espiritu Santo in Vanuatu and here we report that, paradoxically, both the incidence of uncomplicated malaria and the prevalence of splenomegaly, an index of malaria infection, are significantly higher in young children with alpha(+)-thalassnemia than in normal children. Furthermore, this effect is most marked in the youngest children and for the nonlethal parasite Plasmodium vivax. The alpha(+)-thalassaemias may have been selected for their ability beneficially to increase susceptibility to P. vivax, which, by acting as a natural vaccine in this community, induces limited cross-species protection against subsequent severe P. falciparum malaria.	UNIV LONDON LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND; MONASH UNIV,DEPT ANAT,CLAYTON,VIC 3168,AUSTRALIA	University of London; London School of Hygiene & Tropical Medicine; Monash University	Williams, TN (corresponding author), JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DU,ENGLAND.			Maitland, Kathryn/0000-0002-0007-0645; Newbold, Chris/0000-0002-9274-3789	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN SJ, 1993, T ROY SOC TROP MED H, V87, P282, DOI 10.1016/0035-9203(93)90129-E; BALFOUR M. C., 1935, American Journal of Tropical Medicine, V15, P301; BATE CAW, 1992, INFECT IMMUN, V60, P1241, DOI 10.1128/IAI.60.3.1241-1243.1992; BOWDEN DK, 1985, LANCET, V2, P1025; Djaparidze P. S., 1942, Medical Parasitology and Parasitic Diseases Moscow, V11, P3; EARLE W. C., 1939, Puerto Rico Journal of Public Health and Tropical Medicine, V15, P3; FLINT J, 1986, NATURE, V321, P744, DOI 10.1038/321744a0; FLINT J, 1993, BAILLIERE CLIN HAEM, V6, P215, DOI 10.1016/S0950-3536(05)80071-X; GANCZAKOWSKI M, 1995, BRIT J HAEMATOL, V89, P485, DOI 10.1111/j.1365-2141.1995.tb08353.x; GENTON B, 1995, NATURE, V378, P564, DOI 10.1038/378564a0; GILLES HM, 1993, ESSENTIAL MALARIOLOG, P134; GUNEWARDENA DM, 1994, MEM I O CRUZ, V89, P61; HIGGS DR, 1989, BLOOD, V73, P1081; HILL AVS, 1992, BAILLIERE CLIN HAEM, V5, P209, DOI 10.1016/S0950-3536(11)80042-9; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; LUZZI GA, 1990, BRIT J HAEMATOL, V74, P519, DOI 10.1111/j.1365-2141.1990.tb06344.x; LUZZI GA, 1991, J EXP MED, V173, P785, DOI 10.1084/jem.173.4.785; MAITLAND K, IN PRESS T R SOC TRO; Old J. M, 1983, METHODS HAEMATOLOGY, P74; OPPENHEIMER SJ, 1987, T ROY SOC TROP MED H, V81, P322, DOI 10.1016/0035-9203(87)90253-7; PASVOL G, 1977, NATURE, V270, P171, DOI 10.1038/270171a0; PASVOL G, 1980, BRIT J HAEMATOL, V45, P285, DOI 10.1111/j.1365-2141.1980.tb07148.x; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; WEATHERALL DJ, 1987, ANN TROP MED PARASIT, V81, P539, DOI 10.1080/00034983.1987.11812155; WEATHERALL DJ, 1981, THALASSAEMIA SYNDROM, P212; WILLCOX M, 1983, ANN TROP MED PARASIT, V77, P335, DOI 10.1080/00034983.1983.11811722; YATES SNR, 1995, THESIS U OXFORD	27	196	202	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					522	525		10.1038/383522a0	http://dx.doi.org/10.1038/383522a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849722				2022-12-28	WOS:A1996VL75500049
J	Gorlich, D; Kraft, R; Kostka, S; Vogel, F; Hartmann, E; Laskey, RA; Mattaj, IW; Izaurralde, E				Gorlich, D; Kraft, R; Kostka, S; Vogel, F; Hartmann, E; Laskey, RA; Mattaj, IW; Izaurralde, E			Importin provides a link between nuclear protein and U snRNA export	CELL			English	Article							CAP-BINDING PROTEIN; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; ACTIVATING PROTEIN; HNRNP A1; SPECIFICALLY INTERACTS; REV PROTEIN; TRANSPORT; IDENTIFICATION; YEAST	Importin-alpha mediates nuclear protein import by binding nuclear localization signals and importin-beta. We find approximately 30% of SRP1p, the yeast importin-alpha, in a nuclear complex with the Saccharomyces cerevisiae nuclear cap-binding protein complex (CBC). Similarly, a large fraction of Xenopus CBC is associated with importin-alpha in the nucleus. CBC promotes nuclear export of capped U snRNAs and shuttles between nucleus and cytoplasm. The CBC-importin-alpha complex binds specifically to capped RNA, suggesting that CBC might shuttle while bound to importin-alpha. Strikingly, importin-beta binding displaces the RNA from the CBC-importin-alpha complex. Thus, the commitment of CBC for nuclear reentry triggers the release of the export substrate into the cytoplasm. We provide evidence for a mechanism that ensures that importin-mediated RNA release is a specifically cytoplasmic event.	WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY; MAX DELBRUCK ZENTRUM MOL MED,D-13122 BERLIN,GERMANY	University of Cambridge; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Gorlich, D (corresponding author), UNIV HEIDELBERG,ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY.		Izaurralde, Elisa/G-3239-2012; Gorlich, Dirk/B-8296-2017	Mattaj, Iain/0000-0002-5537-8284; Izaurralde, Elisa/0000-0001-7365-2649; Gorlich, Dirk/0000-0002-4343-5210	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; ATKINSON NS, 1985, MOL CELL BIOL, V5, P907, DOI 10.1128/MCB.5.5.907; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; Colot HV, 1996, GENE DEV, V10, P1699, DOI 10.1101/gad.10.13.1699; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; GORLICH D, 1996, IN PRESS EMBO J; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; IZAURRALDE E, 1996, IN PRESS COLD SPRING; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KADOWAKI T, 1992, IN PRESS P NATL ACAD; KAERGEL E, 1996, YEAST, V12, P333; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; KATAOKA N, 1995, NUCLEIC ACIDS RES, V23, P3638, DOI 10.1093/nar/23.18.3638; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; LEWIS JD, 1996, IN PRESS NUCL ACIDS; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PERKINS A, 1989, J ACQ IMMUN DEF SYND, V2, P256; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TERNS MP, 1992, NUCLEIC ACIDS RES, V21, P4569; UEMURA H, 1992, J BACTERIOL, V174, P5526, DOI 10.1128/JB.174.17.5526-5532.1992; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	70	166	167	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					21	32		10.1016/S0092-8674(00)81319-7	http://dx.doi.org/10.1016/S0092-8674(00)81319-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858145	Bronze			2022-12-28	WOS:A1996VL69500005
J	Meyer, E; Duharcourt, S				Meyer, E; Duharcourt, S			Epigenetic programming of developmental genome rearrangements in ciliates	CELL			English	Review							PARAMECIUM-TETRAURELIA; SURFACE-ANTIGEN; DNA; GENE; MUTATIONS; MICROINJECTION; EXPRESSION				Meyer, E (corresponding author), ENS,GENET MOL LAB,46 RUE ULM,F-75005 PARIS,FRANCE.		Duharcourt, Sandra/ABD-4460-2020	Duharcourt, Sandra/0000-0002-8913-8799; Meyer, Eric/0000-0002-3161-8597				Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; Chalker DL, 1996, MOL CELL BIOL, V16, P3658; DUHARCOURT S, 1995, GENE DEV, V9, P2065, DOI 10.1101/gad.9.16.2065; EPSTEIN LM, 1984, MOL CELL BIOL, V4, P1583, DOI 10.1128/MCB.4.8.1583; KIM CS, 1994, GENETICS, V136, P1325; KLOBUTCHER LA, 1996, IN PRESS PROG NUCL A; KOIZUMI S, 1989, MOL CELL BIOL, V9, P4398, DOI 10.1128/MCB.9.10.4398; MEYER E, 1992, GENE DEV, V6, P211, DOI 10.1101/gad.6.2.211; Meyer E, 1996, J EUKARYOT MICROBIOL, V43, P453, DOI 10.1111/j.1550-7408.1996.tb04504.x; MONK M, 1995, DEV GENET, V17, P188, DOI 10.1002/dvg.1020170303; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; Sabl JF, 1996, GENETICS, V142, P447; SCOTT JM, 1994, MOL CELL BIOL, V14, P2479, DOI 10.1128/MCB.14.4.2479; Yao MC, 1996, TRENDS GENET, V12, P26, DOI 10.1016/0168-9525(96)81385-0; YOU Y, 1994, GENETICS, V136, P1319	16	42	43	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					9	12		10.1016/S0092-8674(00)81317-3	http://dx.doi.org/10.1016/S0092-8674(00)81317-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858143	Bronze			2022-12-28	WOS:A1996VL69500003
J	Hou, LH; Martin, LD; Zhou, ZH; Feduccia, A				Hou, LH; Martin, LD; Zhou, ZH; Feduccia, A			Early adaptive radiation of birds: Evidence from fossils from northeastern China	SCIENCE			English	Article							EARLY EVOLUTION; SPAIN	Late Jurassic and Early Cretaceous birds from northeastern China, including many complete skeletons of Confuciusornis, provide evidence for a fundamental dichotomy in the class Aves that may antedate the temporal occurrence of the Late Jurassic Archaeopteryx. The abundance of Confuciusornis may provide evidence of avian social behavior, Jurassic skeletal remains of an ornithurine bird lend further support to the idea of an early separation of the line that gave rise to modern birds, Chaoyangia, an ornithurine bird from the Early Cretaceous of China, has premaxillary teeth.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27514 USA; CHINESE ACAD SCI, IVPP, BEIJING 100044, PEOPLES R CHINA; UNIV KANSAS, MUSEUM NAT HIST, LAWRENCE, KS 66045 USA	University of North Carolina; University of North Carolina Chapel Hill; Chinese Academy of Sciences; University of Kansas								CHIAPPE LM, 1995, NATURE, V378, P349, DOI 10.1038/378349a0; Chiappe Luis M., 1996, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V30, P203; Chiappe Luis M., 1993, American Museum Novitates, V3083, P1; CHINSAMY A, 1994, NATURE, V368, P196, DOI 10.1038/368196a0; DONG ZM, 1993, CAN J EARTH SCI, V30, P2177, DOI 10.1139/e93-189; ELZANOWSKI A, 1976, NATURE, V264, P51, DOI 10.1038/264051a0; ELZANOWSKI A, 1981, PALAEONTOL POLON, V42, P147; FEDUCCIA A, 1995, SCIENCE, V267, P637, DOI 10.1126/science.267.5198.637; HOU L, IN PRESS CHIN SCI B; HOU L, 1995, CHINESE SCI BULL, V40, P1546; HOU LH, 1984, SCI SIN B-CHEM B A M, V27, P1296; HOU LH, 1995, NATURE, V377, P616, DOI 10.1038/377616a0; Hou Lianhai, 1993, Vertebrata Palasiatica, V31, P217; KUROCHKIN EN, 1996, PALAEONTOLOGICAL I R; Lacasa Ruiz A., 1989, Estudios Geologicos (Madrid), V45, P417; Martin L.D., 1983, P291, DOI 10.1017/CBO9780511759994.011; Paul G., 1988, PREDATORY DINOSAURS; RUBEN J, COMMUNICATION; Sanz JL, 1996, NATURE, V382, P442, DOI 10.1038/382442a0; SANZ JL, 1988, NATURE, V331, P433, DOI 10.1038/331433a0; SANZ JL, 1992, PALAEONTOLOGY, V35, P829; Sanz Jose L., 1995, American Museum Novitates, V3133, P1; SERENO PC, 1992, SCIENCE, V255, P845, DOI 10.1126/science.255.5046.845; WALKER CA, 1981, NATURE, V292, P51, DOI 10.1038/292051a0; ZHOU Z, 1995, COUR FORSCHUNGSINST, V181, P9; ZHOU ZH, 1992, CHINESE SCI BULL, V37, P1365; Zhou Zhonghe, 1995, Vertebrata Palasiatica, V33, P99; [No title captured]; [No title captured]	29	138	157	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1164	1167		10.1126/science.274.5290.1164	http://dx.doi.org/10.1126/science.274.5290.1164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895459				2022-12-28	WOS:A1996VT33500045
J	Katz, LC; Shatz, CJ				Katz, LC; Shatz, CJ			Synaptic activity and the construction of cortical circuits	SCIENCE			English	Review							LONG-TERM POTENTIATION; NERVE GROWTH-FACTOR; OCULAR DOMINANCE COLUMNS; CAT VISUAL-CORTEX; LATERAL GENICULATE-NUCLEUS; DEVELOPING NEUROMUSCULAR SYNAPSES; BINOCULAR IMPULSE BLOCKADE; RETINAL GANGLION-CELLS; MONOCULAR DEPRIVATION; HORIZONTAL CONNECTIONS	Vision is critical for the functional and structural maturation of connections in the mammalian visual system. Visual experience, however, is a subset of a more general requirement for neural activity in transforming immature circuits into the organized connections that subserve adult brain function. Early in development, internally generated spontaneous activity sculpts circuits on the basis of the brain's ''best guess'' at the initial configuration of connections necessary for function and survival. With maturation of the sense organs, the developing brain relies less on spontaneous activity and increasingly on sensory experience. The sequential combination of spontaneously generated and experience-dependent neural activity endows the brain with an ongoing ability to accommodate to dynamically changing inputs during development and throughout life.	DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710 USA	Duke University	Katz, LC (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA.							ALLENDOERFER KL, 1994, J NEUROSCI, V14, P1795; [Anonymous], [No title captured]; ANTONINI A, 1993, J NEUROSCI, V13, P3549; ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; Bear MF, 1996, PROG BRAIN RES, V108, P205, DOI 10.1016/S0079-6123(08)62541-8; BEAR MF, 1990, J NEUROSCI, V10, P909; BEAR MF, 1995, NEURON, V15, P1, DOI 10.1016/0896-6273(95)90056-X; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; BERARDI N, 1993, P ROY SOC B-BIOL SCI, V251, P17, DOI 10.1098/rspb.1993.0003; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BODNARENKO SR, 1993, NATURE, V364, P144, DOI 10.1038/364144a0; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CABELLI RJ, IN PRESS J NEUROSCI; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CAMPBELL G, 1992, J NEUROSCI, V12, P1847; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; CLINE H T, 1991, Current Biology, V1, P275, DOI 10.1016/0960-9822(91)90082-8; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; Dailey ME, 1996, J NEUROSCI, V16, P2983; DALVA MB, 1994, SCIENCE, V265, P255, DOI 10.1126/science.7912852; Dan Yang, 1994, Current Opinion in Neurobiology, V4, P95, DOI 10.1016/0959-4388(94)90037-X; DAS A, 1995, NATURE, V375, P780, DOI 10.1038/375780a0; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DAW NW, 1992, J NEUROPHYSIOL, V67, P197, DOI 10.1152/jn.1992.67.1.197; Deisseroth K, 1995, CURR BIOL, V5, P1334, DOI 10.1016/S0960-9822(95)00262-4; DOMENICI L, 1993, P ROY SOC B-BIOL SCI, V251, P25, DOI 10.1098/rspb.1993.0004; Durack JC, 1996, CEREB CORTEX, V6, P178, DOI 10.1093/cercor/6.2.178; EISELE LE, 1988, J NEUROBIOL, V19, P395, DOI 10.1002/neu.480190502; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; Feller MB, 1996, SCIENCE, V272, P1182, DOI 10.1126/science.272.5265.1182; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FRANK E, 1979, J CELL BIOL, V83, P143, DOI 10.1083/jcb.83.1.143; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; Galuske RAW, 1996, EUR J NEUROSCI, V8, P1554, DOI 10.1111/j.1460-9568.1996.tb01618.x; GHOSH A, 1992, J NEUROSCI, V12, P39; Ghosh A, 1996, CURR BIOL, V6, P130, DOI 10.1016/S0960-9822(02)00442-6; GIBBS RB, 1994, J COMP NEUROL, V341, P324, DOI 10.1002/cne.903410304; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; GOODHILL GJ, 1995, TRENDS NEUROSCI, V18, P437, DOI 10.1016/0166-2236(95)94490-V; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, 1993, NEURON, V10, P1; Gordon JA, 1996, J NEUROSCI, V16, P3274; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HEBB DO, 1949, ORG BEHAVIOR; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; Horton JC, 1996, J NEUROSCI, V16, P1791; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; KANDER K, UNPUB; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KASAMATSU T, 1976, SCIENCE, V194, P206, DOI 10.1126/science.959850; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; KATZ LC, 1992, ANNU REV NEUROSCI, V15, P31; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; KOMATSU Y, 1992, J NEUROPHYSIOL, V67, P401, DOI 10.1152/jn.1992.67.2.401; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Lein E., 1995, Society for Neuroscience Abstracts, V21, P1795; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LO YJ, 1994, J NEUROSCI, V14, P4684; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MASLIM J, 1986, BRAIN RES, V373, P35, DOI 10.1016/0006-8993(86)90313-6; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; MCALLISTER AK, IN PRESS; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; MOONEY R, 1993, NEURON, V10, P815, DOI 10.1016/0896-6273(93)90198-Z; MOONEY R, IN PRESS NEURON; MOWER GD, 1985, J COMP NEUROL, V235, P448, DOI 10.1002/cne.902350404; NELSON DA, 1995, NEURON, V15, P23, DOI 10.1016/0896-6273(95)90061-6; NISHIMURA Y, 1985, J COMP NEUROL, V241, P420, DOI 10.1002/cne.902410403; ODONOVAN M, 1992, J EXP ZOOL, V261, P261, DOI 10.1002/jez.1402610306; OROURKE NA, 1994, NEURON, V12, P921, DOI 10.1016/0896-6273(94)90343-3; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; PURVES D, 1988, BODY BRAIN; RAKIC P, 1986, SCIENCE, V232, P232, DOI 10.1126/science.3952506; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; SCHOUPS AA, 1995, DEV BRAIN RES, V86, P326, DOI 10.1016/0165-3806(95)00043-D; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1984, J NEUROSCI, V4, P1378; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SRETAVAN DW, 1986, J NEUROSCI, V6, P234; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; STRYKER MP, 1986, J NEUROSCI, V6, P2117; SWINDALE NV, 1996, COMPUT NEURAL SYS, V7, P161; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TSUMOTO T, 1992, PROG NEUROBIOL, V39, P209, DOI 10.1016/0301-0082(92)90011-3; WANG XQ, 1995, NATURE, V378, P71, DOI 10.1038/378071a0; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P978, DOI 10.1152/jn.1963.26.6.978; Wong ROL, 1996, NEURON, V16, P1087, DOI 10.1016/S0896-6273(00)80135-X; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; WONG ROL, 1992, EUR J NEUROSCI, V4, P1387, DOI 10.1111/j.1460-9568.1992.tb00164.x; WONG ROL, 1995, NATURE, V374, P716, DOI 10.1038/374716a0; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379; YUSTE R, 1995, NEURON, V14, P7, DOI 10.1016/0896-6273(95)90236-8	130	2255	2298	3	198	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1996	274	5290					1133	1138		10.1126/science.274.5290.1133	http://dx.doi.org/10.1126/science.274.5290.1133			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895456				2022-12-28	WOS:A1996VT33500032
J	Clemens, SC; Murray, DW; Prell, WL				Clemens, SC; Murray, DW; Prell, WL			Nonstationary phase of the plio-pleistocene Asian monsoon	SCIENCE			English	Article							WATER-VAPOR TRANSPORT; NORTHWEST ARABIAN SEA; INDIAN-OCEAN; INTERANNUAL VARIABILITY; SOUTHWEST MONSOON; AFRICAN CLIMATE; HEAT-BUDGET; DEEP-SEA; HISTORY; ATMOSPHERE	Paleoclimate records indicate that the strength of the Asian summer monsoon is sensitive to orbital forcing at the obliquity and precession periods (41,000 and 23,000 years, respectively) and the extent of Northern Hemisphere glaciation. Over the past 2.6 million years, the timing (phase) of strong monsoons has changed by similar to 83 degrees in the precession and similar to 124 degrees in the obliquity bands relative to the phase of maximum global ice volume (inferred from the marine oxygen isotope record). These results suggest that one or both of these systems is nonstationary relative to orbital forcing.			Clemens, SC (corresponding author), BROWN UNIV,DEPT GEOL SCI,PROVIDENCE,RI 02912, USA.							ALTABET MA, 1995, NATURE, V373, P506, DOI 10.1038/373506a0; ANDERSON DM, 1993, PALEOCEANOGRAPHY, V8, P193, DOI 10.1029/93PA00256; BERGER A, 1993, J GEOPHYS RES, V98, P10; BONAN GB, 1992, NATURE, V359, P716, DOI 10.1038/359716a0; CADET D, 1981, TELLUS, V33, P476, DOI 10.1111/j.2153-3490.1981.tb01773.x; CADET DL, 1987, MON WEATHER REV, V115, P2358, DOI 10.1175/1520-0493(1987)115<2358:WVTOTI>2.0.CO;2; CADET DL, 1984, MON WEATHER REV, V112, P1921, DOI 10.1175/1520-0493(1984)112<1921:IVOSFO>2.0.CO;2; CERLING TE, 1988, PALAEOGEOGR PALAEOCL, V63, P335, DOI 10.1016/0031-0182(88)90104-6; CHEN JJ, 1995, PALEOCEANOGRAPHY, V10, P21, DOI 10.1029/94PA02290; CLEMENS S, 1991, NATURE, V353, P720, DOI 10.1038/353720a0; CLEMENS SC, 1991, P OCEAN DRILLING PRO, V0117; CLEMENS SC, 1990, THESIS BROWN U PROVI; CLEMENS SC, 1991, J GEOPHYS RES, V96, P22; Clemens SC, 1990, PALEOCEANOGRAPHY, V5, P109, DOI 10.1029/PA005i002p00109; CURRY WB, 1992, UPWELLING SYSTEMS EV, P93; deMenocal PB, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P262; DEMENOCAL PB, 1995, SCIENCE, V270, P53, DOI 10.1126/science.270.5233.53; DEMENOCAL PB, 1993, J GEOPHYS RES-ATMOS, V98, P7265, DOI 10.1029/92JD02924; DOWSETT H, 1994, GLOBAL PLANET CHANGE, V9, P169, DOI 10.1016/0921-8181(94)90015-9; EMEIS KC, 1995, QUATERNARY RES, V43, P355, DOI 10.1006/qres.1995.1041; FARRELL JW, 1991, P OCEAN DRILLING PRO, V0121; FOLEY JA, 1994, NATURE, V371, P52, DOI 10.1038/371052a0; *GEOL SOC AM, 1981, CLIMAP; HAAKE B, 1993, DEEP-SEA RES PT I, V40, P1323, DOI 10.1016/0967-0637(93)90114-I; Hastenrath, 1979, CLIMATIC ATLAS INDIA; HASTENRATH S, 1993, J GEOPHYS RES-OCEANS, V98, P6869, DOI 10.1029/92JC02956; HASTENRATH S, 1980, J PHYS OCEANOGR, V10, P694, DOI 10.1175/1520-0485(1980)010<0694:OTHBOH>2.0.CO;2; Hastenrath S., 1979, CLIMATIC ATLAS IND 2; HASTENRATH S, 1991, CLIMATE DYNAMICS TRO, V8, P182; HOVAN SA, 1989, NATURE, V340, P296, DOI 10.1038/340296a0; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; Jenkins G., 1968, SPECTRAL ANAL ITS AP; KUTZBACH JE, 1986, J ATMOS SCI, V43, P1726, DOI 10.1175/1520-0469(1986)043<1726:TIOCOP>2.0.CO;2; LASKAR J, 1993, ASTRON ASTROPHYS, V270, P522; LIU TW, 1994, J GEOPHYS RES, V99, P12; MORTLOCK RA, 1989, DEEP-SEA RES, V36, P1415, DOI 10.1016/0198-0149(89)90092-7; MURRAY DW, 1992, UPWELLING SYSTEMS EV, P301; NAIR RR, 1989, NATURE, V338, P749, DOI 10.1038/338749a0; NIK LM, 1996, EOS T AM GEOPHYS UN, V76, pOS5; Peterson LC, 1991, PALEOCEANOGRAPHY, V6, P99, DOI 10.1029/90PA02497; Prell W.L., 1984, MILANKOVITCH CLIMATE, P349; Prell W.L., 1992, SYNTHESIS RESULTS SC, DOI [DOI 10.1029/GM070P0447, 10.1029/GM070p0447]; PRELL WL, 1992, NATURE, V360, P647, DOI 10.1038/360647a0; PRELL WL, 1984, GEOPHYS MONOGR SER, V29, P48; PRELL WL, 1991, P ODP SCI RESULTS, V117; RAYMO ME, 1992, START GLACIAL, V13, P207; REA DK, 1994, REV GEOPHYS, V32, P159, DOI 10.1029/93RG03257; SCHAFER P, 1993, NATURWISSENSCHAFTEN, V80, P511, DOI 10.1007/BF01140806; Shackleton N.J., 1995, P ODP SCI RESULTS, V138, P73, DOI DOI 10.2973/0DP.PR0C.SR.138.106.1995; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0; SHIMMIELD GB, 1990, T ROY SOC EDIN-EARTH, V81, P289, DOI 10.1017/S0263593300020800; SIROCKO F, 1989, NATO ADV SCI I C-MAT, V282, P401; STREETPERROTT FA, 1990, T ROY SOC EDIN-EARTH, V81, P407, DOI 10.1017/S0263593300020897; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; Webster P. J, 1987, ELEMENTARY MONSOON; WEBSTER PJ, 1994, REV GEOPHYS, V32, P427, DOI 10.1029/94RG01873; 1988, SCIENCE, V241, P1043	58	248	273	3	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					943	948		10.1126/science.274.5289.943	http://dx.doi.org/10.1126/science.274.5289.943			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875928				2022-12-28	WOS:A1996VR79200037
J	Rubin, SC; Benjamin, I; Behbakht, K; Takahashi, H; Morgan, MA; LiVolsi, VA; Berchuck, A; Muto, MG; Garber, JE; Weber, BL; Lynch, HT; Boyd, J				Rubin, SC; Benjamin, I; Behbakht, K; Takahashi, H; Morgan, MA; LiVolsi, VA; Berchuck, A; Muto, MG; Garber, JE; Weber, BL; Lynch, HT; Boyd, J			Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIES; BREAST; GENE; MANAGEMENT	Background We tested the hypothesis that ovarian cancers associated with germ-line mutations of BRCA1 have distinct clinical and pathological features as compared with sporadic ovarian cancers. Methods We reviewed clinical and pathological data on patients with primary epithelial ovarian cancer found to have germ-fine mutations of BRCA1. Survival among patients with advanced-stage cancer and such mutations was compared with that in control patients matched for age and stage, grade, and histologic subtype of the tumors. A combination of single-strand conformation and sequencing analyses was used to examine the 22 coding exons and intronic splice-donor and splice-acceptor regions of BRCA1 for mutations in pathological specimens. Alternatively, some patients were known to be obligate carriers of the mutant BRCA1 gene because of their parental relationships with documented mutant-gene carriers. Results We identified 53 patients with germ-line mutations of BRCA1. The average age at diagnosis was 48 years (range, 28 to 78). Histologic examination in 43 of the 53 patients showed serous adenocarcinoma. Thirty-seven tumors were of grade 3, 11 were of grade 2, 2 were of grade 1, and 3 were of low malignant potential. In 38 patients, the tumors were of stage III; 9 patients (including those with tumors of low malignant potential) had stage I disease, 5 had stage IV, and 1 had stage II. As of June 1996, with a median follow-up among survivors of 71 months from diagnosis, 20 patients had died of ovarian cancer, 27 had no evidence of the disease, 4 were alive with the disease, and 2 had died of other diseases. Actuarial median survival for the 43 patients with advanced-stage disease was 77 months, as compared with 29 months for the matched controls (P<0.001). Conclusions As compared with sporadic ovarian cancers, cancers associated with BRCA1 mutations appear to have a significantly more favorable clinical course. (C)1996, Massachusetts Medical Society.	UNIV PENN, MED CTR, DEPT LAB MED & PATHOL, DIV ANAT PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, MED CTR, DIV HEMATOL & ONCOL, DEPT MED, PHILADELPHIA, PA 19104 USA; BRIGHAM & WOMENS HOSP, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV CANC EPIDEMIOL & CONTROL, BOSTON, MA 02115 USA; CREIGHTON UNIV, SCH MED, DEPT PREVENT MED & PUBL HLTH, OMAHA, NE USA	University of Pennsylvania; University of Pennsylvania; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Creighton University	Rubin, SC (corresponding author), UNIV PENN, MED CTR, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, 3400 SPRUCE ST, PHILADELPHIA, PA 19104 USA.		Rubin, Stephen/U-8535-2019	Rubin, Stephen/0000-0003-3688-5333; Behbakht, Kian/0000-0003-4793-9958; Boyd, Jeff/0000-0002-3517-7637				BENJAMIN I, 1990, GYNECOL ONCOL, V38, P431, DOI 10.1016/0090-8258(90)90086-Z; BULLER RE, 1993, GYNECOL ONCOL, V51, P160, DOI 10.1006/gyno.1993.1265; EASTON DF, 1993, AM J HUM GENET, V52, P678; EISENKOP SM, 1992, GYNECOL ONCOL, V47, P203, DOI 10.1016/0090-8258(92)90107-T; Eisinger F, 1996, CANCER RES, V56, P471; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LYNCH HT, 1993, OVARIAN CANCER, P189; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER BA, NIH PUBLICATION; Ozols RF, 1992, PRINCIPLES PRACTICE, P731; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P582; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Sankila R, 1996, GASTROENTEROLOGY, V110, P682, DOI 10.1053/gast.1996.v110.pm8608876; STEICHENGERSDORF E, 1994, AM J HUM GENET, V55, P870; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THIGPEN T, 1993, CANCER-AM CANCER SOC, V71, P606	20	361	371	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1413	1416		10.1056/NEJM199611073351901	http://dx.doi.org/10.1056/NEJM199611073351901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT339	8875917	Bronze			2022-12-28	WOS:A1996VT33900001
J	Leonard, F				Leonard, F			Colors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1363	1363		10.1001/jama.276.17.1363	http://dx.doi.org/10.1001/jama.276.17.1363			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892698				2022-12-28	WOS:A1996VQ46400001
J	Hua, XX; Nohturfft, A; Goldstein, JL; Brown, MS				Hua, XX; Nohturfft, A; Goldstein, JL; Brown, MS			Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein	CELL			English	Article							COENZYME-A REDUCTASE; LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; MUTANT HAMSTER-CELLS; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-SEQUENCE; REGULATORY ELEMENT; TRANSCRIPTIONAL ACTIVATION; MEMBRANE DOMAIN; CHOLESTEROL	Through expression cloning we have isolated a cDNA-encoding SREBP cleavage-activating protein (SCAP), which regulates cholesterol metabolism by stimulating cleavage of transcription factors SREBP-1 and -2, thereby releasing them from membranes. The cDNA was isolated from Chinese hamster ovary cells with a dominant mutation that renders them resistant to sterol-mediated suppression of cholesterol synthesis and uptake. Sterol resistance was traced to a G-->A transition at codon 443 of SCAP, changing aspartic acid to asparagine. The D443N mutation enhances the cleavage-stimulating ability of SCAP and renders it resistant to inhibition by sterols. SCAP has multiple membrane-spanning regions, five of which resemble the sterol-sensing domain of HMG CoA reductase, an endoplasmic reticulum enzyme whose degradation is accelerated by sterols. SCAP appears to be a central regulator of cholesterol metabolism in animal cells.			Hua, XX (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235, USA.			Nohturfft, Axel/0000-0001-9484-3209	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIN J, 1981, J BIOL CHEM, V256, P6304; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P481, DOI 10.1007/BF02255839; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LISCUM L, 1985, J BIOL CHEM, V260, P522; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; NAGASE T, 1996, IN PRESS DNA RES; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NOHTURFFT A, 1996, IN PRESS P NATL ACAD; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SATO R, 1994, J BIOL CHEM, V269, P17267; SHIMANO H, 1996, IN PRESS J CLIN INVE; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	42	414	437	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					415	426		10.1016/S0092-8674(00)81362-8	http://dx.doi.org/10.1016/S0092-8674(00)81362-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898195	Bronze			2022-12-28	WOS:A1996VQ46600008
J	vanHelvoort, A; Smith, AJ; Sprong, H; Fritzsche, I; Schinkel, AH; Borst, P; van Meer, G				vanHelvoort, A; Smith, AJ; Sprong, H; Fritzsche, I; Schinkel, AH; Borst, P; van Meer, G			MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine	CELL			English	Article							PLATELET-ACTIVATING FACTOR; CANINE KIDNEY-CELLS; PLASMA-MEMBRANE; CULTURED FIBROBLASTS; TISSUE DISTRIBUTION; GENE LEADS; PHOSPHOLIPIDS; SPHINGOLIPIDS; ANALOGS; GOLGI	The human MDR1 P-glycoprotein (Pgp) extrudes a variety of drugs across the plasma membrane. The homologous MDR3 Pgp is required for phosphatidylcholine secretion into bile. After stable transfection of epithelial LLC-PK1 cells, MDR1 and MDR3 Pgp were localized in the apical membrane. At 15 degrees C, newly synthesized short-chain analogs of various membrane lipids were recovered in the apical albumin-containing medium of MDR1 cells but not control cells. MDR inhibitors and energy depletion reduced apical release. MDR3 cells exclusively released a short-chain phosphatidylcholine. Since no vesicular secretion occurs at 15 degrees C, the short-chain lipids must have been translocated by the Pgps across the plasma membrane before extraction into the medium by the lipid-acceptor albumin.	UNIV UTRECHT, FAC MED, DEPT CELL BIOL, NL-3584 CX UTRECHT, NETHERLANDS; UNIV UTRECHT, INST BIOMEMBRANES, NL-3584 CX UTRECHT, NETHERLANDS; NETHERLANDS CANC INST, NL-1066 CX AMSTERDAM, NETHERLANDS; HUMBOLDT UNIV BERLIN, DEPT NEONATOL, UNIV CHILDRENS HOSP, BERLIN, GERMANY	Utrecht University; Utrecht University; Netherlands Cancer Institute; Humboldt University of Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf			van Helvoort, Ardy/U-7549-2019; van Meer, Gerrit/AAH-1560-2021; Smith, Alexander/A-5142-2009	van Helvoort, Ardy/0000-0002-3585-0676; Sprong, Hein/0000-0002-0218-4320; van Meer, Gerrit/0000-0002-5976-6436				AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; BERR F, 1993, J BIOL CHEM, V268, P3976; BHAMIDIPATI SP, 1995, BIOCHEMISTRY-US, V34, P5666, DOI 10.1021/bi00016a043; BRATTON DL, 1993, J BIOL CHEM, V268, P3364; Burger KNJ, 1996, J CELL BIOL, V133, P15, DOI 10.1083/jcb.133.1.15; Buton X, 1996, J BIOL CHEM, V271, P6651, DOI 10.1074/jbc.271.12.6651; DEVAUX PF, 1994, CHEM PHYS LIPIDS, V73, P107, DOI 10.1016/0009-3084(94)90177-5; GAFFET P, 1995, BIOCHEMISTRY-US, V34, P6762, DOI 10.1021/bi00020a022; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gros P, 1993, Int Rev Cytol, V137C, P169; HANADA K, 1995, J CELL BIOL, V128, P793, DOI 10.1083/jcb.128.5.793; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; MENON A, 1995, TRENDS CELL BIOL, V5, P355, DOI 10.1016/S0962-8924(00)89069-8; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PAGANO RE, 1981, J CELL BIOL, V91, P872, DOI 10.1083/jcb.91.3.872; PASCHER I, 1976, BIOCHIM BIOPHYS ACTA, V455, P433, DOI 10.1016/0005-2736(76)90316-3; Pomorski T, 1996, J CELL SCI, V109, P687; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RUETZ S, 1995, J BIOL CHEM, V270, P25388, DOI 10.1074/jbc.270.43.25388; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; SMIT JJM, 1994, LAB INVEST, V71, P638; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; TANAKA T, 1993, BIOCHIM BIOPHYS ACTA, V1166, P264, DOI 10.1016/0005-2760(93)90107-K; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VALLARI DS, 1990, ARCH BIOCHEM BIOPHYS, V276, P538, DOI 10.1016/0003-9861(90)90756-O; van der Bijl P, 1996, J CELL BIOL, V132, P813, DOI 10.1083/jcb.132.5.813; VAN GENDEREN I, 1995, J CELL BIOL, V131, P645, DOI 10.1083/jcb.131.3.645; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANHELVOORT A, 1995, FEBS LETT, V369, P18, DOI 10.1016/0014-5793(95)00616-H	44	736	752	0	23	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1996	87	3					507	517		10.1016/S0092-8674(00)81370-7	http://dx.doi.org/10.1016/S0092-8674(00)81370-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898203	Green Published, Bronze			2022-12-28	WOS:A1996VQ46600016
J	Alonso, JM; Usrey, WM; Reid, RC				Alonso, JM; Usrey, WM; Reid, RC			Precisely correlated firing in cells of the lateral geniculate nucleus	NATURE			English	Article							CROSS-CORRELATION ANALYSIS; CAT STRIATE CORTEX; RETINAL GANGLION-CELLS; VISUAL-CORTEX; GENICULOCORTICAL AFFERENTS; ORIENTATION SELECTIVITY; ACTION-POTENTIALS; RECEPTIVE-FIELDS; CIRCUITS; NEURONS	SIMPLE cells within layer IV of the cat primary visual cortex are selective for lines of a specific orientation, It has been proposed that their receptive-field properties are established by the pattern of connections that they receive from the lateral geniculate nucleus (LGN) of the thalamus(1-5). Thalamic inputs, however, represent only a small proportion of the synapses made onto simple cells(6-8), and others have argued that corticocortical connections are likely to be important in shaping simple-cell response properties(9,11). Here we describe a mechanism that might be involved in selectively strengthening the effect of thalamic inputs, We show that neighbouring geniculate neurons with overlapping receptive fields of the same type (on-centre or off-centre) often fire spikes that are synchronized to within 1 millisecond, Moreover, these neurons often project to a common cortical target neuron where synchronous spikes are more effective in evoking a postsynaptic response. We propose that precisely correlated firing within a group of geniculate neurons could serve to reinforce the thalamic input to cortical simple cells.			Alonso, JM (corresponding author), ROCKEFELLER UNIV, NEUROBIOL LAB, NEW YORK, NY 10021 USA.							AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CLELAND BG, 1971, NATURE-NEW BIOL, V231, P191, DOI 10.1038/newbio231191a0; Dan Yang, 1996, Society for Neuroscience Abstracts, V22, P1703; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; ECKHORN R, 1993, J NEUROSCI METH, V49, P175, DOI 10.1016/0165-0270(93)90121-7; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; HAMOS JE, 1987, J COMP NEUROL, V259, P165, DOI 10.1002/cne.902590202; HIRSCH JA, 1995, NATURE, V378, P612, DOI 10.1038/378612a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; JONES JP, 1987, J NEUROPHYSIOL, V58, P1233, DOI 10.1152/jn.1987.58.6.1233; LEVAY S, 1976, BRAIN RES, V113, P1, DOI 10.1016/0006-8993(76)90002-0; MASTRONARDE DN, 1989, TRENDS NEUROSCI, V12, P75, DOI 10.1016/0166-2236(89)90140-9; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MEISTER M, 1995, SCIENCE, V270, P1207, DOI 10.1126/science.270.5239.1207; Neuenschwander S, 1996, NATURE, V379, P728, DOI 10.1038/379728a0; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; RODIECK RW, 1967, J NEUROPHYSIOL, V30, P1043, DOI 10.1152/jn.1967.30.5.1043; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SOMERS DC, 1995, J NEUROSCI, V15, P5448; STEVENS JK, 1976, J NEUROPHYSIOL, V39, P239, DOI 10.1152/jn.1976.39.2.239; Stratford KJ, 1996, NATURE, V382, P258, DOI 10.1038/382258a0; Sutter E.E., 1987, ADV METHODS PHYSIOLO, V1, P303; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303; TOYAMA K, 1981, J NEUROPHYSIOL, V46, P191, DOI 10.1152/jn.1981.46.2.191; TSO DY, 1986, J NEUROSCI, V6, P1160	30	358	362	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1996	383	6603					815	819		10.1038/383815a0	http://dx.doi.org/10.1038/383815a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893005				2022-12-28	WOS:A1996VQ14400061
J	dCruzGrote, D				dCruzGrote, D			Prevention of HIV infection in developing countries	LANCET			English	Article								The HIV/AIDS epidemic continues to spread rapidly in developing countries. Heterosexual transmission accounts for almost three-quarters of infections. Current strategies have been effective in the prevention of HIV spread within certain groups but they have had limited impact on the general spread of the epidemic. There is a need to complement these strategies with approaches that will influence the social and environmental determinants of risk to enable those vulnerable to infection to protect themselves.										ANKRAH ME, 1994, AIDS AFRICA, P553; ARMSTRONG S, 1993, WORLDAIDS        MAY; BALDO M, 1993, AM MED ASS MED BRIEF; BALDO M, 1995, 6 C AD HLTH YOUTH HL; BANG R, 1994, LISTENING WOMEN TALK; BELL RA, 1990, AIDS EDUC PREV, V2, P71; BRABIN L, 1995, LANCET, V345, P300, DOI 10.1016/S0140-6736(95)90281-3; Carballo Manuel, 1994, P497; CHANDRAMOULI V, 1993, 7 INT C AIDS AFR DEC; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; DECOSAS J, 1995, EUR C TROP MED HAMB; Fontanet A, 1994, Health Transit Rev, V4 Suppl, P11; FRANSEN L, 1991, HLTH POLICY PLANN, V6, P48; GBILLAH P, 1995, EFFECTIVE APPROACHES; *GERM FDN INT DEV, 1993, INT C POP OCT 1993; GUPTA GR, 1995, 3 USAID HIV AIDS PRE; GUPTA GR, 1993, ICRW POLICY SERIES, V1; HEISE LL, 1995, SOC SCI MED, V40, P931, DOI 10.1016/0277-9536(94)00165-P; JANA S, 1995, EFFECTIVE APPROACH P; *KIT SAFAIDS, 1995, FAC CHALL HIV AIDS S; KLOUDA T, 1995, J INT DEV, V7, P457; LENTON C, 1993, ESTABLISHMENT NATL N; LISKEN LS, 1989, POPULATION REPORTS 8, V8; MERSON MH, 1993, 9TH INT C AIDS BERL; MWIZARUBI BK, 1994, FOCUSING INTERVENTIO, V2, P109; *NAT AIDS CONTR PR, 1994, COUNTR SCEN UPD; OPPONG C, 1993, SOCIOECONOMIC ASPECT; PACHAURI S, 1995, LISTENING WOMEN TALK, P184; PACHAURI S, 1994, LISTENING WOMEN TALK; PIOT P, 1994, SEX TRANSM DIS S2, V21, P7; RADIKA R, 1993, SEXUAL BEHAV NETWORK, P175; Reid Elizabeth, 1992, P657; ROSA D, 1993, EFFECTIVE APPROACHES; SCHOPPER D, 1990, SOC SCI MED, V30, P1265, DOI 10.1016/0277-9536(90)90306-D; SCHULER SR, 1994, STUD FAMILY PLANN, V25, P65, DOI 10.2307/2138085; TAWIL O, 1995, AIDS, V9, P1299, DOI 10.1097/00002030-199512000-00001; *WHO, 1993, GLOB PROGR AIDS EFF; WILSON D, 1994, NARESA MONOGRAPH, V2, P83; *WOM DEV DIV WORLD, 1989, 269 WPS WOM DEV DIV; 1992, 8 INT C AIDS 3 STD W; 1995, GLOBAL PROGRAMME AID; 1995, PAN AFR C YOUTH DEV	42	43	44	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1071	1074		10.1016/S0140-6736(95)11031-3	http://dx.doi.org/10.1016/S0140-6736(95)11031-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VM886	8874461				2022-12-28	WOS:A1996VM88600014
J	FitzHenry, J; Riley, B				FitzHenry, J; Riley, B			Lesson of the Week - Thyrotoxicosis in a patient with multiple trauma: Value of ''AMPLE'' history taking	BRITISH MEDICAL JOURNAL			English	Article							THYROTROPIN; ILLNESS				FitzHenry, J (corresponding author), QUEENS MED CTR,ADULT INTENS CARE UNIT,NOTTINGHAM NG7 2UH,ENGLAND.							*AM COLL SURG COMM, 1993, ADV TRAUM LIF SUPP M; BONE RC, 1995, JAMA-J AM MED ASSOC, V273, P155, DOI 10.1001/jama.273.2.155; HAMBLIN PS, 1986, J CLIN ENDOCR METAB, V62, P717, DOI 10.1210/jcem-62-4-717; LECKIE RG, 1992, CLIN NUCL MED, V17, P859, DOI 10.1097/00003072-199211000-00003; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; WEHMANN RE, 1985, NEW ENGL J MED, V312, P546, DOI 10.1056/NEJM198502283120904	6	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					997	998						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892424				2022-12-28	WOS:A1996VN91600030
J	Roseman, AM; Chen, SX; White, H; Braig, K; Saibil, HR				Roseman, AM; Chen, SX; White, H; Braig, K; Saibil, HR			The chaperonin ATPase cycle: Mechanism of allosteric switching and movements of substrate-binding domains in GroEL	CELL			English	Article							CRYOELECTRON MICROSCOPY; PROTEIN SUBSTRATE; ESCHERICHIA-COLI; COOPERATIVITY; RESOLUTION; HYDROLYSIS; RELEASE; RECONSTITUTION; POLYPEPTIDE; NUCLEOTIDES	Chaperonin-assisted protein folding proceeds through cycles of ATP binding and hydrolysis by the large chaperonin GroEL, which undergoes major allosteric rearrangements. Interaction between the two back-to-back seven-membered rings of GroEL plays an important role in regulating binding and release of folding substrates and of the small chaperonin GroES. Using cryo-electron microscopy, we have obtained three-dimensional reconstructions to 30 Angstrom resolution for GroEL and GroEL-GroES complexes in the presence of ADP, ATP, and the nonhydrolyzable ATP analog, AMP-PNP. Nucleotide binding to the equatorial domains of GroEL causes large rotations of the apical domains, containing the GroES and substrate protein-binding sites. We propose a mechanism for allosteric switching and describe conformational changes that may be involved in critical steps of folding for substrates encapsulated by GroES.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University	Roseman, AM (corresponding author), UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,MALET ST,LONDON WC1E 7HX,ENGLAND.		Roseman, Alan/AAE-6689-2019	Roseman, Alan/0000-0002-4783-2619	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aharoni A, 1996, J MOL BIOL, V258, P732, DOI 10.1006/jmbi.1996.0282; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOROVITS BM, 1995, J BIOL CHEM, V270, P28551, DOI 10.1074/jbc.270.48.28551; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KOVALENKO O, 1994, BIOCHEMISTRY-US, V33, P14974, DOI 10.1021/bi00254a004; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RADERMACHER M, 1994, ULTRAMICROSCOPY, V53, P121, DOI 10.1016/0304-3991(94)90003-5; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028	41	345	347	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					241	251		10.1016/S0092-8674(00)81342-2	http://dx.doi.org/10.1016/S0092-8674(00)81342-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861908	hybrid			2022-12-28	WOS:A1996VN40300012
J	Sharara, AI; Hunt, CM; Hamilton, JD				Sharara, AI; Hunt, CM; Hamilton, JD			Hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Review							NON-B-HEPATITIS; CHRONIC ACTIVE HEPATITIS; POLYMERASE CHAIN-REACTION; INTERFERON-ALFA THERAPY; TERM FOLLOW-UP; CHRONIC NON-A; TRANSFUSION-ASSOCIATED HEPATITIS; RANDOMIZED CONTROLLED TRIAL; CHRONIC LIVER-DISEASE; RECOMBINANT ALPHA-INTERFERON	Objectives: To review the virology, epidemiology, pathogenesis, natural history, clinical manifestations, and current treatment of hepatitis C virus (HCV) infection. Data Sources: The MEDLINE database (1966 to 1996) was searched for English-language articles and abstracts on HCV and non-A, non-B hepatitis. Papers cited in relevant primary articles were also reviewed. Study Selection: More than 500 original and review articles were evaluated, and the most relevant were selected. Data Extraction: Data were extracted and reviewed by all authors. Data Synthesis: in most patients, HCV infection results in chronic hepatitis. The disease is insidious and subclinical but may progress over decades into end-stage liver disease and hepatocellular carcinoma, which makes HCV cirrhosis a leading indication for orthotopic liver transplantation. Current diagnostic methods are highly sensitive and specific, and quantitative assessment of viral load may help to predict and monitor response to treatment. The only available therapeutic option is interferon, and this agent is effective in only a small subset of patients. Conclusions: Infection with HCV is a significant public health problem that has important clinical and financial consequences. The tailoring of specific therapy according to viral load or genotype, better patient selection, and use of combination drug regimens may improve the chance of viral clearance and sustained biochemical and histologic response. Further understanding of the basic virology of HCV and the exact mechanisms of viral persistence and tissue injury is needed to help define future therapeutic and preventive strategies.	VET ADM MED CTR, DURHAM, NC USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Sharara, AI (corresponding author), DUKE UNIV, MED CTR, BOX 3083, DURHAM, NC 27710 USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; AKAHANE Y, 1994, ANN INTERN MED, V120, P748, DOI 10.7326/0003-4819-120-9-199405010-00005; ALFALEH FZ, 1991, HEPATOLOGY, V14, P215, DOI 10.1016/0270-9139(91)91405-P; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; ANDREONE P, 1993, J HEPATOL, V19, P228, DOI 10.1016/S0168-8278(05)80576-8; ANDREONE P, 1993, HEPATOLOGY, V18, pA221; ANDREONE P, 1994, GASTROENTEROLOGY, V106, pA859; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; ASCHER NL, 1994, HEPATOLOGY, V20, pS24; AVERBUCH SD, 1984, NEW ENGL J MED, V310, P32, DOI 10.1056/NEJM198401053100107; BATTEGAY M, 1995, J VIROL, V69, P2462, DOI 10.1128/JVI.69.4.2462-2470.1995; BELLOBUONO A, 1991, TRANSFUSION, V31, P475, DOI 10.1046/j.1537-2995.1991.31591263205.x; BELOQUI O, 1993, J INTERFERON RES, V13, P279, DOI 10.1089/jir.1993.13.279; BERRIS B, 1991, DIGEST DIS SCI, V36, P1657, DOI 10.1007/BF01296413; BJORO K, 1994, NEW ENGL J MED, V331, P1607, DOI 10.1056/NEJM199412153312402; BOKER KH, 1995, HEPATOLOGY, V22, pA134; BOUDART D, 1990, LANCET, V336, P63, DOI 10.1016/0140-6736(90)91585-X; BRILLANTI S, 1994, GASTROENTEROLOGY, V107, P812, DOI 10.1016/0016-5085(94)90131-7; BRIND AM, 1990, J MED VIROL, V32, P243, DOI 10.1002/jmv.1890320409; BRUIX J, 1989, LANCET, V2, P1004; BUCHBINDER SP, 1994, J INFECTION, V29, P263, DOI 10.1016/S0163-4453(94)91128-2; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; BUKH J, 1993, J INFECT DIS, V168, P1343, DOI 10.1093/infdis/168.6.1343; CAMARERO C, 1993, J PEDIATR-US, V123, P98, DOI 10.1016/S0022-3476(05)81549-5; CAMMA C, 1992, HEPATOLOGY, V16, pA131; CAMPS J, 1993, GUT, V34, P1714, DOI 10.1136/gut.34.12.1714; CAMPS J, 1993, J HEPATOL, V19, P408, DOI 10.1016/S0168-8278(05)80550-1; CASTILLA A, 1993, AM J GASTROENTEROL, V88, P233; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CASTILLO I, 1994, HEPATOLOGY, V19, P1342, DOI 10.1016/0270-9139(94)90225-9; CHAN TM, 1993, HEPATOLOGY, V17, P5, DOI 10.1016/0270-9139(93)90183-N; CHANG TT, 1994, J MED VIROL, V42, P91, DOI 10.1002/jmv.1890420117; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; CONLON PJ, 1993, IRISH J MED SCI, V162, P145, DOI 10.1007/BF02942105; DARWISH MA, 1993, AM J TROP MED HYG, V49, P440, DOI 10.4269/ajtmh.1993.49.440; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DAVIS GL, 1990, HEPATOLOGY, V12, P905; DECASTRO M, 1993, HEPATOLOGY, V17, P551, DOI 10.1002/hep.1840170405; DEMEDINA M, 1995, SEMIN LIVER DIS, V15, P33, DOI 10.1055/s-2007-1007261; DEMITRI MS, 1995, LANCET, V345, P413, DOI 10.1016/S0140-6736(95)90400-X; DENY P, 1992, J HEPATOL, V14, P409, DOI 10.1016/0168-8278(92)90197-W; DEYTON LR, 1989, NEW ENGL J MED, V321, P1246, DOI 10.1056/NEJM198911023211806; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIBISCEGLIE AM, 1992, HEPATOLOGY, V16, P649, DOI 10.1002/hep.1840160307; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; DIOGUARDI N, 1992, J HEPATOL, V14, P401; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; ERICKSON AL, 1993, J IMMUNOL, V151, P4189; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; FILIPIAK CL, 1994, HEPATOLOGY, V20, pA347; FINKELSTEIN SD, 1992, HEPATOLOGY, V16, pA132; FONG TL, 1994, GASTROENTEROLOGY, V107, P196, DOI 10.1016/0016-5085(94)90077-9; FRIED MW, 1995, SEMIN LIVER DIS, V15, P82, DOI 10.1055/s-2007-1007265; FUNK J, 1991, BRIT J DERMATOL, V125, P463, DOI 10.1111/j.1365-2133.1991.tb14774.x; GASPARINI V, 1991, EUR J EPIDEMIOL, V7, P665, DOI 10.1007/BF00218679; GERBERDING JL, 1994, J INFECT DIS, V170, P1410, DOI 10.1093/infdis/170.6.1410; GIL B, 1993, HEPATOLOGY, V18, P1050; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; GOODMAN ZD, 1995, SEMIN LIVER DIS, V15, P70, DOI 10.1055/s-2007-1007264; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; HADZIYANNIS SJ, 1993, J HEPATOL, V17, pS72, DOI 10.1016/S0168-8278(05)80428-3; HAYASHI H, 1994, AM J GASTROENTEROL, V89, P986; HOPF U, 1990, J HEPATOL, V10, P69, DOI 10.1016/0168-8278(90)90075-3; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; HSU HH, 1991, HEPATOLOGY, V14, P763, DOI 10.1002/hep.1840140504; HU KQ, 1992, J CLIN INVEST, V89, P2040, DOI 10.1172/JCI115815; IDEO G, 1990, LANCET, V335, P353, DOI 10.1016/0140-6736(90)90636-J; JANSSEN HLA, 1990, LANCET, V336, P1580, DOI 10.1016/0140-6736(90)93356-T; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; KASAHARA A, 1995, HEPATOLOGY, V21, P291, DOI 10.1016/0270-9139(95)90083-7; KATO N, 1994, J VIROL, V68, P4776, DOI 10.1128/JVI.68.8.4776-4784.1994; KATO N, 1993, J VIROL, V67, P3923, DOI 10.1128/JVI.67.7.3923-3930.1993; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KO YC, 1992, J MED VIROL, V38, P288, DOI 10.1002/jmv.1890380411; KORETZ RL, 1993, ANN INTERN MED, V119, P110, DOI 10.7326/0003-4819-119-2-199307150-00003; KOZIEL MJ, 1993, J VIROL, V67, P7522, DOI 10.1128/JVI.67.12.7522-7532.1993; KOZIEL MJ, 1992, J IMMUNOL, V149, P3339; KUBOKI M, 1993, GASTROENTEROLOGY, V104, pA931; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAMPERTICO P, 1994, HEPATOLOGY, V19, P19, DOI 10.1016/0270-9139(94)90047-7; LANFORD RE, 1995, J VIROL, V69, P8079, DOI 10.1128/JVI.69.12.8079-8083.1995; LEFKOWITCH JH, 1993, GASTROENTEROLOGY, V104, P595, DOI 10.1016/0016-5085(93)90432-C; LI XM, 1993, LANCET, V342, P1174, DOI 10.1016/0140-6736(93)92159-Q; LIANG TJ, 1993, HEPATOLOGY, V18, P1326, DOI 10.1016/0270-9139(93)90219-D; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; LIN HH, 1994, J INFECT DIS, V169, P638, DOI 10.1093/infdis/169.3.638; LIN R, 1993, GASTROENTEROL JPN, V28, P101, DOI 10.1007/BF02989217; LINDSAY KL, 1993, HEPATOLOGY, V18, pA106, DOI 10.1016/0270-9139(93)91952-O; LIOU TC, 1992, J MED VIROL, V37, P197, DOI 10.1002/jmv.1890370309; MARCELLIN P, 1991, HEPATOLOGY, V13, P393, DOI 10.1002/hep.1840130302; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; MATTERA D, 1993, GASTROENTEROLOGY, V104, pA951; MCDONALD EM, 1987, LANCET, V2, P1175; MCMAHON BJ, 1991, J NATL CANCER I, V83, P916, DOI 10.1093/jnci/83.13.916; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; MICHEL G, 1992, LANCET, V339, P267, DOI 10.1016/0140-6736(92)91332-3; MILELLA M, 1993, LIVER, V13, P146; MISIANI R, 1994, NEW ENGL J MED, V330, P751, DOI 10.1056/NEJM199403173301104; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; MIYAKAWA H, 1993, ALCOHOL ALCOHOLISM, V28, P85, DOI 10.1093/alcalc/28.Supplement_1A.85; MIZOKAMI M, 1994, HEPATOLOGY, V20, pA245; MOAZAMI G, 1995, AM J OPHTHALMOL, V119, P365, DOI 10.1016/S0002-9394(14)71182-1; MONDELLO P, 1992, INFECTION, V20, P51, DOI 10.1007/BF01704900; NAITO M, 1994, HEPATOLOGY, V19, P871, DOI 10.1002/hep.1840190411; NAKAGIRI I, 1993, J CLIN MICROBIOL, V31, P2974, DOI 10.1128/JCM.31.11.2974-2980.1993; NALPAS B, 1992, J HEPATOL, V14, P381, DOI 10.1016/0168-8278(92)90187-T; NISHIGUCHI S, 1992, ANN INTERN MED, V116, P21, DOI 10.7326/0003-4819-116-1-21; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; NIU MT, 1993, AM J KIDNEY DIS, V22, P568, DOI 10.1016/S0272-6386(12)80930-9; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; OLYNYK JK, 1995, GASTROENTEROLOGY, V108, P1104, DOI 10.1016/0016-5085(95)90209-0; OMATA M, 1991, LANCET, V338, P914, DOI 10.1016/0140-6736(91)91774-O; OSMOND DH, 1993, J INFECT DIS, V167, P66, DOI 10.1093/infdis/167.1.66; PAGLIARO L, 1994, HEPATOLOGY, V19, P820, DOI 10.1002/hep.1840190404; PAPO T, 1992, ANN INTERN MED, V116, P51, DOI 10.7326/0003-4819-116-1-51; PAPPAS SC, 1985, J MED VIROL, V15, P1, DOI 10.1002/jmv.1890150102; PARES A, 1990, HEPATOLOGY, V12, P1295, DOI 10.1002/hep.1840120608; PAWLOTSKY JM, 1994, HEPATOLOGY, V19, P841, DOI 10.1016/0270-9139(94)90281-X; PAWLOTSKY JM, 1995, ANN INTERN MED, V122, P169, DOI 10.7326/0003-4819-122-3-199502010-00002; PEREIRA BJG, 1991, NEW ENGL J MED, V325, P454, DOI 10.1056/NEJM199108153250702; PETERS M, 1989, SEMIN LIVER DIS, V9, P235, DOI 10.1055/s-2008-1040516; PIGNATELLI M, 1986, HEPATOLOGY, V6, P349, DOI 10.1002/hep.1840060303; POLISH LB, 1993, AM J INFECT CONTROL, V21, P196, DOI 10.1016/0196-6553(93)90031-X; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; PRIETO M, 1995, HEPATOLOGY, V22, P413, DOI 10.1016/0270-9139(95)90559-6; PRINCE AM, 1974, LANCET, V2, P241; PROTZER U, 1993, GASTROENTEROLOGY, V104, P903, DOI 10.1016/0016-5085(93)91029-H; READ AE, 1991, ANN INTERN MED, V114, P282, DOI 10.7326/0003-4819-114-4-282; REICHARD O, 1994, HEPATOLOGY, V19, P280; REICHARD O, 1993, J MED VIROL, V41, P99, DOI 10.1002/jmv.1890410203; RENAULT PF, 1987, ARCH INTERN MED, V147, P1577, DOI 10.1001/archinte.147.9.1577; RESNICK RH, 1993, ARCH INTERN MED, V153, P1672, DOI 10.1001/archinte.153.14.1672; REZAKOVIC I, 1993, HEPATOLOGY, V18, pA252, DOI 10.1016/0270-9139(93)92530-D; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SANCHEZQUIJANO A, 1990, EUR J CLIN MICROBIOL, V9, P610, DOI 10.1007/BF01967218; SARACCO G, 1993, HEPATOLOGY, V18, P1300, DOI 10.1002/hep.1840180603; SCARAGGI FA, 1993, LANCET, V342, P1300, DOI 10.1016/0140-6736(93)92391-6; SCHUPPER H, 1993, HEPATOLOGY, V18, P1055; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SEELIG R, 1994, ANN MED, V26, P45, DOI 10.3109/07853899409147326; Serfaty L, 1996, GASTROENTEROLOGY, V110, P291, DOI 10.1053/gast.1996.v110.pm8536870; SERFATY L, 1995, HEPATOLOGY, V21, P725; SHAKIL AO, 1995, ANN INTERN MED, V123, P330, DOI 10.7326/0003-4819-123-5-199509010-00002; SHIELL A, 1994, MED J AUSTRALIA, V160, P268, DOI 10.5694/j.1326-5377.1994.tb125830.x; SHIMIZU YK, 1994, J VIROL, V68, P1494, DOI 10.1128/JVI.68.3.1494-1500.1994; SHINDO M, 1995, ANN INTERN MED, V122, P586, DOI 10.7326/0003-4819-122-8-199504150-00005; SHINDO M, 1995, HEPATOLOGY, V22, P418, DOI 10.1002/hep.1840220208; SHINDO M, 1992, HEPATOLOGY, V15, P1013, DOI 10.1002/hep.1840150607; SHIRAI M, 1994, J VIROL, V68, P3334, DOI 10.1128/JVI.68.5.3334-3342.1994; SILVA M, 1992, Gastroenterology, V102, pA889; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; SIMMONDS P, 1995, HEPATOLOGY, V21, P570, DOI 10.1002/hep.1840210243; SIMONETTI RG, 1992, ANN INTERN MED, V116, P97, DOI 10.7326/0003-4819-116-2-97; SMEDLEY H, 1983, BRIT MED J, V286, P262, DOI 10.1136/bmj.286.6361.262; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; SUGIMOTO M, 1993, GASTROENTEROLOGY, V104, pA1001; SUOU T, 1995, HEPATOLOGY, V22, P426, DOI 10.1016/0270-9139(95)90561-8; TAKAHASHI M, 1994, ACTA MED OKAYAMA, V48, P293; TAKANO S, 1994, HEPATOLOGY, V20, P558, DOI 10.1016/0270-9139(94)90088-4; TANAKA K, 1991, CANCER RES, V51, P2842; THOMAS DL, 1995, J INFECT DIS, V171, P768, DOI 10.1093/infdis/171.4.768; TODROS L, 1991, J HEPATOL, V13, P128, DOI 10.1016/0168-8278(91)90874-B; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TONG MJ, 1993, HEPATOLOGY, V18, pA150, DOI 10.1016/0270-9139(93)92130-R; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0; VILADOMIU L, 1992, HEPATOLOGY, V15, P767, DOI 10.1002/hep.1840150504; VOGEL W, 1993, HEPATOLOGY, V18, pA89, DOI 10.1016/0270-9139(93)91885-V; WANDL UB, 1992, CLIN IMMUNOL IMMUNOP, V65, P70, DOI 10.1016/0090-1229(92)90250-R; WEINER A, 1995, P NATL ACAD SCI USA, V92, P2755, DOI 10.1073/pnas.92.7.2755; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; WEINSTEIN JS, 1994, HEPATOLOGY, V20, pA133; WESTH H, 1993, INFECTION, V21, P115, DOI 10.1007/BF01710745; WILSON SE, 1994, OPHTHALMOLOGY, V101, P736; WRIGHT TL, 1991, ANN INTERN MED, V115, P111, DOI 10.7326/0003-4819-115-2-111; WRIGHT TL, 1992, GASTROENTEROLOGY, V103, P317, DOI 10.1016/0016-5085(92)91129-R; WRIGHT TL, 1994, HEPATOLOGY, V20, P773, DOI 10.1002/hep.1840200402; YANAGI M, 1991, NEW ENGL J MED, V324, P1895, DOI 10.1056/NEJM199106273242615; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203; YOUNG KC, 1993, J MED VIROL, V41, P55, DOI 10.1002/jmv.1890410112; YOUNG KKY, 1993, J CLIN MICROBIOL, V31, P882, DOI 10.1128/JCM.31.4.882-886.1993; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3; ZEIN NN, 1995, MAYO CLIN PROC, V70, P449, DOI 10.4065/70.5.449	203	208	212	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					658	668		10.7326/0003-4819-125-8-199610150-00006	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM889	8849151				2022-12-28	WOS:A1996VM88900008
J	Raistrick, D; Hay, A; Wolff, K				Raistrick, D; Hay, A; Wolff, K			Methadone maintenance and tuberculosis treatment	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEEDS,SCH MED,DIV CLIN SCI,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; LEEDS ADDICT UNIT,LEEDS LS2 9NG,W YORKSHIRE,ENGLAND	University of Leeds			Raistrick, Duncan/AAR-5367-2020; Raistrick, Duncan/AGU-6223-2022	Wolff, Kim/0000-0001-9080-4720				BHATTI N, 1995, BRIT MED J, V310, P967, DOI 10.1136/bmj.310.6985.967; HAVERKOS HW, 1991, J SUBST ABUSE TREAT, V8, P269, DOI 10.1016/0740-5472(91)90050-K; KREEK MJ, 1976, NEW ENGL J MED, V294, P1104, DOI 10.1056/NEJM197605132942008; WOLFF K, 1993, EUR J CLIN PHARMACOL, V44, P189, DOI 10.1007/BF00315479; 1995, DRUG THER B, V33, P28	5	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					925	926						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876100				2022-12-28	WOS:A1996VM75400032
J	Donoghue, J; Tylee, A; Wildgust, H				Donoghue, J; Tylee, A; Wildgust, H			Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,ROYAL COLL GEN PRACTITIONERS,UNIT MENTAL HLTH EDUC,LONDON SW17 0RE,ENGLAND; LILLY IND,BASINGSTOKE RG21 2SY,HANTS,ENGLAND	St Georges University London	Donoghue, J (corresponding author), CLATTERBRIDGE HOSP,WIRRAL HOSP NHS TRUST,DEPT PHARM,PSYCHIAT SERV,WIRRAL L63 4JY,MERSEYSIDE,ENGLAND.		Tylee, Andre T/D-8468-2010					ALI IM, 1994, THESIS U WALES; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; KERR MP, 1994, BRIT J GEN PRACT, V44, P275; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; TURTON P, 1995, ED GEN PRACT, V6, P226	5	71	71	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					861	862						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870576				2022-12-28	WOS:A1996VL55900027
J	Geronimus, AT; Bound, J; Waidmann, TA; Hillemeier, MM; Burns, PB				Geronimus, AT; Bound, J; Waidmann, TA; Hillemeier, MM; Burns, PB			Excess mortality among blacks and whites in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOCIOECONOMIC-STATUS; HEALTH; HENRYISM; JOHN	Background Although the general relations between race, socioeconomic status, and mortality in the United States are well known, specific patterns of excess mortality are not well understood. Methods Using standard demographic techniques, we analyzed death certificates and census data and made sex-specific population-level estimates of the 1990 death rates for people 15 to 64 years of age. We studied mortality among blacks in selected areas of New York City, Detroit, Los Angeles, and Alabama (in one area of persistent poverty and one higher-income area each) and among whites in areas of New York City, metropolitan Detroit, Kentucky, and Alabama (one area of poverty and one higher-income area each). Sixteen areas were studied in all. Results When they were compared with the nationwide age-standardized annual death rare for whites, the death rates for both sexes in each of the poverty areas were excessive, especially among blacks (standardized mortality ratios for men and women in Harlem, 4.11 and 3.38; in Watts, 2.92 and 2.60; in central Detroit, 2.79 and 2.58; and in the Black Belt area of Alabama, 1.81 and 1.89). Boys in Harlem who reached the age of 15 had a 37 percent chance of surviving to the age of 65; for girls, the likelihood was 65 percent, Of the higher-income black areas studied, Queens-Bronx had the income level most similar to that of whites and the lowest standardized mortality ratios (men, 1.18; women, 1.08). Of the areas where poor whites were studied, Detroit had the highest standardized mortality ratios (men, 2.01; women, 1.90). On the Lower East Side of Manhattan, in Appalachia, and in Northeast Alabama, the ratios for whites were below the national average for blacks (men, 1.90; women, 1.95). Conclusions Although differences in mortality rates before the age of 65 between advantaged and disadvantaged groups in the United States are sometimes vast, there are important differences among impoverished communities in patterns of excess mortality. (C) 1996, Massachusetts Medical Society.	UNIV MICHIGAN,CTR POPULAT STUDIES,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT ECON,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT SOCIOL,ANN ARBOR,MI 48109; NATL BUR ECON RES,CAMBRIDGE,MA 02138; URBAN INST,CTR HLTH POLICY,WASHINGTON,DC 20037	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Bureau of Economic Research; Urban Institute	Geronimus, AT (corresponding author), UNIV MICHIGAN,SCH PUBL HLTH,DEPT HLTH BEHAV & HLTH EDUC,1420 WASHINGTON HTS,ANN ARBOR,MI 48109, USA.		Waidmann, Timothy/X-8811-2019; Hillemeier, Marianne/AAD-3566-2021	Waidmann, Timothy/0000-0001-7221-5068; 	PHS HHS [U83/CCU51249-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1985, REPORT SECRETARYS TA; *BUR CENS, 1990, CENS PUBL; *BUR LAB STAT, 1982, USDL PUBL; CHIANG CL, 1961, BIOMETRICS, V17, P57, DOI 10.2307/2527496; Chiang CL, 1984, LIFE TABLE ITS APPL; *DEP HLTH HUM SERV, 1990, DHHS PUBL; Elo IT, 1996, SOC SCI MED, V42, P47, DOI 10.1016/0277-9536(95)00062-3; Geronimus Arline T., 1992, Ethnicity and Disease, V2, P207; Geronimus AT, 1996, J AM STAT ASSOC, V91, P529, DOI 10.2307/2291645; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; JAMES SA, 1994, CULT MED PSYCHIAT, V18, P163, DOI 10.1007/BF01379448; JAMES SA, 1987, AM J EPIDEMIOL, V126, P664, DOI 10.1093/oxfordjournals.aje.a114706; KITAGAWA EM, 1964, DEMOGRAPHY, V1, P296, DOI 10.1007/BF03208469; Kokoski Mary, 1994, 256 BLS; MCCORD C, 1990, NEW ENGL J MED, V322, P173, DOI 10.1056/NEJM199001183220306; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PAPPAS G, 1993, NEW ENGL J MED, V329, P1139; SHRYOCK HS, 1975, METHODS MATERIALS DE; SMITH DP, 1992, FORMAL DEMOGRAPHY; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; WALLACE R, 1990, B NEW YORK ACAD MED, V66, P391	22	260	262	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1996	335	21					1552	1558		10.1056/NEJM199611213352102	http://dx.doi.org/10.1056/NEJM199611213352102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT341	8900087	Bronze			2022-12-28	WOS:A1996VT34100002
J	Kaplan, MM				Kaplan, MM			Medical progress - Primary biliary cirrhosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PRIMARY SCLEROSING CHOLANGITIS; CHRONIC ACTIVE HEPATITIS; PLACEBO-CONTROLLED TRIAL; PYRUVATE-DEHYDROGENASE COMPLEX; TERM FOLLOW-UP; URSODEOXYCHOLIC ACID; NATURAL-HISTORY; DIHYDROLIPOAMIDE ACETYLTRANSFERASE; LIVER-TRANSPLANTATION; HIGH PREVALENCE				Kaplan, MM (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,DIV GASTROENTEROL,750 WASHINGTON ST,BOSTON,MA 02111, USA.							AHRENS EH, 1950, MEDICINE, V29, P299, DOI 10.1097/00005792-195012000-00002; BACH N, 1994, J HEPATOL, V20, P698, DOI 10.1016/S0168-8278(05)80137-0; BACHS L, 1992, GASTROENTEROLOGY, V102, P2077, DOI 10.1016/0016-5085(92)90335-V; BALAN V, 1993, HEPATOLOGY, V18, P1392; BALASUBRAMANIAM K, 1990, GASTROENTEROLOGY, V98, P1567, DOI 10.1016/0016-5085(90)91091-J; BASSENDINE MF, 1985, GUT, V26, P1074, DOI 10.1136/gut.26.10.1074; BERGASA NV, 1992, GASTROENTEROLOGY, V102, P544, DOI 10.1016/0016-5085(92)90102-5; BESWICK DR, 1985, GASTROENTEROLOGY, V89, P267, DOI 10.1016/0016-5085(85)90325-7; BODENHEIMER HC, 1985, HEPATOLOGY, V5, P1139, DOI 10.1002/hep.1840050613; BOYER TD, 1994, HEPATOLOGY, V20, P1482, DOI 10.1002/hep.1840200617; BUSCHER HP, 1993, J HEPATOL, V18, P9, DOI 10.1016/S0168-8278(05)80004-2; BUTLER P, 1995, GUT, V36, P931, DOI 10.1136/gut.36.6.931; CALDWELL SH, 1992, HEPATOLOGY, V16, P899, DOI 10.1002/hep.1840160408; CAMISASCA M, 1994, HEPATOLOGY, V20, P633, DOI 10.1016/0270-9139(94)90098-1; CHRISTENSEN E, 1980, GASTROENTEROLOGY, V78, P236; CHRISTENSEN E, 1985, GASTROENTEROLOGY, V89, P1084, DOI 10.1016/0016-5085(85)90213-6; COHEN LB, 1985, GUT, V26, P291, DOI 10.1136/gut.26.3.291; COLINA F, 1992, GASTROENTEROLOGY, V102, P1319; COLUCCI G, 1986, CLIN IMMUNOL IMMUNOP, V41, P35, DOI 10.1016/0090-1229(86)90049-8; COMBES B, 1995, HEPATOLOGY, V22, P759, DOI 10.1016/0270-9139(95)90294-5; COPPEL RL, 1988, P NATL ACAD SCI USA, V85, P7317, DOI 10.1073/pnas.85.19.7317; CRIPPIN JS, 1992, HEPATOLOGY, V15, P858, DOI 10.1002/hep.1840150518; CULP KS, 1982, MAYO CLIN PROC, V57, P365; DAMICO E, 1995, DIGEST DIS SCI, V40, P2113, DOI 10.1007/BF02208992; DANIELSSON A, 1990, HEPATOLOGY, V11, P458, DOI 10.1002/hep.1840110317; DAVIES MH, 1995, J HEPATOL, V22, P551, DOI 10.1016/0168-8278(95)80450-1; DAVIS PA, 1992, HEPATOLOGY, V16, P1128, DOI 10.1016/0270-9139(92)90004-S; DICKSON ER, 1985, NEW ENGL J MED, V312, P1011, DOI 10.1056/NEJM198504183121602; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; ELTA GH, 1983, DIGEST DIS SCI, V28, P971, DOI 10.1007/BF01311724; FAKUNLE YM, 1979, CLIN EXP IMMUNOL, V38, P204; FLEMING CR, 1975, GASTROENTEROLOGY, V69, P220; FUSSEY SPM, 1989, FEBS LETT, V246, P49, DOI 10.1016/0014-5793(89)80251-0; GALBRAITH RM, 1974, NEW ENGL J MED, V290, P63, DOI 10.1056/NEJM197401102900201; GERSHWIN ME, 1991, GASTROENTEROLOGY, V100, P822, DOI 10.1016/0016-5085(91)80033-6; GHENT CN, 1977, GASTROENTEROLOGY, V73, P1125; GIOVANNINI A, 1985, BRIT J OPHTHALMOL, V69, P832, DOI 10.1136/bjo.69.11.832; GOLDBERG MJ, 1982, GASTROENTEROLOGY, V83, P677; GOODMAN ZD, 1995, DIGEST DIS SCI, V40, P1232, DOI 10.1007/BF02065530; GOUW ASH, 1994, J HEPATOL, V20, P500, DOI 10.1016/S0168-8278(05)80497-0; GRAMBSCH PM, 1989, HEPATOLOGY, V10, P846, DOI 10.1002/hep.1840100516; GREGORY WL, 1993, Q J MED, V86, P393; GREGORY WL, 1994, ATHEROSCLEROSIS, V105, P43, DOI 10.1016/0021-9150(94)90006-X; GUANABENS N, 1992, J HEPATOL, V15, P345, DOI 10.1016/0168-8278(92)90066-X; HASHIMOTO E, 1993, MAYO CLIN PROC, V68, P1049, DOI 10.1016/S0025-6196(12)60897-0; HEATHCOTE EJ, 1995, GASTROENTEROLOGY, V108, pA1082, DOI 10.1016/0016-5085(95)28629-2; HEATHCOTE EJ, 1994, HEPATOLOGY, V19, P1149, DOI 10.1002/hep.1840190512; HERLONG HF, 1982, GASTROENTEROLOGY, V83, P103; HEUMAN DM, 1991, HEPATOLOGY, V14, P920, DOI 10.1002/hep.1840140527; IANNUZZI C, 1993, ACTA CHIR BELG, V93, P147; JAHN CE, 1985, GASTROENTEROLOGY, V89, P1266, DOI 10.1016/0016-5085(85)90642-0; JAMES SP, 1985, J CLIN IMMUNOL, V5, P254, DOI 10.1007/BF00929460; JAMES SP, 1980, J CLIN INVEST, V66, P1305, DOI 10.1172/JCI109982; JAMES SP, 1986, GASTROENTEROLOGY, V90, P283, DOI 10.1016/0016-5085(86)90922-4; JAMES SP, 1983, ANN INTERN MED, V99, P500, DOI 10.7326/0003-4819-99-4-500; JANES CH, 1995, J CLIN INVEST, V95, P2581, DOI 10.1172/JCI117959; JONES DEJ, 1995, HEPATOLOGY, V21, P995, DOI 10.1002/hep.1840210417; JORGENSEN RA, 1995, GUT, V36, P935, DOI 10.1136/gut.36.6.935; KAPLAN M, 1993, HEPATOLOGY, V18, pA176; KAPLAN MM, 1994, NEW ENGL J MED, V330, P1386, DOI 10.1056/NEJM199405123301912; KAPLAN MM, 1987, NEW ENGL J MED, V316, P521, DOI 10.1056/NEJM198702263160907; KAPLAN MM, 1988, GASTROENTEROLOGY, V95, P787, DOI 10.1016/S0016-5085(88)80029-5; KAPLAN MM, 1986, NEW ENGL J MED, V315, P1448, DOI 10.1056/NEJM198612043152304; KAPLAN MM, 1981, GASTROENTEROLOGY, V81, P681; KAPLAN MM, 1995, GASTROENTEROLOGY, V108, pA1094; KAPLAN MM, 1994, HEPATOLOGY, V20, pA152; KAPLAN MM, 1994, NEW ENGL J MED, V331, P952, DOI 10.1056/NEJM199410063311418; KAPLAN MM, 1991, GASTROENTEROLOGY, V101, P1332, DOI 10.1016/0016-5085(91)90085-Y; KAPLAN MM, 1992, HEPATOLOGY, V16, pA92; KNEPPELHOUT JC, 1992, NETH J MED, V41, P11; KOWDLEY KV, 1994, DIGEST DIS SCI, V39, P2416, DOI 10.1007/BF02087659; KRAMS SM, 1989, HEPATOLOGY, V9, P411, DOI 10.1002/hep.1840090311; LANSPA SJ, 1985, HEPATOLOGY, V5, P837, DOI 10.1002/hep.1840050522; LAURIN JM, 1994, AM J GASTROENTEROL, V89, P1840; LINDGREN S, 1982, J LAB CLIN MED, V99, P636; LINDGREN S, 1985, J LAB CLIN MED, V105, P432; LINDOR KD, 1995, HEPATOLOGY, V22, P1158; LINDOR KD, 1994, GASTROENTEROLOGY, V106, P1284, DOI 10.1016/0016-5085(94)90021-3; LINDORKD, 1995, HEPATOLOGY, V21, P389; LOMBARD M, 1993, GASTROENTEROLOGY, V104, P519, DOI 10.1016/0016-5085(93)90422-9; LONG RG, 1977, GASTROENTEROLOGY, V72, P1204; LOOF L, 1994, HEPATOLOGY, V20, P101, DOI 10.1016/0270-9139(94)90140-6; LUDWIG J, 1987, SEMIN LIVER DIS, V7, P293, DOI 10.1055/s-2008-1040584; MACSWEEN RN, 1973, J CLIN PATHOL, V26, P340, DOI 10.1136/jcp.26.5.340; MACSWEEN RNM, 1985, MOL ASPECTS MED, V8, P269, DOI 10.1016/0098-2997(85)90010-X; MAHL TC, 1994, J HEPATOL, V20, P707, DOI 10.1016/S0168-8278(05)80139-4; MARKUS BH, 1989, NEW ENGL J MED, V320, P1709, DOI 10.1056/NEJM198906293202602; MATLOFF DS, 1982, GASTROENTEROLOGY, V83, P97; MELLA JG, 1995, HEPATOLOGY, V21, P398, DOI 10.1002/hep.1840210221; MENENDEZ JL, 1992, HEPATOLOGY, V16, P931, DOI 10.1002/hep.1840160413; MILLER KB, 1984, ANN INTERN MED, V100, P385, DOI 10.7326/0003-4819-100-3-385; MILLER KB, 1983, AM J MED, V75, P75, DOI 10.1016/0002-9343(83)91170-1; MILLER LC, 1995, HEPATOLOGY, V22, P518, DOI 10.1002/hep.1840220222; MINUK GY, 1989, J ALLERGY CLIN IMMUN, V83, P462, DOI 10.1016/0091-6749(89)90134-6; MITCHISON HC, 1992, J HEPATOL, V15, P336, DOI 10.1016/0168-8278(92)90065-W; MIYAMOTO T, 1995, J HEPATOL, V22, P423, DOI 10.1016/0168-8278(95)80105-7; MOEBIUS U, 1990, EUR J IMMUNOL, V20, P889, DOI 10.1002/eji.1830200426; MORADPOUR D, 1994, HEPATOLOGY, V20, P1437, DOI 10.1002/hep.1840200610; MORENOOTERO R, 1994, HEPATO-GASTROENTEROL, V41, P239; MYSZOR M, 1990, Q J MED, V75, P377; NAKANUMA Y, 1993, HEPATOLOGY, V18, P570, DOI 10.1002/hep.1840180315; NAVASA M, 1987, J HEPATOL, V5, P292, DOI 10.1016/S0168-8278(87)80035-1; NOURIARIA KT, 1985, CLIN EXP IMMUNOL, V61, P297; OLOMU AB, 1988, NEW ENGL J MED, V318, P1089, DOI 10.1056/NEJM198804283181703; OUTWATER E, 1989, RADIOLOGY, V171, P731, DOI 10.1148/radiology.171.3.2717743; PALMER JM, 1993, J HEPATOL, V18, P251, DOI 10.1016/S0168-8278(05)80253-3; PARES A, 1981, GASTROENTEROLOGY, V80, P681; PARES A, 1985, DIGEST DIS SCI, V30, P829, DOI 10.1007/BF01309512; PARVEEN S, 1995, J GASTROEN HEPATOL, V10, P438, DOI 10.1111/j.1440-1746.1995.tb01597.x; PENNER E, 1987, CLIN EXP IMMUNOL, V70, P47; PENNER E, 1986, GASTROENTEROLOGY, V90, P724, DOI 10.1016/0016-5085(86)91129-7; PORTMANN B, 1985, GASTROENTEROLOGY, V88, P1777, DOI 10.1016/0016-5085(85)90001-0; POUPON RE, 1993, HEPATOLOGY, V17, P577, DOI 10.1002/hep.1840170408; POUPON RE, 1994, NEW ENGL J MED, V330, P1342, DOI 10.1056/NEJM199405123301903; POUPON RE, 1994, HEPATOLOGY, V19, P635, DOI 10.1002/hep.1840190314; REYNOLDS TB, 1971, AM J MED, V50, P302, DOI 10.1016/0002-9343(71)90218-X; ROBERTSTHOMSON PJ, 1990, GUT, V31, P88, DOI 10.1136/gut.31.1.88; ROLL J, 1983, NEW ENGL J MED, V308, P1, DOI 10.1056/NEJM198301063080101; ROS E, 1984, GASTROENTEROLOGY, V87, P180; SCHAFFNER F, 1975, CLIN GASTROENTEROL, V4, P351; SCHEUER PJ, 1967, P ROY SOC MED, V60, P1257, DOI 10.1177/003591576706001205; SCHUSSLER GC, 1978, NEW ENGL J MED, V299, P510, DOI 10.1056/NEJM197809072991003; SHARMA A, 1994, GASTROENTEROLOGY, V107, P266, DOI 10.1016/0016-5085(94)90085-X; SHERLOCK S, 1973, NEW ENGL J MED, V289, P674, DOI 10.1056/NEJM197309272891306; SHIBATA J, 1992, J GASTROEN HEPATOL, V7, P277, DOI 10.1111/j.1440-1746.1992.tb00980.x; SIMON JB, 1978, GASTROENTEROLOGY, V75, P177; SPENGLER U, 1992, J HEPATOL, V15, P129, DOI 10.1016/0168-8278(92)90024-J; SUMMERFIELD JA, 1976, GASTROENTEROLOGY, V70, P240; SUNDEWALL AC, 1985, ACTA MED SCAND, V217, P519; SUOU T, 1989, HEPATOLOGY, V10, P408, DOI 10.1002/hep.1840100403; THOMAS HC, 1976, GUT, V17, P844, DOI 10.1136/gut.17.11.844; THORNTON JR, 1989, Q J MED, V71, P467; TONG MJ, 1976, GASTROENTEROLOGY, V71, P305; TORNAY AS, 1980, AM J GASTROENTEROL, V73, P223; TSIANOS EV, 1990, HEPATOLOGY, V11, P730, DOI 10.1002/hep.1840110504; TSUNEYAMA K, 1995, HEPATOLOGY, V21, P1031, DOI 10.1016/0270-9139(95)90251-1; UNDERHILL J, 1992, HEPATOLOGY, V16, P1404, DOI 10.1002/hep.1840160616; UNDERHILL JA, 1995, HEPATOLOGY, V21, P959, DOI 10.1002/hep.1840210411; VANDEWATER J, 1989, NEW ENGL J MED, V320, P1377, DOI 10.1056/NEJM198905253202104; VANDEWATER J, 1991, J IMMUNOL, V146, P89; VANDEWATER J, 1988, J IMMUNOL, V141, P2321; VANDEWATER J, 1993, J CLIN INVEST, V91, P2653, DOI 10.1172/JCI116504; VAUX DJT, 1985, J CLIN PATHOL, V38, P653, DOI 10.1136/jcp.38.6.653; VILLENEUVE JP, 1991, CAN J GASTROENTEROL, V5, P174; VUORISTO M, 1995, GASTROENTEROLOGY, V108, P1470, DOI 10.1016/0016-5085(95)90696-7; WALKER JG, 1965, LANCET, V1, P827; WARNES TW, 1987, J HEPATOL, V5, P1, DOI 10.1016/S0168-8278(87)80053-3; WATSON RGP, 1995, GUT, V36, P927, DOI 10.1136/gut.36.6.927; WESIERSKAGADEK J, 1995, J EXP MED, V182, P1159, DOI 10.1084/jem.182.4.1159; WIESNER RH, 1990, NEW ENGL J MED, V322, P1419, DOI 10.1056/NEJM199005173222003; WITTSULLIVAN H, 1990, HEPATOLOGY, V12, P98, DOI 10.1002/hep.1840120116; YASOSHIMA M, 1995, J PATHOL, V175, P319, DOI 10.1002/path.1711750310; ZIFRONI A, 1991, HEPATOLOGY, V14, P990, DOI 10.1016/0270-9139(91)90117-E	153	463	475	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1996	335	21					1570	1580		10.1056/NEJM199611213352107	http://dx.doi.org/10.1056/NEJM199611213352107			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT341	8900092				2022-12-28	WOS:A1996VT34100007
J	Horton, R				Horton, R			Luck, lotteries, and loopholes of grant review	LANCET			English	Editorial Material																		Cole S, 1992, MAKING SCI NATURE SO; HORROBIN DF, 1990, JAMA-J AM MED ASSOC, V263, P1438, DOI 10.1001/jama.263.10.1438; TAYLOR R, 1995, NATURE, V375, P438, DOI 10.1038/375438a0	3	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1255	1256		10.1016/S0140-6736(05)65751-0	http://dx.doi.org/10.1016/S0140-6736(05)65751-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909373				2022-12-28	WOS:A1996VR55500003
J	Juskaitis, R; Wilson, T; Neil, MAA; Kozubek, M				Juskaitis, R; Wilson, T; Neil, MAA; Kozubek, M			Efficient real-time confocal microscopy with white light sources	NATURE			English	Article								THE main advantage of confocal microscopes over their conventional counterparts arises from their ability to optically 'section' nearly transparent materials; the thin image slices thus obtained can be used to reconstruct three-dimensional images, a capability which is particularly useful for the study of biological specimens, Confocal microscopes have previously used either a single laser-illuminated point-source and single point-detector (which are scanned in tandem across the object) or white-light illumination with multiple point-sources and detectors, Single-point-source systems, however, do not usually form images in real time and are restricted to using available laser wavelengths, Multiple-point-source systems, on the other hand, produce images in real time but use light very inefficiently-typically 1% or less is used for imaging, Here we demonstrate a white-light, multiple-point-source method which can in principle produce images in real time,vith light efficiencies as high as 50%. This system is likely to find broad practical application, particularly in the imaging of weakly reflecting or weakly fluorescent specimens.	UNIV OXFORD,DEPT ENGN SCI,OXFORD OX1 3PJ,ENGLAND	University of Oxford			Kozubek, Michal/G-8939-2013; Neil, Mark A/B-1184-2010	Kozubek, Michal/0000-0001-7902-589X; Neil, Mark A/0000-0002-7720-8868				BOYDE A, 1993, ELECT LIGHT MICROSCO; GOLAY MJE, 1949, J OPT SOC AM, V39, P437, DOI 10.1364/JOSA.39.000437; PETRAN M, 1968, J OPT SOC AM, V58, P661, DOI 10.1364/JOSA.58.000661; WILSON T, 1991, J MICROSC-OXFORD, V163, P131, DOI 10.1111/j.1365-2818.1991.tb03167.x; Wilson T., 1990, CONFOCAL MICROSCOPY	5	70	83	1	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					804	806		10.1038/383804a0	http://dx.doi.org/10.1038/383804a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893003				2022-12-28	WOS:A1996VQ14400057
J	Reiser, H; Stadecker, MJ				Reiser, H; Stadecker, MJ			Mechanisms of disease - Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							T-CELL ACTIVATION; IN-VITRO; CD28-MEDIATED COSTIMULATION; MYCOBACTERIAL INFECTION; MURINE-B7 ANTIGEN; ADDITIONAL LIGAND; IMMUNE-RESPONSE; LYMPHOCYTES-T; CTLA-4; EXPRESSION		TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; DANA FARBER CANC INST,DIV LYMPHOCYTE BIOL,BOSTON,MA 02115; TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111	Tufts University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Tufts Medical Center					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033679, R01AI018919, R22AI018919] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18919, AI-33679, AI-35287] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CORRY DB, 1994, J IMMUNOL, V153, P4142; CROFT M, 1994, J IMMUNOL, V152, P2675; DEBOER M, 1993, EUR J IMMUNOL, V23, P3120, DOI 10.1002/eji.1830231212; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; FloresVillanueva PO, 1996, J IMMUNOL, V156, P3315; FREEMAN GJ, 1993, J EXP MED, V178, P2185, DOI 10.1084/jem.178.6.2185; GALVIN F, 1992, J IMMUNOL, V149, P3802; GALVIN F, 1993, EUR J IMMUNOL, V23, P283, DOI 10.1002/eji.1830230145; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; GUINAN EC, 1994, BLOOD, V84, P3261; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; HAFFAR OK, 1993, P NATL ACAD SCI USA, V90, P11094, DOI 10.1073/pnas.90.23.11094; HARDING FA, 1993, J EXP MED, V177, P1791, DOI 10.1084/jem.177.6.1791; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; INABA K, 1994, J EXP MED, V180, P1849, DOI 10.1084/jem.180.5.1849; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KAYE PM, 1994, EUR J IMMUNOL, V24, P2850, DOI 10.1002/eji.1830241140; King CL, 1996, J IMMUNOL, V156, P4715; KNOERZER DB, 1995, J CLIN INVEST, V96, P987, DOI 10.1172/JCI118146; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; LENSCHOW DJ, 1993, P NATL ACAD SCI USA, V90, P11054, DOI 10.1073/pnas.90.23.11054; LEVINE BL, 1995, INT IMMUNOL, V7, P891, DOI 10.1093/intimm/7.6.891; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; LEWIS DE, 1994, J IMMUNOL, V153, P412; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LINSLEY PS, 1995, IMMUNITY, V2, pA203; LIU Y, 1991, INT IMMUNOL, V3, P323, DOI 10.1093/intimm/3.4.323; LUCAS PJ, 1995, J IMMUNOL, V154, P5757; MAHANTY S, 1995, PARASITE IMMUNOL, V17, P385, DOI 10.1111/j.1365-3024.1995.tb00906.x; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Miller SD, 1995, IMMUNITY, V3, P739, DOI 10.1016/1074-7613(95)90063-2; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; MURAILLE E, 1995, CELL IMMUNOL, V162, P315, DOI 10.1006/cimm.1995.1084; NAKAJIMA A, 1995, EUR J IMMUNOL, V25, P3060, DOI 10.1002/eji.1830251112; NANDI D, 1994, J IMMUNOL, V152, P3361; NARESAN M, 1996, J IMMUNOL, V156, P2783; POWRIE F, 1995, IMMUNITY, V3, P171, DOI 10.1016/1074-7613(95)90086-1; Rathore A, 1996, AM J PATHOL, V149, P187; RAZIWOLF Z, 1993, P NATL ACAD SCI USA, V90, P11182, DOI 10.1073/pnas.90.23.11182; RaziWolf Z, 1996, P NATL ACAD SCI USA, V93, P2903, DOI 10.1073/pnas.93.7.2903; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; Reiser H, 1996, EUR J IMMUNOL, V26, P880, DOI 10.1002/eji.1830260424; REISER H, 1992, P NATL ACAD SCI USA, V89, P271, DOI 10.1073/pnas.89.1.271; Rocken M, 1996, IMMUNOL TODAY, V17, P225, DOI 10.1016/0167-5699(96)80556-1; SAHA B, 1994, EUR J IMMUNOL, V24, P2618, DOI 10.1002/eji.1830241108; SCHNEIDER H, 1995, J EXP MED, V181, P351, DOI 10.1084/jem.181.1.351; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SIELING PA, 1994, IMMUNOBIOLOGY, V191, P378, DOI 10.1016/S0171-2985(11)80443-2; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SPERLING AI, 1993, J IMMUNOL, V151, P6043; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; VILLANUEVA POF, 1994, J IMMUNOL, V152, P1847; VILLANUEVA POF, 1994, J IMMUNOL, V153, P5190; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P85; Wetzler LW, 1996, J EXP MED, V183, P1151, DOI 10.1084/jem.183.3.1151; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; WU Y, 1993, J EXP MED, V178, P1789, DOI 10.1084/jem.178.5.1789; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	70	195	204	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1996	335	18					1369	1377		10.1056/NEJM199610313351807	http://dx.doi.org/10.1056/NEJM199610313351807			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP484	8857022				2022-12-28	WOS:A1996VP48400007
J	Simpson, HK; Smith, GB				Simpson, HK; Smith, GB			Survey of paramedic skills in the United Kingdom and Channel Islands	BRITISH MEDICAL JOURNAL			English	Article											Simpson, HK (corresponding author), QUEEN ALEXANDRA HOSP,PORTSMOUTH HOSP NHS TRUST,DEPT INTENS CARE MED,PORTSMOUTH PO6 3LY,HANTS,ENGLAND.							*ADV LIF SUPP GROU, 1993, ADV PAED LIF SUPP PR; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; *DEP HLTH SOC SEC, 1984, DA8412 DHSS; NAKAYAMA DK, 1990, ANN SURG, V211, P218, DOI 10.1097/00000658-199002000-00015	4	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1052	1053						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898597				2022-12-28	WOS:A1996VP74200027
J	Gill, PS; LunardiIskandar, Y; Louie, S; Tulpule, A; Zheng, T; Espina, BM; Besnier, JM; Hermans, P; Levine, AM; Bryant, JL; Gallo, RC				Gill, PS; LunardiIskandar, Y; Louie, S; Tulpule, A; Zheng, T; Espina, BM; Besnier, JM; Hermans, P; Levine, AM; Bryant, JL; Gallo, RC			The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM CULTURE; GROWTH-FACTOR; ONCOSTATIN-M; CELLS; VINCRISTINE; ZIDOVUDINE; BLEOMYCIN; AUTOCRINE; PARACRINE; RECEPTOR	Background Kaposi's sarcoma is the most common cancer in patients with the acquired immunodeficiency syndrome (AIDS). Recently, certain preparations of human chorionic gonadotropin (hCG) have been shown to inhibit the growth of Kaposi's sarcoma cell lines in vitro and in immunodeficient mice. Methods After in vitro evaluation of four commercially available hCG preparations, the most active product was evaluated in 36 patients with AIDS-related Kaposi's sarcoma. In a phase 1-2 trial, 24 patients received intralesional injections of hCG three times a week for two weeks at doses of 250, 500, 1000, or 2000 IU (6 patients each). In each patient three nodular lesions were injected, two with the drug and one with diluent alone. In a double-blind trial, 12 additional patients were randomly assigned to receive intralesional injections of 2000 IU of hCG or diluent alone (6 patients each; two lesions per patient). At the conclusion of therapy, the lesions were measured, their gross appearance assessed, and biopsy specimens evaluated. Results A.P.L. (Wyeth-Ayerst), which had the most in vitro activity against Kaposi's sarcoma cell lines, was selected for the clinical investigation. Treatment with A.P.L. was well tolerated at all doses. In the cohorts given 250, 500, 1000, and 2000 IU, 1, 5, 5, and 10 of the 12 injected lesions responded, respectively (P=0.03 for trend). Complete tumor regression was observed in one lesion each at the 250-IU and 500-IU doses, in two lesions given the 1000-IU dose, and in five lesions given the 2000-IU dose. In the double-blind study, none of the 12 lesions in the six patients injected with diluent had responses, as compared with 10 of the 12 lesions in the six patients injected with hCG (P=0.015). Microscopical evidence of apoptosis was observed only in hCG-treated lesions. The percentage of cells that died increased in a dose-dependent manner (P<0.001). Serum levels of follicle-stimulating hormone (P=0.002) and luteinizing hormone (P=0.001) declined after the last injection of hCG, but there was no effect on these hormones in the diluent-treated patients. Conclusions The intralesional injection of hCG induces the regression of AIDS-related Kaposi's sarcoma lesions in a dose-dependent manner. The response of these tumors appears to be mediated by the induction of apoptosis. (C) 1996, Massachusetts Medical Society.	UNIV SO CALIF,SCH MED,DEPT INTERNAL MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PHARM,LOS ANGELES,CA 90033; UNIV MARYLAND,INST HUMAN VIROL,BALTIMORE,MD 21201; FREE UNIV BRUSSELS,ST PIERRE HOSP,DEPT INFECT DIS,BRUSSELS,BELGIUM; GYNECOL & OBSTET MED CTR,PARIS,FRANCE	University of Southern California; University of Southern California; University System of Maryland; University of Maryland Baltimore; Universite Libre de Bruxelles; Vrije Universiteit Brussel					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048499] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51621] Funding Source: Medline; NHLBI NIH HHS [HL 48499] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; CHAK LY, 1988, J CLIN ONCOL, V6, P863, DOI 10.1200/JCO.1988.6.5.863; *CTR DIS CONTR PRE, 1993, HIV AIDS SURV REP US; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; EVANS LM, 1991, J IMMUNOTHER, V10, P39, DOI 10.1097/00002371-199102000-00006; Gelmann E P, 1987, Am J Med, V82, P456, DOI 10.1016/0002-9343(87)90445-1; GILL P, 1990, AM J CLIN ONCOL-CANC, V13, P315, DOI 10.1097/00000421-199008000-00010; GILL PS, 1991, AM J MED, V90, P427, DOI 10.1016/0002-9343(91)80081-V; GILL PS, 1994, AIDS, V8, P1695, DOI 10.1097/00002030-199412000-00009; HOOVER DR, 1993, AM J EPIDEMIOL, V138, P266, DOI 10.1093/oxfordjournals.aje.a116855; KOVACS JA, 1989, ANN INTERN MED, V111, P280, DOI 10.7326/0003-4819-111-4-280; LOUIE S, 1995, J ACQ IMMUN DEF SYND, V8, P455, DOI 10.1097/00042560-199504120-00004; LUNARDIISKANDAR Y, 1995, NATURE, V375, P64, DOI 10.1038/375064a0; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; LUNARDIISKANDAR Y, 1995, NATURE, V76, P447; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; Popescu NC, 1996, J NATL CANCER I, V88, P450, DOI 10.1093/jnci/88.7.450; ROTH WK, 1989, ONCOGENE, V4, P483; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SAS Inst. Inc, 1988, SAS STAT US GUID REL, P1028; SIEGAL B, 1990, CANCER, V65, P492, DOI 10.1002/1097-0142(19900201)65:3<492::AID-CNCR2820650320>3.0.CO;2-C; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4	28	115	123	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1261	1269		10.1056/NEJM199610243351702	http://dx.doi.org/10.1056/NEJM199610243351702			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857005				2022-12-28	WOS:A1996VN59400002
J	Peters, AL; Davidson, MB; Schriger, DL; Hasselblad, V				Peters, AL; Davidson, MB; Schriger, DL; Hasselblad, V			A clinical approach for the diagnosis of diabetes mellitus - An analysis using glycosylated hemoglobin levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL GLUCOSE-TOLERANCE; FASTING PLASMA-GLUCOSE; GLYCATED HEMOGLOBIN; INSULIN; TESTS; COMPLICATIONS; FRUCTOSAMINE; INTOLERANCE; POPULATION; ASSAY	Objective.-To determine whether a glycosylated hemoglobin level can be used in place of an oral glucose tolerance test (OGTT) to diagnose diabetes. Data Sources/Study Selection.-An augmented MEDLINE search was performed to identify all reports from 1966 through June 1994 in which glycosylated hemoglobin levels were measured concurrently with performance of OGTTs in the same study, The corresponding authors were contacted and asked to provide individual data for all subjects tested. A total of 31 investigators representing 34 possible studies responded, and 18 were able to provide us with the data requested, Overall fasting plasma glucose concentrations, 2-hour postdextrose glucose concentrations, and glycosylated hemoglobin levels were available from 11 276 individuals. Data Extraction-To define normal glucose tolerance, impaired glucose tolerance (IGT), and diabetes, modified World Health Organization criteria were used. Data Synthesis.-An analysis of the methods used for measurement of glycosylated hemoglobin levels revealed that the HbA(1c) assay showed the least variance in normal subjects. Therefore, only data from the 8984 subjects who had HbA(1c) levels measured were used. When we used the mean HbA(1c) level plus 4 SDs as a cutpoint, the sensitivity was 36% and specificity was 100% compared with the results of the OGTT, Because of the lack of agreement between OGTT results and HbA(1c) levels, models were created to analyze the distribution of HbA(1c) levels in each study, Using these models, we identified 3 subpopulations. The third subpopulation was likely to represent subjects with diabetes. When we applied an HbA(1c) level of 7.0% as a cutpoint, the sensitivity was 99.6% for the third subpopulation. When this cutpoint was reapplied to the OGTT results, of those subjects with an HbA(1c) level of at least 7.0%, 89% had diabetes, 7% had IGT, and 4% were normal. Conclusions.-Although the OGTT is the ''gold standard'' for diagnosing diabetes, it is known to be poorly reproducible and is often not performed. Not only is use of an HbA(1c) level to diagnose diabetes more convenient, but therapeutic decisions are based on this value, regardless of the findings on the OGTT. An HbA(1c) level of 7.0% or higher often requires pharmacological intervention and is most often associated with the diagnosis of diabetes by World Health Organization standards. An HbA(1c) level below 7.0% would generally be treated with diet and exercise, regardless of the diagnosis of IGT or diabetes by OGTT. Thus, measurement of HbA(1c) levels may represent a reasonable approach to identifying treatment-requiring diabetes.	CITY HOPE NATL MED CTR, DEPT DIABET ENDOCRINOL & METAB, DUARTE, CA 91010 USA; UNIV CALIF LOS ANGELES, SCH MED, CTR EMERGENCY MED, LOS ANGELES, CA USA; DUKE UNIV, CTR HLTH POLICY RES & EDUC, DURHAM, NC USA	City of Hope; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke University	Peters, AL (corresponding author), UNIV CALIF LOS ANGELES, DEPT MED, SCH MED, 200 UCLA MED PLAZA, SUITE 365, LOS ANGELES, CA 90095 USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Peters, Anne/0000-0003-0520-0776; Schriger, David/0000-0003-0242-1127				ALBUTT EC, 1985, ANN CLIN BIOCHEM, V22, P67, DOI 10.1177/000456328502200106; BOLLI G, 1980, DIABETES, V29, P272, DOI 10.2337/diabetes.29.4.272; BOUCHER BJ, 1981, DIABETOLOGIA, V21, P34, DOI 10.1007/BF03216220; CASTRO A, 1970, DIABETES, V19, P842, DOI 10.2337/diab.19.11.842; CEDERHOLM J, 1984, DIABETES METAB, V10, P224; CHANDALIA HB, 1970, DIABETES, V19, P863, DOI 10.2337/diab.19.11.863; CLARK VA, 1968, JOHNS HOPKINS MED J, V122, P77; CLIPSON KL, 1981, HORM METAB RES, V13, P129, DOI 10.1055/s-2007-1019197; DIX D, 1979, CLIN CHEM, V25, P877; DODS RF, 1979, CLIN CHEM, V25, P764; DUNN PJ, 1979, ANN INTERN MED, V91, P390, DOI 10.7326/0003-4819-91-3-390; Ferrari E, 1985, Quad Sclavo Diagn, V21, P126; FORREST RD, 1987, DIABETIC MED, V4, P254, DOI 10.1111/j.1464-5491.1987.tb00875.x; GUILLAUSSEAU PJ, 1990, DIABETES CARE, V13, P898, DOI 10.2337/diacare.13.8.898; HALL PM, 1984, DIABETES CARE, V7, P147, DOI 10.2337/diacare.7.2.147; HANSON RL, 1993, ARCH INTERN MED, V153, P2133, DOI 10.1001/archinte.153.18.2133; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HASSELBL.V, 1969, J AM STAT ASSOC, V64, P1459, DOI 10.2307/2286083; HASSELBLAD V, 1966, TECHNOMETRICS, V8, P431, DOI 10.2307/1266689; HEDGES LV, 1985, STAT METHODS METAANA, P200; ITO C, 1983, DIABETES, V32, P343, DOI 10.2337/diabetes.32.4.343; JEPPSSON JO, 1986, CLIN CHEM, V32, P1867; JOHN WG, 1986, DIABETIC MED, V3, P46, DOI 10.1111/j.1464-5491.1986.tb00705.x; KANATSUKA A, 1982, HORM METAB RES, V14, P626, DOI 10.1055/s-2007-1019103; KESSON CM, 1982, DIABETES CARE, V5, P395, DOI 10.2337/diacare.5.4.395; KNOWLER WC, 1994, DIABETES CARE, V17, P445, DOI 10.2337/diacare.17.5.445; KOSAKA K, 1966, DIABETES, V15, P901, DOI 10.2337/diab.15.12.901; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; LARSEN ML, 1989, DIABETES RES CLIN EX, V12, P67; LESTER E, 1985, ANN CLIN BIOCHEM, V22, P74, DOI 10.1177/000456328502200107; LEVRAN A, 1979, JAMA-J AM MED ASSOC, V241, P912, DOI 10.1001/jama.241.9.912; LITTLE RR, 1988, DIABETES, V37, P60, DOI 10.2337/diabetes.37.1.60; LIU QZ, 1993, DIABETOLOGIA, V36, P428, DOI 10.1007/BF00402279; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; MCLAREN CE, 1987, AM J PHYSIOL, V252, pH857, DOI 10.1152/ajpheart.1987.252.4.H857; MELTON LJ, 1983, DIABETES CARE, V6, P75, DOI 10.2337/diacare.6.1.75; MODAN M, 1984, AM J EPIDEMIOL, V119, P431, DOI 10.1093/oxfordjournals.aje.a113761; MOTALA AA, 1992, DIABETES RES CLIN PR, V17, P199, DOI 10.1016/0168-8227(92)90095-9; MULKERRIN EC, 1992, AGE AGEING, V21, P175, DOI 10.1093/ageing/21.3.175; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; OLEFSKY JM, 1974, DIABETES, V23, P449, DOI 10.2337/diab.23.5.449; ORCHARD TJ, 1994, DIABETES CARE, V17, P326, DOI 10.2337/diacare.17.4.326; ORCHARD TJ, 1982, PREV MED, V11, P595, DOI 10.1016/0091-7435(82)90071-8; RUSHFORTH NB, 1979, DIABETOLOGIA, V16, P373, DOI 10.1007/BF01223157; SANTIAGO JV, 1978, J CLIN ENDOCR METAB, V47, P578, DOI 10.1210/jcem-47-3-578; Seghieri G, 1981, Quad Sclavo Diagn, V17, P73; SEKIKAWA A, 1990, DIABETES RES CLIN PR, V8, P187, DOI 10.1016/0168-8227(90)90116-B; SEKIKAWA A, 1993, DIABETES CARE, V16, P570, DOI 10.2337/diacare.16.4.570; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIMON D, 1985, AM J EPIDEMIOL, V122, P589, DOI 10.1093/oxfordjournals.aje.a114138; SIMON D, 1989, DIABETOLOGIA, V32, P864, DOI 10.1007/BF00297451; STARKMAN HS, 1987, DIABETES RES CLIN PR, V3, P343, DOI 10.1016/S0168-8227(87)80059-1; SVENDSEN PA, 1981, ACTA MED SCAND, V210, P313; TSUJI I, 1991, DIABETES CARE, V14, P1075, DOI 10.2337/diacare.14.11.1075; TUSTISON WA, 1966, DIABETES, V15, P775, DOI 10.2337/diab.15.11.775; VERRILLO A, 1983, DIABETOLOGIA, V24, P391, DOI 10.1007/BF00251831; *WHO EXP COMM DIAB, 1985, WHO TECHN REP SER, V727; WILKERSON HLC, 1960, DIABETES, V9, P386, DOI 10.2337/diab.9.5.386; 1993, DIABETES CARE S2, V16, P4	61	302	310	1	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1246	1252		10.1001/jama.276.15.1246	http://dx.doi.org/10.1001/jama.276.15.1246			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL691	8849753				2022-12-28	WOS:A1996VL69100034
J	Kemp, TJ; Siebers, RW; Fishwick, D; OGrady, GB; Fitzharris, P; Crane, J				Kemp, TJ; Siebers, RW; Fishwick, D; OGrady, GB; Fitzharris, P; Crane, J			House dust mite allergen in pillows	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ASTHMA		WELLINGTON SCH MED, DEPT MED, WELLINGTON ASTHMA RES GRP, WELLINGTON, NEW ZEALAND	University of Otago			Siebers, Robert/A-4102-2009	Siebers, Robert/0000-0002-6359-3144; Fishwick, David/0000-0001-5941-090X				LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; STONE L, 1996, IN PRESS AUST NZ J M; STRACHAN DP, 1995, BRIT MED J, V311, P1053, DOI 10.1136/bmj.311.7012.1053	4	60	61	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	1996	313	7062					916	916						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876094	Green Published			2022-12-28	WOS:A1996VM75400025
J	Phillips, AN; Wannamethee, SG; Walker, M; Thomson, A; Smith, GD				Phillips, AN; Wannamethee, SG; Walker, M; Thomson, A; Smith, GD			Life expectancy in men who have never smoked and those who have smoked continuously: 15 year follow up of large cohort of middle aged British men	BRITISH MEDICAL JOURNAL			English	Article							SMOKING; RISK	Objective-To estimate the life expectancy in a representative sample of men who have never smoked and of those who have smoked all their adult lives. Design-15 year follow up of a large representative cohort of British men in the British regional heart study and use of national mortality statistics for 1992. Subjects-7735 middle aged British men aged 40-59 at the time of screening (between 1978 and 1980). Main outcome measures-Mortality from all causes and from smoking related causes. Results-1624 men had never smoked at the time of screening and did not take up smoking during the study. 127 of them died during follow up. 3151 men began smoking before they were 30 and were still smoking at the time of screening. Of these, 751 had stopped smoking five years after screening; they were excluded from the analysis five years after the date they had stopped. 560 of the lifelong smokers died during follow up. When study estimates were combined with those from national mortality statistics for men aged 20-40, only an estimated 42% (95% confidence interval 36% to 50%) of lifelong smokers alive at the age of 20 would be alive at 73, compared with 78% (74% to 82%) of lifelong non-smokers, Conclusion-These estimates present the effects of smoking on mortality in a way that is easily communicated to patients and the general public in health promotion initiatives.	UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL,AVON,ENGLAND	University of Bristol	Phillips, AN (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,BRITISH HEART FDN,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008; Davey Smith, George/A-7407-2013; Lennon, Lucy/ABB-9433-2020	Phillips, Andrew N/0000-0003-2384-4807; Davey Smith, George/0000-0002-1407-8314; Lennon, Lucy/0000-0002-1738-1351; Wannamethee, Sasiwarang/0000-0001-9484-9977				COOK DG, 1986, LANCET, V2, P1376; COOK DG, 1990, J SMOKING RELATED DI, V1, P45; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; *OFF POP CENS SURV, 1986, REG GEN DEC SUPPL OC; *OFF POP CENS SURV, 1992, MORT STAT DH1; PEARL R, 1938, SCIENCE, V87, P2253; ROGERS RG, 1991, SOC SCI MED, V32, P1151, DOI 10.1016/0277-9536(91)90092-Q; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SMITH GD, 1992, LANCET, V340, P709; SMITH GD, 1991, SOC SCI MED, V32, P1297, DOI 10.1016/0277-9536(91)90046-F; Tang J, 1992, J SMOKING RELATED DI, V3, P203; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365	12	41	43	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					907	908						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VM754	8876091				2022-12-28	WOS:A1996VM75400022
J	Roth, SY; Allis, CD				Roth, SY; Allis, CD			Histone acetylation and chromatin assembly: A single escort, multiple dances?	CELL			English	Review									UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	University of Rochester	Roth, SY (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030, USA.			Dent, Sharon/0000-0002-4824-3269				Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KIEFF S, 1995, J BIOL CHEM, V270, P24674; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; RUNDLETT SE, 1996, IN PRESS P NATL ACAD; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	18	221	227	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					5	8		10.1016/S0092-8674(00)81316-1	http://dx.doi.org/10.1016/S0092-8674(00)81316-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858142	hybrid			2022-12-28	WOS:A1996VL69500002
J	Stephan, V; Wahn, V; LeDeist, F; Dirksen, U; Broker, B; MullerFleckenstein, I; Horneff, G; Schroten, H; Fischer, A; Basile, GD				Stephan, V; Wahn, V; LeDeist, F; Dirksen, U; Broker, B; MullerFleckenstein, I; Horneff, G; Schroten, H; Fischer, A; Basile, GD			Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECEPTOR-GAMMA-CHAIN; IL-2 RECEPTOR; INTERLEUKIN-2 RECEPTOR; BETA-CHAIN; MUTATION; SCIDX1; LOCUS		UNIV DUSSELDORF,DEPT PEDIAT,KINDERKLIN,D-40225 DUSSELDORF,GERMANY; HOP NECKER ENFANTS MALAD,INSERM,U429,PARIS,FRANCE; BERNHARD NOCHT INST TROP MED,HAMBURG,GERMANY; UNIV ERLANGEN NURNBERG,INST KLIN & MOL VIROL,NURNBERG,GERMANY	Heinrich Heine University Dusseldorf; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Bernhard Nocht Institut fur Tropenmedizin; University of Erlangen Nuremberg			Bröker, Barbara M/O-4850-2015; de Saint Basile, Genevieve/G-9731-2017	Bröker, Barbara M/0000-0002-5020-8542; de Saint Basile, Genevieve/0000-0002-1913-5269				BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BOSCO MC, 1994, BLOOD, V83, P2995, DOI 10.1182/blood.V83.10.2995.2995; DESAINTBASILE G, 1987, P NATL ACAD SCI USA, V84, P7576; DISANTO JP, 1994, P NATL ACAD SCI USA, V91, P9466, DOI 10.1073/pnas.91.20.9466; DISANTO JP, 1994, EUR J IMMUNOL, V24, P475, DOI 10.1002/eji.1830240232; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HIRSCHHORN R, 1994, AM J HUM GENET, V55, P59; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; HOUSSOUFIAN H, 1996, NAT GENET, V13, P255; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MARKIEWICZ S, 1993, HUM MOL GENET, V2, P651, DOI 10.1093/hmg/2.6.651; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MORELON E, IN PRESS BLOOD; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; PUCK JM, 1987, J CLIN INVEST, V79, P1395, DOI 10.1172/JCI112967; ROSEN FS, 1993, IMMUNODEFICIENCIES, P1; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TOSATO G, 1994, CURRENT PROTOCOLS IM, V3; WAHN V, 1991, J IMMUNOL, V147, P2934	27	203	220	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1996	335	21					1563	1567		10.1056/NEJM199611213352104	http://dx.doi.org/10.1056/NEJM199611213352104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT341	8900089				2022-12-28	WOS:A1996VT34100004
J	Peters, JM; King, RW; Hoog, C; Kirschner, MW				Peters, JM; King, RW; Hoog, C; Kirschner, MW			Identification of BIME as a subunit of the anaphase-promoting complex	SCIENCE			English	Article							NIMA PROTEIN-KINASE; ASPERGILLUS-NIDULANS; CELL-CYCLE; UBIQUITIN LIGASE; BUDDING YEAST; MITOSIS; TRANSITION; GENE; DESTRUCTION; CHECKPOINT	The initiation of anaphase and exit from mitosis require the activation of a proteolytic system that ubiquitinates and degrades cyclin B. The regulated component of this system is a large ubiquitin ligase complex, termed the anaphase-promoting complex (APC) or cyclosome. Purified Xenopus laevis APC was found to be composed of eight major subunits, at least four of which became phosphorylated in mitosis. In addition to CDC27, CDC16, and CDC23, APC contained a homolog of Aspergillus nidulans BIME, a protein essential for anaphase. Because mutation of bimE can bypass the interphase arrest induced by either nimA mutation or unreplicated DNA, it appears that ubiquitination catalyzed by APC may also negatively regulate entry into mitosis.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOL BIOL,S-17177 STOCKHOLM,SWEDEN	Harvard University; Harvard Medical School; Karolinska Institutet								Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JAMES SW, 1995, J CELL SCI, V108, P3485; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORRIS NR, 1976, EXP CELL RES, V98, P204, DOI 10.1016/0014-4827(76)90480-8; ODONNELL KL, 1991, J CELL SCI, V99, P711; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PETERS JM, 1996, P NATL ACAD SCI USA, V93, P2670; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; STARBORG M, 1994, J BIOL CHEM, V269, P24133; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	33	177	180	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1199	1201		10.1126/science.274.5290.1199	http://dx.doi.org/10.1126/science.274.5290.1199			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895470				2022-12-28	WOS:A1996VT33500056
J	Dart, RC; Stark, Y; Fulton, B; KoziolMcLain, J; Lowenstein, SR				Dart, RC; Stark, Y; Fulton, B; KoziolMcLain, J; Lowenstein, SR			Insufficient stocking of poisoning antidotes in hospital pharmacies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITALIS	Objective.-To determine whether antidotes for poisoning and overdose are available in hospitals that provide emergency department care. Design.-Written survey of hospital pharmacy directors, each of whom reported the amount currently in stock of 8 different antidotes: antivenin (Crotalidae) polyvalent, cyanide kit, deferoxamine mesylate, digoxin immune Fab, ethanol, naloxone hydrochloride, pralidoxime chloride, and pyridoxine hydrochloride. Participants.-Pharmacy directors of all hospitals with emergency departments in Colorado, Montana, and Nevada. Main Outcome Measures.-Proportions of hospitals with insufficient stocking of each antidote, defined as complete lack of the antidote or an amount inadequate to initiate treatment of 1 seriously poisoned 70-kg patient. Results.-Questionnaires were mailed to 137 hospital pharmacy directors and 108 (79%) responded. Only 1 (0.9%) of the 108 hospitals stacked all 8 antidotes in adequate amounts. The rate of insufficient stocking for individual antidotes ranged from 2% (for naloxone) to 98% (for digoxin immune Fab). In a multiple regression analysis, smaller hospital size and lack of a formal review of antidote stocking were independent predictors of the number of antidotes stocked insufficiently. Conclusions.-Insufficient stocking of antidotes is a widespread problem in Colorado, Montana, and Nevada. Although these states are served by a certified regional poison center, potentially lifesaving antidotes are frequently not available when and where they might be needed to treat a single poisoned patient.	UNIV COLORADO,COLORADO EMERGENCY MED RES CTR,DENVER,CO 80202	University of Colorado System; University of Colorado Denver	Dart, RC (corresponding author), DENVER DEPT HLTH & HOSP,ROCKY MT POISON & DRUG CTR,8802 E 9TH AVE,DENVER,CO 80220, USA.			Koziol-McLain, Jane/0000-0003-3453-023X; Dart, Richard/0000-0001-5989-9354				*AM ASS POIS CONTR, 1991, CRIT CERT REG POIS C; *AM HOSP ASS, 1993, AM HOSP ASS GUID HLT, pA78; ANTMAN EM, 1990, CIRCULATION, V81, P1744, DOI 10.1161/01.CIR.81.6.1744; BISMUTH C, 1973, CLIN TOXICOL, V6, P153, DOI 10.3109/15563657308990513; CHYKA PA, 1994, AM J HOSP PHARM, V51, P1346, DOI 10.1093/ajhp/51.10.1346; COE C, 1994, UPDATE JOINT HOSPITA, P26; DART RC, 1991, VET HUM TOXICOL, V33, P267; HOWLAND MA, 1986, NEW ENGL J MED, V314, P927; HOWLAND MA, 1994, GOLDFRANKS TOXICOLOG, P636; *JOINT COMM ACCR H, 1992, ACCR MAN HOSP, V1, P111; KANATANI M S, 1992, Veterinary and Human Toxicology, V34, P319; LITOVITZ TL, 1994, AM J EMERG MED, V12, P546, DOI 10.1016/0735-6757(94)90276-3; *MED EC CO, 1995, DRUG TOP REDB; *MED EC CO, 1996, PHYS DESK REF, P1092; ROBERTS JR, 1994, GOLDFRANKS TOXICOLOG, P1313; RUMACK BH, 1996, POISINDEX SYSTEM, P87; WEISMAN RS, 1994, GOLDFRANKS TOXICOLOG, P784	17	77	82	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1508	1510		10.1001/jama.276.18.1508	http://dx.doi.org/10.1001/jama.276.18.1508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ774	8903263				2022-12-28	WOS:A1996VQ77400034
J	Wu, Q; Krainer, AR				Wu, Q; Krainer, AR			U1-mediated exon definition interactions between AT-AC and GT-AG introns	SCIENCE			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEINS; SPLICE-SITE SELECTION; CARTILAGE MATRIX PROTEIN; SODIUM-CHANNEL GENE; GENOMIC STRUCTURE; LAST NUCLEOTIDES; U1 SNRNP; INVITRO; BINDING	A minor class of metazoan introns has well-conserved splice sites with 5'-AU-AC-3' boundaries, compared to the 5'-GU-AG-3' boundaries and degenerate splice sites of conventional introns. Splicing of the AT-AC intron 2 of a sodium channel (SCN4A) precursor messenger RNA in vitro did not require inhibition of conventional splicing and required adenosine triphosphate, magnesium, and U12 small nuclear RNA (snRNA). When exon 3 was followed by the 5' splice site from the downstream conventional intron, splicing of intron 2 was greatly stimulated. This effect was U1 snRNA-dependent, unlike the basal AT-AC splicing reaction. Therefore, U1-mediated exon definition interactions can coordinate the activities of major and minor spliceosomes.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Wu, Qiang/A-6751-2009	Wu, Qiang/0000-0003-3841-3591; Krainer, Adrian/0000-0001-9024-9501	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042699] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42699] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga S., 1993, RNA WORLD, P359; BERGET SM, 1986, CELL, V46, P691, DOI 10.1016/0092-8674(86)90344-2; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; CHANFREAU G, 1994, NUCLEIC ACIDS RES, V22, P1981, DOI 10.1093/nar/22.11.1981; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; Deirdre A, 1995, EMBO J, V14, P3236; GEORGE AL, 1993, GENOMICS, V15, P598, DOI 10.1006/geno.1993.1113; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; Hogan K, 1996, GENOMICS, V31, P392, DOI 10.1006/geno.1996.0066; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JENKINS RN, 1990, J BIOL CHEM, V265, P19624; KISS I, 1989, J BIOL CHEM, V264, P8126; Kohrman DC, 1996, J BIOL CHEM, V271, P17576, DOI 10.1074/jbc.271.29.17576; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; KRAWCZAK M, 1992, HUM GENET, V90, P41; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P6956, DOI 10.1093/nar/19.24.6956; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LARSON RG, 1990, CANCER COMMUN, V2, P63, DOI 10.3727/095535490820874704; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; Moore M., 1993, RNA WORLD, P303; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; OHSHIMA J, 1995, GENOMICS, V28, P585, DOI 10.1006/geno.1995.1194; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SERAPHIN B, 1988, EMBO J, V7, P1533; SHUMYATSKY GP, 1990, NUCLEIC ACIDS RES, V18, P6347, DOI 10.1093/nar/18.21.6347; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; YAMADA Y, 1995, GENOMICS, V27, P312, DOI 10.1006/geno.1995.1048; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	54	73	75	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					1005	1008		10.1126/science.274.5289.1005	http://dx.doi.org/10.1126/science.274.5289.1005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875927				2022-12-28	WOS:A1996VR79200056
J	Kustov, AA; Robinson, DL				Kustov, AA; Robinson, DL			Shared neural control of attentional shifts and eye movements	NATURE			English	Article							MONKEY SUPERIOR COLLICULUS; VISUAL-ATTENTION; STIMULATION; MACAQUES; CELLS; LOCALIZATION; SACCADES	WE are able to move visual attention away from the direction of gaze, fixating on one object while attending to something else at a different location. Within the region of peripheral vision, It has been widely assumed that the attentional neural systems are separate from the motor systems, but some studies challenge this idea(1-5). It has now been suggested that the attentional system is part of the premotor processing in the brain(6). This model proposes that attentional processes evolved as part of the motor systems, with isolated attentional shifts representing an artificial separation of a natural linkage, Here we test how attentional shifts might be linked to the preparations for making saccadic eye movements. We studied the superior colliculus in monkeys as they shifted their attention during different tasks, and found that each attentional shift is associated with eye-movement preparation.	NEI,SENSORIMOTOR RES LAB,SECT VISUAL BEHAV,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)								Andersen R A, 1989, Rev Oculomot Res, V3, P315; BOWMAN EM, 1993, J NEUROPHYSIOL, V70, P431, DOI 10.1152/jn.1993.70.1.431; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; CORBETTA M, 1991, J NEUROSCI, V11, P2383; COWIE RJ, 1994, J NEUROPHYSIOL, V72, P2648, DOI 10.1152/jn.1994.72.6.2648; DORRIS MC, 1995, NEUR ABSTR, V21, P1193; James W., 1890, PRINCIPLES PSYCHOL, P449, DOI [https://doi.org/10.1037/11059-009, DOI 10.1037/11059-009]; KOWLER E, 1995, VISION RES, V35, P1897, DOI 10.1016/0042-6989(94)00279-U; KUSTOV AA, 1995, J NEUROPHYSIOL, V73, P1724, DOI 10.1152/jn.1995.73.4.1724; KUYPERS HENRICUS G. J. M., 1967, BRAIN RES, V4, P151, DOI 10.1016/0006-8993(67)90004-2; MAYS LE, 1987, J NEUROPHYSIOL, V58, P300; MOHLER CW, 1976, J NEUROPHYSIOL, V39, P722, DOI 10.1152/jn.1976.39.4.722; MUNOZ DP, 1995, J NEUROPHYSIOL, V73, P2313, DOI 10.1152/jn.1995.73.6.2313; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1982, PHILOS T ROY SOC B, V298, P187, DOI 10.1098/rstb.1982.0081; RIZZOLATTI G, 1994, ATTENTION PERFORM, V15, P231; RIZZOLATTI G, 1983, ADV VERTEBRATE NEURO; ROBINSON DA, 1972, VISION RES, V12, P1795, DOI 10.1016/0042-6989(72)90070-3; ROBINSON DL, 1995, J NEUROPHYSIOL, V74, P713, DOI 10.1152/jn.1995.74.2.713; SCHILLER PH, 1972, J NEUROPHYSIOL, V35, P915, DOI 10.1152/jn.1972.35.6.915; SHELIGA BM, 1994, EXP BRAIN RES, V98, P507; SPARKS DL, 1983, J NEUROPHYSIOL, V49, P45, DOI 10.1152/jn.1983.49.1.45; WRIGHT RD, 1994, CAN J EXP PSYCHOL, V48, P151, DOI 10.1037/1196-1961.48.2.151; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	25	483	489	0	33	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					74	77		10.1038/384074a0	http://dx.doi.org/10.1038/384074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900281	Green Published			2022-12-28	WOS:A1996VR21900057
J	OKeefe, TL; Williams, GT; Davies, SL; Neuberger, MS				OKeefe, TL; Williams, GT; Davies, SL; Neuberger, MS			Hyperresponsive B cells in CD22-Deficient mice	SCIENCE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; LYMPHOCYTES-B; MONOCLONAL-ANTIBODY; PHOSPHATASE 1C; STEM-CELLS; CD22; ACTIVATION; IMMUNOGLOBULIN; STIMULATION	CD22 is a surface glycoprotein of B lymphocytes that is rapidly phosphorylated on cytoplasmic tyrosines after antigen receptor cross-linking. Splenic B cells from mice with a disrupted CD22 gene were found to be hyperresponsive lo receptor signaling: Heightened calcium fluxes and cell proliferation were obtained at lower ligand concentrations. The mice gave an augmented immune response, had an expanded peritoneal B-1 cell population, and contained increased serum titers of autoantibody. Thus, CD22 is a negative regulator of antigen receptor signaling whose onset of expression at the mature B cell stage may serve to raise the antigen concentration threshold required for B cell triggering.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Davies, Sarah/0000-0001-9853-3929				Benatar T, 1996, J EXP MED, V183, P329, DOI 10.1084/jem.183.1.329; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DORKEN B, 1986, J IMMUNOL, V136, P4470; ERIKSON LD, 1996, INT IMMUNOL, V8, P1121; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; JULIUS MH, 1984, EUR J IMMUNOL, V14, P753, DOI 10.1002/eji.1830140816; KLIX N, UNPUB; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MOHAN C, 1995, J IMMUNOL, V154, P1470; OKEEFE TL, UNPUB; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PEZZUTTO A, 1987, J IMMUNOL, V138, P98; POWELL LD, 1993, J BIOL CHEM, V268, P7019; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SHULTZ LD, 1976, J IMMUNOL, V116, P936; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; SYMINGTON FW, 1982, IMMUNOGENETICS, V16, P381, DOI 10.1007/BF00372098; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Tuscano J, 1996, BLOOD, V87, P4723, DOI 10.1182/blood.V87.11.4723.bloodjournal87114723; Tuscano JM, 1996, EUR J IMMUNOL, V26, P1246, DOI 10.1002/eji.1830260610; WELLS SM, 1994, J IMMUNOL, V153, P5503; WILLIAMS GT, 1994, P NATL ACAD SCI USA, V91, P474, DOI 10.1073/pnas.91.2.474	36	445	452	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					798	801		10.1126/science.274.5288.798	http://dx.doi.org/10.1126/science.274.5288.798			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864124				2022-12-28	WOS:A1996VQ14500049
J	Gershon, D				Gershon, D			Counselling comes of age	NATURE			English	Article																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					741	742		10.1038/383741a0	http://dx.doi.org/10.1038/383741a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878489				2022-12-28	WOS:A1996VN91800061
J	Manber, H; Kanzler, M				Manber, H; Kanzler, M			Consequences of cupping	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Manber, H (corresponding author), STANFORD UNIV HOSP,PALO ALTO,CA 94304, USA.								0	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1281	1281		10.1056/NEJM199610243351705	http://dx.doi.org/10.1056/NEJM199610243351705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857008				2022-12-28	WOS:A1996VN59400005
J	Arnold, D				Arnold, D			The rise of western medicine in India	LANCET			English	Article											Arnold, D (corresponding author), UNIV LONDON,SCH ORIENTAL & AFRICAN STUDIES,DEPT HIST,THORNHAUGH ST,RUSSELL SQ,LONDON WC1H 0XG,ENGLAND.							ARNOLD D, 1994, S ASIA RES, V14, P14; ARNOLD D., 1993, COLONIZING BODY; Arnold David, 1993, COLONIZING BODY STAT, P200; AROLD D, 1988, IMPERIAL MED INDIGEN, P45; BALA P, 1991, IMPERIALISM MED BENG, P40; BALFOUR Andrew, 1925, Transactions of the Royal Society of Tropical Medicine and Hygiene, V19, P189, DOI 10.1016/S0035-9203(25)80014-2; Balfour Margaret, 1929, WORK MED WOMEN INDIA; BHARDWAJ SM, 1981, SOCIAL CULTURAL CONT, P31; CHATTERJEE M, 1988, IMPLEMENTING HLTH PO, P6; Crawford DG, 1914, HIST INDIAN MED SERV; *GOV IND, 1946, REP HLTH SURV DEV CO, V1, P8; *GOV IND, 1946, REP HLTH SURV DEV CO, V4, P39; Grove RH, 1995, GREEN IMPERIALISM; HARRISON M, 1994, PUBLIC HLTH BRIT IND, P31; JEFFERY R, 1988, POLITICS HLTH INDIA, P205; Jeffery Roger, 1988, IND NAT C POL EC IND, P160; LAL M, 1994, B HIST MED, V68, P29; Ramasubban Radhika., 1988, DIS MED EMPIRE PERSP, P38; ROSS R, 1923, MEMOIRS, P356; Sinclair HM, 1953, WORK R MCCARRISON; TINKER H, 1968, FDN LOCAL SELF GOVT, V73, P287	21	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1075	1078		10.1016/S0140-6736(96)06114-4	http://dx.doi.org/10.1016/S0140-6736(96)06114-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874462				2022-12-28	WOS:A1996VM88600015
J	Kai, J				Kai, J			What worries parents when their preschool children are acutely ill, and why: A qualitative study	BRITISH MEDICAL JOURNAL			English	Article							FEVER PHOBIA; CONSULT; CARE	Objective-To identify and explore parents' concerns when young children become acutely ill. Design-Qualitative study making use of semistructured one to one and group interviews with parents of preschool children. Setting-Disadvantaged inner city community. Subjects-95 parents of preschool children. Results-Fever, cough, and the possibility of meningitis were parents' primary concerns when their children became acutely ill. Parents' concerns reflected lay beliefs, their interpretation of medical knowledge, and their fears that their child might die or be permanently harmed. Parents worried about failing to recognise a serious problem. Concerns were expressed within the context of keenly felt pressure, emphasising parents' responsibility to protect their child from harm. They were grounded in two linked factors: parents' sense of personal control when faced with illness in their child and the perceived threat posed by an illness. Conclusions-Better understanding of parents' concerns may promote effective communication between health professionals and parents. Modification of parents' personal control and perceived threat using appropriate information and education that acknowledge and address their concerns may be a means of empowering parents.			Kai, J (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Kai, Joe/0000-0001-9040-9384				BOGDAN RC, 1982, AQUALITATIVE RES ED; CAMPION PD, 1984, BRIT MED J, V288, P1426, DOI 10.1136/bmj.288.6428.1426; CORNFORD CS, 1993, FAM PRACT, V10, P193, DOI 10.1093/fampra/10.2.193; Cunningham-Burley Sarah, 1990, READINGS MED SOCIOLO, P85; *DEP HLTH, 1994, KNOW MEN SEPT; Glaser B.G., 1965, AWARENESS DYING; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; Helman C., 1986, CULTURE HLTH ILLNESS; HURWITZ B, 1995, BRIT MED J, V311, P824, DOI 10.1136/bmj.311.7009.824; Kai J, 1996, BRIT MED J, V313, P987; KLUGER NJ, 1991, FEVER BASIC MECH MAN; KRAMER MS, 1985, PEDIATRICS, V75, P1110; Kreuger R, 1988, FOCUS GROUPS PRACTIC; MAYALL B, 1986, KEEPING CHILDREN HLT; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; MCCORMICK A, 1995, MORBIDITY STAT GEN P; *MEN RES, 1994, WHAT DO YOU SUSP MEN; Paterson E., 1982, STUDIES DEPRIVATION, V5; SCHMITT BD, 1980, AM J DIS CHILD, V134, P176, DOI 10.1001/archpedi.1980.02130140050015; Spencer N, 1996, ARCH DIS CHILD, V74, P50, DOI 10.1136/adc.74.1.50; SPENCER NJ, 1984, PROGR CHILD HLTH, P100; STEPHENSON T, 1994, MAT CHILD HLTH, V19, P128; Strauss AL, 1990, BASICS QUALITATIVE G; WIIKIN D, 1987, ANATOMY URBAN GEN PR; WYKE S, 1990, BRIT J GEN PRACT, V40, P226	25	173	180	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					983	986						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892420				2022-12-28	WOS:A1996VN91600026
J	Marquet, P; Francois, B; Vignon, P; Lachatre, G				Marquet, P; Francois, B; Vignon, P; Lachatre, G			A soldier who had seizures after drinking quarter of a litre of wine	LANCET			English	Article									DUPUYTREN HOSP,INTENS CARE UNIT,F-87042 LIMOGES,FRANCE	CHU Limoges	Marquet, P (corresponding author), DUPUYTREN HOSP,DEPT PHARMACOL & TOXICOL,F-87042 LIMOGES,FRANCE.		Vignon, Philippe/O-8886-2016; François, Bruno/O-8404-2016; MARQUET, Pierre/A-1727-2017	Vignon, Philippe/0000-0003-4551-5772; François, Bruno/0000-0002-2531-1652; MARQUET, Pierre/0000-0001-7698-0760				Barborik M., 1972, PRAC LEK, V24, P295; Nicolaou G, 1987, J Trace Elem Electrolytes Health Dis, V1, P73; TAKAHASHI S, 1972, LIFE SCI, V11, P1011; WESTER PO, 1973, ACTA MED SCAND, V194, P505; WIDE M, 1986, ENVIRON RES, V40, P487, DOI 10.1016/S0013-9351(86)80124-4	5	26	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1070	1070		10.1016/S0140-6736(96)05459-1	http://dx.doi.org/10.1016/S0140-6736(96)05459-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874460				2022-12-28	WOS:A1996VM88600013
J	Gertler, FB; Niebuhr, K; Reinhard, M; Wehland, J; Soriano, P				Gertler, FB; Niebuhr, K; Reinhard, M; Wehland, J; Soriano, P			Mena, a relative of VASP and Drosophila enabled, is implicated in the control of microfilament dynamics	CELL			English	Article							ABL TYROSINE KINASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN; ACTIN-BASED MOTILITY; RICH FOCAL ADHESION; LISTERIA-MONOCYTOGENES; HUMAN-PLATELETS; PROTEIN VASP; C-ABL; GROWTH CONES; BINDING-SITE	Drosophila Enabled is required for proper formation of axonal structures and is genetically implicated in signaling pathways mediated by Drosophila Abl. We have identified two murine proteins, Mena and Evl, that are highly related to Enabled as well as VASP (Vasodilator-Stimulated Phosphoprotein). A conserved domain targets Mena to localized proteins containing a specific proline-rich motif. The association of Mena with the surface of the intracellular pathogen Listeria monocytogenes and the G-actin binding protein profilin suggests that this molecule may participate in bacterial movement by facilitating actin polymerization. Expression of neural-enriched isoforms of Mena in fibroblasts induces the formation of abnormal F-actin-rich outgrowths, supporting a role for this protein in microfilament assembly and cell motility.	GESELL BIOTECHNOL FORSCH MBH, D-38124 BRAUNSCHWEIG, GERMANY; UNIV WURZBURG, MED KLIN, D-97080 WURZBURG, GERMANY	Gesellschaft fur Biotechnologische Forschung mbH; University of Wurzburg	Gertler, FB (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT MOL MED, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Reinhard, Martin/A-1006-2008; Soriano, Philippe M/E-5797-2015	Reinhard, Martin/0000-0002-7833-6175; Soriano, Philippe M/0000-0002-0427-926X				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BIXBY JL, 1993, J NEUROSCI, V13, P3421; BUTT E, 1994, J BIOL CHEM, V269, P14509; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; FAIVRE SC, 1993, S SOC EXP BIOL, V47, P317; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FORSCHER P, 1992, NATURE, V357, P515, DOI 10.1038/357515a0; FRIEDERICH E, 1995, EMBO J, V14, P2731, DOI 10.1002/j.1460-2075.1995.tb07274.x; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; IGARASHI M, 1990, EUR J BIOCHEM, V193, P551, DOI 10.1111/j.1432-1033.1990.tb19371.x; JANMEY PA, 1991, METHOD ENZYMOL, V196, P92; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; KOCKS C, 1993, J CELL SCI, V105, P699; Lasa I, 1996, TRENDS CELL BIOL, V6, P109, DOI 10.1016/0962-8924(96)81001-4; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NIEBUHR K, 1993, INFECT IMMUN, V61, P2793, DOI 10.1128/IAI.61.7.2793-2802.1993; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1994, BIOCHEMISTRY-US, V33, P8472, DOI 10.1021/bi00194a011; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; POLLARD TD, 1995, CURR BIOL, V5, P837, DOI 10.1016/S0960-9822(95)00167-9; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Theriot JA, 1995, ANNU REV CELL DEV BI, V11, P213, DOI 10.1146/annurev.cb.11.110195.001241; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	55	554	573	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1996	87	2					227	239		10.1016/S0092-8674(00)81341-0	http://dx.doi.org/10.1016/S0092-8674(00)81341-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861907	Bronze			2022-12-28	WOS:A1996VN40300011
J	Preston, H; Wright, TL				Preston, H; Wright, TL			Interferon therapy for hepatitis C	LANCET			English	Editorial Material							NON-B-HEPATITIS; NON-A		UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Francisco	Preston, H (corresponding author), DEPT VET AFFAIRS MED CTR, GASTROENTEROL SECT, SAN FRANCISCO, CA 94121 USA.							DAVIS GL, 1994, J HEPATOL, V21, P1, DOI 10.1016/S0168-8278(94)80128-2; Pawlotsky JM, 1996, J INFECT DIS, V174, P1, DOI 10.1093/infdis/174.1.1; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Sherlock S, 1995, J HEPATOL, V23, P3; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202	6	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	1996	348	9033					973	974		10.1016/S0140-6736(05)64920-3	http://dx.doi.org/10.1016/S0140-6736(05)64920-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855848				2022-12-28	WOS:A1996VM02700004
J	Priest, RG; Vize, C; Roberts, A; Roberts, M; Tylee, A				Priest, RG; Vize, C; Roberts, A; Roberts, M; Tylee, A			Lay people's attitudes to treatment of depression: Results of opinion poll for Defeat Depression Campaign just before its launch	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MANAGEMENT	Objective-To investigate the attitudes of the general public towards depression before the Defeat Depression Campaign of the Royal Colleges of Psychiatrists and General Practitioners; these results form the baseline to assess the change in attitudes brought about by the campaign. Design-Group discussions generated data for initial qualitative research. The quantitative survey comprised a doorstep survey of 2003 people in 143 places around the United Kingdom. Results-The lay public in general seemed to be sympathetic to those with depression but reluctant to consult. Most (1704 (85%)) believed counselling to be effective but were against antidepressants. Many subjects (1563 (78%)) regarded antidepressants as addictive. Conclusions-Although people are sympathetic towards those with depression, they may project their prejudices about depression on to the medical profession. Doctors have an important role in educating the public about depression and the rationale for antidepressant treatment. In particular, patients should know that dependence is not a problem with antidepressants.	EALING GEN HOSP,JOHN CONNOLLY UNIT,SOUTHALL UB1 3EU,MIDDX,ENGLAND; ST GEORGE HOSP,SCH MED,ROYAL COLL GEN PRACTITIONERS UNIT MENTAL HLTH,LONDON SW17 0RE,ENGLAND	St Georges University London	Priest, RG (corresponding author), ST MARYS,PATERSON CTR,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,DEPT PSYCHIAT,LONDON W2 1PD,ENGLAND.		Tylee, Andre T/D-8468-2010; Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				BRIDGES K, 1987, PRESENTATION DEPRESS, P9; COLLINS M, 1996, CONSUMER MARKET RES, P85; DAVIES R, 1996, CONSUMER MARKET RES, P231; DONAGHUE JM, 1996, BRIT J PSYCHIAT, V168, P164; JOHNSON DAW, 1973, BRIT MED J, V2, P18, DOI 10.1136/bmj.2.5857.18; NEWTH S, 1994, BMA NEWS REV     AUG, P29; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; PRIEST RG, 1994, BRIT J PSYCHIAT, V164, P285, DOI 10.1192/bjp.164.3.285; PRIEST RG, 1991, BRIT J GEN PRACT, V41, P487; 1990, PSYCHIAT B, V14, P452	10	279	279	1	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					858	859						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870574				2022-12-28	WOS:A1996VL55900025
J	Stone, DM; Hynes, M; Armanini, M; Swanson, TA; Gu, QM; Johnson, RL; Scott, MP; Pennica, D; Goddard, A; Phillips, H; Noll, M; Hooper, JE; deSauvage, F; Rosenthal, A				Stone, DM; Hynes, M; Armanini, M; Swanson, TA; Gu, QM; Johnson, RL; Scott, MP; Pennica, D; Goddard, A; Phillips, H; Noll, M; Hooper, JE; deSauvage, F; Rosenthal, A			The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog	NATURE			English	Article							TERMINAL CLEAVAGE PRODUCT; MOTOR-NEURON INDUCTION; FLOOR PLATE; POLARIZING ACTIVITY; DROSOPHILA SEGMENT; LARVAL CUTICLE; FEEDBACK LOOP; ZYGOTIC LOCI; PROTEIN; PATTERN	The protein Sonic hedgehog (Shh) controls patterning and growth during vertebrate development. Here we demonstrate that it binds Patched (vPtc), which has been identified as a tumour-suppressor protein in basal cell carcinoma, with high affinity. We show that Ptc can form a physical complex with a newly cloned vertebrate homologue of the Drosophila protein Smoothened (vSmo), and that vSmo is coexpressed with vPtc in many tissues but does not bind Shh directly. These findings, combined with available genetic evidence from Drosophila, support the hypothesis that Ptc is a receptor for Shh, and that vSmo could be a signalling component that is linked to Ptc.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOL ONCOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOL BIOL,S SAN FRANCISCO,CA 94080; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305; UNIV ZURICH,INST MOL BIOL,DIV 2,CH-8057 ZURICH,SWITZERLAND; UNIV COLORADO,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,DENVER,CO 80262	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; University of Zurich; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Hynes, Mary/0000-0001-6623-6727				Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Currie PD, 1996, NATURE, V382, P452, DOI 10.1038/382452a0; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; Ericson J, 1995, INT J DEV BIOL, V39, P809; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Marigo V, 1996, DEVELOPMENT, V122, P1225; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	39	928	988	0	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					129	134		10.1038/384129a0	http://dx.doi.org/10.1038/384129a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906787				2022-12-28	WOS:A1996VT33600055
J	Hoffman, C; Rice, D; Sung, HY				Hoffman, C; Rice, D; Sung, HY			Persons with chronic conditions - Their prevalence and costs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM-CARE; UNITED-STATES; HEALTH; IMPACT	Objectives.-To determine (1) the number and proportion of Americans living with chronic conditions, and (2) the magnitude of their costs, including direct costs (annual personal health expenditures) and indirect costs to society (lost productivity due to chronic conditions and premature death). Design.-Analysis of the 1987 National Medical Expenditure Survey for prevalence and direct health care costs; indirect costs based on the 1990 National Health Interview Survey and Vital Statistics of the United States. Setting.-US population. Participants.-For the estimate of prevalence and direct costs, the National Medical Expenditure Survey sample of persons who reported health conditions associated with (1) use of health services or supplies or (2) periods of disability. Interventions.-None. Main Outcome Measures.-The number of persons with chronic conditions, their annual direct health care costs, and indirect costs from lost productivity and premature deaths. Results.-In 1987, 90 million Americans were living with chronic conditions, 39 million of whom were living with more than 1 chronic condition. Over 45% of noninstitutionalized Americans have 1 or more chronic conditions and their direct health care costs account for three fourths of US health care expenditures. Total costs projected to 1990 for people with chronic conditions amounted to $659 billion-$425 billion for direct health care costs and $234 billion in indirect costs. Conclusions.-The prevalence and costs of chronic conditions as a whole have rarely been estimated. Because the number of persons with limitations due to chronic conditions is more regularly reported in the literature, the total prevalence of chronic conditions has perhaps been minimized. The majority of persons with chronic conditions are not disabled, nor are they elderly. Chronic conditions affect all ages. Because persons with chronic conditions have greater health needs at any age, their costs are disproportionately high.	UNIV CALIF SAN FRANCISCO, INST HLTH & AGING, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco								BAUMOL WJ, 1968, AM ECON REV, V58, P788; COOPER BS, 1976, SOC SECUR BULL, V39, P21; DAY JC, 1993, CURRENT POPULATI P25, V1104; DOUGLASS J, 1990, J FORENSIC EC, V4, P25, DOI DOI 10.5085/0898-5510-4.1.25; EDWARDS WS, 1989, US DHHS PUBLICATION; GRAMLICH EDWARD M., 1990, GUIDE BENEFIT COST A, V2d; Haddix A, 1996, PREVENTION EFFECTIVE; HING E, 1989, VITAL HLTH STAT 13, V13; *HLTH CAR FIN ADM, 1995, MED PROF; *HLTH CAR FIN ADM, 1995, HLTH CAR FIN REV S S, V20, P368; HODGSON TA, 1982, MILBANK FUND Q, V60, P429, DOI 10.2307/3349801; Johnson AE, 1993, J ECON SOC MEAS, V19, P199; LETSCH SW, 1991, HLTH CARE FINANC REV, V14, P1; MANTON KG, 1993, J GERONTOL, V48, pS153, DOI 10.1093/geronj/48.4.S153; *NAT CTR HLTH STAT, 1995, PUBL PHS; *NAT CTR HLTH STAT, 1994, US DEP HHS PUBL, V2; *NAT CTR HLTH STAT, 1988, VIT HLTH STAT 10, V10; *NAT CTR HLTH STAT, 1993, VIT STAT US MORT, V2; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; OLSEN JA, 1993, J HEALTH ECON, V12, P39, DOI 10.1016/0167-6296(93)90039-H; Pihlbland C. T., 1937, NATL HLTH SURVEY PRE; Rice D P, 1985, Health Care Financ Rev, V7, P61; Rice D P, 1980, World Health Stat Q, V33, P56; Rice D.P., 1966, HLTH EC SERIES, V6; RICE DP, 1991, PUBLIC HLTH REP, V106, P281; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; SHORT PF, 1995, JAMA-J AM MED ASSOC, V274, P1302; STRAUSS A, 1987, SOCIETY, V25, P33, DOI 10.1007/BF02695394; SYDENSTRICKER E, 1933, RECENT TRENDS US, pCH2; TRUPIN L, 1995, MED EXPENDITURES PEO, P6; *US BUR CENS, 1992, CP1 CENS POP; *US BUR CENS, 1995, 1995 STAT ABSTR US; *US BUR CENS, 1990, CURR POP REP P25, V1045; *US BUR CENS, 1992, CURR POP REP P60, V180; *US BUR LAB STAT, 1991, EMPL EARN; *US DEP HHS, 1987, PUBL US DAT TAP DO 3; VERBRUGGE LM, 1995, AM J PUBLIC HEALTH, V85, P173, DOI 10.2105/AJPH.85.2.173; WEISSERT WG, 1988, MILBANK Q, V66, P309, DOI 10.2307/3350034	38	678	680	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1473	1479		10.1001/jama.276.18.1473	http://dx.doi.org/10.1001/jama.276.18.1473			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VQ774	8903258				2022-12-28	WOS:A1996VQ77400029
J	Roldan, CA; Shively, BK; Crawford, MH				Roldan, CA; Shively, BK; Crawford, MH			An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONBACTERIAL THROMBOTIC ENDOCARDITIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CARDIAC ABNORMALITIES; COMPLEMENT ACTIVATION; VALVE DISEASE; ANTIBODIES; PREVALENCE; SEVERITY; STROKE	Background Valvular heart disease is the most important cardiac manifestation of systemic lupus erythematosus. We performed a study to determine the relation of valvular disease to other clinical features of lupus, whether or not the valve disease progresses, and the associated morbidity and mortality. Methods We performed transesophageal echo-cardiography and rheumatologic evaluations in 69 patients with systemic lupus erythematosus. The echocardiographic findings were compared with those in 56 healthy volunteers. Fifty-eight patients (84 percent) had second evaluations a mean (+/-SD) period of 29+/-13 months later. The patients and controls were followed for 57 months. Results Valvular abnormalities were common on the initial and the follow-up echocardiograms (in 61 and 53 percent of the patients, respectively). Valvular thickening was the predominant finding initially and on follow-up (in 51 and 52 percent of the patients, respectively), followed by vegetations (in 43 and 34 percent), valvular regurgitation (in 25 and 28 percent), and stenosis (in 4 and 3 percent). Valvular abnormalities frequently resolved, appeared for the first time, or persisted but changed in appearance or size between the two studies. Mild or moderate valvular regurgitation did not progress to become severe, and new stenoses did not develop. Neither the presence of valvular disease nor changes in the echocardiographic findings were temporally related to the duration, activity, or severity of lupus or to its treatment. The combined incidence of stroke, peripheral embolism, heart failure, infective endocarditis, and the need for valve replacement was 22 percent in the patients with valvular disease, but only 8 percent in those without it. A total of seven patients died during follow-up, in most cases as a result of valvular disease. Valvular abnormalities and complications were uncommon in the controls (occurring in 9 and 2 percent, respectively). Conclusions Valvular heart disease is common in patients with systemic lupus erythematosus, frequently changes over time, appears to be temporally unrelated to other clinical features of lupus, and is associated with substantial morbidity and mortality. (C)1996, Massachusetts Medical Society.	UNIV NEW MEXICO,CTR HLTH SCI,ALBUQUERQUE,NM 87131	University of New Mexico	Roldan, CA (corresponding author), VET AFFAIRS MED CTR,DIV CARDIOL,5B-111,2100 RIDGECREST DR SE,ALBUQUERQUE,NM 87108, USA.							BELMONT HM, 1986, ARTHRITIS RHEUM, V29, P1085, DOI 10.1002/art.1780290905; BIDANI AK, 1980, AM J MED, V69, P849, DOI 10.1016/S0002-9343(80)80010-6; BLANCHARD DG, 1992, CHEST, V102, P954, DOI 10.1378/chest.102.3.954; BULKLEY BH, 1975, AM J MED, V58, P243, DOI 10.1016/0002-9343(75)90575-6; CASTELLO R, 1992, J AM COLL CARDIOL, V19, P1516, DOI 10.1016/0735-1097(92)90612-Q; CURRIE PJ, 1985, CIRCULATION, V71, P1162, DOI 10.1161/01.CIR.71.6.1162; CYT SOFTW, 1995, STATX 3 WIND US MAN; DAJEE H, 1983, J THORAC CARDIOV SUR, V85, P718; DEPPISCH LM, 1976, AM HEART J, V92, P723, DOI 10.1016/S0002-8703(76)80008-7; DEVINSKY O, 1988, ANN NEUROL, V23, P380, DOI 10.1002/ana.410230411; ESTES D, 1971, MEDICINE, V50, P85, DOI 10.1097/00005792-197103000-00001; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; FUTRELL N, 1989, STROKE, V20, P583, DOI 10.1161/01.STR.20.5.583; GALVE E, 1988, NEW ENGL J MED, V319, P817, DOI 10.1056/NEJM198809293191302; GORELICK PB, 1985, ARCH NEUROL-CHICAGO, V42, P813, DOI 10.1001/archneur.1985.04210090081022; HAY E, 1993, ANN RHEUM DIS, V52, P169, DOI 10.1136/ard.52.3.169; HELLMANN DB, 1987, MEDICINE, V66, P341, DOI 10.1097/00005792-198709000-00002; Hojnik M, 1996, CIRCULATION, V93, P1579, DOI 10.1161/01.CIR.93.8.1579; KATZ JD, 1993, LUPUS, V2, P119, DOI 10.1177/096120339300200210; KHAMASHTA MA, 1990, LANCET, V335, P1541, DOI 10.1016/0140-6736(90)91373-I; Klemperer P, 1941, ARCH PATHOL, V32, P569; LEHMAN TJA, 1983, J RHEUMATOL, V10, P655; LEUNG WH, 1990, INT J CARDIOL, V27, P367, DOI 10.1016/0167-5273(90)90294-F; LIANG MH, 1988, ARTHRITIS RHEUM, V31, P817, DOI 10.1002/art.1780310701; Libman E, 1924, ARCH INTERN MED, V33, P701, DOI 10.1001/archinte.1924.00110300044002; LOPEZ JA, 1987, AM J CARDIOL, V59, P478, DOI 10.1016/0002-9149(87)90961-1; NIHOYANNOPOULOS P, 1990, CIRCULATION, V82, P369, DOI 10.1161/01.CIR.82.2.369; NIVED O, 1985, Q J MED, V55, P271; ONG ML, 1992, INT J CARDIOL, V34, P69, DOI 10.1016/0167-5273(92)90084-G; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; PILIERO P, 1990, SEMIN ARTHRITIS RHEU, V20, P185, DOI 10.1016/0049-0172(90)90059-O; PORCEL JM, 1995, CLIN IMMUNOL IMMUNOP, V74, P283, DOI 10.1006/clin.1995.1040; ROLDAN CA, 1992, J AM COLL CARDIOL, V20, P1127, DOI 10.1016/0735-1097(92)90368-W; SAS Institute, 1990, SAS STAT US GUID VER; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3; STURFELT G, 1992, MEDICINE, V71, P216, DOI 10.1097/00005792-199207000-00004; UROWITZ MB, 1984, J RHEUMATOL, V11, P783; WEI JY, 1992, NEW ENGL J MED, V327, P1735, DOI 10.1056/NEJM199212103272408	38	210	223	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1424	1430		10.1056/NEJM199611073351903	http://dx.doi.org/10.1056/NEJM199611073351903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT339	8875919				2022-12-28	WOS:A1996VT33900003
J	Yang, YF; Cole, MD				Yang, YF; Cole, MD			Visual acuity testing in schools: What needs to be done	BRITISH MEDICAL JOURNAL			English	Article									TORBAY HOSP,DEPT OPHTHALMOL,TORQUAY TQ2 7AA,DEVON,ENGLAND									BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001; *BRIT STAND I, 1968, 42741968 BS BRIT STA; EVANSJONES G, 1994, JOINT WORK PART OPHT; INGRAM RM, 1989, BRIT MED J, V298, P935, DOI 10.1136/bmj.298.6678.935	4	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1053	1053						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898598				2022-12-28	WOS:A1996VP74200028
J	Lapham, CK; Ouyang, J; Chandrasekhar, B; Nguyen, NY; Dimitrov, DS; Golding, H				Lapham, CK; Ouyang, J; Chandrasekhar, B; Nguyen, NY; Dimitrov, DS; Golding, H			Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; T-CELL; CD4; COMPONENT(S); MACROPHAGES; MODULATION; TROPISM	Accessory cell-surface molecules involved in the entry of human immunodeficiency virus-type 1 into cells have recently been identified and shown to belong to the family of chemokine receptors, Treatment of human cell lines with soluble monomeric gp120 at 37 degrees C induced an association between the surface CD4-gp120 complex and a 45-kilodalton protein, which can be down-modulated by the phorbol ester phorbol 12-myristate 13-acetate. The three proteins were coprecipitated from the cell membranes with antibodies to CD4 or to gp120, The 45-kilodalton protein comigrated with fusin on sodium dodecyl sulfate gels and reacted with rabbit antisera to fusin in protein immunoblots, No 45-kilodalton protein could be coprecipitated from similarly treated nonhuman cells, However, infection of 3T3.CD4.401 cells with vaccinia-fusin recombinant virus (vCBYF1), followed by gp120 treatment, resulted in coprecipitation of fusin and CD4.401 molecules from their membranes. Together these data provide evidence for physical association between fusin and the CD4-gp120 complex on cell membranes.	NCI, MEMBRANE STRUCT & FUNCT SECT, BETHESDA, MD 20892 USA; US FDA, CTR BIOL EVALUAT & RES, FACIL BIOTECHNOL RESOURCES, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Lapham, CK (corresponding author), US FDA, CTR BIOL EVALUAT & RES,DIV VIRAL PROD,BLDG 29B, ROOM 3G21,HFM 454, 8800 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; ASJO B, 1986, LANCET, V2, P660; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHESEBRO B, 1991, J VIROL, V65, P5782, DOI 10.1128/JVI.65.11.5782-5789.1991; CHOE H, 1996, SCIENCE, V272, P1149; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dimitrov DS, 1996, NAT MED, V2, P640, DOI 10.1038/nm0696-640; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GOLDING H, 1995, J VIROL, V69, P6140, DOI 10.1128/JVI.69.10.6140-6148.1995; GOLDING H, 1994, J VIROL, V68, P1962, DOI 10.1128/JVI.68.3.1962-1969.1994; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409	17	341	351	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					602	605		10.1126/science.274.5287.602	http://dx.doi.org/10.1126/science.274.5287.602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849450				2022-12-28	WOS:A1996VN91900048
J	Collinge, J; Sidle, KCL; Meads, J; Ironside, J; Hill, AF				Collinge, J; Sidle, KCL; Meads, J; Ironside, J; Hill, AF			Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD	NATURE			English	Article							CREUTZFELDT-JAKOB-DISEASE; TRANSMISSIBLE MINK ENCEPHALOPATHY; BOVINE SPONGIFORM ENCEPHALOPATHY; MICE EXPRESSING HUMAN; SCRAPIE; PROTEIN; PRP; REPLICATION; PROPAGATION; MEDICINE	Strains of transmissible spongiform encephalopathies are distinguished by differing physicochemical properties of PrPSc, the disease-related isoform of prion protein, which can be maintained on transmission to transgenic mice. 'New variant' Creutzfeldt-Jakob disease (CJD) has strain characteristics distinct from other types of CJD and which resemble those of BSE transmitted to mice, domestic cat and macaque, consistent with BSE being the source of this new disease. Strain characteristics revealed here suggest that the prion protein may itself encode disease phenotype.	WESTERN GEN HOSP, NATL CJD SURVEILLANCE UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; ST MARYS HOSP, DEPT NEUROL, LONDON W2 1NY, ENGLAND	University of Edinburgh; Imperial College London	Collinge, J (corresponding author), ST MARYS, IMPERIAL COLL SCH MED, DEPT BIOCHEM & MOL GENET, NEUROGENET UNIT, LONDON W2 1PG, ENGLAND.		Hill, Andrew F./GZL-4124-2022; Hill, Andrew F/B-4527-2009; Hill, Andrew F./AAH-2854-2020	Hill, Andrew F./0000-0001-5581-2354; Hill, Andrew F/0000-0001-5581-2354; Ironside, James/0000-0001-5869-2108	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE ME, 1992, HUMAN ANIMALS, P497; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1988, J GEN VIROL, V69, P2953, DOI 10.1099/0022-1317-69-12-2953; KIMBERLIN RH, 1989, VIRUS RES, V12, P201, DOI 10.1016/0168-1702(89)90039-7; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPLANCHE JL, 1994, NEUROLOGY, V44, P2347, DOI 10.1212/WNL.44.12.2347; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; MARSH RF, 1975, J INFECT DIS, V131, P104, DOI 10.1093/infdis/131.2.104; Page G, 1996, NATURE, V382, P381, DOI 10.1038/382381b0; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Palmer MS, 1996, HUM MUTAT, V7, P280, DOI 10.1002/(SICI)1098-1004(1996)7:3<280::AID-HUMU17>3.0.CO;2-Z; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Schreuder BEC, 1996, NATURE, V381, P563, DOI 10.1038/381563a0; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WELLER RO, 1989, PSYCHOL MED, V19, P1, DOI 10.1017/S0033291700010965; WELLS GAH, 1995, BRAIN PATHOL, V5, P91, DOI 10.1111/j.1750-3639.1995.tb00580.x; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; WYATT JM, 1991, VET REC, V129, P233, DOI 10.1136/vr.129.11.233	42	1466	1491	1	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1996	383	6602					685	690		10.1038/383685a0	http://dx.doi.org/10.1038/383685a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878476				2022-12-28	WOS:A1996VN91800044
J	Dickson, D				Dickson, D			Here comes tomorrow's millionaires	NATURE			English	Article																			0	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					743	743		10.1038/383743a0	http://dx.doi.org/10.1038/383743a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878491				2022-12-28	WOS:A1996VN91800063
J	Horton, B				Horton, B			Going to work in genes catches on	NATURE			English	Article								Employment prospects are on the rise in genomics, genetic counselling and biotechnology. For the lucky few the rewards are great, but competition to break into the field can be tough. Nature reports trends from Europe and the United States on the eve of the American Society for Human Genetics meeting on 29 October.											0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					739	740		10.1038/383739a0	http://dx.doi.org/10.1038/383739a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878488				2022-12-28	WOS:A1996VN91800060
J	Lazard, T; Retel, O; Guidet, B; Maury, E; Valleron, AJ; Offenstadt, G				Lazard, T; Retel, O; Guidet, B; Maury, E; Valleron, AJ; Offenstadt, G			AIDS in a medical intensive care unit - Immediate prognosis and long-term survival	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RESPIRATORY-FAILURE; MECHANICAL VENTILATION; ADMISSION; INFECTION; MORTALITY; OUTCOMES; COUNT	Objective.-To help physicians decide whether to admit patients with acquired immunodeficiency syndrome (AIDS) to the medical intensive care unit (MICU). Design.-Case series study of AIDS patients admitted to the MICU between October 1990 and October 1992 and followed up until April 1993 (median follow-up, 1 year). Setting.-The MICU in a 970-bed teaching hospital in Paris, France. Patients.-A total of 120 consecutive AIDS patients with acute respiratory failure (50%), central nervous system dysfunction (22.5%), pneumothorax (12.5%), shock (10.8%), or miscellaneous conditions (4.2%), A fetal of 86 patients were discharged alive from the MICU. Main Outcome Measures.-Predictive factors for mortality during and after MICU stay. Results.-Multivariate analysis identified 3 factors predicting poor MICU outcome: Simplified Acute Physiology Score I (SAPS I) above 10 (relative risk [RR], 6.1, 95% confidence interval [CI]: 1.5-26.6), time between AIDS diagnosis and MICU admission more than 1 year(RR, 6.0; 95% CI, 2.1-17.5), serum albumin level less than 30 g/L (RR, 4.9; 95% CI, 1.3-18.2). The CD4 cell count, beta(2)-microglobulinemia, and previous opportunistic infections had no influence on MICU mortality. After MICU discharge, survival rates were 86% al 1 week, 82% at 1 month, 53% at 6 months, and 39% at 1 year, The Karnofsky scale score and the number of previous opportunistic infections were simultaneously associated with post-MICU outcome. Predictive factors for MICU survival did not influence post-MICU survival. Conclusion.-The MICU mortality was related to immediate severity (assessed within 48 hours of admission) and the time between AIDS diagnosis and MICU admission. Long-term survival after MICU discharge depended only on the severity of AIDS. We conclude that AIDS patients should be admitted to the MICU on the same basis as other patients.	HOP ST ANTOINE,UNITE BIOSTAT & INFORMAT MED,F-75571 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Lazard, T (corresponding author), HOP ST ANTOINE,SERV REANIMAT POLYVALENTE,184 RUE FAUBOURG ST ANTOINE,F-75012 PARIS,FRANCE.							BEDOS JP, 1995, JAMA-J AM MED ASSOC, V273, P35, DOI 10.1001/jama.273.1.35; DEAM R, 1988, ANAESTHESIA, V43, P150; DEPALO VA, 1995, CHEST, V107, P506, DOI 10.1378/chest.107.2.506; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; FRIEDMAN Y, 1990, CRIT CARE MED, V18, P346, DOI 10.1097/00003246-199003000-00027; FRIEDMAN Y, 1991, JAMA-J AM MED ASSOC, V266, P89, DOI 10.1001/jama.266.1.89; HAWLEY PH, 1994, CHEST, V106, P1456, DOI 10.1378/chest.106.5.1456; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MILLS GD, 1993, AIDS, V7, P1383, DOI 10.1097/00002030-199310000-00013; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1993, CRIT CARE CLIN, V9, P107, DOI 10.1016/S0749-0704(18)30210-0; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; STAIKOWSKY F, 1993, CHEST, V104, P756, DOI 10.1378/chest.104.3.756; TEASDALE G, 1974, LANCET, V2, P81; TUCKER KJ, 1992, WESTERN J MED, V157, P637; WACHTER RM, 1991, AM REV RESPIR DIS, V143, P251, DOI 10.1164/ajrccm/143.2.251; WACHTER RM, 1995, JAMA-J AM MED ASSOC, V273, P230, DOI 10.1001/jama.273.3.230; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WACHTER RM, 1992, JAMA-J AM MED ASSOC, V267, P541, DOI 10.1001/jama.267.4.541; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1986, REANIM SOINS INTENSI, V2, P219; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1993, B EPIDEMIOL HEBDOMAD, V7, P25	30	27	28	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1240	1245		10.1001/jama.276.15.1240	http://dx.doi.org/10.1001/jama.276.15.1240			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL691	8849752				2022-12-28	WOS:A1996VL69100033
J	Anderson, RM; Garnett, GP				Anderson, RM; Garnett, GP			Low-efficacy HIV vaccines: Potential for community-based intervention programmes	LANCET			English	Article							DEVELOPING-COUNTRIES; SPREAD; TRANSMISSION; POPULATIONS; INFECTION; IMPACT; TRIALS; RATES; AGE	To combat the spread of HIV, progress on vaccine development is eagerly awaited. Haynes in this series has described the progress made so far with various vaccine types. This article describes how mathematical modelling techniques can be used to predict the likely impact of low-efficacy vaccines in community transmission of the virus. The answers are often not what one would predict by intuition alone, and they have great bearing on the likely success of such vaccination strategies.			Anderson, RM (corresponding author), UNIV OXFORD, DEPT ZOOL, CTR EPIDEMIOL INFECT DIS, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Garnett, Geoffrey P/A-9312-2008	Anderson, Roy/0000-0002-9528-3175				ANDERSON R M, 1991; ANDERSON RM, 1991, NATURE, V350, P356, DOI 10.1038/350356a0; ANDERSON RM, 1995, P ROY SOC B-BIOL SCI, V261, P147, DOI 10.1098/rspb.1995.0129; Bloom BR, 1996, SCIENCE, V272, P1888, DOI 10.1126/science.272.5270.1888; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; GARNETT GP, 1993, PHILOS T R SOC B, V342, P137, DOI 10.1098/rstb.1993.0143; GARNETT GP, 1995, J ACQ IMMUN DEF SYND, V9, P500; GARNETT GP, 1994, IMA J MATH APPL MED, V11, P161; Gregson S, 1994, Health Transit Rev, V4 Suppl, P65; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HALLORAN ME, 1991, AM J EPIDEMIOL, V133, P323, DOI 10.1093/oxfordjournals.aje.a115884; HALLORAN ME, 1994, STAT MED, V13, P357, DOI 10.1002/sim.4780130404; JACKSON DJ, 1995, AIDS, V9, P1279, DOI 10.1097/00002030-199511000-00010; MCLEAN AR, 1993, P ROY SOC B-BIOL SCI, V253, P9, DOI 10.1098/rspb.1993.0075; MOORE J, 1994, NATURE, V372, P313, DOI 10.1038/372313a0; MULDER D, 1995, BRIT MED J, V311, P833, DOI 10.1136/bmj.311.7009.833; PARKER G, IN PRESS IMAJ MATH A; RIDA WN, 1994, STAT MED, V13, P2155, DOI 10.1002/sim.4780131922; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59	19	70	70	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	1996	348	9033					1010	1013		10.1016/S0140-6736(96)07100-0	http://dx.doi.org/10.1016/S0140-6736(96)07100-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855867				2022-12-28	WOS:A1996VM02700023
J	Ramos, R; Kennedy, KI; Visness, CM				Ramos, R; Kennedy, KI; Visness, CM			Effectiveness of lactational amenorrhoea in prevention of pregnancy in Manila, the Philippines: Non-comparative prospective trial	BRITISH MEDICAL JOURNAL			English	Article							CONTRACEPTIVE FAILURE	Objective-To determine the contraceptive efficacy of the lactational amenorrhoea method. Design-Non-comparative prospective trial. Setting-Urban Manila, the Philippines. Subjects-485 lower income, educated women with extensive experience of breast feeding. Intervention-Women were offered all available contraceptives for use after birth. Those who chose the lactational amenorrhoea method were taught the method, screened for the study, and followed for 12 months to determine the risk of pregnancy when the method was used. Main outcome measures-Life table pregnancy rates during correct and incorrect use of the method, censored monthly in the event of sexual abstinence or the use of another contraceptive method. Results-The lactational amenorrhoea method was 99% effective when used correctly (that is, during lactational amenorrhoea and full or nearly full breast feeding for up to six months). At 12 months the effectiveness during amenorrhoea dropped to 97%. Conclusions-The lactational amenorrhoea method provided as much protection from pregnancy as non-breast feeding women experience with non-medicated intrauterine devices and barrier methods. The contraceptive effect of lactation cannot be attributed to lactational or postpartum abstinence.	JOSE FABELLA MEM HOSP,COMPREHENS FAMILY PLANNING CTR,MANILA,PHILIPPINES; FAMILY HLTH INT,RES TRIANGLE PK,NC 27709									COX DR, 1984, ANAL SURVIVAL DATA, P2; Francis B., 1993, GLIM SYSTEM RELEASE; KAZI A, 1995, FERTIL STERIL, V64, P717, DOI 10.1016/S0015-0282(16)57845-5; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; LABBOK M, 1994, GUIDELINES BREASFEED; MOGGIA AV, 1991, CONTRACEPTION, V44, P31, DOI 10.1016/0010-7824(91)90104-N; PEREZ A, 1992, LANCET, V339, P968, DOI 10.1016/0140-6736(92)91538-J; ROLLAND R, 1976, BIBLIO REPROD, V8, P1; ROLLAND R, 1976, BIBLIO REPROD, V8, P93; *SAS I, 1991, SAS STAT REL 6 07; SIMPSONHEBERT M, 1981, STUD FAMILY PLANN, V12, P125, DOI 10.2307/1965593; TRUSSELL J, 1987, STUD FAMILY PLANN, V18, P237, DOI 10.2307/1966856; TRUSSELL J, 1991, STAT MED, V10, P201, DOI 10.1002/sim.4780100206; VANGINNE.JK, 1974, STUD FAMILY PLANN, V5, P201, DOI 10.2307/1965371; 1988, LANCET, V2, P1204	15	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					909	912						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876092	Green Published			2022-12-28	WOS:A1996VM75400023
J	Bush, TL; Wells, HB; James, MK; BarrettConnor, E; Marcus, R; Greendale, G; Hunsberger, S; McGowan, J				Bush, TL; Wells, HB; James, MK; BarrettConnor, E; Marcus, R; Greendale, G; Hunsberger, S; McGowan, J			Effects of hormone therapy on bone mineral density - Results from the postmenopausal estrogen/progestin interventions (PEPI) trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN REPLACEMENT THERAPY; HIP FRACTURE; PERCUTANEOUS ESTRADIOL; TRABECULAR BONE; ELDERLY WOMEN; RISK-FACTORS; OLDER WOMEN; OSTEOPOROSIS; MENOPAUSE; MASS	Objective.-To assess the effects of hormone therapy on bone mineral density (BMD) in the spine and hip of postmenopausal women. Design.-A 3-year, multicenter, randomized, double-blinded, placebo-controlled clinical trial. Participants.-A total of 875 healthy women aged 45 to 64 years recruited at 7 clinical centers. Interventions.-Treatments were (1) placebo; (2) conjugated equine estrogens (CEE), 0.625 mg/d; (3) CEE, 0.625 mg/d plus medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo; (4) CEE, 0.625 mg/d plus MPA, 2.5 mg/d daily; or (5) GEE, 0.625 mg/d plus micronized progesterone (MP), 200 mg/d for 12 d/mo. Main Outcome Measures.-Bone mineral density at baseline, 12 months, and 36 months. Results.-Participants assigned to the placebo group lost an average of 1.8% of spine BMD and 1.7% of hip BMD by the 36-month visit, while those assigned to active regimens gained BMD at both sites, ranging from 3.5% to 5.0% mean total increases in spinal BMD and a mean total increase of 1.7% of BMD in the hip. Changes in BMD for women assigned to active regimens were significantly greater than those assigned to placebo. Women assigned to CEE plus continuous MPA had significantly greater increases in spinal BMD (increase of 5%) than those assigned to the other 3 active regimens (average increase, 3.8%). Findings were similar among those adhering to assigned therapy, although, among adherent participants, there were no significant differences in BMD changes among the 4 active treatment groups, Older women, women with low initial BMD, and those with no previous hormone use gained significantly more bone than younger women, women with higher initial BMD, and those who had used hormones previously. Conclusions.-Postmenopausal women assigned to placebo demonstrated decreased BMD at the spine and hip, whereas women assigned to estrogen therapy increased BMD during a 36-month period, These findings demonstrate that estrogen replacement therapy increases BMD at clinically important sites.	PARKE DAVIS & CO, MORRIS PLAINS, NJ USA; ELI LILLY & CO, INDIANAPOLIS, IN 46285 USA; ORTHO PHARMACEUT CORP, RARITAN, NJ 08869 USA; FOREST LABS INC, ST LOUIS, MO USA; ORGANON INC, W ORANGE, NJ USA	Pfizer; Eli Lilly					NHLBI NIH HHS [U01-HL40185, U01-HL40154, U01-HL40195] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040154, U01HL040195, U01HL040185] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMAMENTOVILLAREAL R, 1995, J CLIN ENDOCR METAB, V80, P776, DOI 10.1210/jc.80.3.776; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BLACK DM, 1992, J BONE MINER RES, V7, P633; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CHRISTIANSEN C, 1990, MATURITAS, V12, P247, DOI 10.1016/0378-5122(90)90006-R; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; FROST HM, 1989, BONE MINER, V7, P47, DOI 10.1016/0169-6009(89)90062-7; GALLAGHER JC, 1991, AM J MED, V90, P171; GREENDALE GA, 1995, MENOPAUSE, V2, P27; GREENDALE GA, 1995, J WOMENS HEALTH, V4, P231; GRISSO JA, 1994, NEW ENGL J MED, V330, P1555, DOI 10.1056/NEJM199406023302202; GRYNPAS M, 1993, CALCIFIED TISSUE INT, V53, P557; HEANEY RP, 1994, J BONE MINER RES, V9, P1515; HOLLAND EFN, 1994, OBSTET GYNECOL, V83, P43; HOLLAND EFN, 1993, BRIT J OBSTET GYNAEC, V100, P966, DOI 10.1111/j.1471-0528.1993.tb15124.x; JAGLAL SB, 1993, AM J EPIDEMIOL, V138, P107, DOI 10.1093/oxfordjournals.aje.a116833; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KIEL DP, 1992, ANN INTERN MED, V116, P716, DOI 10.7326/0003-4819-116-9-716; LINDSAY R, 1978, LANCET, V1, P1325; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LINDSAY R, 1990, ANN NY ACAD SCI, V592, P326; LOOKER AC, 1995, J BONE MINER RES, V10, P796; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MARCUS R, 1994, J BONE MINER RES, V9, P1467, DOI 10.1002/jbmr.5650090920; MELTON LJ, 1995, J BONE MINER RES, V10, P175; NOTELOVITZ M, 1991, J BONE MINER RES, V6, P583, DOI 10.1002/jbmr.5650060609; ODELL WE, 1993, DIS MON, V19, P789; PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386; RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, P61, DOI 10.1016/0002-9378(87)90203-1; SARTORIS DJ, 1989, AM J ROENTGENOL, V152, P241, DOI 10.2214/ajr.152.2.241; *SAS I INC, 1992, P229 SAS; SAS&REG; Procedures, 1990, VERSION 6; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SESSION DR, 1993, FERTIL STERIL, V59, P277; Smith Everett L, 1982, Phys Sportsmed, V10, P72, DOI 10.1080/00913847.1982.11947184; SOWERS MR, 1993, OSTEOPOROSIS INT, V3, P314, DOI 10.1007/BF01637317; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; WIMALAWANSA SJ, 1995, AM J MED, V99, P36, DOI 10.1016/S0002-9343(99)80102-8; WOOD H, 1993, J GEN INTERN MED, V8, P451, DOI 10.1007/BF02599627; 1995, CONTROL CLIN TRIALS, V16, pS3; 1996, JAMA-J AM MED ASSOC, V274, P1676; 1995, JAMA-J AM MED ASSOC, V273, P199	49	576	584	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1389	1396		10.1001/jama.276.17.1389	http://dx.doi.org/10.1001/jama.276.17.1389			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892713				2022-12-28	WOS:A1996VQ46400024
J	Coates, TJ; Aggleton, P; Gutzwiller, F; DesJarlais, D; Kihara, M; Kippax, S; Schechter, M; vandenHoek, JAR				Coates, TJ; Aggleton, P; Gutzwiller, F; DesJarlais, D; Kihara, M; Kippax, S; Schechter, M; vandenHoek, JAR			HIV prevention in developed countries	LANCET			English	Article							INJECTING DRUG-USERS; RISK-FACTORS; INFECTION; HEALTH; SEROPREVALENCE; EXPERIENCE; EDUCATION; BEHAVIOR; TRENDS; MEN	HIV prevention in developed countries is marked by impressive successes and dismal failures. The successes point the way to what works; the failures highlight obstacles that must be overcome. Successes include important behavioural changes among gay and bisexual men, antiviral use to prevent vertical transmission, and securing the safety of the blood supply. New strategies are needed to reach the residual of individuals continuing with unsafe practices (a special hazard in high-prevalence areas); to reach young people who are beginning to engage in sexual relations and injection drug use; and to overcome political opposition to prevention strategies.	UNIV LONDON,INST EDUC,THOMAS CORAM RES UNIT,LONDON WC1N 1AZ,ENGLAND; UNIV ZURICH,INST SOCIAL & PREVENT MED,CH-8006 ZURICH,SWITZERLAND; BETH ISRAEL MED CTR,NEW YORK,NY 10003; KANAGAWA CANC CTR,RES INST,YOKOHAMA,KANAGAWA,JAPAN; MACQUARIE UNIV,NATL CTR HIV SOCIAL RES,SYDNEY,NSW 2109,AUSTRALIA; ST PAULS HOSP,BC CTR EXCELLENCE HIV AIDS,VANCOUVER,BC V6Z 1Y6,CANADA; UNIV BRITISH COLUMBIA,FAC MED,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER,BC,CANADA; MUNICIPAL HLTH SERV,AMSTERDAM,NETHERLANDS	University of London; University College London; UCL Institute of Education; University of Zurich; Harvard University; Beth Israel Deaconess Medical Center; Kanagawa Prefectural Cancer Center; Macquarie University; B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia	Coates, TJ (corresponding author), UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,DIV GEN INTERNAL MED,DEPT MED,SAN FRANCISCO,CA 94105, USA.			Schechter, Martin/0000-0001-6063-2155	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAJOS N, 1995, AIDS, V9, P735, DOI 10.1097/00002030-199507000-00011; BATTJES RJ, 1995, J ACQ IMMUN DEF SYND, V10, P90; BERRIOS DC, 1993, JAMA-J AM MED ASSOC, V270, P1576, DOI 10.1001/jama.270.13.1576; BROERS B, 1994, 10 INT C AIDS 5 STD; *CAN AIDS SOC, 1993, GAIL FORW; *CAN AIDS SOC, 1993, DOING 90S WHAT YOU S; CATANIA JA, 1995, AM J PUBLIC HEALTH, V85, P1492, DOI 10.2105/AJPH.85.11.1492; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; COATES TJ, 1995, DOES HIV PREVENTION; DESJARLAIS DC, 1994, NEW ENGL J MED, V331, P1451, DOI 10.1056/NEJM199411243312112; DESJARLAIS DC, 1995, JAMA-J AM MED ASSOC, V274, P1226, DOI 10.1001/jama.274.15.1226; DUBOISARBER F, 1994, SOZ PREVENTIMED S1, V37, pS3; *EUR CTR EP MON AI, 1994, 43 HOSP NAT SAINTM; FRANCIS DP, 1987, JAMA-J AM MED ASSOC, V257, P1357, DOI 10.1001/jama.257.10.1357; HANVELT RA, 1994, AIDS, V8, pF7, DOI 10.1097/00002030-199410000-00001; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; *HIV AIDS DIV, 1995, 1995 HIV AIDS DIV LA; HOGG RS, 1994, LANCET, V344, P1120, DOI 10.1016/S0140-6736(94)90631-9; HOGG RS, 1993, CAN J PUBLIC HEALTH, V84, P423; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; KAHN JG, 1994, COST EFFECTIVENESS H; KEGELES SM, IN PRESS AM J PUBL H; LEHMANN P, 1987, BRIT MED J, V2, P1118; LURIE P, 1995, AIDS, V9, P539, DOI 10.1097/00002030-199506000-00002; LURIE P, 1994, JAMA-J AM MED ASSOC, V271, P295, DOI 10.1001/jama.271.4.295; *NAT CTR HIV EP CL, 1995, 3 NAT CTR HIV EP CLI, P11; NICOLOSI A, 1992, J ACQ IMMUN DEF SYND, V5, P365; OAKLEY A, 1995, BRIT MED J, V310, P158, DOI 10.1136/bmj.310.6973.158; OSMOND DH, 1994, AM J PUBLIC HEALTH, V84, P1933, DOI 10.2105/AJPH.84.12.1933; PETERS AD, 1994, AIDS, V8, P521, DOI 10.1097/00002030-199404000-00016; Ramsay S, 1996, LANCET, V347, P109, DOI 10.1016/S0140-6736(96)90225-1; REKART ML, 1993, 9 INT C AIDS BERL; REZZA G, 1994, SOZ PREVENTIV MED S1, V37, pS61; ROMANO N, 1992, AM J EPIDEMIOL, V135, P1189, DOI 10.1093/oxfordjournals.aje.a116225; ROSENBERG PS, 1995, SCIENCE, V270, P1322; STALL R, 1990, J ACQ IMMUN DEF SYND, V3, P1181; STALL R, 1994, BRIT MED J, V309, P585; STRYKER J, 1995, JAMA-J AM MED ASSOC, V273, P1143, DOI 10.1001/jama.273.14.1143; SUSSER M, 1995, AM J PUBLIC HEALTH, V85, P156, DOI 10.2105/AJPH.85.2.156; Sweat M D, 1995, AIDS, V9 Suppl A, pS251; TEMMERMAN M, 1995, LANCET, V345, P969, DOI 10.1016/S0140-6736(95)90707-6; VALDISERRI RO, 1995, J COMMUN HEALTH, V20, P87, DOI 10.1007/BF02260331; van Ameijden E J, 1995, AIDS, V9 Suppl A, pS75; VANAMEIJDEN EJC, 1992, AM J EPIDEMIOL, V136, P236, DOI 10.1093/oxfordjournals.aje.a116489; VONGRIENSVEN GJP, 1989, BRIT MED J, V298, P218; WELLINGS K, 1995, BRIT MED J, V311, P417, DOI 10.1136/bmj.311.7002.417; *WHO, 1995, GLOB PROGR AIDS EUR; ZACCARELLI M, 1990, AIDS, V4, P1007, DOI 10.1097/00002030-199010000-00010; 1995, MMWR-MORBID MORTAL W, V44, P849; 1995, AIDS NZ          AUG, V26	50	54	54	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1143	1148		10.1016/S0140-6736(96)02307-0	http://dx.doi.org/10.1016/S0140-6736(96)02307-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VP106	8888170				2022-12-28	WOS:A1996VP10600014
J	Kai, J				Kai, J			Parents' difficulties and information needs in coping with acute illness in preschool children: A qualitative study	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MINOR ILLNESS; BABY-CHECK; MOTHERS; BABIES	Objectives-To identify and explore difficulties parents experience with acute illness in young children and the information they seek to help them. Design-Qualitative study using semistructured one to one and group interviews with parents of preschool children. Setting-Disadvantaged inner city community, Subjects-95 parents of preschool children. Results-Parents felt disempowered when dealing with acute illness in their children because of difficulties making sense of the illness. Central to parents' difficulties were their experiences of inadequate information sharing by their general practitioners and variations in their doctors) decisions and behaviour. Disparity between parents' beliefs and expectations about illness and treatment and professionals' behaviour further frustrated parents' attempts to understand illness. Parents expressed a need for a range of accessible and specific information to support them through their negotiation of children's illness. Conclusions-Communication with parents requires greater recognition of parents) difficulties. Professionals have considerable potential to empower parents by sharing more information and skills. Such information should be consistent and address parents' concerns, beliefs, and expressed needs if this potential is to be realised.			Kai, J (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Kai, Joe/0000-0001-9040-9384				ANDERSON JE, 1980, BRIT MED J, V281, P924, DOI 10.1136/bmj.281.6245.924; BENSON P, 1988, J ROY COLL GEN PRACT, V38, P539; BLAXTER M, 1982, MTOHERS DAUGHTERS 3; Bloor MJ C., 1975, SOCIOLOGY MEDICAL PR, V1st ed, P271; Cunningham-Burley Sarah, 1990, READINGS MED SOCIOLO, P85; FIELD P, 1985, NURSING RES APPL QUA, P91; IRVINE S, 1991, BRIT J GEN PRACT, V41, P371; KAI J, 1993, BRIT MED J, V307, P660, DOI 10.1136/bmj.307.6905.660; KAI J, 1994, FAM PRACT, V11, P245, DOI 10.1093/fampra/11.3.245; Kai J, 1996, BRIT MED J, V313, P983; MARSH GN, 1995, BRIT MED J, V310, P778, DOI 10.1136/bmj.310.6982.778; MAYALL B, 1986, KEEPING CHILDREN HLT; MORRELL DC, 1980, BRIT MED J, V280, P769, DOI 10.1136/bmj.280.6216.769; MORRISON JM, 1991, BRIT MED J, V303, P1111, DOI 10.1136/bmj.303.6810.1111; Pike L A, 1980, J R Coll Gen Pract, V30, P517; Ruel A, 1981, J R Coll Gen Pract, V31, P496; Strauss A. L., 1990, GROUNDED THEORY PROC; THORNTON AJ, 1991, ARCH DIS CHILD, V66, P106, DOI 10.1136/adc.66.1.106; USHERWOOD TP, 1991, BRIT J GEN PRACT, V41, P58; WILKIN D, 1987, ANATOMY URBAN GEN P, P136	20	149	152	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					987	990						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892421				2022-12-28	WOS:A1996VN91600027
J	Spanopoulou, E; Zaitseva, F; Wang, FH; Santagata, S; Baltimore, D; Panayotou, G				Spanopoulou, E; Zaitseva, F; Wang, FH; Santagata, S; Baltimore, D; Panayotou, G			The homeodomain region of Rag-1 reveals the parallel mechanisms of bacterial and V(D)J recombination	CELL			English	Article							STRAND BREAK REPAIR; SITE-SPECIFIC RECOMBINATION; DNA-BINDING DOMAIN; IMMUNE-SYSTEM; HIN RECOMBINASE; CAENORHABDITIS-ELEGANS; RAG-1-DEFICIENT MICE; JOINING SIGNALS; TC1 TRANSPOSASE; SEQUENCE	The V(D)J recombinase subunits Rag-1 and Rag-2 mediate assembly of antigen receptor gene segments. We studied the mechanisms of DNA recognition by Rag-1/Rag-2 using surface plasmon resonance. The critical step for signal recognition is binding of Rag-1 to the nonamer. This is achieved by a region of Rag-1 homologous to the DNA-binding domain of the Hin family of bacterial invertases and to homeodomain proteins. Strikingly, the Hin homeodomain can functionally substitute for the Rag-1 homologous region. Rag-1 also interacts with the heptamer but with low affinity. Rag-2 shows no direct binding to DNA. Once the Rag-1/Rag-2 complex is engaged on the DNA, subsequent cleavage is directed by the heptamer sequence. This order of events remarkably parallels mechanisms that mediate transposition in bacteria and nematodes.	MIT,CAMBRIDGE,MA 02139; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Massachusetts Institute of Technology (MIT); Ludwig Institute for Cancer Research	Spanopoulou, E (corresponding author), MT SINAI SCH MED,RUTTENBERG CANC CTR,NEW YORK,NY 10029, USA.		Santagata, Sandro/A-7714-2009	Santagata, Sandro/0000-0002-7528-9668				AFFOLTER M, 1991, CELL, V64, P879, DOI 10.1016/0092-8674(91)90311-L; BARTL S, 1994, P NATL ACAD SCI USA, V91, P10769, DOI 10.1073/pnas.91.23.10769; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; BONDESON K, 1993, ANAL BIOCHEM, V214, P245, DOI 10.1006/abio.1993.1484; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; DERBYSHIRE KM, 1992, EMBO J, V11, P3449, DOI 10.1002/j.1460-2075.1992.tb05424.x; DREYFUS DH, 1992, MOL IMMUNOL, V29, P807, DOI 10.1016/0161-5890(92)90191-Y; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; HANSEN JD, 1995, IMMUNOGENETICS, V42, P188, DOI 10.1007/BF00191224; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HUGHES KT, 1992, EMBO J, V11, P2695, DOI 10.1002/j.1460-2075.1992.tb05335.x; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JONSSON U, 1991, BIOTECHNIQUES, V11, P520; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PANAYOTOU G, 1993, CURR BIOL, V3, P913, DOI 10.1016/0960-9822(93)90236-H; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; Rathbun G.A., 1987, P85; Roman CAJ, 1996, P NATL ACAD SCI USA, V93, P2333, DOI 10.1073/pnas.93.6.2333; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Spanopoulou E, 1996, Int Rev Immunol, V13, P257, DOI 10.3109/08830189609061752; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VANGENT DC, 1995, CELL, V81, P825; VOS JC, 1993, GENE DEV, V7, P1244, DOI 10.1101/gad.7.7a.1244; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x; WHITE R, 1994, CURR BIOL, V4, P48, DOI 10.1016/S0960-9822(00)00010-5; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	56	187	189	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					263	276		10.1016/S0092-8674(00)81344-6	http://dx.doi.org/10.1016/S0092-8674(00)81344-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861910	Bronze			2022-12-28	WOS:A1996VN40300014
J	Brooke, TY; Tokunaga, AT; Weaver, HA; Crovisier, J; BockeleeMorvan, D; Crisp, D				Brooke, TY; Tokunaga, AT; Weaver, HA; Crovisier, J; BockeleeMorvan, D; Crisp, D			Detection of acetylene in the infrared spectrum of comet Hyakutake	NATURE			English	Article							CHEMICAL-MODELS; MOLECULES; FLUORESCENCE; ATMOSPHERES; RESOLUTION; HALLEY; GAS	COMETS are rich in volatile materials, of which roughly 80% (by number) are mater molecules(1). Considerable progress(2-4) being made in identifying the other volatile species, the abundances of which should enable us to determine whether comets formed primarily from ice-covered interstellar grains(5), or from material that was chemically processed in the early solar nebula(6,7). Here we report the detection of acetylene (C2H2,) in the infrared spectrum of comet C/1996 B2 (Hyakutake). The estimated abundance is 0.3-0.9%, relative to water, which is comparable to the predicted solid-phase abundance in cold interstellar clouds. This suggests that the volatiles in comet Hyakotake may have come from ice-covered interstellar grains, rather than material processed in the accretion disk out of which the Solar System formed.	UNIV HAWAII, INST ASTRON, HONOLULU, HI 96822 USA; JOHNS HOPKINS UNIV, DEPT PHYS & ASTRON, BALTIMORE, MD 21218 USA; OBSERV PARIS, F-92195 MEUDON, FRANCE	University of Hawaii System; Johns Hopkins University; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Brooke, TY (corresponding author), CALTECH, JET PROP LAB, 4800 OAK GROVE DR, M-S 169-237, PASADENA, CA 91109 USA.		Crisp, David/F-6642-2017; Weaver, Harold A/D-9188-2016	Crisp, David/0000-0002-4573-9998; Weaver, Harold A/0000-0003-0951-7762; Tokunaga, Alan/0000-0001-8136-9704				BOCKELEEMORVAN D, 1989, ASTRON ASTROPHYS, V216, P278; BOCKELEEMORVAN D, 1991, NATURE, V350, P318, DOI 10.1038/350318a0; CARR JS, 1995, ASTROPHYS J, V450, P667, DOI 10.1086/176174; CROVISIER J, 1989, ASTRON ASTROPHYS, V213, P459; CROVISIER J, 1983, ASTRON ASTROPHYS, V126, P170; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; Fegley B.J., 1989, FORMATION EVOLUTION, P171; Greenberg J., 1982, COMETS, P131; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P313, DOI 10.1117/12.158684; HASEGAWA TI, 1993, MON NOT R ASTRON SOC, V263, P589, DOI 10.1093/mnras/263.3.589; Herzberg G., 1945, INFRARED RAMAN SPECT, V2; HUEBNER WF, 1992, ASTROPHYS SPACE SCI, V195, P1, DOI 10.1007/BF00644558; JACKSON WM, 1976, J PHOTOCHEM, V5, P107, DOI 10.1016/0047-2670(76)85014-9; KRANKOWSKY D, 1986, NATURE, V321, P326, DOI 10.1038/321326a0; LUNINE JI, 1989, FORMATION EVOLUTION, P213; MATTHEWS HE, 1996, 6353 IAU; Meadows VS, 1996, J GEOPHYS RES-PLANET, V101, P4595, DOI 10.1029/95JE03567; Mumma M. J., 1993, PROTOSTARS PLANETS, P1177; Mumma MJ, 1996, SCIENCE, V272, P1310, DOI 10.1126/science.272.5266.1310; ODELL CR, 1988, ASTROPHYS J, V334, P476, DOI 10.1086/166852; PRINN RG, 1981, ASTROPHYS J, V249, P308, DOI 10.1086/159289; SCHLEICHER D, 1996, 6344 IAU; SCHLEICHER DG, 1988, ASTROPHYS J, V331, P1058, DOI 10.1086/166622; STRAZZULLA G, 1991, ASTROPHYS SPACE SC L, V167, P243; TOKUNAGA AT, 1990, P SOC PHOTO-OPT INS, V1235, P131, DOI 10.1117/12.19082; VANDERAUWERA J, 1993, J MOL SPECTROSC, V157, P337, DOI 10.1006/jmsp.1993.1027; WEAVER HA, 1984, ASTROPHYS J, V276, P782, DOI 10.1086/161664; WOOTTEN A, 1996, INT C AST COM MET 39; YAMAMOTO T, 1991, ASTROPHYS SPACE SC L, V167, P361	29	127	127	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					606	608		10.1038/383606a0	http://dx.doi.org/10.1038/383606a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857534				2022-12-28	WOS:A1996VM75500047
J	Bruno, G; CavalloPerin, P; Bargero, G; Borra, M; DErrico, N; Pagano, G				Bruno, G; CavalloPerin, P; Bargero, G; Borra, M; DErrico, N; Pagano, G			Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; RISK FACTOR; MICROALBUMINURIA; NIDDM	Background: The high prevalence of classic cardiac risk factors in patients with non-insulin-dependent diabetes mellitus does not explain the increased cardiovascular-related morbidity and mortality in these patients. Fibrinogen may have a role in this excess risk. Objective: To evaluate the following in patients with non-insulin-dependent diabetes mellitus: 1) the distribution of plasma fibrinogen levels and the prevalence of hyperfibrinogenemia and 2) the association of fibrinogen level with hemoglobin A(1c) value and albumin excretion rate. Design: Cross-sectional study of a population-based cohort. Setting: Rural area in northern Italy. Patients: 1574 patients with non-insulin-dependent diabetes mellitus who represented 81% of the initial cohort of 1967 patients. Measurements: Albumin excretion rate was measured in urine samples obtained during an overnight collection. Venous blood samples were collected while patients fasted. Results: Fibrinogen levels were available for 1525 of the 1574 patients who were examined (669 men and 856 women). The mean age (+/- SD) was 67.3 +/- 10.3 years for men and 70.7 +/- 10.7 years for women. The mean plasma fibrinogen level (+/- SD) was 3.6 +/- 0.9 g/L; levels slightly differed between men and women. In 50.3% of patients, plasma fibrinogen level exceeded 3.5 g/L. In men, fibrinogen level increased with age (P < 0.001). In both men and women, fibrinogen level adjusted for age and sex was significantly and linearly related to hemoglobin A(1c) value (P < 0.001) and albumin excretion rate (P < 0.001). In a multiple regression analysis, hemoglobin A(1c) value (b = 0.06; P < 0.001) and albumin excretion rate (b = 0.09; P = 0.005) were associated with fibrinogen level independent of other cardiovascular risk factors (sex, age, hypertensive status, total cholesterol level, smoking habit, and body mass index). Conclusions: Patients with non-insulin-dependent diabetes mellitus had a high prevalence of hyperfibrinogenemia. Fibrinogen level was independently associated with hemoglobin A(1c) value and albumin excretion rate, which suggests that fibrinogen may be involved in the increased cardiovascular risk of patients with diabetes mellitus.	OSPED SANTO SPIRITO, SERV DIABETOL, I-15033 CASALE MONFERRATO, ALESSANDRIA, ITALY		Bruno, G (corresponding author), UNIV TURIN, DIPARTIMENTO MED INTERNA, CORSO DOGLIOTTI 14, I-10126 TURIN, ITALY.		Bruno, Graziella/E-9673-2012	BRUNO, Graziella/0000-0002-3011-8304				BRUNO G, 1994, DIABETES CARE, V17, P548, DOI 10.2337/diacare.17.6.548; BRUNO G, 1992, DIABETOLOGIA, V35, P851, DOI 10.1007/BF00399931; Bruno G, 1996, DIABETES CARE, V19, P43, DOI 10.2337/diacare.19.1.43; CERIELLO A, 1995, NUTR METAB CARDIOVAS, V5, P237; CERIELLO A, 1994, DIABETES, V43, P430, DOI 10.2337/diabetes.43.3.430; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLIER A, 1992, DIABETES, V41, P909, DOI 10.2337/diabetes.41.8.909; DEFEO P, 1991, J CLIN INVEST, V88, P833, DOI 10.1172/JCI115384; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; GANDA OP, 1992, DIABETES CARE, V15, P1245, DOI 10.2337/diacare.15.10.1245; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; KANNEL WB, 1990, AM HEART J, V120, P672, DOI 10.1016/0002-8703(90)90026-T; KNOBL P, 1993, DIABETOLOGIA, V36, P1045, DOI 10.1007/BF02374497; LEE AJ, 1993, BRIT HEART J, V69, P338; MATTOCK MB, 1988, DIABETOLOGIA, V31, P82, DOI 10.1007/BF00395552; NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996; PAGANO G, 1994, DIABETIC MED, V11, P475, DOI 10.1111/j.1464-5491.1994.tb00309.x; SCHMITZ A, 1990, DIABETIC MED, V7, P521, DOI 10.1111/j.1464-5491.1990.tb01435.x; SCHWARTZ CJ, 1988, SEMIN THROMB HEMOST, V14, P189, DOI 10.1055/s-2007-1002775; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003	20	62	62	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					653	657		10.7326/0003-4819-125-8-199610150-00005	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM889	8849150				2022-12-28	WOS:A1996VM88900007
J	Novack, DH				Novack, DH			The bet	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Novack, DH (corresponding author), MED COLL PENN & HAHNEMANN UNIV, SCH MED, 2900 QUEEN LANE, PHILADELPHIA, PA 19129 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					692	693		10.7326/0003-4819-125-8-199610150-00012	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM889	8849157				2022-12-28	WOS:A1996VM88900014
J	Brook, RH				Brook, RH			United States of America - Practice guidelines: To be or not to be	LANCET			English	Article											Brook, RH (corresponding author), RAND CORP,HLTH SCI PROGRAM,POB 2138,SANTA MONICA,CA 90407, USA.								0	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					1005	1006						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855863				2022-12-28	WOS:A1996VM02700019
J	Tanaka, S; Amling, M; Neff, L; Peyman, A; Uhlmann, E; Levy, JB; Baron, R				Tanaka, S; Amling, M; Neff, L; Peyman, A; Uhlmann, E; Levy, JB; Baron, R			c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption	NATURE			English	Article							TYROSINE KINASE; PROTEIN PRODUCT; SH3 DOMAIN; PROTOONCOGENE; PHOSPHORYLATION; OSTEOCLASTS; STIMULATION; RECEPTOR; MICE; OSTEOPETROSIS	THE primacy defect in mice lacking the c-src gene is osteopetrosis, a deficiency in bone resorption by osteoclasts(1). Osteoclasts express high levels of the c-Src protein(2,3) and the defect responsible for the osteopetrotic phenotype of the c-src-deficient (src(-)) mouse is fell-autonomous and occurs in mature osteoclasts(4,5). However, the specific signalling pathways that require c-Src expression for normal osteoclast activity have not been elucidated. We report here that the proto-oncogene product c-Cbl is tyrosine-phosphorylated in a Src-dependent manner in osteoclasts, where the two proteins colocalize on some vesicular structures. In vitro bone resorption by osteoclast-like cells (OCLs) is inhibited by both c-src and c-cbl antisense oligonucleotides, Furthermore, tryosine phosphorylation of c-Cbl and the localization of c-Cbl-containing structures to the peripheral cytoskeleton are impaired in resorption-deficient c-src(-) OCLs, as well as in wild-type OCLs that have been treated with c-src antisense oligonucleotides. These results indicate that c-Cbl may act downstream of c-Src in a signalling pathway that is required for bone resorption.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT ORTHOPED, NEW HAVEN, CT 06510 USA; HOECHST AG, CENT PHARMA RES, D-65926 FRANKFURT, GERMANY	Yale University; Yale University; Sanofi-Aventis			Tanaka, Sakae/Y-3061-2019	Tanaka, Sakae/0000-0001-9210-9414				AKATSU T, 1992, J BONE MINER RES, V7, P1297; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BARON R, 1988, J CELL BIOL, V106, P1863, DOI 10.1083/jcb.106.6.1863; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLAKE TJ, 1991, ONCOGENE, V6, P653; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Peyman A, 1996, BIOL CHEM H-S, V377, P67; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509	21	245	250	0	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 10	1996	383	6600					528	531		10.1038/383528a0	http://dx.doi.org/10.1038/383528a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849724				2022-12-28	WOS:A1996VL75500051
J	Nagao, K; Kikuchi, A				Nagao, K; Kikuchi, A			Sister Joseph's node in non-Hodgkin's lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Nagao, K (corresponding author), KEIO UNIV,SCH MED,TOKYO 160,JAPAN.		Nagao, Keisuke/P-3837-2018; Nagao, Keisuke/J-5116-2013	Nagao, Keisuke/0000-0002-7005-3138; Nagao, Keisuke/0000-0002-7005-3138					0	10	10	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1996	335	21					1569	1569		10.1056/NEJM199611213352106	http://dx.doi.org/10.1056/NEJM199611213352106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT341	8900091				2022-12-28	WOS:A1996VT34100006
J	Cirelli, C; Pompeiano, M; Tononi, G				Cirelli, C; Pompeiano, M; Tononi, G			Neuronal gene expression in the waking state: A role for the locus coeruleus	SCIENCE			English	Review							IMMEDIATE-EARLY GENE; LONG-TERM POTENTIATION; FOS-LIKE IMMUNOREACTIVITY; SLEEP CYCLE OSCILLATION; HIGH BASAL EXPRESSION; C-FOS; RAT-BRAIN; NORADRENERGIC NEURONS; NERVOUS-SYSTEM; MESSENGER-RNA	Several transcription factors are expressed at higher levels in the waking than in the sleeping brain. In experiments with rats, the locus coeruleus, a noradrenergic nucleus with diffuse projections, was found to regulate such expression. In brain regions depleted of noradrenergic innervation, amounts of c-Fos and nerve growth factor-induced A after waking were as low as after sleep. Phosphorylation of cyclic adenosine monophosphate response element-binding protein was also reduced. In contrast, electroencephalographic activity was unchanged. The reduced activity of locus coeruleus neurons may explain why the induction of certain transcription factors, with potential effects on plasticity and learning, does not occur during sleep.	INST NEUROSCI,SAN DIEGO,CA 92121					Pompeiano, Maria/0000-0001-9418-3896				AARONS L, 1976, PSYCHOL BULL, V83, P1, DOI 10.1037/0033-2909.83.1.1; ABRAHAM WC, 1993, NEUROSCIENCE, V56, P717, DOI 10.1016/0306-4522(93)90369-Q; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; AOKI C, 1987, BRAIN RES, V437, P264, DOI 10.1016/0006-8993(87)91642-8; ASTONJONES G, 1981, J NEUROSCI, V1, P887; ASTONJONES G, 1985, PHYSIOL PSYCHOL, V13, P118; ASTONJONES G, 1981, J NEUROSCI, V1, P876; ASTONJONES G, 1991, PROG BRAIN RES, V88, P501; ASTONJONES G, 1994, J NEUROSCI, V14, P4467; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; BERRIDGE CW, 1993, NEUROSCIENCE, V55, P381, DOI 10.1016/0306-4522(93)90507-C; BERRIDGE CW, 1991, J NEUROSCI, V11, P3135; BHAT RV, 1992, EUR J PHARM-MOLEC PH, V227, P447, DOI 10.1016/0922-4106(92)90165-R; BING GY, 1991, MOL BRAIN RES, V11, P43, DOI 10.1016/0169-328X(91)90019-T; BLOOM FE, 1969, SCIENCE, V166, P1284, DOI 10.1126/science.166.3910.1284; BRAMHAM CR, 1989, BRAIN RES, V493, P74, DOI 10.1016/0006-8993(89)91001-9; BRENNAN PA, 1992, NEUROSCIENCE, V49, P277, DOI 10.1016/0306-4522(92)90095-J; CARTER DA, 1993, EUR J PHARM-MOLEC PH, V244, P285, DOI 10.1016/0922-4106(93)90154-2; CESPUGLIO R, 1982, ELECTROEN CLIN NEURO, V54, P570, DOI 10.1016/0013-4694(82)90042-6; CIRELLI C, 1993, ARCH ITAL BIOL, V131, P327; CIRELLI C, 1995, J SLEEP RES, V4, P92, DOI 10.1111/j.1365-2869.1995.tb00157.x; CIRELLI C, 1995, ARCH ITAL BIOL, V133, P143; Cirelli C., 1996, Society for Neuroscience Abstracts, V22, P688; CIRELLI C, UNPUB; DUJARDIN K, 1990, PHYSIOL BEHAV, V47, P1271, DOI 10.1016/0031-9384(90)90382-E; Duman Ronald S., 1995, P303; ENGELBRECHT AH, 1994, J NEUROSCI METH, V52, P57, DOI 10.1016/0165-0270(94)90056-6; EVERITT BJ, 1983, NEUROSCIENCE, V10, P397, DOI 10.1016/0306-4522(83)90142-2; FLICKER C, 1981, CELL MOL NEUROBIOL, V1, P123, DOI 10.1007/BF00710716; FOOTE SL, 1987, ANNU REV NEUROSCI, V10, P67, DOI 10.1146/annurev.ne.10.030187.000435; FOOTE SL, 1991, PROG BRAIN RES, V88, P521; FOOTE SL, 1980, P NATL ACAD SCI-BIOL, V77, P3033, DOI 10.1073/pnas.77.5.3033; FOOTE SL, 1975, BRAIN RES, V86, P229, DOI 10.1016/0006-8993(75)90699-X; FOOTE SL, 1983, PHYSIOL REV, V63, P844, DOI 10.1152/physrev.1983.63.3.844; FRITSCHY JM, 1991, PROG BRAIN RES, V88, P257; FRITSCHY JM, 1989, NEUROSCIENCE, V30, P181, DOI 10.1016/0306-4522(89)90364-3; GRASSIZUCCONI G, 1993, EUR J NEUROSCI, V5, P1071, DOI 10.1111/j.1460-9568.1993.tb00960.x; GRASSIZUCCONI G, 1994, J PHYSIOLOGY-PARIS, V88, P91, DOI 10.1016/0928-4257(94)90096-5; GUBITS RM, 1989, MOL BRAIN RES, V6, P39, DOI 10.1016/0169-328X(89)90026-0; HARLEY C, 1991, PROG BRAIN RES, V88, P307; HARTMANN E, 1971, NATURE, V233, P425, DOI 10.1038/233425a0; HEDREEN JC, 1972, BRAIN RES, V47, P1, DOI 10.1016/0006-8993(72)90248-X; HEURTEAUX C, 1993, MOL BRAIN RES, V18, P17, DOI 10.1016/0169-328X(93)90169-P; HOBSON JA, 1975, SCIENCE, V189, P55, DOI 10.1126/science.1094539; HOBSON JA, 1988, ARCH ITAL BIOL, V126, P209; HOFFMAN GE, 1992, NEUROPROTOCOLS, V1, P52; HOLMES PV, 1995, PSYCHOPHARMACOLOGY 4, P2002; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; HUGHES P, 1995, PHARMACOL REV, V47, P133; JAIMETCHEVERRY G, 1980, BRAIN RES, V188, P513, DOI 10.1016/0006-8993(80)90049-9; JARVIS ED, 1995, LEARN MEMORY, V2, P62, DOI 10.1101/lm.2.2.62; JONES BE, 1977, BRAIN RES, V124, P473, DOI 10.1016/0006-8993(77)90948-9; JONES SL, 1992, J COMP NEUROL, V325, P435, DOI 10.1002/cne.903250309; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KACZMAREK L, 1992, BEHAV NEURAL BIOL, V57, P263, DOI 10.1016/0163-1047(92)90276-A; KASAMATSU T, 1976, SCIENCE, V194, P206, DOI 10.1126/science.959850; KASAMATSU T, 1991, PROG BRAIN RES, V88, P599; KOSTRZEWA RM, 1974, PHARMACOL REV, V26, P199; LEONARD BJ, 1987, BRAINRES, V435, P174; LIDBRINK P, 1974, BRAIN RES, V74, P19, DOI 10.1016/0006-8993(74)90109-7; MCCORMICK DA, 1989, TRENDS NEUROSCI, V12, P215, DOI 10.1016/0166-2236(89)90125-2; MCLEAN J, 1994, BRAIN RES, V667, P83, DOI 10.1016/0006-8993(94)91716-7; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MONTI JM, 1988, SLEEP, V11, P370, DOI 10.1093/sleep/11.4.370; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90066-8; NEUMAN RS, 1983, BRAIN RES, V273, P162, DOI 10.1016/0006-8993(83)91106-X; OHARA BF, 1993, SLEEP, V16, P1; PALACIOS JM, 1980, SCIENCE, V208, P1378, DOI 10.1126/science.6246585; PERTOVAARA A, 1993, NEUROSCIENCE, V54, P117, DOI 10.1016/0306-4522(93)90387-U; POMPEIANO M, 1992, ARCH ITAL BIOL, V130, P325; POMPEIANO M, 1994, J SLEEP RES, V3, P80, DOI 10.1111/j.1365-2869.1994.tb00111.x; Pompeiano M., 1993, Society for Neuroscience Abstracts, V19, P572; RAINBOW TC, 1984, P NATL ACAD SCI-BIOL, V81, P1585, DOI 10.1073/pnas.81.5.1585; RASMUSSEN K, 1986, BRAIN RES, V371, P324, DOI 10.1016/0006-8993(86)90370-7; RIEKKINEN P, 1992, BRAIN RES, V570, P293, DOI 10.1016/0006-8993(92)90593-X; ROBINSON TE, 1977, BRAIN RES, V138, P75, DOI 10.1016/0006-8993(77)90785-5; ROGAWSKI MA, 1980, NATURE, V287, P731, DOI 10.1038/287731a0; ROSE SPR, 1991, TRENDS NEUROSCI, V14, P390, DOI 10.1016/0166-2236(91)90027-R; ROSEN KM, 1992, P NATL ACAD SCI USA, V89, P5437, DOI 10.1073/pnas.89.12.5437; ROSS SB, 1976, BRIT J PHARMACOL, V58, P521, DOI 10.1111/j.1476-5381.1976.tb08619.x; ROUSSEL B, 1976, ARCH ITAL BIOL, V114, P188; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; SARA SJ, 1991, PROG BRAIN RES, V88, P571; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHLINGENSIEPEN KH, 1991, NEUROSCI LETT, V122, P67, DOI 10.1016/0304-3940(91)90195-Y; SEGAL M, 1976, BRAIN RES, V107, P513, DOI 10.1016/0006-8993(76)90141-4; SHEN PJ, 1995, MOL BRAIN RES, V28, P222, DOI 10.1016/0169-328X(94)00208-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Silva Alcino J., 1994, Current Opinion in Neurobiology, V4, P413, DOI 10.1016/0959-4388(94)90104-X; STANTON PK, 1987, BRAIN RES BULL, V18, P115, DOI 10.1016/0361-9230(87)90039-6; Steriade M., 1990, BRAINSTEM CONTROL WA; Steriade M., 1991, NORMAL ALTERED STATE, V9, P279, DOI [10.1007/978-1-4615-6622-9_8, DOI 10.1007/978-1-4615-6622-9_8]; STONE EA, 1993, BRAIN RES, V603, P181, DOI 10.1016/0006-8993(93)91236-L; TOBLER I, 1983, NEUROSCI LETT, V35, P297, DOI 10.1016/0304-3940(83)90333-6; TONONI G, 1994, BRAIN RES BULL, V35, P589, DOI 10.1016/0361-9230(94)90173-2; Tononi G, 1995, ARCH ITAL BIOL, V134, P21; URETSKY NJ, 1969, NATURE, V221, P557, DOI 10.1038/221557a0; VANKOV A, 1995, EUR J NEUROSCI, V7, P1180, DOI 10.1111/j.1460-9568.1995.tb01108.x; VIDEEN TO, 1984, J NEUROSCI, V4, P1607; Watanabe Y, 1996, J NEUROSCI, V16, P3827; WATERHOUSE BD, 1980, EXP NEUROL, V67, P11, DOI 10.1016/0014-4886(80)90159-4; WATERHOUSE BD, 1983, J COMP NEUROL, V217, P418, DOI 10.1002/cne.902170406; WORLEY PF, 1991, P NATL ACAD SCI USA, V88, P5106, DOI 10.1073/pnas.88.12.5106; Yin JCP, 1996, CURR OPIN NEUROBIOL, V6, P264, DOI 10.1016/S0959-4388(96)80082-1	105	193	194	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1211	1215		10.1126/science.274.5290.1211	http://dx.doi.org/10.1126/science.274.5290.1211			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895474				2022-12-28	WOS:A1996VT33500060
J	LeClerc, JE; Li, BG; Payne, WL; Cebula, TA				LeClerc, JE; Li, BG; Payne, WL; Cebula, TA			High mutation frequencies among Escherichia coli and Salmonella pathogens	SCIENCE			English	Article							MISMATCH-REPAIR; HEMORRHAGIC COLITIS; SINGLE ORGANISM; STRAINS; TYPHIMURIUM; GENE; DNA; IDENTIFICATION; RECOMBINATION; AMPLIFICATION	Here it is reported that the incidence of mutators among isolates of pathogenic Escherichia coli and Salmonella enterica is high (over 1 percent). These findings counter the theory, founded on studies with laboratory-attenuated strains, that suggests mutators are rare among bacterial populations. Defects in methyl-directed mismatch repair underlie all mutator phenotypes described here. Of nine independently derived hypermutable strains, seven contained a defective mutS allele. Because these mutant alleles increase the mutation rate and enhance recombination among diverse species, these studies may help explain both the rapid emergence of antibiotic resistance and the penetrance of virulence genes within the prokaryotic community.	US FDA,MOL BIOL BRANCH,CTR FOOD SAFETY & APPL NUTR HFS235,WASHINGTON,DC 20204	US Food & Drug Administration (FDA)								Barinaga M, 1996, SCIENCE, V272, P1261, DOI 10.1126/science.272.5266.1261; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Boyd EF, 1996, APPL ENVIRON MICROB, V62, P804, DOI 10.1128/AEM.62.3.804-808.1996; CHAO L, 1983, EVOLUTION, V37, P125, DOI 10.1111/j.1558-5646.1983.tb05521.x; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; COX EC, 1995, BIOESSAYS, V17, P747, DOI 10.1002/bies.950170902; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; FENG C, 1996, J BACTERIOL, V178, P2388; GIBSON TC, 1970, SCIENCE, V169, P686, DOI 10.1126/science.169.3946.686; GROSS MD, 1981, MUTAT RES, V91, P107, DOI 10.1016/0165-7992(81)90081-6; HARTL DL, 1989, PRINCIPLES POPULATIO, P198; HAYES W, 1968, GENETICS BACTERIA TH, P190; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; JYSSUM K., 1960, ACTA PATHOL ET MICROBIOL SCAND, V48, P113; KUPCHELLA E, 1994, ENVIRON MOL MUTAGEN, V23, P81, DOI 10.1002/em.2850230202; LEIGH EG, 1970, AM NAT, V104, P301, DOI 10.1086/282663; MATIC I, 1995, CELL, V80, P507, DOI 10.1016/0092-8674(95)90501-4; MILLS DM, 1995, MOL MICROBIOL, V15, P749, DOI 10.1111/j.1365-2958.1995.tb02382.x; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MOXON ER, 1978, P NATL ACAD SCI USA, V75, P1534, DOI 10.1073/pnas.75.3.1534; OCHMAN H, 1984, J BACTERIOL, V157, P690, DOI 10.1128/JB.157.2.690-693.1984; ORBACH MJ, 1982, J BACTERIOL, V149, P985, DOI 10.1128/JB.149.3.985-994.1982; PANG PP, 1985, J BACTERIOL, V163, P1007, DOI 10.1128/JB.163.3.1007-1015.1985; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; RILEY LW, 1995, MMWR-MORBID MORTAL W, V44, P157; RUBIN LG, 1987, REV INFECT DIS, V9, P488; SNIEGOWSKI PD, COMMUNICATION; STLOUIS ME, 1988, JAMA-J AM MED ASSOC, V259, P2103, DOI 10.1001/jama.259.14.2103; TAUCHERSCHOLZ G, 1983, EUR J BIOCHEM, V137, P573, DOI 10.1111/j.1432-1033.1983.tb07864.x; TROBNER W, 1984, MOL GEN GENET, V198, P177, DOI 10.1007/BF00328720; WHITTAM TS, 1993, INFECT IMMUN, V61, P1619, DOI 10.1128/IAI.61.5.1619-1629.1993	33	668	689	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1208	1211		10.1126/science.274.5290.1208	http://dx.doi.org/10.1126/science.274.5290.1208			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895473				2022-12-28	WOS:A1996VT33500059
J	MacLeod, K; Laurent, G				MacLeod, K; Laurent, G			Distinct mechanisms for synchronization and temporal patterning of odor-encoding neural assemblies	SCIENCE			English	Article							OLFACTORY-BULB; SYNAPTIC INHIBITION; NEURONAL-ACTIVITY; CHLORIDE CHANNEL; PIRIFORM CORTEX; NERVOUS-SYSTEM; MANDUCA-SEXTA; NITRIC-OXIDE; OSCILLATIONS; INTERNEURONS	Stimulus-evoked oscillatory synchronization of neural assemblies and temporal patterns of neuronal activity have been observed in many sensory systems, such as the visual and auditory cortices of mammals or the olfactory system of insects. In the locust olfactory system, single odor puffs cause the immediate formation of odor-specific neural assemblies, defined both by their transient synchronized firing and their progressive transformation over the course of a response. The application of an antagonist of ionotropic gamma-aminobutyric acid (GABA) receptors to the first olfactory relay neuropil selectively blocked the fast inhibitory synapse between local and projection neurons. This manipulation abolished the synchronization of the odor-coding neural ensembles but did not affect each neuron's temporal response patterns to odors, even when these patterns contained periods of inhibition. Fast GABA-mediated inhibition, therefore, appears to underlie neuronal synchronization but not response tuning in this olfactory system. The selective desynchronization of stimulus-evoked oscillating neural assemblies in vivo is now possible, enabling direct functional tests of their significance for sensation and perception.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology			Laurent, Gilles/A-4583-2012; MacLeod, Katrina/F-4595-2015	Laurent, Gilles/0000-0002-2296-114X; MacLeod, Katrina/0000-0003-0632-1158				Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; BACON JP, 1977, BRAIN RES, V138, P359, DOI 10.1016/0006-8993(77)90753-3; Boeckh J, 1990, CHEMOSENSORY INFORM, P201, DOI [10.1007/978-3-642-75127-1_13, DOI 10.1007/978-3-642-75127-1_13]; BUSH P, 1996, COMPUT NEUROSCI, V3, P91; CHAPUT M, 1980, J PHYSIOL-PARIS, V76, P551; CHRISTENSEN TA, 1993, J COMP PHYSIOL A, V173, P385, DOI 10.1007/BF00193512; CINELLI AR, 1995, J NEUROPHYSIOL, V73, P2053, DOI 10.1152/jn.1995.73.5.2053; CLAIBORNE BJ, 1984, J NEUROSCI, V4, P708; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; FREEMAN WJ, 1968, J NEUROPHYSIOL, V31, P349, DOI 10.1152/jn.1968.31.3.349; FREEMAN WJ, 1961, SCIENCE, V133, P2058, DOI 10.1126/science.133.3470.2058; FREEMAN WJ, OLFACTION MODEL SYST, P225; GELPERIN A, 1994, NATURE, V369, P61, DOI 10.1038/369061a0; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; HARDIE RC, 1989, NATURE, V339, P704, DOI 10.1038/339704a0; HILDEBRAND JG, 1995, P NATL ACAD SCI USA, V92, P67, DOI 10.1073/pnas.92.1.67; JAHR CE, 1982, J PHYSIOL-LONDON, V326, P213, DOI 10.1113/jphysiol.1982.sp014187; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; KETCHUM KL, 1993, J NEUROSCI, V13, P3980; LAURENT G, 1994, J NEUROSCI, V14, P2993; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; Laurent G, 1996, NEURON, V16, P473, DOI 10.1016/S0896-6273(00)80066-5; LAURENT G, IN PRESS TRENDS NEUR; Leitch B, 1996, J COMP NEUROL, V372, P487; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MACLEOD K, UNPUB; MCCLINTOCK TS, 1989, P NATL ACAD SCI USA, V86, P8137, DOI 10.1073/pnas.86.20.8137; MEREDITH M, 1986, J NEUROPHYSIOL, V56, P572, DOI 10.1152/jn.1986.56.3.572; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; MULLER U, 1993, NATURWISSENSCHAFTEN, V80, P524, DOI 10.1007/BF01140811; RALL W, 1966, EXP NEUROL, V14, P44, DOI 10.1016/0014-4886(66)90023-9; SATOU M, 1990, PROG NEUROBIOL, V34, P115, DOI 10.1016/0301-0082(90)90004-Z; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SHURMANN FW, 1974, EXP BRAIN RES, V19, P406; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; WALDROP B, 1987, J COMP PHYSIOL A, V161, P23, DOI 10.1007/BF00609452; WEHR M, IN PRESS NATURE; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; WILSON M, 1992, J NEUROPHYSIOL, V67, P981, DOI 10.1152/jn.1992.67.4.981; YOKOI M, 1995, P NATL ACAD SCI USA, V92, P3371, DOI 10.1073/pnas.92.8.3371	42	279	280	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					976	979		10.1126/science.274.5289.976	http://dx.doi.org/10.1126/science.274.5289.976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875938				2022-12-28	WOS:A1996VR79200047
J	Mitsuguchi, T; Matsumoto, E; Abe, O; Uchida, T; Isdale, PJ				Mitsuguchi, T; Matsumoto, E; Abe, O; Uchida, T; Isdale, PJ			Mg/Ca thermometry in coral-skeletons	SCIENCE			English	Article							TEMPERATURE; STRONTIUM; MAGNESIUM; CALCIUM; GROWTH; SR/CA	The magnesium-to-calcium (Mg/Ca) ratio of coral skeletons from Ishigaki Island, Ryukyu Islands, Japan, closely tracked sea surface temperature (SST) over an 8-year period. Measurements were made with the fast technique of inductively coupled plasma-atomic emission spectrometry. The variation of the coral Mg/Ca ratio with SST change is about four times that of the current, widely used coral strontium-to-calcium ratio. The temporal and geographic variation of the seawater Mg2+/Ca2+ ratio probably has little influence on coral Mg/Ca variation. Results indicate that the coral Mg/Ca ratio has the potential to provide fast, precise, high-resolution proxies for past tropical SSTs.	NAGOYA INST TECHNOL,NAGOYA,AICHI 466,JAPAN; AUSTRALIAN INST MARINE SCI,TOWNSVILLE,QLD 4810,AUSTRALIA	Nagoya Institute of Technology; Australian Institute of Marine Science	Mitsuguchi, T (corresponding author), NAGOYA UNIV,INST HYDROSPHER ATMOSPHER SCI,NAGOYA,AICHI 46401,JAPAN.		Mitsuguchi, Takehiro/O-4915-2014					AMIEL AJ, 1973, SEDIMENTOLOGY, V20, P47, DOI 10.1111/j.1365-3091.1973.tb01606.x; BECK JW, 1994, SCIENCE, V264, P891; BECK JW, 1992, SCIENCE, V257, P644, DOI 10.1126/science.257.5070.644; Broecker W.S., 1982, TRACERS SEA; CARPENTER JH, 1973, J GEOPHYS RES, V78, P3621, DOI 10.1029/JC078i018p03621; CHAVE KE, 1954, J GEOL, V62, P266, DOI 10.1086/626162; CROSS TS, 1983, J SEDIMENT PETROL, V53, P587; Delaney ML, 1996, CORAL REEFS, V15, P181, DOI 10.1007/s003380050040; DEVILLIERS S, 1994, GEOCHIM COSMOCHIM AC, V58, P197, DOI 10.1016/0016-7037(94)90457-X; DEVILLIERS S, 1995, SCIENCE, V269, P1247, DOI 10.1126/science.269.5228.1247; Hart SR, 1996, GEOCHIM COSMOCHIM AC, V60, P3075, DOI 10.1016/0016-7037(96)00154-8; HORIBE Y, 1974, EARTH PLANET SC LETT, V23, P136, DOI 10.1016/0012-821X(74)90040-5; ISDALE P, 1989, MAR TECHNOL SOC J, V23, P3; KATZ A, 1973, GEOCHIM COSMOCHIM AC, V37, P1563, DOI 10.1016/0016-7037(73)90091-4; MCCONNAUGHEY T, 1989, GEOCHIM COSMOCHIM AC, V53, P151, DOI 10.1016/0016-7037(89)90282-2; MIN GR, 1995, GEOCHIM COSMOCHIM AC, V59, P2025; Oomori T., 1982, Galaxea, V1, P77; OOMORI T, 1987, MAR CHEM, V20, P327, DOI 10.1016/0304-4203(87)90066-1; SHEN GT, 1995, GEOCHIM COSMOCHIM AC, V59, P2009, DOI 10.1016/0016-7037(95)00123-9; SWART PK, 1981, PALAEOGEOGR PALAEOCL, V34, P115, DOI 10.1016/0031-0182(81)90060-2; TSUNOGAI S, 1973, DEEP-SEA RES, V20, P717, DOI 10.1016/0011-7471(73)90087-9; WEBER JN, 1974, AM J SCI, V274, P84, DOI 10.2475/ajs.274.1.84	22	274	300	0	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					961	963		10.1126/science.274.5289.961	http://dx.doi.org/10.1126/science.274.5289.961			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875933				2022-12-28	WOS:A1996VR79200042
J	Sundstrom, L; Chapuisat, M; Keller, L				Sundstrom, L; Chapuisat, M; Keller, L			Conditional manipulation of sex ratios by ant workers: A test of kin selection theory	SCIENCE			English	Article							QUEEN MATING FREQUENCY; SOCIAL HYMENOPTERA; RELATEDNESS; ALLOCATION; EVOLUTION; COLONIES; INSECT	Variable queen mating frequencies provide a unique opportunity to study the resolution of worker-queen conflict over sex ratio in social Hymenoptera, because the conflict is maximal in colonies headed by a singly mated queen and is weak or nonexistent in colonies headed by a multiply mated queen. In the wood ant Formica exsecta, workers in colonies with a singly mated queen, but not those in colonies with a multiply mated queen, altered the sex ratio of queen-laid eggs by eliminating males to preferentially raise queens. By this conditional response to queen mating frequency, workers enhance their inclusive fitness.	UNIV LAUSANNE,IZEA,CH-1015 LAUSANNE,SWITZERLAND; UNIV BERN,ETHOL STN HASLI,CH-3032 HINTERKAPELEN,SWITZERLAND; AARHUS UNIV,DEPT ECOL & GENET,DK-8000 AARHUS C,DENMARK; ZOOL MUSEUM,CH-1000 LAUSANNE 17,SWITZERLAND	University of Lausanne; University of Bern; Aarhus University	Sundstrom, L (corresponding author), UNIV HELSINKI,DEPT ECOL & SYSTEMAT,POB 17,FIN-00014 HELSINKI,FINLAND.		keller, laurent/AAI-7175-2020; Chapuisat, Michel/T-8686-2017; Sundstrom, Liselotte/G-5080-2010	Chapuisat, Michel/0000-0001-7207-199X; Sundstrom, Liselotte/0000-0002-6176-8940; keller, laurent/0000-0002-5046-9953				ARON S, 1995, ANIM BEHAV, V49, P749, DOI 10.1016/0003-3472(95)80207-X; ARON S, 1994, J EVOLUTION BIOL, V7, P403, DOI 10.1046/j.1420-9101.1994.7040403.x; BOOMSMA J, 1995, AM NAT, V145, P969; BOOMSMA JJ, 1990, EVOLUTION, V44, P1026, DOI [10.2307/2409564, 10.1111/j.1558-5646.1990.tb03823.x]; Bourke A. F., 1995, SOCIAL EVOLUTION ANT; CHAN GL, 1994, P ROY SOC B-BIOL SCI, V258, P261, DOI 10.1098/rspb.1994.0171; Chapuisat M, 1996, MOL ECOL, V5, P599, DOI 10.1111/j.1365-294X.1996.tb00354.x; CHARNOV EL, 1978, AM NAT, V112, P317, DOI 10.1086/283274; CROZIER R H, 1970, Genetica (Dordrecht), V41, P551, DOI 10.1007/BF00958934; Crozier R.H., 1996, EVOLUTION SOCIAL INS; EVANS JD, 1995, P NATL ACAD SCI USA, V92, P6514, DOI 10.1073/pnas.92.14.6514; Gosswald K., 1989, WALDAMEISE; HAMILTON WD, 1964, J THEOR BIOL, V7; HAUSCHTECKJUNGEN E, 1976, INSECT SOC, V23, P513, DOI 10.1007/BF02223478; KELLER L, 1993, SCIENCE, V260, P1107, DOI 10.1126/science.260.5111.1107; Keller L, 1996, ANIM BEHAV, V51, P445, DOI 10.1006/anbe.1996.0041; MUELLER UG, 1991, SCIENCE, V254, P442, DOI 10.1126/science.254.5030.442; NONACS P, 1986, Q REV BIOL, V61, P1, DOI 10.1086/414723; Nonacs Peter, 1993, P384; PAMILO P, 1991, AM NAT, V137, P83, DOI 10.1086/285147; QUELLER DC, 1993, NATURE, V365, P639, DOI 10.1038/365639a0; RATNIEKS FLW, 1992, J THEOR BIOL, V158, P33, DOI 10.1016/S0022-5193(05)80647-2; RATNIEKS FLW, 1990, J THEOR BIOL, V142, P87, DOI 10.1016/S0022-5193(05)80014-1; RATNIEKS FLW, 1991, EVOLUTION, V45, P281, DOI 10.1111/j.1558-5646.1991.tb04403.x; SMITH RH, 1980, NATURE, V287, P728, DOI 10.1038/287728a0; SUNDSTROM L, 1994, NATURE, V367, P266, DOI 10.1038/367266a0; SUNDSTROM L, 1994, NATURE, V370, P257, DOI 10.1038/370257a0; SUNDSTROM L, 1995, AM NAT, V146, P232; TRIVERS RL, 1976, SCIENCE, V191, P249, DOI 10.1126/science.1108197; VANDIJKEN MJ, 1991, ENTOMOL EXP APPL, V60, P301, DOI 10.1007/BF00354223; WARD PS, 1983, BEHAV ECOL SOCIOBIOL, V12, P301, DOI 10.1007/BF00302897; Wilson E.O., 1971, INSECT SOC; [No title captured]	33	220	221	2	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					993	995		10.1126/science.274.5289.993	http://dx.doi.org/10.1126/science.274.5289.993			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875943	Green Submitted			2022-12-28	WOS:A1996VR79200052
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			A 47-year-old man with asymptomatic hepatitis C infection, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Sorrell MF, 1996, JAMA-J AM MED ASSOC, V275, P1023, DOI 10.1001/jama.275.13.1023	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1428	1428		10.1001/jama.276.17.1428	http://dx.doi.org/10.1001/jama.276.17.1428			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892719				2022-12-28	WOS:A1996VQ46400030
J	VanAntwerp, DJ; Martin, SJ; Kafri, T; Green, DR; Verma, IM				VanAntwerp, DJ; Martin, SJ; Kafri, T; Green, DR; Verma, IM			Suppression of TNF-alpha-induced apoptosis by NF-kappa B	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-INDUCED PHOSPHORYLATION; ACTIVATION; EXPRESSION; PHOSPHATIDYLSERINE; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; TRANSCRIPTION; PROTEOLYSIS; INHIBITION	Tumor necrosis factor alpha (TNF-alpha) signaling gives rise to a number of events, including activation of transcription factor NF-kappa B and programmed cell death (apoptosis). Previous studies of TNF-alpha signaling have suggested that these two events occur independently. The sensitivity and kinetics of TNF-alpha-induced apoptosis are shown to be enhanced in a number of cell types expressing a dominant-negative I kappa B alpha (I kappa B alpha M). These findings suggest that a negative feedback mechanism results from TNF-alpha signaling in which NF-kappa B activation suppresses the signals for cell death.	SALK INST BIOL STUDIES,GENET LAB,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; LA JOLLA INST ALLERGY & IMMUNOL,SAN DIEGO,CA 92121	Salk Institute; University of California System; University of California San Diego; La Jolla Institute for Immunology			Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NIGMS NIH HHS [GM52735] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052735, R37GM052735] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CAULEY K, 1994, P NATL ACAD SCI USA, V91, P390, DOI 10.1073/pnas.91.1.390; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Lin RT, 1996, MOL CELL BIOL, V16, P1401; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; RUBIN BY, 1988, CANCER RES, V48, P6006; SATAKE H, 1995, BIOCHEM BIOPH RES CO, V216, P568, DOI 10.1006/bbrc.1995.2660; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANANTWERP D, UNPUB	30	1619	1649	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					787	789		10.1126/science.274.5288.787	http://dx.doi.org/10.1126/science.274.5288.787			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864120				2022-12-28	WOS:A1996VQ14500045
J	Matsumura, JS; Pearce, WH				Matsumura, JS; Pearce, WH			Traumatic carotid-artery dissection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																			0	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1996	335	18					1368	1368		10.1056/NEJM199610313351806	http://dx.doi.org/10.1056/NEJM199610313351806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP484	8857021				2022-12-28	WOS:A1996VP48400006
J	Timmerman, LA; Clipstone, NA; Ho, SN; Northrop, JP; Crabtree, GR				Timmerman, LA; Clipstone, NA; Ho, SN; Northrop, JP; Crabtree, GR			Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression	NATURE			English	Article							CAPACITATIVE CALCIUM-ENTRY; T-CELL ACTIVATION; CYCLOSPORINE-A; NUCLEAR FACTOR; NERVOUS-SYSTEM; GENE FAMILY; LYMPHOCYTES; CALCINEURIN; RECEPTOR; PROTEINS	CELLS need to distinguish between transient Ca2+ signals that induce events such as muscle contraction, secretion, adhesion and synaptic transmission, and sustained Ca2+ signals that are involved in cell proliferation and differentiation, The latter class of events is blocked in lymphocytes by the immunosuppressive drugs cyclosporin A and FK506, which inhibit calcineurin, a Ca2+-activated serine/threonine phosphatase necessary for the nuclear import of NF-AT transcription factors(1-4). Here we report that sustained high concentrations of Ca2+, but not transient pulses, are required to maintain NF-AT transcription factors in the nucleus, where they participate in Ca2+-dependent induction of genes required for lymphocyte activation and proliferation, Furthermore, overexpression and constitutive nuclear localization of NF-AT, but not Jun, Fos, NF-kappa B, Oct or Ets family members, renders the interleukin-2 enhancer in Jurkat T lymphocytes resistant to FK506 and cyclosporin A, Thus a primary effect of these immunosuppressive reagents is to control the subcellular localization of the NF-AT family of transcription factors.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,PROGRAM IMMUNOL,STANFORD,CA 94305	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University			Agena, Fabiana A/C-5819-2015	Agena, Fabiana A/0000-0002-4526-4857				CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; HO AM, 1994, J BIOL CHEM, V269, P28181; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1993, J IMMUNOL, V151, P837; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCKNIGHT SL, 1992, TRANSCRIPTIONAL REGU, V1; MCKNIGHT SL, 1992, TRANSCRIPTIONAL REGU, V2; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NOWELL PC, 1960, CANCER RES, V20, P462; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; SANDER B, 1993, J IMMUNOL METHODS, V166, P201, DOI 10.1016/0022-1759(93)90361-A; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEISS A, 1987, J IMMUNOL, V138, P2169; WHITNEY RB, 1972, J CELL PHYSIOL, V80, P329, DOI 10.1002/jcp.1040800303	31	457	475	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					837	840		10.1038/383837a0	http://dx.doi.org/10.1038/383837a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893011				2022-12-28	WOS:A1996VQ14400067
J	Bachmann, MO; Bevan, G				Bachmann, MO; Bevan, G			Determining the size of a total purchasing site to manage the financial risks of rare costly referrals: Computer simulation model	BRITISH MEDICAL JOURNAL			English	Article							FUNDHOLDING PRACTICES; GENERAL-PRACTICE	Objective-To estimate the financial risks of 15 categories of rare costly referrals for total purchasing sites of different population sizes. Design-Computer simulation of 100 fund years assuming Poisson distribution of referrals. Setting-British general practices that have opted to become total purchasing sites. Referral rates and price estimates were supplied by South and West Devon Health Commission. Main outcome measures-Variation in referral costs to purchasers in relation to size of risk pool (person years at risk). Results-Random variation in referral costs increased as the size of the risk pool decreased. Variation increased greatly below 30 000 person years. The mean simulated cost of the referral categories considered was 2.8% of total NHS hospital and community service costs, and the maximum simulated cost for 7000 person years was 6.8%. Simulated variation was robust to assumptions about prices and referral rates for specific types of referral. Conclusion-Rare costly referrals seem unlikely to bankrupt total purchasing sites. The management of risk is not in itself justification for total purchasing to be based in several general practices in order to generate large populations. There are other ways of managing risk. Sites can easily explore options by simulations using local referral rates and prices.			Bachmann, MO (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND.							[Anonymous], 1995, COMP HLTH STAT; ARROW KJ, 1963, AM ECON REV, V53, P941; CRUMP BJ, 1991, BRIT MED J, V302, P1582, DOI 10.1136/bmj.302.6792.1582; *DEP HLTH, 1994, EL9479 NHS EX DEP HL; DIXON J, 1995, BRIT MED J, V311, P727, DOI 10.1136/bmj.311.7007.727; DIXON J, 1994, BRIT MED J, V308, P772, DOI 10.1136/bmj.308.6931.772; DIXON J, 1994, BRIT MED J, V309, P30, DOI 10.1136/bmj.309.6946.30; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; *LOND EC, 1996, GP FUNDH NAT VAR HOS; *MICR, 1993, EXC VERS 5 0 US GUID; National Audit Office, 1994, GEN PRACT FUNDH ENGL; PETCHEY R, 1995, LANCET, V346, P1139, DOI 10.1016/S0140-6736(95)91805-1; *REG SPEC AG, 1994, 1993 1994 W MIDL REG; SCHEFFLER R, 1989, LANCET, V1, P950; *SECR STAT HLTH WL, 1989, WORK PAT; WEINER J, 1990, GP BUDGET HOLDING UK; WILKIN D, 1992, HOSP REFERRALS, P16	17	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1054	1057						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898599				2022-12-28	WOS:A1996VP74200029
J	Banerjee, S; Shamash, K; Macdonald, JD; Mann, AH				Banerjee, S; Shamash, K; Macdonald, JD; Mann, AH			Randomised controlled trial of effect of intervention by psychogeriatric team on depression in frail elderly people at home	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MENTAL STATE; OLDER-PEOPLE; PRIMARY-CARE; DEMENTIA; PREVALENCE; PROGNOSIS; SERVICES; CONTACT; ILLNESS	Objective-To investigate the efficacy of intervention by a psychogeriatric team in the treatment of depression in elderly disabled people receiving home care from their local authority. Design-Randomised controlled trial with blind follow up six months after recruitment. Setting-Community of south east London. Subjects-69 people aged 65 or over who received home care and were depressed according to criteria of the standardised automatic geriatric examination for computer assisted taxonomy (AGECAT). 33 were randomly allocated to an intervention group and 36 to a control group. Intervention-Members of the intervention group received an individual package of care that was formulated by the community psychogeriatric team in their catchment area and implemented by a researcher working as a member of that team. The control group received normal general practitioner care. Main outcome measures-Recovery from depression (AGECAT case at recruitment but non-case at follow up). Results-Data were analysed on an intention to treat basis. 19 (58%) of the intervention group recovered compared with only nine (25%) of the control group, a difference of 33% (95% confidence interval 10% to 55%). This powerful treatment effect persisted after controlling for possible confounders in logistic regression analysis, with members of the intervention group more likely than members of the control group to have recovered at follow up (odds ratio 9.0 (2.0 to 41.5)). This did not seem to be a simple effect of antidepressant prescription: use of antidepressants at follow up did not have a significant effect (multiply adjusted odds ratio 0.3 (0.0 to 1.9)). Conclusions-Depression is treatable in elderly people receiving home care. Therapeutic nihilism based on an assumed poor response to treatment in these socially isolated, disabled elderly people in the community is not supported.	UNITED MED & DENT SCH,GUYS HOSP,OLD AGE PSYCHIAT SECT,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Banerjee, S (corresponding author), INST PSYCHIAT,SECT EPIDEMIOL & GEN PRACTICE,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.		mann, anthony/A-8911-2011; Banerjee, Sube/E-3757-2010	Banerjee, Sube/0000-0002-8083-7649				American Psychiatric Association, 1988, DIAGN STAT MAN MENT; AMES D, 1990, INT J GERIATR PSYCH, V5, P193, DOI 10.1002/gps.930050308; BALDWIN RC, 1986, BRIT J PSYCHIAT, V149, P574, DOI 10.1192/bjp.149.5.574; Banerjee S, 1996, BRIT J PSYCHIAT, V168, P750, DOI 10.1192/bjp.168.6.750; BANERJEE S, 1993, INT J GERIATR PSYCH, V8, P125, DOI 10.1002/gps.930080204; BIRD AS, 1987, INT J GERIATR PSYCH, V2, P31, DOI 10.1002/gps.930020106; BLANCHARD MR, 1995, INT J GERIATR PSYCH, V10, P289, DOI 10.1002/gps.930100405; BLANCHARD MR, 1994, BRIT J PSYCHIAT, V164, P396, DOI 10.1192/bjp.164.3.396; BLAZER D, 1980, AM J PSYCHIAT, V137, P439; COPELAND JRM, 1990, INT J GERIATR PSYCH, V5, P47, DOI 10.1002/gps.930050108; COPELAND JRM, 1992, BRIT J PSYCHIAT, V161, P230, DOI 10.1192/bjp.161.2.230; COPELAND JRM, 1986, PSYCHOL MED, V16, P89, DOI 10.1017/S0033291700057779; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; *DUK U CTR STUD AG, 1987, MULT FUNCT ASS OARS; Gardner M. J., 1989, STAT CONFIDENCE; GODDARD E, 1994, SERIES GHS SA, V22; HARRISON R, 1990, AGE AGEING, V19, P97, DOI 10.1093/ageing/19.2.97; ILIFFE S, 1991, BRIT J GEN PRACT, V41, P9; ILIFFE S, 1993, BRIT J GEN PRACT, V43, P371; JENKINS D, 1994, INT J GERIATR PSYCH, V9, P461, DOI 10.1002/gps.930090604; MANN AH, 1981, PSYCHOL MED, V11, P535, DOI 10.1017/S0033291700052855; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; MURPHY E, 1983, BRIT J PSYCHIAT, V142, P111, DOI 10.1192/bjp.142.2.111; PHILPOT M, 1995, DEV DEMENTIA FUNCTIO, P179; *SOC SERV INSP, 1988, MAN POL CHANG HOM CA; *STAT EP RES CORP, 1991, EGRET REF MAN	26	106	106	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1058	1061						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VP742	8898601				2022-12-28	WOS:A1996VP74200031
J	CasacciaBonnefil, P; Carter, BD; Dobrowsky, RT; Chao, MV				CasacciaBonnefil, P; Carter, BD; Dobrowsky, RT; Chao, MV			Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75	NATURE			English	Article							AFFINITY NEUROTROPHIN RECEPTOR; NGF RECEPTOR; CELL-DEATH; CERAMIDE; BINDING; COEXPRESSION; APOPTOSIS; SURVIVAL; EXPRESS; DOMAIN	MEMBERS of the nerve growth factor (NGF) family promote the survival of neurons during development(1). NGF specifically activates the receptor trkA, initiating a signal transduction cascade which ultimately blocks cell death. Here we show that NGF can have the opposite effect, inducing the death of mature oligodendrocytes cultured from postnatal rat cerebral cortex. This effect was highly specific, because NGF had no effect on oligodendrocyte precursors and astrocytes. Other neurotrophins such as brain-derived neurotrophin factor (BDNF) and neurotrophin-3 (NT-3) did not induce cell death. NGF binding to mature oligodendrocytes expressing the p75 neurotrophin receptor, but not trkA, resulted in a sustained increase of intracellular ceramide and c-Jun amino-terminal kinase (JNK) activity, which are thought to participate in a signal transduction pathway leading to cell death. Taken together, these results indicate that NGF has the ability to promote cell death in specific cell types through a ligand-dependent signalling mechanism involving the p75 neurotrophin receptor.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,DIV HEMATOL ONCOL,NEW YORK,NY 10021; UNIV KANSAS,DEPT PHARMACOL & TOXICOL,LAWRENCE,KS 66045	Cornell University; University of Kansas				Chao, Moses/0000-0002-6969-3744				ALTHAUS HH, 1992, NEUROSCI LETT, V135, P219, DOI 10.1016/0304-3940(92)90440-I; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, J NEUROSCI RES, V43, P382, DOI 10.1002/(SICI)1097-4547(19960201)43:3<382::AID-JNR13>3.0.CO;2-7; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HUBER LJ, 1995, DEV BIOL, V167, P227, DOI 10.1006/dbio.1995.1019; ITOH N, 1993, J BIOL CHEM, V268, P10932; JUNIER MP, 1994, MOL BRAIN RES, V24, P247, DOI 10.1016/0169-328X(94)90138-4; KUMAR S, 1993, MOL BRAIN RES, V17, P163, DOI 10.1016/0169-328X(93)90086-5; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	30	664	687	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					716	719		10.1038/383716a0	http://dx.doi.org/10.1038/383716a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878481				2022-12-28	WOS:A1996VN91800053
J	Wu, XH; Haber, JE				Wu, XH; Haber, JE			A 700 bp cis-acting region controls mating-type dependent recombination along the entire left arm of yeast chromosome III	CELL			English	Article							LOCUS-CONTROL REGION; SACCHAROMYCES-CEREVISIAE; X-CHROMOSOME; DOSAGE COMPENSATION; DONOR PREFERENCE; GENE; INTERCONVERSION; DIRECTIONALITY; REPRESSION; BETA	Homothallic switching of the mating-type MATa gene in Saccharomyces cerevisiae results from replacement by gene conversion of MAT-Ya DNA with Ya sequences copied from one of two unexpressed donors. MATa preferentially recombines with HML alpha, located near the left end of chromosome III, but can use HMR alpha, near the right chromosome end. MATa donor preference depends on a 700 bp orientation-independent cis-acting recombination enhancer, located 17 kb proximal to HML. Deletion of this element markedly reduces MATa's use of a donor inserted at any of four different locations along the leftmost 92 kb of chromosome III. This enhancer is sufficient for donor activation, since it stimulates use of the ''wrong'' donor, when it is inserted 7 kb proximal to HMR.	BRANDEIS UNIV,ROSENSTIEL CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610	NIGMS NIH HHS [GM20056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020056, R37GM020056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; CAPONE M, 1993, EMBO J, V12, P4335, DOI 10.1002/j.1460-2075.1993.tb06118.x; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; HABER JE, 1992, TRENDS GENET, V8, P446, DOI 10.1016/0168-9525(92)90329-3; HABER JE, 1974, GENETICS, V78, P843; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; HICKS JB, 1977, GENETICS, V85, P373; JENSEN RE, 1984, COLD SPRING HARB SYM, V49, P97, DOI 10.1101/SQB.1984.049.01.013; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KLAR AJS, 1982, CELL, V28, P551, DOI 10.1016/0092-8674(82)90210-0; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; LIRAS P, 1978, GENETICS, V88, P651; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SMITH DL, 1994, EMBO J, V13, P2378, DOI 10.1002/j.1460-2075.1994.tb06521.x; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; STRATHERN JN, 1989, GENETIC RECOMBINATIO, P445; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; THOMPSON JS, 1994, MOL CELL BIOL, V14, P446, DOI 10.1128/MCB.14.1.446; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; WEILER KS, 1992, GENETICS, V132, P929; WEILER KS, 1995, GENETICS, V139, P1495; WU XH, 1995, GENE DEV, V9, P1922, DOI 10.1101/gad.9.15.1922; Wu XH, 1996, MOL CELL BIOL, V16, P657	31	85	86	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					277	285		10.1016/S0092-8674(00)81345-8	http://dx.doi.org/10.1016/S0092-8674(00)81345-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861911	Bronze			2022-12-28	WOS:A1996VN40300015
J	Bone, RC				Bone, RC			Lemonade: The last refreshing taste	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		UPDIKE J, RABBIT AT REST; UPDIKE J, RABBIT RUN; UPDIKE J, RABBIT REDUX; UPDIKE JH, RABBIT IS RICH	4	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1216	1216		10.1001/jama.276.15.1216	http://dx.doi.org/10.1001/jama.276.15.1216			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL691	8849739				2022-12-28	WOS:A1996VL69100015
J	Behar, O; Golden, JA; Mashimo, H; Schoen, FJ; Fishman, MC				Behar, O; Golden, JA; Mashimo, H; Schoen, FJ; Fishman, MC			Semaphorin III Is needed for normal patterning and growth of nerves, bones and heart	NATURE			English	Article							SPINAL-CORD; CONE GUIDANCE; GENE; FAMILY; EXPRESSION; COLLAPSIN; MEMBER	THE expression patterns of the recently discovered family of semaphorin genes suggests that they have widespread roles in embryonic development(1-9). Some seem to guide neuronal growth cones, but otherwise their functions are unknown(2,10-12). Semaphorin III is a membrane-associated secreted protein with a developmentally dynamic pattern of expression, including particular domains of the nervous system, the borders of developing bones, and the heart(6,7). In vitro, semaphorin III causes growth-cone collapse, and repels cutaneous sensory axons from the ventral spinal cord(2,11). Mutants in the Drosophila gene semaII, which encodes a related semaphorin, die after eclosion, but no responsible abnormality is evident(3). We have generated mice mutant in the semaIII gene by homologous recombination. Here we show that in the mutants, some sensory axons project into inappropriate regions of the spinal cord where semaIII is normally expressed. The cerebral cortex of hymozygous mutant mice shows a paucity of neuropil and abnormally oriented neuronal processes, especially of the large pyramidal neurons. Certain embryonic bones and cartilaginous structures develop abnormally, with vertebral fusions and partial rib duplications. The few mice that survive more than a few days postnatally manifest pronounced and selective hypertrophy of the right ventricle of the heart and dilation of the right atrium. Thus, semaphorin III might serve as a signal that restrains growth in several developing organs.	MASSACHUSETTS GEN HOSP EAST,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Behar, Oded/AAH-8806-2019	Behar, Oded/0000-0001-6913-2827; Golden, Jeffrey/0000-0001-9933-5502				BEHAR O, 1994, ENDOCRINOLOGY, V134, P475, DOI 10.1210/en.134.1.475; DODD J, 1995, CELL, V81, P471, DOI 10.1016/0092-8674(95)90066-7; GIBSON SJ, 1984, J NEUROSCI, V4, P3101, DOI 10.1523/jneurosci.04-12-03101.1984; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; INAGAKI S, 1995, FEBS LETT, V370, P269, DOI 10.1016/0014-5793(95)00850-9; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; LYONS GE, 1994, TRENDS CARDIOVAS MED, V4, P70, DOI 10.1016/1050-1738(94)90012-4; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MISCHEL PS, 1995, J NEUROPATH EXP NEUR, V54, P137, DOI 10.1097/00005072-199503000-00001; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	22	500	512	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					525	528		10.1038/383525a0	http://dx.doi.org/10.1038/383525a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849723				2022-12-28	WOS:A1996VL75500050
J	Ludewig, U; Pusch, M; Jentsch, TJ				Ludewig, U; Pusch, M; Jentsch, TJ			Two physically distinct pores in the dimeric CIC-0 chloride channel	NATURE			English	Article							TORPEDO ELECTROPLAX; VOLTAGE; MUTATIONS; DOMINANT; MYOTONIA	THE Torpedo chloride channel ClC-0 (ref, 1) is the prototype of a large family of chloride channels that have roles in transepithelial transport(2) and in regulating electrical excitability(3-6) and cell volume(7). ClC-0 opens in bursts with two identical conductance levels of similar to 8 pS (refs 8-10), Hyperpolarization slowly increases the probability of bursts ('slow gating'), and depolarization increases channel opening within bursts ('fast gating'). Replacing serine 123 by threonine changes rectification, ion selectivity and gating, but retains the typical bursting behaviour with two identical independent albeit reduced, conductance states (similar to 1.5 pS), Coexpression with wild-type ClC-0, either as covalently linked concatamers or as independent proteins, leads to bursting channels with two different pores. Our experiments strongly suggest that conductance, ion selectivity and 'fast' gating are determined only by the single subunit forming a single pore, independent from the attached pore; in contrast, 'slow' gating is a function of both subunits. Thus ClC-0 is a homodimer with two largely independent pores.	UNIV HAMBURG,CTR MOL NEUROBIOL HAMBURG ZMNH,D-20246 HAMBURG,GERMANY	University of Hamburg				Pusch, Michael/0000-0002-8644-8847; Jentsch, Thomas/0000-0002-3509-2553				BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; FUJITA N, 1994, NUCLEIC ACIDS RES, V22, P1637, DOI 10.1093/nar/22.9.1637; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Pusch M, 1995, NEURON, V15, P1455, DOI 10.1016/0896-6273(95)90023-3; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0	16	235	238	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					340	343		10.1038/383340a0	http://dx.doi.org/10.1038/383340a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848047				2022-12-28	WOS:A1996VJ43900046
J	TessierLavigne, M; Goodman, CS				TessierLavigne, M; Goodman, CS			The molecular biology of axon guidance	SCIENCE			English	Review							CELL-ADHESION MOLECULE; GROWTH CONE GUIDANCE; CENTRAL-NERVOUS-SYSTEM; MYELIN-ASSOCIATED GLYCOPROTEIN; NEURONAL RECOGNITION MOLECULE; IMMUNOGLOBULIN-LIKE DOMAINS; POSTERIOR TECTAL MEMBRANES; NEURITE OUTGROWTH INVITRO; RECEPTOR TYROSINE KINASES; RETINAL GANGLION-CELLS	Neuronal growth cones navigate over long distances along specific pathways to find their correct targets. The mechanisms and molecules that direct this pathfinding are the topics of this review. Growth cones appear to be guided by at least four different mechanisms: contact attraction, chemoattraction, contact repulsion, and chemorepulsion. Evidence is accumulating that these mechanisms act simultaneously and in a coordinated manner to direct pathfinding and that they are mediated by mechanistically and evolutionarily conserved ligand-receptor systems.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	TessierLavigne, M (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, SAN FRANCISCO, CA 94143 USA.							ABERCROMBIE M, 1970, IN VITRO CELL DEV B, V6, P128; AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BAIER H, 1994, SCIENCE, V265, P1541, DOI 10.1126/science.8079167; BALL EE, 1985, J NEUROSCI, V5, P1808; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BASTIANI MJ, 1984, J NEUROSCI, V4, P2311; BATE CM, 1976, J EMBRYOL EXP MORPH, V35, P107; BAUMGARTNER S, COMMUNICATION; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BENTLEY D, 1992, NERVE GROWTH CONE, P265; BIXBY JL, 1994, J CELL BIOL, V127, P1461, DOI 10.1083/jcb.127.5.1461; BIXBY JL, 1993, J NEUROSCI, V13, P3421; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; BONHOEFFER F, 1982, EMBO J, V1, P427, DOI 10.1002/j.1460-2075.1982.tb01186.x; BONHOEFFER F, 1985, NATURE, V315, P408, DOI 10.1038/315409a0; BONHOEFFER F, 1980, NATURE, V288, P162, DOI 10.1038/288162a0; BRITTIS PA, 1995, MOL CELL NEUROSCI, V6, P433, DOI 10.1006/mcne.1995.1032; BRUECKNER K, COMMUNICATION; BRUMMENDORF T, 1993, NEURON, V10, P711; BUCHSTALLER A, IN PRESS J CELL BIOL; Cajal SR., 1893, CELLULE, V9, P119; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CASH S, 1992, J NEUROSCI, V12, P2051; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; CHIBA A, 1993, J NEUROSCI, V13, P714; COHEN J, 1989, DEVELOPMENT, V107, P381; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; Culotti JG, 1996, CURR OPIN NEUROBIOL, V6, P81, DOI 10.1016/S0959-4388(96)80012-2; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DeBernardo AP, 1996, J CELL BIOL, V133, P657, DOI 10.1083/jcb.133.3.657; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EBENDAL T, 1977, EXP CELL RES, V105, P379, DOI 10.1016/0014-4827(77)90135-5; EBENDAL T, 1981, J EMBRYOL EXP MORPH, V61, P289; EBENDAL T, 1982, CELL BEHAVIOUR TRIBU, P281; EDELMAN GM, 1993, CELL ADHES COMMUN, V1, P1, DOI 10.3109/15419069309095677; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; Elshamy WM, 1996, DEVELOPMENT, V122, P491; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FAMBROUGH D, IN PRESS CELL; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; FAZELI A, UNPUB; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; GarciaAlonso L, 1996, DEVELOPMENT, V122, P2611; GARCIAALONSO L, 1995, P NATL ACAD SCI USA, V92, P10501, DOI 10.1073/pnas.92.23.10501; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GIERER A, 1987, DEVELOPMENT, V101, P479; Godement P, 1993, Perspect Dev Neurobiol, V1, P217; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GOODMAN CS, IN PRESS MOL CELLULA; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; GRUMET M, 1993, CELL ADHES COMMUN, V1, P177, DOI 10.3109/15419069309095693; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HALL DE, 1987, J CELL BIOL, V104, P623, DOI 10.1083/jcb.104.3.623; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HO RK, 1982, NATURE, V297, P404, DOI 10.1038/297404a0; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HOYLE GW, 1993, NEURON, V10, P1019, DOI 10.1016/0896-6273(93)90051-R; Hu HY, 1996, NEURON, V16, P933, DOI 10.1016/S0896-6273(00)80116-6; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; JOUET M, 1993, NAT GENET, V4, P331, DOI 10.1038/ng0893-331; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P201; KAPRIELIAN Z, 1994, BIOESSAYS, V16, P1, DOI 10.1002/bies.950160102; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; KESHISHIAN H, 1983, DEV BIOL, V96, P116, DOI 10.1016/0012-1606(83)90316-0; KEYNES R, 1990, CELL, V62, P609, DOI 10.1016/0092-8674(90)90103-L; KEYNES RJ, 1984, NATURE, V310, P786, DOI 10.1038/310786a0; KIDD T, UNPUB; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLINZ SG, 1995, J NEUROCHEM, V65, P84; KLOSE M, 1989, SCIENCE, V245, P982, DOI 10.1126/science.2772651; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; Kunz S, 1996, J CELL BIOL, V135, P253, DOI 10.1083/jcb.135.1.253; LANDER AD, 1987, MOL NEUROBIOL, V1, P213, DOI 10.1007/BF02936609; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LETOURNEAU PC, 1975, DEV BIOL, V44, P92, DOI 10.1016/0012-1606(75)90379-6; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI W, 1992, GENETICS, V132, P675; LILIENBAUM A, 1995, MOL CELL NEUROSCI, V6, P139, DOI 10.1006/mcne.1995.1013; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUMSDEN AGS, 1986, NATURE, V323, P538, DOI 10.1038/323538a0; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; LUMSDEN AGS, 1988, MAKING NERVOUS SYSTE, P166; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Luo Yuling, 1994, Current Opinion in Neurobiology, V4, P648, DOI 10.1016/0959-4388(94)90005-1; Maness P F, 1990, Adv Exp Med Biol, V265, P117; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MCCAIG CD, 1986, J PHYSIOL-LONDON, V375, P39, DOI 10.1113/jphysiol.1986.sp016104; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; McFarlane S, 1996, NEURON, V17, P245, DOI 10.1016/S0896-6273(00)80156-7; MCKENNA MP, 1988, DEV BIOL, V130, P232, DOI 10.1016/0012-1606(88)90429-0; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MEIMA L, IN PRESS EUR J NEURO; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; MONSCHAU B, IN PRESS EMBO J; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; MORALES G, 1993, NEURON, V11, P1113, DOI 10.1016/0896-6273(93)90224-F; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; MURPHYERDOSH C, 1995, J CELL BIOL, V129, P1379, DOI 10.1083/jcb.129.5.1379; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; NOSE A, COMMUNICATION; OAKLEY RA, 1993, J NEUROSCI, V13, P3773; OCONNOR TP, 1993, J CELL BIOL, V123, P935, DOI 10.1083/jcb.123.4.935; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; ORIOLL D, IN PRESS EMBO J; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; Park S. H., COMMUNICATION; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PIMENTA AF, 1995, NEURON, V15, P287, DOI 10.1016/0896-6273(95)90034-9; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; PLACZEK M, 1990, DEVELOPMENT, V110, P19; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; RAMOS RGP, 1993, GENE DEV, V7, P2533, DOI 10.1101/gad.7.12b.2533; RAPER JA, 1983, COLD SPRING HARB SYM, V48, P587, DOI 10.1101/SQB.1983.048.01.063; RAPER JA, 1984, J NEUROSCI, V4, P2329; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; ROSENTHAL A, 1993, NAT GENET, V3, P273, DOI 10.1038/ng0393-273c; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; ROY P, COMMUNICATION; Rugarli EI, 1996, HUM MOL GENET, V5, P1109, DOI 10.1093/hmg/5.8.1109; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Rutishauser U, 1993, Curr Opin Neurobiol, V3, P709, DOI 10.1016/0959-4388(93)90142-L; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Rutishauser U., 1991, SEMIN NEUROSCI, V3, P265, DOI 10.1016/1044-5765(91)90044-O; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; SCHNEIDER T, 1995, NEURON, V15, P259, DOI 10.1016/0896-6273(95)90032-2; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SERAFINI T, IN PRESS CELL; SHIRASAKI R, 1995, NEURON, V14, P961, DOI 10.1016/0896-6273(95)90334-8; SHIRASAKI R, IN PRESS NEURON; Silver J, 1993, Perspect Dev Neurobiol, V1, P227; Sink H., 1994, Society for Neuroscience Abstracts, V20, P1283; SINK H, 1991, DEVELOPMENT, V113, P701; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; SoussiYanicostas N, 1996, J CELL SCI, V109, P1749; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Sretavan D W, 1993, Curr Opin Neurobiol, V3, P45, DOI 10.1016/0959-4388(93)90034-V; STOECKLI E, COMMUNICATION; Stoeckli ET, 1996, DEV BIOL, V177, P15, DOI 10.1006/dbio.1996.0141; STOECKLI ET, 1995, COMMUNICATION, V14, P1165; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; SUTER DM, 1995, J CELL BIOL, V131, P1067, DOI 10.1083/jcb.131.4.1067; TAIRA E, 1994, NEURON, V12, P861, DOI 10.1016/0896-6273(94)90338-7; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; TAMADA A, 1995, NEURON, V14, P1083, DOI 10.1016/0896-6273(95)90347-X; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; Tear G, 1993, Perspect Dev Neurobiol, V1, P183; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TUCKER A, COMMUNICATION; VANBERKUM MFA, 1995, NEURON, V14, P43, DOI 10.1016/0896-6273(95)90239-2; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; VITS L, 1994, NAT GENET, V7, P408, DOI 10.1038/ng0794-408; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1987, DEVELOPMENT, V101, P909; WEHRLE B, 1990, DEVELOPMENT, V110, P401; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; WILLIAMS EJ, 1995, MOL CELL NEUROSCI, V6, P69, DOI 10.1006/mcne.1995.1007; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WIZENMANN A, 1993, DEVELOPMENT, V117, P725; WONG J, COMMUNICATION; WU DY, 1993, J CELL BIOL, V123, P653, DOI 10.1083/jcb.123.3.653; YAMAGATA M, 1995, DEVELOPMENT, V121, P189; YANG PF, 1994, J BIOL CHEM, V269, P23039; Zhang JH, 1996, J NEUROSCI, V16, P7182; ZHUKAREVA V, 1995, DEVELOPMENT, V121, P1161; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	231	2573	2632	2	223	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1996	274	5290					1123	1133		10.1126/science.274.5290.1123	http://dx.doi.org/10.1126/science.274.5290.1123			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895455				2022-12-28	WOS:A1996VT33500031
J	Schindler, MB; Bohn, D; Cox, PN; McCrindle, BW; Jarvis, A; Edmonds, J; Barker, G				Schindler, MB; Bohn, D; Cox, PN; McCrindle, BW; Jarvis, A; Edmonds, J; Barker, G			Outcome of out-of-hospital cardiac or respiratory arrest in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC CARDIOPULMONARY-RESUSCITATION; HIGH-DOSE EPINEPHRINE; LIFE-SUPPORT; CARE; EMERGENCY; COST	Background Among adults who have a cardiac arrest outside the hospital, the survival rate is known to be poor. However, less information is available on out-of-hospital cardiac arrest among children. This study was performed to determine the survival rate among children after out-of-hospital cardiac arrest and to identify predictors of survival. Methods We reviewed the records of 101 children (median age, two years) with apnea or no palpable pulse (or both) who presented to the emergency department at the Hospital for Sick Children in Toronto. The characteristics of the patients and the outcomes ;of illness were analyzed. We assessed the functional outcome of the survivors using the Pediatric Cerebral and Overall Performance Category scores. Results Overall, there was a return of vital signs in 64 of the 101 patients; 15 survived to discharge from the hospital, and 13 were alive 12 months after discharge. Factors that predicted survival to hospital discharge included a short interval between the arrest and arrival at the hospital, a palpable pulse on presentation, a short duration of resuscitation in the emergency department, and the administration of fewer doses of epinephrine in the emergency department. No patients who required more than two doses of epinephrine or resuscitation for longer than 20 minutes in the emergency department survived to hospital discharge. The survivors who were neurologically normal after arrest had had a respiratory arrest only and were resuscitated within five minutes after arrival in the emergency department. Of the 80 patients who had had a cardiac arrest, only 6 survived to hospital discharge, and all had neurologic sequelae. Conclusions These results suggest that out-of-hospital cardiac arrest among children has a very poor prognosis, especially when efforts at resuscitation continue for longer than 20 minutes and require more than two doses of epinephrine. (C) 1996, Massachusetts Medical Society.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT CRIT CARE MED,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DEPT CRIT CARE MED,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BARZILAY Z, 1988, J MED, V19, P229; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; CORNELI HM, 1992, J PEDIATR-US, V120, P671, DOI 10.1016/S0022-3476(05)80226-4; Emergency Cardiac Care Committee and Subcommittees American Heart Association, 1992, JAMA-J AM MED ASSOC, V268, P2262; FIELDS AI, 1993, CRIT CARE MED, V21, P1890, DOI 10.1097/00003246-199312000-00016; Fiser D H, 1987, Pediatr Emerg Care, V3, P235, DOI 10.1097/00006565-198712000-00004; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; FISER DH, 1994, CRIT CARE MED, V22, pA212; FRIESEN RM, 1982, CAN MED ASSOC J, V126, P1055; GILLIS J, 1986, CRIT CARE MED, V14, P469, DOI 10.1097/00003246-198605000-00007; GOETTING MG, 1989, CRIT CARE MED, V17, P1258, DOI 10.1097/00003246-198912000-00004; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; INNES PA, 1993, ARCH DIS CHILD, V68, P487, DOI 10.1136/adc.68.4.487; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; Nichols D G, 1986, Pediatr Emerg Care, V2, P1, DOI 10.1097/00006565-198603000-00001; NIEMANN JT, 1992, NEW ENGL J MED, V327, P1075; OMARCAIGH AS, 1993, MAYO CLIN PROC, V68, P332, DOI 10.1016/S0025-6196(12)60126-8; ORLOWSKI JP, 1987, PEDIATR CLIN N AM, V34, P75; OROURKE PP, 1986, CRIT CARE MED, V14, P466, DOI 10.1097/00003246-198605000-00006; QUAN L, 1990, PEDIATRICS, V86, P586; RONCO R, 1995, ARCH PEDIAT ADOL MED, V149, P210, DOI 10.1001/archpedi.1995.02170140092017; SHEIKH A, 1994, PEDIATRICS, V93, P392; THOMPSON JE, 1990, PEDIATRICS, V86, P302; WEAVER WD, 1991, NEW ENGL J MED, V325, P1437, DOI 10.1056/NEJM199111143252008; ZARITSKY A, 1987, ANN EMERG MED, V16, P1107, DOI 10.1016/S0196-0644(87)80465-1; ZARITSKY A, 1995, PEDIATRICS, V96, P765	27	195	199	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1473	1479		10.1056/NEJM199611143352001	http://dx.doi.org/10.1056/NEJM199611143352001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT340	8890097				2022-12-28	WOS:A1996VT34000001
J	Jaffrey, SR; Snyder, SH				Jaffrey, SR; Snyder, SH			PIN: An associated protein inhibitor of neuronal nitric oxide synthase	SCIENCE			English	Article							CIS-TRANS ISOMERASE; BINDING PROTEIN; BRAIN; PURIFICATION; CLONING; ENZYME; TETRAHYDROBIOPTERIN; CYCLOPHILIN; APOPTOSIS; DOMAINS	The neurotransmitter functions of nitric oxide are dependent on dynamic regulation of its biosynthetic enzyme, neuronal nitric oxide synthase (nNOS), By means of a yeast two-hybrid screen, a 10-kilodalton protein was identified that physically interacts with and inhibits the activity of nNOS. This inhibitor, designated PIN, appears to be one of the most conserved proteins in nature, showing 92 percent amino acid identity with the nematode and rat homologs,Binding of PIN destabilizes the nNOS dimer, a conformation necessary for activity. These results suggest that PIN may regulate numerous biological processes through its effects on nitric oxide synthase activity.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Jaffrey, Samie/0000-0003-3615-6958	NIDA NIH HHS [DA00074] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1995, P NATL ACAD SCI USA, V92, P6753, DOI 10.1073/pnas.92.15.6753; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dick T, 1996, MOL CELL BIOL, V16, P1966; DINERMAN JL, 1994, NEUROPHARMACOLOGY, V33, P1245, DOI 10.1016/0028-3908(94)90023-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; HEVEI JM, 1991, J BIOL CHEM, V266, P289; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JAFFREY SR, UNPUB; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	35	411	448	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					774	777		10.1126/science.274.5288.774	http://dx.doi.org/10.1126/science.274.5288.774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864115				2022-12-28	WOS:A1996VQ14500040
J	Neitz, J; Neitz, M; Kainz, PM				Neitz, J; Neitz, M; Kainz, PM			Visual pigment gene structure and the severity of color vision defects	SCIENCE			English	Article							MOLECULAR-GENETICS; HUMAN RED; GREEN; POLYMORPHISM; CONE; DISCRIMINATION; PHOTOPIGMENT	Rearrangements of the visual pigment genes are associated with defective color vision and with differences between types of red-green color blindness. Among individuals within the most common category of defective color vision, deuteranomaly, there is a large variation in the severity of color vision loss. An examination of specific photopigment gene sites responsible for tuning photopigment absorption spectra revealed differences that predict these variations in the color defect. The results indicate that the severity of the defect in deuteranomalous color vision depends on the degree of similarity among the residual photopigments that serve vision in the color-anomalous eye.	MED COLL WISCONSIN,DEPT OPHTHALMOL,MILWAUKEE,WI 53226	Medical College of Wisconsin	Neitz, J (corresponding author), MED COLL WISCONSIN,DEPT CELLULAR BIOL & ANAT,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.			Neitz, Maureen/0000-0002-5404-3343	NEI NIH HHS [EY09620, EY01931, EY09303] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009620, R01EY009303, P30EY001931] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALPERN M, 1977, J PHYSIOL-LONDON, V266, P647, DOI 10.1113/jphysiol.1977.sp011786; ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; CHAN T, 1992, J BIOL CHEM, V267, P9478; DEEB SS, 1992, AM J HUM GENET, V51, P687; DEMARCO P, 1992, J OPT SOC AM A, V9, P1465, DOI 10.1364/JOSAA.9.001465; JAMESON D, 1956, J OPT SOC AM, V46, P1075, DOI 10.1364/JOSA.46.001075; MERBS SL, 1992, SCIENCE, V258, P464, DOI 10.1126/science.1411542; NAGY AL, 1982, J OPT SOC AM, V72, P571, DOI 10.1364/JOSA.72.000571; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1989, NATURE, V342, P679, DOI 10.1038/342679a0; NEITZ J, 1990, VISION RES, V30, P621, DOI 10.1016/0042-6989(90)90073-T; NEITZ J, 1986, NATURE, V323, P623, DOI 10.1038/323623a0; NEITZ J, 1994, MOL GENETICS INHERIT; NEITZ M, 1995, VISION RES, V35, P2095, DOI 10.1016/0042-6989(94)00306-8; NEITZ M, 1995, VISION RES, V35, P2395, DOI 10.1016/0042-6989(95)00008-9; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; NEITZ M, 1995, SCIENCE, V267, P1013, DOI 10.1126/science.7863325; PIANTANIDA T, 1976, AM J OPTOM PHYS OPT, V53, P647; POKORNY J, 1982, COLOR RES APPL, V7, P159, DOI 10.1002/col.5080070222; POKORNY J, 1977, J OPT SOC AM, V67, P1196, DOI 10.1364/JOSA.67.001196; POKORNY J, 1987, FRONTIERS VISUAL SCI, P150; REGAN BC, 1994, VISION RES, V34, P1279, DOI 10.1016/0042-6989(94)90203-8; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WILLIAMS AJ, 1992, EMBO J, V11, P2039, DOI 10.1002/j.1460-2075.1992.tb05261.x; WINDERICKX J, 1992, P NATL ACAD SCI USA, V89, P9710, DOI 10.1073/pnas.89.20.9710	26	81	84	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					801	804		10.1126/science.274.5288.801	http://dx.doi.org/10.1126/science.274.5288.801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864125				2022-12-28	WOS:A1996VQ14500050
J	Ophoff, RA; Terwindt, GM; Vergouwe, MN; vanEijk, R; Oefner, PJ; Hoffman, SMG; Lamerdin, JE; Mohrenweiser, HW; Bulman, DE; Ferrari, M; Haan, J; Lindhout, D; vanOmmen, GJB; Hofker, MH; Ferrari, MD; Frants, RR				Ophoff, RA; Terwindt, GM; Vergouwe, MN; vanEijk, R; Oefner, PJ; Hoffman, SMG; Lamerdin, JE; Mohrenweiser, HW; Bulman, DE; Ferrari, M; Haan, J; Lindhout, D; vanOmmen, GJB; Hofker, MH; Ferrari, MD; Frants, RR			Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4	CELL			English	Article							HYPOKALEMIC PERIODIC PARALYSIS; CALCIUM-CHANNEL; POINT MUTATIONS; SKELETAL-MUSCLE; SEROTONIN; BRAIN; MAPS; DNA; HETEROGENEITY; MAGNESIUM	Genes for familial hemiplegic migraine (FHM) and episodic ataxia type-2 (EA-2) have been mapped to chromosome 19p13. We characterized a brain-specific P/Q-type Ca2+ channel alpha 1-subunit gene, CACNL1A4, covering 300 kb with 47 exons. Sequencing of all exons and their surroundings revealed polymorphic variations, including a (CA)(n)-repeat (D19S1150), a (CAG)(n)-repeat in the 3'-UTR, and different types of deleterious mutations in FHM and EA-2. In FHM, we found four different missense mutations in conserved functional domains. One mutation has occurred on two different haplotypes in unrelated FHM families. In EA-2, we found two mutations disrupting the reading frame. Thus, FHM and EA-2 can be considered as allelic channelopathies. A similar etiology may be involved in common types of migraine.	LEIDEN UNIV HOSP, DEPT NEUROL, NL-2333 AL LEIDEN, NETHERLANDS; STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA; LAWRENCE LIVERMORE NATL LAB, BBRP, LIVERMORE, CA 94550 USA; LONDON HLTH SCI CTR, DEPT CLIN NEUROL SCI, LONDON, ON N6A 5A5, CANADA; IRCCS S RAFFAELE, CLIN MOL BIOL LAB, I-20132 MILAN, ITALY; ERASMUS UNIV ROTTERDAM, MGC, DEPT CLIN GENET, NL-3000 DR ROTTERDAM, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Stanford University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; London Health Sciences Centre; Erasmus University Rotterdam	Ophoff, RA (corresponding author), LEIDEN UNIV, MGC, DEPT HUMAN GENET, SYLVIUS LAB, WASSENAARSEWEG 72, NL-2333 AL LEIDEN, NETHERLANDS.		Lindhout, Dick/AAH-5765-2019; Hoffman, Susan/K-1995-2019; Ferrari, Michel D./ABE-3758-2021; Ferrari, Maurizio/D-9107-2013	Ferrari, Michel D./0000-0001-9691-9449; Lindhout, Dick/0000-0001-9580-624X				ALTURA B M, 1985, Magnesium, V4, P169; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; Cannon SC, 1996, TRENDS NEUROSCI, V19, P3, DOI 10.1016/0166-2236(96)81859-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CODIGNOLA A, 1993, J BIOL CHEM, V268, P26240; DEWAARD M, 1996, ION CHANNELS, V4; Diriong S, 1995, GENOMICS, V30, P605, DOI 10.1006/geno.1995.1284; Elliott MA, 1996, ANN NEUROL, V39, P100, DOI 10.1002/ana.410390115; FERRARI MD, 1993, CEPHALALGIA, V13, P151, DOI 10.1046/j.1468-2982.1993.1303151.x; FERRARI MD, 1989, NEUROLOGY, V39, P1239, DOI 10.1212/WNL.39.9.1239; FERRARI MD, 1995, EUR J NEUROL, V2, P5, DOI 10.1111/j.1468-1331.1995.tb00087.x; GRIGGS RC, 1995, ANN NEUROL, V37, P285, DOI 10.1002/ana.410370302; GUY HR, 1996, ION CHANNELS, V4; HAAN J, 1996, ADV HEADACHE; HAYWARDLESTER A, 1996, GENE QUANTIFICATION; HUBER CG, 1995, ANAL CHEM, V67, P578, DOI 10.1021/ac00099a015; HUDSON AJ, 1995, BRAIN, V118, P547, DOI 10.1093/brain/118.2.547; JOUTEL A, 1994, AM J HUM GENET, V55, P1166; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; JURKATROTT K, 1994, HUM MOL GENET, V3, P1415, DOI 10.1093/hmg/3.8.1415; KRAMER PL, 1995, AM J HUM GENET, V57, P182; LAURITZEN M, 1996, SCI MED, V3, P32; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARGOLIS RL, 1995, SOMAT CELL MOLEC GEN, V21, P279, DOI 10.1007/BF02255782; MAY A, 1995, HUM GENET, V96, P604, DOI 10.1007/BF00197420; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MOSKOWITZ MA, 1992, TRENDS PHARMACOL SCI, V13, P307, DOI 10.1016/0165-6147(92)90097-P; Oefner P. J., 1995, American Journal of Human Genetics, V57, pA266; OPHOFF RA, 1994, GENOMICS, V22, P21, DOI 10.1006/geno.1994.1340; OPHOFF RA, 1996, IN PRESS EUR J HUM G; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Peikert A, 1996, CEPHALALGIA, V16, P257, DOI 10.1046/j.1468-2982.1996.1604257.x; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1994, CELL, V77, P863; RAMADAN NM, 1989, HEADACHE, V29, P416, DOI 10.1111/j.1526-4610.1989.hed2907416.x; RAVNIKGLAVAC M, 1994, HUM MOL GENET, V3, P801, DOI 10.1093/hmg/3.5.801; RUSSELL MB, 1995, INT J EPIDEMIOL, V24, P612, DOI 10.1093/ije/24.3.612; RUSSELL MB, 1995, BRIT MED J, V311, P541, DOI 10.1136/bmj.311.7004.541; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1995, LIGAND VOLTAGE GATED, P113; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TEH BT, 1995, AM J HUM GENET, V56, P1443; Terwindt GM, 1996, CEPHALALGIA, V16, P153, DOI 10.1046/j.1468-2982.1996.1603153.x; VONBREDERLOW B, 1995, HUM MOL GENET, V4, P279, DOI 10.1093/hmg/4.2.279; ZHANG A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P25, DOI 10.1016/0167-4889(92)90024-6; 1988, CEPHALALGIA, V8, P19	49	1791	1848	1	203	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1996	87	3					543	552		10.1016/S0092-8674(00)81373-2	http://dx.doi.org/10.1016/S0092-8674(00)81373-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898206	Green Published, Bronze			2022-12-28	WOS:A1996VQ46600019
J	Antman, EM; Tanasijevic, MJ; Thompson, B; Schactman, M; McCabe, CH; Cannon, CP; Fischer, GA; Fung, AY; Thompson, C; Wybenga, D; Braunwald, E				Antman, EM; Tanasijevic, MJ; Thompson, B; Schactman, M; McCabe, CH; Cannon, CP; Fischer, GA; Fung, AY; Thompson, C; Wybenga, D; Braunwald, E			Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CREATINE-KINASE-MB; UNSTABLE ANGINA; PROGNOSTIC-SIGNIFICANCE; ARTERY DISEASE; CK-MB; ISOENZYME; DIAGNOSIS; INJURY; PATHOGENESIS	Background In patients with acute coronary syndromes, it is desirable to identify a sensitive serum marker that is closely related to the degree of myocardial damage, provides prognostic information, and can be measured rapidly. We studied the prognostic value of cardiac troponin I levels in patients with unstable angina or non-Q-wave myocardial infarction. Methods In a multicenter study, blood specimens from 1404 symptomatic patients were analyzed for cardiac troponin I, a serum marker not detected in the blood of healthy persons. The relation between mortality at 42 days and the level of cardiac troponin in the specimen obtained on enrollment was determined both before and after adjustment for base-line characteristics. Results The mortality rate at 42 days was significantly higher in the 573 patients with cardiac troponin I levels of at least 0.4 ng per milliliter (21 deaths, or 3.7 percent) than in the 831 patients with cardiac troponin I levels below 0.4 ng per milliliter (8 deaths, or 1.0 percent; P<0.001). There were statistically significant increases in mortality with increasing levels of cardiac troponin I (P<0.001). Each increase of 1 ng per milliliter in the cardiac troponin I level was associated with a significant increase (P=0.03) in the risk ratio for death after adjustment for the base-line characteristics that were independently predictive of mortality (ST-segment depression and age greater than or equal to 65 years). Conclusions In patients with acute coronary syndromes, cardiac troponin I levels provide useful prognostic information and permit the early identification of patients with an increased risk of death. (C) 1996, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP,CLIN LABS,BOSTON,MA 02115; MARYLAND MED RES INST,BALTIMORE,MD; UNIV BRITISH COLUMBIA,VANCOUVER,BC V5Z 1M9,CANADA	Harvard University; Brigham & Women's Hospital; University of British Columbia	Antman, EM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.		Cannon, Christopher P/AAY-7644-2020; KANDEMIR, Fatih Mehmet/S-2385-2016; Thompson, Christopher/F-3967-2010	Cannon, Christopher P/0000-0003-4596-2791; KANDEMIR, Fatih Mehmet/0000-0002-8490-2479; Thompson, Christopher/0000-0001-9206-376X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042428, R01HL042311] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-42428, R01-HL-42311] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JE, 1994, CLIN CHEM, V40, P1291; ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; AMBROSE JA, 1988, AM J CARDIOL, V61, P244, DOI 10.1016/0002-9149(88)90924-1; [Anonymous], 1993, CIRCULATION, V87, P38; ARMSTRONG PW, 1982, AM J CARDIOL, V49, P1849, DOI 10.1016/0002-9149(82)90201-6; BODOR GS, 1995, CLIN CHEM, V41, P1710; BODOR GS, 1992, CLIN CHEM, V38, P2203; CANNON CP, 1995, AM J CARDIOL, V75, P977, DOI 10.1016/S0002-9149(99)80707-3; CLYNE CA, 1989, AM HEART J, V118, P901, DOI 10.1016/0002-8703(89)90221-4; CUMMINS B, 1987, AM HEART J, V113, P1333, DOI 10.1016/0002-8703(87)90645-4; CUMMINS P, 1987, EUR J CLIN INVEST, V17, P317, DOI 10.1111/j.1365-2362.1987.tb02194.x; DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418; DEWOOD MA, 1986, NEW ENGL J MED, V315, P417, DOI 10.1056/NEJM198608143150703; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GELTMAN EM, 1979, CIRCULATION, V60, P805, DOI 10.1161/01.CIR.60.4.805; GUEST TM, 1995, JAMA-J AM MED ASSOC, V273, P1945, DOI 10.1001/jama.273.24.1945; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; Lindahl B, 1996, CIRCULATION, V93, P1651, DOI 10.1161/01.CIR.93.9.1651; MACGEOCH C, 1991, HUM GENET, V88, P101, DOI 10.1007/BF00204938; MAIR J, 1995, CLIN CHEM, V41, P1266; RAVKILDE J, 1993, SCAND J CLIN LAB INV, V53, P677, DOI 10.3109/00365519309092571; ROBERTS R, 1994, CIRCULATION, V89, P872, DOI 10.1161/01.CIR.89.2.872; ROGERS WJ, 1977, CIRCULATION, V56, P199, DOI 10.1161/01.CIR.56.2.199; TSUNG JS, 1986, CLIN CHEM, V32, P1568; TSUNG SH, 1981, AM J CLIN PATHOL, V75, P711, DOI 10.1093/ajcp/75.5.711; WADE R, 1990, GENOMICS, V7, P346, DOI 10.1016/0888-7543(90)90168-T; WHITE RD, 1985, AM J CARDIOL, V55, P1478, DOI 10.1016/0002-9149(85)90957-9; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; 1994, CIRCULATION, V89, P1545	32	1363	1433	1	49	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1996	335	18					1342	1349		10.1056/NEJM199610313351802	http://dx.doi.org/10.1056/NEJM199610313351802			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP484	8857017				2022-12-28	WOS:A1996VP48400002
J	Gaiano, N; Amsterdam, A; Kawakami, K; Allende, M; Becker, T; Hopkins, N				Gaiano, N; Amsterdam, A; Kawakami, K; Allende, M; Becker, T; Hopkins, N			Insertional mutagenesis and rapid cloning of essential genes In zebrafish	NATURE			English	Article							DROSOPHILA GENOME; MUTATION; VECTOR; CELLS; MICE	LARGE-SCALE chemical mutagenesis screens in zebrafish have led to the isolation of thousands of lethal mutations in genes that are essential for embryonic development(1,2). However, the cloning of these mutated genes is difficult at present as it requires positional cloning methods, In Drosophila, chemical mutagenesis screens were complemented with P-element insertional mutagenesis which facilitated the cloning of many genes that had been identified by chemical lesions(3,4). To facilitate the cloning of vertebrate genes that are important during embryogenesis, we have developed an insertional mutagenesis strategy in zebrafish using a retroviral vector, Here, in a pilot screen of 217 proviral insertions, we obtained three insertional mutants with embryonic lethal phenotypes, and identified two of the disrupted genes, One of these, no arches, is essential for normal pharyngeal arch development, and is homologous to the recently characterized Drosophila zinc-finger gene, clipper, which encodes a novel type of ribonuclease(5). As it is easy to generate tens to hundreds of thousands of proviral transgenes in zebrafish(6), it should now be possible to use this screening method to mutate and then rapidly clone a large number of genes affecting vertebrate developmental and cellular processes.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Becker, Thomas S/A-3125-2012; Allende, Miguel L/C-5167-2008; Kawakami, Koichi/AAF-1380-2019	Allende, Miguel L/0000-0002-2783-2152; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAI C, IN PRESS MOL CELL BI; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHEN J, 1994, METH MOL G, V4, P123; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DINGERKUS G, 1977, STAIN TECHNOL, V52, P229, DOI 10.3109/10520297709116780; Driever W, 1996, DEVELOPMENT, V123, P37; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gaiano N, 1996, P NATL ACAD SCI USA, V93, P7777, DOI 10.1073/pnas.93.15.7777; Haffter P, 1996, DEVELOPMENT, V123, P1; HOPKINS N, 1993, P NATL ACAD SCI USA, V90, P8759, DOI 10.1073/pnas.90.19.8759; LIN S, 1994, SCIENCE, V265, P666, DOI 10.1126/science.8036514; MEISLER MH, 1992, TRENDS GENET, V8, P341, DOI 10.1016/0168-9525(92)90278-C; SCHILLING TF, 1994, DEVELOPMENT, V120, P483; SUMMERS MF, 1991, J CELL BIOCHEM, V45, P41, DOI 10.1002/jcb.240450110; Westerfield M, 1993, ZEBRAFISH BOOK	17	200	211	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					829	832		10.1038/383829a0	http://dx.doi.org/10.1038/383829a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893009				2022-12-28	WOS:A1996VQ14400065
J	Kapadia, LH				Kapadia, LH			ABC of work related disorders - Women at work	BRITISH MEDICAL JOURNAL			English	Article											Kapadia, LH (corresponding author), MARKS & SPENCER,MICHAEL HOUSE,LONDON,ENGLAND.								0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1073	1076						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898605				2022-12-28	WOS:A1996VP74200040
J	Dyck, PJ				Dyck, PJ			Nerve growth factor and diabetic neuropathy	LANCET			English	Editorial Material											Dyck, PJ (corresponding author), MAYO CLIN,DEPT NEUROL,ROCHESTER,MN 55905, USA.							Anand P, 1996, NAT MED, V2, P703, DOI 10.1038/nm0696-703; APFEL SC, 1994, BRAIN RES, V634, P7, DOI 10.1016/0006-8993(94)90252-6; Dyck Peter James, 1993, Neurology, V43, P1050; HELLWEG R, 1991, NEUROSCI LETT, V125, P1, DOI 10.1016/0304-3940(91)90114-9; LEWIN GR, 1993, TRENDS NEUROSCI, V16, P353, DOI 10.1016/0166-2236(93)90092-Z; Thomas P.K., 1993, PERIPHERAL NEUROPATH, V3rd ed., P1219; 1995, ANN INTERN MED, V122, P561; 1995, ANN NEUROL, V38, P869	8	24	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1044	1045		10.1016/S0140-6736(05)64409-1	http://dx.doi.org/10.1016/S0140-6736(05)64409-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874450				2022-12-28	WOS:A1996VM88600003
J	Taylor, R				Taylor, R			Insulin resistance: Circumventing nature's blocks	LANCET			English	Editorial Material							RECEPTOR GENE; MUTANT ALLELES; SUBUNIT				Taylor, R (corresponding author), SCH MED,HUMAN METAB RES CTR,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.			Taylor, Roy/0000-0001-6273-0170				ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; HANSEN L, 1995, HUM MOL GENET, V4, P1313, DOI 10.1093/hmg/4.8.1313; KADOWAKI T, 1990, J CLIN INVEST, V86, P254, DOI 10.1172/JCI114693; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; Krook A, 1996, LANCET, V347, P1586, DOI 10.1016/S0140-6736(96)91076-4; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; TAYLOR R, 1991, CLIN ENDOCRINOL, V34, P159, DOI 10.1111/j.1365-2265.1991.tb00287.x; TAYLOR R, 1987, BIOCHEM J, V242, P123, DOI 10.1042/bj2420123; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407	11	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1045	1046		10.1016/S0140-6736(05)64410-8	http://dx.doi.org/10.1016/S0140-6736(05)64410-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874451				2022-12-28	WOS:A1996VM88600004
J	Block, SM				Block, SM			Fifty ways to love your lever: Myosin motors	CELL			English	Review							MUSCLE-CONTRACTION; NANO-MANIPULATION; FORCE GENERATION; SKELETAL-MUSCLE; ATOMIC MODEL; LIGHT-CHAIN; ADP RELEASE; ACTIN; COMPLEX; MECHANISM				Block, SM (corresponding author), PRINCETON UNIV, DEPT MOL BIOL, PRINCETON, NJ 08544 USA.							ANSON M, 1996, IN PRESS EMBO J; Bagshaw CR., 1993, MUSCLE CONTRACTION, DOI 10.1007/978-94-015-6839-5; BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169, DOI 10.1016/S0962-8924(00)88982-5; BURKE M, 1977, BIOCHEMISTRY-US, V16, P5559, DOI 10.1021/bi00644a026; BURTON K, 1992, J MUSCLE RES CELL M, V13, P590, DOI 10.1007/BF01738249; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; COOKE R, 1996, IN PRESS PHYSL REV; Duke T, 1996, BIOPHYS J, V71, P1235, DOI 10.1016/S0006-3495(96)79323-2; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gollub J, 1996, NAT STRUCT BIOL, V3, P796, DOI 10.1038/nsb0996-796; Highsmith S, 1983, Cell Muscle Motil, V4, P207; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY AF, 1980, SHERRINGTON LECT, V14; Huxley HE, 1996, ANNU REV PHYSIOL, V58, P1, DOI 10.1146/annurev.ph.58.030196.000245; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; PESKIN CS, 1995, BIOPHYS J, V68, pS202; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SCHOLEY J, 1993, METH CELL BIOL, V39; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1992, P NATL ACAD SCI USA, V89, P319, DOI 10.1073/pnas.89.1.319; Simmons RM, 1996, BIOPHYS J, V70, P1813, DOI 10.1016/S0006-3495(96)79746-1; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Squire J, 1981, STRUCTURAL BASIS MUS; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Sweeney HL, 1996, ANNU REV PHYSIOL, V58, P751, DOI 10.1146/annurev.ph.58.030196.003535; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P12403, DOI 10.1073/pnas.91.26.12403; WELLS JA, 1979, P NATL ACAD SCI USA, V76, P4966, DOI 10.1073/pnas.76.10.4966; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T	49	87	89	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1996	87	2					151	157		10.1016/S0092-8674(00)81332-X	http://dx.doi.org/10.1016/S0092-8674(00)81332-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861898	Bronze			2022-12-28	WOS:A1996VN40300002
J	Difilippantonio, MJ; McMahan, CJ; Eastman, QM; Spanopoulou, E; Schatz, DG				Difilippantonio, MJ; McMahan, CJ; Eastman, QM; Spanopoulou, E; Schatz, DG			RAG1 mediates signal sequence recognition and recruitment of RAG2 in V(D)J recombination	CELL			English	Article							GENE-EXPRESSION; IMMUNE-SYSTEM; MICE; TRANSPOSASE; SPECIFICITY; DEFINITION; EVOLUTION; ELEMENTS; INSIGHTS; BINDING	Recent studies have demonstrated that DNA cleavage during V(D)J recombination is mediated by the RAG-1 and RAG2 proteins. These proteins must therefore bind to the recombination signals, but the specific binding interaction has been difficult to study in vitro. Here, we use an in vivo one-hybrid DNA binding assay to demonstrate that RAG1, in the absence of RAG2, can mediate signal recognition via the nonamer, with the heptamer acting to enhance its binding. A region of RAG1 with sequence similarity to bacterial invertases is essential for DNA binding. Localization of RAG2 to the signal is dependent upon the presence of RAG1 and is substantially more efficient with a 12 bp spacer signal than with a 23 bp spacer signal.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; MT SINAI SCH MED,RUTTENBERG CANC CTR,NEW YORK,NY 10021	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Icahn School of Medicine at Mount Sinai			Difilippantonio, Michael/AAF-2839-2021; Schatz, David/A-6748-2013	Difilippantonio, Michael/0000-0002-4676-7034; Schatz, David/0000-0002-5669-1176	NIAID NIH HHS [T32-AI07019, AI32524] Funding Source: Medline; NICHD NIH HHS [T32-HD70194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007019, R01AI032524] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKAMATSU Y, 1994, J IMMUNOL, V153, P4520; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; DERBYSHIRE KM, 1992, EMBO J, V11, P3449, DOI 10.1002/j.1460-2075.1992.tb05424.x; DREYFUS DH, 1992, MOL IMMUNOL, V29, P807, DOI 10.1016/0161-5890(92)90191-Y; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HANSEN JD, 1995, IMMUNOGENETICS, V42, P188, DOI 10.1007/BF00191224; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HUISMAN O, 1989, EMBO J, V8, P2101, DOI 10.1002/j.1460-2075.1989.tb03619.x; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; Rathbun G.A., 1987, P85; Rodgers KK, 1996, J MOL BIOL, V260, P70, DOI 10.1006/jmbi.1996.0382; Roman CAJ, 1996, P NATL ACAD SCI USA, V93, P2333, DOI 10.1073/pnas.93.6.2333; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V22, P550; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SIMON M, 1980, SCIENCE, V209, P1370, DOI 10.1126/science.6251543; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x	38	167	173	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					253	262		10.1016/S0092-8674(00)81343-4	http://dx.doi.org/10.1016/S0092-8674(00)81343-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861909	hybrid			2022-12-28	WOS:A1996VN40300013
J	PablosMendez, A; Sterling, TR; Frieden, TR				PablosMendez, A; Sterling, TR; Frieden, TR			The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MULTIDRUG-RESISTANT TUBERCULOSIS; HIV-INFECTED PATIENTS; PULMONARY TUBERCULOSIS; UNITED-STATES; EPIDEMIOLOGY; THERAPY; DIAGNOSIS; SURVIVAL	Objective.-To analyze the factors associated with survival in patients with pulmonary and extrapulmonary tuberculosis in New York City. Design.-Observational study of a citywide cohort of tuberculosis cases. Setting.-New York City, April 1991, before the strengthening of its control program. Patients.-All 229 newly diagnosed cases of tuberculosis documented by culture in April 1991. Most patients (74%) were male, and the median age was 37 years (range, 1-89 years). In all, 89% belonged to minority groups. Human immunodeficiency virus (HIV) infection was present in 50% and multidrug resistance in 7% of the cases. Twenty-one patients (9%) were not treated. Main Outcome Measures.-Follow-up information was collected through the New York City tuberculosis registry; death from any cause was verified through the National Death Index. Results.-Cumulative all-cause mortality by October 1994 was 44%; the median survival for those who died was 6.3 months (range, 0 days to 3 years). The most important baseline predictors of mortality, adjusted for baseline clinical and demographic factors, were acquired immunodeficiency syndrome (AIDS) (91% vs 11% in HIV-seronegative patients; Cox relative risk [RR], 7.8; 95% confidence interval [CI], 2.1-29.1), multidrug resistance (87% vs 39% in pansensitive cases; adjusted RR, 5.8; 95% CI, 2.3-14.5), and lack of treatment (81% vs 40%; adjusted RR, 3.1; 95% CI, 1.0-9.7). Also, 11 of 13 HIV-infected patients who started treatment after a 1-month delay died. Among 173 patients surviving the recommended treatment period, those who completed therapy (66%) had a lower subsequent mortality (20% vs 37%; RR, 0.5; 95% CI, 0.3-0.9). Conclusions.-Mortality from tuberculosis was high, even among patients without multidrug resistance who were not known to be infected with HIV. Most HIV-seropositive patients with delayed therapy died. Multidrug resistance predicted higher mortality, and treatment completion was associated with improved subsequent patient survival.	NEW YORK CITY DEPT HLTH, BUR TB CONTROL, NEW YORK, NY 10013 USA; KEESLER MED CTR, KEESLER AFB, MS USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA	PablosMendez, A (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DIV GEN MED, 622 W 168TH ST, PH-9E-105, NEW YORK, NY 10032 USA.							ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; BARNES PF, 1993, ANN INTERN MED, V119, P400, DOI 10.7326/0003-4819-119-5-199309010-00009; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BLOCH AB, 1989, CLIN CHEST MED, V10, P297; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRAUN MM, 1993, JAMA-J AM MED ASSOC, V269, P2865, DOI 10.1001/jama.269.22.2865; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; *BUR TUB CONTR, 1995, INF SUMM 1994; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P961; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; COX DR, 1972, J R STAT SOC B, V34, P187; *CTR DIS CONTR, 1989, US DEPT HLTH HUM SER; *CTR DIS CONTR, 1986, US DEPT HLTH HUM SER; *CTR DIS CONTR, 1990, US DEPT HLTH HUM SER; DEAN AG, 1994, EPI INFO VERSION 6; DRUCKER E, 1994, LANCET, V343, P1482, DOI 10.1016/S0140-6736(94)92588-7; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306; MENDELSON MH, 1990, MT SINAI J MED, V57, P221; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; NARAIN R, 1974, B WORLD HEALTH ORGAN, V51, P273; NEVILLE K, 1994, CHEST, V105, P45, DOI 10.1378/chest.105.1.45; Norusis M J, 1993, SPSS WINDOWS ADV STA; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; *NY CIT DEPT HLTH, 1981, TUB NEW YORK CIT 199; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RIEDER HL, 1991, CHEST, V100, P678, DOI 10.1378/chest.100.3.678; Shirai T, 1990, Kekkaku, V65, P397; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STONEBURNER R, 1992, ARCH INTERN MED, V152, P2033, DOI 10.1001/archinte.152.10.2033; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; WASHKO RM, 1992, P 43 ANN EP INT SERV; *WHO TUB PROGR, 1994, WHO PUBL	43	189	195	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1223	1228		10.1001/jama.276.15.1223	http://dx.doi.org/10.1001/jama.276.15.1223			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL691	8849749				2022-12-28	WOS:A1996VL69100030
J	McLellan, MF				McLellan, MF			Literature and medicine: Some major works	LANCET			English	Article									UNIV TEXAS, MED BRANCH, INST MED HUMANITIES, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	McLellan, MF (corresponding author), UNIV TEXAS, MED BRANCH, DEPT ANESTHESIOL, GALVESTON, TX 77555 USA.			McLellan, Faith/0000-0003-0744-1450				BANKS JT, 1990, LIT MED, V9, P162; Bloom H., 1994, THE W CANON; Camus A., 1991, PLAGUE; CAMUS A, 1955, COMMUNICATION   0111; COLES R, 1979, NEW ENGL J MED, V301, P444, DOI 10.1056/NEJM197908233010831; CONNELLY JE, 1990, LIT MED, V9, P150, DOI 10.1353/lm.2011.0150; DEFOE D, 1969, JOURNAL PLAGUE YEAR; Eliot George, 1977, MIDDLEMARCH; HUNTER KM, 1996, PMLA, V111, P303; Jones AH, 1996, LANCET, V348, P734, DOI 10.1016/S0140-6736(96)07315-1; Lewis S., 1925, ARROWSMITH; MANN T, 1992, MAGIC MOUNTAIN, P727; MANN T, 1992, MAGIC MOUNTAIN; McLellan MF, 1996, LANCET, V348, P458, DOI 10.1016/S0140-6736(96)02421-X; Nussbaum M.C.., 1986, FRAGILITY GOODNESS; Nussbaum Martha C., 1995, POETIC JUSTICE LIT I; SOLZHENITSYN A, 1974, CANCER WARD; SONTAG S, 1990, ILLNESS AS METAPHOR; Tolstoy L, 1981, DEATH I ILYICH; WOODCOCK J, 1990, ST COMPAR L, V22, P41	20	16	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					1014	1016		10.1016/S0140-6736(96)07316-3	http://dx.doi.org/10.1016/S0140-6736(96)07316-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	VM027	8855868				2022-12-28	WOS:A1996VM02700024
J	Konig, M; Zimmer, AM; Steiner, H; Holmes, PV; Crawley, JN; Brownstein, MJ; Zimmer, A				Konig, M; Zimmer, AM; Steiner, H; Holmes, PV; Crawley, JN; Brownstein, MJ; Zimmer, A			Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin	NATURE			English	Article							INDUCED ANALGESIA; RATS; MORPHINE; BEHAVIOR; AMYGDALA; BRAIN; FEAR; EXPRESSION; MECHANISMS; SYSTEMS	ENKEPHALINS are endogenous opioid peptides that are derived from a pre-proenkephalin precursor protein(1,2). They are thought to be vital in regulating many physiological functions, including pain perception and analgesia, responses to stress, aggression and dominance (3-5). Here we have used a genetic approach to study the role of the mammalian opioid system. We disrupted the preproenkephalin gene using homologous recombination in embryonic stem cells to generate enkephalin-deficient mice. Mutant enk(-/-) animals are healthy, fertile, and care for their offspring, but display significant behavioural abnormalities. Mice with the enk(-/-) genotype are more anxious and males display increased offensive aggressiveness. Mutant animals show marked differences from controls in supraspinal, but not in spinal, responses to painful stimuli. Unexpectedly, enk(-/-) mice exhibit normal stress-induced analgesia. Our results show that enkephalins modulate responses to painful stimuli. Thus, genetic factors may contribute significantly to the experience of pain.	NIMH,DEV BIOL UNIT,CELL BIOL LAB,BETHESDA,MD 20892; NIMH,NEUROANAT SECT,NEUROPHYSIOL LAB,BETHESDA,MD 20892; NIMH,SECT BEHAV NEUROPHARMACOL,EXPT THERAPEUT BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Brownstein, Michael/B-8609-2009; Zimmer, Andreas/B-8357-2009					ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; CHOZICK BS, 1985, INT J NEUROSCI, V26, P197, DOI 10.3109/00207458508985617; COMB M, 1983, DNA-J MOLEC CELL BIO, V2, P213, DOI 10.1089/dna.1983.2.213; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; DIAZ JL, 1990, BEHAV BRAIN RES, V39, P275, DOI 10.1016/0166-4328(90)90033-B; FANSELOW MS, 1984, BEHAV NEUROSCI, V98, P79, DOI 10.1037/0735-7044.98.1.79; FILE SE, 1979, PHARMACOL BIOCHEM BE, V11, P313, DOI 10.1016/0091-3057(79)90141-2; FLINT J, 1995, SCIENCE, V269, P1432, DOI 10.1126/science.7660127; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; GIRAUD P, 1981, NEUROPEPTIDES, V1, P237, DOI 10.1016/0143-4179(81)90002-0; GOOD AJ, 1995, BEHAV NEUROSCI, V109, P631, DOI 10.1037/0735-7044.109.4.631; KRUK MR, 1991, NEUROSCI BIOBEHAV R, V15, P527, DOI 10.1016/S0149-7634(05)80144-7; LIPP J, 1991, CLIN NEUROPHARMACOL, V14, P131, DOI 10.1097/00002826-199104000-00003; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; MAREK P, 1992, BRAIN RES, V578, P197, DOI 10.1016/0006-8993(92)90248-8; MENENDEZ L, 1993, BRAIN RES, V611, P264, DOI 10.1016/0006-8993(93)90512-L; NIEUWENHUYS R, 1985, CHEMOARCHITECTURE BR, P1; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; RODGERS RJ, 1979, PHARMACOL BIOCHEM BE, V11, P505, DOI 10.1016/0091-3057(79)90033-9; ROSENFELD JP, 1994, NEUROSCI BIOBEHAV R, V18, P403, DOI 10.1016/0149-7634(94)90053-1; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; SIEGEL A, 1995, REV NEUROSCIENCE, V6, P47; TREIT D, 1989, PHARM BIOCH BEHAV, V31, P959; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WALKER JM, 1981, EUR J PHARMACOL, V69, P71, DOI 10.1016/0014-2999(81)90603-8; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; YAMADA K, 1995, BEHAV BRAIN RES, V67, P133, DOI 10.1016/0166-4328(94)00150-E	30	364	365	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					535	538		10.1038/383535a0	http://dx.doi.org/10.1038/383535a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849726				2022-12-28	WOS:A1996VL75500053
J	Tett, SFB; Mitchell, JFB; Parker, DE; Allen, MR				Tett, SFB; Mitchell, JFB; Parker, DE; Allen, MR			Human influence on the atmospheric vertical temperature structure: Detection and observations	SCIENCE			English	Article							FINGERPRINT DETECTION; TRENDS	Recent work suggests a discernible human influence on climate. This finding is supported, with less restrictive assumptions than those used in earlier studies, by a 1961 through 1995 data set of radiosonde observations and by ensembles of coupled atmosphere-ocean simulations forced with changes in greenhouse gases, tropospheric sulfate aerosols, and stratospheric ozone. On balance, agreement between the simulations and observations is best for a combination of greenhouse gas, aerosol, and ozone forcing. The uncertainties remaining are due to imperfect knowledge of radiative forcing, natural climate variability, and errors in observations and model response.	RUTHERFORD APPLETON LAB,DEPT SPACE SCI,DIDCOT OX11 0QX,OXON,ENGLAND	UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory	Tett, SFB (corresponding author), UK METEROL OFF,HADLEY CTR CLIMATE PREDICT & RES,LONDON RD,BRACKNELL RG12 2SY,BERKS,ENGLAND.		Tett, Simon F. B./B-1504-2013; Allen, Myles R/A-5172-2012	Tett, Simon F. B./0000-0001-7526-560X; 				CUBASCH U, 1994, CLIM DYYN, V19, P1; Efron B, 1993, INTRO BOOTSTRAP, DOI DOI 10.1111/1467-9639.00050; ESKRIDGE RE, 1995, B AM METEOROL SOC, V76, P1759, DOI 10.1175/1520-0477(1995)076<1759:ACARDS>2.0.CO;2; HANSEN J, 1995, CLIMATIC CHANGE, V30, P103, DOI 10.1007/BF01093228; HEATH D, 1984, J GEOPHYS RES, V89, P5199; JOHNS TC, IN PRESS CLIM DYN; KAROLY DJ, 1994, CLIM DYNAM, V10, P97, DOI 10.1007/s003820050038; KEATING GM, 1987, ADV SPACE RES, V7, P105; MILLER AJ, 1992, GEOPHYS RES LETT, V19, P929, DOI 10.1029/92GL00778; MITCHELL JFB, 1995, J CLIMATE, V8, P2364, DOI 10.1175/1520-0442(1995)008<2364:OSTGGA>2.0.CO;2; MITCHELL JFB, 1995, NATURE, V376, P501, DOI 10.1038/376501a0; OORT AH, 1993, J CLIMATE, V6, P292, DOI 10.1175/1520-0442(1993)006<0292:UATTOT>2.0.CO;2; PARKER DE, 1995, INT J CLIMATOL, V15, P473, DOI 10.1002/joc.3370150502; Press W., 1992, NUMERICAL RECIPES FO; Ramaswamy V, 1996, NATURE, V382, P616, DOI 10.1038/382616a0; Santer BD, 1996, NATURE, V382, P39, DOI 10.1038/382039a0; SANTER BD, 1993, CLIM DYNAM, V8, P265, DOI 10.1007/BF00209666; Santer BD, 1995, CLIM DYNAM, V12, P77, DOI 10.1007/BF00223722; SANTER BD, 1996, CLIMATE CHANGE 1995, P407; TETT S, IN PRESS CLIM DYN; *WORD MET ORG, 1994, 37 WORD MET ORG; ZWIERS FW, 1995, J CLIMATE, V8, P336, DOI 10.1175/1520-0442(1995)008<0336:TSCIAI>2.0.CO;2; [No title captured]	23	165	166	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1170	1173		10.1126/science.274.5290.1170	http://dx.doi.org/10.1126/science.274.5290.1170			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895461				2022-12-28	WOS:A1996VT33500047
J	Chang, WT; Newell, PC; Gross, JD				Chang, WT; Newell, PC; Gross, JD			Identification of the cell fate gene stalky in Dictyostelium	CELL			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; DISCOIDEUM; DIFFERENTIATION; EXPRESSION; CAMP; CULMINATION; PRESTALK; MUTANTS; MORPHOGENESIS	Using insertional mutagenesis, we have isolated a ''stalky'' mutant in which cells destined to become spores end up as stalk cells. Similar mutants were previously observed after chemical mutagenesis, but the affected gene could not be isolated. Our mutant, like the previous ones, is in stkA. Its defect is cell-autonomous and not overcome by overexpressing cAMP-dependent protein kinase. stkA is strongly expressed in the prespore region of aggregates but not in the anterior prestalk zone. The mutant expresses normal levels of prespore-cell transcripts but fails to produce the spore transcript spiA. stkA encodes a predicted 99 kDa protein (STKA) with two putative C4 zinc fingers, one of which is a GATA-type finger, indicating that it may be a transcription factor. This conclusion is supported by localization of STKA in the nucleus.			Chang, WT (corresponding author), UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANJARD C, 1992, DEVELOPMENT, V115, P785; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BERKS M, 1988, DEV BIOL, V126, P108, DOI 10.1016/0012-1606(88)90244-8; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; BOWERMAN B, 1995, BIOESSAYS, V17, P405, DOI 10.1002/bies.950170508; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COEN ES, 1991, ANNU REV PLANT PHYS, V42, P241, DOI 10.1146/annurev.pp.42.060191.001325; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; EARLY A, 1995, CELL, V83, P91, DOI 10.1016/0092-8674(95)90237-6; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOPPER NA, 1993, DEVELOPMENT, V119, P147; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JERMYN KA, 1991, DEVELOPMENT, V111, P779; KAY RR, 1978, NATURE, V271, P58, DOI 10.1038/271058a0; KAY RR, 1989, DEVELOPMENT, V105, P753; KESSIN RH, 1974, J BACTERIOL, V119, P776, DOI 10.1128/JB.119.3.776-783.1974; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; MARZLUF GA, 1993, ANNU REV MICROBIOL, V47, P31, DOI 10.1146/annurev.micro.47.1.31; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; MORRISSEY JH, 1981, GENETICS, V99, P183; MORRISSEY JH, 1981, DEV BIOL, V83, P1, DOI 10.1016/S0012-1606(81)80002-4; NEWELL PC, 1977, J GEN MICROBIOL, V100, P207, DOI 10.1099/00221287-100-1-207; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; RICHARDSON DL, 1994, DEVELOPMENT, V120, P2891; RICHARDSON DL, 1991, DEV BIOL, V144, P269, DOI 10.1016/0012-1606(91)90421-X; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAKAI Y, 1976, DEV GROWTH DIFFER, V15, P11; SCHNITZLER GR, 1994, GENE DEV, V8, P502, DOI 10.1101/gad.8.4.502; Shaulsky G, 1996, DEV BIOL, V174, P214, DOI 10.1006/dbio.1996.0067; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; VANES S, 1994, P NATL ACAD SCI USA, V91, P8219, DOI 10.1073/pnas.91.17.8219; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; WEST CM, 1983, CELL DIFFER DEV, V13, P69, DOI 10.1016/0045-6039(83)90079-9; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WILLIAMS KL, 1974, J GEN MICROBIOL, V84, P59, DOI 10.1099/00221287-84-1-59; WILLIAMS KL, 1978, FEMS MICROBIOL LETT, V4, P155, DOI 10.1016/0378-1097(78)90049-6	56	42	43	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					471	481		10.1016/S0092-8674(00)81367-7	http://dx.doi.org/10.1016/S0092-8674(00)81367-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898200	Bronze			2022-12-28	WOS:A1996VQ46600013
J	Verrees, M				Verrees, M			Touch me	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1285	1286		10.1001/jama.276.16.1285	http://dx.doi.org/10.1001/jama.276.16.1285			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM825	8861971				2022-12-28	WOS:A1996VM82500002
J	Picarelli, A; Maiuri, L; Frate, A; Greco, M; Auricchio, S; Londei, M				Picarelli, A; Maiuri, L; Frate, A; Greco, M; Auricchio, S; Londei, M			Production of antiendomysial antibodies after in-vitro gliadin challenge of small intestine biopsy samples from patients with coeliac disease	LANCET			English	Article							CELIAC-DISEASE; MARKERS; CELLS	Background Diagnosis of many immune-mediated diseases is helped by detection of antibodies directed against the pathogenetic (self or foreign) antigen. In coeliac disease (CD), we have a situation in which antiendomysial antibodies (EMA), which are not specific for the pathogenetic antigen, reach a specificity and sensitivity of detection of CD approaching 100%, whereas detection of antibodies against gliadin (AGA), the pathogenetic antigen, is far less specific and sensitive in diagnosis. No direct evidence of a relation between gluten/gliadin challenge and EMA production exists. We tried to establish whether the small intestine of CD patients is the site of EMA production and whether gliadin challenge could induce their release. Methods Small intestine biopsy samples from treated (23) and untreated (16) CD patients and controls (18) were cultured in vitro for 24-48 h in the presence of gliadin, another alimentary antigen, or medium. EMA and AGA were detected in the supernatants of these organ culture biopsy samples by ELISA and immunofluorescence technique, respectively. Findings No EMA were found in the culture supernatants of biopsy samples of 18 controls, whereas they were detected in the culture supernatants of all 16 untreated CD patients irrespective of gliadin challenge. Conversely, EMA were not detected in supernatants of biopsy samples cultured in medium only from 23 treated CD patients, but were detected in 17 of the 23 biopsy samples challenged with gliadin. Interpretation Our results suggest that a more complex pathogenetic mechanism than normally accepted is involved in CD, Furthermore, our findings raise the possibility that EMA, or the antigen recognised by them, are involved directly in the pathogenesis of CD.	KENNEDY INST,LONDON W6 8LW,ENGLAND; UNIV ROMA LA SAPIENZA,CATTEDRA GASTROENTEROL,MED CLIN 2,ROME,ITALY; CHILDRENS HOSP PAUSILIPON,NAPLES,ITALY; UNIV NAPLES FEDERICO II,DEPT PEDIAT,NAPLES,ITALY	University of Oxford; Sapienza University Rome; University of Naples Federico II			Picarelli, Antonio/L-3229-2019	Picarelli, Antonio/0000-0002-6104-8193				CORRAO G, 1994, GUT, V35, P771, DOI 10.1136/gut.35.6.771; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; FRANCO A, 1994, CLIN IMMUNOL IMMUNOP, V71, P75, DOI 10.1006/clin.1994.1054; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; Maiuri L, 1996, GASTROENTEROLOGY, V110, P1368, DOI 10.1053/gast.1996.v110.pm8613040; MAKI M, 1991, LANCET, V338, P724, DOI 10.1016/0140-6736(91)91445-Z; MAKI M, 1991, LANCET, V338, P1350, DOI 10.1016/0140-6736(91)92234-S; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; MARTTINEN A, 1993, PEDIATR RES, V34, P420, DOI 10.1203/00006450-199310000-00007; OFARRELLY C, 1983, BRIT MED J, V286, P2007, DOI 10.1136/bmj.286.6383.2007; QUARATINO S, 1995, P NATL ACAD SCI USA, V92, P10398, DOI 10.1073/pnas.92.22.10398; Quaratino S, 1996, J EXP MED, V183, P349, DOI 10.1084/jem.183.2.349; TRONCONE R, 1991, J PEDIATR GASTR NUTR, V12, P150, DOI 10.1097/00005176-199102000-00002; VOLTA U, 1985, GUT, V26, P667, DOI 10.1136/gut.26.7.667	14	130	130	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1065	1067		10.1016/S0140-6736(96)03060-7	http://dx.doi.org/10.1016/S0140-6736(96)03060-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874458				2022-12-28	WOS:A1996VM88600011
J	Kim, JL; Morgenstern, KA; Lin, C; Fox, T; Dwyer, MD; Landro, JA; Chambers, SP; Markland, W; Lepre, CA; OMalley, ET; Harbeson, SL; Rice, CM; Murcko, MA; Caron, PR; Thomson, JA				Kim, JL; Morgenstern, KA; Lin, C; Fox, T; Dwyer, MD; Landro, JA; Chambers, SP; Markland, W; Lepre, CA; OMalley, ET; Harbeson, SL; Rice, CM; Murcko, MA; Caron, PR; Thomson, JA			Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide	CELL			English	Article							YELLOW-FEVER VIRUS; NON-B-HEPATITIS; PUTATIVE NONSTRUCTURAL PROTEINS; SERINE-TYPE PROTEINASE; NON-A; VIRAL REPLICATION; TERMINAL DOMAIN; HEPATOCELLULAR-CARCINOMA; INTERFERON THERAPY; SEQUENCE-ANALYSIS	An estimated 1% of the global human population is infected by hepatitis C viruses (HCVs), and there are no broadly effective treatments for the debilitating progression of chronic hepatitis C. A serine protease located within the HCV NS3 protein processes the viral polyprotein at four specific sites and is considered essential for replication. Thus, it emerges as an attractive target for drug design. We report here the 2.5 Angstrom resolution X-ray crystal structure of the NS3 protease domain complexed with a synthetic NS4A activator peptide. The protease has a chymotrypsin-like fold and features a tetrahedrally coordinated metal ion distal to the active site. The NS4A peptide intercalates within a beta sheet of the enzyme core.	WASHINGTON UNIV, SCH MED, DEPT MOL MICROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	Kim, JL (corresponding author), VERTEX PHARMACEUT INC, 130 WAVERLY ST, CAMBRIDGE, MA 02139 USA.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1994, GASTROENTEROL CLIN N, V23, P437; APPEL W, 1986, CLIN BIOCHEM, V19, P317, DOI 10.1016/S0009-9120(86)80002-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAMBERS TJ, 1993, J VIROL, V67, P6797, DOI 10.1128/JVI.67.11.6797-6807.1993; CHAMBERS TJ, 1995, J VIROL, V69, P1600, DOI 10.1128/JVI.69.3.1600-1605.1995; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1989, VIROLOGY, V169, P100, DOI 10.1016/0042-6822(89)90045-7; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429; EDWARDS PD, 1994, MED RES REV, V14, P127, DOI 10.1002/med.2610140202; FAILLA C, 1995, J VIROL, V69, P1769, DOI 10.1128/JVI.69.3.1769-1777.1995; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; Failla CM, 1996, FOLD DES, V1, P35, DOI 10.1016/S1359-0278(96)00010-7; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; Francki RIB, 1991, ARCH VIROL         S, V2, P223; FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7; FUREY W, 1996, IN PRESS METH ENZYMO; GOMEZ JE, 1977, BIOCHIM BIOPHYS ACTA, V495, P177, DOI 10.1016/0005-2795(77)90252-5; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HAHM B, 1995, J VIROL, V69, P2534, DOI 10.1128/JVI.69.4.2534-2539.1995; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; IWARSON S, 1994, FEMS MICROBIOL REV, V14, P201, DOI 10.1111/j.1574-6976.1994.tb00089.x; JANSSEN HLA, 1994, J HEPATOL, V21, P241, DOI 10.1016/S0168-8278(05)80402-7; JIN L, 1995, ARCH BIOCHEM BIOPHYS, V323, P47, DOI 10.1006/abbi.1995.0008; KANAI A, 1995, FEBS LETT, V376, P221, DOI 10.1016/0014-5793(95)01283-X; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KEW MC, 1994, FEMS MICROBIOL REV, V14, P211, DOI 10.1111/j.1574-6976.1994.tb00091.x; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Koch JO, 1996, VIROLOGY, V221, P54, DOI 10.1006/viro.1996.0352; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; LIN C, 1995, P NATL ACAD SCI USA, V92, P7622, DOI 10.1073/pnas.92.17.7622; MANABE S, 1994, VIROLOGY, V198, P636, DOI 10.1006/viro.1994.1075; Mangel WF, 1996, J BIOL CHEM, V271, P536, DOI 10.1074/jbc.271.1.536; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; MIZUSHIMA H, 1994, J VIROL, V68, P2731, DOI 10.1128/JVI.68.4.2731-2734.1994; NESTOROWICZ A, 1994, VIROLOGY, V199, P114, DOI 10.1006/viro.1994.1103; PIZZI E, 1994, P NATL ACAD SCI USA, V91, P888, DOI 10.1073/pnas.91.3.888; PURCELL RH, 1994, FEMS MICROBIOL REV, V14, P181, DOI 10.1111/j.1574-6976.1994.tb00087.x; RENAULT PF, 1989, SEMIN LIVER DIS, V9, P273, DOI 10.1055/s-2008-1040523; ROST B, 1995, PROTEIN SCI, V4, P521; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SATOH S, 1995, J VIROL, V69, P4255, DOI 10.1128/JVI.69.7.4255-4260.1995; Shimizu Y, 1996, J VIROL, V70, P127, DOI 10.1128/JVI.70.1.127-132.1996; Simmonds Peter, 1994, V61, P12; SOMMERGRUBER W, 1994, VIROLOGY, V204, P815, DOI 10.1006/viro.1994.1599; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Tomei L, 1996, J GEN VIROL, V77, P1065, DOI 10.1099/0022-1317-77-5-1065; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; TSAI DE, 1992, P NATL ACAD SCI USA, V89, P8864, DOI 10.1073/pnas.89.19.8864; Van Der Poel C. L., 1994, V61, P137; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WEILAND O, 1994, FEMS MICROBIOL REV, V14, P279, DOI 10.1016/0168-6445(94)90044-2; YU SYF, 1992, VIROLOGY, V186, P725, DOI 10.1016/0042-6822(92)90039-R; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	79	632	681	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1996	87	2					343	355		10.1016/S0092-8674(00)81351-3	http://dx.doi.org/10.1016/S0092-8674(00)81351-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861917	Bronze			2022-12-28	WOS:A1996VN40300021
J	Rovner, J				Rovner, J			United States of America - The health care system evolves	LANCET			English	Article								No one in the USA knows where medicine is heading. Perhaps that is why no one is short of opinion. Traditionalists bemoan that the glory days-of enviable physician independence and reimbursement and generous government research budgets-are long since past and that the future belongs only to corporate planners. Others, more sanguine, leap into the new ''medical marketplace'', extolling a new conviviality in progressive managed care and venture-capitalist-inspired biotechnology. Why the fuss, they wonder. Change is on from all quarters. We invited the following impressions.											0	2	2	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					1001	1002		10.1016/S0140-6736(96)08389-4	http://dx.doi.org/10.1016/S0140-6736(96)08389-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855859				2022-12-28	WOS:A1996VM02700015
J	Chen, YS; Smith, PE; Evensen, NM; York, D; Lajoie, KR				Chen, YS; Smith, PE; Evensen, NM; York, D; Lajoie, KR			The edge of time: Dating young volcanic ash layers with the 40Ar-39Ar laser probe	SCIENCE			English	Article							CALIBRATION; POTASSIUM; PRECISION; RANGE; BC	Argon-40-argon-39 single-crystal dating of young (5000 to 30,000 years ago) volcanic ash layers erupted from the Mono Craters, California, shows that the method can yield meaningful ages in Holocene tephra. Because of ubiquitous xenocrystic contamination, the data do not form isochrons but plot in wedge-shaped regions on an argon isotopic diagram. The upper boundary of the region is an isochron matching the C-14-derived age of the eruption. Such contamination-related patterns may be common in dating young materials by the single-crystal method. Argon dating by this method can help refine the time scale of physical and biological evolution over the past 100,000 years.	US GEOL SURVEY, MENLO PK, CA 94025 USA	United States Department of the Interior; United States Geological Survey	Chen, YS (corresponding author), UNIV TORONTO, DEPT PHYS, 60 ST GEORGE ST, TORONTO, ON M5S 1A7, CANADA.							BARD E, 1993, RADIOCARBON, V35, P191, DOI 10.1017/S0033822200013886; BENSON LV, 1990, PALAEOGEOGR PALAEOCL, V78, P241, DOI 10.1016/0031-0182(90)90217-U; CURTIS GH, 1966, POTASSIUM ARGON DATI, P151; DALRYMPLE GB, 1968, EARTH PLANET SC LETT, V3, P289; DALRYMPLE GB, 1969, POTASSIUM ARGON DATI; DALRYMPLE GB, 1967, MEANS CORRELATION QU, P175; DAMON PE, 1967, RADIOACTIVE DATING M, P463; DAVIS JO, 1978, NEV ARCHEOL SURV PAP, V7, P1; EVERNDEN JF, 1965, CURR ANTHROPOL, V6, P343; GILLOT PY, 1986, CHEM GEOL, V59, P205, DOI 10.1016/0168-9622(86)90072-2; HALLIDAN AN, 1990, EARTH PLANET SC LETT, V94, P274; HILDRETH W, 1994, GEOL SOC AM BULL, V106, P1413, DOI 10.1130/0016-7606(1994)106<1413:PAGOAB>2.3.CO;2; HU Q, 1994, EARTH PLANET SC LETT, V123, P331; KROMER B, 1993, RADIOCARBON, V35, P125, DOI 10.1017/S0033822200013862; Lajoie K.R., 1968, THESIS U CALIFORNIA; LAJOIE KR, 1983, GEOL SOC AM ABSTR, V15, P300; LAJOIE KR, 1993, PUBL QUATERNARY SCI, V8, P64; LIDDICOAT JC, 1982, EOS T AGU, V63, P920; MERRIHUE C, 1966, J GEOPHYS RES, V71, P2852, DOI 10.1029/JZ071i011p02852; SARNAWOJCIKI AM, 1991, DECADE N AM GEOLOG K, V2, P17; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; VONDERBOGAARD P, 1995, EARTH PLANET SC LETT, V133, P163; VONDERBOGAARD P, 1989, NATURE, V342, P523; VONDERBOGAARD P, 1995, GEOLOGY, V23, P759; YORK D, 1981, GEOPHYS RES LETT, V8, P1136, DOI 10.1029/GL008i011p01136; YORK D, 1969, EARTH PLANET SC LETT, V5, P320; ZEITLER PK, 1987, CHEM GEOL, V65, P167, DOI 10.1016/0168-9622(87)90071-6	27	51	56	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1996	274	5290					1176	1178		10.1126/science.274.5290.1176	http://dx.doi.org/10.1126/science.274.5290.1176			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895463				2022-12-28	WOS:A1996VT33500049
J	Harada, K; Kamimura, O; Kasai, H; Matsuda, T; Tonomura, A; Moshchalkov, VV				Harada, K; Kamimura, O; Kasai, H; Matsuda, T; Tonomura, A; Moshchalkov, VV			Direct observation of vortex dynamics in superconducting films with regular arrays of defects	SCIENCE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTORS; COLUMNAR DEFECTS; MAGNETIC-FLUX; MICROSCOPY; LATTICES; VORTICES; HOLES; LINE	The microscopic mechanism of the matching effect in a superconductor, which manifested itself as the production of peaks or cusps in the critical current at specific values of the applied magnetic field, was investigated with Lorentz microscopy to allow direct observation of the behavior of vortices in a niobium thin film having a regular array of artificial defects. Vortices were observed to form regular and consequently rigid lattices at the matching magnetic field, at its multiples, and at its fractions. The dynamic observation furthermore revealed that vortices were most difficult to move at the matching field, whereas excess vortices moved easily.	KATHOLIEKE UNIV LEUVEN,VASTE STOF FYS & MAGNETISME LAB,B-3001 LOUVAIN,BELGIUM	KU Leuven	Harada, K (corresponding author), HITACHI LTD,ADV RES LAB,HATOYAMA,SAITAMA 35003,JAPAN.		Moshchalkov, Victor V/I-7232-2013					BAERT M, 1995, PHYS REV LETT, V74, P3269, DOI 10.1103/PhysRevLett.74.3269; BEHLER S, 1994, PHYS REV LETT, V72, P1750, DOI 10.1103/PhysRevLett.72.1750; Bezryadin A, 1996, J LOW TEMP PHYS, V102, P73, DOI 10.1007/BF00755110; BLATTER G, 1994, REV MOD PHYS, V66, P1125, DOI 10.1103/RevModPhys.66.1125; BONEVICH JE, 1993, PHYS REV LETT, V70, P2952, DOI 10.1103/PhysRevLett.70.2952; DAI HJ, 1994, SCIENCE, V265, P1552, DOI 10.1126/science.265.5178.1552; HARADA K, 1992, NATURE, V360, P51, DOI 10.1038/360051a0; HARADA K, 1996, PHYS REV B, V253, P9400; HERRING CP, 1974, PHYS LETT A, VA 47, P105, DOI 10.1016/0375-9601(74)90367-3; KHALFIN IB, 1993, PHYSICA C, V207, P359, DOI 10.1016/0921-4534(93)90318-K; LYKOV AN, 1993, SOLID STATE COMMUN, V86, P531, DOI 10.1016/0038-1098(93)90103-T; Matsuda T, 1996, SCIENCE, V271, P1393, DOI 10.1126/science.271.5254.1393; MEBARD AF, 1977, IEEE T MAGN, V1, P589; METLUSHKO VV, 1994, SOLID STATE COMMUN, V91, P331, DOI 10.1016/0038-1098(94)90628-9; MOSHCHALKOV VV, 1995, JPN J APPL PHYS, V34, P4459; NELSON DR, 1993, PHYS REV B, V48, P13060, DOI 10.1103/PhysRevB.48.13060; OSBORNE KE, 1971, PHILOS MAG, V23, P1113, DOI 10.1080/14786437108217399; RADZIHOVSKY L, 1995, PHYS REV LETT, V74, P4923, DOI 10.1103/PhysRevLett.74.4923; Rosseel E, 1996, PHYS REV B, V53, pR2983, DOI 10.1103/PhysRevB.53.R2983; VU LN, 1993, APPL PHYS LETT, V63, P1693, DOI 10.1063/1.110687; ZELDOV E, 1994, PHYS REV LETT, V73, P1428, DOI 10.1103/PhysRevLett.73.1428	21	412	414	4	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1167	1170		10.1126/science.274.5290.1167	http://dx.doi.org/10.1126/science.274.5290.1167			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895460				2022-12-28	WOS:A1996VT33500046
J	Romanowicz, B; Li, XD; Durek, J				Romanowicz, B; Li, XD; Durek, J			Anisotropy in the inner core: Could it be due to low-order convection?	SCIENCE			English	Article							PKIKP TRAVEL-TIMES; FREE-OSCILLATIONS; EARTH; MODES; IRON	A recently assembled data set of inner core-sensitive free oscillation splitting measurements and body wave differential travel times provides constraints on the patterns of anisotropy in the Earth's inner core. Applying a formalism that allows departures from radial symmetry and cylindrical anisotropy results in models with P-wave velocity distributions whose strength and pattern are incompatible with frozen-in anisotropy, but rather suggest a simple large-scale convection regime in the inner core.	UNIV CALIF BERKELEY,DEPT GEOL & GEOPHYS,BERKELEY,CA 94720	University of California System; University of California Berkeley	Romanowicz, B (corresponding author), UNIV CALIF BERKELEY,SEISMOG STN,BERKELEY,CA 94720, USA.		Romanowicz, barbara A/H-6726-2017	Romanowicz, barbara A/0000-0002-6208-6044				CORMIER VF, 1994, EOS T AM GEOPHYS UN, V75, P67; CREAGER KC, 1992, NATURE, V356, P309, DOI 10.1038/356309a0; DOORNBOS DJ, 1974, GEOPHYS J ROY ASTR S, V38, P397, DOI 10.1111/j.1365-246X.1974.tb04131.x; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; FEARN DR, 1981, NATURE, V292, P232, DOI 10.1038/292232a0; GIARDINI D, 1987, NATURE, V325, P405, DOI 10.1038/325405a0; GIARDINI D, 1988, J GEOPHYS RES-SOLID, V93, P13716, DOI 10.1029/JB093iB11p13716; GIARDINI D, 1991, J GEOPHYS RES, V96, P551; JEANLOZ R, 1988, GEOPHYS RES LETT, V15, P72, DOI 10.1029/GL015i001p00072; JOHNSON S, 1994, EOS T AGU, V75, P475; KARATO S, 1993, SCIENCE, V262, P1708, DOI 10.1126/science.262.5140.1708; Li XD, 1996, J GEOPHYS RES-SOL EA, V101, P22245, DOI 10.1029/96JB01306; LI XD, 1990, THESIS HARVARD U; MASTERS G, 1981, GEOPHYS RES LETT, V8, P569, DOI 10.1029/GL008i006p00569; MEGNIN, 1995, EOS FALL S, V76, P46; MORELLI A, 1986, GEOPHYS RES LETT, V13, P1545, DOI 10.1029/GL013i013p01545; POUPINET G, 1983, NATURE, V305, P204, DOI 10.1038/305204a0; RESOVSKY JS, 1995, GEOPHYS RES LETT, V22, P2301, DOI 10.1029/95GL01996; RITZWOLLER M, 1986, J GEOPHYS RES-SOLID, V91, P203, DOI 10.1029/JB091iB10p10203; SHEARER PM, 1994, J GEOPHYS RES-SOL EA, V99, P19647, DOI 10.1029/94JB01470; SHEARER PM, 1988, NATURE, V333, P228, DOI 10.1038/333228a0; SONG XD, 1995, J GEOPHYS RES-SOL EA, V100, P9805, DOI 10.1029/95JB00244; Song XD, 1996, J GEOPHYS RES-SOL EA, V101, P16089, DOI 10.1029/96JB01152; SONG XD, 1993, GEOPHYS RES LETT, V20, P2591, DOI 10.1029/93GL02812; Souriau A, 1996, GEOPHYS RES LETT, V23, P1, DOI 10.1029/95GL03583; SOURIAU A, IN PRESS PHYS EARTH; STIXRUDE L, 1995, SCIENCE, V267, P1972, DOI 10.1126/science.267.5206.1972; SU W, 1994, J GEOPHYS RES, V100, P9831; SU WJ, 1994, J GEOPHYS RES-SOL EA, V99, P6945, DOI 10.1029/93JB03408; TROMP J, 1993, NATURE, V366, P678, DOI 10.1038/366678a0; TROMP J, 1995, GEOPHYS RES LETT, V22, P2297, DOI 10.1029/95GL01810; Tromp J, 1995, GSA TODAY, V5, P137; VINNIK L, 1994, GEOPHYS RES LETT, V21, P1671, DOI 10.1029/94GL01600; WEBER P, 1992, GEOPHYS RES LETT, V19, P2107, DOI 10.1029/92GL02148; WIDMER R, 1992, GEOPHYS J INT, V111, P559, DOI 10.1111/j.1365-246X.1992.tb02112.x; WOODHOUSE JH, 1986, GEOPHYS RES LETT, V13, P1549, DOI 10.1029/GL013i013p01549	36	58	59	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					963	966		10.1126/science.274.5289.963	http://dx.doi.org/10.1126/science.274.5289.963			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875934				2022-12-28	WOS:A1996VR79200043
J	Cui, JS; OShea, KS; Purkayastha, A; Saunders, TL; Ginsburg, D				Cui, JS; OShea, KS; Purkayastha, A; Saunders, TL; Ginsburg, D			Fatal haemorrhage and incomplete block to embryogenesis in mice locking coagulation factor V	NATURE			English	Article							ACTIVATED PROTEIN-C; WARFARIN EMBRYOPATHY; TARGETED DISRUPTION; HEMOPHILIA-A; MECHANISM; PROTHROMBINASE; DEFICIENCY; RESISTANCE; THROMBOSIS; PHENOTYPE	COAGULATION factor V is a critical cofactor for the activation of prothrombin to thrombin, the penultimate step in the generation of a fibrin blood clot(1,2). Genetic deficiency of factor V results in a congenital bleeding disorder (parahaemophilia)(3), whereas inheritance of a mutation rendering factor V resistant to inactivation is an important risk factor for thrombosis(4,5). We report here that approximately half of homozygous embryos deficient in factor V (F upsilon(-/-)), which have been generated by gene targeting, die at embryonic day (E) 9-10, possibly as a result of an abnormality in the yolk-sac vasculature. The remaining F upsilon(-/-) mice progress normally to term, but die from massive haemorrhage within 2 hours or birth. Considered together with the milder phenotypes generally associated with deficiencies of other clotting factors(6,7), our findings demonstrate the primary role of the common coagulation pathway and the absolute requirement for functional factor V for prothrombinase activity. They also provide direct evidence for the existence of other critical haemostatic functions for thrombin in addition to fibrin clot formation, and identify a previously unrecognized role for the coagulation system in early mammalian development.	UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Saunders, Thom/0000-0003-2015-101X				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FLIER JS, 1992, NEW ENGL J MED, V326, P800; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; GALANAKIS DK, 1992, HEMATOL ONCOL CLIN N, V6, P1171, DOI 10.1016/S0889-8588(18)30303-4; HAN YM, 1993, J ASSIST REPROD GEN, V10, P151, DOI 10.1007/BF01207739; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HOYER LW, 1994, NEW ENGL J MED, V330, P38, DOI 10.1056/NEJM199401063300108; Kaufman M.H., 1992, ATLAS MOUSE DEV; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; PAULI RM, 1987, AM J HUM GENET, V41, P566; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SOIFER SJ, 1994, AM J PATHOL, V144, P60; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TRACY PB, 1987, HUM PATHOL, V18, P162, DOI 10.1016/S0046-8177(87)80334-9; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Zheng XX, 1995, P NATL ACAD SCI USA, V92, P12426, DOI 10.1073/pnas.92.26.12426	25	206	209	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					66	68		10.1038/384066a0	http://dx.doi.org/10.1038/384066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900278	Green Published			2022-12-28	WOS:A1996VR21900054
J	Rulifson, EJ; Micchelli, CA; Axelrod, JD; Perrimon, N; Blair, SS				Rulifson, EJ; Micchelli, CA; Axelrod, JD; Perrimon, N; Blair, SS			wingless refines its own expression domain on the Drosophila wing margin	NATURE			English	Article							SPLIT COMPLEX GENES; SIGNALING PATHWAY; PROTEIN; POLARITY; NOTCH; BOUNDARY; ZESTE-WHITE-3; NEUROGENESIS; SUPPRESSOR; ACTIVATION	THE imaginal discs of Drosophila, which give rise to the adult appendages, are patterned during a period of intense cell proliferation. The specification of differing regions occurs in some cases by subdividing the disc epithelium into lineage compartments(1). However, in most cases precise boundaries are formed between different cell types without early compartmentalization(2). One such boundary occurs between the wingless (wg)-expressing cells of the wing margin and the adjacent proneural cells, which give rise to margin sensory bristles. Here we show that this boundary arises in part by a mechanism of 'self-refinement', by which wingless protein (Wg) represses wg expression in adjacent cells. Cells unable to receive the Wg signal do not resolve the boundary between wg-expressing and proneural cells.	UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; UNIV WISCONSIN,PROGRAM NEUROSCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; University of Wisconsin System; University of Wisconsin Madison				Perrimon, Norbert/0000-0001-7542-472X				Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BALLYCUIF L, 1995, MECH DEVELOP, V53, P23, DOI 10.1016/0925-4773(95)00421-1; BLAIR SS, 1994, DEV BIOL, V162, P229, DOI 10.1006/dbio.1994.1081; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1992, DEV BIOL, V152, P263, DOI 10.1016/0012-1606(92)90134-3; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1994, DEVELOPMENT, V120, P621; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1989, GENOME, V31, P612; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HING HK, 1994, MECH DEVELOP, V47, P261, DOI 10.1016/0925-4773(94)90044-2; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; PEIFER M, 1994, DEVELOPMENT, V120, P369; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SIMPSON P, 1988, DEVELOPMENT, V103, P391; THEISEN H, 1994, DEVELOPMENT, V120, P347; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	30	101	101	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					72	74		10.1038/384072a0	http://dx.doi.org/10.1038/384072a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900280				2022-12-28	WOS:A1996VR21900056
J	Timsit, JF; Sebille, V; Farkas, JC; Misset, B; Martin, JB; Chevret, S; Carlet, J				Timsit, JF; Sebille, V; Farkas, JC; Misset, B; Martin, JB; Chevret, S; Carlet, J			Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients - A prospective randomized multicenter study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CENTRAL VENOUS CATHETERS; INTENSIVE-CARE UNITS; PARENTERAL-NUTRITION; CONTROLLED TRIAL; RISK-FACTORS; COMPLICATIONS; INFECTION; PREVENTION; CULTURES; DIAGNOSIS	Objective.-To evaluate the effect of catheter tunneling on internal jugular catheter-related sepsis in critically ill patients. Design.-A prospective randomized controlled study involving 3 intensive care units (ICUs), stratified by number of catheter lumina (1 or 2) and center. Setting.-The 10-bed medical-surgical and 10-bed surgical ICUs at Saint Joseph Hospital and 8-bed surgical ICU at Clinique de la Defense, Paris, France. Patients.-Every patient older than 18 years admitted to the ICUs between March 1, 1993, and July 17, 1996, who required a jugular venous catheter for more than 48 hours. Intervention.-Random allocation to tunneled or nontunneled catheters. Measurements-Times to occurrence of systemic catheter-related sepsis, catheter-related septicemia, or a quantitative catheter-tip culture with a cutoff of 103 colony-forming units per milliliter. Results.-A total of 241 patients were randomized, Ten patients in whom jugular puncture was not achieved were subsequently excluded, The proportion of patients receiving mechanical ventilation (87%) and mean+/-SD age (65+/-4 years), Simplified Acute Physiologic Score (13.3+/-4.9), Organ System Failure score (1.5+/-1.0), and duration of catheterization (8.7+/-5.0 days) were similar in both groups. Taking into account the first 231 catheters (114 nontunneled [control], 117 tunneled), we found that tunnelization decreased catheter-related sepsis (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.13-0.83; P=.02), catheter-related septicemia (OR, 0.23; 95% CI, 0.07-0.81; P=.02), and, though not statistically significant, positive quantitative tip-culture rate (OR, 0.62; 95% CI, 0.35-1.10; P=.10). These results were slightly modified after adjustment on parameters either imbalanced between both groups (duration of catheter placement and cancer at admission) or prognostic (insertion by a resident, use of antibiotics at catheter insertion, cancer, and sex). Conclusion.-The incidence of internal jugular catheter-related infections in critically ill patients can be reduced by using subcutaneous tunnelization.	HOP ST JOSEPH,MED SURG INTENS CARE UNIT,F-75674 PARIS,FRANCE; HOP ST JOSEPH,SURG INTENS CARE UNIT,F-75674 PARIS,FRANCE; HOP ST ANTOINE,INST FEDERAT ST ANTOINE RECH SANTE,INSERM,U444,F-75571 PARIS,FRANCE; CLIN DEF,SURG INTENS CARE UNIT,NANTERRE,FRANCE; HOP ST LOUIS,DEPT BIOSTAT,PARIS,FRANCE	Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Sebille, Veronique/I-3309-2015; Misset, Benoit/P-7817-2018	Misset, Benoit/0000-0001-6466-0065; Sebille, Veronique/0000-0002-0780-7742; chevret, sylvie/0000-0001-6449-4730				ANDRIVET P, 1994, CLIN INFECT DIS, V18, P199, DOI 10.1093/clinids/18.2.199; ARNOW PM, 1993, CLIN INFECT DIS, V16, P778, DOI 10.1093/clind/16.6.778; BJORNSON HS, 1982, SURGERY, V92, P720; BRUNBUISSON C, 1987, ARCH INTERN MED, V147, P873, DOI 10.1001/archinte.147.5.873; FAN ST, 1988, J HOSP INFECT, V12, P191, DOI 10.1016/0195-6701(88)90006-0; FARKAS JC, 1992, AM J MED, V93, P277, DOI 10.1016/0002-9343(92)90233-2; FLOWERS RH, 1989, JAMA-J AM MED ASSOC, V261, P878, DOI 10.1001/jama.261.6.878; GIRAUD T, 1993, CRIT CARE MED, V21, P40, DOI 10.1097/00003246-199301000-00011; KEOHANE PP, 1983, LANCET, V2, P1388; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LINARES J, 1985, J CLIN MICROBIOL, V21, P357; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MANSFIELD PF, 1994, NEW ENGL J MED, V331, P1735, DOI 10.1056/NEJM199412293312602; MORO ML, 1994, INFECT CONT HOSP EP, V15, P253; PINILLA JC, 1994, INFECT CONT HOSP EP, V15, P253; RAAD II, 1992, CLIN INFECT DIS, V15, P197, DOI 10.1093/clinids/15.2.197; RICHET H, 1990, J CLIN MICROBIOL, V28, P2520, DOI 10.1128/JCM.28.11.2520-2525.1990; SEGURA M, 1993, CLIN NUTR, V12, P103, DOI 10.1016/0261-5614(93)90059-D; VONMEYENFELDT MMF, 1980, JPEN-PARENTER ENTER, V4, P514, DOI 10.1177/0148607180004005514	22	95	97	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1416	1420		10.1001/jama.276.17.1416	http://dx.doi.org/10.1001/jama.276.17.1416			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892717	Green Submitted			2022-12-28	WOS:A1996VQ46400028
J	Kirby, M				Kirby, M			Human rights and the HIV paradox	LANCET			English	Article								Faced with the grave challenge to public health posed by HIV infection, governments are obliged to ''do something''. One response, which often finds favour with the general public, is to enact laws that criminalise the activities of certain target groups. However, such laws maginalise individuals in these groups and have very little impact on containment of the epidemic. It is far better to introduce measures that protect the rights of people most at risk of infection and thereby encourage and sustain behaviour modification.	INT COMMISS JURISTS,GENEVA,SWITZERLAND		Kirby, M (corresponding author), HIGH COURT AUSTRALIA,POB E435 QUEEN VICTORIA TERRACE,CANBERRA,ACT 2600,AUSTRALIA.								0	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1217	1218		10.1016/S0140-6736(96)05468-2	http://dx.doi.org/10.1016/S0140-6736(96)05468-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VQ467	8898041				2022-12-28	WOS:A1996VQ46700015
J	Lagna, G; Hata, A; HemmatiBrivanlou, A; Massague, J				Lagna, G; Hata, A; HemmatiBrivanlou, A; Massague, J			Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways	NATURE			English	Article							MESODERM INDUCTION; ACTIVIN-A; XENOPUS; RECEPTOR; EMBRYOS; HOMOLOG; INDUCER	THE TGF-beta/activin/BMP superfamily of growth factors signals through heteromeric receptor complexes of type I and type II serine/threonine kinase receptors(1) The signal originated by TGF-beta-like molecules appears to be transduced by a set of evolutionarily conserved proteins known as SMADs, which upon activation directly translocate to the nucleus where they may activate transcription(2), Five SMAD proteins have so far been characterized in vertebrates(1), These factors are related to the mediator of decapentaplegic (dpp) signalling, mothers against dpp (Mad), in Drosophila(3) and to the Sma genes from Caenorhabditis elegans(4). Smad1 and Smad2 have been shown to mimic the effects of BMP and activin, respectively, both in Xenopus and in mammalian cells(2,5-9), whereas Smad3 (a close homologue of Smad2) and the related protein DPC4, a tumour-suppressor gene product(10), mediate TGF-beta actions(11). We report here that DPC4 is essential for the function of Smad1 and Smad2 in pathways that signal mesoderm induction and patterning in Xenopus embryos, as well as antimitogenic and transcriptional responses in breast epithelial cells, DPC4 associates with Smad1 in response to BMP and with Smad2 in response to activin or TGF-beta. DPC4 is therefore a regulated partner of SMADs that function in different signalling pathways of the TGF-beta family.	MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOL EMBRYOL LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Rockefeller University				Massague, Joan/0000-0001-9324-8408				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Harland RM, 1991, METHODS CELL BIOL; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; LIU F, 1995, MOL CELL BIOL, V15, P3479; LIU F, 1996, NATURE, V381, P622; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	29	792	835	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					832	836		10.1038/383832a0	http://dx.doi.org/10.1038/383832a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893010				2022-12-28	WOS:A1996VQ14400066
J	Uusitalo, U; Feskens, EJM; Tuomilehto, J; Dowse, G; Haw, U; Fareed, D; Hemraj, F; Gareeboo, H; Alberti, KGMM; Zimmet, P				Uusitalo, U; Feskens, EJM; Tuomilehto, J; Dowse, G; Haw, U; Fareed, D; Hemraj, F; Gareeboo, H; Alberti, KGMM; Zimmet, P			Fall in total cholesterol concentration over five years in association with changes in fatty acid composition of cooking oil in Mauritius: Cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; PREVALENCE; POPULATION; DISEASE; LIPIDS	Objective-To determine the extent to which reducing the saturated fatty acid composition of a ubiquitously used cooking oil influenced changes in cholesterol concentration in the population during a five year intervention programme in Mauritius. Design-Cross sectional surveys in 1987 and 1992 determined mean total cholesterol concentrations in the population. A random sample of respondents in the 1992 survey completed a nutrition questionnaire that included questions on diet in the previous 24 hours. Setting-Mauritius. Intervention-In 1987 the government of Mauritius changed the composition of the commonly used cooking oil from being mostly palm oil (high in saturated fatty acids) to being wholly soya bean oil (high in unsaturated fatty acids). Subjects-5080 and 5162 subjects in 1987 and 1992 cross sectional surveys, 2059 subjects aged 30-64 years were randomly selected from the respondents of the 1992 survey to take part in the nutrition survey Main outcome measures-Fatty acid composition of phospholipids in pooled serum samples from men and women from the two surveys; measured and predicted change in serum cholesterol concentration. Results-From 1987 to 1992 total cholesterol concentrations fell significantly by 0.79 mmol/l (P<0.001) in men and 0.82 mmol/l (P<0.001) in women. The estimated intake of saturated fatty acids decreased by 3.5% of energy intake in men and by 3.6% in women, and the intake of polyunsaturated fatty acids increased by 5.5% and 5.6% of energy intake, respectively. These changes were reflected in changes in the fatty acid composition of serum phospholipids, and according to Keys' formula these changes explained much of the decrease in serum cholesterol concentrations (predicted decrease of 0.38 mmol/l in men and by 0.40 mmol/l in women). Conclusion-Dietary changes that entailed a reduction in the saturated fat content of a ubiquitous cooking oil explained most of the observed decrease in serum cholesterol concentration over five years in the population of Mauritius.	NATL PUBL HLTH INST,DIABET & GENET EPIDEMIOL UNIT,DEPT EPIDEMIOL & HLTH PROMOT,FIN-00300 HELSINKI,FINLAND; NATL INST PUBL HLTH & ENVIRONM,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,NL-3720 BA BILTHOVEN,NETHERLANDS; INT DIABET INST,MELBOURNE,VIC,AUSTRALIA; MINIST HLTH,PORT LOUIS,MAURITIUS; WHO,PORT LOUIS,MAURITIUS; UNIV NEWCASTLE UPON TYNE,HUMAN DIABET & METAB RES CTR,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Finland National Institute for Health & Welfare; Netherlands National Institute for Public Health & the Environment; World Health Organization; Newcastle University - UK			Zimmet, Paul/O-8486-2019; Feskens, Edith JM/A-3757-2012; Feskens, Edith/ABI-1446-2020	Zimmet, Paul/0000-0003-0627-0776; Feskens, Edith/0000-0001-5819-2488; Uusitalo, Ulla/0000-0001-9132-7727	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025446] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25446] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNS M, 1990, EUR J CLIN NUTR, V12, P911; BONANOME A, 1988, NEW ENGL J MED, V318, P1244, DOI 10.1056/NEJM198805123181905; DENKE MA, 1992, AM J CLIN NUTR, V56, P895, DOI 10.1093/ajcn/56.5.895; DOWSE GK, 1990, DIABETES, V39, P390, DOI 10.2337/diabetes.39.3.390; DOWSE GK, 1995, BRIT MED J, V311, P1255, DOI 10.1136/bmj.311.7015.1255; GAREEBOO H, 1988, HLTH LIFESTYLE MAURI; Houwelingen A. C. V., 1992, Early Human Development, V31, P97, DOI 10.1016/0378-3782(92)90038-I; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; LAVECCHIA C, 1993, SOZ PRAVENTIV MED, V38, pS3, DOI 10.1007/BF02026086; LI N, 1991, J HYPERTENS, V9, P859; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; NG TKW, 1991, AM J CLIN NUTR, V53, pS1015, DOI 10.1093/ajcn/53.4.1015S; REAVEN P, 1993, J CLIN INVEST, V91, P668, DOI 10.1172/JCI116247; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TUOMILEHTO J, 1993, J INTERN MED, V233, P187, DOI 10.1111/j.1365-2796.1993.tb00672.x; WILLETT W, 1990, NUT EPIDEMIOLOGY	16	74	76	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1044	1046						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898594	Green Published			2022-12-28	WOS:A1996VP74200023
J	Watt, GCM; Britton, A; Gilmour, WH; Moore, MR; Murray, GD; Robertson, SJ; Womersley, J				Watt, GCM; Britton, A; Gilmour, WH; Moore, MR; Murray, GD; Robertson, SJ; Womersley, J			Is lead in tap water still a public health problem? An observational study in Glasgow	BRITISH MEDICAL JOURNAL			English	Article							BLOOD LEAD; CHILDREN; EDINBURGH; EXPOSURE; ABILITY	Objective-To assess the relation between tap water lead and maternal blood lead concentrations and assess the exposure of infants to lead in tap water in a water supply area subjected to maximal water treatment to reduce plumbosolvency. Design-Postal questionnaire survey and collection of kettle water from a representative sample of mothers; blood and further water samples were collected in a random sample of households and households with raised water lead concentrations. Setting-Loch Katrine water supply area, Glasgow. Subjects-1812 mothers with a live infant born between October 1991 and September 1992. Blood lead concentrations were measured in 342 mothers. Main outcome measures-Mean geometric blood lead concentrations and the prevalence of raised tap water lead concentrations. Results-17% of households had water lead concentrations of 10 mu g/l (48.3 nmol/l) or more in 1993 compared with 49% of households in 1981. Tap water lead remained the main correlate of raised maternal blood lead concentrations and accounted for 62% and 76% of cases of maternal blood lead concentrations above 5 and 10 mu g/dl (0.24 and 0.48 mu mol/l) respectively. The geometric mean maternal blood lead concentration was 3.65 mu g/dl (0.18 mu mol/l) in a random sample of mothers and 3.16 mu g/dl (0.15 mu mol/l) in mothers whose tap water lead concentrations were consistently below 2 mu g/l (9.7 nmol/l). No mother in the study had a blood lead concentration above 25 mu g/dl (1.21 mu mol/l). An estimated 13% of infants were exposed via bottle feeds to tap water lead concentrations exceeding the World Health Organisation's guideline of 10 mu g/l (48.3 nmol/l). Conclusions-Tap water lead and maternal blood lead concentrations in the Loch Katrine water supply area have fallen substantially since the early 1980s. Maternal blood lead concentrations are well within limits currently considered safe for human health. Tap water lead is still a public health problem in relation to the lead exposure of bottle fed infants.	W SCOTLAND WATER AUTHOR,GLASGOW G22 6NU,LANARK,SCOTLAND; GREATER GLASGOW HLTH BOARD,GLASGOW G2 4JT,LANARK,SCOTLAND		Watt, GCM (corresponding author), UNIV GLASGOW,WOODSIDE HLTH CTR,DEPT GEN PRACTICE,GLASGOW G20 7LR,LANARK,SCOTLAND.		Moore, Michael R/C-4163-2012	Moore, Michael R/0000-0002-7012-9534; Murray, Gordon/0000-0001-9866-4734				Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; *CIT GLASG DISTR C, 1994, 1992 93 CGDC ENV HLT; *COMM EUR UN, 1995, 80778EEC COMM EUR UN; Delves HT, 1996, BRIT MED J, V313, P883; *DEP ENV, 1983, 18 DEP ENV POLL; *DEP ENV MIN AGR F, 1982, GLASG DUPL DIET STUD; FORWELL GD, 1989, ANN REPORT DIRECTOR, P59; FULTON M, 1987, LANCET, V1, P1221; HALLS DJ, 1984, ANALYST, V109, P1081, DOI 10.1039/an9840901081; LACEY RF, 1985, SCI TOTAL ENVIRON, V41, P235, DOI 10.1016/0048-9697(85)90144-5; MACDONALD C, 1994, ENV HLTH, V102, P165; MCINTOSH L, 1992, STRATHCLYDE WATER SE; MILLSTONE E, 1995, J ROY SOC HEALTH, V115, P347, DOI 10.1177/146642409511500603; MOORE MR, 1985, ENVIRON RES, V38, P67, DOI 10.1016/0013-9351(85)90073-8; MOORE MR, 1982, SCOTT MED J, V26, P354; MOORE MR, 1979, CLIN CHIM ACTA, V95, P113; MOORE MR, 1982, SCOTT MED J, V27, P112; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; POCOCK SJ, 1994, BRIT MED J, V309, P1189, DOI 10.1136/bmj.309.6963.1189; QUINN MJ, 1990, FOOD ADDIT CONTAM, V7, P387, DOI 10.1080/02652039009373904; RAAB GM, 1990, BRIT J DEV PSYCHOL, V8, P101, DOI 10.1111/j.2044-835X.1990.tb00826.x; Richards W., 1980, J I WATER ENG SCI, p[34, 315]; SCHWARTZ J, 1991, ARCH ENVIRON HEALTH, V46, P300, DOI 10.1080/00039896.1991.9934391; *STAND COMM AN, 1986, LEAD CADM FRESH WAT; STOEPPLER M, 1978, ANALYST, V103, P714, DOI 10.1039/an9780300714; Tong SL, 1996, BRIT MED J, V312, P1569, DOI 10.1136/bmj.312.7046.1569; *WHO, 1995, LEAD HLTH LOC HLTH A; *WHO, 1993, GUID DRINK WAT QUAL, V1; WROATH AS, 1995, 295 UK WAT IND RES	29	33	33	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					979	981						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892418	Green Published			2022-12-28	WOS:A1996VN91600023
J	Wevrick, R; Francke, U				Wevrick, R; Francke, U			Diagnostic test for the Prader-Willi syndrome by SNRPN expression in blood	LANCET			English	Article							MOLECULAR DIAGNOSIS; ANGELMAN SYNDROMES; CRITICAL REGION; GENE	Background Prader-Willi syndrome (PWS) is caused by alterations of the paternally derived chromosome 15 or by maternal uniparental disomy. The gene for the small nuclear ribonucleoprotein polypeptide N (SNRPN) is expressed only from the paternally derived chromosome 15, due to epigenetic imprinting. The SNRPN gene is not expressed in any patients with PWS regardless of the underlying cytogenetic or molecular causes. Methods To develop a rapid molecular diagnostic assay for PWS, we tested the expression of the SNRPN gene and a control gene in 9 patients with PWS and 40 control individuals by PCR analysis of reverse transcribed mRNA from blood leucocytes. We then tested 11 blood samples from patients with suspected PWS. Findings SNRPN expression could readily be detected in blood leucocytes by PCR analysis in all control samples but not in samples from known PWS patients. Four suspected plus were negative for SNRPN expression were found to have chromosome 15 rearrangements, while the diagnosis of PWS was excluded in the remaining seven with normal SNRPN expression based on clinical, molecular, and cytogenetic findings. Interpretation The SNRPN-expression test is rapid and reliable in the molecular diagnosis of Prader-Willi syndrome.	STANFORD UNIV,MED CTR,DEPT PAEDIAT,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT GENET,STANFORD,CA 94305	Stanford University; Stanford University	Wevrick, R (corresponding author), STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.			Wevrick, Rachel/0000-0002-3343-5794				DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DITTRICH B, 1992, HUM GENET, V90, P313; GLENN CC, 1993, HUM MOL GENET, V2, P2001, DOI 10.1093/hmg/2.12.2001; HOLM VA, 1993, PEDIATRICS, V91, P398; KNOLL JHM, 1993, AM J MED GENET, V46, P2, DOI 10.1002/ajmg.1320460103; MUTIRANGURA A, 1993, HUM MOL GENET, V2, P143, DOI 10.1093/hmg/2.2.143; NAKAO M, 1994, HUM MOL GENET, V3, P309, DOI 10.1093/hmg/3.2.309; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; ROBINSON WP, 1991, AM J HUM GENET, V49, P1219; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; 1996, AM J HUM GENET, V58, P1085	11	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1068	1069		10.1016/S0140-6736(96)04342-5	http://dx.doi.org/10.1016/S0140-6736(96)04342-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874459				2022-12-28	WOS:A1996VM88600012
J	Rubenfeld, GD; Crawford, SW				Rubenfeld, GD; Crawford, SW			Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: A case for evidence-based guidelines	ANNALS OF INTERNAL MEDICINE			English	Article						bone marrow transplantation; outcome assessment (health care); ventilators, mechanical; respiration, artificial; hepatorenal syndrome	RESPIRATORY-DISTRESS-SYNDROME; INTENSIVE-CARE; SURVIVAL; FAILURE; MALIGNANCY; DISEASE; ORDERS	Background: Mechanical ventilation after bone marrow transplantation is associated with a high mortality rate. The available literature provides conflicting predictors of outcome in relatively small study groups. Objective: To identify predictors of death and mortality trends in mechanically ventilated transplant recipients. Design: Nested case-control study. Setting: The Fred Hutchinson Cancer Research Center in Seattle, Washington, which specializes in bone marrow transplantation. Patients: All survivors (cases, n = 53) and a group of patients matched for year of transplantation who did not survive (controls, n = 106) were selected from all mechanically ventilated patients (n = 865) who received a bone marrow transplant between January 1980 and July 1992. Patients who received mechanical ventilation for less than 24 hours after a procedure or who received mechanical ventilation after a second bone marrow transplantation were excluded. Measurements: Surviving patients were defined as those who were alive 30 days after extubation and who were discharged from the hospital. Daily laboratory, physiologic, and treatment variables were collected. Results: Survival was statistically associated with younger age, lower score on the Acute Physiology and Chronic Health Evaluation III, and a shorter time from transplantation to intubation. There were no survivors among an estimated 398 patients who had lung injury and either required more than 4 hours of vasopressor support or had sustained hepatic and renal failure. Through the use of these factors, an accurate prediction of death could have been made in the first 4 days of mechanical ventilation for more than half of the patients who did not survive. During the past 5 years, survival rate has changed from 5% to 16% (P = 0.008), an increase that was not explained by changes in the age of the patients, the rate or timing of intubation, or the percentage of allogeneic transplants that were not HLA-identical. Conclusion: Of the patients who required mechanical ventilation after bone marrow transplantation, no one survived with lung injury combined with either hemodynamic instability or hepatic and renal failure. However, survival after mechanical ventilation seems to be improving.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center	Rubenfeld, GD (corresponding author), UNIV WASHINGTON, HARBORVIEW MED CTR, DIV PULM & CRIT CARE MED, 325 9TH AVE, BOX 359762, SEATTLE, WA 98104 USA.				NATIONAL CANCER INSTITUTE [P01CA018221, P01CA018029, P30CA015704] Funding Source: NIH RePORTER; NCI NIH HHS [CA-18029, CA-18221, CA-15704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFESSA B, 1992, MAYO CLIN PROC, V67, P117, DOI 10.1016/S0025-6196(12)61310-X; ALPERS A, 1995, JAMA-J AM MED ASSOC, V273, P156, DOI 10.1001/jama.273.2.156; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; BELLAMY PE, 1984, CRIT CARE MED, V12, P622, DOI 10.1097/00003246-198408000-00002; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; CHRISTAKIS NA, 1993, LANCET, V342, P642, DOI 10.1016/0140-6736(93)91759-F; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; CRAWFORD SW, 1992, AM REV RESPIR DIS, V145, P510, DOI 10.1164/ajrccm/145.3.510; CRAWFORD SW, 1988, AM REV RESPIR DIS, V137, P682, DOI 10.1164/ajrccm/137.3.682; CRAWFORD SW, 1991, WESTERN J MED, V155, P488; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; DEES A, 1990, NETH J MED, V37, P183; DENARDO SJ, 1989, CRIT CARE MED, V17, P4, DOI 10.1097/00003246-198901000-00002; FABERLANGENDOEN K, 1993, BONE MARROW TRANSPL, V12, P501; Fleiss JL, 1981, STAT METHODS RATES P; JAYES RL, 1993, JAMA-J AM MED ASSOC, V270, P2213, DOI 10.1001/jama.270.18.2213; Jonsen A R, 1986, Law Med Health Care, V14, P172; Kahneman D., 1987, JUDGMENT UNCERTAINTY; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LANKEN PN, 1991, AM REV RESPIR DIS, V144, P726, DOI 10.1164/ajrccm/144.3_Pt_1.726; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; MARTIN C, 1990, CRIT CARE MED, V18, P120, DOI 10.1097/00003246-199001000-00029; MCDONALD GB, 1993, ANN INTERN MED, V118, P255, DOI 10.7326/0003-4819-118-4-199302150-00003; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MURPHY DJ, 1993, ARCH INTERN MED, V153, P1641, DOI 10.1001/archinte.153.14.1641; PAZ HL, 1993, CHEST, V104, P527, DOI 10.1378/chest.104.2.527; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHUSTER DP, 1992, AM REV RESPIR DIS, V145, P508, DOI 10.1164/ajrccm/145.3.508; SHEWMON DA, 1987, STAT MED, V6, P535, DOI 10.1002/sim.4780060503; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; TODD K, 1994, CRIT CARE MED, V22, P171, DOI 10.1097/00003246-199401000-00030; TORRECILLA C, 1988, INTENS CARE MED, V14, P393, DOI 10.1007/BF00262895; 1992, JAMA-J AM MED ASSOC, V268, P2282	35	250	256	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					625	+		10.7326/0003-4819-125-8-199610150-00001	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM889	8849146				2022-12-28	WOS:A1996VM88900003
J	Bruner, AB; Joffe, A; Duggan, AK; Casella, JF; Brandt, J				Bruner, AB; Joffe, A; Duggan, AK; Casella, JF; Brandt, J			Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls	LANCET			English	Article							BRAIN IRON; MANIFESTATIONS; THERAPY; PERFORMANCE; BEHAVIOR; INFANTS; ANEMIA	Background Up to 25% of adolescent girls in the USA are iron deficient. This double-blind, placebo-controlled clinical trial assessed the effects of iron supplementation on cognitive function in adolescent girls with non-anaemic iron deficiency. Methods 716 girls who enrolled at four Baltimore high schools were screened for non-anaemic iron deficiency (serum ferritin less than or equal to 12 mu g/L with normal haemoglobin). 98 (13 . 7%) girls had non-anaemic iron deficiency of whom 81 were enrolled in the trial. Participants were randomly assigned oral ferrous sulphate (650 mg twice daily) or placebo for 8 weeks. The effect of iron treatment was assessed by questionnaires and haematological and cognitive tests, which were done before treatment started and repeated after the intervention. We used four tests of attention and memory to measure cognitive functioning. intention-to-treat and per-protocol analyses were done. Findings Of the 81 enrolled girls with non-anaemic iron deficiency, 78 (96%) completed the study (39 in each group). Five girls (three control, two treatment) developed anaemia during the intervention and were excluded from the analyses. Thus, 73 girls were included in the perprotocol analysis. Ethnic distribution, mean age, serum ferritin concentrations, haemoglobin concentrations, and cognitive test scores of the groups did not differ significantly at baseline. Postintervention haematological measures of iron Status were significantly improved in the treatment group (serum ferritin 27 . 3 vs 12 . 1 mu g/L, p<0 . 001). Regression analysis showed that girls who received iron performed better on a test of verbal learning and memory than girls in the control group (p<0 . 02). Interpretation In this urban population of non-anaemic iron-deficient adolescent girls, iron supplementation improved verbal learning and memory.	JOHNS HOPKINS UNIV, SCH MED, DEPT HEMATOL, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, DIV MED PSYCHOL, BALTIMORE, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Bruner, AB (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, DIV GEN PEDIAT, BALTIMORE, MD 21287 USA.			Brandt, Jason/0000-0001-7381-6244				BALLIN A, 1992, AM J DIS CHILD, V146, P803, DOI 10.1001/archpedi.1992.02160190035015; BEARD JL, 1993, PROG FOOD NUTR SCI, V17, P183; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; COOK JD, 1979, AM J CLIN NUTR, V32, P2115, DOI 10.1093/ajcn/32.10.2115; COOK JD, 1989, J INTERN MED, V226, P349, DOI 10.1111/j.1365-2796.1989.tb01408.x; DALLMAN PR, 1986, ANNU REV NUTR, V6, P13, DOI 10.1146/annurev.nu.06.070186.000305; DALLMAN PR, 1980, AM J CLIN NUTR, V33, P86, DOI 10.1093/ajcn/33.1.86; DALLMAN PR, 1982, SEMIN HEMATOL, V19, P19; FAIRBANKS V, 1995, HEMATOLOGY, P495; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; FORDY J, 1994, J HUM NUTR DIET, V7, P127, DOI 10.1111/j.1365-277X.1994.tb00420.x; GRONER JA, 1986, J ADOLESCENT HEALTH, V7, P44, DOI 10.1016/S0197-0070(86)80094-8; HALLBERG L, 1993, PEDIATR RES, V34, P680, DOI 10.1203/00006450-199311000-00023; LOZOFF B, 1987, PEDIATRICS, V79, P981; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; OSKI FA, 1983, PEDIATRICS, V71, P877; OSKI FA, 1979, AM J DIS CHILD, V133, P315, DOI 10.1001/archpedi.1979.02130030091017; OSKI FA, 1978, J PEDIATR-US, V92, P21, DOI 10.1016/S0022-3476(78)80063-8; POLLITT E, 1976, J PEDIATR-US, V88, P372, DOI 10.1016/S0022-3476(76)80250-8; *PSYCH ASS RES, 1990, VIS SEARCH ATT TEST; Schretlen D, 1996, CLIN NEUROPSYCHOL, V10, P80, DOI 10.1080/13854049608406666; SCOTT DE, 1967, J AMER MED ASSOC, V199, P897, DOI 10.1001/jama.199.12.897; Smith A., 1973, SYMBOL DIGIT MODALIT, DOI 10.1037/t27513-000; TUCKER DM, 1982, PHYSIOL BEHAV, V29, P737, DOI 10.1016/0031-9384(82)90248-7; VOORHESS ML, 1975, J PEDIATR-US, V86, P542, DOI 10.1016/S0022-3476(75)80144-2; WALTER T, 1994, BAILLIERE CLIN HAEM, V7, P815, DOI 10.1016/S0950-3536(05)80126-X; WEBB TE, 1973, J PEDIATR-US, V82, P827, DOI 10.1016/S0022-3476(73)80074-5; WILLIAMS WJ, 1995, WILLIAMS HEMATOLOGY, P8; YEHUDA S, 1989, AM J CLIN NUTR, V50, P618, DOI 10.1093/ajcn/50.3.618	29	403	418	1	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	1996	348	9033					992	996		10.1016/S0140-6736(96)02341-0	http://dx.doi.org/10.1016/S0140-6736(96)02341-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855856	hybrid			2022-12-28	WOS:A1996VM02700012
J	Renwick, D				Renwick, D			Caring for older people - Community care and social services	BRITISH MEDICAL JOURNAL			English	Article								The aim of community care is to enable people with various types of disability to live in their own homes, rather than in institutions. This involves the provision of support and services at home by various agencies. After a critical report in 1986 identified problems with coordination and flexibility of community care services, the white paper Caring for People (1989) stated the government's aim to provide a ''needs led,'' responsive range of services, promoting maximum independence of those wishing to five at home rather than enter institutional care. New arrangements were introduced in 1993, involving a formal assessment procedure and the production of a personalised care plan for each individual, incorporating services provided by private and voluntary agencies as well as by social services departments. This article describes the components of community care services supplied by local social services authorities, including housing adaptations, equipment, telephones and alarms, home care, meals, and respite care.	ST JAMESS UNIV TRUST HOSP,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Saint James's University Hospital								Barodawala S, 1996, BRIT MED J, V313, P740; Groves T., 1993, COUNTDOWN COMMUNITY; MANDELSTAM M, 1994, GET EQUIPMENT DISABI; MEREDITH B, 1993, COMMUNITY CARE HDB N; Pushpangadan M, 1996, BRIT MED J, V313, P805; Wanklyn P, 1996, BRIT MED J, V313, P218, DOI 10.1136/bmj.313.7051.218	6	6	7	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					869	872						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870580				2022-12-28	WOS:A1996VL55900032
J	Madireddi, MT; Coyne, RS; Smothers, JF; Mickey, KM; Yao, MC; Allis, CD				Madireddi, MT; Coyne, RS; Smothers, JF; Mickey, KM; Yao, MC; Allis, CD			Pdd1p, a novel chromodomain-containing protein, links heterochromatin assembly and DNA elimination in Tetrahymena	CELL			English	Article							POSITION-EFFECT VARIEGATION; STYLONYCHIA-MYTILUS; CHROMOSOME ELIMINATION; THERMOPHILA; CHROMATIN; DOMAIN; REARRANGEMENTS; IDENTIFICATION; SEQUENCES; GENE	During Tetrahymena conjugation, programmed DNA degradation occurs in two separate nuclei. Thousands of germline-specific deletion elements are removed from the genome of the developing somatic macronucleus, and the old parental macronucleus is degraded by an apoptotic mechanism. An abundant polypeptide, Pdd1p (formerly p65), localizes to both of these nuclei at the time of DNA degradation. Here we report that, in developing macronuclei, Pdd1p localizes to electron-dense, heterochromatic structures that contain germline-specific deletion elements. Pdd1p also associates with parental macronuclei during terminal stages of apoptosis. Sequencing of the PDD1 gene reveals it to be a member of the chromodomain family, suggesting a molecular link between heterochromatin assembly and programmed DNA degradation.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,PROGRAM MOL & CELLULAR BIOL,SEATTLE,WA 98104	University of Rochester; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026210, R01GM053512, F32GM016129, R37GM053512] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26210, GM16129, GM53512] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; ALLIS CD, 1986, J BIOL CHEM, V261, P1941; AMMERMANN D, 1971, CHROMOSOMA, V33, P209, DOI 10.1007/BF00285634; AMMERMANN D, 1974, CHROMOSOMA, V45, P401, DOI 10.1007/BF00283386; AUSTERBERRY CF, 1984, P NATL ACAD SCI-BIOL, V81, P7383, DOI 10.1073/pnas.81.23.7383; BALDWIN GS, 1983, NATURE, V301, P435, DOI 10.1038/301435a0; BARNARD R, 1994, BIOTECHNIQUES, V16, P251; BAROICH A, 1992, NUCLEIC ACIDS RES, V20, P2013; BEERMANN S, 1977, CHROMOSOMA, V60, P297, DOI 10.1007/BF00292858; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; Boveri T., 1887, ANAT ANZEIGER, V22, P685; BRUNK CF, 1990, NUCLEIC ACIDS RES, V18, P323, DOI 10.1093/nar/18.2.323; CALLAHAN RC, 1984, CELL, V36, P441, DOI 10.1016/0092-8674(84)90237-X; Chalker DL, 1996, MOL CELL BIOL, V16, P3658; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COYNE RS, 1996, IN PRESS ANN REV GEN, V30; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; DAVIS MC, 1992, DEV BIOL, V154, P419, DOI 10.1016/0012-1606(92)90080-Z; Dernburg AF, 1996, CELL, V86, P135, DOI 10.1016/S0092-8674(00)80084-7; EISSENBERG JC, 1994, J BIOL CHEM, V269, P1; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; FRELS JS, 1996, MOL BIOL CELL, V5, P755; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GODAY C, 1984, SCIENCE, V224, P411, DOI 10.1126/science.224.4647.411; GODISKA R, 1990, CELL, V61, P1237, DOI 10.1016/0092-8674(90)90688-B; GODISKA R, 1993, GENE DEV, V7, P2357, DOI 10.1101/gad.7.12a.2357; GUTTMAN SD, 1980, CELL, V22, P299, DOI 10.1016/0092-8674(80)90177-4; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HENIKOFF S, 1994, GENETICS, V138, P1; HENNIG W, 1988, GERM LINE SOMA DIFFE, P176; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; KLAR AJS, 1993, CURR OPIN GENET DEV, V3, P745, DOI 10.1016/S0959-437X(05)80093-0; Klobutcher LA, 1991, CURR OPIN GENET DEV, V1, P397, DOI 10.1016/S0959-437X(05)80306-5; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; KUBOTA S, 1993, CHROMOSOMA, V102, P163, DOI 10.1007/BF00387731; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; Madireddi Malavi T., 1995, Seminars in Developmental Biology, V6, P305, DOI 10.1016/S1044-5781(06)80072-1; MADIREDDI MT, 1994, DEV BIOL, V165, P418, DOI 10.1006/dbio.1994.1264; MARTINDALE DW, 1982, EXP CELL RES, V140, P227, DOI 10.1016/0014-4827(82)90172-0; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MARTINDALE DW, 1983, MOL CELL BIOL, V3, P1857, DOI 10.1128/MCB.3.10.1857; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; MEYER GF, 1980, CHROMOSOMA, V77, P285, DOI 10.1007/BF00286054; Mpoke S, 1996, EXP CELL RES, V225, P357, DOI 10.1006/excr.1996.0186; Muller F, 1996, BIOESSAYS, V18, P133, DOI 10.1002/bies.950180209; NAKAI Y, 1991, CYTOGENET CELL GENET, V56, P196, DOI 10.1159/000133087; NAKAI Y, 1995, CHROMOSOME RES, V3, P321, DOI 10.1007/BF00713071; NEIL JC, 1981, NATURE, V291, P675, DOI 10.1038/291675a0; OCHMAN H, 1988, GENETICS, V120, P621; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; SPRADLING A, 1980, P NATL ACAD SCI USA, V17, P1096; SPRADLING AC, 1993, COLD SPRING HARB SYM, V58, P585, DOI 10.1101/SQB.1993.058.01.065; SPRADLING AC, 1993, EVOLUTIONARY CONSERV, V4, P39; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; TOBLER H, 1988, GERM LINE SOMA DIFFE, P1; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P81; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEISKEBENNER A, 1985, DIFFERENTIATION, V28, P225, DOI 10.1111/j.1432-0436.1985.tb00829.x; WENKERT D, 1984, J CELL BIOL, V98, P2107, DOI 10.1083/jcb.98.6.2107; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; YAO M, 1974, CHROMOSOMA, V48, P1; YAO MC, 1982, J CELL BIOL, V92, P783, DOI 10.1083/jcb.92.3.783; Yao MC, 1996, TRENDS GENET, V12, P26, DOI 10.1016/0168-9525(96)81385-0; YAO MC, 1984, CELL, V36, P433, DOI 10.1016/0092-8674(84)90236-8; YOKOYAMA RW, 1982, NUCLEIC ACIDS RES, V12, P6103	71	138	145	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					75	84		10.1016/S0092-8674(00)81324-0	http://dx.doi.org/10.1016/S0092-8674(00)81324-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858150	hybrid			2022-12-28	WOS:A1996VL69500010
J	Verreault, A; Kaufman, PD; Kobayashi, R; Stillman, B				Verreault, A; Kaufman, PD; Kobayashi, R; Stillman, B			Nucleosome assembly by a complex of CAF-1 and acetylated histones H3/H4	CELL			English	Article							DNA-REPLICATION INVITRO; NEWLY SYNTHESIZED HISTONES; NEGATIVE REGULATOR; CHROMATIN; PROTEINS; TRANSCRIPTION; YEAST; CELLS; RAS; H4	Chromatin assembly factor 1 (CAF-1) assembles nucleosomes in a replication-dependent manner. The small subunit of CAF-1 (p48) is a member of a highly conserved subfamily of WD-repeat proteins. There are at least two members of this subfamily in both human (p46 and p48) and yeast cells (Hat2p, a subunit of the B-type H4 acetyltransferase, and Msi1p). Human p48 can bind to histone H4 in the absence of CAF-1 p150 and p60. p48, also a known subunit of a histone deacetylase, copurifies with a chromatin assembly complex (CAC), which contains the three subunits of CAF-1 (p150, p60, p48) and H3 and H4, and promotes DNA replication-dependent chromatin assembly. CAC histone H4 exhibits a novel pattern of lysine acetylation that overlaps with, but is distinct from, that reported for newly synthesized H4 isolated from nascent chromatin. Our data suggest that CAC is a key intermediate of the de novo nucleosome assembly pathway and that the p48 subunit participates in other aspects of histone metabolism.			Verreault, A (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Stillman, Bruce/0000-0002-9453-4091; Kaufman, Paul/0000-0003-3089-313X	NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANERJEE S, 1991, NUCLEIC ACIDS RES, V19, P5999, DOI 10.1093/nar/19.21.5999; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; DAVIE JR, 1982, ANAL BIOCHEM, V120, P276, DOI 10.1016/0003-2697(82)90348-7; DELCUVE GP, 1992, ANAL BIOCHEM, V200, P339, DOI 10.1016/0003-2697(92)90475-M; Harlow E., 1988, ANTIBODIES LAB MANUA; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; LUCCHINI R, 1995, NATURE, V374, P276, DOI 10.1038/374276a0; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1996, CELL, V84, P176; NOLL M, 1977, J MOL BIOL, V109, P303; PERRY CA, 1991, EXP CELL RES, V196, P337, DOI 10.1016/0014-4827(91)90269-Z; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Sambrook J., 2002, MOL CLONING LAB MANU; SIMANIS V, 1985, VIROLOGY, V144, P80; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Thomas J O, 1978, Methods Cell Biol, V18, P429; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TYLER JK, 1996, IN PRESS MOL CELL BI; Wolffe A., 1995, CHROMATIN STRUCTURE; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5	44	518	526	1	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					95	104		10.1016/S0092-8674(00)81326-4	http://dx.doi.org/10.1016/S0092-8674(00)81326-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858152	Bronze			2022-12-28	WOS:A1996VL69500012
J	Moll, S				Moll, S			Sister Joseph's node in carcinoma of the cecum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Moll, S (corresponding author), DUKE UNIV,MED CTR,DURHAM,NC 27710, USA.								0	4	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1996	335	21					1568	1568		10.1056/NEJM199611213352105	http://dx.doi.org/10.1056/NEJM199611213352105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT341	8900090				2022-12-28	WOS:A1996VT34100005
J	Monafo, WW				Monafo, WW			Current concepts - Initial management of burns	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							THERMAL-INJURY; SHOCK RESUSCITATION; SILVER SULFADIAZINE; INHALATION INJURY; RANDOMIZED TRIAL; CLINICAL-TRIAL; EARLY EXCISION; CHILDREN; THERAPY; MORTALITY		WASHINGTON UNIV,SCH MED,BURN TRAUMA SURG CRIT CARE SECT,ST LOUIS,MO 63110	Washington University (WUSTL)	Monafo, WW (corresponding author), WASHINGTON UNIV,SCH MED,DEPT SURG,1 BARNES HOSP PLAZA,SUITE 6104,QUEENY TOWER ST,ST LOUIS,MO 63110, USA.							AHN ST, 1991, ARCH SURG-CHICAGO, V126, P499; ARTURSON G, 1979, SCAND J PLAST RECONS, V13, P29, DOI 10.3109/02844317909013016; Arturson G, 1996, BURNS, V22, P255, DOI 10.1016/0305-4179(95)00153-0; BAXTER CR, 1978, SURG CLIN N AM, V58, P1313; Brigham Peter A., 1996, Journal of Burn Care and Rehabilitation, V17, P95, DOI 10.1097/00004630-199603000-00003; CIOFFI WG, 1991, ANN SURG, V214, P213, DOI 10.1097/00000658-199109000-00004; Cobb JP, 1996, JAMA-J AM MED ASSOC, V275, P1192, DOI 10.1001/jama.275.15.1192; DEITCH EA, 1983, J TRAUMA, V23, P895, DOI 10.1097/00005373-198310000-00009; DEMLING RH, 1978, J TRAUMA, V18, P124, DOI 10.1097/00005373-197802000-00009; DESAI MH, 1996, P AM BURN ASS 28 ANN, P48; EDSTROM LE, 1979, SCAND J PLAST RECONS, V13, P131, DOI 10.3109/02844317909013040; ENGRAV LH, 1983, J TRAUMA, V23, P1001, DOI 10.1097/00005373-198311000-00007; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; GAMELLI RL, 1993, SURG GYNECOL OBSTET, V177, P115; GERDING RL, 1990, ANN EMERG MED, V19, P121, DOI 10.1016/S0196-0644(05)81793-7; GILPIN DA, 1994, ANN SURG, V220, P19, DOI 10.1097/00000658-199407000-00004; GIROIR BP, 1994, AM J PHYSIOL, V267, pH118, DOI 10.1152/ajpheart.1994.267.1.H118; GOODWIN CW, 1983, ANN SURG, V197, P520, DOI 10.1097/00000658-198305000-00004; GOODWIN CW, 1983, J TRAUMA, V23, P510, DOI 10.1097/00005373-198306000-00012; Gore DC, 1996, J TRAUMA, V40, P356, DOI 10.1097/00005373-199603000-00005; GORETSKY MJ, 1995, J PEDIATR SURG, V30, P620, DOI 10.1016/0022-3468(95)90145-0; GRAVES TA, 1988, J TRAUMA, V28, P1656, DOI 10.1097/00005373-198812000-00007; GRAY DT, 1982, AM J SURG, V144, P76, DOI 10.1016/0002-9610(82)90605-5; Grube B J, 1988, J Burn Care Rehabil, V9, P249, DOI 10.1097/00004630-198805000-00002; GUNN ML, 1989, J TRAUMA, V29, P1261, DOI 10.1097/00005373-198909000-00013; HALL KV, 1978, BURNS, V5, P107, DOI 10.1016/0305-4179(78)90054-2; HEIMBACH D, 1988, ANN SURG, V208, P313, DOI 10.1097/00000658-198809000-00008; HERNDON DN, 1989, ANN SURG, V209, P547, DOI 10.1097/00000658-198905000-00006; HUANG PP, 1995, ANN SURG, V221, P543, DOI 10.1097/00000658-199505000-00012; Kealey GP, 1996, J AM COLL SURGEONS, V182, P201; LALONDE C, 1991, SURGERY, V109, P645; LEVINE BA, 1978, J TRAUMA, V18, P188, DOI 10.1097/00005373-197803000-00007; LUND T, 1989, AM J PHYSIOL, V256, pH940, DOI 10.1152/ajpheart.1989.256.4.H940; MATSUDA T, 1995, WORLD J SURG, V19, P287, DOI 10.1007/BF00308640; MONAFO WW, 1990, DRUGS, V40, P364, DOI 10.2165/00003495-199040030-00004; MONAFO WW, 1984, SURGERY, V95, P129; MONAFO WW, 1978, ARCH SURG-CHICAGO, V113, P397; Nguyen TT, 1996, ANN SURG, V223, P14, DOI 10.1097/00000658-199601000-00004; PITT RM, 1987, J SURG RES, V42, P693, DOI 10.1016/0022-4804(87)90013-8; POULSEN TD, 1991, BURNS, V17, P59, DOI 10.1016/0305-4179(91)90014-8; Rennekampff HO, 1996, J SURG RES, V62, P288, DOI 10.1006/jsre.1996.0210; RUE LW, 1993, ARCH SURG-CHICAGO, V128, P772; RUE LW, 1993, J TRAUMA, V34, P662, DOI 10.1097/00005373-199305000-00008; Saffle Jeffrey R., 1995, Journal of Burn Care and Rehabilitation, V16, P219, DOI 10.1097/00004630-199505000-00002; SHERIDAN RL, 1995, J TRAUMA, V39, P854, DOI 10.1097/00005373-199511000-00008; SHERIDAN RL, 1996, P AM BURN ASS 28 ANN, P49; SMITH G, 1962, LANCET, V1, P816; SNELLING CFT, 1992, J TRAUMA, V33, P258, DOI 10.1097/00005373-199208000-00016; SOKAWA J, 1981, ANN SURG, V193, P237; TOMPKINS RG, 1988, ANN SURG, V208, P577, DOI 10.1097/00000658-198811000-00006	50	110	113	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1996	335	21					1581	1586		10.1056/NEJM199611213352108	http://dx.doi.org/10.1056/NEJM199611213352108			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT341	8900093				2022-12-28	WOS:A1996VT34100008
J	Balbach, J; Forge, V; Lau, WS; vanNuland, NAJ; Brew, K; Dobson, CM				Balbach, J; Forge, V; Lau, WS; vanNuland, NAJ; Brew, K; Dobson, CM			Protein folding monitored at individual residues during a two-dimensional NMR experiment	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; MOLTEN GLOBULE STATE; ALPHA-LACTALBUMIN; STOPPED-FLOW; SPECTROSCOPY; EXCHANGE; LYSOZYME; INTERMEDIATE; EQUILIBRIUM; RATES	An approach is described to monitor directly at the level of individual residues the formation of structure during protein folding. A two-dimensional heteronuclear nuclear magnetic resonance (NMR) spectrum was recorded after the rapid initiation of the refolding of a protein labeled with nitrogen-15. The intensities and line shapes of the cross peaks in the spectrum reflected the kinetic time course of the folding events that occurred during the spectral accumulation. The method was used to demonstrate the cooperative nature of the acquisition of the native main chain fold of apo bovine alpha-lactalbumin. The general approach, however, should be applicable to the investigation of a wide range of chemical reactions.	UNIV OXFORD,OXFORD CTR MOL SCI,NEW CHEM LAB,OXFORD OX1 3QT,ENGLAND; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOL BIOL,MIAMI,FL 33101	University of Oxford; University of Miami			Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019	Brew, Keith/0000-0003-1306-1032; 				ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P5681; Arai M, 1996, FOLD DES, V1, P275, DOI 10.1016/S1359-0278(96)00041-7; BALBACH J, 1995, NAT STRUCT BIOL, V2, P865, DOI 10.1038/nsb1095-865; BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BAX A, 1994, CURR OPIN STRUC BIOL, V4, P738, DOI 10.1016/S0959-440X(94)90173-2; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BODENHAUSEN G, 1982, J AM CHEM SOC, V104, P1304, DOI 10.1021/ja00369a027; CHEN BL, 1989, BIOCHEMISTRY-US, V28, P691, DOI 10.1021/bi00428a042; Dill KA, 1996, CURR OPIN STRUC BIOL, V6, P1, DOI 10.1016/S0959-440X(96)80087-X; DOBSON CM, 1984, BIOCHEMISTRY-US, V23, P4267, DOI 10.1021/bi00314a001; Dobson CM., 1992, CURR OPIN STRUC BIOL, V2, P6; Engelhard M, 1996, FOLD DES, V1, pR31, DOI 10.1016/S1359-0278(96)00016-8; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; ERNST RR, 1987, PRINCIPLES NUCLEAR M, pCH9; EVANS PA, 1994, CURR OPIN STRUC BIOL, V4, P100, DOI 10.1016/S0959-440X(94)90066-3; FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431; FRIEDEN C, 1993, PROTEIN SCI, V2, P2007, DOI 10.1002/pro.5560021202; GROBLER JA, 1994, J BIOL CHEM, V269, P5106; HOELTZLI SD, 1995, P NATL ACAD SCI USA, V92, P9318, DOI 10.1073/pnas.92.20.9318; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KIEFHABER T, 1995, NATURE, V375, P513, DOI 10.1038/375513a0; KIM PS, 1990, ANNU REV BIOCHEM, V59, P63; KUHNE RO, 1979, J MAGN RESON, V35, P39, DOI 10.1016/0022-2364(79)90077-5; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P894; Liu XY, 1996, BIOCHEMISTRY-US, V35, P4306, DOI 10.1021/bi952270d; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; Miranker AD, 1996, CURR OPIN STRUC BIOL, V6, P31, DOI 10.1016/S0959-440X(96)80092-3; MUCKE M, 1994, BIOCHEMISTRY-US, V33, P14608; OLSEN HB, 1993, J AM CHEM SOC, V115, P1456, DOI 10.1021/ja00057a033; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; SERRANO L, 1994, CURR OPIN STRUC BIOL, V4, P107, DOI 10.1016/S0959-440X(94)90067-1; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUGAI S, 1994, ADV BIOPHYS, V30, P37, DOI 10.1016/0065-227X(94)90010-8; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281; [No title captured]	42	128	128	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1161	1163		10.1126/science.274.5290.1161	http://dx.doi.org/10.1126/science.274.5290.1161			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895458				2022-12-28	WOS:A1996VT33500044
J	Estabrook, CH; Kind, R				Estabrook, CH; Kind, R			The nature of the 660-kilometer upper-mantle seismic discontinuity from precursors to the PP phase	SCIENCE			English	Article							TRANSITION ZONE; BENEATH; REFLECTIONS; CONSTRAINTS; VELOCITIES; SHARPNESS; MODELS; EARTH	Global Seismic Network data were used to image upper-mantle seismic discontinuities. Stacks of phases that precede the PP phase, thought to be underside reflections from the upper-mantle discontinuities at depths of 410 and 660 kilometers, show that the reflection from 410 kilometers is present, but the reflection from 660 kilometers is not observed. A continuous Lame's constant lambda and seismic parameter at the 660-kilometer discontinuity explain the missing underside P reflections and lead to a P-wave velocity jump of only 2 percent, whereas the S-wave velocity and density remain unchanged with respect to previous global models. The model deemphasizes the role of Lame's constant lambda with regard to the shear modulus and constrains the mineralogical composition across the discontinuity.	FREE UNIV BERLIN,D-1000 BERLIN,GERMANY	Free University of Berlin	Estabrook, CH (corresponding author), GEOFORSCHUNGSZENTRUM POTSDAM,D-14473 POTSDAM,GERMANY.							Aki K., 1980, QUANTITATIVE SEISMOL, VI and II, DOI [10.1002/gj.3350160110, DOI 10.1002/GJ.3350160110]; BENZ HM, 1993, NATURE, V365, P147, DOI 10.1038/365147a0; BOCK G, 1991, GEOPHYS J INT, V107, P117, DOI 10.1111/j.1365-246X.1991.tb01161.x; Bostock MG, 1996, GEOPHYS RES LETT, V23, P1593, DOI 10.1029/96GL00972; BOWMAN JR, 1990, GEOPHYS J INT, V101, P411, DOI 10.1111/j.1365-246X.1990.tb06578.x; Bunge HP, 1996, NATURE, V379, P436, DOI 10.1038/379436a0; Christensen UR, 1996, EARTH PLANET SC LETT, V140, P27, DOI 10.1016/0012-821X(96)00023-4; CHRISTENSEN UR, 1984, J GEOPHYS RES, V89, P4389, DOI 10.1029/JB089iB06p04389; DUFFY TS, 1989, J GEOPHYS RES-SOLID, V94, P1895, DOI 10.1029/JB094iB02p01895; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; FORTE AM, 1995, SCIENCE, V268, P386, DOI 10.1126/science.268.5209.386; Gossler J, 1996, EARTH PLANET SC LETT, V138, P1, DOI 10.1016/0012-821X(95)00215-X; GRAND SP, 1984, GEOPHYS J ROY ASTR S, V76, P399, DOI 10.1111/j.1365-246X.1984.tb05053.x; HAGER BH, 1989, PHILOS T R SOC A, V328, P309, DOI 10.1098/rsta.1989.0038; IRIFUNE T, 1987, PHYS EARTH PLANET IN, V45, P324, DOI 10.1016/0031-9201(87)90040-9; ITA J, 1992, J GEOPHYS RES-SOL EA, V97, P6849, DOI 10.1029/92JB00068; ITO E, 1989, J GEOPHYS RES-SOLID, V94, P10637, DOI 10.1029/JB094iB08p10637; Jaeger J. C., 1969, ELASTICITY FRACTURE; JONES LE, 1992, J GEOPHYS RES-SOL EA, V97, P8765, DOI 10.1029/92JB00887; KENNETT BLN, 1991, GEOPHYS J INT, V105, P429, DOI 10.1111/j.1365-246X.1991.tb06724.x; KENNETT BLN, 1995, GEOPHYS J INT, V122, P108, DOI 10.1111/j.1365-246X.1995.tb03540.x; KIND R, 1979, J GEOPHYS-Z GEOPHYS, V45, P373; KIND R, 1976, J GEOPHYS-Z GEOPHYS, V42, P191; LEES AC, 1983, J GEOPHYS RES, V88, P8145, DOI 10.1029/JB088iB10p08145; NEELE F, UNPUB; PETERSEN N, 1993, GEOPHYS RES LETT, V20, P859, DOI 10.1029/93GL00684; RYBERG T, 1996, ANN GEOPHYS, pC68; SHEARER PM, 1991, J GEOPHYS RES-SOL EA, V96, P18147, DOI 10.1029/91JB01592; SHEARER PM, 1993, GEOPHYS J INT, V115, P878, DOI 10.1111/j.1365-246X.1993.tb01499.x; STAMMLER K, 1992, GEOPHYS RES LETT, V19, P1563, DOI 10.1029/92GL01504; TACKLEY PJ, 1994, J GEOPHYS RES-SOL EA, V99, P15877, DOI 10.1029/94JB00853; VACHER P, 1996, ANN GEOPHYS, pC41; VANDERHILST RD, 1993, GEOPHYS J INT, V115, P264, DOI 10.1111/j.1365-246X.1993.tb05603.x; Vinnik L, 1996, GEOPHYS RES LETT, V23, P1485, DOI 10.1029/96GL01261; VINNIK LP, 1977, PHYS EARTH PLANET IN, V15, P39, DOI 10.1016/0031-9201(77)90008-5; WAJEMAN N, 1988, GEOPHYS RES LETT, V15, P669, DOI 10.1029/GL015i007p00669; WALCK MC, 1984, GEOPHYS J ROY ASTR S, V76, P697, DOI 10.1111/j.1365-246X.1984.tb01918.x; WICKS CW, 1991, GEOPHYS J INT, V107, P279; [No title captured]	39	72	72	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1179	1182		10.1126/science.274.5290.1179	http://dx.doi.org/10.1126/science.274.5290.1179			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895464				2022-12-28	WOS:A1996VT33500050
J	Lundquist, PM; Wortmann, R; Geletneky, C; Twieg, RJ; Jurich, M; Lee, VY; Moylan, CR; Burland, DM				Lundquist, PM; Wortmann, R; Geletneky, C; Twieg, RJ; Jurich, M; Lee, VY; Moylan, CR; Burland, DM			Organic glasses: A new class of photorefractive materials	SCIENCE			English	Article							POLYMER; GAIN	The performance of amorphous organic photorefractive (PR) materials in applications such as optical data storage is generally limited by the concentration of active molecules (chromophores) that can be incorporated into the host without forming a crystalline material with poor optical quality. In polymeric PR systems described previously, performance has been limited by the necessity of devoting a large fraction of the material to inert polymer and plasticizing components in order to ensure compositional stability. A new class of organic PR materials composed of multifunctional glass-forming organic chromophores is described that have long-term stability and greatly improved PR properties.	IBM CORP,ALMADEN RES CTR,DIV RES,SAN JOSE,CA 95120	International Business Machines (IBM)								ASHKIN A, 1966, APPL PHYS LETT, V9, P72, DOI 10.1063/1.1754607; BELSKY I, 1974, J ORG CHEM, V39, P989, DOI 10.1021/jo00921a028; Bernal MP, 1996, APPL OPTICS, V35, P2360, DOI 10.1364/AO.35.002360; CHEN FS, 1967, J APPL PHYS, V38, P3418, DOI 10.1063/1.1710138; CHEN FS, 1968, APPL PHYS LETT, V13, P223, DOI 10.1063/1.1652580; Cox AM, 1996, APPL PHYS LETT, V68, P2801, DOI 10.1063/1.116329; DONCKERS MCJM, 1993, OPT LETT, V18, P1044, DOI 10.1364/OL.18.001044; DUCHARME S, 1991, PHYS REV LETT, V66, P1846, DOI 10.1103/PhysRevLett.66.1846; EICH M, 1989, J OPT SOC AM B, V6, P1590, DOI 10.1364/JOSAB.6.001590; GUNTER P, 1988, PHOTOREFRACTIVE MAT, V1; GUNTER P, 1989, PHOTOREFRACTIVE MAT, V2; HEANUE JF, 1994, SCIENCE, V265, P749, DOI 10.1126/science.265.5173.749; LIPHARDT M, 1994, SCIENCE, V263, P367, DOI 10.1126/science.263.5145.367; LUNDQUIST PM, 1996, OPT LETT, V12, P890; MARDER SR, 1991, SCIENCE, V252, P103, DOI 10.1126/science.252.5002.103; MEERHOLZ K, 1994, NATURE, V371, P497, DOI 10.1038/371497a0; MEERHOLZ K, 1996, C LASERS ELECTROOPT, V9, P497; MOERNER WE, 1994, J OPT SOC AM B, V11, P320, DOI 10.1364/JOSAB.11.000320; MOERNER WE, 1994, CHEM REV, V94, P127, DOI 10.1021/cr00025a005; MOERNER WE, 1991, P SOC PHOTO-OPT INST, V1564, P278; POGA C, 1995, P SOC PHOTO-OPT INS, V2526, P82, DOI 10.1117/12.217306; Poga C, 1996, APPL PHYS LETT, V69, P1047, DOI 10.1063/1.116926; SILENCE SM, 1994, PHYS REV LETT, V73, P2047, DOI 10.1103/PhysRevLett.73.2047; SILENCE SM, 1995, J PHYS CHEM-US, V99, P4096, DOI 10.1021/j100012a034; TWIEG RJ, 1996, SCI TECHNOLOGY ORGAN; VANHEERDEN PJ, 1963, APPL OPTICS, V2, P393, DOI 10.1364/AO.2.000393; Volodin BL, 1996, OPT LETT, V21, P519, DOI 10.1364/OL.21.000519; WALSH CA, 1992, J OPT SOC AM B, V9, P1642, DOI 10.1364/JOSAB.9.001642; WALSH CA, 1993, J OPT SOC AM B, V10, P753, DOI 10.1364/JOSAB.10.000753; WORTMANN R, IN PRESS J CHEM PHYS; Yu LP, 1996, ACCOUNTS CHEM RES, V29, P13, DOI 10.1021/ar9501176; Zhang Y, 1996, ADV MATER, V8, P111, DOI 10.1002/adma.19960080203; ZHANG Y, 1995, APPL PHYS LETT, V66, P256, DOI 10.1063/1.114194; ZOBEL O, 1995, ADV MATER, V11, P911	34	174	180	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1182	1185		10.1126/science.274.5290.1182	http://dx.doi.org/10.1126/science.274.5290.1182			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895465				2022-12-28	WOS:A1996VT33500051
J	Gold, HS; Moellering, RC				Gold, HS; Moellering, RC			Drug therapy - Antimicrobial-drug resistance	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SPECTRUM BETA-LACTAMASES; EXPERIMENTAL PENICILLIN-RESISTANT; NUMEROUS MEDICAL-CENTERS; ENTEROCOCCUS-FAECIUM; VANCOMYCIN-RESISTANT; KLEBSIELLA-PNEUMONIAE; STREPTOCOCCUS-PNEUMONIAE; ANTIBIOTIC-RESISTANCE; NOSOCOMIAL OUTBREAK; 3RD-GENERATION CEPHALOSPORINS		DEACONESS HOSP, DEPT MED, BOSTON, MA 02215 USA; DEACONESS HOSP, DIV INFECT DIS, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School								APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; BATES J, 1994, J ANTIMICROB CHEMOTH, V34, P507, DOI 10.1093/jac/34.4.507; BILLOTKLEIN D, 1994, J BACTERIOL, V176, P2398, DOI 10.1128/JB.176.8.2398-2405.1994; BINGEN E, 1990, J ANTIMICROB CHEMOTH, V26, P619, DOI 10.1093/jac/26.5.619; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; BOYLE JF, 1993, J CLIN MICROBIOL, V31, P1280, DOI 10.1128/JCM.31.5.1280-1285.1993; BRUNBUISSON C, 1987, LANCET, V2, P302; BRYCE EA, 1995, INFECT CONT HOSP EP, V16, P331; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; CARON F, 1995, J INFECT DIS, V171, P106, DOI 10.1093/infdis/171.1.106; CARON F, 1990, ANTIMICROB AGENTS CH, V34, P2070, DOI 10.1128/AAC.34.11.2070; CLEWELL DB, 1990, EUR J CLIN MICROBIOL, V9, P90, DOI 10.1007/BF01963632; COFFEY TJ, 1993, FEMS MICROBIOL LETT, V110, P335, DOI 10.1016/0378-1097(93)90125-L; COLLIS CM, 1995, ANTIMICROB AGENTS CH, V39, P155, DOI 10.1128/AAC.39.1.155; DELACRUZ F, 1982, J BACTERIOL, V151, P222, DOI 10.1128/JB.151.1.222-228.1982; Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P1208, DOI 10.1128/AAC.40.5.1208; DUBOIS SK, 1995, J ANTIMICROB CHEMOTH, V35, P7; DUTKAMALEN S, 1990, ANTIMICROB AGENTS CH, V34, P1875, DOI 10.1128/AAC.34.10.1875; ENA J, 1993, JAMA-J AM MED ASSOC, V269, P598, DOI 10.1001/jama.269.5.598; FANTIN B, 1991, ANTIMICROB AGENTS CH, V35, P1570, DOI 10.1128/AAC.35.8.1570; FANTIN B, 1990, ANTIMICROB AGENTS CH, V34, P581, DOI 10.1128/AAC.34.4.581; FIGUEIREDO AMS, 1992, ANTIMICROB AGENTS CH, V36, P886, DOI 10.1128/AAC.36.4.886; Finland M, 1942, MEDICINE, V21, P307, DOI 10.1097/00005792-194209010-00003; FRAIMOW HS, 1992, ANTIMICROB AGENTS CH, V36, P1563, DOI 10.1128/AAC.36.7.1563; FRIEDLAND IR, 1993, ANTIMICROB AGENTS CH, V37, P1630, DOI 10.1128/AAC.37.8.1630; GARDNER P, 1969, LANCET, V2, P774; GAYNES R, 1996, INFECT CONT HOSP E S, V17, pP18; GEHANNO P, 1995, ANTIMICROB AGENTS CH, V39, P271, DOI 10.1128/AAC.39.1.271; GRAYSON ML, 1991, ANTIMICROB AGENTS CH, V35, P2180, DOI 10.1128/AAC.35.11.2180; HANDWERGER S, 1993, CLIN INFECT DIS, V16, P750, DOI 10.1093/clind/16.6.750; HAYDEN MK, 1993, J INFECT DIS, V167, P1224, DOI 10.1093/infdis/167.5.1224; Hooper David C., 1993, P97; *HOSP INF CONTR PR, 1995, MMWR-MORBID MORTAL W, V44, P1; Ingerman M J, 1989, Infect Dis Clin North Am, V3, P641; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; JACOBS RF, 1994, CLIN INFECT DIS, V19, P1, DOI 10.1093/clinids/19.1.1; JARLIER V, 1988, REV INFECT DIS, V10, P867; JONES RN, 1994, DIAGN MICR INFEC DIS, V19, P203, DOI 10.1016/0732-8893(94)90033-7; JORGENSEN JH, 1994, J CLIN MICROBIOL, V32, P159, DOI 10.1128/JCM.32.1.159-163.1994; KANRA GY, 1995, PEDIATR INFECT DIS J, V14, P490, DOI 10.1097/00006454-199506000-00005; KLARE I, 1995, FEMS MICROBIOL LETT, V125, P165, DOI 10.1111/j.1574-6968.1995.tb07353.x; KLARE I, 1995, FEMS MICROBIOL LETT, V127, P273; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; KROGSTAD DJ, 1980, ANTIMICROB AGENTS CH, V17, P965, DOI 10.1128/AAC.17.6.965; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; LECLERCQ R, 1989, ANTIMICROB AGENTS CH, V33, P10, DOI 10.1128/AAC.33.1.10; Lederberg J., 1992, I MED US COMMITTEE; LEVESQUE C, 1995, ANTIMICROB AGENTS CH, V39, P185, DOI 10.1128/AAC.39.1.185; LIVERMORE DM, 1995, CLIN MICROBIOL REV, V8, P557, DOI 10.1128/CMR.8.4.557; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MENTEC H, 1992, ANTIMICROB AGENTS CH, V36, P1883, DOI 10.1128/AAC.36.9.1883; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; Moellering R, 1981, TREATMENT INFECTIVE, P81; MOELLERING RC, 1990, SCAND J INFECT DIS, P18; MOELLERING RC, 1992, CLIN INFECT DIS, V14, P1173, DOI 10.1093/clinids/14.6.1173; MOELLERING RC, 1979, MICROBIOLOGY 1979, P293; MONTECALVO MA, 1994, 34TH INT C ANT AG CH, P145; MUNFORD RS, 1994, J INVEST MED, V42, P613; MUNOZ R, 1992, CLIN INFECT DIS, V15, P112, DOI 10.1093/clinids/15.1.112; MURRAY BE, 1978, MED CLIN N AM, V62, P899, DOI 10.1016/S0025-7125(16)31746-1; *NAT COMM CLIN LAB, 1993, PERF STAND ANT DISK, V13; *NAT COMM CLIN LAB, 1995, PERF STAND ANT SUS S, V15; NAUMOVSKI L, 1992, ANTIMICROB AGENTS CH, V36, P1991, DOI 10.1128/AAC.36.9.1991; NAUMOVSKI L, 1993, ANTIMICROB AGENTS CH, V37, P375, DOI 10.1128/AAC.37.2.375; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; NORRIS AH, 1995, CLIN INFECT DIS, V20, P1137, DOI 10.1093/clinids/20.5.1137; ODONOVAN CA, 1994, DIAGN MICR INFEC DIS, V18, P105, DOI 10.1016/0732-8893(94)90074-4; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; PANGON B, 1989, J INFECT DIS, V159, P1005, DOI 10.1093/infdis/159.5.1005; PARIS MM, 1994, ANTIMICROB AGENTS CH, V38, P1320, DOI 10.1128/AAC.38.6.1320; PARIS MM, 1995, ANTIMICROB AGENTS CH, V39, P2171, DOI 10.1128/AAC.39.10.2171; PAYNE DJ, 1994, ANTIMICROB AGENTS CH, V38, P767, DOI 10.1128/AAC.38.4.767; PHILIPPON A, 1989, ANTIMICROB AGENTS CH, V33, P1131, DOI 10.1128/AAC.33.8.1131; QUINTILIANI R, 1993, J INFECT DIS, V167, P1220, DOI 10.1093/infdis/167.5.1220; REVES RR, 1990, SEMIN PEDIAT INFECT, V1, P212; RICE LB, 1994, ANTIMICROB AGENTS CH, V38, P2663, DOI 10.1128/AAC.38.11.2663; RICE LB, 1991, ANTIMICROB AGENTS CH, V35, P1243, DOI 10.1128/AAC.35.6.1243; RICE LB, 1990, ANTIMICROB AGENTS CH, V34, P2193, DOI 10.1128/AAC.34.11.2193; SADER HS, 1994, J CLIN MICROBIOL, V32, P2840, DOI 10.1128/JCM.32.11.2840-2842.1994; SADER HS, 1994, DIAGN MICR INFEC DIS, V20, P203, DOI 10.1016/0732-8893(94)90004-3; SANDERS WE, 1988, REV INFECT DIS, V10, P830; SCHABERG DR, 1991, AM J MED S3B, V91; SHAY DK, 1995, J INFECT DIS, V172, P993, DOI 10.1093/infdis/172.4.993; SHLAES DM, 1991, ANTIMICROB AGENTS CH, V35, P776, DOI 10.1128/AAC.35.4.776; SIROT D, 1991, ANTIMICROB AGENTS CH, V35, P1576, DOI 10.1128/AAC.35.8.1576; SIROT J, 1988, REV INFECT DIS, V10, P850; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732; SOUGAKOFF W, 1988, REV INFECT DIS, V10, P879; SPRATT BG, 1988, NATURE, V332, P173, DOI 10.1038/332173a0; SWENSON JM, 1994, J CLIN MICROBIOL, V32, P1700, DOI 10.1128/JCM.32.7.1700-1704.1994; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P1524, DOI 10.1128/JCM.33.6.1524-1527.1995; THACKER SB, 1992, JAMA-J AM MED ASSOC, V268, P1720, DOI 10.1001/jama.268.13.1720; THOMSON CJ, 1992, FEMS MICROBIOL LETT, V91, P113; THOMSON KS, 1990, ANTIMICROB AGENTS CH, V34, P622, DOI 10.1128/AAC.34.4.622; THORNSBERRY C, 1993, INFECT MED S, P15; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; UNAL S, 1993, J ANTIMICROB CHEMOTH, V31, P711, DOI 10.1093/jac/31.5.711; *US FOOD DRUG ADM, 1995, ANTIMICROB AGENTS CH, V39, P1010; UTTLEY AHC, 1988, LANCET, V1, P57; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; WALSH CT, 1993, SCIENCE, V262, P164; WARD JI, 1981, ANTIMICROB AGENTS CH, V20, P204, DOI 10.1128/AAC.20.2.204; WEBB V, 1993, ANTIMICROB AGENTS CH, V37, P2379, DOI 10.1128/AAC.37.11.2379; WILLEY BM, 1993, J CLIN MICROBIOL, V31, P2777, DOI 10.1128/JCM.31.10.2777-2779.1993; ZERVOS MJ, 1987, ANN INTERN MED, V106, P687, DOI 10.7326/0003-4819-106-5-687	107	681	716	6	115	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1445	1453		10.1056/NEJM199611073351907	http://dx.doi.org/10.1056/NEJM199611073351907			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT339	8875923				2022-12-28	WOS:A1996VT33900007
J	Olliaro, P; Nevill, C; LeBras, J; Ringwald, P; Mussano, P; Garner, P; Brasseur, P				Olliaro, P; Nevill, C; LeBras, J; Ringwald, P; Mussano, P; Garner, P; Brasseur, P			Systematic review of amodiaquine treatment in uncomplicated malaria	LANCET			English	Article							DRUG-REACTIONS	Background Opinion and policy over the use of amodiaquine for treating malaria vary. Amodiaquine is more palatable than chloroquine and may be more effective but serious adverse events have been reported in travellers taking it as prophylaxis. It is not recommended as first-line treatment. In the light of the global debate over the use of this drug, we conducted a systematic review of the effectiveness and tolerability of amodiaquine in the treatment of uncomplicated falciparum malaria. Methods This is a systematic review of published and unpublished randomised or pseudorandomised trials of amodiaquine. Observational reports were also systematically identified and reviewed to access evidence of serious adverse events. Findings 40 trials met the inclusion criteria. Symptomatic patients were enrolled in 24 studies in comparisons of amodiaquine (n=1071) with chloroquine (n=1097). Amodiaquine was significantly more effective than chloroquine, with adds ratios and 99% confidence intervals (OR [99% CI]) of 4 . 29 (3 . 30-5 . 58) on day 7 and 6 . 00 (3 . 97-9 . 06) on day 14. Time to parasite clearance was significantly shorter with amodiaquine and fever clearance times were marginally faster. Eight studies compared amodiaquine with chloroquine in asymptomatic parasitaemia, with effects on parasitological outcomes similar to those for symptomatic malaria. At twelve sites, 692 amodiaquine and 679 sulfadoxine/pyrimethamine (S/P) recipients were enrolled. The two drugs did not differ significantly on day 7 (OR 0 . 74 [0 . 48-1 . 15]) but the odds ratios favoured S/P on day 14 (OR 0 . 51 [0 . 28-0 . 93]) and on day 28 (OR 0 . 30 [0 . 16-0 . 55]). The time to parasitological clearance was similar in the two groups; fever clearance times were significantly shorter with amodiaquine. Tolerability was assessed for both comparative and non-comparative trials. The rates of adverse events in controlled trials were 10 . 7%, 8 . 8%, and 14 . 3% with amodiaquine, chloroquine, and S/P, respectively. No life-threatening adverse events and no significant shifts in laboratory indices were reported. Interpretation This systematic review of published and unpublished trials supports the use of amodiaquine in the treatment of uncomplicated malaria. However, there is partial cross-resistance between chloroquine and amodiaquine, and monitoring of the effectiveness of this drug and surveillance for evidence of toxicity must continue.	AMREF,NAIROBI,KENYA; HOP BICHAT CLAUDE BERNARD,INST MED & EPIDEMIOL TROP,F-75877 PARIS 18,FRANCE; ORSTOM,OCEAC,YAOUNDE,CAMEROON; COCHRANE TROP DIS GRP,LIVERPOOL,MERSEYSIDE,ENGLAND; HOP CHARLES NICOLLE,PARASITOL LAB,ROUEN,FRANCE	African Medical & Research Foundation (AMREF); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut de Recherche pour le Developpement (IRD); CHU de Rouen	Olliaro, P (corresponding author), WHO,SPECIAL PROGRAMME TRAINING & RES TROP DIS TDR,UNDP,WORLD BANK,20 AVE APPIA,CH-1211 GENEVA 27,SWITZERLAND.		Garner, Paul/HII-5856-2022	Garner, Paul/0000-0002-0607-6941				CLARKE JB, 1991, INT ARCH ALLER A IMM, V95, P369, DOI 10.1159/000235475; CLARKE JB, 1990, INT ARCH ALLER A IMM, V91, P335, DOI 10.1159/000235138; COOPMAN SA, 1993, NEW ENGL J MED, V328, P1670, DOI 10.1056/NEJM199306103282304; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, P13; GARNER P, 1996, TROPICAL DIS MODULE; HATTON CSR, 1986, LANCET, V1, P411; MAGGS JL, 1988, BIOCHEM PHARMACOL, V37, P305; NEFTEL KA, 1986, BRIT MED J, V292, P721, DOI 10.1136/bmj.292.6522.721; OLLIARO P, 1996, TROPICAL DIS MODULE; PHILLIPSHOWARD PA, 1990, J ROY SOC MED, V83, P82, DOI 10.1177/014107689008300208; Radloff PD, 1996, LANCET, V347, P1511, DOI 10.1016/S0140-6736(96)90671-6; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; *WHO, 1990, TECH REP SER WHO, V805; *WHO, 1993, 19 EXP COMM MAL; WINSTANLEY PA, 1990, BRIT J CLIN PHARMACO, V29, P479, DOI 10.1111/j.1365-2125.1990.tb03667.x	15	191	194	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1196	1201		10.1016/S0140-6736(96)06217-4	http://dx.doi.org/10.1016/S0140-6736(96)06217-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898036				2022-12-28	WOS:A1996VQ46700010
J	Denu, JM; Stuckey, JA; Saper, MA; Dixon, JE				Denu, JM; Stuckey, JA; Saper, MA; Dixon, JE			Form and function in protein dephosphorylation	CELL			English	Review							TYROSINE-PHOSPHATASE 1B; PURPLE ACID-PHOSPHATASE; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; COMPLEX; CALCINEURIN; TUNGSTATE	The phosphate ester is an extremely important chemical bond within the living cell, serving as an energy source, as a means of joining RNA/DNA molecules, and as an efficient mechanism to regulate the activity of enzymes and proteins by modifying amino acid side-chains. Protein phosphorylation is a highly regulated process by which information can be shuttled from the cell surface to the nucleus. There are two classes of enzymes that regulate signalling through the phosphorylation and dephosphorylation of proteins, namely protein kinases and protein phosphatases. This review will focus on the structure and function of the protein phosphatases. Protein phosphatases are generally divided into two main groups based on substrate specificity. Protein Phosphatases (PPs) specifically hydrolyze serine/threonine phosphoesters and Protein Tyrosine Phosphatases (PTPs) are phosphotyrosine-specific. A sub-family of PTPs, dual specificity phosphatases or dual specificity PTPs, are capable of efficient hydrolysis of both phosphotyrosine and phosphoserine/threonine. Recently solved X-ray structures of both PTPs and PPs have provided a wealth of new knowledge on the structure and catalytic mechanism of both enzyme families. Although both PPs and PTPs catalyze phosphoester hydrolysis, they utilize completely different structures and distinct catalytic mechanisms. These differences among the phosphatases are in stark contrast to the serine/threonine and tyrosine protein kinases which are all predicted to have a common structure (reviewed by Johnson et al., 1996).	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BILWES AM, 1996, NATURE, V383, P555; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; MUELLER EG, 1993, J AM CHEM SOC, V115, P2974, DOI 10.1021/ja00060a055; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHIOZAKI K, 1995, EMBO J, V14, P494; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199	19	290	303	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					361	364		10.1016/S0092-8674(00)81356-2	http://dx.doi.org/10.1016/S0092-8674(00)81356-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898189	Bronze			2022-12-28	WOS:A1996VQ46600002
J	Abbas, AK; Murphy, KM; Sher, A				Abbas, AK; Murphy, KM; Sher, A			Functional diversity of helper T lymphocytes	NATURE			English	Review							CELL-MEDIATED-IMMUNITY; STIMULATORY FACTOR-I; INTERFERON-GAMMA; PHENOTYPE DEVELOPMENT; AUTOIMMUNE-DISEASES; CYTOKINE PROFILES; LEISHMANIA-MAJOR; INTERLEUKIN-12; ANTIGEN; MICE	The existence of subsets of CD4(+) helper T lymphocytes that differ in their cytokine secretion patterns and effector functions provides a framework for understanding the heterogeneity of normal and pathological immune responses. Defining the cellular and molecular mechanisms of helper-T-cell differentiation should lead to rational strategies for manipulating immune responses for prophylaxis and therapy.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; NIAID, NIH, PARASIT DIS LAB, IMMUNOBIOL SECT, BETHESDA, MD 20892 USA	Harvard University; Harvard Medical School; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Abbas, AK (corresponding author), BRIGHAM & WOMENS HOSP, DEPT PATHOL, IMMUNOL RES DIV, 75 FRANCIS ST, BOSTON, MA 02115 USA.							AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; ASHERSON GL, 1965, IMMUNOLOGY, V9, P205; BIRON CA, 1994, CURR OPIN IMMUNOL, V6, P530, DOI 10.1016/0952-7915(94)90137-6; BIRON CA, 1995, CURR OPIN IMMUNOL, V7, P485, DOI 10.1016/0952-7915(95)80093-X; BLOOM BR, 1992, ANNU REV IMMUNOL, V10, P453, DOI 10.1146/annurev.iy.10.040192.002321; BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; BUCY RP, 1994, J EXP MED, V180, P1251, DOI 10.1084/jem.180.4.1251; BURSTEIN HJ, 1993, J EXP MED, V177, P457, DOI 10.1084/jem.177.2.457; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CROFT M, 1995, J IMMUNOL, V154, P4269; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; Davies JD, 1996, J IMMUNOL, V156, P3602; DEWIT D, 1992, J EXP MED, V175, P9, DOI 10.1084/jem.175.1.9; EINER SL, 1995, ANNU REV IMMUNOL, V13, P151; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FINKELMAN FD, IN PRESS ANN REV IMM; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gazzinelli RT, 1996, J IMMUNOL, V157, P798; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Guler ML, 1996, SCIENCE, V271, P984, DOI 10.1126/science.271.5251.984; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Kruisbeek AM, 1996, CURR OPIN IMMUNOL, V8, P233, DOI 10.1016/S0952-7915(96)80062-8; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; LICHTMAN AH, 1987, P NATL ACAD SCI USA, V84, P824, DOI 10.1073/pnas.84.3.824; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Mason D, 1996, J EXP MED, V183, P717, DOI 10.1084/jem.183.3.717; MCKNIGHT AJ, 1994, J IMMUNOL, V152, P5220; MILLER JFAP, 1994, CURR OPIN IMMUNOL, V6, P892, DOI 10.1016/0952-7915(94)90010-8; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; MURPHY EE, 1994, J EXP MED, V180, P223, DOI 10.1084/jem.180.1.223; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PEREZ VL, 1995, INT IMMUNOL, V7, P869, DOI 10.1093/intimm/7.5.869; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rocken M, 1996, IMMUNOL TODAY, V17, P225, DOI 10.1016/0167-5699(96)80556-1; ROMAGNANI S, 1995, J LEUKOCYTE BIOL, V57, P726, DOI 10.1002/jlb.57.5.726; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; SCHMITZ J, 1994, J EXP MED, V179, P1349, DOI 10.1084/jem.179.4.1349; SCOTT B, 1994, IMMUNITY, V1, P73, DOI 10.1016/1074-7613(94)90011-6; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SOMASSE T, 1996, J EXP MED, V184, P473; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Turk J L, 1971, Adv Immunol, V13, P209, DOI 10.1016/S0065-2776(08)60185-6; vonHerrath MG, 1995, IMMUNITY, V3, P727, DOI 10.1016/1074-7613(95)90062-4; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; WYNN TA, 1995, CURR OPIN IMMUNOL, V7, P505, DOI 10.1016/0952-7915(95)80095-6; WYNN TA, 1994, J EXP MED, V179, P1551, DOI 10.1084/jem.179.5.1551; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; Yoshida T, 1996, IMMUNITY, V4, P483, DOI 10.1016/S1074-7613(00)80414-8; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285	94	3642	3838	7	268	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1996	383	6603					787	793		10.1038/383787a0	http://dx.doi.org/10.1038/383787a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893001				2022-12-28	WOS:A1996VQ14400053
J	Iglehart, JK				Iglehart, JK			Reform of the Veterans Affairs health care system	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		BAINE DP, 1994, GAOTHEHS94148; BROWN J, 1996, COMMUNICATION   0329; *DEP VET AFF, 1996, UNPUB REP RES REAL R; *DEP VET AFF, 1996, REC RES REAL ADV COM; *DEP VET AFF, 1995, VIS CHANG PLAN RESTR; Department of Veterans Affairs, 1991, REP COMM FUT STRUCT; DUNCAN PD, 1996, POLITICS AM, P1469; FISHER ES, 1995, JAMA-J AM MED ASSOC, V273, P651, DOI 10.1001/jama.273.8.651; *GEN ACC OFF, 1996, GAOHEHS96160; *GEN ACC OFF, 1994, GAOHEHS94104BR; *GEN ACC OFF, 1996, GAOHEHS96198; *GEN ACC OFF, 1994, GAOHEHS94210BR; HOLLINGSWORTH JW, 1990, NEW ENGL J MED, V322, P1851, DOI 10.1056/NEJM199006283222605; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; IGLEHART JK, 1985, NEW ENGL J MED, V313, P1552, DOI 10.1056/NEJM198512123132429; Kizer KW, 1996, JAMA-J AM MED ASSOC, V275, P1069, DOI 10.1001/jama.275.14.1069; KIZER KW, 1996, US MED, V32, P25; 1994, GAOHEHS94113FS	18	53	53	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1996	335	18					1407	1411		10.1056/NEJM199610313351821	http://dx.doi.org/10.1056/NEJM199610313351821			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP484	8857026				2022-12-28	WOS:A1996VP48400029
J	Michels, KB; Rosner, BA				Michels, KB; Rosner, BA			Data trawling: To fish or not to fish	LANCET			English	Article									HARVARD UNIV, SCH MED, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Michels, KB (corresponding author), HARVARD UNIV, SCH MED, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.							COLE P, 1993, EPIDEMIOLOGY, V4, P271, DOI 10.1097/00001648-199305000-00012; GREENLAND S, 1991, EPIDEMIOLOGY, V2, P387, DOI 10.1097/00001648-199109000-00015; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Marsick V.J, 1990, HUM RESOUR DEV Q, V1, P5, DOI DOI 10.1002/HRDQ.3920010103; Poole C, 1991, Epidemiology, V2, P241; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Savitz D A, 1990, Epidemiology, V1, P78, DOI 10.1097/00001648-199001000-00017; SAVITZ DA, 1995, AM J EPIDEMIOL, V142, P904, DOI 10.1093/oxfordjournals.aje.a117737; *US DEPT HHS, 1989, 59 M CARD REN DRUGS; Vandenbroucke J P, 1990, Epidemiology, V1, P83, DOI 10.1097/00001648-199001000-00018	10	44	45	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 26	1996	348	9035					1152	1153		10.1016/S0140-6736(96)05418-9	http://dx.doi.org/10.1016/S0140-6736(96)05418-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888172				2022-12-28	WOS:A1996VP10600016
J	Piletta, PA; Salomon, D; Beani, JC; Saurat, JH				Piletta, PA; Salomon, D; Beani, JC; Saurat, JH			A pilot with an itchy rash	LANCET			English	Article							POLYMORPHOUS LIGHT ERUPTION		CHU GRENOBLE,DEPT DERMATOL,UNIT PHOTOBIOL,F-38043 GRENOBLE,FRANCE	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Piletta, PA (corresponding author), UNIV HOSP GENEVA,DEPT DERMATOL,CH-1211 GENEVA 14,SWITZERLAND.		Pierre, PILETTA/HDO-6915-2022					EPSTEIN JH, 1980, J AM ACAD DERMATOL, V3, P329, DOI 10.1016/S0190-9622(80)80324-0; GOULD JW, 1995, J AM ACAD DERMATOL, V33, P551, DOI 10.1016/0190-9622(95)91271-1; MCFADDEN JP, 1994, ACTA DERM-VENEREOL, V74, P283; NORRIS PG, 1992, J INVEST DERMATOL, V99, P504, DOI 10.1111/1523-1747.ep12616175; VANPRAAG MCG, 1994, INT J DERMATOL, V33, P233	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1142	1142		10.1016/S0140-6736(96)08435-8	http://dx.doi.org/10.1016/S0140-6736(96)08435-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888169				2022-12-28	WOS:A1996VP10600013
J	Rickinson, AB				Rickinson, AB			Changing seroepidemiology of HHV-8	LANCET			English	Editorial Material							KAPOSIS-SARCOMA; DNA-SEQUENCES				Rickinson, AB (corresponding author), UNIV BIRMINGHAM,CRC,INST CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.							CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003	7	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1110	1111		10.1016/S0140-6736(05)65265-8	http://dx.doi.org/10.1016/S0140-6736(05)65265-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888158				2022-12-28	WOS:A1996VP10600002
J	Blumenthal, D; Epstein, AM				Blumenthal, D; Epstein, AM			Quality of health care .6. The role of physicians in the future of quality management	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Blumenthal, D (corresponding author), MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA.							ANDERS G, 1996, WALL STREET J   1015, pB1; BANTA HD, 1981, SPRINGER SERIES HLTH, V5; Berwick D. M, 1990, CURING HLTH CARE NEW; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; Blumenthal D, 1996, JAMA-J AM MED ASSOC, V276, P725; Blumenthal D, 1996, NEW ENGL J MED, V335, P1146, DOI 10.1056/NEJM199610103351511; Blumenthal D, 1996, NEW ENGL J MED, V335, P891, DOI 10.1056/NEJM199609193351213; BLUMENTHAL D, 1995, IMPROVING CLIN PRACT; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Chassin MR, 1996, NEW ENGL J MED, V335, P1060, DOI 10.1056/NEJM199610033351413; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; EPSTEIN AM, 1996, STRATEGIC CHOICES CH, P207; GIBSON PG, 1995, ANN INTERN MED, V123, P488, DOI 10.7326/0003-4819-123-7-199510010-00002; GOLD M, 1994, WHAT WE KNOW DONT KN; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; *NAT COMM QUAL ASS, 1995, REP CARD PIL PROJ KE; *NAT COMM QUAL ASS, 1996, HEDIS 30 DRAFT PUBL; *NAT COMM QUAL ASS, 1995, HLTH PLAN EMPL DAT I; NOBLE HB, 1995, NY TIMES        0703, P1; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406	21	112	115	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1328	1331		10.1056/NEJM199610243351721	http://dx.doi.org/10.1056/NEJM199610243351721			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857015				2022-12-28	WOS:A1996VN59400031
J	Morgan, CL; Donnelly, PD; Lester, CA; Assar, DH				Morgan, CL; Donnelly, PD; Lester, CA; Assar, DH			Effectiveness of the BBC's 999 training roadshows on cardiopulmonary resuscitation: Video performance of cohort of unforewarned participants at home six months afterwards	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC-ARREST; CPR SKILLS; RETENTION; SURVIVAL; IMPACT	Objective-To examine the competence of a cohort trained in cardiopulmonary resuscitation by the BBC's 999 training roadshows. Design-Descriptive cohort study applying an innovative testing procedure to a nationwide systematic sample. The test sample received an unsolicited home visit and without warning were required to perform cardiopulmonary resuscitation on a manikin while being videoed. The videos were then analysed for effectiveness and safety using the new test. Setting-Nine cities and surrounding areas in the United Kingdom, Subjects-280 people aged between 11 and 72. Results-Thirty three (12%) trainees were able to perform effective cardiopulmonary resuscitation, but of these 14 (5%) performed one or more elements in a way that was deemed to be potentially injurious, Thus only 19 (7%) trainees were able at six months to provide safe cardiopulmonary resuscitation, In addition, large numbers of subjects failed to shout for help, effectively assess the status of the patient, or alert an ambulance, Significantly better performances were recorded by those under 45 years old (31 (14%) v 2 (4%) gave effective performances respectively, P<0.05), those who had attended a subsequent cardiopulmonary resuscitation course (8 (40%) v 25 (10%) gave effective performances respectively, P<0.0001), and those confident in their initial ability (26 (20%) v 7 (6%) gave effective performances respectively, P<0.005). Females were significantly less likely than males to perform procedures in a harmful way (117 (62%) v 10 (12%) performed safely respectively, P<0.005). Conclusion-Television is an effective means of generating large training cohorts, Volunteers will cooperate with unsolicited testing in their home, such testing being a realistic simulation of the stress and lack of forewarning that would surround a real event, Under such conditions the performance of cardiopulmonary resuscitation was disappointing. However, retraining greatly improves performance.	UNIV WALES COLL CARDIFF,COLL MED,CTR APPL PUBL HLTH MED,CARDIFF F1 8UL,S GLAM,WALES	Cardiff University								ASSAR D, 1995, SHOULD S GLAMORGAN H, P41; BASKETT PJF, 1985, ANAESTHAESIA, V37, P74; BERDEN HJJM, 1993, BRIT MED J, V306, P1576, DOI 10.1136/bmj.306.6892.1576; COBB LA, 1982, ANN NY ACAD SCI, V382, P330, DOI 10.1111/j.1749-6632.1982.tb55228.x; COBB LA, 1980, ANNU REV MED, V31, P453, DOI 10.1146/annurev.me.31.020180.002321; CUMMINS RO, 1985, BRIT MED J, V291, P1401, DOI 10.1136/bmj.291.6506.1401; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; CUMMINS RO, 1991, CIRCULATION, V83, P1833; DAVID J, 1993, BRIT MED J, V306, P1578, DOI 10.1136/bmj.306.6892.1578; DELIERE DM, 1980, EMT J, V4, P57; FOSSEL M, 1983, J MED EDUC, V58, P568; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; GASS DA, 1983, CAN MED ASSOC J, V128, P550; GOMBESKI WR, 1982, AM J PUBLIC HEALTH, V72, P849, DOI 10.2105/AJPH.72.8.849; HEARNE TR, 1988, PACING CLIN ELECTROP, V2, P1968; Hughes R J, 1988, Health Educ J, V47, P53, DOI 10.1177/001789698804700205; JONES J, 1994, AM J EMERG MED, V12, P687, DOI 10.1016/0735-6757(94)90042-6; KALMTHOUT P, 1985, BRIT HEART J, V53, P562; KAYE W, 1991, RESUSCITATION, V21, P67, DOI 10.1016/0300-9572(91)90080-I; KORTTILA K, 1979, ACTA ANAESTH SCAND, V23, P235, DOI 10.1111/j.1399-6576.1979.tb01445.x; KOWALSKI R, 1984, ANN EMERG MED, V13, P1016, DOI 10.1016/S0196-0644(84)80061-X; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; MARTIN WJ, 1983, AM J PUBLIC HEALTH, V73, P1310, DOI 10.2105/AJPH.73.11.1310; MCKENNA SP, 1985, J OCCUP PSYCHOL, V58, P109, DOI 10.1111/j.2044-8325.1985.tb00186.x; MOSER DK, 1992, HEART LUNG, V21, P372; WEAVER FJ, 1979, JAMA-J AM MED ASSOC, V241, P901, DOI 10.1001/jama.241.9.901; WESTON CFM, 1994, J ROY COLL PHYS LOND, V28, P402; WIK L, 1994, RESUSCITATION, V28, P195, DOI 10.1016/0300-9572(94)90064-7; 1992, RESUSCITATION, V24, P103	29	53	53	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					912	916						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876093				2022-12-28	WOS:A1996VM75400024
J	Chaturvedi, N; Jarrett, J; Morrish, N; Keen, H; Fuller, JH				Chaturvedi, N; Jarrett, J; Morrish, N; Keen, H; Fuller, JH			Differences in mortality and morbidity in African Caribbean and European people with non-insulin dependent diabetes mellitus: Results of 20 year follow up of a London cohort of a multinational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STAGE RENAL-DISEASE; BLOOD-PRESSURE; VASCULAR-DISEASE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; RACIAL-DIFFERENCES; BLACK; WHITE; TRANSPLANTATION; INDIVIDUALS	Objective-To examine differences in morbidity and mortality due to non-insulin dependent diabetes in African Caribbeans and Europeans. Design-Cohort study of patients with noninsulin dependent diabetes drawn from diabetes clinics in London, Baseline investigations were performed in 1975-7; follow up continued until 1995. Patients-150 Europeans and 77 African Caribbeans with non-insulin dependent diabetes. Main outcome measures-All cause and cardiovascular mortality; prevalence of microvascular and macrovascular complications. Results-Duration of diabetes was shorter in African Caribbeans, particularly women, African Caribbeans were more likely than the Europeans to have been given a diagnosis after the onset of symptoms and less likely to be taking insulin, Mean cholesterol concentration was lower in African Caribbeans, but blood pressure and body mass index were not different in the two ethnic groups, Prevalence of microvascular and macrovascular complications was insignificantly lower in African Caribbeans than in Europeans. 59 Europeans and 16 African Caribbeans had died by the end of follow up, The risk ratio for all cause mortality was 0.41 (95% confidence interval 0.23 to 0.73) (P=0.002) for African Caribbeans v Europeans, This was attenuated to 0.59 (0.32 to 1.10) (P=0.1) after adjustment for sex, smoking, proteinuria, and body mass index. Further adjustment for systolic blood pressure, cholesterol concentration, age, duration of diabetes, and treatment made little difference to the risk ratio, Unadjusted risk ratios for cardiovascular and ischaemic heart disease were 0.33 (0.15 to 0.70) (P=0.004) and 0.37 (0.16 to 0.85) (P=0.02) respectively. Conclusions-African Caribbeans with noninsulin dependent diabetes maintain a low risk of heart disease, Management priorities for diabetes developed in one ethnic group may not necessarily be applicable to ether groups.	BEDFORD HOSP, S WING, BEDFORD MK42 9DJ, ENGLAND; GUYS HOSP, METAB MED UNIT, LONDON SE1 9RT, ENGLAND	Guy's & St Thomas' NHS Foundation Trust	Chaturvedi, N (corresponding author), UCL, DEPT EPIDEMIOL & PUBL HLTH, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.							[Anonymous], 1985, DIABETOLOGIA, V28, P615, DOI [10.1007/BF00290267, DOI 10.1007/BF00290267]; ASHCROFT MT, 1970, B WORLD HEALTH ORGAN, V42, P205; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BANERJI MA, 1991, AM J MED, V91, P51, DOI 10.1016/0002-9343(91)90073-7; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Blackburn H, 1969, J Electrocardiol, V2, P305; CHATURVEDI N, 1993, HYPERTENSION, V22, P90, DOI 10.1161/01.HYP.22.1.90; Chaturvedi N, 1996, J EPIDEMIOL COMMUN H, V50, P137, DOI 10.1136/jech.50.2.137; CHATURVEDI N, 1994, DIABETOLOGIA, V37, P765, DOI 10.1007/s001250050177; CHATURVEDI N, 1994, J EPIDEMIOL COMMUN H, V48, P107, DOI 10.1136/jech.48.2.107; Collett D, 1994, MODELLING SURVIVAL D, P149; Collett D, 1994, MODELLING SURVIVAL D, P53; COWIE CC, 1994, DIABETES CARE, V17, P681, DOI 10.2337/diacare.17.7.681; COWIE CC, 1994, CIRCULATION, V90, P1185, DOI 10.1161/01.CIR.90.3.1185; CRUICKSHANK JK, 1987, DIABETES CARE, V10, P170, DOI 10.2337/diacare.10.2.170; Destefano Frank, 1993, Ethnicity and Disease, V3, P145; *EP RES, 1991, EGRET EP GRAPH EST T; FALASE AO, 1973, TROP GEOGR MED, V25, P147; FULLER JH, 1983, DIABETOLOGIA, V24, P336; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HARRIS EL, 1993, DIABETES CARE, V16, P748, DOI 10.2337/diacare.16.5.748; HARRIS MI, 1990, DIABETES METAB REV, V6, P71, DOI 10.1002/dmr.5610060202; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; KLEINMAN JC, 1988, AM J EPIDEMIOL, V128, P389, DOI 10.1093/oxfordjournals.aje.a114979; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; MEYER LC, 1994, DIABETIC MED, V11, P670; MIALL WE, 1972, B WORLD HEALTH ORGAN, V46, P429; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; MORRISH NJ, 1991, DIABETOLOGIA, V34, P584, DOI 10.1007/BF00400278; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; *OFF POP CENS SURV, 1990, MORT GEOGR REV MI DS, V9; PACY PJ, 1987, DIABETES RES CLIN EX, V4, P187; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; *SAS I, 1988, SAS US GUID; SELBY JV, 1995, DIABETES CARE, V18, P509, DOI 10.2337/diacare.18.4.509; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Summerson J H, 1996, Ethn Health, V1, P9; TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7; WHITE IR, 1994, STAT MED, V13, P1635, DOI 10.1002/sim.4780131604; YOUNG EW, 1994, KIDNEY INT, V45, P907, DOI 10.1038/ki.1994.120	41	67	67	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	1996	313	7061					848	852						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870570				2022-12-28	WOS:A1996VL55900020
J	Cohen, G; Forbes, J; Garraway, M				Cohen, G; Forbes, J; Garraway, M			Can different patient satisfaction survey methods yield consistent results? Comparison of three surveys	BRITISH MEDICAL JOURNAL			English	Article							CARE	Objective-To examine the consistency of survey estimates of patient satisfaction with interpersonal aspects of hospital experience. Design-Interview and postal surveys, evidence from three independent population surveys being compared. Setting-Scotland and Lothian. Subjects-Randomly selected members of the general adult population who had received hospital care in the past 12 months. Main outcome measures-Percentages of respondents dissatisfied with aspects of patient care. Results-For items covering respect for privacy, treatment with dignity, sensitivity to feelings, treatment as an individual, and clear explanation of care there was good agreement among the surveys despite differences in wording. But for items to do with being encouraged and given time to ask questions and being listened to by doctors there was substantial disagreement. Conclusions-Evidence regarding levels of patient dissatisfaction from national or local surveys should be calibrated against evidence from other surveys to improve reliability. Some important aspects of patient satisfaction seem to have been reliably estimated by surveys of all Scottish NHS users commissioned by the management executive, but certain questions may have underestimated the extent of dissatisfaction, possibly as a result of choice of wording.			Cohen, G (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							Audit Commission, 1993, WHAT SEEMS BE MATT C; BELSON WA, 1981, DESIGN UNDERSTANDING; CAPEWELL S, 1994, HLTH B, V52, P26; CARRHILL RA, 1992, J PUBLIC HEALTH MED, V14, P236; COHEN G, 1994, LOTHIAN HLTH SURVEY; FITZPATRICK R, 1991, BRIT MED J, V302, P887, DOI 10.1136/bmj.302.6781.887; HALL JA, 1988, SOC SCI MED, V27, P935, DOI 10.1016/0277-9536(88)90284-5; Hopkins A, 1994, Qual Health Care, V3, P203, DOI 10.1136/qshc.3.4.203; Hopkins A., 1990, MEASURING QUALITY ME; *NAT HLTH SERV SCO, 1993, PAT CHART WHAT US TH; *NAT HLTH SERV SCO, 1994, PAT CHART WHAT US TH; *NAT HLTH SERV SCO, 1994, SCOTT HLTH STAT 1994; *OFF POP CENS SURV, 1994, GEN HOUS SURV 1992; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; WILLIAMS SJ, 1991, SOC SCI MED, V33, P707, DOI 10.1016/0277-9536(91)90025-8	15	89	92	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					841	844						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870568				2022-12-28	WOS:A1996VL55900018
J	MacDonald, TM; McMahan, AD; Reid, IC; Fenton, GW; McDevitt, DG				MacDonald, TM; McMahan, AD; Reid, IC; Fenton, GW; McDevitt, DG			Antidepressant drug use in primary care: A record linkage study in Tayside, Scotland	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT PSYCHIAT,DUNDEE DD1 9SY,SCOTLAND	University of Dundee	MacDonald, TM (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,MED MONITORING UNIT,DUNDEE DD1 9SY,SCOTLAND.		Reid, Ian C/B-8326-2008; McMahon, Alex D/C-4304-2008	MacDonald, Thomas/0000-0001-5189-6669				BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; *CLIN RES AUD GROU, 1993, DEPR ILLN CRIT REV C; Donoghue J. M., 1996, British Journal of Psychiatry, V168, P164, DOI 10.1192/bjp.168.2.164; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198	5	68	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					860	861						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870575				2022-12-28	WOS:A1996VL55900026
J	Devchand, PR; Keller, H; Peters, JM; Vazquez, M; Gonzalez, FJ; Wahli, W				Devchand, PR; Keller, H; Peters, JM; Vazquez, M; Gonzalez, FJ; Wahli, W			The PPAR alpha-leukotriene B-4 pathway to inflammation control	NATURE			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; RETINOID-X RECEPTOR; PEROXISOME PROLIFERATOR; FATTY-ACIDS; CDNA CLONING; HETERODIMER FORMATION; TARGETED DISRUPTION; BETA-OXIDATION; EXPRESSION; GAMMA	Inflammation is a local immune response to 'foreign' molecules, infection and injury. Leukotriene B-4, a potent chemotactic agent that initiates, coordinates, sustains and amplifies the inflammatory response, is shown to be an activating ligand for the transcription factor PPAR alpha. Because PPAR alpha regulates the oxidative degradation of fatty acids and their derivatives, like this lipid mediator, a feedback mechanism is proposed that controls the duration of an inflammatory response and the clearance of leukotriene B-4 in the liver. Thus PPAR alpha offers a new route to the development of anti- or pro-inflammatory reagents.	UNIV LAUSANNE, INST BIOL ANIM, CH-1015 LAUSANNE, SWITZERLAND; NCI, MOL CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA	University of Lausanne; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Vázquez-Carrera, Manuel/H-2612-2015; Wahli, Walter/B-1398-2009; Peters, Jeffrey/D-8847-2011; Wahli, Walter/I-3194-2019	Vázquez-Carrera, Manuel/0000-0001-7138-8207; Wahli, Walter/0000-0002-5966-9089; Peters, Jeffrey/0000-0003-2782-2998				AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CARLSON RP, 1985, AGENTS ACTIONS, V17, P197, DOI 10.1007/BF01966592; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; COUVE AO, 1992, EXP CELL RES, V202, P541, DOI 10.1016/0014-4827(92)90109-L; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE, V1, P142; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GAD SC, 1986, TOXICOL APPL PHARM, V84, P93, DOI 10.1016/0041-008X(86)90419-9; GOTTLICHER M, 1993, BIOCHEM PHARMACOL, V46, P2177, DOI 10.1016/0006-2952(93)90607-X; Greene M. E., 1995, Gene Expression, V4, P281; HARPER TW, 1986, J BIOL CHEM, V261, P5414; Hertz R, 1996, EUR J BIOCHEM, V235, P242, DOI 10.1111/j.1432-1033.1996.00242.x; HUSSAIN H, 1994, AM J PHYSIOL, V266, pC243, DOI 10.1152/ajpcell.1994.266.1.C243; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JEDLITSCHKY G, 1991, J BIOL CHEM, V266, P24763; JEDLITSCHKY G, 1993, ADV ENZYME REGUL, V33, P181; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MILLER AM, 1993, PROSTAG LEUKOTR ESS, V49, P561, DOI 10.1016/0952-3278(93)90161-O; OPAS EE, 1985, J INVEST DERMATOL, V84, P253, DOI 10.1111/1523-1747.ep12265320; Peters JM, 1996, MOL PHARMACOL, V50, P67; ROLAPLESZCZYNSKI M, 1991, ADV EXP MED BIOL, V314, P205; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SERHAN CN, 1982, J BIOL CHEM, V257, P4746; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; TAYLOR BM, 1985, BIOCHEM PHARMACOL, V34, P3495, DOI 10.1016/0006-2952(85)90723-3; VONSCHACKY C, 1993, BIOCHIM BIOPHYS ACTA, V1166, P20, DOI 10.1016/0005-2760(93)90278-H; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	43	1106	1130	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					39	43		10.1038/384039a0	http://dx.doi.org/10.1038/384039a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900274				2022-12-28	WOS:A1996VR21900046
J	Robey, E; Chang, D; Itano, A; Cado, D; Alexander, H; Lans, D; Weinmaster, G; Salmon, P				Robey, E; Chang, D; Itano, A; Cado, D; Alexander, H; Lans, D; Weinmaster, G; Salmon, P			An activated form of notch influences the choice between CD4 and CD8 T cell lineages	CELL			English	Article							II-DEFICIENT MICE; DROSOPHILA-NOTCH; C-ELEGANS; POSITIVE SELECTION; HEMATOPOIETIC-CELLS; XENOPUS-EMBRYOS; MOUSE HOMOLOG; EXPRESSION; GENE; FATE	Notch is a transmembrane receptor that controls cell fate decisions in Drosophila and whose role in mammalian cell fate decisions is beginning to be explored. We are investigating the role of Notch in a well-studied mammalian cell fate decision: the choice between the CD8 and CD4 T cell lineages. Here we report that expression of an activated form of Notch1 in developing T cells of the mouse leads to both an increase in CD8 lineage T cells and a decrease in CD4 lineage T cells. Expression of activated Notch permits the development of mature CD8 lineage thymocytes even in the absence of class I major histocompatability complex (MHC) proteins, ligands that are normally required for the development of these cells. However, activated Notch is not sufficient to promote CD8 cell development when both class I and class II MHC are absent. These results implicate Notch as a participant in the CD4 versus CD8 lineage decision.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,INST MOL BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Robey, E (corresponding author), UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.			Itano, Andrea/0000-0002-4766-6876; Salmon, Patrick/0000-0002-1993-4984	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032985] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32985] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AUSTIN CP, 1995, DEVELOPMENT, V121, P3637; BEITEL G, 1995, IN PRESS GENES DEV; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CONLON RA, 1995, DEVELOPMENT, V121, P1533; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DELAMO FF, 1993, GENOMICS, V15, P259, DOI 10.1006/geno.1993.1055; DELAMO FF, 1992, DEVELOPMENT, V115, P737; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Itano A, 1996, J EXP MED, V183, P731, DOI 10.1084/jem.183.3.731; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MARKOWITZ JS, 1993, P NATL ACAD SCI USA, V90, P2779, DOI 10.1073/pnas.90.7.2779; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; RAVICHANDRAN KS, 1994, J EXP MED, V179, P727, DOI 10.1084/jem.179.2.727; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIMPSON P, 1995, NATURE, V375, P736, DOI 10.1038/375736a0; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	50	443	479	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					483	492		10.1016/S0092-8674(00)81368-9	http://dx.doi.org/10.1016/S0092-8674(00)81368-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898201	Bronze			2022-12-28	WOS:A1996VQ46600014
J	Matthes, HWD; Maldonado, R; Simonin, F; Valverde, O; Slowe, S; Kitchen, I; Befort, K; Dierich, A; LeMeur, M; Dolle, P; Tzavara, E; Hanoune, J; Roques, BP; Kieffer, BL				Matthes, HWD; Maldonado, R; Simonin, F; Valverde, O; Slowe, S; Kitchen, I; Befort, K; Dierich, A; LeMeur, M; Dolle, P; Tzavara, E; Hanoune, J; Roques, BP; Kieffer, BL			Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene	NATURE			English	Article							PEPTIDES; PHARMACOLOGY; MECHANISMS; ACTIVATION; DEPENDENCE; OPIATES; ABUSE; DRUGS; RATS	DESPITE tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Opioids exert their pharmacological actions through three opioid-receptor classes(1,2), mu, delta and kappa, whose genes have been cloned(3). Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo. Here we disrupt the mu-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioural abnormalities or major compensatory changes within the opioid system in these animals. Investigation of the behavioural effects of morphine reveals that a lack of mu receptors abolishes the analgesic effect of morphine, as well as place-preference activity and physical dependence. We observed no behavioural responses related to delta- or kappa-receptor activation with morphine, although these receptors are present and bind opioid ligands. We conclude that the mu-opioid-receptor gene product is the molecular target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.	UNIV STRASBOURG 1,ESBS,CNRS,UPR 9050,F-67400 ILLKIRCH GRAFFENS,FRANCE; UNIV PARIS 05,CNRS,URA D1500,INSERM,U266,DEPT PHARMACOCHIM MOL & STRUCT,F-75270 PARIS,FRANCE; UNIV SURREY,SCH BIOL SCI,RECEPTORS & CELLULAR REGULAT RES GRP,GUILDFORD GU2 5XH,SURREY,ENGLAND; INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; HOP HENRI MONDOR,INSERM,U99,UNITE RECH,F-94010 CRETEIL,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Surrey; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Maldonado, Rafael/F-5657-2014; Valverde, Olga/D-8654-2012; Dolle, Pascal/A-8037-2010	Maldonado, Rafael/0000-0002-4359-8773; Valverde, Olga/0000-0003-2264-7852; Dolle, Pascal/0000-0002-9294-9090				BAAMONDE A, 1991, J PHARMACOL EXP THER, V257, P767; BROWNSTEIN MJ, 1993, P NATL ACAD SCI USA, V90, P5391, DOI 10.1073/pnas.90.12.5391; COWAN A, 1988, J PHARMACOL EXP THER, V246, P950; COWAN A, 1993, HDB EXPT PHARM, V104, P393; DECIMO D, 1995, GENE PROBES PRACTICA, V2, P183; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; DICKENSON AH, 1991, BRIT MED BULL, V47, P690, DOI 10.1093/oxfordjournals.bmb.a072501; GACEL G, 1988, J MED CHEM, V31, P374, DOI 10.1021/jm00397a019; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; HANOUNE J, 1977, J BIOL CHEM, V252, P2039; ILIEN B, 1988, BIOCHEM PHARMACOL, V37, P3843, DOI 10.1016/0006-2952(88)90065-2; KATZ RJ, 1979, PHARMACOL BIOCHEM BE, V11, P231, DOI 10.1016/0091-3057(79)90019-4; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KITCHEN I, 1995, J PHARMACOL EXP THER, V275, P1595; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; ROQUES BP, 1993, PHARMACOL REV, V45, P87; ROSSIER J, 1982, NATURE, V298, P221, DOI 10.1038/298221a0; SCHMIDT C, 1991, EUR J PHARMACOL, V192, P253, DOI 10.1016/0014-2999(91)90050-Z; SHIPPENBERG TS, 1987, BRAIN RES, V436, P234, DOI 10.1016/0006-8993(87)91667-2; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; Valverde O, 1996, PSYCHOPHARMACOLOGY, V123, P119, DOI 10.1007/BF02246168; WEI ET, 1981, J PHARMACOL EXP THER, V216, P12	29	1325	1380	3	159	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					819	823		10.1038/383819a0	http://dx.doi.org/10.1038/383819a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893006				2022-12-28	WOS:A1996VQ14400062
J	Smith, R				Smith, R			What clinical information do doctors need?	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL INFORMATION; PRIMARY-CARE; HEALTH-CARE; PHYSICIANS; QUESTIONS; KNOWLEDGE; AIDS											BOWDEN VM, 1994, B MED LIBR ASSOC, V82, P189; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; ELY JW, 1992, J FAM PRACTICE, V35, P265; FORSYTHE DE, 1992, COMPUT BIOMED RES, V25, P181, DOI 10.1016/0010-4809(92)90020-B; GORMAN PN, 1994, B MED LIBR ASSOC, V82, P140; GORMAN PN, 1995, J AM SOC INFORM SCI, V46, P729, DOI 10.1002/(SICI)1097-4571(199512)46:10<729::AID-ASI3>3.0.CO;2-2; GORMAN PN, 1995, MED DECIS MAKING, V15, P113, DOI 10.1177/0272989X9501500203; GUISE NB, 1994, J AM MED INFORM ASSN, V1, P395; HERSH WR, 1995, J AM SOC INFORM SCI, V46, P726; NEGROPONTE N, 1995, BEING DIGITAL, P92; NORTHUP DE, 1983, J MED EDUC, V58, P873; OSHEROFF JA, 1991, ANN INTERN MED, V114, P576, DOI 10.7326/0003-4819-114-7-576; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PAUKER SD, 1976, AM J MED, V65, P981; SELF PC, 1989, SCIENTOMETRICS, V17, P49, DOI 10.1007/BF02017722; SENGUPTA IN, 1991, SCIENTOMETRICS, V20, P297, DOI 10.1007/BF02018160; SHAUGHNESSY AF, 1994, J FAM PRACTICE, V39, P489; STINSON ER, 1980, JAMA-J AM MED ASSOC, V243, P140, DOI 10.1001/jama.243.2.140; STRASSER TC, 1978, B MED LIBR ASSOC, V66, P200; Tannenbaum S. J., 1994, J HLTH POLIT POLICY, V19, P27; TIMPKA T, 1989, Scandinavian Journal of Primary Health Care, V7, P105, DOI 10.3109/02813438909088656; TIMPKA T, 1990, METHOD INFORM MED, V29, P23; WEINBERG AD, 1981, J MED EDUC, V56, P1474; WILLIAMSON JW, 1989, ANN INTERN MED, V110, P151, DOI 10.7326/0003-4819-110-2-151; WOOLF SH, 1989, B MED LIBR ASSOC, V77, P372; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W; WYATT JC, 1996, METHOD INFORM MED, V35, P314	27	376	382	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1062	1068						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VP742	8898602				2022-12-28	WOS:A1996VP74200033
J	Strang, JIG				Strang, JIG			Tracing patients in rural Africa	LANCET			English	Editorial Material							PREDNISOLONE; TRIAL		CECILIA MAKLWANE HOSP, DEPT MED, MDANTSANE, EASTERN CAPE, SOUTH AFRICA									GELFAND M, 1957, SICK AFRICAN, P494; STRANG JIG, 1988, LANCET, V2, P759; STRANG JIG, 1987, LANCET, V2, P1418	3	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	1996	348	9034					1083	1084		10.1016/S0140-6736(96)05130-6	http://dx.doi.org/10.1016/S0140-6736(96)05130-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874464				2022-12-28	WOS:A1996VM88600017
J	Gulbis, JM; Kelman, Z; Hurwitz, J; ODonnell, M; Kuriyan, J				Gulbis, JM; Kelman, Z; Hurwitz, J; ODonnell, M; Kuriyan, J			Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA	CELL			English	Article							CELL NUCLEAR ANTIGEN; DEPENDENT KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; DNA-REPLICATION; POTENTIAL MEDIATOR; BINDING DOMAINS; CYCLIN; PROTEIN; CLONING; CDK	The crystal structure of the human DNA polymerase delta processivity factor PCNA (proliferating cell nuclear antigen) complexed with a 22 residue peptide derived from the C-terminus of the cell-cycle checkpoint protein p21(WAF1/CIP1) has been determined at 2.6 Angstrom resolution. p21 binds to PCNA in a 1:1 stoichiometry with an extensive array of interactions that include the formation of a beta sheet with the interdomain connector loop of PCNA. An intact trimeric ring is maintained in the structure of the p21-PCNA complex, with a central hole available for DNA interaction. The ability of p21 to inhibit the action of PCNA is therefore likely to be due to its masking of elements on PCNA that are required for the binding of other components of the polymerase assembly.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV MED COLL,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV MED COLL,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University; Cornell University; Cornell University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Gulbis, JM (corresponding author), ROCKEFELLER UNIV,LAB MOL BIOPHYS,NEW YORK,NY 10021, USA.			O'Donnell, Michael/0000-0001-9002-4214	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38839, GM 38559, GM 45547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1993, CELL, V75, P805; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KELMAN Z, 1996, THESIS CORNELL U MED; KLEWEGT GJ, 1994, P CCP4 STUD WEEK, P59; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REDINBO MR, 1993, ACTA CRYSTALLOGR D, V49, P375, DOI 10.1107/S090744499300294X; ROBBINS J, 1991, CELL, V64, P616; ROOS G, 1996, IN PRESS EXP CELL RE; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	47	640	658	1	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					297	306		10.1016/S0092-8674(00)81347-1	http://dx.doi.org/10.1016/S0092-8674(00)81347-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861913	hybrid			2022-12-28	WOS:A1996VN40300017
J	KeinoMasu, K; Masu, M; Hinck, L; Leonardo, ED; Chan, SSY; Culotti, JG; TessierLavigne, M				KeinoMasu, K; Masu, M; Hinck, L; Leonardo, ED; Chan, SSY; Culotti, JG; TessierLavigne, M			Deleted in Colorectal Cancer (DCC) encodes a netrin receptor	CELL			English	Article							CELL-ADHESION MOLECULE; PIONEER AXON MIGRATIONS; C-ELEGANS; IMMUNOGLOBULIN SUPERFAMILY; COMMISSURAL AXONS; NERVOUS-SYSTEM; SPINAL-CORD; MOUSE-BRAIN; GUIDES CELL; FLOOR PLATE	The guidance of developing axons in the nervous system is mediated partly by diffusible chemoattractants secreted by axonal target cells. Netrins are chemoattractants for commissural axons in the vertebrate spinal cord, but the mechanisms through which they produce their effects are unknown. We show that Deleted in Colorectal Cancer (DCC), a transmembrane protein of the immunoglobulin superfamily, is expressed on spinal commissural axons and possesses netrin-1-binding activity. Moreover, an antibody to DCC selectively blocks the netrin-1-dependent outgrowth of commissural axons in vitro. These results indicate that DCC is a receptor or a component of a receptor that mediates the effects of netrin-1 on commissural axons, and they complement genetic evidence for interactions between DCC and netrin homologs in C. elegans and Drosophila.	NATL DEF MED COLL,DEPT PHYSIOL,TOKOROZAWA,SAITAMA 359,JAPAN; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	National Defense Medical College - Japan; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Howard Hughes Medical Institute; University of California System; University of California San Francisco	KeinoMasu, K (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143, USA.		Culotti, Joseph/G-6467-2013; Leonardo, Eduardo/AAH-1525-2020	Leonardo, Eduardo/0000-0001-7426-0217; Hinck, Lindsay/0000-0002-4009-3913; Culotti, Joseph/0000-0001-6325-4612				ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; BRUMMENDORF T, 1994, PROTEIN PROFILE CELL, V1, P1001; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Cooper HM, 1995, ONCOGENE, V11, P2243; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EASTER SS, 1993, J NEUROSCI, V13, P285; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; GRUMET M, 1993, CELL ADHES COMMUN, V1, P177, DOI 10.3109/15419069309095693; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V2, P61; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; PLACZEK M, 1990, DEVELOPMENT, V110, P19; REALE MA, 1994, CANCER RES, V54, P4493; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHIMAMURA K, 1994, DEVELOPMENT, V120, P2225; SHIRASAKI R, 1995, NEURON, V14, P961, DOI 10.1016/0896-6273(95)90334-8; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; TAIRA E, 1994, NEURON, V12, P861, DOI 10.1016/0896-6273(94)90338-7; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	39	829	856	0	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					175	185		10.1016/S0092-8674(00)81336-7	http://dx.doi.org/10.1016/S0092-8674(00)81336-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861902	Bronze			2022-12-28	WOS:A1996VN40300006
J	Macdonald, R; Khan, MA; Singleton, C				Macdonald, R; Khan, MA; Singleton, C			Continuing medical education and training for associate specialists: Results of a survey in Yorkshire	BRITISH MEDICAL JOURNAL			English	Article									HUDDERSFIELD ROYAL INFIRM,HUDDERSFIELD HD3 3EA,W YORKSHIRE,ENGLAND		Macdonald, R (corresponding author), UNIV LEEDS,NO & YORKSHIRE NHS EXECUT,SEACROFT HOSP,POSTGRAD DEPT MED & DENT EDUC,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND.							*BRIT MED ASS, 1994, MOD WORKL DOC ASS SP, P306; *NHS MAN EX, 1991, JUN DOCT NEW DEAL; *NHS MAN EX, 1990, EL91150 DEP HLTH; *NHS MAN EX, 1994, HSG9410 DEP HLTH	4	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					918	918						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876096				2022-12-28	WOS:A1996VM75400027
J	Potts, M				Potts, M			Cairo dreams shattered	LANCET			English	Editorial Material											Potts, M (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720, USA.								0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					976	976		10.1016/S0140-6736(05)64923-9	http://dx.doi.org/10.1016/S0140-6736(05)64923-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855851				2022-12-28	WOS:A1996VM02700007
J	Smith, TJ; Chase, ES; Schmidt, TJ; Olson, NH; Baker, TS				Smith, TJ; Chase, ES; Schmidt, TJ; Olson, NH; Baker, TS			Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon	NATURE			English	Article							COMMON COLD VIRUS; CONFORMATIONAL-CHANGES; FAB FRAGMENTS; ATTACHMENT; COMPLEX; VIRION; SITE	THE three-dimensional structure of intact human rhinovirus 14 (HRV-14) complexed with Fab fragments (Fab17-IA) from a strongly neutralizing antibody that binds bivalently to the virion(1,2) has been determined to 4.0 Angstrom resolution by a combination of X-ray crystallography and cryo-electron microscopy. In contradiction to the most commonly held model of antibody-mediated neutralization, Fab17-IA does not induce a conformational change in the HRV-14 capsid. Instead, the paratope of the antibody undergoes a large conformational change to accommodate the epitope. Unlike any previously described antibody-antigen structure, the conserved framework region of the antibody makes extensive contact with the viral surface. Fab17-IA penetrates deep within the canyon in which the cellular receptor for HRV-14 binds(3,4). Hence, it is unlikely that viral quaternary structure evolves merely to evade immune recognition, Instead, the shape and position of the receptor-binding region on a virus probably dictates receptor binding and subsequent uncoating events and has little or no influence on concealing the virus from the immune system.			Smith, TJ (corresponding author), PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907, USA.		Smith, Thomas J/K-9086-2013	Smith, Thomas J/0000-0003-3528-6793; , Timothy/0000-0001-6543-8968	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033050] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM033050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ARNOLD E, 1984, J MOL BIOL, V177, P417, DOI 10.1016/0022-2836(84)90293-6; BIZEBARD T, 1995, NATURE, V376, P92, DOI 10.1038/376092a0; BRUNGER AT, 1992, X PLOR VERSION 3 1 U; COLONNO RJ, 1989, J VIROL, V63, P36, DOI 10.1128/JVI.63.1.36-42.1989; Harber J, 1995, VIROLOGY, V214, P559, DOI 10.1006/viro.1995.0067; HOOVERLITTY H, 1993, J VIROL, V67, P390, DOI 10.1128/JVI.67.1.390-397.1993; LEE WM, 1991, THESIS U WISCONSIN U; LIU HS, 1994, J MOL BIOL, V240, P127, DOI 10.1006/jmbi.1994.1427; LUO M, 1987, SCIENCE, V235, P182, DOI 10.1126/science.3026048; MCCULLOUGH KC, 1992, J VIROL, V66, P1835, DOI 10.1128/JVI.66.4.1835-1840.1992; MOSSER AG, 1989, MOL ASPECTS PICORNAV, P00155; OLIVEIRA MA, 1993, STRUCTURE, V1, P51, DOI 10.1016/0969-2126(93)90008-5; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; ROSSMANN MG, 1992, J APPL CRYSTALLOGR, V25, P166, DOI 10.1107/S002188989101141X; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SHERIFF S, 1993, IMMUNOMETHODS, V3, P191; SMITH TJ, 1993, P NATL ACAD SCI USA, V90, P7015, DOI 10.1073/pnas.90.15.7015; SMITH TJ, 1993, J VIROL, V67, P1148, DOI 10.1128/JVI.67.3.1148-1158.1993; SMITH TJ, 1995, P NATL ACAD SCI USA, V92, P10648, DOI 10.1073/pnas.92.23.10648; SMITH TJ, 1986, SCIENCE, V233, P1286, DOI 10.1126/science.3018924; STANFIELD RL, 1994, TRENDS BIOTECHNOL, V12, P275, DOI 10.1016/0167-7799(94)90139-2; Tomlinson IM, 1996, J MOL BIOL, V256, P813, DOI 10.1006/jmbi.1996.0127; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; VERDAGUER N, 1995, EMBO J, V14, P1690, DOI 10.1002/j.1460-2075.1995.tb07158.x; WANG KS, 1991, VIROLOGY, V181, P694, DOI 10.1016/0042-6822(91)90903-O; WIEN MW, 1995, NAT STRUCT BIOL, V2, P232, DOI 10.1038/nsb0395-232	29	137	140	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					350	354		10.1038/383350a0	http://dx.doi.org/10.1038/383350a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848050	Green Submitted, Green Accepted			2022-12-28	WOS:A1996VJ43900049
J	Bloom, FE				Bloom, FE			An Internet review: The compleat neuroscientist scours the World Wide Web	SCIENCE			English	Article								The World Wide Web provides a graphical interface that allows users to explore the multiple databases of information that are accessible on the Internet. In the field of neuroscience, several hundred sites contain potentially pertinent information. This article takes a critical look at those sites and offers recommendations to those seeking broad neuroscience resources as well as those desiring sites specialized for the developmental neurosciences.			Bloom, FE (corresponding author), Scripps Res Inst, DEPT NEUROPHARMACOL, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							GIBSON W, 1981, NEUROMANCER; 1996, NY TIMES MAGAZI 0714	2	8	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1104	1108		10.1126/science.274.5290.1104	http://dx.doi.org/10.1126/science.274.5290.1104			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895452				2022-12-28	WOS:A1996VT33500028
J	Li, YM; Milne, JC; Madison, LL; Kolter, R; Walsh, CT				Li, YM; Milne, JC; Madison, LL; Kolter, R; Walsh, CT			From peptide precursors to oxazole and thiazole-containing peptide antibiotics: Microcin B17 synthase	SCIENCE			English	Article							ESCHERICHIA-COLI; DNA GYRASE; BACKBONE MODIFICATIONS; RECOGNITION SITE; INHIBITOR; PROTEIN; SEQUENCE; CARBOXYLATION; PURIFICATION; MATURATION	Esherichia coli microcin B17 is a posttranslationally modified peptide that inhibits bacterial DNA gyrase. it contains four oxazole and four thiazole rings and is representative of a broad class of pharmaceutically important natural products with five-membered heterocycles derived from peptide precursors. An in vitro assay was developed to detect heterocycle formation, and an enzyme complex, microcin B17 synthase, was purified and found to contain three proteins, McbB, McbC, and McbD, that convert 14 residues into the eight mono- and bisheterocyclic moieties in vitro that confer antibiotic activity on mature microcin B17. These enzymatic reactions alter the peptide backbone connectivity, The propeptide region of premicrocin is the major recognition determinant for binding and downstream heterocycle formation by microcin B17 synthase, A general pathway for the enzymatic biosynthesis of these heterocycles is formulated.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NIAID NIH HHS [5T32AI07410-03] Funding Source: Medline; NIGMS NIH HHS [GM20011, 5T32GM07306-19] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007306, R01GM020011, R37GM020011] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BARRY AL, 1995, ANTIMICROB AGENTS CH, V39, P238, DOI 10.1128/AAC.39.1.238; BAYER A, 1993, ANGEW CHEM INT EDIT, V32, P1336, DOI 10.1002/anie.199313361; BAYER A, 1995, EUR J BIOCHEM, V234, P414, DOI 10.1111/j.1432-1033.1995.414_b.x; BENSON TE, 1993, BIOCHEMISTRY-US, V32, P2024, DOI 10.1021/bi00059a019; Bergmeyer H., 1974, METHODS ENZYMATIC AN, V1, P457; Chen T., UNPUB; CLARKE ND, 1994, P NATL ACAD SCI USA, V91, P11084, DOI 10.1073/pnas.91.23.11084; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; DAVAGNINO J, 1986, Proteins Structure Function and Genetics, V1, P230, DOI 10.1002/prot.340010305; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; FLOSS HG, 1989, ANGEW CHEM INT EDIT, V28, P146, DOI 10.1002/anie.198901461; FREEMAN C, 1995, DIAGN MICR INFEC DIS, V21, P47, DOI 10.1016/0732-8893(94)00113-B; GARRIDO MD, 1988, EMBO J, V7, P1853, DOI 10.1002/j.1460-2075.1988.tb03018.x; GENILLOUD O, 1989, J BACTERIOL, V171, P1126, DOI 10.1128/jb.171.2.1126-1135.1989; GILSON L, 1987, J BACTERIOL, V169, P2466, DOI 10.1128/jb.169.6.2466-2470.1987; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6153, DOI 10.1093/nar/20.23.6153; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; IRELAND CM, 1982, J ORG CHEM, V47, P1807, DOI 10.1021/jo00349a002; JANSEN R, 1992, LIEBIGS ANN CHEM, P357; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; JURKIEWICZ E, 1992, ANTIVIR CHEM CHEMOTH, V3, P189, DOI 10.1177/095632029200300401; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEWIS JR, 1995, NAT PROD REP, V12, P135, DOI 10.1039/np9951200135; LI Y, UNPUB; MADISON LL, IN PRESS MOL MICROBI; MANDERVILLE RA, 1994, J AM CHEM SOC, V116, P10851, DOI 10.1021/ja00102a087; MILLAN JLS, 1985, J BACTERIOL, V163, P1016; MILLAN JLS, 1985, J BACTERIOL, V163, P275, DOI 10.1128/JB.163.1.275-281.1985; PASCAL RA, 1983, BIOCHEMISTRY-US, V22, P171, DOI 10.1021/bi00270a025; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RUZICKA FJ, 1977, J BIOL CHEM, V252, P8440; SCARPULLA RC, 1978, J BIOL CHEM, V253, P5997; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; Siegers K, 1996, J BIOL CHEM, V271, P12294, DOI 10.1074/jbc.271.21.12294; TAKITA T, 1972, J ANTIBIOT, V25, P197, DOI 10.7164/antibiotics.25.197; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; WILLIAMS AB, 1993, CANCER LETT, V71, P97, DOI 10.1016/0304-3835(93)90103-G; WU W, 1994, J AM CHEM SOC, V116, P10843, DOI 10.1021/ja00102a083; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; YORGEY P, 1993, MOL MICROBIOL, V9, P897, DOI 10.1111/j.1365-2958.1993.tb01747.x; YORGEY P, 1994, P NATL ACAD SCI USA, V91, P4519, DOI 10.1073/pnas.91.10.4519; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	46	246	252	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1996	274	5290					1188	1193		10.1126/science.274.5290.1188	http://dx.doi.org/10.1126/science.274.5290.1188			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895467				2022-12-28	WOS:A1996VT33500053
J	Wehr, M; Laurent, G				Wehr, M; Laurent, G			Odour encoding by temporal sequences of firing in oscillating neural assemblies	NATURE			English	Article							NEURONAL-ACTIVITY; BEHAVING MONKEYS; OLFACTORY-BULB; CORTEX; RECOGNITION; PATTERN; RABBIT; CODE; CAT	STIMULUS-EVOKED oscillatory synchronization of activity has been observed in many neural systems, including the cerebral cortex of mammals and the brain of insects(1-8). The possible functions of such rhythmic synchronization in neural coding, however, remain largely speculative(9-13). In the locust, odours evoke activity in dynamic (evolving) ensembles of transiently synchronized neurons(8,14,15). We report here that the active neurons composing these ensembles change in a stimulus-specific manner and with a high degree of reliability on a cycle-by-cycle basis during an odour response. Hence, information about an odour is contained not only in the neural assembly active at each oscillation cycle, but also in the precise temporal sequence in which these assemblies are updated during an odour response. Neural coding with oscillations thus allows combinatorial representations in time as well as in space.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X				ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; BIALEK W, 1991, SCIENCE, V252, P1854, DOI 10.1126/science.2063199; BRESSLER SL, 1980, ELECTROEN CLIN NEURO, V50, P19, DOI 10.1016/0013-4694(80)90319-3; Brillinger D.R., 1981, TIME SERIES; CINELLI AR, 1995, J NEUROPHYSIOL, V73, P2053, DOI 10.1152/jn.1995.73.5.2053; FREEMAN WJ, 1960, J NEUROPHYSIOL, V23, P111, DOI 10.1152/jn.1960.23.2.111; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; GRAY CM, 1988, EXP BRAIN RES, V69, P378; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; HOPPEL E, 1986, NATURWISSENSCHAFTEN, V73, P267; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; LAURENT G, 1994, J NEUROSCI, V14, P2993; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; LAURENT G, IN PRESS TRENDS NEUR; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; PAULIN MG, 1992, BIOL CYBERN, V66, P525, DOI 10.1007/BF00204117; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; SMITH BH, 1989, ETHOLOGY, V82, P68; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; VONDERMALSBURG C, 1981, CORRELATION THEORY B, P81	29	371	377	2	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					162	166		10.1038/384162a0	http://dx.doi.org/10.1038/384162a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906790				2022-12-28	WOS:A1996VT33600064
J	Ambrosone, CB; Freudenheim, JL; Graham, S; Marshall, JR; Vena, JE; Brasure, JR; Michalek, AM; Laughlin, R; Nemoto, T; Gillenwater, KA; Harrington, AM; Shields, PG				Ambrosone, CB; Freudenheim, JL; Graham, S; Marshall, JR; Vena, JE; Brasure, JR; Michalek, AM; Laughlin, R; Nemoto, T; Gillenwater, KA; Harrington, AM; Shields, PG			Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RAT MAMMARY-GLAND; METABOLIC-ACTIVATION; ALCOHOL-CONSUMPTION; COLORECTAL-CANCER; BLADDER-CANCER; ACETYLATOR POLYMORPHISM; EPITHELIAL-CELLS; DNA ADDUCTS; PHENOTYPE; WOMEN	Objective.-To determine if N-acetyltransferase 2 (NAT2) polymorphisms result in decreased capacity to detoxify carcinogenic aromatic amines in cigarette smoke, thus making some women who smoke more susceptible to breast cancer. Design.-Case-control study with genetic analyses, DNA analyses were performed for 3 polymorphisms accounting for 90% to 95% of the slow acetylation phenotype among whites. Setting and Participants.-White women with incident primary breast cancer (n=304) and community controls (n=327). Results.-Neither smoking nor NAT2 status was independently associated with breast cancer risk. There were no clear patterns of increased risk associated with smoking by NAT2 status among premenopausal women. In postmenopausal women, NAT2 strongly modified the association of smoking with risk. For slow acetylators, current smoking and smoking in the distant past increased breast cancer risk in a dose-dependent manner (odds ratios [95% confidence intervals] for the highest quartile of cigarettes smoked 2 and 20 years previously, 4.4 [1.3-14.8] and 3.9 [1.4-10.8], respectively). Among rapid acetylators, smoking was not associated with increased breast cancer risk. Conclusions.-Our results suggest that smoking may be an important risk factor for breast cancer among postmenopausal women who are slow acetylators, demonstrate heterogeneity in response to carcinogenic exposures, and may explain previous inconsistent findings for cigarette smoking as a breast cancer risk factor.	SUNY BUFFALO,DEPT SOCIAL & PREVENT MED,BUFFALO,NY 14260; SUNY BUFFALO,DEPT SURG,BUFFALO,NY 14260; NCI,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ambrosone, CB (corresponding author), NATL CTR TOXICOL RES,DIV MOL EPIDEMIOL,3900 NCTR RD,JEFFERSON,AR 72079, USA.		Shields, Peter G/I-1644-2012	Freudenheim, Jo/0000-0002-9301-0499	NCI NIH HHS [CA-11535, CA-01633, CA-62995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA062995, P01CA011535, R01CA062995, K04CA001633] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1988, BRIT J CANCER, V58, P832, DOI 10.1038/bjc.1988.320; ALLABEN WT, 1982, CARCINOGENESIS, V3, P233, DOI 10.1093/carcin/3.3.233; ALLABEN WT, 1983, CARCINOGENESIS, V4, P1067, DOI 10.1093/carcin/4.8.1067; AMBROSONE CB, 1995, CANCER RES, V55, P3483; BARON JA, 1984, AM J EPIDEMIOL, V119, P9, DOI 10.1093/oxfordjournals.aje.a113730; BARON JA, 1986, J NATL CANCER I, V77, P677, DOI 10.1093/jnci/77.3.677; BEGG CB, 1994, CANCER EPIDEM BIOMAR, V3, P173; BELL DA, 1993, CARCINOGENESIS, V14, P1689, DOI 10.1093/carcin/14.8.1689; BLUM M, 1991, P NATL ACAD SCI USA, V99, P523; BRINTON LA, 1986, AM J EPIDEMIOL, V123, P614, DOI 10.1093/oxfordjournals.aje.a114281; BROWNSON RC, 1988, ARCH INTERN MED, V148, P140, DOI 10.1001/archinte.148.1.140; BULOVSKAYA LN, 1978, ONCOLOGY, V35, P185, DOI 10.1159/000225282; CARTWRIGHT RA, 1984, GENETIC VARIABILITY, P359; CHU SY, 1990, AM J EPIDEMIOL, V131, P244, DOI 10.1093/oxfordjournals.aje.a115494; COLDITZ GA, 1995, CANCER EPIDEM BIOMAR, V4, P67; Debiec-Rychter M., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P133; DEVITA VT, 1989, CANCER PRINCIPLES PR; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; ELDRIDGE SR, 1992, CANCER RES, V52, P5617; ELLARD GA, 1976, CLIN PHARMACOL THER, V19, P610; Evans D A, 1986, Prog Clin Biol Res, V214, P209; EWARTZ M, 1990, CANCER CAUSE CONTROL, V1, P31; FIELD NA, 1992, INT J EPIDEMIOL, V21, P842, DOI 10.1093/ije/21.5.842; GRAHAM S, 1991, AM J EPIDEMIOL, V134, P552, DOI 10.1093/oxfordjournals.aje.a116129; HANSSEN HP, 1985, EUR UROL, V11, P263; HARRIS HW, 1958, AM REV TUBERC PULM, V78, P944; HEIN DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37, DOI 10.1016/0304-419X(88)90004-2; HIATT RA, 1986, JNCI-J NATL CANCER I, V76, P833; HIATT RA, 1988, CANCER RES, V48, P2284; HIRVONEN A, 1994, CARCINOGENESIS, V15, P813, DOI 10.1093/carcin/15.5.813; ILETT KF, 1987, CANCER RES, V47, P1466; *INT AG RES CANC, 1972, MON EV CARC RISK C 1, P74; Josephy PD, 1996, MUTAGENESIS, V11, P3, DOI 10.1093/mutage/11.1.3; KADLUBAR FF, 1992, ENVIRON HEALTH PERSP, V98, P69, DOI 10.2307/3431249; KARIM AKMB, 1981, J MED GENET, V18, P325, DOI 10.1136/jmg.18.5.325; KAUFMAN DW, 1980, AM J PUBLIC HEALTH, V70, P420, DOI 10.2105/AJPH.70.4.420; KING CM, 1979, CANCER RES, V39, P3369; LADERO JM, 1987, ONCOLOGY, V44, P341, DOI 10.1159/000226508; LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675; LANG NP, 1986, ARCH SURG-CHICAGO, V121, P1259, DOI 10.1001/archsurg.121.11.1259; LESKO SM, 1985, NEW ENGL J MED, V313, P593, DOI 10.1056/NEJM198509053131001; Li DH, 1996, CANCER RES, V56, P287; LIN HJ, 1993, AM J HUM GENET, V52, P827; LONDON SJ, 1989, JNCI-J NATL CANCER I, V81, P1625, DOI 10.1093/jnci/81.21.1625; MEARA J, 1989, BRIT J CANCER, V60, P70, DOI 10.1038/bjc.1989.222; MINCHIN RF, 1993, MUTAT RES, V290, P35, DOI 10.1016/0027-5107(93)90030-J; MOMMSEN S, 1983, CARCINOGENESIS, V4, P335, DOI 10.1093/carcin/4.3.335; Morabia A, 1996, AM J EPIDEMIOL, V143, P918, DOI 10.1093/oxfordjournals.aje.a008835; NAKACHI K, 1991, CANCER RES, V51, P5177; OCONNELL DL, 1987, J NATL CANCER I, V78, P229; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1; PERERA FP, 1995, CANCER EPIDEM BIOMAR, V4, P233; PETRAKIS NL, 1978, SCIENCE, V199, P303, DOI 10.1126/science.619458; PETRAKIS NL, 1980, CANCER RES, V40, P188; PHILIP PA, 1987, EUR J CANCER CLIN ON, V23, P1701, DOI 10.1016/0277-5379(87)90453-6; PIERGORSCH WW, 1994, STAT MED, V13, P153; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; ROHAN TE, 1989, AM J EPIDEMIOL, V129, P36, DOI 10.1093/oxfordjournals.aje.a115122; ROSENBERG L, 1984, NEW ENGL J MED, V310, P92, DOI 10.1056/NEJM198401123100205; ROSS RK, 1988, DIAGNOSIS MANAGEMENT, P23; Sadrieh N, 1996, CANCER RES, V56, P2683; SALBER EJ, 1969, JNCI-J NATL CANCER I, V43, P1013; SARDAS S, 1990, INT J CANCER, V46, P1138, DOI 10.1002/ijc.2910460633; SCHATZKIN A, 1989, J NATL CANCER I, V81, P31, DOI 10.1093/jnci/81.1.31; SCHECTER MT, 1980, AM J EPIDEMIOL, V130, P213; SHIRAI T, 1981, CANCER RES, V41, P4346; STOCKWELL HG, 1987, AM J OBSTET GYNECOL, V157, P35, DOI 10.1016/S0002-9378(87)80341-1; SWAMINATHAN S, 1994, CARCINOGENESIS, V15, P611, DOI 10.1093/carcin/15.4.611; Taylor J. A., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P282; TONELLI QJ, 1979, CANCER RES, V39, P1784; VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001; VATTEN LJ, 1990, EUR J CANCER, V26, P830, DOI 10.1016/0277-5379(90)90164-O; VESSEY M, 1983, BRIT J CANCER, V47, P455, DOI 10.1038/bjc.1983.74; VINEIS P, 1994, NATURE, V369, P154, DOI 10.1038/369154a0; VINEIS P, 1990, CANCER RES, V50, P3002; WANG CY, 1988, CANCER RES, V48, P4227; YU MC, 1994, J NATL CANCER I, V86, P712, DOI 10.1093/jnci/86.9.712	77	289	293	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1494	1501		10.1001/jama.276.18.1494	http://dx.doi.org/10.1001/jama.276.18.1494			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ774	8903261				2022-12-28	WOS:A1996VQ77400032
J	Fajardo, AM; Lewis, NS				Fajardo, AM; Lewis, NS			Rate constants for charge transfer across semiconductor-liquid interfaces	SCIENCE			English	Article							ELECTRON-TRANSFER; ACETONITRILE SOLUTIONS; REDOX COUPLES; KINETICS; MOLECULES; CONTACT	Interfacial charge-transfer rate constants have been measured for n-type Si electrodes in contact with a series of viologen-based redox couples in methanol through analyses of the behavior of these junctions with respect to their current density versus potential and differential capacitance versus potential properties. The data allow evaluation of the maximum rate constant (and therefore the electronic coupling) for majority carriers in the solid as well as of the dependence of the rate constant on the driving force for transfer of delocalized electrons from the n-Si semiconducting electrode into the localized molecular redox species in the solution phase. The data are in good agreement with existing models of this interfacial electron transfer process and provide insight into the fundamental kinetic events underlying the use of semiconducting photoelectrodes in applications such as solar energy conversion.	CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA	California Institute of Technology								Bard A. J., 1980, ELECTROCHEMICAL METH; BOWLER BE, 1990, PROG INORG CHEM, V38, P259; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; DAI S, 1990, THESIS U TENNESSEE K; Deisenhofer J, 1993, PHOTOSYNTHETIC REACT; FINKLEA H, 1988, STUDIES PHYSICAL THE, V55; FREUND T, 1968, SURF SCI, V9, P119, DOI 10.1016/0039-6028(68)90167-2; GERISCHER H, 1991, J PHYS CHEM-US, V95, P1356, DOI 10.1021/j100156a060; HOMER RF, 1960, J CHEM SOC, P2498, DOI 10.1039/jr9600002498; HORROCKS BR, 1994, J PHYS CHEM-US, V98, P9106, DOI 10.1021/j100088a003; HOWARD JN, 1994, ANAL CHEM, V66, P4525, DOI 10.1021/ac00096a020; HUNIG S, 1979, LIEBIGS ANN CHEM, P727; KOBAYASHI H, 1991, J PHYS CHEM-US, V95, P813, DOI 10.1021/j100155a061; KOVAL CA, 1992, CHEM REV, V92, P411, DOI 10.1021/cr00011a004; LEWIS NS, 1991, ANNU REV PHYS CHEM, V42, P543, DOI 10.1146/annurev.physchem.42.1.543; MARCUS RA, 1965, J CHEM PHYS, V43, P679, DOI 10.1063/1.1696792; MEMMING R, 1988, TOP CURR CHEM, V143, P79; Morrison S.R., 1980, ELECTROCHEMISTRY SEM; MORRISON SR, 1969, SURF SCI, V15, P363, DOI 10.1016/0039-6028(69)90129-0; NAGASUBRAMANIAN G, 1982, J ELECTROCHEM SOC, V129, P1742, DOI 10.1149/1.2124262; NAGASUBRAMANIAN G, 1983, J ELECTROCHEM SOC, V130, P1680, DOI 10.1149/1.2120062; NAGASUBRAMANIAN G, 1983, J ELECTROCHEM SOC, V130, P385, DOI 10.1149/1.2119716; NOZIK AJ, 1981, ACS S SERIES, V146; PETER LM, 1984, ELECTROCHEMISTRY, P66; Pomykal KE, 1996, J PHYS CHEM-US, V100, P3652, DOI 10.1021/jp951779f; ROSENBLUTH ML, 1986, J AM CHEM SOC, V108, P4689, DOI 10.1021/ja00276a001; ROSENWAKS Y, 1994, J PHYS CHEM-US, V98, P2739, DOI 10.1021/j100062a007; ROSENWAKS Y, 1992, J PHYS CHEM-US, V96, P10096, DOI 10.1021/j100204a004; ROYEA WJ, UNPUB; SMITH BB, 1990, J ELECTROANAL CHEM, V277, P43, DOI 10.1016/0022-0728(90)85090-R; Smith BB, 1996, CHEM PHYS, V205, P47, DOI 10.1016/0301-0104(95)00315-0; Smith BB, 1996, CHEM PHYS, V205, P245, DOI 10.1016/0301-0104(95)00393-2; SZE SM, 1981, PHYSICS SEMICONDUCTO; TAN MX, 1994, J PHYS CHEM-US, V98, P4959, DOI 10.1021/j100070a002; TOMKIEWICZ M, 1990, ELECTROCHIM ACTA, V35, P1631, DOI 10.1016/0013-4686(90)80019-K; Uhlendorf I, 1996, J PHYS CHEM-US, V100, P4930, DOI 10.1021/jp952256a; WILLIAMS F, 1991, 91015008 US DEP EN	37	68	68	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	1996	274	5289					969	972		10.1126/science.274.5289.969	http://dx.doi.org/10.1126/science.274.5289.969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875936				2022-12-28	WOS:A1996VR79200045
J	Wu, GY; Malinow, R; Cline, HT				Wu, GY; Malinow, R; Cline, HT			Maturation of a central glutamatergic synapse	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; HIPPOCAMPAL SLICE NEURONS; NMDA RECEPTORS; VISUAL-CORTEX; TRANSMISSION; LTP; EXPRESSION; PLASTICITY; COMPONENT	Whole-cell recordings from optic tectal neurons in Xenopus tadpoles were used to study the maturation of a glutamatergic synapse. The first glutamatergic transmission is mediated only by N-methyl-D-aspartate (NMDA) receptors and is silent at resting potentials. More mature synapses acquire transmission by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors. This maturational program is mimicked by postsynaptic expression of constitutively active calcium-calmodulin-dependent protein kinase II (CaMKII). Newly formed synapses may be silent unless sufficient depolarization is provided by coincident activity that could activate postsynaptic CaMKII, resulting in the appearance of AMPA responses.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory								ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; FOX K, 1989, J NEUROSCI, V9, P2443; Glazewski S, 1996, SCIENCE, V272, P421, DOI 10.1126/science.272.5260.421; GOSHIMA Y, 1993, J NEUROSCI, V13, P559; GRIFFITH LC, 1993, NEURON, V10, P501, DOI 10.1016/0896-6273(93)90337-Q; HESTRIN S, 1990, COLD SH Q B, V55, P87; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Katz B., 1969, SHERRINGTON LECT; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, J NEUROSCI, V3, P818; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LAZAR G, 1973, J ANAT, V116, P347; LIAO D, IN PRESS LEARN MEM; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; OTMAKHOV N, 1993, NEURON, V10, P1101, DOI 10.1016/0896-6273(93)90058-Y; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; RASTAAD M, 1995, EUR J NEUROSCI, V7, P1882; SCHOLZ WK, 1988, J NEUROSCI, V8, P1039; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9; WU GY, 1995, NEURON, V14, P681, DOI 10.1016/0896-6273(95)90211-2; Zou DJ, 1996, NEURON, V16, P529, DOI 10.1016/S0896-6273(00)80072-0	35	450	455	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					972	976		10.1126/science.274.5289.972	http://dx.doi.org/10.1126/science.274.5289.972			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875937				2022-12-28	WOS:A1996VR79200046
J	Reiser, SJ				Reiser, SJ			Medicine and public health - Pursuing a common destiny	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									MED PUBL HLTH INITIAT,HOUSTON,TX		Reiser, SJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,PROGRAM HUMANITIES & TECHNOL HLTH CARE,POB 20708,6431 FANNIN,HOUSTON,TX 77225, USA.							JONES WHS, 1923, HIPPOCRATES, P1; SHALALA DE, 1996, NAT C MED PUBL HLTH; 1996, NATIONS HLTH     APR, P1	3	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1429	1430		10.1001/jama.276.17.1429	http://dx.doi.org/10.1001/jama.276.17.1429			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ464	8892720				2022-12-28	WOS:A1996VQ46400031
J	Bowie, C				Bowie, C			Tetanus toxoid for adults - Too much of a good thing	LANCET			English	Editorial Material														Bowie, Cam/0000-0002-6956-3691				BALESTRA DJ, 1993, J GEN INTERN MED, V8, P405, DOI 10.1007/BF02599616; GEORGEN PJ, 1995, NEW ENGL J MED, V332, P761; HEATH TC, 1969, MED J AUSTRALIA, V164, P593; Prevots Rebecca, 1992, Morbidity and Mortality Weekly Report, V41, P1; *UK HLTH DEP, 1996, IMM INF DIS; 1993, CDR WEEKLY, V3, P73	6	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1185	1186		10.1016/S0140-6736(05)65476-1	http://dx.doi.org/10.1016/S0140-6736(05)65476-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898031				2022-12-28	WOS:A1996VQ46700004
J	Petri, M; Roubenoff, R; Dallal, GE; Nadeau, MR; Selhub, J; Rosenberg, IR				Petri, M; Roubenoff, R; Dallal, GE; Nadeau, MR; Selhub, J; Rosenberg, IR			Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus	LANCET			English	Article							MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; HOMOCYST(E)INE; POPULATION; GROWTH; STROKE; ASSAY	Background The aim of this study was to asses whether plasma homocysteine is a risk factor for stroke and other thrombotic events in patients with systemic lupus erythematosus (SLE)-a condition known to be associated with premature atherothrombotic complications. Methods in this prospective study, we investigated the association between homocysteine and risk of stroke and thrombotic events in 337 SLE patients in the Hopkins Lupus Cohort Study, with follow-up of 1619 person-years (mean 4 . 8 [SD 1 . 7] years), Each patient had four follow-up assessments per year to obtain information about established risk factors for thrombosis and coronary artery disease. The prospectively defined endpoints were occurrence of stroke and arterial or venous thrombotic events between 1987 and 1995. Blood samples were taken at study entry from fasting patients. Plasma homocysteine, folate, vitamin B12, and pyridoxal 5'-phosphate (PLP) concentrations were measured. Raised homocysteine concentrations were defined as more than 14 . 1 mu mol/L. Findings 93% of the study population were women, 54% African American, and 45% white. The mean age of participants was 34 . 9 (SD 11 . 7) years. During follow-up there were 29 cases of stroke and 31 arterial thrombotic events. Raised homocysteine concentrations were found in 51 (15%) SLE patients. The log-transformed total homocysteine concentrations correlated with serum folate (r=0 . 31, p=0 . 0001). In univariate analyses, raised homocysteine concentrations were significantly associated with stroke (odds ratio 2 . 24 [95% CI 1 . 22-4 . 13], p=0 . 01) and arterial thrombotic events (3 . 74 [1 . 96-7 . 13], p=0 . 0001). After adjustment for established risk factors, total plasma homocysteine concentrations remained an independent risk factor for stroke (2 . 44 [1 . 04-5 . 75], p=0 . 04) and arterial thromboses (3 . 49 [0 . 97-12 . 54], p=0 . 05). Interpretation Homocysteine is a potentially modifiable, independent risk factor for stroke and thrombotic events in patients with SLE.	TUFTS UNIV,USDA,JEAN MAYER HUMAN NUTR RES CTR AGING,BOSTON,MA 02111; JOHNS HOPKINS MED INST,DEPT MED,DIV MOL & CLIN RHEUMATOL,BALTIMORE,MD 21205; TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,TUPPER RES INST,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts University; United States Department of Agriculture (USDA); Johns Hopkins University; Johns Hopkins Medicine; Tufts Medical Center; Tufts University				Roubenoff, Ronenn/0000-0002-3959-3179	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002120] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00722] Funding Source: Medline; NHLBI NIH HHS [HL 47080] Funding Source: Medline; NIDDK NIH HHS [DK 02120] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BROWN JH, 1988, BRIT MED J, V296, P1505, DOI 10.1136/bmj.296.6635.1505; BULKLEY BH, 1975, AM J MED, V58, P243, DOI 10.1016/0002-9343(75)90575-6; CAMP VM, 1983, CLIN CHEM, V29, P642; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; CUMMING RG, 1989, MED J AUSTRALIA, V150, P551, DOI 10.5694/j.1326-5377.1989.tb136692.x; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; HARPER AE, 1970, PHYSIOL REV, V50, P428, DOI 10.1152/physrev.1970.50.3.428; KATTWINKEL N, 1992, ANN INTERN MED, V116, P974, DOI 10.7326/0003-4819-116-12-974; LINDER MC, 1991, NUTR BIOCH METABOLIS, P127; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; PETRI M, 1991, J RHEUMATOL, V18, P1823; PETRI M, 1992, AM J MED, V93, P513, DOI 10.1016/0002-9343(92)90578-Y; PETRI M, 1987, ANN INTERN MED, V106, P624; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; ROUBENOFF R, 1990, ANN INTERN MED, V113, P501, DOI 10.7326/0003-4819-113-7-501; RUSSELL RM, 1993, AM J CLIN NUTR, V58, P4, DOI 10.1093/ajcn/58.1.4; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAMURA T, 1990, CLIN CHEM, V36, P1993; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; UELAND PM, 1989, ATHEROSCLEROTIC CARD, P182; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; [No title captured]; 1979, DIABETES, V28, P1039	28	341	351	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1120	1124		10.1016/S0140-6736(96)03032-2	http://dx.doi.org/10.1016/S0140-6736(96)03032-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888164	hybrid			2022-12-28	WOS:A1996VP10600008
J	Goffeau, A; Barrell, BG; Bussey, H; Davis, RW; Dujon, B; Feldmann, H; Galibert, F; Hoheisel, JD; Jacq, C; Johnston, M; Louis, EJ; Mewes, HW; Murakami, Y; Philippsen, P; Tettelin, H; Oliver, SG				Goffeau, A; Barrell, BG; Bussey, H; Davis, RW; Dujon, B; Feldmann, H; Galibert, F; Hoheisel, JD; Jacq, C; Johnston, M; Louis, EJ; Mewes, HW; Murakami, Y; Philippsen, P; Tettelin, H; Oliver, SG			Life with 6000 genes	SCIENCE			English	Article							YEAST CHROMOSOME-III; COMPLETE DNA-SEQUENCE; TRANSFER-RNA GENES; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; MEIOTIC RECOMBINATION; TY TRANSPOSITION; PHYSICAL MAPS; HOT-SPOT	The genome of the yeast Saccharomyces cerevisiae has been completely sequenced through a worldwide collaboration. The sequence of 12,068 kilobases defines 5885 potential protein-encoding genes, approximately 140 genes specifying ribosomal RNA, 40 genes for small nuclear RNA molecules, and 275 transfer RNA genes. In addition, the complete sequence provides information about the higher order organization of yeast's 16 chromosomes and allows some insight into their evolutionary history. The genome shows a considerable amount of apparent genetic redundancy, and one of the major problems to be tackled during the next stage of the yeast genome project is to elucidate the biological functions of all of these genes.	SANGER CTR,HINXTON CB10 1SA,CAMBRIDGE,ENGLAND; MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA; STANFORD UNIV,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305; UNIV PARIS 06,CNRS,URA 1149,UNITE GENET MOL LEVURES,F-75724 PARIS 15,FRANCE; UNIV PARIS 06,UPR927,F-75724 PARIS 15,FRANCE; UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY; FAC MED,CNRS,UPR 41,LAB BIOCHIM MOL,F-35043 RENNES,FRANCE; DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY; ECOLE NORMALE SUPER,CNRS,URA 1302,F-75230 PARIS 05,FRANCE; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DU,ENGLAND; MAX PLANCK INST BIOCHEM,MARTINSRIED INST PROT STRUCT,D-82152 MARTINSRIED,GERMANY; UNIV BASEL,INST APPL MICROBIOL,BASEL,SWITZERLAND; UNIV MANCHESTER,INST SCI & TECHNOL,DEPT BIOCHEM & APPL MOL BIOL,MANCHESTER M60 1QD,LANCS,ENGLAND; RIKEN,TSUKUBA LIFE SCI CTR,DIV HUMAN GENOME RES,TSUKUBA,IBARAKI 305,JAPAN	Wellcome Trust Sanger Institute; McGill University; Stanford University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; University of Munich; Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; German Cancer Research Center (DKFZ); Centre National de la Recherche Scientifique (CNRS); Washington University (WUSTL); University of Oxford; Max Planck Society; University of Basel; University of Manchester; RIKEN	Goffeau, A (corresponding author), UNIV CATHOLIQUE LOUVAIN,UNITE BIOCHIM PHYSIOL,PL CROIX SUD 2-20,B-1348 LOUVAIN,BELGIUM.		Johnston, Mark/R-6156-2019; Dujon, Bernard A/F-4971-2010; Louis, Edward/B-7920-2008; Oliver, Stephen/AAQ-5992-2021; Johnston, Mark/K-3543-2019; Mewes, Hans-Werner/A-8204-2019	Louis, Edward/0000-0003-1157-3608; Oliver, Stephen/0000-0003-3410-6439; Johnston, Mark/0000-0002-4932-7229; Mewes, Hans-Werner/0000-0002-9713-6398	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AltmannJohl R, 1996, MOL GEN GENET, V250, P69, DOI 10.1007/BF02191826; BARRELL B, UNPUB; Bassett DE, 1996, NATURE, V379, P589, DOI 10.1038/379589a0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BECAM AM, 1995, YEAST, V11, pS300; BIESSMANN H, 1992, MOL CELL BIOL, V12, P3910, DOI 10.1128/MCB.12.9.3910; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; BUSSEY H, UNPUB; CARLSON M, 1985, MOL CELL BIOL, V5, P410; CHAN CSM, 1980, P NATL ACAD SCI-BIOL, V77, P6329, DOI 10.1073/pnas.77.11.6329; CHARRON MJ, 1989, GENETICS, V122, P307; CHU WS, 1993, J BACTERIOL, V175, P6637, DOI 10.1128/jb.175.20.6637-6651.1993; DANILEVSKAYA O, 1992, MOL CELL BIOL S, V35, P83; DEMASSY B, 1995, EMBO J, V14, P4589, DOI 10.1002/j.1460-2075.1995.tb00138.x; DIETRICH FS, UNPUB; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DUJON B, UNPUB; EIGEL A, 1982, EMBO J, V1, P1245, DOI 10.1002/j.1460-2075.1982.tb00020.x; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOURY F, COMMUNICATION; FRAZER CM, 1995, SCIENCE, V270, P397; GAFNER J, 1983, EMBO J, V2, P583, DOI 10.1002/j.1460-2075.1983.tb01467.x; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; GRIESBACH CR, 1993, ENERGY ENVIRONMENT ECONOMICS: 28TH INTERSOCIETY ENERGY CONVERSION ENGINEERING CONFERENCE (IECEC-93), VOL 1, P31; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HAUBER J, 1988, NUCLEIC ACIDS RES, V16, P10623, DOI 10.1093/nar/16.22.10623; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HODGKIN J, 1995, SCIENCE, V270, P410, DOI 10.1126/science.270.5235.410; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; JACQU C, UNPUB; JI H, 1993, CELL, V73, P1007, DOI 10.1016/0092-8674(93)90278-X; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JOHNSTON MR, UNPUB; KABACK DB, 1989, P NATL ACAD SCI USA, V86, P3694, DOI 10.1073/pnas.86.10.3694; LALO D, 1993, CR ACAD SCI III-VIE, V316, P367; LANGLEROUAULT F, 1995, NUCLEIC ACIDS RES, V23, P3079, DOI 10.1093/nar/23.15.3079; LINK AJ, 1991, GENETICS, V127, P681; LOCHMULLER H, 1989, CURR GENET, V16, P247, DOI 10.1007/BF00422110; Louis EJ, 1995, YEAST, V11, P1553, DOI 10.1002/yea.320111604; LOUIS EJ, 1992, GENETICS, V131, P559; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; MEWES H, COMMUNICATION; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; MORTIMER RK, 1986, GENETICS, V113, P35; MORTIMER RK, 1995, YEAST, V11, pS574; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; MURRAY AW, 1986, CELL, V45, P529, DOI 10.1016/0092-8674(86)90284-9; NAUMOV GI, 1995, YEAST, V11, P481, DOI 10.1002/yea.320110512; NELISSEN B, 1995, FEBS LETT, V377, P32; Ohno S., 1970, EVOLUTION GENE DUPLI; Oliver S, 1996, TRENDS GENET, V12, P241, DOI 10.1016/0168-9525(96)30053-X; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; Olson M., 1991, MOL CELLULAR BIOL YE, P1; PHILIPPSEN P, UNPUB; PLANTA RJ, 1996, BIOCH CELL BIOL, V73, P825; PUMELLE B, IN PRESS YEAST; RILES L, 1993, GENETICS, V134, P81; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL P, 1986, CELL, V45, P781, DOI 10.1016/0092-8674(86)90550-7; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SAGLIOCCO S, IN PRESS YEAST; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; STEENSMA HY, 1987, MOL CELL BIOL, V7, P2894; Svetlov VV, 1995, YEAST, V11, P1439, DOI 10.1002/yea.320111502; TETTELIN H, UNPUB; THIERRY A, 1995, YEAST, V11, P121, DOI 10.1002/yea.320110204; USHINSKY SC, IN PRESS YEAST; VISWANATHAN M, 1994, GENE, V148, P149, DOI 10.1016/0378-1119(94)90249-6; VOYTAS DF, 1992, NATURE, V358, P717, DOI 10.1038/358717a0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Walsh S, 1996, TRENDS GENET, V12, P276, DOI 10.1016/0168-9525(96)60029-8; WARMINGTON JR, 1986, NUCLEIC ACIDS RES, V14, P3475, DOI 10.1093/nar/14.8.3475; WARMINGTON JR, 1987, NUCLEIC ACIDS RES, V15, P8963, DOI 10.1093/nar/15.21.8963; WICKSTEED BL, 1994, YEAST, V10, P39, DOI 10.1002/yea.320100105; Wilkins MR, 1996, BIO-TECHNOL, V14, P61, DOI 10.1038/nbt0196-61; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	82	2690	2873	13	369	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					546	&		10.1126/science.274.5287.546	http://dx.doi.org/10.1126/science.274.5287.546			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849441				2022-12-28	WOS:A1996VN91900038
J	Schuler, GD; Boguski, MS; Stewart, EA; Stein, LD; Gyapay, G; Rice, K; White, RE; RodriguezTome, P; Aggarwal, A; Bajorek, E; Bentolila, S; Birren, BB; Butler, A; Castle, AB; Chiannilkulchai, N; Chu, A; Clee, C; Cowles, S; Day, PJR; Dibling, T; Drouot, N; Dunham, I; Duprat, S; East, C; Edwards, C; Fan, JB; Fang, N; Fizames, C; Garrett, C; Green, L; Hadley, D; Harris, M; Harrison, P; Brady, S; Hicks, A; Holloway, E; Hui, L; Hussain, S; LouisDitSully, C; Ma, J; MacGilvery, A; Mader, C; Maratukulam, A; Matise, TC; McKusick, KB; Morissette, J; Mungall, A; Muselet, D; Nusbaum, HC; Page, DC; Peck, A; Perkins, S; Piercy, M; Qin, F; Quackenbush, J; Ranby, S; Reif, T; Rozen, S; Sanders, C; She, X; Silva, J; Slonim, DK; Soderlund, C; Sun, WL; Tabar, P; Thangarajah, T; VegaCzamy, N; Vollrath, D; Voyticky, S; Wilmer, T; Wu, X; Adams, MD; Auffray, C; Walter, NAR; Brandon, R; Dehejia, A; Goodfellow, PN; Houlgatte, R; Hudson, JR; Ide, SE; Iorio, KR; Lee, WY; Seki, N; Nagase, T; Ishikawa, K; Nomura, N; Phillips, C; Polymeropoulos, MH; Sandusky, M; Schmitt, K; Berry, R; Swanson, K; Torres, R; Venter, JC; Sikela, JM; Beckmann, JS; Weissenbach, J; Myers, RM; Cox, DR; James, MR; Bentley, D; Deloukas, P; Lander, ES; Hudson, TJ				Schuler, GD; Boguski, MS; Stewart, EA; Stein, LD; Gyapay, G; Rice, K; White, RE; RodriguezTome, P; Aggarwal, A; Bajorek, E; Bentolila, S; Birren, BB; Butler, A; Castle, AB; Chiannilkulchai, N; Chu, A; Clee, C; Cowles, S; Day, PJR; Dibling, T; Drouot, N; Dunham, I; Duprat, S; East, C; Edwards, C; Fan, JB; Fang, N; Fizames, C; Garrett, C; Green, L; Hadley, D; Harris, M; Harrison, P; Brady, S; Hicks, A; Holloway, E; Hui, L; Hussain, S; LouisDitSully, C; Ma, J; MacGilvery, A; Mader, C; Maratukulam, A; Matise, TC; McKusick, KB; Morissette, J; Mungall, A; Muselet, D; Nusbaum, HC; Page, DC; Peck, A; Perkins, S; Piercy, M; Qin, F; Quackenbush, J; Ranby, S; Reif, T; Rozen, S; Sanders, C; She, X; Silva, J; Slonim, DK; Soderlund, C; Sun, WL; Tabar, P; Thangarajah, T; VegaCzamy, N; Vollrath, D; Voyticky, S; Wilmer, T; Wu, X; Adams, MD; Auffray, C; Walter, NAR; Brandon, R; Dehejia, A; Goodfellow, PN; Houlgatte, R; Hudson, JR; Ide, SE; Iorio, KR; Lee, WY; Seki, N; Nagase, T; Ishikawa, K; Nomura, N; Phillips, C; Polymeropoulos, MH; Sandusky, M; Schmitt, K; Berry, R; Swanson, K; Torres, R; Venter, JC; Sikela, JM; Beckmann, JS; Weissenbach, J; Myers, RM; Cox, DR; James, MR; Bentley, D; Deloukas, P; Lander, ES; Hudson, TJ			A gene map of the human genome	SCIENCE			English	Article							FAMILIAL ALZHEIMER-DISEASE; RET PROTOONCOGENE; COLON-CANCER; MUTATIONS; EXPRESSION; SEQUENCE; INHIBITOR; CLONING; LINKAGE; BINDING	The human genome is thought to harbor 50,000 to 100,000 genes, of which about half have been sampled to date in the form of expressed sequence tags. An international consortium was organized to develop and map gene-based sequence tagged site markers on a set of two radiation hybrid panels and a yeast artificial chromosome library. More than 16,000 human genes have been mapped relative to a framework map that contains about 1000 polymorphic genetic markers. The gene map unifies the existing genetic and physical maps with the nucleotide and protein sequence databases in a fashion that should speed the discovery of genes underlying inherited human disease. The integrated resource is available through a site on the World Wide Web al http://www.ncbi.nlm.nih.gov/SCIENCE96/.	STANFORD UNIV, SCH MED, CTR HUMAN GENOME, DEPT GENET, STANFORD, CA 94305 USA; MIT, WHITEHEAD INST BIOMED RES, CTR GENOME RES, CAMBRIDGE, MA 02142 USA; GENETHON, CNRS, URA 1922, F-91000 EVRY, FRANCE; SANGER CTR, HINXTON CB10 1SA, CAMBRIDGE, ENGLAND; UNIV OXFORD, WELLCOME TRUST CTR HUMAN GENET, NUFFIELD DEPT CLIN MED, OXFORD OX3 7BN, ENGLAND; ROCKEFELLER UNIV, LAB STAT GENET, NEW YORK, NY 10021 USA; CHU LAVAL, CTR RECH, ST FOY, PQ G1V 4G2, CANADA; INST GENOM RES, ROCKVILLE, MD 20850 USA; EUROPEAN MOL BIOL LAB OUTSTN, EUROPEAN BIOINFORMAT INST, CAMBRIDGE CB10 1SD, ENGLAND; CNRS, UPR 420, F-94801 VILLEJUIF, FRANCE; UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, PROGRAM MOL BIOL, DENVER, CO 80262 USA; NIH, NATL CTR HUMAN GENOME RES, LAB GENET DIS RES, BETHESDA, MD 20892 USA; UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE CB2 3EH, ENGLAND; RES GENET INC, HUNTSVILLE, AL 35801 USA; KAZUSA DNA RES INST, CHIBA 292, JAPAN; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1A4, CANADA; MCGILL UNIV, DEPT HUMAN GENET, MONTREAL, PQ H3G 1A4, CANADA; MCGILL UNIV, MONTREAL GEN HOSP, RES INST, MONTREAL, PQ H3G 1A4, CANADA	Stanford University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Centre National de la Recherche Scientifique (CNRS); Wellcome Trust Sanger Institute; University of Oxford; Wellcome Centre for Human Genetics; Rockefeller University; Laval University; J. Craig Venter Institute; European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Cambridge; Kazusa DNA Research Institute; Massachusetts Institute of Technology (MIT); McGill University; McGill University; McGill University	Schuler, GD (corresponding author), NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, NIH, 8600 ROCKVILLE PIKE, BETHESDA, MD 20894 USA.		Houlgatte, Remi/P-3020-2017; Deloukas, Panos/B-2922-2013; Beckmann, Jacques S/A-9772-2008; Hicks, Andrew Anthony/E-9518-2017; Mungall, Andrew J./U-7067-2018; Schuler, Gregory/A-5591-2016; Rozen, Steven G./J-5939-2013	Deloukas, Panos/0000-0001-9251-070X; Beckmann, Jacques S/0000-0002-9741-1900; Hicks, Andrew Anthony/0000-0001-6320-0411; Mungall, Andrew J./0000-0002-0905-2742; Walter, Nicole/0000-0003-0431-8078; White, Robert/0000-0002-5115-2173; Schuler, Gregory/0000-0003-0162-1135; Rozen, Steven G./0000-0002-4288-0056; Dunham, Ian/0000-0003-2525-5598; Quackenbush, John/0000-0002-2702-5879; Fizames, Cecile/0000-0002-0551-8250; Hudson, Thomas/0000-0002-1376-4849	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000835, P50HG000206] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00098, HG00206, HG00835] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; ALTSCHUL SF, 1993, J MOL EVOL, V36, P290, DOI 10.1007/BF00160485; ANTEQUERA F, 1994, NAT GENET, V8, P114, DOI 10.1038/ng1094-114a; ARONSON JS, 1996, KGENOME RES, V6, P829; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P21, DOI 10.1093/nar/24.1.21; BAIROCH A, COMMUNICATION; Bassett DE, 1996, NATURE, V379, P589, DOI 10.1038/379589a0; BATTEY J, 1978, CELL, V14, P143, DOI 10.1016/0092-8674(78)90309-4; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; BILLINGSLEY GD, 1993, AM J HUM GENET, V52, P343; Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; BrayWard P, 1996, GENOMICS, V32, P1, DOI 10.1006/geno.1996.0070; BRENNER S, 1990, CIBA F SYMP, V149, P6; CHAO KM, 1992, COMPUT APPL BIOSCI, V8, P481; CHUMAKOV IM, 1995, NATURE, V377, P175; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; CRAIG JM, 1993, BIOESSAYS, V15, P349, DOI 10.1002/bies.950150510; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DIB C, 1996, NATURE, V380, pR3; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FASMAN KH, 1994, NUCLEIC ACIDS RES, V22, P3462, DOI 10.1093/nar/22.17.3462; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hieter P, 1996, NAT GENET, V13, P253, DOI 10.1038/ng0796-253; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JACOB F, 1964, CR HEBD ACAD SCI, V258, P3125; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Makalowski W, 1996, GENOME RES, V6, P846, DOI 10.1101/gr.6.9.846; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; NOWAK R, 1994, SCIENCE, V263, P608, DOI 10.1126/science.7508142; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; ROMANO V, 1988, CYTOGENET CELL GENET, V48, P148, DOI 10.1159/000132612; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Schuler GD, 1996, METHOD ENZYMOL, V266, P141; Sharp P A, 1980, Methods Enzymol, V65, P750; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SIKELA JM, 1993, NAT GENET, V3, P189, DOI 10.1038/ng0393-189; STEWART E, COMMUNICATION; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TUGENDREICH S, 1994, HUM MOL GENET, V3, P1509, DOI 10.1093/hmg/3.suppl_1.1509; WILCOX AS, 1991, NUCLEIC ACIDS RES, V19, P1837, DOI 10.1093/nar/19.8.1837	62	893	936	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	1996	274	5287					540	546		10.1126/science.274.5287.540	http://dx.doi.org/10.1126/science.274.5287.540			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849440				2022-12-28	WOS:A1996VN91900037
J	Boehler, A; Speich, R; Russi, EW; Weder, W				Boehler, A; Speich, R; Russi, EW; Weder, W			Lung transplantation for lymphangioleiomyomatosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY LYMPHANGIOLEIOMYOMATOSIS; ALLOGRAFT RECIPIENTS; CT FINDINGS; LYMPHANGIOMYOMATOSIS; RECURRENCE; SINGLE; RETROPERITONEAL; ANGIOMYOLIPOMA; TAMOXIFEN	Background Lymphangioleiomyomatosis is a rare disease of unknown origin that usually leads to progressive deterioration of lung function and eventual death from respiratory failure. It occurs in women of reproductive age and people with tuberous sclerosis. Lung transplantation is a recent therapeutic approach. Methods We conducted a retrospective study by questionnaire of 34 patients, treated at 16 transplantation centers, who underwent lung transplantation for end-stage lymphangioleiomyomatosis between 1983 and 1995. Results Of the 34 patients, 27 received single-lung transplants; 6, bilateral transplants; and 1, a heart-lung transplant. As of August 31, 1995, the actuarial survival calculated by the Kaplan-Meier method was 69 percent after one year and 58 percent after two years. Eighteen patients were alive a mean (+/-SD) of 33+/-20 months (range, 3 to 74) after transplantation. Forced expiratory volume in one second increased from 24+/-12 percent of the predicted value before transplantation to 48+/-16 percent six months after transplantation. Five early deaths (within one month) were due to hemorrhage (in one patient), acute lung injury (in three), and dehiscence of the bronchial anastomosis (in one). Eleven late deaths (after one month) were due to infections (in eight patients), bronchiolitis obliterans (in two), and metastatic nephroblastoma (in one). Disease-associated problems were extensive pleural adhesions in 18 patients, leading to moderate-to-severe intraoperative hemorrhage in 4; pneumothorax in the native lung after single-lung transplantation in 6 patients; postoperative chylothorax in 3; and recurrent lymphangioleiomyomatosis in the allograft in 1 patient, who died of disseminated aspergillosis. Conclusions Although disease-related complications are frequent, lung transplantation can be a valuable therapy for patients with end-stage lymphangioleiomyomatosis. (C) 1996, Massachusetts Medical Society.	UNIV ZURICH HOSP,DEPT SURG,CH-8091 ZURICH,SWITZERLAND; ST LOUIS INT LUNG TRANSPLANT REGISTRY,ST LOUIS,FRANCE	University of Zurich; University Zurich Hospital	Boehler, A (corresponding author), UNIV ZURICH HOSP,DEPT INTERNAL MED,CH-8091 ZURICH,SWITZERLAND.		Russi, Erich/AGN-8387-2022					BAZ MA, 1995, AM J RESP CRIT CARE, V151, P895; BLUTE ML, 1988, J UROLOGY, V139, P20, DOI 10.1016/S0022-5347(17)42276-2; BOEHLER A, 1995, CHEST, V107, P582; BRADLEY SL, 1980, LUNG, V158, P69, DOI 10.1007/BF02713706; BURGER CD, 1991, AM REV RESPIR DIS, V143, P1030, DOI 10.1164/ajrccm/143.5_Pt_1.1030; CARRINGTON CB, 1977, AM REV RESPIR DIS, V116, P977; CLEMM C, 1987, KLIN WOCHENSCHR, V65, P391, DOI 10.1007/BF01745582; CORRIN B, 1975, AM J PATHOL, V79, P348; ELIASSON AH, 1989, CHEST, V96, P1352, DOI 10.1378/chest.96.6.1352; ESTENNE M, 1987, AM REV RESPIR DIS, V135, P976, DOI 10.1164/arrd.1987.135.4.976; ESTENNE M, 1984, LANCET, V1, P275; FROST AE, 1993, AM REV RESPIR DIS, V148, P1401, DOI 10.1164/ajrccm/148.5.1401; JOHNSON BA, 1993, AM REV RESPIR DIS, V148, P1373, DOI 10.1164/ajrccm/148.5.1373; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERR LA, 1993, UROLOGY, V41, P440, DOI 10.1016/0090-4295(93)90504-4; KITAICHI M, 1995, AM J RESP CRIT CARE, V151, P527, DOI 10.1164/ajrccm.151.2.7842216; KLEIN M, 1992, ARCH GYNECOL OBSTET, V252, P99, DOI 10.1007/BF02389635; KNOOP C, 1994, TRANSPLANTATION, V57, P1679; LIZOTTE PE, 1990, CHEST, V98, P1044, DOI 10.1378/chest.98.4.1044; NINE JS, 1994, J HEART LUNG TRANSPL, V13, P714; OBRIEN JD, 1995, AM J RESP CRIT CARE, V151, P2033, DOI 10.1164/ajrccm.151.6.7767554; RADERMECKER M, 1992, CHEST, V101, P1724, DOI 10.1378/chest.101.6.1724; RAPPAPORT DC, 1989, AM J ROENTGENOL, V152, P961, DOI 10.2214/ajr.152.5.961; ROSSI GA, 1991, AM REV RESPIR DIS, V143, P174, DOI 10.1164/ajrccm/143.1.174; SIDER L, 1995, CHEST, V107, P860, DOI 10.1378/chest.107.3.860; SILVERSTEIN EF, 1974, AM J ROENTGENOL, V120, P832, DOI 10.2214/ajr.120.4.832; SLEIMAN C, 1992, AM REV RESPIR DIS, V145, P964, DOI 10.1164/ajrccm/145.4_Pt_1.964; SPEICH R, 1995, SCHWEIZ MED WSCHR, V125, P786; SPENCER JA, 1992, EUR J RADIOL, V14, P192, DOI 10.1016/0720-048X(92)90085-N; TAYLOR JR, 1990, NEW ENGL J MED, V323, P1254, DOI 10.1056/NEJM199011013231807; von Stossel E, 1937, BEITR KLIN TUBERK, V90, P432; WELLENS F, 1985, J THORAC CARDIOV SUR, V89, P872; WOODRING JH, 1994, CLIN IMAG, V18, P7, DOI 10.1016/0899-7071(94)90138-4; Yeatman M, 1996, J HEART LUNG TRANSPL, V15, P144	34	141	145	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1275	1280		10.1056/NEJM199610243351704	http://dx.doi.org/10.1056/NEJM199610243351704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857007				2022-12-28	WOS:A1996VN59400004
J	Hopton, J; Hogg, R; McKee, I				Hopton, J; Hogg, R; McKee, I			Patients' accounts of calling the doctor out of hours: Qualitative study in one general practice	BRITISH MEDICAL JOURNAL			English	Article							NIGHT VISITING RATES; NORMAL WORKING HOURS; CARE; ORGANIZATION; SERVICES; DEMAND	Objective-To investigate patients' accounts of calling the doctor out of hours, Design-Qualitative analysis of semi-structured interviews with two groups of patients who called their doctors out of hours from one general practice. Subjects-23 people who had called the doctor on their behalf or on behalf of another adult and 23 people who had called on behalf of a child between 6 pm and 8 am on a week day (omitting the weekend from 6 pm on Friday to 8 am on Monday). Results-Although respondents described symptoms as the main reason for the call, they also described a range of other factors that led to the call, including their feelings, concerns about specific illnesses, their responsibility for others, and their previous attempts to manage the problem themselves. They also described past experiences with health services that were important in explaining the current out of hours call or explaining their general approach to using services. Conclusions-The pursuit of a model of out of hours care based on medical necessity that neglects the psychosocial context of illness may not be appropriate. The importance of previous experiences of health services and contacts with health professionals in explaining current service use requires wider acknowledgement by health professionals across sectors. Separate educational programmes to encourage patients to use out of hours services more appropriately that neglect these issues may be too simplistic.	WESTERHAILES HLTH CTR,EDINBURGH EH14 2SS,MIDLOTHIAN,SCOTLAND		Hopton, J (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,MIDLOTHIAN,SCOTLAND.							ARMSTRONG D, 1979, SOC SCI MED-MED SOC, VA13, P1, DOI 10.1016/0271-7123(79)90002-6; BUXTON MJ, 1977, BRIT MED J, V1, P827, DOI 10.1136/bmj.1.6064.827; CARTISLE RD, 1993, BRIT MED J, V306, P1383; COWIE B, 1976, SOC SCI MED, V10, P87, DOI 10.1016/0037-7856(76)90059-7; CUBITT T, 1983, BRIT MED J, V287, P28, DOI 10.1136/bmj.287.6384.28; Cunningham-Burley Sarah, 1990, READINGS MED SOCIOLO, P85; CUNNINGHAMBURLEY S, 1987, BMJ-BRIT MED J, V295, P700, DOI 10.1136/bmj.295.6600.700; DONABEDIAN A, 1973, ASPECTS MED CARE ADM; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; HALLAM L, 1994, BRIT MED J, V309, P1621, DOI 10.1136/bmj.309.6969.1621; HOPTON JL, 1995, BRIT MED J, V310, P1369, DOI 10.1136/bmj.310.6991.1369; LIVINGSTONE AE, 1984, BRIT MED J, V289, P474; Lofland J., 1996, ANAL SOCIAL SETTINGS; MAIN JA, 1989, BRIT MED J, V299, P627, DOI 10.1136/bmj.299.6699.627-b; MAJEED FA, 1995, BRIT J GEN PRACT, V45, P531; MORGAN M, 1985, SOCIOLOGICAL APPROAC, P76; MORRISON JM, 1991, BRIT MED J, V303, P1111, DOI 10.1136/bmj.303.6810.1111; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; Robinson D., 1973, PATIENTS PRACTITIONE; SALISBURY C, 1993, BRIT MED J, V306, P762, DOI 10.1136/bmj.306.6880.762; Stott N C, 1979, J R Coll Gen Pract, V29, P201; Strauss A., 1990, BASICS QUALITATIVE R; TELLES JL, 1981, SOC SCI MED A, V13, P243; USHERWOOD TP, 1985, J ROY COLL GEN PRACT, V35, P395; WILLIAMS G, 1984, SOCIOL HEALTH ILL, V6, P175, DOI 10.1111/1467-9566.ep10778250; ZOLA IK, 1973, SOC SCI MED, V7, P677, DOI 10.1016/0037-7856(73)90002-4	26	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					991	994						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892422				2022-12-28	WOS:A1996VN91600028
J	Corlett, AJ				Corlett, AJ			Aids to compliance with medication	BRITISH MEDICAL JOURNAL			English	Article								Elderly people may need to take several forms of medication, including tablets and capsules, inhalers, insulin, and eye drops. This article describes various aids that are designed to facilitate compliance.			Corlett, AJ (corresponding author), ST JAMES UNIV HOSP,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							MORRISON J, 1993, HOSP PHARM PRACTICE, V3, P413; *ROYAL PHARM SOC G, 1994, MED ETH PRACT GUID P, V12, P9; WALKER R, 1992, PHARM J, V249, P608; 1989, DRUGS THERAPEUTICS B, V27, P66; 1992, DRUGS THERAPEUTICS B, V30, P3	5	37	38	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					926	929						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876101				2022-12-28	WOS:A1996VM75400033
J	Jarlais, DCD; Marmor, M; Paone, D; Titus, S; Shi, QH; Perlis, T; Jose, B; Friedman, SR				Jarlais, DCD; Marmor, M; Paone, D; Titus, S; Shi, QH; Perlis, T; Jose, B; Friedman, SR			HIV incidence among injecting drug users in New York City syringe-exchange programmes	LANCET			English	Article							INFECTION; ABUSERS; AIDS	Background There have been no studies showing that participation in programmes which provide legal access to drug-injection equipment leads to individual-level protection against incident HIV infection. We have compared HIV incidence among injecting drug users participating in syringe-exchange programmes in New York City with that among non-participants. Methods We used meta-analytic techniques to combine HIV incidence data from injecting drug users in three studies: the Syringe Exchange Evaluation (n=280), in which multiple interviews and saliva samples were collected from participants at exchange sites; the Vaccine Preparedness Initiative cohort (n=133 continuing exchangers and 188 non-exchangers, in which participants were interviewed and tested for HIV every 3 months; and very-high-seroprevalence cities in the National AIDS Demonstration Research (NADR) programme (n=1029), in which street-recruited individuals were interviewed and tested for HIV every 6 months. In practice, participants in the NADR study had not used syringe exchanges. Findings HIV incidence among continuing exchange-users in the Syringe Exchange Evaluation was 1 . 58 per 100 person . years at risk (95% CI 0 . 54, 4 . 65) and among continuing exchange-users in the Vaccine Preparedness Initiative it was 1 . 38 per 100 person-years at risk (0 . 23, 4 . 57), Incidence among non-users of the exchange in the Vaccine Preparedness Initiative was 5 . 26 per 100 person-years at risk (2 . 41, 11 . 49), and in the NADR cities, 6 . 23 per 100 person-years at risk (4 . 4, 8 . 6). In a pooled-data, multivariate proportional-hazards analysis, not using the exchanges was associated with a hazard ratio of 3 . 35 (95% CI 1 . 29, 8 . 65) for incident HIV infection compared with using the exchanges. Interpretation We observed an individual-level protective effect against HIV infection associated with participation in a syringe-exchange programme. Sterile injection equipment should be legally provided to reduce the risk of HIV infection in persons who inject illicit drugs.	NYU MED CTR, NEW YORK, NY 10016 USA; NATL DEV & RES INST INC, NEW YORK, NY USA	New York University; National Development & Research Institutes, Inc	Jarlais, DCD (corresponding author), BETH ISRAEL MED CTR, INST CHEM DEPENDENCY, 1ST AVE & 16TH ST, NEW YORK, NY 10003 USA.			Marmor, Michael/0000-0001-6605-2661; Friedman, Sam/0000-0003-2083-1226	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003574] Funding Source: NIH RePORTER; NIDA NIH HHS [DA03574, DA06001, DA05283] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERSON W, 1991, AM J PUBLIC HEALTH, V81, P1506, DOI 10.2105/AJPH.81.11.1506; Brown B. S., 1993, HDB RISK AIDS INJECT; CAUSSY D, 1990, AIDS RES HUM RETROV, V6, P1459, DOI 10.1089/aid.1990.6.1459; Collett D., 1995, MODELLING SURVIVAL D; COLON H, 1992, C HIV AIDS EP COMM P; COOK TD, 1994, META ANAL EXPLANATIO; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P503; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DESJARLAIS DC, 1992, ANN AM ACAD POLIT SS, V521, P42; DESJARLAIS DC, 1985, ANN INTERN MED, V103, P755; DESJARLAIS DC, 1994, CURRENT FINDINGS SYR; DESJARLAIS DC, 1996, CURR ISSUES PUBLIC H, V2, P130; FRIEDMAN SR, 1995, AM J EPIDEMIOL, V142, P864, DOI 10.1093/oxfordjournals.aje.a117726; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; HORSBURGH CR, 1989, LANCET, V2, P637; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; MARMOR M, 1987, AIDS, V1, P39; MARMOR T, 1994, AIDS RES HUMAN RET S, V10, pS207; NEAIGUS A, 1993, ANN AM PUBL HLTH ASS; NORMAND J, 1995, PREVENTING HIV TRANS; ORR MF, IN PRESS JAMA; Orwin R.G., 1994, HDB RES SYNTHESIS; PAONE D, 1994, P WORKSH NEEDL EXCH, P47; *SAS I, 1993, SAS STAT US GUID; SIDDIQUI NS, 1993, J PSYCHOACTIVE DRUGS, V25, P245, DOI 10.1080/02791072.1993.10472275; SPITZER WO, 1995, J CLIN EPIDEMIOL, V48, P1, DOI 10.1016/0895-4356(94)00109-4; STIMSON GV, 1989, AIDS, V3, P253, DOI 10.1097/00002030-198905000-00001; *US GOV ACC OFF, 1993, NEED EXCH PROGR RES	30	296	299	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	1996	348	9033					987	991		10.1016/S0140-6736(96)02536-6	http://dx.doi.org/10.1016/S0140-6736(96)02536-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855855	hybrid			2022-12-28	WOS:A1996VM02700011
J	Olsen, SF; Martuzzi, M; Elliott, P				Olsen, SF; Martuzzi, M; Elliott, P			Cluster analysis and disease mapping - Why, when, and how? A step by step guide	BRITISH MEDICAL JOURNAL			English	Article							RISKS	Growing public awareness of environmental hazards has led to an increased demand for public health authorities to investigate geographical clustering of diseases. Although such cluster analysis is nearly always ineffective in identifying causes of disease, it often has to be used to address public concern about environmental hazards. Interpreting the resulting data is not straightforward, however, and this paper presents a guide for the non-specialist. The pitfalls include the fact that cluster analyses are usually done post hoc, and not as a result of a prior hypothesis. This is particularly true for investigations prompted by reported clusters, which have the inherent danger of overestimating the disease rate through ''boundary shrinkage'' of the population from which the cases are assumed to have arisen. In disease surveillance the problem of making multiple comparisons can be overcome by testing for clustering and autocorrelation. When rates of disease are illustrated in disease maps undue focus on areas where random fluctuation is greatest can be minimised by smoothing techniques. Despite the fact that cluster analyses rarely prove fruitful in identifying causation, they may-like single case reports-have the potential to generate new knowledge.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND; ST MARYS HOSP,SCH MED,IMPERIAL COLL,DEPT EPIDEMIOL & PUBL HLTH,LONDON W2 1PG,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; Imperial College London	Olsen, SF (corresponding author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DK-2300 COPENHAGEN S,DENMARK.			Olsen, Sjurdur/0000-0003-3017-7096				BULPITT CJ, 1987, LANCET, V1, P494; CLAYTON D, 1987, BIOMETRICS, V43, P671, DOI 10.2307/2532003; Clayton D., 1992, GEOGRAPHICAL ENV EPI; ELLIOTT P, 1995, OCCUP ENVIRON MED, V52, P785, DOI 10.1136/oem.52.12.785; Elliott P, 1996, BRIT J CANCER, V73, P702, DOI 10.1038/bjc.1996.122; ELLIOTT P, 1992, LANCET, V339, P854, DOI 10.1016/0140-6736(92)90290-J; Esteve J, 1994, STAT METHODS CANC RE; GARDNER MJ, 1989, J ROY STAT SOC A STA, V152, P307, DOI 10.2307/2983129; Knox E.G., 1989, METHODOLOGY ENQUIRIE, P17; NEUTRA RR, 1990, AM J EPIDEMIOL, V132, P1; ROTHMAN KJ, 1990, J EPIDEMIOLOGY S, V132, pS6; WALTER LA, 1995, EPIDEMIOLOGY, V6, P584; [No title captured]; [No title captured]; 1990, MORBIDITY MORTALITY, V39, P1	15	77	80	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					863	866						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870578				2022-12-28	WOS:A1996VL55900029
J	Cohen, B; Novick, D; Rubinstein, M				Cohen, B; Novick, D; Rubinstein, M			Modulation of insulin activities by leptin	SCIENCE			English	Article							NECROSIS-FACTOR-ALPHA; RECEPTOR SUBSTRATE-1; TYROSINE PHOSPHORYLATION; OBESE GENE; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNALING SYSTEM; BODY-WEIGHT; OB PROTEIN; IRS-1; MOUSE	Leptin mediates its effects on food intake through the hypothalamic form of its receptor OB-R. Variants of OB-R are found in other tissues, but their function is unknown. Here, an OB-R variant was found in human hepatic cells. Exposure of these cells to leptin, at concentrations comparable with those present in obese individuals, caused attenuation of several insulin-induced activities, including tyrosine phosphorylation of the insulin receptor substrate-1 (IRS-1), association of the adapter molecule growth factor receptor-bound protein 2 with IRS-1, and down-regulation of gluconeogenesis. In contrast, leptin increased the activity of IRS-1-associated phosphatidylinositol 3-kinase. These in vitro studies raise the possibility that leptin modulates insulin activities in obese individuals.	WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; COHEN B, 1995, MOL CELL BIOL, V15, P4208; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FELBER JP, 1995, METABOLISM, V44, P4, DOI 10.1016/0026-0495(95)90201-5; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PERNIS A, 1995, P NATL ACAD SCI USA, V92, P7971, DOI 10.1073/pnas.92.17.7971; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; WHITE MF, 1994, J BIOL CHEM, V269, P1; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; YIN TG, 1994, J BIOL CHEM, V269, P26614; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	41	608	636	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1185	1188		10.1126/science.274.5290.1185	http://dx.doi.org/10.1126/science.274.5290.1185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895466				2022-12-28	WOS:A1996VT33500052
J	Egerman, RS; Emerson, DS				Egerman, RS; Emerson, DS			A fetal yawn	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Egerman, RS (corresponding author), UNIV TENNESSEE,MEMPHIS,TN 38103, USA.								0	4	4	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1497	1497		10.1056/NEJM199611143352005	http://dx.doi.org/10.1056/NEJM199611143352005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT340	8890101				2022-12-28	WOS:A1996VT34000005
J	Dickson, RM; Norris, DJ; Tzeng, YL; Moerner, WE				Dickson, RM; Norris, DJ; Tzeng, YL; Moerner, WE			Three-dimensional imaging of single molecules solvated in pores of poly(acrylamide) gels	SCIENCE			English	Article							FIELD OPTICAL MICROSCOPY; FLUORESCENCE MICROSCOPY; ELECTROPHORESIS; SPECTROSCOPY	Individual fluorescent molecules and individual singly labeled proteins were observed in the water-filled pores oi poly(acrylamide) gels by tar-field microscopy. Brownian motion was markedly reduced by the gel framework, thus enabling extended study of single fluorophores in aqueous environments. A highly axially dependent laser field was used both to excite the fluorophores and to image the molecules in three dimensions. Single molecules were followed as they moved within and through the porous gel structure. In contrast to dry polymeric hosts, these water-based gels may form a useful medium for single-molecule studies of biological systems in vitro.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute			Moerner, William E/C-3260-2008; Norris, David J/F-4022-2010	Moerner, William E/0000-0002-2830-209X; Norris, David J/0000-0002-3765-0678				AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; AXELROD D, 1989, FLUORESCENCE MICRO B, P399; BERNE BJ, 1990, DYNAMIC LIGHT SCATTE, P143; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; DABAN JR, 1991, ANAL BIOCHEM, V199, P162, DOI 10.1016/0003-2697(91)90084-7; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; Fawcett J. S., 1966, SEP SCI, V1, P9; FEINSTEI.A, 1965, NATURE, V205, P147, DOI 10.1038/205147a0; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GUTTLER F, 1994, CHEM PHYS LETT, V217, P393, DOI 10.1016/0009-2614(94)87003-9; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; HAAB BB, 1995, ANAL CHEM, V67, P3253, DOI 10.1021/ac00114a023; JACKSON JD, 1975, CLASSICAL ELECTRODYN, P283; Jasny J, 1996, REV SCI INSTRUM, V67, P1425, DOI 10.1063/1.1146868; Macklin JJ, 1996, SCIENCE, V272, P255, DOI 10.1126/science.272.5259.255; MEIXNER AJ, 1995, OPT ENG, V34, P2324, DOI 10.1117/12.200620; MOERNER WE, 1989, PHYS REV LETT, V62, P2535, DOI 10.1103/PhysRevLett.62.2535; MOERNER WE, 1994, SCIENCE, V265, P46, DOI 10.1126/science.265.5168.46; NIE SM, 1994, SCIENCE, V266, P1018, DOI 10.1126/science.7973650; OGSTON AG, 1958, T FARADAY SOC, V54, P1754, DOI 10.1039/tf9585401754; ORRIT M, 1990, PHYS REV LETT, V65, P2716, DOI 10.1103/PhysRevLett.65.2716; RODBARD D, 1976, METHODS PROTEIN SEPA, V2, P145; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; SHERA EB, 1990, CHEM PHYS LETT, V174, P553, DOI 10.1016/0009-2614(90)85485-U; Shi Q., 1990, GEL ELECTROPHORESIS; Trautman JK, 1996, CHEM PHYS, V205, P221, DOI 10.1016/0301-0104(95)00391-6; TRAUTMAN JK, 1994, NATURE, V369, P40, DOI 10.1038/369040a0; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WILKERSON CW, 1993, APPL PHYS LETT, V62, P2030, DOI 10.1063/1.109495; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361; ZIMM BH, 1993, MACROMOLECULES, V26, P226, DOI 10.1021/ma00053a035	31	324	343	5	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					966	969		10.1126/science.274.5289.966	http://dx.doi.org/10.1126/science.274.5289.966			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875935				2022-12-28	WOS:A1996VR79200044
J	Matteucci, MD; Wagner, RW				Matteucci, MD; Wagner, RW			In pursuit of antisense	NATURE			English	Article							ADHESION MOLECULE-1 EXPRESSION; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; THERAPEUTIC AGENTS; GENE INHIBITION; NUCLEIC-ACIDS; OLIGODEOXYNUCLEOTIDES; RNA; BINDING; OLIGODEOXYRIBONUCLEOTIDE; PHARMACOKINETICS				Matteucci, MD (corresponding author), GILEAD SCI INC,353 LAKESIDE DR,FOSTER CITY,CA 94404, USA.							AGRAWAL S, 1995, CLIN PHARMACOKINET, V28, P7, DOI 10.2165/00003088-199528010-00002; ALTMANN KH, IN PRESS CHIMIA; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BERGAN R, 1993, NUCLEIC ACIDS RES, V21, P3567, DOI 10.1093/nar/21.15.3567; BONHAM MA, 1995, NUCLEIC ACIDS RES, V23, P1197, DOI 10.1093/nar/23.7.1197; CHAVANY C, 1995, MOL PHARMACOL, V48, P738; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHRISTOFFERSEN RE, 1995, J MED CHEM, V38, P2023, DOI 10.1021/jm00012a001; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DEMESMAEKER A, 1995, ACCOUNTS CHEM RES, V28, P366, DOI 10.1021/ar00057a002; DEMPCY RO, 1995, P NATL ACAD SCI USA, V92, P6097, DOI 10.1073/pnas.92.13.6097; FLANAGAN WM, IN PRESS NATURE BIOT; FLANAGAN WM, IN PRESS MOL CELL BI; GALBRAITH WM, 1994, ANTISENSE RES DEV, V4, P201, DOI 10.1089/ard.1994.4.201; GHOSH MK, 1993, NUCLEIC ACIDS RES, V21, P5761, DOI 10.1093/nar/21.24.5761; GILES RV, 1995, NUCLEIC ACIDS RES, V23, P954, DOI 10.1093/nar/23.6.954; GLAZER V, 1996, GENET ENG NEWS, V16, P16; GLAZER V, 1996, GENET ENG NEWS, V16, P21; GLAZER V, 1996, GENET ENG NEWS, V16, P17; GLAZER V, 1996, GENET ENG NEWS, V16, P1; Gryaznov S, 1996, NUCLEIC ACIDS RES, V24, P1508, DOI 10.1093/nar/24.8.1508; GRYAZNOV S, 1994, J AM CHEM SOC, V116, P3143, DOI 10.1021/ja00086a062; GUERRIERTAKADA C, 1995, P NATL ACAD SCI USA, V92, P11115, DOI 10.1073/pnas.92.24.11115; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HERTL M, 1995, J INVEST DERMATOL, V104, P813, DOI 10.1111/1523-1747.ep12607006; HYRUP B, IN PRESS BIOORG BIOM; James William, 1995, Current Opinion in Biotechnology, V6, P44, DOI 10.1016/0958-1669(95)80008-5; Knudsen H, 1996, NUCLEIC ACIDS RES, V24, P494, DOI 10.1093/nar/24.3.494; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; KRIEG AM, IN PRESS LAB CLIN ME; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LIN KY, 1995, J AM CHEM SOC, V117, P3873, DOI 10.1021/ja00118a026; MAITRA RK, 1995, J BIOL CHEM, V270, P15071, DOI 10.1074/jbc.270.25.15071; MALTESE JY, 1995, NUCLEIC ACIDS RES, V23, P1146, DOI 10.1093/nar/23.7.1146; Matthews M. C., 1996, PERSPECT DRUG DISCOV, P1; MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Morvan F, 1996, J AM CHEM SOC, V118, P255, DOI 10.1021/ja9533959; MOULDS C, 1995, BIOCHEMISTRY-US, V34, P5044, DOI 10.1021/bi00015a015; SRINIVASAN SK, 1995, J CLIN LAB ANAL, V9, P129, DOI 10.1002/jcla.1860090210; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; VANAERSCHOT A, 1995, ANGEW CHEM INT EDIT, V34, P1338; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WAGNER RW, 1996, NATURE BIOTECHNOL, V14, P838; ZHANG RW, 1995, CLIN PHARMACOL THER, V58, P44, DOI 10.1016/0009-9236(95)90071-3; Zhao QY, 1996, BIOCHEM PHARMACOL, V51, P173, DOI 10.1016/0006-2952(95)02177-9	53	103	113	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604		S			20	22						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR392	8895596				2022-12-28	WOS:A1996VR39200007
J	[Anonymous]				[Anonymous]			Redesigning drug discovery	NATURE			English	Article																			0	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1996	384	6604		S			1	5						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR392	8895591				2022-12-28	WOS:A1996VR39200002
J	Kawashima, M; Nakagawa, H; Ohtsuki, M; Tamaki, K; Ishibashi, Y				Kawashima, M; Nakagawa, H; Ohtsuki, M; Tamaki, K; Ishibashi, Y			Tacrolimus concentrations in brood during topical treatment of atopic dermatitis	LANCET			English	Letter									UNIV TOKYO,FAC MED,DEPT DERMATOL,TOKYO 113,JAPAN	University of Tokyo	Kawashima, M (corresponding author), TOKYO WOMENS MED COLL,DEPT DERMATOL,TOKYO 162,JAPAN.							ABUELMAGD K, 1991, TRANSPLANT P, V23, P3322; Hanifin J., 1980, ACTA DERM-VENEREOL, V92, P42; NAKAGAWA H, 1994, LANCET, V344, P883, DOI 10.1016/S0140-6736(94)92855-X	3	58	58	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1240	1241		10.1016/S0140-6736(05)65512-2	http://dx.doi.org/10.1016/S0140-6736(05)65512-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898050				2022-12-28	WOS:A1996VQ46700046
J	Pazmany, L; Mandelboim, O; ValesGomez, M; Davis, DM; Reyburn, HT; Strominger, JL				Pazmany, L; Mandelboim, O; ValesGomez, M; Davis, DM; Reyburn, HT; Strominger, JL			Protection from natural killer cell-mediated lysis by HLA-G expression on target cells	SCIENCE			English	Article							LARGE GRANULAR LYMPHOCYTES; CLASS-I MOLECULE; NK CELLS; TROPHOBLAST; ANTIGEN; CLONES; RECOGNITION; RECEPTORS; LINE; RESISTANCE	The outermost layer of the human placenta is devoid of classical class I human leukocyte antigens (HLA-A, HLA-B, and HLA-C) and class II proteins (HLA-DR, HLA-DQ, and HLA-DP). Although this prevents recognition by maternal T lymphocytes, the lack of class I molecules leaves these cells susceptible to attack by natural killer (NK) cells. However, trophoblast cells directly in contact with the maternal tissues express the class I molecule HLA-G, which may be involved in protecting the trophoblast from recognition by NK cells. Here evidence is provided that expression of HLA-G is sufficient to protect otherwise susceptible target cells from lysis by activated NK1 and NK2 cell lines and clones that are specific for distinct groups of HLA-C alleles. The receptors on NK cells that recognize HLA-G are also identified.			Pazmany, L (corresponding author), HARVARD UNIV,DEPT MOL & CELL BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Valés-Gómez, Mar/F-5351-2012; Vales-Gomez, Mar/ABG-7808-2020; Reyburn, Hugh T/B-4338-2009	Valés-Gómez, Mar/0000-0001-7424-3206; Vales-Gomez, Mar/0000-0001-7424-3206; Reyburn, Hugh T/0000-0003-2855-1595; Davis, Daniel/0000-0002-9182-291X; Mandelboim, Ofer/0000-0002-9354-1855	NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; CHUMBLEY G, 1994, CELL IMMUNOL, V155, P312, DOI 10.1006/cimm.1994.1125; COLBERN GT, 1994, AM J OBSTET GYNECOL, V170, P1244, DOI 10.1016/S0002-9378(94)70134-2; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P7983, DOI 10.1073/pnas.89.17.7983; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; DANDREA A, 1995, J IMMUNOL, V155, P2306; DENIZ G, 1994, J IMMUNOL, V152, P4255; ELLIS SA, 1986, IMMUNOLOGY, V59, P595; ELLIS SA, 1990, J IMMUNOL, V144, P731; FAULK WP, 1976, NATURE, V262, P799, DOI 10.1038/262799a0; GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145; GONG JH, 1994, LEUKEMIA, V8, P652; KING A, 1989, HUM IMMUNOL, V24, P195, DOI 10.1016/0198-8859(89)90060-8; King A, 1996, J IMMUNOL, V156, P2068; KING A, 1991, IMMUNOL TODAY, V12, P432, DOI 10.1016/0167-5699(91)90014-K; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; LANIER LL, 1995, J IMMUNOL, V154, P3320; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MANDELBOIM O, 1986, J EXP MED, V184, P913; MELERO I, 1994, J IMMUNOL, V152, P1662; MORALES P, 1993, IMMUNOGENETICS, V38, P323; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; NATUK RJ, 1987, J IMMUNOL, V138, P877; PAZMANY L, UNPUB; REDMAN CWG, 1984, IMMUNOLOGY, V52, P457; REYNBURN HT, UNPUB; SCHMIDT CM, 1993, CRIT REV IMMUNOL, V13, P207; STARKEY PM, 1988, IMMUNOLOGY, V65, P129; STEWART I, 1984, J ANAT, V139, P627; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VANDERVEN K, 1994, J IMMUNOL, V153, P5628; VITALE M, 1995, P NATL ACAD SCI USA, V92, P3536, DOI 10.1073/pnas.92.8.3536; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Wagtmann N, 1995, IMMUNITY, V3, P801, DOI 10.1016/1074-7613(95)90069-1	35	311	331	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					792	795		10.1126/science.274.5288.792	http://dx.doi.org/10.1126/science.274.5288.792			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864122				2022-12-28	WOS:A1996VQ14500047
J	Ohman, EM; Armstrong, PW; Christenson, RH; Granger, CB; Katus, HA; Hamm, CW; OHanesian, MA; Wagner, GS; Kleiman, NS; Harrell, FE; Califf, RM; Topol, EJ				Ohman, EM; Armstrong, PW; Christenson, RH; Granger, CB; Katus, HA; Hamm, CW; OHanesian, MA; Wagner, GS; Kleiman, NS; Harrell, FE; Califf, RM; Topol, EJ			Cardiac troponin T levels for risk stratification in acute myocardial ischemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNSTABLE ANGINA; CREATINE-KINASE; PROGNOSTIC VALUE; EMERGENCY ROOM; REPERFUSION THERAPY; CLINICAL-CRITERIA; MB ISOENZYME; INFARCTION; SERUM; IDENTIFICATION	Background The prognosis of patients hospitalized with acute myocardial ischemia is quite variable. We examined the value of serum levels of cardiac troponin T, serum creatine kinase MB (CK-MB) levels, and electrocardiographic abnormalities for risk stratification in patients with acute myocardial ischemia. Methods We studied 855 patients within 12 hours of the onset of symptoms. Cardiac troponin T levels, CK-MB levels, and electrocardiograms were analyzed in a blinded fashion at the core laboratory. We used logistic regression to assess the usefulness of baseline levels of cardiac troponin T and CK-MB and the electrocardiographic category assigned at admission ST-segment elevation, ST-segment depression, T-wave inversion, or the presence of confounding factors that impair the detection of ischemia (bundle-branch block and paced rhythms) - in predicting outcome. Results On admission, 289 of 801 patients with base-line serum samples had elevated troponin T levels (>0.1 ng per milliliter). Mortality within 30 days was significantly higher in these patients than in patients with lower levels of troponin T (11.8 percent vs. 3.9 percent, P<0.001). The troponin T level was the variable most strongly related to 30-day mortality (chi-square = 21, P<0.001), followed by the electrocardiographic category (chi-square = 14, P=0.003) and the CK-MB level (chi-square = 11, P=0.004). Troponin T levels remained significantly predictive of 30-day mortality in a model that contained the electrocardiographic categories and CK-MB levels (chi-square = 9.2, P=0.027). Conclusions The cardiac troponin T level is a powerful, independent risk marker in patients who present with acute myocardial ischemia. It allows further stratification of risk when combined with standard measures such as electrocardiography and the CKMB level. (C) 1996, Massachusetts Medical Society.	DUKE UNIV, DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC USA; UNIV ALBERTA, DEPT MED, EDMONTON, AB, CANADA; UNIV MARYLAND, MED SYST, DEPT PATHOL, BALTIMORE, MD 21201 USA; UNIV HEIDELBERG, HEIDELBERG, GERMANY; UNIV HAMBURG HOSP, MED CLIN, DEPT CARDIOL, HAMBURG, GERMANY; BAYLOR COLL MED, METHODIST HOSP, HOUSTON, TX 77030 USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA	Duke University; University of Alberta; University System of Maryland; University of Maryland Baltimore; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Cleveland Clinic Foundation	Ohman, EM (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, BOX 3151, DURHAM, NC 27710 USA.		Granger, Christopher B/D-3458-2014; Hamm, Christian W./I-3155-2017	Granger, Christopher B/0000-0002-0045-3291; Hamm, Christian W./0000-0001-6763-4161; Topol, Eric/0000-0002-1478-4729; Armstrong, Paul/0000-0002-0460-3445				ABBAS SA, 1995, J AM COLL CARDIOL, V25, pA147; AKAIKE H, 1973, BIOMETRIKA, V60, P255, DOI 10.2307/2334537; [Anonymous], 1994, Circulation, V90, P1631; ANTMAN EM, 1995, JAMA-J AM MED ASSOC, V273, P1279, DOI 10.1001/jama.273.16.1279; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ARMSTRONG PW, 1982, AM J CARDIOL, V49, P1849, DOI 10.1016/0002-9149(82)90201-6; BETRIU A, 1992, J AM COLL CARDIOL, V19, P1659, DOI 10.1016/0735-1097(92)90633-X; BHAYANA V, 1995, CLIN CHEM, V41, P312; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BURLINA A, 1994, CLIN BIOCHEM, V27, P113, DOI 10.1016/0009-9120(94)90021-3; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CALVIN JE, 1995, JAMA-J AM MED ASSOC, V273, P136; COHEN M, 1991, AM J CARDIOL, V67, P1368, DOI 10.1016/0002-9149(91)90467-Y; DONNELLY R, 1993, LANCET, V341, P410, DOI 10.1016/0140-6736(93)92996-7; Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; Friedman J. H., 1984, VARIABLE SPAN SMOOTH; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HAMPTON J, 1993, LANCET, V342, P759; HARPER RW, 1979, AM HEART J, V97, P178, DOI 10.1016/0002-8703(79)90353-3; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HEDGES JR, 1992, ANN EMERG MED, V21, P1445, DOI 10.1016/S0196-0644(05)80057-5; HINDMAN NB, 1985, AM J CARDIOL, V55, P1485, DOI 10.1016/0002-9149(85)90958-0; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; HORDER M, 1979, SCAND J CLIN LAB INV, V39, P1, DOI 10.3109/00365517909104932; KARLSON BW, 1991, AM J CARDIOL, V68, P171, DOI 10.1016/0002-9149(91)90739-8; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KATUS HA, 1992, CLIN CHEM, V38, P386; LATNER BP, 1989, CLIN CHEM, V35, P1965; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; Lindhal B., 1995, European Heart Journal, V16, P40; MAIR J, 1991, CLIN CHEM, V37, P845; NORREGAARDHANSEN K, 1992, EUR HEART J, V13, P188, DOI 10.1093/oxfordjournals.eurheartj.a060145; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; RAVKILDE J, 1995, J AM COLL CARDIOL, V25, P574, DOI 10.1016/0735-1097(94)00430-X; RAVKILDE J, 1993, SCAND J CLIN LAB INV, V53, P677, DOI 10.3109/00365519309092571; REMPPIS A, 1994, BRIT HEART J, V71, P242; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; SEINO Y, 1993, LANCET, V342, P1236, DOI 10.1016/0140-6736(93)92216-G; *STAT SCI, 1995, S PLUS US MAN VERS 3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VAIDYA HC, 1986, CLIN CHEM, V32, P657; VANDIEIJENVISSE.MP, 1995, NED TIJDSCHR KLIN CH, V20, P120; WAGNER I, 1993, CORONARY ARTERY DIS, V4, P537, DOI 10.1097/00019501-199306000-00008; WU AHB, 1994, CLIN CHEM, V40, P900; YUSUF S, 1984, EUR HEART J, V5, P690, DOI 10.1093/oxfordjournals.eurheartj.a061728; ZABEL M, 1993, CIRCULATION, V87, P1542, DOI 10.1161/01.CIR.87.5.1542	47	907	960	0	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1996	335	18					1333	1341		10.1056/NEJM199610313351801	http://dx.doi.org/10.1056/NEJM199610313351801			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP484	8857016				2022-12-28	WOS:A1996VP48400001
J	Chen, X; Rubock, MJ; Whitman, M				Chen, X; Rubock, MJ; Whitman, M			A transcriptional partner for MAD proteins in TGF-beta signalling	NATURE			English	Article							MESODERM INDUCTION; XENOPUS EMBRYOS; TRUNCATED ACTIVIN; AXIAL MESODERM; FAMILY; IDENTIFICATION; RECEPTORS; MEMBER; RESPONSES; INDUCERS	The transforming-growth-factor-beta (TGF-beta) superfamily is critical for establishing mesoderm during early embryogenesis in Xenopus. The transcriptional activation of Mix.2, an immediate-early response gene specific to activin-like members of the TGF-beta superfamily, is associated with the rapid appearance of a site-specific DNA-binding activity that recognizes a fifty-basepair regulatory element known as ARE in the Mix.2 promoter. Cloning of the site-specific DNA-binding component of this activity revealed it to be a new winged-helix transcription factor and a direct target for signalling by the TGF-beta superfamily. XMAD2, a recently identified TGF-beta signal transducer, forms a complex with the transcription factor in an activin-dependent fashion to generate an activated ARE-binding complex. A model is proposed to explain how TGF-beta superfamily signals might regulate the expression of specific genes in the early embryo.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOLCE ME, 1992, DEVELOPMENT, V115, P681; Conlon FL, 1996, SEMIN CELL DEV BIOL, V7, P95, DOI 10.1006/scdb.1996.0014; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V269, P6259; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Grunz H, 1996, INT J DEV BIOL, V40, P279; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Henry GL, 1996, DEVELOPMENT, V122, P1007; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Jones CM, 1996, DEVELOPMENT, V122, P1545; JONES CM, 1992, DEVELOPMENT, V115, P639; JONES CM, 1995, DEVELOPMENT, V121, P3651; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MASSAGUE J, 1992, CELL, V69, P167; Mead PE, 1996, NATURE, V382, P357, DOI 10.1038/382357a0; MIURA N, 1993, FEBS LETT, V326, P171, DOI 10.1016/0014-5793(93)81785-X; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; Vize PD, 1996, DEV BIOL, V177, P226, DOI 10.1006/dbio.1996.0158; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WELGEL D, 1990, CELL, V63, P455; WHITMAN M, 1989, SCIENCE, V244, P803, DOI 10.1126/science.2658054; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	52	621	652	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					691	696		10.1038/383691a0	http://dx.doi.org/10.1038/383691a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878477				2022-12-28	WOS:A1996VN91800045
J	Maki, M				Maki, M			Coeliac disease and autoimmunity due to unmasking of cryptic epitopes?	LANCET			English	Editorial Material											Maki, M (corresponding author), UNIV TAMPERE,INST MED TECHNOL,TAMPERE 33101,FINLAND.							Jalava T, 1996, HUM IMMUNOL, V49, P106, DOI 10.1016/0198-8859(96)00043-2; LANZAVECCHIA A, 1995, J EXP MED, V181, P1945, DOI 10.1084/jem.181.6.1945; MAKI M, 1995, BAILLIERE CLIN GASTR, V9, P231, DOI 10.1016/0950-3528(95)90030-6; Maki M, 1994, GASTROINTESTINAL IMM, P246; Quaratino S, 1996, J EXP MED, V183, P349, DOI 10.1084/jem.183.2.349; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729	6	45	45	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1046	1047		10.1016/S0140-6736(05)64411-X	http://dx.doi.org/10.1016/S0140-6736(05)64411-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874452				2022-12-28	WOS:A1996VM88600005
J	Kolodziej, PA; Timpe, LC; Mitchell, KJ; Fried, SR; Goodman, CS; Jan, LY; Jan, YN				Kolodziej, PA; Timpe, LC; Mitchell, KJ; Fried, SR; Goodman, CS; Jan, LY; Jan, YN			frazzled Encodes a Drosophila member of the DCC immunoglobulin subfamily and is required for CNS and motor axon guidance	CELL			English	Article							C-ELEGANS; COLORECTAL-CANCER; GENE-PRODUCT; CELL; OUTGROWTH; PROTEIN; UNC-6; DIFFERENTIATION; EXPRESSION; MIGRATIONS	We have identified a Drosophila member of the deleted in colorectal cancer (DCC) gene family. The frazzled gene encodes transmembrane proteins that contain four immunoglobulin C2 type domains, six fibronectin type III repeats, and a cytoplasmic domain of 278 amino acids. Like vertebrate members of the DCC family, Frazzled is expressed on axons in the embryonic central nervous system and on motor axons in the periphery. Frazzled is also expressed on epidermis and gut epithelium. Null mutants in frazzled are defective in axon guidance in the central nervous system and in motor axon guidance and targeting in the periphery. The phenotypes strongly resemble those of a deletion of the two Drosophila Netrin genes. We have rescued the frazzled CNS and motor axon defects by expressing Frazzled specifically in neurons; expression in target tissues does not rescue the phenotype. These data, together with vertebrate studies showing binding of DCC to netrin, suggest that Frazzled may function in vivo as a receptor or component of a receptor mediating Netrin-dependent axon guidance.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; VANDERBILT UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DIV NEUROBIOL, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Vanderbilt University; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Kolodziej, PA (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT PHYSIOL, 3RD & PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.			Mitchell, Kevin/0000-0002-3433-4530; Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; Higgins D G, 1994, Methods Mol Biol, V25, P307; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KOLODZIEJ PA, 1995, NEURON, V15, P273, DOI 10.1016/0896-6273(95)90033-0; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; PIROTTA V, 1986, DROSOPHILA PRACTICAL, P83; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; TESSIERLAVIGNE M, 1994, CURR OPIN GENET DEV, V4, P596, DOI 10.1016/0959-437X(94)90078-H; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	27	378	383	0	12	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1996	87	2					197	204		10.1016/S0092-8674(00)81338-0	http://dx.doi.org/10.1016/S0092-8674(00)81338-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861904	Bronze			2022-12-28	WOS:A1996VN40300008
J	Frieden, TR; Sherman, LF; Maw, KL; Fujiwara, PI; Crawford, JT; Nivin, B; Sharp, V; Hewlett, D; Brudney, K; Alland, D; Kreiswirth, BN				Frieden, TR; Sherman, LF; Maw, KL; Fujiwara, PI; Crawford, JT; Nivin, B; Sharp, V; Hewlett, D; Brudney, K; Alland, D; Kreiswirth, BN			A multi-institutional outbreak of highly drug-resistant tuberculosis - Epidemiology and clinical outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE WORKERS; HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTION; NOSOCOMIAL TRANSMISSION; RISK	Objective.-To investigate a multi-institutional outbreak of highly resistant tuberculosis and evaluate patient outcome. Design.-Epidemiologic investigation of every tuberculosis case reported in New York City. Setting.-Patients cared for at all public and nonpublic institutions from January 1, 1990, to August 1, 1993 (43 months). Patients.-We reviewed medical and public health records and conducted clinical, epidemiologic, drug susceptibility, and restriction fragment length polymorphism (RFLP) analyses. A case was defined as tuberculosis in a patient with an isolate resistant to isoniazid, rifampin, ethambutol hydrochloride, and streptomycin (and rifabutin, if sensitivity testing included it), and, if RFLP testing was done, a pattern identical to or closely related to strain W. Main Outcome Measures.-Patient survival and the conversion of sputum cultures from positive to negative. Results.-Of the 357 patients who met the case definition, 267 had identical or nearly identical RFLP patterns; isolates from the other 90 patients were not available for RFLP testing. Among these 267 patients, 86% were human immunodeficiency virus (HIV)-infected, 7% were HIV-negative, and 7% had unknown HIV status. All-cause mortality was 83%. Epidemiologic linkages were identified for 70% of patients, of whom 96% likely had nosocomially acquired disease at 11 hospitals. Survival was prolonged among patients who recieved medications to which their isolate was susceptible, especially capreomycin sulfate, and among patients with a CD4(+) T-lymphocyte count greater than 0.200x10(9)/L (200/mu L). Treatment with isoniazid and a fluoroquinolone antibiotic was also independently associated with longer survival. Conclusions.-This outbreak accounted for nearly one fourth of the cases of multidrug-resistant tuberculosis in the United States during a 43-month period. Most patients had nosocomially acquired disease, were infected with HIV, and unless promptly and appropriately treated, died rapidly. With appropriate directly observed treatment, especially combinations including an injectable medication, even severely immunocompromised patients had culture conversion and prolonged, tuberculosis-free survival.	CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,ATLANTA,GA; NATL CTR INFECT DIS,DIV AIDS STD & TB LAB RES,ATLANTA,GA; ST CLARES HOSP,NEW YORK,NY; LINCOLN MED & MENTAL HLTH CTR,BRONX,NY 10451; COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032; ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10467; PUBL HLTH RES INST,NEW YORK,NY	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Columbia University; NewYork-Presbyterian Hospital; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Frieden, TR (corresponding author), NEW YORK CITY DEPT HLTH,BUR TB CONTROL,125 WORTH ST,BOX 74,NEW YORK,NY 10013, USA.							ALFALLA C, 1992, 32 INT C ANT AG CHEM; AUSINA V, 1995, EUR J CLIN MICROBIOL, V14, P105, DOI 10.1007/BF02111867; AZMEH W, 1993, 33 INT C ANT AG CHEM; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P585; COHN ML, 1954, AM REV TUBERC PULM, V70, P641; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; Dean A., 1995, EPI INFO VERSION 6 0; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; Goble M, 1986, Semin Respir Infect, V1, P220; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; HEWLETT D, 1995, JAMA-J AM MED ASSOC, V273, P916, DOI 10.1001/jama.273.12.916; HORN DL, 1995, INFECT DIS CLIN PRAC, V4, P219, DOI 10.1097/00019048-199505000-00018; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; MITCHISON DA, 1971, POSTGRAD MED J, V47, P737, DOI 10.1136/pgmj.47.553.737; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; PLIKAYTIS BB, 1994, J CLIN MICROBIOL, V32, P1542, DOI 10.1128/JCM.32.6.1542-1546.1994; SALOMON N, 1995, CLIN INFECT DIS, V21, P1245, DOI 10.1093/clinids/21.5.1245; *SAS I INC, 1993, SAS STAT SOFTW SYNT; SATHYAKUMAR C, 1995, 95 GEN M AM SOC MICR; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; VALWAY S, 1993, 33 INT C ANT AG CHEM; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VILLARINO M E, 1992, Morbidity and Mortality Weekly Report, V41, P59; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7; 1989, MMWR-MORBID MORTAL W, V38, P313; 1995, ANN INTERN MED, V122, P90; 1994, MMWR-MORBID MORTAL W, V43, P1; 1989, MMWR-MORBID MORTAL W, V38, P325	40	309	318	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1229	1235		10.1001/jama.276.15.1229	http://dx.doi.org/10.1001/jama.276.15.1229			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL691	8849750				2022-12-28	WOS:A1996VL69100031
J	Hamburg, MA				Hamburg, MA			United States of America - Public health and urban medicine	LANCET			English	Article											Hamburg, MA (corresponding author), NEW YORK CITY DEPT HLTH,NEW YORK,NY 10013, USA.								0	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					1008	1010						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855866				2022-12-28	WOS:A1996VM02700022
J	Dong, JW; Albertini, DF; Nishimori, K; Kumar, TR; Lu, NF; Matzuk, MM				Dong, JW; Albertini, DF; Nishimori, K; Kumar, TR; Lu, NF; Matzuk, MM			Growth differentiation factor-9 is required during early ovarian folliculogenesis	NATURE			English	Article							FACTOR-BETA SUPERFAMILY; PRIMORDIAL GERM-CELLS; MOUSE OOCYTES; FUNCTIONAL-ANALYSIS; MICE DEFICIENT; GENE; EXPRESSION; CULTURE; PATTERN; PROLIFERATION	GROWTH factors synthesized by ovarian somatic cells directly affect oocyte growth and function(1-6), but it is unclear whether oocyte-secreted factors(6-9) play a reciprocal role in modulating somatic cell functions in vivo. During the functional analysis of members of the transforming growth factor-beta superfamily in mouse development(10-15), we have uncovered a new family member, growth differentiation factor-9 (GDF-9), which is required for ovarian folliculogenesis. GDF-9 messenger RNA is synthesized only in the oocyte from the primary one-layer follicle stage until after ovulation(16,17). Here we analyse ovaries from GDF-9-deficient female mice and demonstrate that primordial and primary one-layer follicles can be formed, but there is a block in follicular development beyond the primary one-layer follicle stage which leads to complete infertility. Oocyte growth and zona pellucida formation proceed normally, but other aspects of oocyte differentiation are compromised. Thus, GDF-9 is the first oocyte-derived growth factor required for somatic cell function in vivo.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Tufts University			Albertini, David/AAD-3856-2021	Albertini, David/0000-0001-6536-2828				ALBERTINI DF, 1992, MUTAT RES, V296, P57, DOI 10.1016/0165-1110(92)90032-5; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; Eppig John J., 1994, Seminars in Developmental Biology, V5, P51, DOI 10.1006/sedb.1994.1007; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; Hakuno N, 1996, ENDOCRINOLOGY, V137, P1938, DOI 10.1210/en.137.5.1938; HAMILTON SA, 1995, BIOL REPROD, V53, P890, DOI 10.1095/biolreprod53.4.890; HAMOUDI M, BIOTECHNIQUES, V7, P331; INCERTI B, 1994, BBA-MOL CELL RES, V1222, P125, DOI 10.1016/0167-4889(94)90034-5; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MATTSON BA, 1990, MOL REPROD DEV, V25, P374, DOI 10.1002/mrd.1080250411; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MATZUK MM, 1995, TRENDS ENDOCRIN MET, V6, P120, DOI 10.1016/1043-2760(95)00032-D; MCGRATH SA, 1995, MOL ENDOCRINOL, V9, P131, DOI 10.1210/me.9.1.131; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; PEDERSEN T, 1968, J REPROD FERTIL, V17, P555, DOI 10.1530/jrf.0.0170555; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; VANDERHYDEN BC, 1992, BIOL REPROD, V46, P1196, DOI 10.1095/biolreprod46.6.1196; VANDERHYDEN BC, 1990, DEV BIOL, V140, P307, DOI 10.1016/0012-1606(90)90081-S; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; Wassarman Paul M., 1994, P79; WICKRAMASINGHE D, 1991, DEV BIOL, V143, P162, DOI 10.1016/0012-1606(91)90063-9	27	976	1072	1	83	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					531	535		10.1038/383531a0	http://dx.doi.org/10.1038/383531a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849725				2022-12-28	WOS:A1996VL75500052
J	Murphy, R; Wente, SR				Murphy, R; Wente, SR			An RNA-export mediator with an essential nuclear export signal	NATURE			English	Article							HIV-1 REV PROTEIN; SACCHAROMYCES-CEREVISIAE; BINDING; YEAST; IDENTIFICATION; INTERACTS; CYTOPLASM; SEQUENCE; DOMAIN; IMPORT	THE Rev protein of human immunodeficiency virus type 1 (HIV-1) mediates the translocation of viral messenger RNAs from the nucleus to the cytoplasm. In yeast, Rev can mediate the nuclear export of Rev response element containing RNAs(1). The export of Rev itself proceeds through the nuclear pore complex and requires a nuclear export signal (NES)(2,3) and interaction with a cellular cofactor, the protein Rip1 (refs 1, 4, 5). Endogenous RNA export mediators that interact with Rip1 and harbour NESs are thought to exist(6,7) but have yet to be identified, Here we report the characterization of a new and essential yeast protein, Gle1, which contains an NES and has a relative molecular mass of 62,000. Mutation of the NES in Gle1 prevents export of polyadenylated RNA from the nucleus. Gle1 interacts with Rip1 and the nucleo-porin Nup100 and is localized predominantly at nuclear pore complexes. These properties indicate that Gle1 is an RNA-export factor and that Rev may mediate viral RNA export by mimicking the function of Gle1.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BOHNLEIN E, 1991, J VIROL, V65, P7051; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; SCHNEITER R, 1995, MOL BIOL CELL, V6, P357, DOI 10.1091/mbc.6.4.357; SHULGA N, IN PRESS J CELL BIOL; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; YANG X, 1992, SCIENCE, V257, P68; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	29	203	210	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					357	360		10.1038/383357a0	http://dx.doi.org/10.1038/383357a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848052				2022-12-28	WOS:A1996VJ43900051
J	Swalla, BJ; Jeffery, WR				Swalla, BJ; Jeffery, WR			Requirement of the Manx gene for expression of chordate features in a tailless ascidian larva	SCIENCE			English	Article							ANURAL DEVELOPMENT; INTERSPECIFIC HYBRIDIZATION; ANTISENSE OLIGONUCLEOTIDES; MARINE-INVERTEBRATES; EVOLUTIONARY CHANGE; ALTERNATE MODES; MESSENGER-RNA; SHORT-GERM; EMBRYO; MUSCLE	An evolutionary change in development was studied in two closely related ascidian species, one exhibiting a conventional tadpole larva and the other a modified tailless larva. Interspecific hybridization restores chordate features to the tailless larva. The zinc finger gene Manx is expressed in cells that generate chordate features in the tailed species but is down-regulated in the tailless species. Manx expression is restored in hybrid embryos. Antisense oligodeoxynucleotide treatment inhibited Manx expression and chordate features in hybrid embryos, which suggests that Manx is required for development of the chordate larval phenotype in ascidians.	CNRS,BIOL STN,ROSCOFF,FRANCE; UNIV CALIF BODEGA,MARINE LAB,BODEGA BAY,CA 94923; UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DAVIS,CA 95616	Centre National de la Recherche Scientifique (CNRS); University of California System; University of California Davis	Swalla, BJ (corresponding author), VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013970] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-13970] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUGUSTINE K, 1993, DEV GENET, V14, P500, DOI 10.1002/dvg.1020140611; BATES WR, 1993, MICROSC RES TECHNIQ, V26, P285, DOI 10.1002/jemt.1070260404; Berrill NJ, 1931, PHILOS T R SOC LON B, V219, P281, DOI 10.1098/rstb.1931.0006; DELACAZEDUTHIER.FJ, 1874, ARCH ZOOL EXP GEN, V3, P119; Elinson R.P., 1990, Seminars in Developmental Biology, V1, P263; ERICKSON RP, 1993, DEV GENET, V14, P251, DOI 10.1002/dvg.1020140402; HADFIELD KA, 1995, J MOL EVOL, V40, P413, DOI 10.1007/BF00164028; HALL BK, 1984, BIOL REV, V59, P89, DOI 10.1111/j.1469-185X.1984.tb00402.x; HENRY JQ, 1994, DEV GENET, V15, P64, DOI 10.1002/dvg.1020150108; Jagersten G, 1972, EVOLUTION METAZOAN L; Jeffery W.R., 1990, Seminars in Developmental Biology, V1, P253; JEFFERY WR, 1992, BIOESSAYS, V14, P219, DOI 10.1002/bies.950140404; JEFFERY WR, 1994, J MAR BIOL ASSOC UK, V74, P35, DOI 10.1017/S0025315400035645; JEFFERY WR, 1993, ROUX ARCH DEV BIOL, V202, P103, DOI 10.1007/BF00636535; JEFFERY WR, 1992, DEV BIOL, V153, P194, DOI 10.1016/0012-1606(92)90105-P; JEFFERY WR, 1991, DEV BIOL, V145, P328, DOI 10.1016/0012-1606(91)90131-L; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KATZ MJ, 1983, BIOL BULL-US, V164, P1, DOI 10.2307/1541186; Kusakabe T, 1996, DEV BIOL, V174, P379, DOI 10.1006/dbio.1996.0082; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MEEDEL TH, 1983, P NATL ACAD SCI-BIOL, V80, P4761, DOI 10.1073/pnas.80.15.4761; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; NISHIDA H, 1992, ROUX ARCH DEV BIOL, V201, P81, DOI 10.1007/BF00420418; NISHIDA H, 1992, DEVELOPMENT, V116, P521; NISHIDA H, 1991, DEVELOPMENT, V112, P389; NISHIDA H, 1989, DEV BIOL, V132, P355, DOI 10.1016/0012-1606(89)90232-7; PARIA BC, 1992, P NATL ACAD SCI USA, V89, P10051, DOI 10.1073/pnas.89.21.10051; PATEL NH, 1994, NATURE, V367, P429, DOI 10.1038/367429a0; PERRY HE, 1983, CELL DIFFER DEV, V13, P233, DOI 10.1016/0045-6039(83)90094-5; RAFF RA, 1992, BIOESSAYS, V14, P211, DOI 10.1002/bies.950140403; REVERBERI G., 1960, ACTA EMBRYOL MORPHOL EXPTL, V3, P296; Satoh N., 1994, DEV BIOL ASCIDIANS; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; SOMMER RJ, 1994, DEV GENET, V15, P32, DOI 10.1002/dvg.1020150105; SOMMER RJ, 1992, P NATL ACAD SCI USA, V89, P10782, DOI 10.1073/pnas.89.22.10782; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STRATHMANN RR, 1978, EVOLUTION, V32, P894, DOI 10.1111/j.1558-5646.1978.tb04642.x; SWALLA BJ, 1991, DEVELOPMENT, V111, P425; SWALLA BJ, 1990, DEV BIOL, V142, P319, DOI 10.1016/0012-1606(90)90353-K; SWALLA BJ, 1993, DEVELOPMENT, V119, P307; SWALLA BM, UNPUB; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WHITTAKER JR, 1979, BIOL BULL-US, V156, P393, DOI 10.2307/1540926; WRAY GA, 1991, TRENDS ECOL EVOL, V6, P45, DOI 10.1016/0169-5347(91)90121-D; YOUNG CM, 1988, BIOL BULL, V174, P39, DOI 10.2307/1541757	46	103	104	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1205	1208		10.1126/science.274.5290.1205	http://dx.doi.org/10.1126/science.274.5290.1205			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895472				2022-12-28	WOS:A1996VT33500058
J	Willman, VL				Willman, VL			Aortocoronary bypass with saphenous vein graft	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTERNAL MAMMARY ARTERY; CORONARY; EXPERIENCE		ST LOUIS UNIV, HLTH SCI CTR, DEPT SURG, ST LOUIS, MO 63103 USA	Saint Louis University								ABSOLON KB, 1956, SURG GYNECOL OBSTET, V103, P180; *AM HEART ASS, 1996, HEART STROK FACTS 19; Bailey C P, 1968, Int Surg, V49, P416; BAILEY CP, 1957, JAMA-J AM MED ASSOC, V164, P641, DOI 10.1001/jama.1957.02980060017005; BARNER HB, 1985, J THORAC CARDIOV SUR, V90, P668; Beck CS, 1935, ANN SURG, V102, P801, DOI 10.1097/00000658-193511000-00001; BECK CS, 1954, JAMA-J AM MED ASSOC, V156, P1226, DOI 10.1001/jama.1954.02950130006002; BIGELOW WG, 1963, J THORAC CARDIOV SUR, V45, P67, DOI 10.1016/S0022-5223(19)32899-5; Blumgart HL, 1933, ARCH INTERN MED, V51, P866, DOI 10.1001/archinte.1933.00150250050002; BRAUNWALD E, 1971, HOSP PRACT, V6, P9; CALIFF RM, 1985, CIRCULATION, V72, P136; CANNON JA, 1959, SURGERY, V46, P197; Carrel A, 1910, ANN SURG, V52, P83, DOI 10.1097/00000658-191007000-00009; Comroe J H Jr, 1974, Circ Res, V35, P661; Cutler EC, 1927, AM J MED SCI, V173, P613, DOI 10.1097/00000441-192705000-00003; DETRE K, 1977, AM J CARDIOL, V40, P212, DOI 10.1016/0002-9149(77)90011-X; DOTTER CT, 1964, CIRCULATION, V30, P654, DOI 10.1161/01.CIR.30.5.654; EFFLER DB, 1964, J THORAC CARDIOV SUR, V47, P98, DOI 10.1016/S0022-5223(19)33522-6; EFFLER DB, 1963, ANN SURG, V158, P526, DOI 10.1097/00000658-196310000-00002; EFFLER DB, 1970, SURGICAL TREATMENT C, pR11; Favaloro R G, 1968, Ann Thorac Surg, V5, P334; FAVALORO RG, 1970, J THORAC CARDIOV SUR, V60, P469, DOI 10.1016/S0022-5223(19)42327-1; GARRETT HE, 1973, JAMA-J AM MED ASSOC, V223, P792, DOI 10.1001/jama.223.7.792; GLOVER RP, 1957, J THORAC SURG, V34, P661; GOETZ RH, 1961, J THORAC CARDIOV SUR, V41, P378; Green G E, 1968, Ann Thorac Surg, V5, P443; GRUNTZIG AR, 1979, NEW ENGL J MED, V301, P61, DOI 10.1056/NEJM197907123010201; HALLMAN GL, 1965, CIRCULATION, V32, P293, DOI 10.1161/01.CIR.32.2.293; HEIMBECKER P, 1941, ANN SURG, V114, P186; JOHNSON WD, 1969, ANN SURG, V170, P460, DOI 10.1097/00000658-196909010-00014; JUDKINS MP, 1968, RADIOL CLIN N AM, V6, P467; JULIAN OC, 1957, J THORAC SURG, V34, P654; KAHN DJ, 1971, J THORAC CARDIOVASC, V62, P503; KOLESSOV VI, 1967, J THORAC CARDIOV SUR, V54, P535, DOI 10.1016/S0022-5223(19)43061-4; LEIGHNINGER DS, 1963, J THORAC CARDIOV SUR, V45, P412, DOI 10.1016/S0022-5223(19)32875-2; Lilienthal H, 1925, ARCH SURG-CHICAGO, V10, P531, DOI 10.1001/archsurg.1925.01120100543030; LONGMIRE WP, 1958, NEW ENGL J MED, V259, P993, DOI 10.1056/NEJM195811202592101; LONGMIRE WP, 1992, EVOLUTION CARDIAC SU, P141; LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248; MAMIYA RT, 1961, SURG GYNECOL OBSTET, V113, P598; MAYO CH, 1925, ARCH SURG-CHICAGO, V10, P541; Moritz AR, 1932, J EXP MED, V56, P927, DOI 10.1084/jem.56.6.927; MURRAY G, 1954, CAN MED ASSOC J, V71, P594; *NAT CTR HLTH STAT, 1993, VIT HLTH STAT, V13; O'Shaughnessy L, 1936, BRIT J SURG, V23, P665, DOI 10.1002/bjs.1800239122; Principal Investigators of CASS and Associates, 1981, CIRCULATION S1, V63, pI1; Rosenblum HH, 1933, AM J MED SCI, V185, P219, DOI 10.1097/00000441-193302000-00008; SABISTON DC, 1961, POSTGRAD MED, V29, P439, DOI 10.1080/00325481.1961.11692463; SABISTON DC, 1974, JOHNS HOPKINS MED J, V134, P314; SABISTON DC, 1957, ANN SURG, V145, P927, DOI 10.1097/00000658-195706000-00014; SAUVAGE LE, 1963, J THORAC CARDIOV SUR, V46, P826, DOI 10.1016/S0022-5223(19)33624-4; Schlesinger MJ, 1941, ARCH PATHOL, V32, P178; SONES F M Jr, 1962, Mod Concepts Cardiovasc Dis, V31, P735; SPENCER FC, 1964, J CARDIOVASC SURG, V5, P292; Suma K, 1969, Ann Thorac Surg, V7, P13; SZILAGYI DE, 1958, ANN SURG, V148, P447, DOI 10.1097/00000658-195809000-00013; THAL A, 1956, SURGERY, V40, P1023; THOMAS L, 1979, MEDUSA SNAIL MORE NO, P158; Thompson SA, 1942, ANN INTERN MED, V16, P495, DOI 10.7326/0003-4819-16-3-495; VARNAUSKAS E, 1980, LANCET, V2, P491; VINEBERG A, 1975, J THORAC CARDIOV SUR, V70, P381; VINEBERG A, 1953, Geriatrics, V8, P579; VINEBERG A, 1955, J THORAC SURG, V29, P1; VINEBERG AM, 1946, CAN MED ASSOC J, V55, P117; WAKABAYA A, 1968, J THORAC CARDIOV SUR, V56, P633, DOI 10.1016/S0022-5223(19)42789-X	65	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1996	276	18					1521	+		10.1001/jama.276.18.1521	http://dx.doi.org/10.1001/jama.276.18.1521			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ774	8903267				2022-12-28	WOS:A1996VQ77400039
J	Phillips, DM				Phillips, DM			Klebsiella pneumoniae	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Phillips, DM (corresponding author), POPULAT COUNCIL,1230 YORK AVE,NEW YORK,NY 10021, USA.								0	2	2	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1437	1437		10.1056/NEJM199611073351905	http://dx.doi.org/10.1056/NEJM199611073351905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT339	8875921				2022-12-28	WOS:A1996VT33900005
J	Mangiarini, L; Sathasivam, K; Seller, M; Cozens, B; Harper, A; Hetherington, C; Lawton, M; Trottier, Y; Lehrach, H; Davies, SW; Bates, GP				Mangiarini, L; Sathasivam, K; Seller, M; Cozens, B; Harper, A; Hetherington, C; Lawton, M; Trottier, Y; Lehrach, H; Davies, SW; Bates, GP			Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice	CELL			English	Article							SPINOCEREBELLAR ATAXIA TYPE-1; PALLIDOLUYSIAN ATROPHY DRPLA; HUNTINGTONS-DISEASE; PROTEIN; BRAIN; EXPANSION; EXPRESSION; TISSUES	Huntington's disease (HD) is one of an increasing number of neurodegenerative disorders caused by a CAG/ polyglutamine repeat expansion. Mice have been generated that are transgenic for the 5' end of the human HD gene carrying (CAG)(115)-(CAG)(150) repeat expansions. In three lines, the transgene is ubiquitously expressed at both mRNA and protein level. Transgenic mice exhibit a progressive neurological phenotype that exhibits many of the features of HD, including choreiform-like movements, involuntary stereotypic movements, tremor, and epileptic seizures, as well as nonmovement disorder components. This transgenic model will greatly assist in an eventual understanding of the molecular pathology of HD and may open the way to the testing of intervention strategies.	UMDS,TRANSGEN UNIT,RAYNE INST,LONDON SE1 7EH,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,BIOMED SERV,OXFORD OX3 9DU,ENGLAND; UMDS,GUYS HOSP,BIOL SERV DIV,LONDON SE1 9RT,ENGLAND; UNIV STRASBOURG 1,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY; UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND	University of London; King's College London; University of Oxford; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Max Planck Society; University of London; University College London	Mangiarini, L (corresponding author), UMDS,GUYS HOSP,DIV MED & MOL GENET,LONDON SE1 9RT,ENGLAND.		Bates, Gillian P/E-1146-2012; Trottier, Yvon/H-8852-2016; Longo, Kenneth A/A-5631-2010	Bates, Gillian P/0000-0002-4041-6305; Trottier, Yvon/0000-0001-7230-4810				BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; DELAMONTE SM, 1988, J NEUROPATH EXP NEUR, V47, P516, DOI 10.1097/00005072-198809000-00003; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Durr A, 1996, ANN NEUROL, V39, P490, DOI 10.1002/ana.410390411; HARPER PS, 1991, J NEUROPATH EXP NEUR, V54, P105; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LAUDER I. M., 1954, Veterinary Record, V66, P607; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LYON MF, 1990, GENETIC VARIANTS STR; MONACO AP, 1985, NATURE, V316, P842, DOI 10.1038/316842a0; MYERS RH, 1991, J NEUROPATH EXP NEUR, V50, P729, DOI 10.1097/00005072-199111000-00005; MYERS RH, 1988, NEUROLOGY, V38, P341, DOI 10.1212/WNL.38.3.341; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; SANBERG PR, 1981, MED J AUSTRALIA, V1, P407, DOI 10.5694/j.1326-5377.1981.tb135681.x; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; Sidman Richard L., 1971, ATLAS MOUSE BRAIN SP; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; TAKAHASHI H, 1988, NEUROLOGY, V38, P1065, DOI 10.1212/WNL.38.7.1065; TELENIUS H, 1993, HUM MOL GENET, V2, P1535, DOI 10.1093/hmg/2.10.1535; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WHEELER JS, 1985, BRIT J UROL, V57, P63, DOI 10.1111/j.1464-410X.1985.tb08987.x; YAZAWA I, 1995, NAT GENET, V10, P99, DOI 10.1038/ng0595-99; ZOGHBI HY, 1993, CURRENT NEUROLOGY, P87; 1993, CELL, V72, P971	31	2442	2531	3	110	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					493	506		10.1016/S0092-8674(00)81369-0	http://dx.doi.org/10.1016/S0092-8674(00)81369-0			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898202	Bronze			2022-12-28	WOS:A1996VQ46600015
J	Eastman, N				Eastman, N			Inquiry into homicides by psychiatric patients: Systematic audit should replace mandatory inquiries	BRITISH MEDICAL JOURNAL			English	Article								Inquiries into homicides committed by psychiatric patients are currently mandatory under Department of Health guidance. They are often broadly defined in their terms of reference and almost always address not only the cause of the incident but also professional skill, practice, and culpability. Concurrent pursuit of both purposes is unlikely to maximise ''learning from experience.'' Also, since inquiries can set their own thresholds for culpability, doctors can potentially be judged to a higher standard than would be required by the General Medical Council or negligence law. Lack of strict legal process increases the inherent potential unfairness to doctors. Investigation of cause and culpability should be separated and inquiries restricted to the former. There should also be a standing secretariat for inquiries to set terms of reference and to collate and distribute findings of inquiries. Widespread mandatory systematic audit of professional practice and service efficiency concerning risk assessment and management should largely replace costly ad hoc mandatory inquiries after homicides.			Eastman, N (corresponding author), ST GEORGE HOSP,SCH MED,SECT FORENS PSYCHIAT,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.							BLOMCOOPER L, 1993, CURRENT LEGAL PROBLE; CARSON D, 1996, INQUIRIES HOMICIDE; CLOTHIER C, 1996, INQUIRIES HOMICIDE; *DEP HLTH, 1994, HSG9427 NHS DOH; Department of Health and Social Security (DoHSS), 1974, REP COMM INQ CAR SUP; EASTMAN N, 1996, INQUIRIES HOMICIDE; House A, 1996, BRIT MED J, V312, P135; MARTIN J, 1984, HOSP TROUBLE; PEAY J, 1996, INQUIRIES HOMOCIDE; Reder P, 1996, INQUIRIES HOMICIDE; Ritchie J., 1994, REPORT INQUIRY CARE; *ROYAL COLL PSYCH, 1996, REP CONF INQ HOM SUI; Sheppard D, 1995, LEARNING LESSONS MEN; THOROLD O, 1996, INQUIRIES HOMOCIDE; VINESTOCK MD, 1996, ADV PSYCHIAT TREATME, V2, P3	15	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1069	1071						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	8898603				2022-12-28	WOS:A1996VP74200037
J	Gore, SM; Bird, AG				Gore, SM; Bird, AG			Cost implications of random mandatory drugs tests in prisons	LANCET			English	Article							ANONYMOUS HIV SURVEILLANCE; PREVALENCE; INJECTION; INFECTION; SCOTLAND	Background Compulsory urine testing of prisoners for drugs, a control initiative, was introduced in eight prisons in England and Wales early in 1995, Despite no evidence of effectiveness, testing was extended to all prisons in England and Wales by March 1996. We consider the cost of testing. Methods We combined the costs of refusals, confirmatory tests, punishment of confirmed positives for cannabis or for class A drugs to estimate the average costs of random compulsory drugs testing. These costs were then compared to: i) the healthcare budget for a prison; and ii) the cost of putting in place a credible prisons' drugs reduction programme. We then used Scottish data on incarceration and regional prevalence of injecting drug users to estimate the extent of the injecting drug use problem that prisons face. Findings Costs per 28 days of the random mandatory drugs testing control initiative in an establishment for 500 inmates where refusal rate is a) 10% or b) nil; and 35% of urine samples test positive, one tenth of them for class A drugs were estimated at between a) pound UK22 800 and b) pound UK16 000 per 28 days [a) $US35 100 and b) $US24 600]. This cost was equivalent to twice the cost of running a credible drugs reduction and rehabilitation programme, and around half the total healthcare expenditure for a prison of 500 which averaged pound UK41 114 per 28 days [$US64 860]. Major cost-generating events were the punishment of refusals-over one third of cost a)-and testing positive for cannabis-over 50% of cost a). In Scotland, around 5% of injecting drug users (IDUs) are incarcerated at any time: 5% of Lothian's drugs care, treatment and prevention costs and 2 . 5% of its HIV/AIDS prevention budget in 1993-94 amounted to pound EUK101 300 per annum-or pound UK7770 per 28 days ($US11 970)-and about 35% of monthly MDT costs. Interpretation We suggest that 5% of current resources for drugs prevention and treatment and for IDU-targetted HIV/AIDS prevention should be directed towards the prisons because in the prisons, where 5% of the clients are at any time. injectors have less access to harm reduction measures than on the outside.	CHURCHILL HOSP,DEPT IMMUNOL,OXFORD OX3 7LJ,ENGLAND	University of Oxford	Gore, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							BATH GE, 1993, BRIT MED J, V306, P1414, DOI 10.1136/bmj.306.6889.1414-a; BATH GE, 1993, LANCET, V342, P1368, DOI 10.1016/0140-6736(93)92279-3; BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1995, AIDS, V9, P801, DOI 10.1097/00002030-199507000-00019; BIRD AG, 1994, AIDS, V8, P1345, DOI 10.1097/00002030-199409000-00021; BIRD AG, 1996, HERALD          0122, P12; CARRELL S, 1995, SCOTSMAN        0901, P1; DOLAN K, 1995, AIDS, V9, P825, DOI 10.1097/00002030-199508000-00001; FREEMAN J, 1996, HERALD          0115, P3; FRISCHER M, 1993, AM J EPIDEMIOL, V138, P170, DOI 10.1093/oxfordjournals.aje.a116843; GOLDBERG D, 1994, ANSWER          0930, P1; GORE SM, 1995, BRIT MED J, V311, P1135, DOI 10.1136/bmj.311.7013.1135; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; Gore SM, 1996, BRIT MED J, V312, P1411; GORE SM, 1995, BRIT MED J, V310, P595, DOI 10.1136/bmj.310.6979.595; GORE SM, 1996, IN PRESS INT J STD A; GORE SM, 1995, ANSWER          0929; HAW S, 1987, DRUG PROBLEMS EDINBU; *HIV SURV STEER GR, 1995, REPORT UNL AN HIV SU, P11; *HM INSP PRIS, 1995, REP UN SHORT INSP HM; *HM INSP PRIS SCOT, 1996, REP HM PRIS YOUNG OF, P52; *HM PRIS SERV, 1995, PRIS SERV ANN REP AC; *HM PRIS SERV HLTH, 1996, REP DIR HLTH CAR PRI; *HM PRIS SERV HLTH, 1995, REP DIR HLTH CAR PRI; MILLS H, 1995, INDEPENDENT     0322; NOTARIANNI LJ, 1995, LANCET, V345, P1115, DOI 10.1016/S0140-6736(95)90846-3; NOTARIANNI LJ, 1995, UNPUB J CLIN FORENSI; *SCOTT CTR INF ENV, 1995, 1994 SCOTT CTR INF E; SQUIRES NF, 1995, J PUBLIC HEALTH MED, V17, P103; World Health Organization (WHO), 1993, WHO GUID HIV INF AID; 1994, DRUG ABUSE SCOTLAND, V1, pR6	32	7	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1124	1127		10.1016/S0140-6736(96)06318-0	http://dx.doi.org/10.1016/S0140-6736(96)06318-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888165				2022-12-28	WOS:A1996VP10600009
J	Lacasse, Y; Wong, E; Guyatt, GH; King, D; Cook, DJ; Goldstein, RS				Lacasse, Y; Wong, E; Guyatt, GH; King, D; Cook, DJ; Goldstein, RS			Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; QUALITY-OF-LIFE; AIR-FLOW LIMITATION; LUNG-DISEASE; EXERCISE CAPACITY; COPD; DYSPNEA; HOME; INDEXES; PROGRAM	Background Respiratory rehabilitation is increasingly recognised as an important part of the management of patients with chronic obstructive pulmonary disease (COPD), The widespread application of such programmes should be preceded by evidence of directly attributable improvements in function. We assessed the effect of respiratory rehabilitation on exercise capacity and health-related quality of life (HRQL) in patients with COPD. Methods We carried out a meta-analysis of randomised controlled trials of respiratory rehabilitation in patients with COPD that assessed functional or maximal exercise capacity, HRQL, or both. Respiratory rehabilitation was defined as exercise training (for at least 4 weeks) with or without education, psychological support, or both. The most commonly used measure for HRQL was the chronic respiratory questionnaire, in which responses were presented on a 7-point scale. The control groups received no rehabilitation. Within each trial and for each outcome an effect size was calculated; the effect sizes were then pooled by a random-effects model. The overall effect of treatment was compared with its minimum clinically important difference (MCID)-defined as the smallest difference perceived as important by the average patient. Findings We included 14 trials. Significant improvements were found for all the outcomes. For two important features of HRQL, dyspnoea and mastery, the overall treatment effect was larger than the MCID: 1 . 0 (95% CI 0 . 6-1 . 5) and 0 . 8 (0 . 5-1 . 2), respectively, compared with an MCID of 0 . 5. For functional exercise capacity (g-min walk test), the overall effect was 55 . 7 m (27 . 8-92 . 8), and for maximum exercise capacity (incremental cycle ergometer test), 8 . 3 W (2 . 8-16 . 5). Functional exercise capacity showed heterogeneity that could not be explained by the sensitivity analyses. Interpretation Respiratory rehabilitation relieves dyspnoea and improves control over COPD. These improvements are clinically important. The value of the improvement in exercise capacity is not clear. Respiratory rehabilitation is an effective part of care in patients with COPD.	UNIV TORONTO,DEPT MED,DIV RESP MED,W PK HOSP,TORONTO,ON M6M 25J,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON,CANADA	University of Toronto; McMaster University; McMaster University								Booker H A, 1984, Physiotherapy, V70, P258; BUSCH AJ, 1988, PHYS THER, V68, P469, DOI 10.1093/ptj/68.4.469; CASABURI R, 1991, AM REV RESPIR DIS, V143, P9, DOI 10.1164/ajrccm/143.1.9; COCKCROFT A, 1982, THORAX, V37, P413, DOI 10.1136/thx.37.6.413; DONNER CF, 1992, EUR RESPIR J, V5, P266; FEINLEIB M, 1989, AM REV RESPIR DIS, V140, pS9, DOI 10.1164/ajrccm/140.3_Pt_2.S9; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; GOLDSTEIN RS, 1995, P 5 INT C PULM REH H, P99; Guell R, 1995, EUR RESPIR J, V8, P356; GUYATT GH, 1985, J CHRON DIS, V38, P517, DOI 10.1016/0021-9681(85)90035-9; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; GUYATT GH, 1984, THORAX, V39, P818, DOI 10.1136/thx.39.11.818; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JAESCHKE R, 1994, THORAX, V49, P479, DOI 10.1136/thx.49.5.479; JONES DT, 1985, EUR J RESPIR DIS, V67, P159; Jones NL, 1988, CLIN EXERCISE TESTIN, P123; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; LAKE FR, 1990, CHEST, V97, P1077, DOI 10.1378/chest.97.5.1077; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; MCGAVIN CR, 1977, THORAX, V32, P307, DOI 10.1136/thx.32.3.307; MCKAY SE, 1993, THORAX, V48, P227, DOI 10.1136/thx.48.3.227; REARDON J, 1994, CHEST, V105, P1046, DOI 10.1378/chest.105.4.1046; REID WD, 1984, PHYSIOTHER CAN, V36, P305; RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIMPSON K, 1992, THORAX, V47, P70, DOI 10.1136/thx.47.2.70; Stanton M., 1995, JGIM, V10, P50; Strijbos JH, 1996, CHEST, V109, P366, DOI 10.1378/chest.109.2.366; VALLET G, 1994, REV MAL RESPIR, V11, P493; WEINER P, 1992, CHEST, V102, P1351, DOI 10.1378/chest.102.5.1351; WIJKSTRA PJ, 1994, EUR RESPIR J, V7, P269, DOI 10.1183/09031936.94.07020269; WIJKSTRA PJ, 1994, THORAX, V49, P468, DOI 10.1136/thx.49.5.468; 1981, AM REV RESPIR DIS, V124, P663	35	481	506	2	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1115	1119		10.1016/S0140-6736(96)04201-8	http://dx.doi.org/10.1016/S0140-6736(96)04201-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888163				2022-12-28	WOS:A1996VP10600007
J	ONeill, D				ONeill, D			Dementia and driving: Screening, assessment, and advice	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE; ELDERLY DRIVERS; CRASHES				ONeill, D (corresponding author), MEATH HOSP,CTR MOBIL ENHANCEMENT,DUBLIN 8,IRELAND.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				BAHRO M, 1995, INT J GERIATR PSYCH, V10, P871, DOI 10.1002/gps.930101010; Bedard M., 1996, Journal of the American Geriatrics Society, V44, pS9; CARR D, 1991, J AM GERIATR SOC, V39, P1132, DOI 10.1111/j.1532-5415.1991.tb02882.x; DRACHMAN DA, 1993, NEUROLOGY, V43, P2448, DOI 10.1212/WNL.43.12.2448; HakamiesBlomqvist L, 1996, J AM GERIATR SOC, V44, P650, DOI 10.1111/j.1532-5415.1996.tb01826.x; HUNT L, 1993, J AM GERIATR SOC, V41, P747, DOI 10.1111/j.1532-5415.1993.tb07465.x; JOHANSSON K, 1994, AGEING DRIVING, P85; LEVY DT, 1995, JAMA-J AM MED ASSOC, V274, P1026, DOI 10.1001/jama.274.13.1026; MITCHELL RK, 1995, INT J GERIATR PSYCH, V10, P865, DOI 10.1002/gps.930101009; ONEILL D, 1992, LANCET, V339, P41, DOI 10.1016/0140-6736(92)90155-V; Trobe JD, 1996, ARCH NEUROL-CHICAGO, V53, P411, DOI 10.1001/archneur.1996.00550050033021	11	7	7	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1114	1114		10.1016/S0140-6736(05)65269-5	http://dx.doi.org/10.1016/S0140-6736(05)65269-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VP106	8888162				2022-12-28	WOS:A1996VP10600006
J	Stick, SM; Burton, PR; Gurrin, L; Sly, PD; LeSouef, PN				Stick, SM; Burton, PR; Gurrin, L; Sly, PD; LeSouef, PN			Effects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants	LANCET			English	Article							PULMONARY-FUNCTION; PARENTAL SMOKING; LUNG-FUNCTION; CHILDREN; OBSTRUCTION; EXPOSURE; NICOTINE; ILLNESS; LIFE	Introduction Infants of mothers who smoke have reduced respiratory function and are more likely to develop wheezing, Little evidence is available on the effect of inutero cigarette-smoke exposure as opposed to postnatal exposure to environmental tobacco smoke, We used a previously validated non-invasive method to measure the time to peak tidal expiratory flow (tPTEF) as a proportion of expiratory time (tE) in newborn infants soon after birth to examine the effects of a family history of asthma and in-utero cigarette-smoke exposure on the infants' respiratory function. Methods We collected respiratory-function data from 500 healthy infants of mothers taking part in the Western Australia Pregnancy Cohort Study, During behaviourally defined quiet sleep, measurements were obtained a median of 58 h (range 26-159) after the infants were born, We used uncalibrated inductance plethysmography. The uncalibrated volume signal was differentiated to flow and used to calculate respiratory rate, total inspiratory time, tE, and tPTEF, Mothers answered questionnaires on demographic, medical, and pregnancy characteristics, including smoking history. Serum cotinine measurements were available to validate self-reported smoking history in a subset of mothers (238). Results Data suitable for analysis were obtained from 461 infants. In multivariate regression analysis, lower values of tPTEF/tE were independently associated with respiratory rate (beta coefficient per 10 breaths/min 0.018 [SE 0.005], p<0.01), age (beta coefficient per 10 h -0.008 [0.003], p<0.01), maternal smoking during pregnancy (>10 cigarettes daily; beta coefficient -0.049 [0.022], p<0.05), maternal hypertension during pregnancy (-0.037 [0.015], p<0.02), and a family history of asthma (-0.028 [0.014], p<0.05). Conclusions In-utero smoke exposure, a family history of asthma, and maternal hypertension during pregnancy are associated with reduced respiratory function after birth. We speculate that these factors adversely affect lung development in utero.	CHILDRENS HOSP,MED CTR,INST CHILD HLTH RES,DIV CLIN SCI,PERTH,WA,AUSTRALIA; CHILDRENS HOSP,MED CTR,INST CHILD HLTH RES,DIV BIOSTAT,PERTH,WA,AUSTRALIA	Telethon Kids Institute; University of Western Australia; Telethon Kids Institute; University of Western Australia	Stick, SM (corresponding author), PRINCESS MARGARET HOSP CHILDREN,DEPT RESP MED,GPO BOX D184,PERTH,WA 6001,AUSTRALIA.		Study, Raine/K-4517-2013; Stick, Stephen/O-5683-2014; Stick, Stephen/AAA-5945-2021; Le Souef, Peter N/H-5256-2014; Sly, Peter D/F-1486-2010; Stick, Stephen/GZG-7584-2022; Burton, Paul R/H-7527-2016	Stick, Stephen/0000-0002-5386-8482; Sly, Peter D/0000-0001-6305-2201; Gurrin, Lyle/0000-0001-7052-1969; Le Souef, Peter/0000-0003-0930-1654				BASSI JA, 1984, PEDIATR RES, V18, P127, DOI 10.1203/00006450-198402000-00002; BROWN RW, 1995, PEDIATR PULM, V19, P23, DOI 10.1002/ppul.1950190105; CHEN MF, 1987, PEDIATR PULM, V3, P51, DOI 10.1002/ppul.1950030113; COLLINS MH, 1985, PEDIATR RES, V19, P408, DOI 10.1203/00006450-198519040-00018; CUTRERA R, 1991, PEDIATR PULM, V10, P6, DOI 10.1002/ppul.1950100103; ELLIS E, 1993, AM REV RESPIR DIS, V148, pA222; FOUCARD T, 1984, ACTA PAEDIATR SCAND, V73, P577, DOI 10.1111/j.1651-2227.1984.tb09977.x; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129, DOI 10.1164/ajrccm/145.5.1129; MARITZ GS, 1988, BIOL NEONATE, V53, P163; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MILICEMILI J, 1976, CHEST, V70, P131, DOI 10.1378/chest.70.1.131; MORRIS MJ, 1981, THORAX, V36, P135, DOI 10.1136/thx.36.2.135; PARK ES, 1986, ARCH DIS CHILD, V61, P642, DOI 10.1136/adc.61.7.642; Seddon PC, 1996, AM J RESP CRIT CARE, V153, P1248, DOI 10.1164/ajrccm.153.4.8616549; SHERRILL DL, 1992, AM REV RESPIR DIS, V145, P1136, DOI 10.1164/ajrccm/145.5.1136; STICK SM, 1992, PEDIATR PULM, V14, P187, DOI 10.1002/ppul.1950140308; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786, DOI 10.1136/adc.62.8.786; VANVUNAKIS H, 1987, ENV CARCINOGENS METH, V9; WALL MA, 1988, AM J PUBLIC HEALTH, V78, P699, DOI 10.2105/AJPH.78.6.699; WANG NS, 1984, J PATHOL, V144, P89, DOI 10.1002/path.1711440204; WRIGHT AL, 1991, J PEDIATR-US, V118, P207, DOI 10.1016/S0022-3476(05)80484-6; YOUNG S, 1991, NEW ENGL J MED, V325, P747; YOUNG S, 1994, J PEDIATR-US, V124, P681, DOI 10.1016/S0022-3476(05)81355-1; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; 1984, EUR J RESPIR DIS S, V132, P1	28	316	329	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1996	348	9034					1060	1064		10.1016/S0140-6736(96)04446-7	http://dx.doi.org/10.1016/S0140-6736(96)04446-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM886	8874457				2022-12-28	WOS:A1996VM88600010
J	Kannel, WB; Wolf, PA; Verter, J; McNamara, PM				Kannel, WB; Wolf, PA; Verter, J; McNamara, PM			Epidemiologic assessment of the role of blood pressure in stroke - The Framingham study (Reprinted from JAMA, vol 214, pg 301-310, 1970)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint								Control of hypertension, labile or fixed, systolic or diastolic, at any age, in either sex appears to be central to prevention of atherothrombotic brain infarction (ABI), Prospectively, hypertension proved the most common and potent precursor of ABI's, Its contribution was direct and could not be attributed to factors related both to stroke and hypertension, Asymptomatic causal ''hypertension'' was associated with a risk of ABI about four times that of normotensives. The probability of occurrence of an ABI was predicted no better with both blood pressure measurements or the mean arterial pressure than with systolic alone, Since there was no diminishing impact of systolic pressure with advancing age, the concept that systolic elevations are, even in the aged, innocuous is premature. Comparing normotensives and hypertensives in each sex, women did not tolerate hypertension better than men.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA 01701 USA; NATL HEART INST, WASHINGTON, DC USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; NATL HEART INST, BIOMETR RES SECT, BETHESDA, MD USA	Framingham Heart Study; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Wolf, Philip/0000-0002-3628-301X				[Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; BRONTESTEWART B, 1954, J PATHOL BACTERIOL, V68, P407, DOI 10.1002/path.1700680214; CORNFIELD J, 1960, B INT STATIST INST, V38, P97; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DEMING QB, 1958, J EXP MED, V107, P581, DOI 10.1084/jem.107.4.581; DUGUID JB, 1948, J PATHOL BACTERIOL, V60, P57, DOI 10.1002/path.1700600107; DUNCAN LE, 1963, MECH FACTORS LOCALIZ, P171; KANNEL WB, 1967, JOM-J OCCUP MED, V9, P611; KANNEL WB, 1970, J AMER MED ASSOC, V214, P301, DOI 10.1001/jama.214.2.301; KANNEL WB, 1965, AM J PUBLIC HEALTH N, V55, P1355, DOI 10.2105/AJPH.55.9.1355; KANNEL WB, 1964, ANN INTERN MED, V61, P888, DOI 10.7326/0003-4819-61-5-888; KANNEL WB, 1966, CEREBRAL VASCULAR DI, P53; MEYER JS, 1968, NEUROLOGY, V18, P772, DOI 10.1212/WNL.18.8.772; MOSES C, 1954, CIRC RES, V2, P243, DOI 10.1161/01.RES.2.3.243; SAKO Y, 1962, JAMA-J AM MED ASSOC, V179, P36, DOI 10.1001/jama.1962.03050010000008; TEXON M, 1960, ARCH SURG-CHICAGO, V80, P47, DOI 10.1001/archsurg.1960.01290180049006; WAKERLIN GE, 1957, CIRC RES, V5, P426, DOI 10.1161/01.RES.5.4.426; YOUNG W, 1960, AM J CARDIOL, V6, P288, DOI 10.1016/0002-9149(60)90317-9	19	48	52	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1996	276	15					1269	1278		10.1001/jama.276.15.1269	http://dx.doi.org/10.1001/jama.276.15.1269			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL691	8849757				2022-12-28	WOS:A1996VL69100039
J	Schneiderman, LJ; Jecker, NS; Jonsen, AR				Schneiderman, LJ; Jecker, NS; Jonsen, AR			Medical futility: Response to critiques	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOPULMONARY-RESUSCITATION; ETHICAL ANALYSIS; CARE; LIMITS; EMERGENCY; MORTALITY; OUTCOMES; REQUEST; REFUSAL; ORDERS	Six years ago, we proposed a patient benefit-centered definition of medical futility that included both quantitative and qualitative components. We distinguished between an effect of a treatment that is limited to some part of a patient's body and a benefit that improves the patient as a whole. The quantitative portion of our definition stipulated that physicians should regard a treatment as futile if empirical data show that the treatment has less than a 1 in 100 chance of benefiting the patient. The qualitative portion of our definition stipulated that if a treatment merely preserves permanent unconsciousness or cannot end dependence on intensive medical care, physicians should consider the treatment futile. In this paper, we clarify and modify our original proposal and respond to the following major criticisms: 1) Medical futility is simply an attempt to increase the power of the physician over the patient and to repeal recent hard-gained advances in patient autonomy; 2) no professional or societal consensus has been achieved about the definition of futility; 3) futility is a value-laden determination, the usurpation of which by medicine is inappropriate unless only a so-called value-free or strict physiologic definition of futility is used; 4) the concept of futility is not practically useful because empirical treatment data cannot be applied with certainty to any given patient; 5) futility undermines our pluralistic society and threatens, among other things, the free exercise of religion; and 6) because cost considerations will ultimately dictate all such decisions, futility is an unnecessary concept.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV WASHINGTON, DEPT MED HIST & ETH, SEATTLE, WA 98195 USA	University of California System; University of California San Diego; University of Washington; University of Washington Seattle	Schneiderman, LJ (corresponding author), UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, LA JOLLA, CA 92093 USA.		Jecker, Nancy/AAJ-6303-2020	Jecker, Nancy/0000-0002-5642-748X	AHRQ HHS [R18 HS 5617] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ACKERMAN F, 1991, HASTINGS CENT REP, V21, P27, DOI 10.2307/3562998; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BONNIN MJ, 1989, ANN EMERG MED, V18, P507, DOI 10.1016/S0196-0644(89)80834-0; Brennan T A, 1988, Law Med Health Care, V16, P204; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; BRODY BA, 1995, J MED PHILOS, V20, P123, DOI 10.1093/jmp/20.2.123; BRODY H, 1994, J AM GERIATR SOC, V42, P875, DOI 10.1111/j.1532-5415.1994.tb06562.x; BRODY H, 1992, HEALERS POWER; BRODY H, 1996, IN PRESS MED FUTILIT; CAPRON AM, 1991, HASTINGS CENT REP, V21, P26, DOI 10.2307/3562887; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; *DEP VET AFF VET H, 1993, MAN M2 CLIN AFF; FABERLANGENDOEN K, 1991, ARCH INTERN MED, V151, P235, DOI 10.1001/archinte.151.2.235; GATTER RA, 1995, J MED PHILOS, V20, P191, DOI 10.1093/jmp/20.2.191; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GRIMES DA, 1993, JAMA-J AM MED ASSOC, V269, P3030, DOI 10.1001/jama.269.23.3030; Jecker N S, 1993, Camb Q Healthc Ethics, V2, P151; JECKER NS, 1995, WESTERN J MED, V163, P287; JECKER NS, 1993, ARCH INTERN MED, V153, P2195, DOI 10.1001/archinte.153.19.2195; JECKER NS, 1995, J MED PHILOS, V20, P145, DOI 10.1093/jmp/20.2.145; JECKER NS, 1995, J CLIN ETHIC, V6, P133; JECKER NS, 1994, J CLIN ETHIC, V5, P138; JECKER NS, 1992, ARCH INTERN MED, V152, P1140, DOI 10.1001/archinte.152.6.1140; JECKER NS, 1992, AM J MED, V92, P189, DOI 10.1016/0002-9343(92)90111-N; JECKER NS, 1991, HASTINGS CENT REP, V21, P5, DOI 10.2307/3563315; JECKER NS, 1992, ARCH INTERN MED, V152, P2392, DOI 10.1001/archinte.152.12.2392; JECKER NS, 1995, HASTINGS CENT REP, V25, P6, DOI 10.2307/3562484; JECKER NS, 1995, CAMB Q HEALTHC ETHIC, V4, P23, DOI 10.1017/S0963180100005612; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kolata Gina, 1995, N Y Times Web, P6; LANTOS JD, 1988, NEW ENGL J MED, V318, P91, DOI 10.1056/NEJM198801143180206; MCCORMICK RA, 1974, JAMA-J AM MED ASSOC, V229, P172, DOI 10.1001/jama.229.2.172; MORREIM EH, 1994, HASTINGS CENT REP, V24, P33, DOI 10.2307/3562386; MORREIM EH, 1991, NEW MED ETHICS MED N; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; PARIS JJ, 1990, NEW ENGL J MED, V322, P1012, DOI 10.1056/NEJM199004053221420; PLATO, 1980, REPUBLIC; Popper K., 1968, SYST ZOOL; POST SG, 1995, J LAW MED ETHICS, V23, P20, DOI 10.1111/j.1748-720X.1995.tb01326.x; PRENDERGAST TJ, 1995, CHEST, V107, P836, DOI 10.1378/chest.107.3.836; Ramsey Paul, 1970, PATIENT PERSON; Reiser SJ, 1977, ETHICS MED HIST PERS, P6; SCHNEIDERMAN LJ, 1994, AM J MED, V96, P110, DOI 10.1016/0002-9343(94)90130-9; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; Schneiderman LJ, 1996, THEOR MED, V17, P33, DOI 10.1007/BF00489739; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; Schneiderman LJ, 1996, CAMB Q HEALTHC ETHIC, V5, P248, DOI 10.1017/S0963180100007003; SCHNEIDERMAN LJ, 1994, J AM GERIATR SOC, V42, P883, DOI 10.1111/j.1532-5415.1994.tb06564.x; SCHNEIDERMAN LJ, 1991, ANN INTERN MED, V114, P170; Schneiderman LJ, 1995, WRONG MED DOCTORS PA; SCOFIELD GR, 1994, GENERATIONS, V18, P66; SCOFIELD GR, 1991, HASTINGS CENT REP, V21, P28, DOI 10.2307/3562360; TOMLINSON T, 1995, HASTINGS CENT REP, V25, P28, DOI 10.2307/3562112; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; VANMCCRARY S, 1994, J CLIN ETHIC, V5, P100; VEATCH RM, 1992, AM J LAW MED, V18, P15; Wolf S M, 1988, Law Med Health Care, V16, P197; Yankelovich D., 1991, COMING PUBLIC JUDGME; YOUNGNER SJ, 1988, PERSPECT BIOL MED, V31, P299; YOUNGNER SJ, 1995, SETON HALL LAW REV, V25, P1015; 1992, JAMA-J AM MED ASSOC, V268, P2282	64	112	112	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1996	125	8					669	674		10.7326/0003-4819-125-8-199610150-00007	http://dx.doi.org/10.7326/0003-4819-125-8-199610150-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VM889	8849152				2022-12-28	WOS:A1996VM88900009
J	Koepp, DM; Silver, PA				Koepp, DM; Silver, PA			A GTPase controlling nuclear trafficking: Running the right way or walking RANdomly?	CELL			English	Review							PROTEIN IMPORT; RNA EXPORT; BINDING; RAN/TC4; TRANSLOCATION; DISSOCIATION; INHIBITION		DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Koepp, DM (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA.							AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1996, IN PRESS EMBO J; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; WEIS K, 1996, IN PRESS EMBO J	18	145	146	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1996	87	1					1	4		10.1016/S0092-8674(00)81315-X	http://dx.doi.org/10.1016/S0092-8674(00)81315-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858141	Bronze			2022-12-28	WOS:A1996VL69500001
J	Trkola, A; Dragic, T; Arthos, J; Binley, JM; Olson, WC; Allaway, GP; ChengMayer, C; Robinson, J; Maddon, PJ; Moore, JP				Trkola, A; Dragic, T; Arthos, J; Binley, JM; Olson, WC; Allaway, GP; ChengMayer, C; Robinson, J; Maddon, PJ; Moore, JP			CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5	NATURE			English	Article							MONOCLONAL-ANTIBODIES; VIRUS; EXPRESSION; GP120	THE beta-chemokine receptor CCR-5 is an essential co-factor for fusion of HIV-1 strains of the non-syncytium-inducing (NSI) phenotype with CD4(+) T-cells(1-5). The primary binding site for human immunodeficiency virus (HIV)-1 is the CD4 molecule, and the interaction is mediated by the viral surface glycoprotein gp120 (refs 6, 7). The mechanism of CCR-5 function during HIV entry has not been defined, but we have shown previously that its beta-chemokine ligands prevent HIV-1 from fusing with the cell(1). We therefore investigated whether CCR-5 acts as a second binding site for HIV-1 simultaneously with or subsequent to the interaction between gp120 and CD4, We used a competition assay based on gp120 inhibition of the binding of the CCR-5 ligand, macrophage inflammatory protein (MIP)-1 beta, to its receptor on activated CD4(+) T cells or CCR-5-positive CD4(-) cells. We conclude that CD4 binding, although not absolutely necessary for the gp120-CCR-5 interaction, greatly increases its efficiency, Neutralizing monoclonal antibodies against several sites on gp120, including the V3 loop and CD4-induced epitopes, inhibited the interaction of gp120 with CCR-5, without affecting gp120-CD4 binding, Interference with HIV-1 binding to one or both of its receptors (CD4 and CCR-5) may be an important mechanism of virus neutralization.	ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; NIAID,IMMUNOREGULAT LAB,NIH,BETHESDA,MD 20892; PROGEN PHARMACEUT INC,TARRYTOWN,NY 10591; TULANE UNIV,MED CTR,DEPT PEDIAT,NEW ORLEANS,LA 70112	Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Tulane University			Trkola, Alexandra/K-2115-2012	Trkola, Alexandra/0000-0003-1013-876X				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DORANZ B, 1996, J CELL, V86, P1149; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Moore J P, 1995, AIDS, V9 Suppl A, pS117; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53	20	968	1031	0	48	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					184	187		10.1038/384184a0	http://dx.doi.org/10.1038/384184a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906796				2022-12-28	WOS:A1996VT33600070
J	Onishi, HR; Pelak, BA; Gerckens, LS; Silver, LL; Kahan, FM; Chen, MH; Patchett, AA; Galloway, SM; Hyland, SA; Anderson, MS; Raetz, CRH				Onishi, HR; Pelak, BA; Gerckens, LS; Silver, LL; Kahan, FM; Chen, MH; Patchett, AA; Galloway, SM; Hyland, SA; Anderson, MS; Raetz, CRH			Antibacterial agents that inhibit lipid A biosynthesis	SCIENCE			English	Article							ESCHERICHIA-COLI; ENDOTOXIN BIOSYNTHESIS; 1ST STEP; RESISTANCE; ACYLTRANSFERASE; ANTIBIOTICS; RELEASE; GENE	Lipid A constitutes the outer monolayer of the outer membrane of Gram-negative bacteria and is essential for bacterial growth. Synthetic antibacterials were identified that inhibit the second enzyme (a unique deacetylase) of lipid A biosynthesis. The inhibitors are chiral hydroxamic acids bearing certain hydrophobic aromatic moieties. They may bind to a metal in the active site of the deacetylase. The most potent analog (with an inhibition constant of about 50 nM) displayed a minimal inhibitory concentration of about 1 microgram per milliliter against Escherichia coli, caused three logs of bacterial killing in 4 hours, and cured mice infected with a lethal intraperitoneal dose of E. coli.	MERCK RES LABS,DEPT MICROBIOL,RAHWAY,NJ 07065; MERCK RES LABS,DEPT MED CHEM,RAHWAY,NJ 07065; MERCK RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065	Merck & Company; Merck & Company; Merck & Company			Silver, Lynn L/A-7789-2009	Silver, Lynn L/0000-0002-8416-0487				ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; BEALL B, 1987, J BACTERIOL, V169, P5408, DOI 10.1128/jb.169.12.5408-5415.1987; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; GRUNDSTROM T, 1980, J BACTERIOL, V144, P884; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; JACKMAN JA, UNPUB; JACKSON JJ, 1992, J INFECT DIS, V165, P1033, DOI 10.1093/infdis/165.6.1033; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KNUDSEN LF, 1947, J AM STAT ASSOC, V42, P282, DOI 10.2307/2280657; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PRINS JM, 1994, ANTIMICROB AGENTS CH, V38, P1211, DOI 10.1128/AAC.38.6.1211; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; Rich D. H., 1990, COMPREHENSIVE MED CH, V2, P391; SPRATT BG, 1994, SCIENCE, V264, P388, DOI 10.1126/science.8153626; STAMMER CH, 1957, J AM CHEM SOC, V79, P3236, DOI 10.1021/ja01569a065; VUORIO R, 1992, ANTIMICROB AGENTS CH, V37, P354; Williamson J. J., UNPUB; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384; YOUNG K, 1991, J BACTERIOL, V173, P3609, DOI 10.1128/JB.173.12.3609-3614.1991	23	342	360	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					980	982		10.1126/science.274.5289.980	http://dx.doi.org/10.1126/science.274.5289.980			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875939				2022-12-28	WOS:A1996VR79200048
J	Kellermann, AL; Rivara, FP; Lee, RK; Banton, JG; Cummings, P; Hackman, BB; Somes, G				Kellermann, AL; Rivara, FP; Lee, RK; Banton, JG; Cummings, P; Hackman, BB; Somes, G			Injuries due to firearms in three cities	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; DEATHS; COSTS; HOSPITALIZATION; EPIDEMIOLOGY; FATALITIES; CALIFORNIA; VIOLENCE; GUNSHOT; WOUNDS	Background To describe the incidence and outcome of injuries due to firearms, we conducted a population-based study of fatal and nonfatal gunshot wounds in three cities: Memphis, Tennessee; Seattle, Washington; and Galveston, Texas. Methods Records of the police, medical examiners, ambulance crews, and hospital emergency departments and hospital admissions were monitored to identify all injuries caused by firearms that were severe enough to prompt emergency medical treatment. These records were linked to generate a complete picture of each event. Census data were used to calculate rates of injury for various population groups. Results A total of 1915 cases of injury due to firearms were identified between November 16, 1992, and May 15, 1994. The crude rate of firearm injury per 100,000 person-years was 222.6 in Memphis, 143.6 in Galveston, and 54.1 in Seattle. Approximately 88 percent of the injuries were incurred during confirmed or probable assaults; 7 percent were sustained in the course of suicide or attempted suicide; unintentional injuries accounted for 4 percent of the cases. Handguns were used in 88 percent of the cases in which the type of weapon was recorded. Five percent of the 1677 victims who were brought to a hospital emergency department could not be resuscitated; 53 percent were hospitalized, and 42 percent were treated and released. Ninety-seven percent of the deaths occurred within 24 hours of the injury. Emergency department and inpatient charges exceeded $16.5 million. Conclusions Injuries due to firearms, most involving handguns, are a major cause of morbidity and mortality in U.S. urban areas. The incidence varies greatly from city to city. (C)1996, Massachusetts Medical Society.	UNIV WASHINGTON,HARBORVIEW INJURY PREVENT & RES CTR,SEATTLE,WA 98195; UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550; UNIV TENNESSEE,DEPT PREVENT MED,MEMPHIS,TN	University of Washington; University of Washington Seattle; University of Texas System; University of Texas Medical Branch Galveston; University of Tennessee System; University of Tennessee Health Science Center	Kellermann, AL (corresponding author), EMORY UNIV,ROLLINS SCH PUBL HLTH,CTR INJURY CONTROL,1518 CLIFTON RD,NE,ATLANTA,GA 30322, USA.				PHS HHS [CCR-407419] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEXANDER GR, 1985, AM J PUBLIC HEALTH, V75, P165, DOI 10.2105/AJPH.75.2.165; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; Ash P, 1996, JAMA-J AM MED ASSOC, V275, P1754, DOI 10.1001/jama.275.22.1754; Blumstein A, 1995, J CRIM LAW CRIM, V86, P10, DOI 10.2307/1143998; Cook PJ, 1996, JAMA-J AM MED ASSOC, V275, P1765, DOI 10.1001/jama.275.22.1765; *FED BUR INV, 1993, UN CRIM REP CRIM US; FINGERHUT LA, 1993, ADV DATA VITAL HLTH, V231; JAGGER J, 1986, JAMA-J AM MED ASSOC, V255, P3143, DOI 10.1001/jama.255.22.3143; KECK NJ, 1988, AM J DIS CHILD, V142, P623, DOI 10.1001/archpedi.1988.02150060057029; KELLERMANN AL, 1994, AM J PUBLIC HEALTH, V84, P541, DOI 10.2105/AJPH.84.4.541; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KELLERMANN AL, 1993, HEALTH AFFAIR, V12, P142, DOI 10.1377/hlthaff.12.4.142; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; Lee R K, 1991, Tex Med, V87, P78; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MARKUSH RE, 1984, AM J PUBLIC HEALTH, V74, P123, DOI 10.2105/AJPH.74.2.123; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MERCY JA, 1988, NEW ENGL J MED, V319, P1283, DOI 10.1056/NEJM198811103191911; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; MORROW PL, 1986, AM J PUBLIC HEALTH, V76, P1120, DOI 10.2105/AJPH.76.9.1120; *NAT COMM INJ PREV, 1989, INJ PREV M CHALL, P261; OZONOFF VV, 1994, AM J PUBLIC HEALTH, V84, P2024; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Reiss A., 1993, UNDERSTANDING PREVEN; Rice DP, 1989, COST INJURY US REPOR; ROTH JA, NCJ PUBLICATION; Sadowski LS, 1996, JAMA-J AM MED ASSOC, V275, P1762, DOI 10.1001/jama.275.22.1762; *US BUR CENS, 1992, CPH149 US BUR CENS; *US BUR CENS, 1990, CPH145 US BUR CENS; *US BUR CENS, 1990, CPH144 US BUR CENS; *WEAP REL INJ SURV, 1995, 2500 SHOT STABB VIOL; WINTEMUTE GJ, 1987, WESTERN J MED, V146, P374; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; WINTEMUTE GJ, 1987, J TRAUMA, V27, P532, DOI 10.1097/00005373-198705000-00013; Wintemute GJ, 1996, JAMA-J AM MED ASSOC, V275, P1749, DOI 10.1001/jama.275.22.1749; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; ZAWITZ MW, NCJ PUBLICATION; ZWERLING C, 1993, AM J PREV MED, V9, P21, DOI 10.1016/S0749-3797(18)30674-3; 1995, MMWR-MORBID MORTAL W, V44, P160; 1987, MMWR-MORBID MORTAL W, V36, P634; 1995, MMWR-MORBID MORTAL W, V44, P169; 1985, MMWR-MORBID MORTAL W, V34, P353	43	86	87	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1438	1444		10.1056/NEJM199611073351906	http://dx.doi.org/10.1056/NEJM199611073351906			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT339	8875922				2022-12-28	WOS:A1996VT33900006
J	Verdine, GL				Verdine, GL			The combinatorial chemistry of nature	NATURE			English	Article							MODULAR POLYKETIDE SYNTHASE; POLYMERASE CHAIN-REACTION; RECOMBINANT PROTEINS; BIOSYNTHESIS; OVERPRODUCTION; RAPAMYCIN; PRODUCTS; COMPLEX; DOMAIN				Verdine, GL (corresponding author), HARVARD UNIV,DEPT CHEM & CHEM BIOL,CAMBRIDGE,MA 02138, USA.							ARNOLD FH, 1991, BIO-TECHNOL, V9, P151, DOI 10.1038/nbt0291-151; Blundell TL, 1996, NATURE, V384, P23; Broach JR, 1996, NATURE, V384, P14; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Corey E. J., 1989, LOGIC CHEM SYNTHESIS; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; FANTEANY G, 1995, SCIENCE, V268, P726; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Hogan JC, 1996, NATURE, V384, P17; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; LEE JC, 1995, CHEM BIOL, V2, P721, DOI 10.1016/1074-5521(95)90100-0; LIU J, 1991, CELL, V66, P1; MACFERRIN KD, 1993, METHOD ENZYMOL, V217, P79; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; Nicolaou K. C., 1995, CLASSICS TOTAL SYNTH; Roessner C A, 1994, Chem Biol, V1, P119; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; SMITH MC, 1988, J BIOL CHEM, V263, P7211; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TSOI CJ, 1995, CHEM BIOL, V2, P355; VAGELOS PR, 1991, SCIENCE, V252, P1080, DOI 10.1126/science.252.5009.1080; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551	28	105	114	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604		S			11	13						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR392	8895593				2022-12-28	WOS:A1996VR39200004
J	Stocklin, E; Wissler, M; Gouilleux, F; Groner, B				Stocklin, E; Wissler, M; Gouilleux, F; Groner, B			Functional interactions between Stat5 and the glucocorticoid receptor	NATURE			English	Article							COLONY-STIMULATING FACTOR; MAMMARY EPITHELIAL-CELLS; TRANSCRIPTION FACTOR; BETA-CASEIN; RESPONSIVE EXPRESSION; NUCLEAR FACTOR; DNA-BINDING; TUMOR VIRUS; PROLACTIN; GENE	SIGNAL transduction pathways enable extracellular signals to activate latent transcription factors in the cytoplasm of cells. Dimerization, nuclear localization and binding to specific DNA sequences result in the induction of gene transcription by these proteins. These events are necessary for the functioning of the JAK/STAT pathway and of the glucocorticoid-receptor pathway. In the former, the protein Stat5, which is a member of a family of signal transducers and activators of transcription, is activated by cytokines, hormones and growth factors(1-7). These polypeptide ligands bind at the outside of the cell to specific transmembrane receptors and activate intracellular Janus protein tyrosine kinases (JAKs) to tyrosine-phosphorylate STAT proteins; interaction with the SH2 domain of the dimerization partner then confers the ability to bind to DNA at the STAT-response element and induce transcription(8-10). In the glucocorticoid-receptor pathway, the receptor interacts with its steroid hormone ligand in the cytoplasm, undergoes an allosteric change that enables the hormone receptor complex to bind to specific DNA-response elements (glucocorticoid response elements, or GRE) and modulate transcription(11,12). Although these pathways appear to he unrelated, we show here that the glucocorticoid receptor can act as a transcriptional co-activator for Stat5 and enhance Stat5-dependent transcription. Stat5 forms a complex with the glucocorticoid receptor which binds to DNA independently of the GRE. This complex formation between Stat5 and the glucocorticoid receptor diminishes the glucocorticoid response of a GRE-containing promoter.	TUMOR BIOL CTR,INST EXPT CANC RES,D-79106 FREIBURG,GERMANY					Gouilleux, Fabrice/0000-0001-6047-1718				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRONER B, 1994, MOL CELL ENDOCRINOL, V100, P109, DOI 10.1016/0303-7207(94)90288-7; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; HOCK W, 1990, J BIOL CHEM, V265, P5403; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; HYNES NE, 1981, P NATL ACAD SCI-BIOL, V78, P2038, DOI 10.1073/pnas.78.4.2038; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; LAVOIE HA, 1995, P SOC EXP BIOL MED, V209, P257; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WELLE T, 1993, J STEROID BIOCH MOL, V47, P75; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	30	536	541	3	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					726	728		10.1038/383726a0	http://dx.doi.org/10.1038/383726a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878484	Green Submitted			2022-12-28	WOS:A1996VN91800056
J	Saudek, CD; Duckworth, WC; GiobbieHurder, A; Henderson, WG; Henry, RR; Kelley, DE; Edelman, SV; Zieve, FJ; Adler, RA; Anderson, JW; Anderson, RJ; Hamilton, BP; Donner, TW; Kirkman, MS; Morgan, NA				Saudek, CD; Duckworth, WC; GiobbieHurder, A; Henderson, WG; Henry, RR; Kelley, DE; Edelman, SV; Zieve, FJ; Adler, RA; Anderson, JW; Anderson, RJ; Hamilton, BP; Donner, TW; Kirkman, MS; Morgan, NA			Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus - A randomized clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WEIGHT-GAIN; INTRAPERITONEAL; HYPOGLYCEMIA; RESISTANCE; FREQUENCY; INFUSION; THERAPY	Objective.-To determine whether implantable insulin pump (IIP) therapy and multiple daily insulin (MDI) injections could equally attain improved blood glucose control, and to compare the 2 treatments with respect to reducing daily blood glucose fluctuations: reducing serious hypoglycemic insulin reactions, and improving patients' quality of life, Design.-Randomized clinical trial, Setting.-Seven Veterans Affairs medical centers. Patients.-One hundred twenty-one male type II diabetic patients between the ages of 40 and 69 years, receiving at least 1 injection of insulin per day and having hemoglobin A(1c) (HbA(1c)) levels of 8% or above, Intervention.-Intensive therapy (IIP or MDI) for 1 year, Main Outcome Measures.-Hemoglobin A(1c) and blood glucose levels, Results.-Blood glucose levels declined to 7.96+/-1.08 mmol/L (143.4+/-19.5 mg/dL) and 8.30+/-1.52 mmol/L (149.6+/-27.4 mg/dL) (mean +/- SD) for IIP and MDI, respectively (P=.57), Hemoglobin A(1c) levels improved in both groups (time effect P<.001), to means of 7.54%+/-0.83% (MDI) vs 7.34%+/-0.79% (IIP), IIP reduced blood glucose fluctuations compared with MDI (P<.001), and reduced the incidence of mild clinical hypoglycemia by 68% (P<.001); IIP also eliminated the weight gain associated with MDI therapy and yielded better overall quality-of-life (P=.03) and impact-of-disease subscale scores (P=.05), Adverse events included 25% of subjects with episodes of insulin underdelivery due to microprecipitates of insulin within the pump, Conclusions.-Intensive insulin therapy with IIP and MDI is effective in controlling non-insulin-dependent diabetes mellitus, IIP has significant advantages in reducing glycemic variability, clinical hypoglycemia, and weight gain, while improving aspects of quality of life.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; VET AFFAIRS MED CTR, OMAHA, NE USA; UNIV NEBRASKA, MED CTR, OMAHA, NE USA; VET AFFAIRS MED CTR, COOPERAT STUDIES PROGRAM COORDINATING CTR, HINES, IL USA; VET AFFAIRS MED CTR, SAN DIEGO, CA 92161 USA; UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA; VET AFFAIRS MED CTR, PITTSBURGH, PA USA; UNIV PITTSBURGH, MED CTR, PITTSBURGH, PA USA; VET AFFAIRS MED CTR, RICHMOND, VA USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, RICHMOND, VA 23298 USA; VET AFFAIRS MED CTR, LEXINGTON, KY USA; UNIV KENTUCKY, LEXINGTON, KY USA; VET AFFAIRS MED CTR, OMAHA, NE USA; CREIGHTON UNIV, OMAHA, NE 68178 USA; VET AFFAIRS MED CTR, BALTIMORE, MD USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA; DUKE UNIV, DURHAM, NC USA; VET AFFAIRS MED CTR, DURHAM, NC 27705 USA; INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA; CENT RES PHARM COORDINATING CTR, COOPERAT STUDIES PROGRAM, ALBUQUERQUE, NM USA	Johns Hopkins University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hunter Holmes McGuire Veterinary Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Virginia Commonwealth University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Creighton University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Maryland; University of Maryland Baltimore; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Indiana University System; Indiana University-Purdue University Indianapolis								*AM DIAB ASS, 1993, DIAB 1993 VIT STAT, P13; BALLARD DJ, 1988, DIABETES, V37, P405, DOI 10.2337/diabetes.37.4.405; BLACKSHEAR PJ, 1979, MED PROG TECHNOL, V6, P149; BLACKSHEAR PJ, 1985, J CLIN ENDOCR METAB, V61, P753, DOI 10.1210/jcem-61-4-753; BRUNZELL JD, 1976, J CLIN ENDOCR METAB, V42, P222, DOI 10.1210/jcem-42-2-222; CARLSON MG, 1993, DIABETES, V42, P1700, DOI 10.2337/diabetes.42.12.1700; COX DJ, 1994, J CLIN ENDOCR METAB, V79, P1659, DOI 10.1210/jc.79.6.1659; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; DCCT Res Grp, 1988, DIABETES CARE, V11, P725; DCCT Res Grp, 1988, DIABETES CARE, V11, P567; DIABET CONTROL COMPLICATIONS TRIAL RES GRP, 1995, DIABETES CARE, V18, P1468; DUCKWORTH WC, 1992, DIABETES, V41, P657, DOI 10.2337/diabetes.41.6.657; GRAU U, 1987, DIABETES, V36, P1453, DOI 10.2337/diabetes.36.12.1453; HAARDT MJ, 1994, DIABETES CARE, V17, P847, DOI 10.2337/diacare.17.8.847; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; HENRY RR, 1993, DIABETES CARE, V16, P21, DOI 10.2337/diacare.16.1.21; HEPBURN DA, 1993, DIABETIC MED, V10, P231, DOI 10.1111/j.1464-5491.1993.tb00050.x; HEPP KD, 1988, LANCET, V2, P866; IRSIGLER K, 1981, DIABETES, V30, P1072, DOI 10.2337/diabetes.30.12.1072; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; LAAKSO M, 1989, DIABETES CARE, V12, P83, DOI 10.2337/diacare.12.2.83; MICOSSI P, 1986, DIABETES CARE, V9, P575, DOI 10.2337/diacare.9.6.575; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SAUDEK CD, 1992, DIABETES CARE, V15, P567, DOI 10.2337/diacare.15.4.567; SAUDEK CD, 1989, NEW ENGL J MED, V321, P574, DOI 10.1056/NEJM198908313210904; SAUDEK CD, 1993, ENDOCRINOLOGIST, V3, P15; SAUDEK CD, 1991, DIABETES ANN, V6, P524; SCHADE DS, 1981, METABOLISM, V30, P149, DOI 10.1016/0026-0495(81)90164-5; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; WING RR, 1990, DIABETES CARE, V13, P1106, DOI 10.2337/diacare.13.11.1106; YKIJARVINEN H, 1992, NEW ENGL J MED, V327, P1426, DOI 10.1056/NEJM199211123272005	31	114	117	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1322	1327		10.1001/jama.276.16.1322	http://dx.doi.org/10.1001/jama.276.16.1322			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM825	8861991				2022-12-28	WOS:A1996VM82500035
J	Zimmet, P; Hodge, A; Nicolson, M; Staten, M; deCourten, M; Moore, J; Morawiecki, A; Lubina, J; Collier, G; Alberti, G; Dowse, G				Zimmet, P; Hodge, A; Nicolson, M; Staten, M; deCourten, M; Moore, J; Morawiecki, A; Lubina, J; Collier, G; Alberti, G; Dowse, G			Serum leptin concentration, obesity, and insulin resistance in Western Samoans: Cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							GENE-EXPRESSION; ADIPOSE-TISSUE; MESSENGER-RNA; OB GENE; PREVALENCE; POPULATION; INCREASE; CLONING; PRODUCT; PERIOD	Objective-To measure serum leptin concentrations in the Polynesian population of Western Samoa and to examine epidemiological associations of leptin with anthropometric, demographic, behavioural, and metabolic factors in this population with a high prevalence of obesity and non-insulin dependent diabetes mellitus. Design-Cross sectional study, leptin concentration being measured in a subgroup of a population based sample. Subjects-240 Polynesian men and women aged 28-74 years were selected to cover the full range of age, body mass index, and glucose tolerance, Main outcome measurements-Serum leptin, insulin, and glucose concentrations; anthropometric measures; physical activity; and area of residence. Results-Leptin concentrations were correlated with body mass index (r = 0.80 in men, 0.79 in women) and waist circumference (r = 0.82 in men, 0.78 in women) but less so with waist to hip ratio, At any body mass index, leptin concentration was higher in women than men (geometric mean adjusted for body mass index 15.3 v 3.6 pg/l, P < 0.001). Leptin concentration also correlated with fasting insulin concentration (r = 0.63 in men, 0.64 in women) and insulin concentration 2 hours after a glucose load (r = 0.58 in men, 0.52 in women). These associations remained significant after controlling for body mass index; effects of physical activity and of rural or urban living on leptin concentration were eliminated after adjusting for obesity, except values remained high in urban men. 78% of variance in leptin was explained by a model including fasting insulin concentration, sex, body mass index, and a body mass index by sex interaction term. Similar results were obtained if waist circumference replaced body mass index. Conclusions-The strong relation of leptin with obesity is consistent with leptin production being proportional to mass of adipose tissue. The relation with insulin independent of body mass index suggests a possible role for leptin in insulin resistance or hyperinsulinaemia.	AMGEN INC,CLIN RES,THOUSAND OAKS,CA 91320; AMGEN INC,BIOSTAT,THOUSAND OAKS,CA 91320; DEAKIN UNIV,GEELONG,VIC 3220,AUSTRALIA; UNIV NEWCASTLE UPON TYNE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Amgen; Amgen; Deakin University; Newcastle University - UK	Zimmet, P (corresponding author), INT DIABET INST,CAULFIELD,VIC 3162,AUSTRALIA.		de Courten, Maximilian P. J./AAH-5104-2020; Zimmet, Paul/O-8486-2019; de Courten, Maximilian/B-3300-2012	Zimmet, Paul/0000-0003-0627-0776; de Courten, Maximilian/0000-0001-9997-9359; Hodge, Allison/0000-0001-5464-2197	NIDDK NIH HHS [DK-25446] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025446] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bouchard C, 1993, Obes Res, V1, P133; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLLIER GR, IN PRESS DIABETOLOGI; COLLINS VR, 1994, DIABETES CARE, V17, P288, DOI 10.2337/diacare.17.4.288; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; CUSIN I, 1995, DIABETES, V44, P1467, DOI 10.2337/diabetes.44.12.1467; FREDERICH RC, 1995, NAT MED, V1, P311; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; HODGE AM, 1994, INT J OBESITY, V18, P419; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; NORUSIS M, 1990, SPSS PC 4 0 IBM PC X; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SOELDNER JS, 1965, DIABETES, V14, P771, DOI 10.2337/diab.14.12.771; TARTAGLIA LA, 1995, CELL, V85, P1265; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; *WHO STUD GROUP, 1985, WHO TECH REP SER, V727; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZIMMET P, 1981, DIABETES, V30, P45, DOI 10.2337/diabetes.30.1.45	28	206	208	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1996	313	7063					965	969						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN916	8892415	Green Published			2022-12-28	WOS:A1996VN91600019
J	Byrne, GJ; McCarthy, MJ; Silverman, SH				Byrne, GJ; McCarthy, MJ; Silverman, SH			Improving uptake of prophylaxis for venous thromboembolism in general surgical patients using prospective audit	BRITISH MEDICAL JOURNAL			English	Article									KIDDERMINSTER HOSP,DEPT SURG,KIDDERMINSTER,W MIDLANDS,ENGLAND; CITY HOSP,DEPT SURG,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND	University of Birmingham				Byrne, Ged/0000-0002-8194-7540				Bahal V, 1993, J R Coll Surg Edinb, V38, P33; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; LINDBLAD B, 1991, BRIT MED J, V302, P709, DOI 10.1136/bmj.302.6778.709; SCURR JH, 1988, SWISS MED, V10, P77; VANEK VW, 1991, CURR SURG, V48, P539	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1996	313	7062					917	917						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876095				2022-12-28	WOS:A1996VM75400026
J	Jick, H; Derby, LE; Myers, MW; Vasilakis, C; Newton, KM				Jick, H; Derby, LE; Myers, MW; Vasilakis, C; Newton, KM			Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens	LANCET			English	Article							ENDOMETRIAL CANCER; ESTROGENS	Background At the request of researchers in the UK, we conducted a case-control study to explore the relation between use of postmenopausal oestrogen hormone replacement therapy (HRT) and idiopathic venous thromboembolism (VTE). Methods The study was based on information derived from Group Health Cooperative of Puget Sound for the period 1980 to 1994. Women aged 50-74 years admitted to hospital for idiopathic VTE were identified from hospital records. The diagnosis of idiopathic VTE was validated from the clinical record. Women who had medical conditions predisposing to VTE (a history of VTE or cancer, recent trauma, or surgery) were excluded as cases. Four control subjects matched to each case by age, duration of Cooperative membership, and calendar time were identified from the base population. Various potential risk factors were recorded based on record review. Findings An initial analysis of 42 cases and 168 matched controls yielded a matched relative risk estimate of 3 . 6 (95% CI 1 . 6-7 . 8) for current users of oestrogens compared with non-users. There was a substantial effect of daily oestrogen dose. The matched relative risk estimates for oestrogen users of 0 . 325 mg, 0 . 625 mg, and 1 . 25 mg or more daily were 2 . 1, 3 . 3, and 6 . 9, respectively. Body-mass index was independently associated with the risk of VTE but did not materially confound the relation of oestrogen and VTE. The absolute risk of idiopathic VTE is estimated to be low (0 . 9x10(-4) woman-years) in non-users of oestrogen; the risk in current users is estimated at 3 . 2x10(-4) woman-years. Interpretation The risk of idiopathic VTE is about three times higher among current users of replacement oestrogens than among non-users. However, the absolute risk is low for both groups and accounts for only a modest increase in morbidity.	GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101	Group Health Cooperative	Jick, H (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,244 WOOD ST,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992				Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; JICK H, 1979, NEW ENGL J MED, V300, P218, DOI 10.1056/NEJM197902013000502; JICK H, 1984, PHARMACOTHERAPY, V4, P99; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; JICK SS, 1993, EPIDEMIOLOGY, V4, P20, DOI 10.1097/00001648-199301000-00005	5	499	506	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					981	983		10.1016/S0140-6736(96)07114-0	http://dx.doi.org/10.1016/S0140-6736(96)07114-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855853	hybrid			2022-12-28	WOS:A1996VM02700009
J	Kanabar, DJ; Wright, A; Marsh, MJ				Kanabar, DJ; Wright, A; Marsh, MJ			An emotional 13-year-old girl	LANCET			English	Article											Kanabar, DJ (corresponding author), GUYS HOSP,DEPT PAEDIAT,ST THOMAS ST,LONDON SE1 9RT,ENGLAND.							[Anonymous], 1965, CIRCULATION, V32, P664; MAJEED HA, 1992, CURR PAEDIAT, V2, P1; STOLLERMAN GH, 1995, LANCET, V346, P390, DOI 10.1016/S0140-6736(95)92776-X; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					1000	1000		10.1016/S0140-6736(96)07075-4	http://dx.doi.org/10.1016/S0140-6736(96)07075-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855858				2022-12-28	WOS:A1996VM02700014
J	Parthun, MR; Widom, J; Gottschling, DE				Parthun, MR; Widom, J; Gottschling, DE			The major cytoplasmic histone acetyltransferase in yeast: Links to chromatin replication and histone metabolism	CELL			English	Article							NEWLY SYNTHESIZED HISTONES; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; NEGATIVE REGULATOR; ACETYLATION SITES; H4; PROTEINS; TETRAHYMENA; VECTORS; DOMAINS	We have isolated the predominant cytoplasmic histone acetyltransferase activity from Saccharomyces cerevisiae. This enzyme acetylates the lysine at residue 12 of free histone H4 but does not modify histone H4 when packaged in chromatin. The activity contains two proteins, Hat1p and Hat2p. Hat1p is the catalytic subunit of the histone acetyltransferase and has an intrinsic substrate specificity that modifies lysine in the recognition sequence GXG (K) under bar XG. The specificity of the enzyme in the yeast cytoplasm is restricted relative to recombinant Hat1p suggesting that it is negatively regulated in vivo. Hat2p, which is required for high affinity binding of the acetyltransferase to histone H4, is highly related to Rbap48, which is a subunit of the chromatin assembly factor, CAF-1, and copurifies with the human histone deacetylase HD1. We propose that the Hat2p/Rbap48 family serve as escorts of histone metabolism enzymes to facilitate their interaction with histone H4.	NORTHWESTERN UNIV,DEPT BIOCHEM MOL BIOL & CELL BIOL,EVANSTON,IL 60208	Northwestern University	Parthun, MR (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043893, R01GM050932] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50932, GM43893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P329; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BROTHERTON TW, 1981, NUCLEIC ACIDS RES, V9, P5061, DOI 10.1093/nar/9.19.5061; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FENG HP, 1993, BIOCHEMISTRY-US, V32, P7824, DOI 10.1021/bi00081a030; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; Harlow E., 1988, ANTIBODIES LAB MANUA; HENIKOFF S, 1987, GENETICS, V117, P711; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; LOPEZRODAS G, 1989, J BIOL CHEM, V264, P19028; LOWARY PT, 1989, P NATL ACAD SCI USA, V86, P8266, DOI 10.1073/pnas.86.21.8266; Means G.E., 1971, CHEM MODIFICATION PR; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P306; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; van Holde KE., 1989, SPRINGER SERIES MOL; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WIDOM J, 1986, J MOL BIOL, V190, P411, DOI 10.1016/0022-2836(86)90012-4; WILLIAMS KR, 1995, TECH PROT CHEM, V6, P143, DOI 10.1016/S1080-8914(06)80020-7; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3	46	365	374	2	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					85	94		10.1016/S0092-8674(00)81325-2	http://dx.doi.org/10.1016/S0092-8674(00)81325-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858151	Bronze			2022-12-28	WOS:A1996VL69500011
J	Kourtis, AP; Ibegbu, C; Nahmias, AJ; Lee, FK; Clark, WS; Sawyer, MK; Nesheim, S				Kourtis, AP; Ibegbu, C; Nahmias, AJ; Lee, FK; Clark, WS; Sawyer, MK; Nesheim, S			Early progression of disease in HIV-infected infants with thymus dysfunction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; B-CELLS; THYMOCYTE DEPLETION; SEROPOSITIVE WOMEN; T-CELLS; IN-VIVO; CHILDREN; SUBPOPULATIONS; ADULTS; MICE	Background Infants with congenital thymic deficiency (the DiGeorge syndrome) have immunodeficiency and a characteristic pattern of low CD4+ and CD8+ T-lymphocyte counts and low CD5+ B-lymphocyte counts. Because the thymus is essential for the generation of CD4+ cells, we sought evidence of thymus dysfunction in infants infected perinatally with the human immunodeficiency virus (HIV). Methods We studied the immunophenotypes of 59 infants with maternally transmitted HIV, 5 infants with the DiGeorge syndrome, and 168 infants exposed to HIV but not infected. The criteria for a presumed thymic defect were reductions in both the CD4+ and CD8+ T-cell subgroups during the first six months of life that were confirmed in a subgroup of infants by low counts of CD4+CD45RA+ and CD4+CD45RO+ T cells and CD5+ B cells. Results Of the 59 HIV-infected infants, 17 had immunophenotypes similar to those of infants with the DiGeorge syndrome. The risks of the acquired immunodeficiency syndrome (AIDS) by the ages of 12 and 24 months were, respectively, 75 percent and 92 percent in these 17 infants, as compared with 14 and 34 percent in the other 42 infants (P<0.001). Nine of the HIV-infected infants with the DiGeorge-like immunophenotype (53 percent) died within six months of the progression to AIDS, as compared with only three of the other infants (7 percent, P=0.006). Conclusions In some infants infected perinatally with HIV, a pattern of lymphocyte depletion develops that resembles the pattern in congenital thymic deficiency. Since HIV disease progresses rapidly in such infants, they may be candidates for early antiviral therapy and attempts at immune reconstitution. (C)1996, Massachusetts Medical Society.	EMORY UNIV, DEPT PEDIAT, DIV INFECT DIS EPIDEMIOL & IMMUNOL, ATLANTA, GA 30303 USA	Emory University				Kourtis, Athena/0000-0003-1585-1310	NIAID NIH HHS [R01-AI32456, R01-AI39081] Funding Source: Medline; PHS HHS [U64-CCU404456-06] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039081, R01AI032456] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASTIAN J, 1989, J PEDIATR-US, V115, P391, DOI 10.1016/S0022-3476(89)80837-6; BROSSARD Y, 1995, AIDS, V9, P359, DOI 10.1097/00002030-199509040-00007; CALABRO ML, 1995, AIDS RES HUM RETROV, V11, P11, DOI 10.1089/aid.1995.11.11; DeRossi A, 1996, J CLIN INVEST, V97, P323, DOI 10.1172/JCI118419; FREDERICK T, 1994, PEDIATR INFECT DIS J, V13, P1091, DOI 10.1097/00006454-199412000-00004; GREENBERG F, 1984, J PEDIATR, V115, P412; IBEGBU C, 1994, CLIN IMMUNOL IMMUNOP, V71, P27, DOI 10.1006/clin.1994.1047; IBEGBU C, 1992, ANN NY ACAD SCI, V651, P572; INABA M, 1995, EUR J IMMUNOL, V25, P1244, DOI 10.1002/eji.1830250517; ISAACSON PG, 1987, LANCET, V2, P1488; JOSHI VV, 1985, ARCH PATHOL LAB MED, V109, P142; KOLLMANN TR, 1995, J IMMUNOL, V154, P907; LANGSTON C, 1995, J INFECT DIS, V172, P1451, DOI 10.1093/infdis/172.6.1451; LEE FK, 1991, J CLIN IMMUNOL, V11, P213, DOI 10.1007/BF00917427; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LI SL, 1995, J ACQ IMMUN DEF SYND, V9, P1; LIDINJANSSON G, 1994, PEDIATRICS, V94, P815; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; Mayaux MJ, 1996, JAMA-J AM MED ASSOC, V275, P606, DOI 10.1001/jama.275.8.606; NAHMIAS AJ, 1995, 1995 INT S CLIN IMM; NANGO K, 1991, CELL IMMUNOL, V133, P109, DOI 10.1016/0008-8749(91)90183-C; NESHEIM S, 1992, PEDIATR INFECT DIS J, V11, P635; Oxtoby MJ, 1994, PEDIATRIC AIDS CHALL, P3; Papaevangelou V, 1996, J INFECT DIS, V173, P574, DOI 10.1093/infdis/173.3.574; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; ROSENZWEIG M, 1993, AIDS, V7, P1601, DOI 10.1097/00002030-199312000-00009; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P7727, DOI 10.1073/pnas.87.19.7727; SPITS H, 1995, BLOOD, V85, P2654, DOI 10.1182/blood.V85.10.2654.bloodjournal85102654; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; UITTENBOGAART C, 1995, INT C IMM SOC SAN FR; US Public Health Service, 1994, MMWR-MORBID MORTAL W, V43, P1; VALENTIN H, 1994, J VIROL, V68, P3041, DOI 10.1128/JVI.68.5.3041-3050.1994; 1995, MMWR-MORBID MORTAL W, V44, P1; 1994, MMWR-MORBID MORTAL W, V43, P1	37	154	155	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1996	335	19					1431	1436		10.1056/NEJM199611073351904	http://dx.doi.org/10.1056/NEJM199611073351904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT339	8875920				2022-12-28	WOS:A1996VT33900004
J	Beaglehole, R				Beaglehole, R			Garlic for flavour, not cardioprotection	LANCET			English	Editorial Material							METAANALYSIS; LIPIDS				Beaglehole, R (corresponding author), UNIV AUCKLAND,FAC MED & HLTH SCI,AUCKLAND 1,NEW ZEALAND.							JAIN AK, 1993, AM J MED, V94, P632, DOI 10.1016/0002-9343(93)90216-C; MINDELL E, 1994, GARLIC MIRACLE NUTR; Neil HAW, 1996, J ROY COLL PHYS LOND, V30, P329; SILAGY CA, 1994, J ROY COLL PHYS LOND, V28, P39; SILAGY CAS, 1994, J HYPERTENS, V12, P463; SIMONS LA, 1995, ATHEROSCLEROSIS, V113, P219, DOI 10.1016/0021-9150(94)05449-S; WARSHAFSKY S, 1993, ANN INTERN MED, V119, P599, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00009	7	16	19	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1186	1187		10.1016/S0140-6736(05)65477-3	http://dx.doi.org/10.1016/S0140-6736(05)65477-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898032				2022-12-28	WOS:A1996VQ46700005
J	Cox, JS; Walter, P				Cox, JS; Walter, P			A novel mechanism for regulating activity of a transcription factor that controls the unfolded protein response	CELL			English	Article							KAR2 BIP GENE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; SHUTTLE VECTORS; YEAST; DEGRADATION; UBIQUITIN; KINASE; INDUCTION	Cells respond to an accumulation of unfolded proteins in the endoplasmic reticulum (ER) by increasing transcription of genes encoding ER-resident proteins. The information is transmitted from the ER lumen to the nucleus by an intracellular signaling pathway, the unfolded protein response (UPR). We have identified a basic-leucine zipper transcription factor, Hac1p, that is required for the UPR and binds to the UPR element in the promoter of UPR-regulated genes. Surprisingly, Hac1p is found in UPR-activated cells only, and its level is controlled by regulated splicing of its mRNA. Splicing replaces the C-terminal tail of Hac1p with a different peptide that renders Hac1p more resistant to an otherwise extremely rapid ubiquitin-dependent degradation. We propose that the complex regulation of Hac1p expression serves to provide multiple levels at which the UPR can be controlled.			Cox, JS (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Longo, Kenneth A/A-5631-2010					BAIRN SB, 1985, MOL CELL BIOL, V5, P1839; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; EIBLE R, 1992, BIOTECHNIQUES, V13, P18; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; NOJIMA H, 1994, NUCLEIC ACIDS RES, V22, P5279, DOI 10.1093/nar/22.24.5279; Nunnari J, 1996, CELL, V84, P389, DOI 10.1016/S0092-8674(00)81283-0; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; SWEET DJ, 1993, CURR BIOL, V3, P622, DOI 10.1016/0960-9822(93)90014-F	35	762	796	2	58	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1996	87	3					391	404		10.1016/S0092-8674(00)81360-4	http://dx.doi.org/10.1016/S0092-8674(00)81360-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898193	Bronze			2022-12-28	WOS:A1996VQ46600006
J	Malashkevich, VN; Kammerer, RA; Efimov, VP; Schulthess, T; Engel, J				Malashkevich, VN; Kammerer, RA; Efimov, VP; Schulthess, T; Engel, J			The crystal structure of a five-stranded coiled coil in COMP: A prototype ion channel?	SCIENCE			English	Article							OLIGOMERIC MATRIX PROTEIN; CARTILAGE; PHOSPHOLAMBAN; THROMBOSPONDIN-4; RESIDUES; PROGRAM; DOMAIN	Oligomerization by the formation of alpha-helical bundles is common in many proteins. The crystal structure of a parallel pentameric coiled coil, constituting the oligomerization domain in the cartilage oligomeric matrix protein (COMP), was determined at 2.05 angstroms resolution. The same structure probably occurs in two other extracellular matrix proteins, thrombospondins 3 and 4. Complementary hydrophobic interactions and conserved disulfide bridges between the or helices result in a thermostable structure with unusual properties. The long hydrophobic axial pore is filled with water molecules but can also accommodate small apolar groups. An ''ion trap'' is formed inside the pore by a ring of conserved glutamines, which binds chloride and probably other monatomic anions. The oligomerization domain of COMP has marked similarities with proposed models of the pentameric transmembrane ion channels in phospholamban and the acetylcholine receptor.	UNIV BASEL,BIOZENTRUM,DEPT BIOPHYS CHEM,CH-4056 BASEL,SWITZERLAND	University of Basel	Malashkevich, VN (corresponding author), UNIV BASEL,BIOZENTRUM,DEPT BIOL STRUCT,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Kammerer, Richard/0000-0003-4570-5197				ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ARKIN IT, 1995, J MOL BIOL, V248, P824, DOI 10.1006/jmbi.1995.0263; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; ATKINS PW, 1994, PHYSICAL CHEM; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P685, DOI 10.1107/S0365110X53001952; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; EFIMOV VP, 1994, FEBS LETT, V341, P54, DOI 10.1016/0014-5793(94)80239-4; Efimov VP, 1996, PROTEINS, V24, P259, DOI 10.1002/(SICI)1097-0134(199602)24:2<259::AID-PROT13>3.0.CO;2-M; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAUSER N, 1995, FEBS LETT, V368, P307, DOI 10.1016/0014-5793(95)00675-Y; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kajava AV, 1996, PROTEINS, V24, P218, DOI 10.1002/(SICI)1097-0134(199602)24:2<218::AID-PROT8>3.3.CO;2-I; KAMMERER R, UNPUB; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; Leslie AGW, 1994, MOSFLM USERS GUIDE; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; QABAR A, 1995, J BIOL CHEM, V270, P12725, DOI 10.1074/jbc.270.21.12725; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSCHOPP J, 1980, FEBS LETT, V112, P152, DOI 10.1016/0014-5793(80)80168-2; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0	31	263	280	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					761	765		10.1126/science.274.5288.761	http://dx.doi.org/10.1126/science.274.5288.761			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864111				2022-12-28	WOS:A1996VQ14500036
J	SanMiguel, P; Tikhonov, A; Jin, YK; Motchoulskaia, N; Zakharov, D; MelakeBerhan, A; Springer, PS; Edwards, KJ; Lee, M; Avramova, Z; Bennetzen, JL				SanMiguel, P; Tikhonov, A; Jin, YK; Motchoulskaia, N; Zakharov, D; MelakeBerhan, A; Springer, PS; Edwards, KJ; Lee, M; Avramova, Z; Bennetzen, JL			Nested retrotransposons in the intergenic regions of the maize genome	SCIENCE			English	Article							ZEA-MAYS; TRANSPOSABLE ELEMENTS; REPETITIVE SEQUENCES; GENES; DNA; FAMILY; ORGANIZATION; RETROELEMENTS; EVOLUTION; PLANTS	The relative organization of genes and repetitive DNAs in complex eukaryotic genomes is not well understood. Diagnostic sequencing indicated that a 280-kilobase region containing the maize Adh1-F and u22 genes is composed primarily of retrotransposons inserted within each other. Ten retroelement families were discovered, with reiteration frequencies ranging from 10 to 30,000 copies per haploid genome, These retrotransposons accounted for more than 60 percent of the Adh1-F region and at least 50 percent of the nuclear DNA of maize. These elements were largely intact and are dispersed throughout the gene-containing regions of the maize genome.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; UNIV BRISTOL, LONG ASHTON RES STN, BRISTOL BS18 9AF, AVON, ENGLAND	Purdue University System; Purdue University; Purdue University West Lafayette Campus; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Bristol			SanMiguel, Phillip J/I-2196-2015; Tikhonov, Alexander/I-1453-2012	SanMiguel, Phillip J/0000-0002-3742-9527; Tikhonov, Alexander/0000-0003-3808-9701				ABLER ML, 1993, PLANT MOL BIOL, V22, P1031, DOI 10.1007/BF00028975; ALLEN RL, 1993, PLANT J, V3, P261, DOI 10.1046/j.1365-313X.1993.t01-14-00999.x; Arumuganathan K, 1991, PLANT MOL BIOL REP, V9, P208, DOI DOI 10.1007/BF02672069; AVRAMOVA Z, 1995, PLANT CELL, V7, P1667, DOI 10.1105/tpc.7.10.1667; AVRAMOVA Z, IN PRESS PLANT J; Bennetzen JL, 1996, TRENDS MICROBIOL, V4, P347, DOI 10.1016/0966-842X(96)10042-1; BENNETZEN JL, 1994, GENOME, V37, P565, DOI 10.1139/g94-081; CRESSE AD, 1995, GENETICS, V140, P315; DEININGER PL, 1993, EVOL BIOL, V27, P157; Edwards KJ, 1996, GENOME, V39, P811, DOI 10.1139/g96-102; FLAVELL RB, 1974, BIOCHEM GENET, V12, P257, DOI 10.1007/BF00485947; GATTI M, 1992, ANNU REV GENET, V26, P239, DOI 10.1146/annurev.ge.26.120192.001323; GRANDBASTIEN MA, 1992, TRENDS GENET, V8, P103, DOI 10.1016/0168-9525(92)90198-D; GUPTA M, 1984, EMBO J, V3, P133, DOI 10.1002/j.1460-2075.1984.tb01773.x; HAKE S, 1980, CHROMOSOMA, V79, P251, DOI 10.1007/BF00327318; HU WM, 1995, MOL GEN GENET, V248, P471, DOI 10.1007/BF02191647; KERSANACH R, 1994, NATURE, V367, P387, DOI 10.1038/367387a0; KIRIHARA JA, 1988, GENE, V71, P359, DOI 10.1016/0378-1119(88)90053-4; KRIZ AL, 1987, MOL GEN GENET, V207, P90, DOI 10.1007/BF00331495; LEVIN HL, 1995, MOL CELL BIOL, V15, P3310; MONTOLIU L, 1990, PLANT MOL BIOL, V14, P1, DOI 10.1007/BF00015650; QUAYLE TJA, 1989, GENE, V80, P249, DOI 10.1016/0378-1119(89)90289-8; SANMIGUEL P, UNPUB; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; SPRINGER PS, 1994, P NATL ACAD SCI USA, V91, P863, DOI 10.1073/pnas.91.3.863; Turcich MP, 1996, SEX PLANT REPROD, V9, P65, DOI 10.1007/BF02153053; WESSLER SR, 1995, CURR OPIN GENET DEV, V5, P814, DOI 10.1016/0959-437X(95)80016-X	29	1076	1146	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	1996	274	5288					765	768		10.1126/science.274.5288.765	http://dx.doi.org/10.1126/science.274.5288.765			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864112				2022-12-28	WOS:A1996VQ14500037
J	Luo, D; Carpenter, R; Vincent, C; Copsey, L; Coen, E				Luo, D; Carpenter, R; Vincent, C; Copsey, L; Coen, E			Origin of floral asymmetry in Antirrhinum	NATURE			English	Article							FLOWER DEVELOPMENT; HOMEOTIC GENES; MAJUS; TRANSPOSON; ELEMENT	Dorsoventral asymmetry in flowers is thought to have evolved many times from a radially symmetrical ancestral condition. The first gene controlling floral asymmetry, cycloidea in Antirrhinum, has been isolated. The cycloidea gene is expressed at a very early stage in dorsal regions of floral meristems, where it affects growth rate and primordium initiation. Expression continues through to later stages in dorsal primordia to affect the asymmetry, size and cell types of petals and stamens.	JOHN INNES CTR PLANT SCI RES,DEPT GENET,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center								BONAS U, 1984, EMBO J, V3, P1015, DOI 10.1002/j.1460-2075.1984.tb01921.x; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CARPENTER R, 1987, MOL GEN GENET, V207, P82, DOI 10.1007/BF00331494; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1991, ANNU REV PLANT PHYS, V42, P241, DOI 10.1146/annurev.pp.42.060191.001325; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COEN ES, 1994, DEVELOPMENT, P107; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Hammer K., 1990, Kulturpflanze, V38, P91; KREBBERS E, 1987, MOL GEN GENET, V209, P499, DOI 10.1007/BF00331156; KUCKUCK H, 1930, Z IND ABST VER, V56, P51; LINNAEUS C, 1749, THESIS UPPSALA; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; Running MP, 1996, DEVELOPMENT, V122, P1261; SIMON R, 1994, CELL, V78, P99, DOI 10.1016/0092-8674(94)90576-2; SOMER H, 1988, PLANT TRANSPOSABLE E, P227; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; Tucker SC, 1984, CONT PROBLEMS PLANT, P351; Vincent CA, 1995, CURR BIOL, V5, P1449, DOI 10.1016/S0960-9822(95)00282-X; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7	23	552	638	10	122	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					794	799		10.1038/383794a0	http://dx.doi.org/10.1038/383794a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893002				2022-12-28	WOS:A1996VQ14400054
J	Clower, DM; Hoffman, JM; Votaw, JR; Faber, TL; Woods, RP; Alexander, GE				Clower, DM; Hoffman, JM; Votaw, JR; Faber, TL; Woods, RP; Alexander, GE			Role of posterior parietal cortex in the recalibration of visually guided reaching	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; AUTOMATED ALGORITHM; FUNCTIONAL-ANATOMY; ATTENTION; PET; MOVEMENTS; MECHANISMS; AREAS	VISUALLY guided reaching requires complex neural transformations to link visual and proprioceptive inputs with appropriate motor outputs(1,2). Despite the complexity of these transformations, hand-eye coordination in humans is remarkably flexible, as demonstrated by the ease with which reaching can be adapted to distortions in visual feedback. If subjects attempt to reach to visual targets while searing displacing prisms, they initially misreach in the direction of, visual displacement. Given feedback about their reaching errors, however, they quickly adapt to the visual distortion. This is shown by the gradual resumption of accurate reaching while the prisms remain in place, and by the immediate onset of reaching errors in the opposite direction after the prisms have been removed. Despite an abundance of psychophysical data on adaptation to prisms, the functional localization of this form of sensorimotor adaptation is uncertain, Here we use positron emission tomography (PET) to localize changes in regional cerebral blood flow (rCBF) in subjects who performed a prism-adaptation task as well as a task that controlled for the sensory, motor and cognitive conditions of the adaptation experiment. Difference images that reflected the net effects of the adaptation process showed selective activation of posterior parietal cortex contralateral to the reaching limb.	EMORY UNIV,SCH MED,DEPT NEUROL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT RADIOL,ATLANTA,GA 30322; UNIV CALIF LOS ANGELES,SCH MED,DIV BRAIN MAPPING,LOS ANGELES,CA 90095	Emory University; Emory University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BAILY JS, 1972, Q J EXP PSYCHOL, V24, P8, DOI 10.1080/14640747208400261; BECKETT PA, 1980, J EXP PSYCHOL HUMAN, V6, P433, DOI 10.1037/0096-1523.6.3.433; BONDA E, 1995, P NATL ACAD SCI USA, V92, P11180, DOI 10.1073/pnas.92.24.11180; CHOE CS, 1974, J EXP PSYCHOL, V102, P1076, DOI 10.1037/h0036325; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; CORBETTA M, 1995, SCIENCE, V270, P802, DOI 10.1126/science.270.5237.802; CORBETTA M, 1993, J NEUROSCI, V13, P1202; DEIBER MP, 1991, EXP BRAIN RES, V84, P393; EIDELBERG D, 1984, ARCH NEUROL-CHICAGO, V41, P843, DOI 10.1001/archneur.1984.04050190049013; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; GEORGOPOULOS AP, 1991, ANNU REV NEUROSCI, V14, P361, DOI 10.1146/annurev.ne.14.030191.002045; GRAFTON ST, 1992, BRAIN, V115, P565, DOI 10.1093/brain/115.2.565; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; KAWASHIMA R, 1994, J NEUROSCI, V14, P3462; Neter J, 1990, APPL LINEAR STAT MOD; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PARSONS LM, 1995, NATURE, V375, P54, DOI 10.1038/375054a0; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; REDDING GM, 1985, COGNITIVE PSYCHOL, V17, P1, DOI 10.1016/0010-0285(85)90002-7; REDDING GM, 1988, PERCEPT PSYCHOPHYS, V44, P59, DOI 10.3758/BF03207476; SELTZER B, 1980, BRAIN RES, V192, P339, DOI 10.1016/0006-8993(80)90888-4; STEPHAN KM, 1995, J NEUROPHYSIOL, V73, P373, DOI 10.1152/jn.1995.73.1.373; Talairach J., 1988, COPLANAR STEREOTAXIC; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; WELCH RB, 1974, J EXP PSYCHOL, V103, P700, DOI 10.1037/h0037152; WILKINSON DA, 1971, J EXP PSYCHOL, V89, P250, DOI 10.1037/h0031162; Woods R. P., 1996, QUANTIFICATION BRAIN, P353, DOI [10.1016/B978-012389760-2/50070-0, DOI 10.1016/B978-012389760-2/50070-0]; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; [No title captured]	30	324	326	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					618	621		10.1038/383618a0	http://dx.doi.org/10.1038/383618a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857536				2022-12-28	WOS:A1996VM75500052
J	Teng, SC; Kim, B; Gabriel, A				Teng, SC; Kim, B; Gabriel, A			Retrotransposon reverse-transcriptase-mediated repair of chromosomal breaks	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CRITHIDIA-FASCICULATA; TY1; RECOMBINATION; ELEMENT; RNA; TRANSPOSITION; LOCUS; YEAST; SITE	THE abundance of short and long interspersed nuclear sequences (SINEs and LINEs) and pseudogenes in eukaryotic genomes indicates that reverse transcriptase (RT)-mediated phenomena are important in genome evolution. However, the mechanisms involved in their spread are largely unknown. We have developed a selection system in the yeast Saccharomyces cerevisiae to test whether RT-mediated events could be linked to the repair of double-strand breaks (DSBs). Here we show that DSBs can be fixed by the insertion of complementary DNAs at the break site. In the presence of functional RT (from human L1, yeast Ty1 or Crithidia CRE1), and in the absence of homologous recombination, an HO endonuclease-induced DSB at the mating type (MAT) locus is the primary site at which a marked cDNA is observed among surviving cells. The structure and junctional sequences of these insertions suggest that repair occurs primarily by nonhomologous recombination. Our data support a role for endogenous retroelements in the repair of chromosomal breaks.			Teng, SC (corresponding author), RUTGERS STATE UNIV,DEPT MOL BIOL & BIOCHEM,PISCATAWAY,NJ 08855, USA.			TENG, SHU-CHUN/0000-0002-6492-2560				BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; CURCIO MJ, 1994, GENETICS, V136, P1245; CURCIO MJ, 1991, P NATL ACAD SCI USA, V88, P936, DOI 10.1073/pnas.88.3.936; DERR LK, 1993, NATURE, V361, P170, DOI 10.1038/361170a0; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; GABRIEL A, 1991, P NATL ACAD SCI USA, V88, P9794, DOI 10.1073/pnas.88.21.9794; GABRIEL A, 1990, MOL CELL BIOL, V10, P615, DOI 10.1128/MCB.10.2.615; George JA, 1996, GENETICS, V142, P853; GLETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MONOKIAN GM, 1994, GENE, V139, P9, DOI 10.1016/0378-1119(94)90517-7; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Nissley DV, 1996, NATURE, V380, P30, DOI 10.1038/380030a0; Roth D., 1988, GENETIC RECOMBINATIO, P621; SHARON G, 1994, MOL CELL BIOL, V14, P6540, DOI 10.1128/MCB.14.10.6540; SHEEN FM, 1994, P NATL ACAD SCI USA, V91, P12510, DOI 10.1073/pnas.91.26.12510; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6; ZOU S, 1995, P NATL ACAD SCI USA, V92, P920, DOI 10.1073/pnas.92.3.920; [No title captured]	25	200	205	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					641	644		10.1038/383641a0	http://dx.doi.org/10.1038/383641a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857543				2022-12-28	WOS:A1996VM75500059
J	ONeill, P; Kelly, P				ONeill, P; Kelly, P			Postal questionnaire study of disability in the community associated with psoriasis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH SURVEY QUESTIONNAIRE; OUTCOME MEASURE; SF-36; SMOKING; INDEX	Objective-To study the disability caused by psoriasis in patients recorded as having psoriasis by their general practitioner, Design-Postal questionnaire survey using the psoriasis disability index and SF-36. Setting-Five general practices in Cleveland. Subjects-Of 767 patients identified, 546 completed the questionnaire and 435 were eligible and gave informed consent. Main outcome measures-scores on SF-36 and psoriasis disability index. Results-The psoriasis disability index score was highly negatively correlated with all eight of the SF-36 health measures (P<0.0001 for each), and the manual social classes scored higher than the non-manual social classes (P<0.0001). The manual social class group scored significantly lower scores than the controls on all the SF-36 scales, and the non-manual group scored significantly lower for physical and mental role limitation (P<0.0004 and P=0.026), mental health (P<0.0001), energy and vitality (P<0.0004), and health perception (P<0.0001). Also, the manual group had poorer health perception on five of the SF-36 variables when compared with the non-manual group. Conclusions-Patients with psoriasis have an overall lower perception of their quality of life than healthy controls, and those in the lower social classes suffer a greater degree of disability from their disease than the higher social classes.	UNIV TEESSIDE, CTR HLTH & MED RES, MIDDLESBROUGH TS1 3BA, CLEVELAND, ENGLAND	University of Teesside	ONeill, P (corresponding author), NORTON MED CTR, STOCKTON ON TEES TS20 1AN, ENGLAND.							BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; FINLAY AY, 1990, BRIT J DERMATOL, V123, P751, DOI 10.1111/j.1365-2133.1990.tb04192.x; FINLAY AY, 1995, BRIT MED J, V310, P1673, DOI 10.1136/bmj.310.6995.1673; FINLAY AY, 1987, CLIN EXP DERMATOL, V12, P8, DOI 10.1111/j.1365-2230.1987.tb01844.x; FINLAY AY, 1995, BRIT J DERMATOL, V132, P236; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; HIGGINS EM, 1994, BRIT MED J, V308, P1572, DOI 10.1136/bmj.308.6943.1572c; HUNTER JAA, 1989, CLIN DERMATOL, P2; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; JOBLING RG, 1976, CLIN EXP DERMATOL, V1, P233, DOI 10.1111/j.1365-2230.1976.tb01424.x; LYONS RA, 1995, J PUBLIC HEALTH MED, V17, P46; REA JN, 1976, BRIT J PREV SOC MED, V30, P107; STANKLER L, 1981, CLIN EXP DERMATOL, V6, P303, DOI 10.1111/j.1365-2230.1981.tb02308.x; WEINGARTEN S, 1995, BRIT MED J, V310, P1076, DOI 10.1136/bmj.310.6986.1076a; WILLIAMS HC, 1994, BMJ-BRIT MED J, V308, P428, DOI 10.1136/bmj.308.6926.428	15	65	65	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	1996	313	7062					919	921						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM754	8876097				2022-12-28	WOS:A1996VM75400028
J	Schubart, DB; Rolink, A; KoscoVilbois, MH; Botteri, F; Matthias, P				Schubart, DB; Rolink, A; KoscoVilbois, MH; Botteri, F; Matthias, P			B-cell-specific coactivator OBF-1/OCA-B/Bob1 required for immune response and germinal centre formation	NATURE			English	Article							BINDING TRANSCRIPTION FACTORS; IMMUNOGLOBULIN GENES; PROMOTER ACTIVITY; PROTEIN; OCT-2; MICE; ACTIVATION; EXPRESSION; MECHANISM; DEFICIENT	THE B-lymphocyte-specific transcriptional factor called Oct binding factor (OBF)-1, OCA-B or Bob1 (refs 13) is thought to be involved in the transcription of immunoglobulin genes through recruitment to the highly conserved octamer site of immunoglobulin promoters, mediated by either Oct-1 or Oct-2. To define the in vivo role of OBP-1 we have used gene targeting in embryonic stem cells to generate mice lacking the coactivator OBP-1. Such OBF-1(-/-) mice are born normally, are fertile and seem healthy, and surprisingly, rearrangement and transcription of immunoglobulin genes are largely unaffected. However, mice deficient in OBF-1 have reduced numbers of mature B cells and a severe reduction in the number of recirculating B cells, but otherwise show normal B-cell differentiation. Serum IgA and particularly IgG levels are greatly reduced. If mutant mice are immunized with either a thymus-independent or a thymus-dependent antigen, their immune responses are dramatically weakened. Strikingly, germinal centres completely fail to develop after immunization with thymus-dependent antigen. Our results demonstrate that in vivo OBF-1 is not required for initial transcription of immunoglobulin genes or for B cell development, but instead is essential for the response of B cells to antigens, and is required for the formation of germinal centres.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; GLAXO INST MOL BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; GlaxoSmithKline			Schubart, Daniel/AAV-6487-2021	Schubart, Daniel/0000-0002-8069-0122				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CORCORAN LM, 1994, IMMUNITY, V1, P635, DOI 10.1016/1074-7613(94)90035-3; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DREYFUS M, 1987, EMBO J, V6, P1685, DOI 10.1002/j.1460-2075.1987.tb02418.x; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HUMPHREY JH, 1984, EUR J IMMUNOL, V14, P859, DOI 10.1002/eji.1830140916; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; PFISTERER P, 1994, EMBO J, V13, P1655; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; ROLINK A, 1995, IMMUNOLOGIST, V3, P125; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; Schubart DB, 1996, NUCLEIC ACIDS RES, V24, P1913, DOI 10.1093/nar/24.10.1913; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STREF A, 1994, J IMMUNOL, V152, P3378; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; WOOD SA, 1993, P NATL ACAD SCI USA, V90, P4582, DOI 10.1073/pnas.90.10.4582; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	30	238	242	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					538	542		10.1038/383538a0	http://dx.doi.org/10.1038/383538a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849727				2022-12-28	WOS:A1996VL75500054
J	He, S; Cavanagh, P; Intriligator, J				He, S; Cavanagh, P; Intriligator, J			Attentional resolution and the locus of visual awareness	NATURE			English	Article							LATERAL MASKING; CORTEX; OBJECTS; HUMANS; FIELDS	VISUAL spatial resolution is limited by factors ranging from optics to neuronal filters in the visual cortex(1,2), but it is not known to what extent it is also limited by the resolving pow er of attention. To investigate this, we studied adaptation to lines of specific orientation, a process that occurs in primary visual cortex(3). When a single grating is presented in the periphery of the visual field, human observers are aware of its orientation, but when it is flanked by other similar gratings ('crowding'), its orientation becomes impossible to discern(4,5). Nevertheless, we show that orientation-specific adaptation is not affected by crowding, implying that spatial resolution is limited by an attentional filter acting beyond the primary visual cortex. Consistent with this, we find that attentional resolution is greater in the lower than in the upper visual field, whereas there is no corresponding asymmetry in the primary visual cortex. We suggest that the attentional filter acts in one or more higher visual cortical areas to restrict the availability of visual information to conscious awareness(6).			He, S (corresponding author), HARVARD UNIV,DEPT PSYCHOL,33 KIRKLAND ST,CAMBRIDGE,MA 02138, USA.							BLAKEMORE C, 1969, J PHYSIOL-LONDON, V203, P237, DOI 10.1113/jphysiol.1969.sp008862; BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0; BUTLER BE, 1986, PSYCHOL RES-PSYCH FO, V48, P201, DOI 10.1007/BF00309084; CAMPBELL FW, 1966, J PHYSIOL-LONDON, V186, P558, DOI 10.1113/jphysiol.1966.sp008056; CHAMBERS L, 1983, B PSYCHONOMIC SOC, V21, P459, DOI 10.3758/BF03330008; CHASTAIN G, 1983, PSYCHOL RES-PSYCH FO, V45, P147, DOI 10.1007/BF00308666; CHRISTMAN SD, 1993, B PSYCHONOMIC SOC, V31, P275; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; DEYOE EA, 1988, P NATL ACAD SCI USA, V93, P2382; GAZZANIGA MS, 1987, NEUROPHYSIOLOGICAL N, P203; HE S, 1995, INVEST OPHTH VIS SCI, V36, P2010; HORTON JC, 1991, ARCH OPHTHALMOL-CHIC, V109, P816, DOI 10.1001/archopht.1991.01080060080030; INTRILIGATOR J, 1991, INVEST OPHTH VIS SCI, V32, P1040; KOLB FC, 1995, NATURE, V377, P336, DOI 10.1038/377336a0; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; POSNER MI, 1994, NEUROPSYCHOL REHABIL, V4, P183, DOI 10.1080/09602019408402280; PREVIC FH, 1990, BEHAV BRAIN SCI, V13, P519, DOI 10.1017/S0140525X00080018; PYLYSHYN Z W, 1988, Spatial Vision, V3, P179, DOI 10.1163/156856888X00122; Rubin N, 1996, SCIENCE, V271, P651, DOI 10.1126/science.271.5249.651; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; TAYLOR SG, 1972, PERCEPT PSYCHOPHYS, V12, P97, DOI 10.3758/BF03212851; TOET A, 1992, VISION RES, V32, P1349, DOI 10.1016/0042-6989(92)90227-A; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104	23	736	748	4	53	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					334	337		10.1038/383334a0	http://dx.doi.org/10.1038/383334a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848045				2022-12-28	WOS:A1996VJ43900044
J	Gorina, S; Pavletich, NP				Gorina, S; Pavletich, NP			Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2	SCIENCE			English	Article							WILD-TYPE P53; CELL-CYCLE CONTROL; P53-DEPENDENT APOPTOSIS; GENE AMPLIFICATION; MUTANT P53; BINDING; PROTEIN; DNA; TRANSCRIPTION; INHIBITION	Mutations in the p53 tumor suppressor are among the most frequently observed genetic alterations in human cancer and map to the 200-amino acid core domain of the protein. The core domain contains the sequence-specific DNA binding activity and the in vitro 53BP2 protein binding activity of p53. The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure-consisting of a 3 hairpin and two ct helices, binds the L2 loop of p53. The structure of the complex shows that the 53BP2 binding site on the p53 core domain consists of evolutionarily conserved regions that are frequently mutated in cancer and that it overlaps the site of DNA binding. The six most frequently observed p53 mutations disrupt 53BP2 binding in vitro. The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.			Gorina, S (corresponding author), MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA065698] Funding Source: NIH RePORTER; NCI NIH HHS [CA65698] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BRUNGER AT, 1991, X PLOR SYSTEM CRYSTA; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; *EUR MOL BIOL LAB, 1995, DAT P53 MUT; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMPSON CC, 1991, SCIENCE, V253, P253; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	38	386	411	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	1996	274	5289					1001	1005		10.1126/science.274.5289.1001	http://dx.doi.org/10.1126/science.274.5289.1001			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875926				2022-12-28	WOS:A1996VR79200055
J	Hyatt, BA; Lohr, JL; Yost, HJ				Hyatt, BA; Lohr, JL; Yost, HJ			Initiation of vertebrate left-right axis formation by maternal Vg1	NATURE			English	Article							LEFT-RIGHT ASYMMETRY; XENOPUS-EMBRYOS; MESODERM; PROTEIN; RNA; EXPRESSION; INDUCTION; CLONING	IN the development of the three-dimensional vertebrate body plant the left-right axis is linked to the dorsoventral and anterioposterior axes(1,2). In humans, altered left-right development results in severe cardiovascular and visceral abnormalities in individuals and in conjoined twins(3,4). Although zygotically transcribed genes that are asymmetrically expressed have been identified(5-8), the mechanism by which left-right asymmetries are established during embryogenesis is unknown(9). Here we show that the Xenopus maternal gene Vg1, a member of the TGF-beta family of cell-signalling molecules which are implicated in dorsoanterior development(10), initiates left-right axis formation. Altered expression of Vg1 on the right side of 16-cell embryos or disruption of endogenous Vg1 signalling on the left side randomizes cardiac and visceral left-right orientation and alters expression of Xnr-1, a nodal-related molecular marker for left-right developments, Furthermore, the orientation of the left-right asis in conjoined twins is dependent upon which cell-signalling molecule initiated twin formation and on whether the secondary axis is on the left or right side of the primary embryonic axis, implicating a molecular pathway leading to the formation of conjoined twins.	UNIV MINNESOTA, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities								ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BOTERENBROOD EC, 1973, ROUX ARCH DEV BIOL, V173, P319, DOI 10.1007/BF00575837; Bowers PN, 1996, PROG PEDIATR CARDIOL, V6, P53, DOI 10.1016/1058-9813(96)00171-3; BURN J, 1991, CIBA F SYMP, V162, P282; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DANOS MC, 1995, DEVELOPMENT, V121, P1467; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Dohrmann CE, 1996, DEV BIOL, V175, P108, DOI 10.1006/dbio.1996.0099; GERHART J, 1989, DEVELOPMENT, V107, P37; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; Henry GL, 1996, DEVELOPMENT, V122, P1007; JONES CM, 1995, DEVELOPMENT, V121, P3651; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; Spemann H, 1919, ARCH ENTWICKLUNG ORG, V45, P371, DOI 10.1007/BF02554405; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; YOSH HJ, 1995, CELL, V82, P689; YOSH HJ, 1992, NATURE, V357, P158	28	136	140	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1996	384	6604					62	65		10.1038/384062a0	http://dx.doi.org/10.1038/384062a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900277				2022-12-28	WOS:A1996VR21900053
J	Slupphaug, G; Mol, CD; Kavli, B; Arvai, AS; Krokan, HE; Tainer, JA				Slupphaug, G; Mol, CD; Kavli, B; Arvai, AS; Krokan, HE; Tainer, JA			A nucleotide-flipping mechanism from the structure of human uracil-DNA glycosylase bound to DNA	NATURE			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; EXCISION; SPECIFICITY; REFINEMENT; SUBSTRATE; DYNAMICS; BASE	ANY uracil bases in DNA, a result of either misincorporation or deamination of cytosine, are removed by uracil-DNA glycosylase (UDG), one of the most efficient and specific of the base-excision DNA-repair enzymes(1). Crystal structures of human(2,3) and viral(4) UDGs complexed with free uracil have indicated that the enzyme binds an extrahelical uracil. Such binding of undamaged extra-helical bases has been seen in the structures of two bacterial methyltransferases(5,6) and bacteriophage T4 endonuclease V (ref. 7). Here we characterize the DNA binding and kinetics of several engineered human UDG mutants and present the crystal structure of one of these, which to our knowledge represents the first structure of any eukaryotic DNA repair enzyme in complex with its damaged, target DNA. Electrostatic orientation along the UDG active site, insertion of an amino acid (residue 272) into the DNA through the minor groove, and compression of the DNA backbone flanking the uracil all result in the flipping-out of the damaged base from the DNA major groove, allowing specific recognition of its phosphate, deoxyribose and uracil moieties. Our structure thus provides a view of a productive complex specific for cleavage of uracil from DNA and also reveals the basis for the enzyme-assisted nucleotide flipping by this critical DNA-repair enzyme.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; NORWEGIAN UNIV SCI & TECHNOL, UNIGEN CTR MOL BIOL, N-7005 TRONDHEIM, NORWAY	Scripps Research Institute; Norwegian University of Science & Technology (NTNU)			Slupphaug, Geir/AAN-3794-2020; Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Slupphaug, Geir/0000-0002-7498-3500				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DAVIS ME, 1990, CHEM REV, V90, P509, DOI 10.1021/cr00101a005; DELORT AM, 1985, NUCLEIC ACIDS RES, V13, P319, DOI 10.1093/nar/13.2.319; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ENSLON HCM, 1996, CHEM BIOL, V3, P419; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; KUBAREVA EA, 1995, GENE, V157, P167, DOI 10.1016/0378-1119(94)00771-J; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1990, P CCP4 STUD WEEK JAN, V29, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Sawa R., 1995, NATURE, V373, P487; SAWA R, 1995, NAT STRUCT BIOL, V2, P752; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; VARSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055, DOI 10.1021/bi00230a033; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6	25	480	487	4	53	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					87	92		10.1038/384087a0	http://dx.doi.org/10.1038/384087a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900285				2022-12-28	WOS:A1996VR21900061
J	Zakany, J; Duboule, D				Zakany, J; Duboule, D			Synpolydactyly in mice with a targeted deficiency in the HoxD complex	NATURE			English	Article							GENE; DISRUPTION; HOMEOSIS	THE morphogenesis of mammalian digits requires the function of several genes of the HoxD complex during development of limb buds(1-4). Using embryonic stem (ES) cells and a site-specific recombination system (loxP/Cre), we have induced a deficiency(5,6) that eliminates the products of the Hoxd-13, Hoxd-12 and Hoxd-11 genes simultaneously. A Hoxd-11/lacz reporter gene replaced the deleted region in order to monitor the effect of this triple inactivation at the cellular level. Mice homozygous for this deficiency showed small digit primordia, a disorganized cartilage pattern and impaired skeletal mass. These alterations are similar to the defects seen in a human synpolydactyly(7,8), suggesting that this syndrome, which is associated with a subtle mutation in HOXD13 (ref. 8), may involve the loss of function of several Herd genes. These results indicate the existence of a functional hierarchy among these genes and provide us with an animal model to study human digit malformations.	UNIV GENEVA, DEPT ZOOL & ANIM BIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva				duboule, denis/0000-0001-9961-2960				AKARSU AN, 1995, J MED GENET, V32, P435, DOI 10.1136/jmg.32.6.435; Davis AP, 1996, DEVELOPMENT, V122, P1175; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; FAVIER B, 1995, P NATL ACAD SCI USA, V92, P310, DOI 10.1073/pnas.92.1.310; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; KONDO T, IN PRESS DEVELOPMENT; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Nelson CE, 1996, DEVELOPMENT, V122, P1449; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; SARFARAZI M, 1995, HUM MOL GENET, V4, P1453, DOI 10.1093/hmg/4.8.1453; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3	17	173	177	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1996	384	6604					69	71		10.1038/384069a0	http://dx.doi.org/10.1038/384069a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900279				2022-12-28	WOS:A1996VR21900055
J	Wynia, MK				Wynia, MK			The Oregon capitation initiative - Lessons and warnings, from the forefront of the backlash	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED-CARE; FINANCIAL INCENTIVES; MEDICAL-CARE; PHYSICIANS; PERFORMANCE		TUFTS UNIV NEW ENGLAND MED CTR, DIV GEOG MED & INFECT DIS, BOSTON, MA 02111 USA	Tufts Medical Center	Wynia, MK (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DIV CLIN CARE RES, 750 WASHINGTON ST, 63, BOSTON, MA 02111 USA.		Wynia, Matthew/T-2210-2019		AHRQ HHS [T32HS00060] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bilchik GS, 1996, HOSP HEALTH NETWORK, V70, P24; BODENHEIMER T, 1995, JAMA-J AM MED ASSOC, V274, P85, DOI 10.1001/jama.274.1.85; Cassel CK, 1996, ANN INTERN MED, V124, P604, DOI 10.7326/0003-4819-124-6-199603150-00010; CRAWSHAW R, 1995, JAMA-J AM MED ASSOC, V273, P1553, DOI 10.1001/jama.273.19.1553; DOLNICK E, 1996, GLAMOUR          FEB, V94, P158; Emanuel EJ, 1996, ANN INTERN MED, V124, P229, DOI 10.7326/0003-4819-124-2-199601150-00007; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GRANNEMANN TW, 1991, INQUIRY-J HEALTH CAR, V28, P300; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HOLOHAN J, 1995, HEALTH AFFAIR, V14, P199, DOI 10.1377/hlthaff.14.1.199; HUGHES J, 1995, NEW YORK NEWSDA 0701; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; LARSON E, 1996, TIME            0122, P44; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MONROE LR, 1996, OREGON HLTH FORUM, V6, P10; NEWHOUSE JP, 1992, J ECON PERSPECT, V6, P3, DOI 10.1257/jep.6.3.3; ONEILL P, 1996, OREGONIAN       0925, P1; PAGE L, 1996, AM MED NEWS     0826, V39, P3; PAGE L, 1996, AM MED NEWS     0826, V39, P20; PAULY M, 1988, HLTH CARE AM, P27; PAULY MV, 1992, PAYING PHYSICIANS OP, P101; PEARSON SD, 1994, HEALTH SERV RES, V29, P59; Rodwin M. A., 1993, MED MONEY MORALS PHY; Selker HP, 1996, ANN INTERN MED, V124, P449, DOI 10.7326/0003-4819-124-4-199602150-00010; SHERMAN W, 1996, VOGUE            FEB, V186, P154; SPRAGINS EE, 1995, NEWSWEEK        1023, P54; Swartz K, 1996, ANN INTERN MED, V124, P442, DOI 10.7326/0003-4819-124-4-199602150-00009; TODD JS, 1992, JAMA-J AM MED ASSOC, V268, P98, DOI 10.1001/jama.268.1.98; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510; WYNIA MK, IN PRESS J INVESTIG; 1995, JAMA-J AM MED ASSOC, V273, P330; 1996, OREGON HLTH FORUM, V6, P1	37	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1996	276	17					1441	1444		10.1001/jama.276.17.1441	http://dx.doi.org/10.1001/jama.276.17.1441			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VQ464	8892727				2022-12-28	WOS:A1996VQ46400033
J	Contreras, D; Destexhe, A; Sejnowski, TJ; Steriade, M				Contreras, D; Destexhe, A; Sejnowski, TJ; Steriade, M			Control of spatiotemporal coherence of a thalamic oscillation by corticothalamic feedback	SCIENCE			English	Article							NUCLEUS-RETICULARIS THALAMI; IN-VITRO; SYNCHRONIZED OSCILLATIONS; MECHANISMS; CAT	The mammalian thalamus is the gateway to the cortex for most sensory modalities, Nearly all thalamic nuclei also receive massive feedback projections from the cortical region to which they project, In this study, the spatiotemporal properties of synchronized thalamic spindle oscillations (7 to 14 hertz) were investigated in barbiturate-anesthetized cats, before and after removal of the cortex, After complete ipsilateral decortication, the long-range synchronization of thalamic spindles in the intact cortex hemisphere changed into disorganized patterns with low spatiotemporal coherence. Local thalamic synchrony was still present, as demonstrated by dual intracellular recordings from nearby neurons. In the cortex, synchrony was insensitive to the disruption of horizontal intracortical connections, These results indicate that the global coherence of thalamic oscillations is determined by corticothalamic projections.	UNIV LAVAL,FAC MED,NEUROPHYSIOL LAB,QUEBEC CITY,PQ G1K 7P4,CANADA; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Laval University; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego			Sejnowski, Terrence/AAV-5558-2021	Destexhe, Alain/0000-0001-7405-0455				AMZICA F, 1995, J NEUROSCI, V15, P4658; [Anonymous], [No title captured]; AVENDANO C, 1988, J COMP NEUROL, V278, P1, DOI 10.1002/cne.902780102; BAL T, 1993, J PHYSIOL-LONDON, V468, P669, DOI 10.1113/jphysiol.1993.sp019794; BAL T, 1995, J PHYSIOL-LONDON, V483, P641, DOI 10.1113/jphysiol.1995.sp020612; Contreras D, 1996, J PHYSIOL-LONDON, V490, P159, DOI 10.1113/jphysiol.1996.sp021133; CONTRERAS D, 1995, J NEUROSCI, V15, P604; DESTEXHE A, 1994, NEUROREPORT, V5, P2217, DOI 10.1097/00001756-199411000-00003; Destexhe A, 1996, J NEUROPHYSIOL, V76, P2049, DOI 10.1152/jn.1996.76.3.2049; Golomb D, 1996, J NEUROPHYSIOL, V75, P750, DOI 10.1152/jn.1996.75.2.750; Jones EG, 1985, THALAMUS; KIM U, 1995, J NEUROPHYSIOL, V74, P1301, DOI 10.1152/jn.1995.74.3.1301; KOCH C, 1987, NEUROSCIENCE, V23, P399, DOI 10.1016/0306-4522(87)90064-9; MORISON RS, 1945, J NEUROPHYSIOL, V8, P309, DOI 10.1152/jn.1945.8.5.309; Morison RS, 1943, AM J PHYSIOL, V138, P0297, DOI 10.1152/ajplegacy.1943.138.2.297; NICOLELIS MAL, 1993, P NATL ACAD SCI USA, V90, P2212, DOI 10.1073/pnas.90.6.2212; Press W.H., NUMERICAL RECIPES AR, Vthird; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; STERIADE M, 1984, J COMP NEUROL, V229, P531, DOI 10.1002/cne.902290407; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERIADE M, 1985, J NEUROPHYSIOL, V54, P1473, DOI 10.1152/jn.1985.54.6.1473; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Steriade M., 1988, CELLULAR THALAMIC ME, P51; Steriade M, 1972, CORTICOTHALAMIC PROJ, P221; STERIADE M, 1990, THALAMIC OSSCILLATIO; TIMOFEEV I, IN PRESS J NEUROPHYS; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750	27	348	353	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					771	774		10.1126/science.274.5288.771	http://dx.doi.org/10.1126/science.274.5288.771			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864114				2022-12-28	WOS:A1996VQ14500039
J	Hicks, KA; Millar, AJ; Carre, IA; Somers, DE; Straume, M; MeeksWagner, DR; Kay, SA				Hicks, KA; Millar, AJ; Carre, IA; Somers, DE; Straume, M; MeeksWagner, DR; Kay, SA			Conditional circadian dysfunction of the Arabidopsis early-flowering 3 mutant	SCIENCE			English	Article							DARK CYCLES; DROSOPHILA; BEHAVIOR; LIGHT	Photoperiodic responses, such as the daylength-dependent control of reproductive development, are associated with a circadian biological clock. The photoperiod-insensitive early-flowering 3 (elf3) mutant of Arabidopsis thaliana lacks rhythmicity in two distinct circadian-regulated processes, This defect was apparent only when plants were assayed under constant light conditions. elf3 mutants retain rhythmicity in constant dark and anticipate light/dark transitions under most light/dark regimes. The conditional arrhythmic phenotype suggests that the circadian pacemaker is intact in darkness in elf3 mutant plants, but the transduction of light signals to the circadian clock is impaired.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV VIRGINIA,NSF,CTR BIOL TIMING,DEPT BIOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,NSF,CTR BIOL TIMING,DEPT MED,CHARLOTTESVILLE,VA 22908	University of Oregon; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia			Kay, Steve A/F-6025-2011; Millar, Andrew J/G-2423-2012; Somers, David E/A-9209-2010; CARRE, Isabelle A/D-8802-2011	Kay, Steve A/0000-0002-0402-2878; Millar, Andrew J/0000-0003-1756-3654; CARRE, Isabelle A/0000-0002-0548-7378; Hicks, Karen/0000-0003-2785-0614	NIGMS NIH HHS [1R01GM46006] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Deitzer G.F., 1987, MANIPULATION FLOWERI, P241; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; Hicks KA, 1996, SEMIN CELL DEV BIOL, V7, P409, DOI 10.1006/scdb.1996.0051; HICKS KB, UNPUB; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Loros J J, 1986, J Biol Rhythms, V1, P187, DOI 10.1177/074873048600100302; LUMSDEN PJ, 1991, ANNU REV PLANT PHYS, V42, P351, DOI 10.1146/annurev.pp.42.060191.002031; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MILLAR AJ, UNPUB; SOMERS DE, UNPUB; THOMPSON NJ, 1993, DATABASE, V16, P6; Wetherell D. F., 1990, PULVINUS MOTOR ORGAN, P72; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; ZAGOTTA MT, 1996, PLANT J, V10, P101	16	290	301	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					790	792		10.1126/science.274.5288.790	http://dx.doi.org/10.1126/science.274.5288.790			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8864121				2022-12-28	WOS:A1996VQ14500046
J	Spiegelman, BM; Flier, JS				Spiegelman, BM; Flier, JS			Adipogenesis and obesity: Rounding out the big picture	CELL			English	Review							PROLIFERATOR-ACTIVATED RECEPTORS; BINDING PROTEIN-ALPHA; NECROSIS-FACTOR-ALPHA; BROWN ADIPOSE-TISSUE; NEUROPEPTIDE-Y; FATTY-ACIDS; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR; INSULIN-RESISTANCE; GENE-EXPRESSION		HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DIV ENDOCRINOL,BETH ISRAEL DEACONESS MED CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School	Spiegelman, BM (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.		Flier, jeffrey/AAG-6223-2019		NIDDK NIH HHS [R37DK315405, R37DK28082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT WGH, 1987, METABOLISM, V36, P576, DOI 10.1016/0026-0495(87)90170-3; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ARASE K, 1988, AM J PHYSIOL, V255, pE255, DOI 10.1152/ajpendo.1988.255.3.E255; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; BILLINGTON CJ, 1991, AM J PHYSIOL, V260, pR321, DOI 10.1152/ajpregu.1991.260.2.R321; BOUCHARD C, 1995, INT J OBESITY, V19, pS10; BRAY GA, 1990, FRONT NEUROENDOCRIN, V11, P128; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, DIABETES, V45, P1141, DOI 10.2337/diabetes.45.8.1141; Clement K, 1996, INT J OBESITY, V20, P507; CLEMENT K, 1995, NEW ENGL J MED, V333, P352, DOI 10.1056/NEJM199508103330605; Clement K, 1996, DIABETES, V45, P687, DOI 10.2337/diabetes.45.5.687; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; CONSIDINE RV, 1996, DIABETES, V19, P992; CONSIDINE RV, 1995, NEW ENGL J MED, V334, P292; DERIAZ O, 1994, J CLIN INVEST, V93, P838, DOI 10.1172/JCI117038; DRYDEN S, 1994, EUR J CLIN INVEST, V24, P293, DOI 10.1111/j.1365-2362.1994.tb01089.x; DUGGIRALA R, 1996, IN PRESS AM J HUM GE; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; FREDERICH RC, 1992, HYPERTENSION, V19, P339, DOI 10.1161/01.HYP.19.4.339; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; GRUNFELD C, 1996, J CLIN INVEST, V97, P2151; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HARRIS PKW, 1994, MOL PHARMACOL, V45, P439; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1996, CURR OPIN ENDOCRINOL, V3, P16; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; LOWELL BB, 1996, IN PRESS ANN REV MED; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MANNE J, 1995, P NATL ACAD SCI USA, V92, P4721, DOI 10.1073/pnas.92.11.4721; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; MARKS JL, 1992, MOL CELL NEUROSCI, V3, P199, DOI 10.1016/1044-7431(92)90039-5; NAGGERT J, 1995, NAT GENET, V10, P134; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; ORAHILLY S, 1995, NEW ENGL J MED, V333, P1386, DOI 10.1056/NEJM199511233332104; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; RANCE T, 1979, GEN COMP ENDOCR, V37, P64, DOI 10.1016/0016-6480(79)90047-9; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; SAMAD F, 1996, IN PRESS MOL MED; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Schwartz MW, 1994, ENDOCR REV, V2, P109; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; STANLEY BG, 1986, PEPTIDES, V7, P1189; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; SVEDBERG J, 1991, DIABETES, V40, P783, DOI 10.2337/diabetes.40.6.783; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TEBOUL L, 1995, J BIOL CHEM, V270, P28183, DOI 10.1074/jbc.270.47.28183; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WEST D, 1995, J CLIN INVEST, V94, P1410; WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; ZHANG E, 1996, J BIOL CHEM, V271, P9455; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHENG Z, 1995, P NATL ACAD SCI USA, V92, P935; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	112	1087	1132	0	103	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					377	389		10.1016/S0092-8674(00)81359-8	http://dx.doi.org/10.1016/S0092-8674(00)81359-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898192	Bronze			2022-12-28	WOS:A1996VQ46600005
J	Lydall, D; Nikolsky, Y; Bishop, DK; Weinert, T				Lydall, D; Nikolsky, Y; Bishop, DK; Weinert, T			A meiotic recombination checkpoint controlled by mitotic checkpoint genes	NATURE			English	Article							SYNAPTONEMAL COMPLEX PROTEIN; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SYNAPSIS; DROSOPHILA-MELANOGASTER; YEAST; MEIOSIS; REPAIR; DNA; MUTANTS	IN budding yeast, meiotic recombination occurs at about 200 sites per cell and involves DNA double-strand break (DSB) intermediates(1-3). Here we provide evidence that a checkpoint control requiring the mitotic DNA-damage checkpoint genes RAD17, RAD24 and MEC1 ensures that meiotic recombination is complete before the first meiotic division (MI). First, RAD17, RAD24 and MEC1 are required for the meiotic arrest caused by blocking the repair of DSBs with a mutation in the recA homologue DMC1. Second, mec1 and rad24 single mutants (DMC1(+)) appear to undergo MI before all recombination events are complete. Curiously, the mitosis-specific checkpoint gene RAD9 is not required for meiotic arrest of dmc1 mutants(4), This shows that although mitotic and meiotic control mechanisms are related, they differ significantly, Rad17 and Rad24 proteins may contribute directly to formation of an arrest signal by association with single-strand DNA in mitosis and meiosis.	UNIV ARIZONA,DEPT MOL & CELLULAR BIOL,TUCSON,AZ 85721; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,DEPT MOL GENET & CELL BIOL,CHICAGO,IL 60638	University of Arizona; University of Chicago								ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BAKER BS, 1972, GENETICS, V71, P255; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; GAME JC, 1980, GENETICS, V94, P51; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KLAPHOLZ S, 1985, GENETICS, V110, P187; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1996, CURR OPIN GENET DEV, V6, P4, DOI 10.1016/S0959-437X(96)90003-9; MALONE RE, 1981, MOL CELL BIOL, V1, P891, DOI 10.1128/MCB.1.10.891; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; WEBER L, 1992, GENETICS, V131, P55; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WEINERT TA, IN PRESS DNA DAMAGE; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; XU L, IN PRESS GENES DEV	30	269	278	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1996	383	6603					840	843		10.1038/383840a0	http://dx.doi.org/10.1038/383840a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ144	8893012				2022-12-28	WOS:A1996VQ14400068
J	Clark, CJ				Clark, CJ			Is pulmonary rehabilitation effective for patients with COPD?	LANCET			English	Editorial Material							DISEASE				Clark, CJ (corresponding author), HAIRMYRES HOSP,DEPT RESP MED,GLASGOW G75 8RG,LANARK,SCOTLAND.							CASABURI R, 1991, AM REV RESPIR DIS, V143, P9, DOI 10.1164/ajrccm/143.1.9; CELLI B, 1996, MED CLIN N AM; CLARK CJ, 1994, THORAX, V49, P270, DOI 10.1136/thx.49.3.270; CLARK CJ, 1995, CHRONIC OBSTRUCTIVE; CURTIS JR, 1994, THORAX, V49, P162, DOI 10.1136/thx.49.2.162; Jones NL., 1988, CLIN EXERCISE TESTIN, V3rd edn; Maltais F, 1996, AM J RESP CRIT CARE, V154, P442, DOI 10.1164/ajrccm.154.2.8756820; 1995, J CARDIOPULMONARY RE, V15, P394; 1994, AM REV RESPIR DIS, V49, P825	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1111	1112		10.1016/S0140-6736(05)65266-X	http://dx.doi.org/10.1016/S0140-6736(05)65266-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888159				2022-12-28	WOS:A1996VP10600003
J	Lapham, EV; Kozma, C; Weiss, JO				Lapham, EV; Kozma, C; Weiss, JO			Genetic discrimination: Perspectives of consumers	SCIENCE			English	Article								In a study of the perceptions of 332 members of genetic support groups with one or more of 101 different genetic disorders in the family, it was found that as a result of a genetic disorder 25 percent of the respondents or affected family members believed they were refused life insurance, 22 percent believed they were refused health insurance, and 13 percent believed they were denied or let go from a job. Fear of genetic discrimination resulted in 9 percent of respondents or family members refusing to be tested for genetic conditions, 18 percent not revealing genetic information to insurers, and 17 percent not revealing information to employers. The level of perceived discrimination points to the need for more information to determine the extent and scope of the problem.	ALLIANCE GENET SUPPORT GRP,CHEVY CHASE,MD 20815		Lapham, EV (corresponding author), GEORGETOWN UNIV,CHILD DEV CTR,3307 M ST NW,WASHINGTON,DC 20007, USA.				NHGRI NIH HHS [R01-HG00786-03] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000786] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ANDREWS L, 1994, ASESSING GENETIC RIS; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; COLLINS FS, 1991, J CLIN ETHIC, V2, P4; COOKDEEGAN RM, 1991, BIOMEDICAL POLITICS, P148; Geller G, 1993, J Law Med Ethics, V21, P238, DOI 10.1111/j.1748-720X.1993.tb01246.x; KAHN MJE, 1995, OVERVIEW HUMAN GENOM; KASS NE, 1992, HASTINGS CENT REP, V22, pS12; KASS NE, 1992, HASTINGS CENT REP, V22, pS6; KASS NE, 1992, HASTINGS CENT REP, V22, pS15; MURRAY TH, 1991, C ETH LEG IMPL GEN T; *NIH, 1993, GEN INF HLTH INS REP; *NIH NAT CTR HUM G, 1995, NIH PUBL; OSTRER H, 1993, AM J HUM GENET, V52, P565; ROTHENBERG KH, 1995, J LAW MED ETHICS, V23, P313; *US C, 1990, OTABA455; WERTZ DC, 1993, ETHICAL ISSUES GEN 1, P33; 1995, AM J HUM GENET, V56, P325; 1995, AM J HUM GENET, V56, P327	18	223	224	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					621	624		10.1126/science.274.5287.621	http://dx.doi.org/10.1126/science.274.5287.621			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VN919	8849455				2022-12-28	WOS:A1996VN91900053
J	Every, NR; Parsons, LS; Hlatky, M; Martin, JS; Weaver, WD				Every, NR; Parsons, LS; Hlatky, M; Martin, JS; Weaver, WD			A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS STREPTOKINASE; IMMEDIATE ANGIOPLASTY; REINFARCTION; MORTALITY	Background Several relatively small randomized trials have shown that primary angioplasty results in a better short-term outcome than thrombolytic therapy in patients with acute myocardial infarction. These results, however, have not been duplicated other than in investigational trials. Methods. We compared mortality during hospitalization and long-term mortality, as well as the use of resources, among 1050 patients in a primary-angioplasty group and 2095 patients in a thrombolytic-therapy group. Patients were selected from the Myocardial Infarction Triage and Intervention Project Registry cohort of 12,331 consecutive patients admitted with acute myocardial infarction to 19 Seattle hospitals between 1988 and 1994. Because of the potential for selection bias, several subgroup analyses were performed that included patients eligible for thrombolysis, high-risk patients, and patients in the primary-angioplasty group who were treated at hospitals with high volumes of angioplasty. Results There was no significant difference in mortality during hospitalization or long-term followup between patients in the thrombolytic-therapy group and those in the primary-angioplasty group (mortality during hospitalization, 5.6 percent and 5.5 percent, respectively; P=0.93; adjusted hazard ratio for the risk of death within three years after primary angioplasty, 0.95; 95 percent confidence interval, 0.8 to 1.2). There was also no significant difference in mortality between high-risk subgroups of patients in the two treatment groups. The rates of procedures and costs were lower among patients in the thrombolytic-therapy group both at the time of hospital discharge and after three years of follow-up (30 percent fewer coronary angiograms, 15 percent fewer coronary angioplasties, and 13 percent lower costs after three years of follow-up). Conclusions In a community setting, we observed no benefit in terms of either mortality or the use of resources with a strategy of primary angioplasty rather than thrombolytic therapy in a large cohort of patients with acute myocardial infarction. (C) 1996. Massachusetts Medical Society.	VET AFFAIRS MED CTR, NW HLTH SERV RES & DEV FIELD PROGRAM, SEATTLE, WA 98108 USA; STANFORD UNIV, DEPT HLTH POLICY, STANFORD, CA 94305 USA; UNIV WASHINGTON, DIV CARDIOL, MYOCARDIAL INFARCT TRIAGE & INTERVENT PROJECT, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; University of Washington; University of Washington Seattle				Hlatky, Mark/0000-0003-4686-9441	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008362] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038454] Funding Source: NIH RePORTER; AHRQ HHS [HS08362] Funding Source: Medline; NHLBI NIH HHS [R01 HL38454] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DEBOER MJ, 1994, J AM COLL CARDIOL, V23, P1004, DOI 10.1016/0735-1097(94)90582-7; DEBOER MJ, 1995, AM J CARDIOL, V76, P830, DOI 10.1016/S0002-9149(99)80238-0; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; Grines CL, 1996, J AM COLL CARDIOL, V27, P1381, DOI 10.1016/0735-1097(96)00040-X; GRINES CL, 1995, BRIT HEART J, V73, P405; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HUNT D, 1992, LANCET, V339, P753; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; Narins CR, 1996, CIRCULATION, V93, P667, DOI 10.1161/01.CIR.93.4.667; OKEEFE JH, 1993, AM J CARDIOL, V72, pG107, DOI 10.1016/0002-9149(93)90115-S; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; ROGERS WJ, 1994, AM J CARDIOL, V74, P111, DOI 10.1016/0002-9149(94)90082-5; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; ZIJLSTRA F, 1995, BRIT HEART J, V73, P403; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	17	286	293	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1996	335	17					1253	1260		10.1056/NEJM199610243351701	http://dx.doi.org/10.1056/NEJM199610243351701			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN594	8857004				2022-12-28	WOS:A1996VN59400001
J	Gray, R; Rajan, AS; Radcliffe, KA; Yakehiro, M; Dani, JA				Gray, R; Rajan, AS; Radcliffe, KA; Yakehiro, M; Dani, JA			Hippocampal synaptic transmission enhanced by low concentrations of nicotine	NATURE			English	Article							HIGH-CALCIUM PERMEABILITY; ACETYLCHOLINE-RECEPTORS; ALPHA-BUNGAROTOXIN; NEURONS; RAT; CHANNEL; BLOCKADE; FACILITATION; RECORDINGS; DENDRITES	NICOTINE obtained from tobacco can improve learning and memory on various tasks and has been linked to arousal, attention, rapid information processing, working memory, and longterm memories that can cause craving years after someone has stopped smoking(1,2). One likely target for these effects is the hippocampus, a centre for learning and memory that has rich cholinergic innervation and dense nicotinic acetylcholine receptor (nAChR) expression(3-6). During Alzheimer's dementia there are fewer nAChRs and the cholinergic inputs to the hippocampus degenerate(7). However, there is no evidence for fast synaptic transmission mediated by nAChRs in the hippocampus, and their role is not understood(8,9). Nicotine is known to act on presynaptic nAChRs within the habenula of chick to enhance glutamatergic transmission(10); here we report that a similar mechanism operates in the hippocampus. Measurements of intracellular Ca2+ in single mossy-fibre presynaptic terminals indicate that nAChRs containing the alpha 7 subunit can mediate a Ca2+ influx that is sufficient to induce vesicular neurotransmitter release. We propose that nicotine from tobacco influences cognition by enhancing synaptic transmission. Conversely, a decreased efficacy of transmission may account for the deficits associated with the loss of cholinergic innervation during Alzheimer's disease.	BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine				Gray, Richard/0000-0002-5890-1819				ALKONDON M, 1991, J RECEPTOR RES, V11, P1001, DOI 10.3109/10799899109064693; ALKONDON M, 1992, MOL PHARMACOL, V41, P802; ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; HENNINGFIELD JE, 1993, DRUG ALCOHOL DEPEN, V33, P23, DOI 10.1016/0376-8716(93)90030-T; KASA P, 1986, PROG NEUROBIOL, V26, P211, DOI 10.1016/0301-0082(86)90016-X; LEVIN ED, 1992, PSYCHOPHARMACOLOGY, V108, P417, DOI 10.1007/BF02247415; LEVRAM V, 1992, J NEUROPHYSIOL, V68, P1167, DOI 10.1152/jn.1992.68.4.1167; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; NORDBERG A, 1994, NEUROCHEM INT, V25, P93, DOI 10.1016/0197-0186(94)90059-0; OHNO M, 1993, PHARMACOL BIOCHEM BE, V45, P89, DOI 10.1016/0091-3057(93)90091-7; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SEGUELA P, 1993, J NEUROSCI, V13, P596; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; VERNINO S, 1994, J NEUROSCI, V14, P5514; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; VIJAYARAGHAVAN S, 1992, NEURON, V8, P353, DOI 10.1016/0896-6273(92)90301-S; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WONNACOTT S, 1990, CIBA F SYMP, V152, P87; WOOLF NJ, 1991, PROG NEUROBIOL, V37, P475, DOI 10.1016/0301-0082(91)90006-M; WU LG, 1994, J NEUROSCI, V14, P645; ZAREI MM, 1995, J NEUROSCI, V15, P1446; ZORUMSKI CF, 1992, MOL PHARMACOL, V41, P931	30	827	840	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	1996	383	6602					713	716		10.1038/383713a0	http://dx.doi.org/10.1038/383713a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN918	8878480				2022-12-28	WOS:A1996VN91800052
J	Grossman, E; Messerli, FH; Grodzicki, T; Kowey, P				Grossman, E; Messerli, FH; Grodzicki, T; Kowey, P			Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREGNANCY-INDUCED HYPERTENSION; ACUTE MYOCARDIAL-INFARCTION; CALCIUM ENTRY BLOCKERS; IMMEDIATE TREATMENT; CRISIS; MANAGEMENT; CAPTOPRIL; THERAPY; HYPOTENSION; URGENCIES	Over the past 2 decades, nifedipine in the form of capsules has become widely popular in the treatment of hypertensive emergencies. Unlike other agents, such as sodium nitroprusside, nicardipine hydrochloride, diazoxide, and nitroglycerin which require intravenous administration and monitoring of blood pressure nifedipine can be given orally, and close monitoring is said not to be necessary, Although administration of nifedipine capsules has been reported to be expedient and safe, it has not been approved by the Food and Drug Administration for labeling for treatment of hypertensive emergencies or of any other form of hypertension because of lack of outcome data. A review of the literature revealed reports of serious adverse effects such as cerebrovascular ischemia, stroke, numerous instances of severe hypotension, acute myocardial infarction, conduction disturbances, fetal distress, and death, Sublingual absorption of nifedipine has been found to be poor; most of the drug is absorbed by the intestinal mucosa. Given the seriousness of the reported adverse events and the lack of any clinical documentation attesting to a benefit, the use of nifedipine capsules for hypertensive emergencies and pseudoemergencies should be abandoned.	ALTON OCHSNER MED FDN & OCHSNER CLIN, DEPT INTERNAL MED, HYPERTENS DIS SECT, NEW ORLEANS, LA 70121 USA; CHAIM SHEBA MED CTR, HYPERTENS UNIT, IL-52621 TEL HASHOMER, ISRAEL; UNIV KRAKOW, SCH MED, DEPT GERIATR, KRAKOW, POLAND; LANKENAU HOSP & MED RES CTR, WYNNEWOOD, PA USA	Ochsner Health System; Chaim Sheba Medical Center; Jagiellonian University; Lankenau Medical Center; Lankenau Institute for Medical Research			Grodzicki, Tomasz/K-4451-2012; Messerli, Franz/AAR-4783-2021	Grodzicki, Tomasz/0000-0003-0159-4915; Grossman, Ehud/0000-0001-8353-0661				ABRAHAM G, 1986, BRIT J CLIN PRACT, V40, P478; ADLER AG, 1986, ARCH INTERN MED, V146, P1927, DOI 10.1001/archinte.146.10.1927; ANGELI P, 1991, ARCH INTERN MED, V151, P678, DOI 10.1001/archinte.151.4.678; AROMATORIO GJ, 1985, CHEST, V87, P265, DOI 10.1378/chest.87.2.265; BAUER JH, 1987, CIRCULATION, V75, P174; BEER N, 1981, CHEST, V79, P571, DOI 10.1378/chest.79.5.571; CALHOUN DA, 1990, NEW ENGL J MED, V323, P1177; CHENG TO, 1989, CRIT CARE MED, V17, P1364, DOI 10.1097/00003246-198912000-00028; COVE DH, 1979, BRIT MED J, V2, P245, DOI 10.1136/bmj.2.6184.245; Dadkar V N, 1993, Indian Heart J, V45, P185; DIKER E, 1992, ANGIOLOGY, V43, P477, DOI 10.1177/000331979204300604; DIRE DJ, 1988, AM J EMERG MED, V6, P125; ELLRODT AG, 1985, AM J MED, V79, P19, DOI 10.1016/0002-9343(85)90496-6; ERBEL R, 1983, POSTGRAD MED J, V59, P134; ERNE P, 1983, HYPERTENSION, V5, P97; EVANS JHC, 1988, ARCH DIS CHILD, V63, P975, DOI 10.1136/adc.63.8.975; FAGAN TC, 1989, ARCH INTERN MED, V149, P2169, DOI 10.1001/archinte.149.10.2169; FERGUSON RK, 1989, ARCH INTERN MED, V149, P257, DOI 10.1001/archinte.149.2.257; FRANKLIN C, 1986, CHEST, V90, P500, DOI 10.1378/chest.90.4.500; FRISHMAN WH, 1984, AM J MED, V77, P35, DOI 10.1016/S0002-9343(84)80083-2; Gambhir I S, 1991, J Indian Med Assoc, V89, P231; GARCIA JY, 1987, DRUGS, V34, P263, DOI 10.2165/00003495-198734020-00004; GIBSON RG, 1987, AM HEART J, V113, P406, DOI 10.1016/0002-8703(87)90293-6; GIFFORD RW, 1991, JAMA-J AM MED ASSOC, V266, P829, DOI 10.1001/jama.266.6.829; GLOCK JL, 1993, AM J OBSTET GYNECOL, V169, P960, DOI 10.1016/0002-9378(93)90035-H; GONZALEZCARMONA VM, 1991, ANGIOLOGY, V42, P908, DOI 10.1177/000331979104201106; HAFT JI, 1984, ARCH INTERN MED, V144, P2357, DOI 10.1001/archinte.144.12.2357; HASDAI D, 1992, ARCH INTERN MED, V152, P1725, DOI 10.1001/archinte.152.8.1725; HATTON RC, 1989, ARCH DIS CHILD, V64, P633, DOI 10.1136/adc.64.4.633; HOUSTON MC, 1986, AM HEART J, V111, P963, DOI 10.1016/0002-8703(86)90647-2; HUYSMANS FTM, 1983, BRIT J CLIN PHARMACO, V16, P725, DOI 10.1111/j.1365-2125.1983.tb02250.x; IMPEY L, 1993, BRIT J OBSTET GYNAEC, V100, P959, DOI 10.1111/j.1471-0528.1993.tb15120.x; KANADA SA, 1976, ANN INTERN MED, V84, P696, DOI 10.7326/0003-4819-84-6-696; KARACHALIOS GN, 1988, INT J CLIN PHARM TH, V26, P351; Kedas A, 1989, J Cardiovasc Nurs, V3, P31; KUMAR N, 1993, CAN J ANAESTH, V40, P329, DOI 10.1007/BF03009631; LEAVITT AD, 1988, ANN INTERN MED, V108, P305, DOI 10.7326/0003-4819-108-2-305; LEDINGHAM JGG, 1979, Q J MED, V48, P25; Lo Cicero G, 1986, Minerva Ginecol, V38, P631; LOPEZHERCE J, 1989, EUR J PEDIATR, V149, P136, DOI 10.1007/BF01995865; LOPEZHERCE J, 1988, INTENS CARE MED, V14, P519, DOI 10.1007/BF00263523; MCALLISTER RG, 1986, AM J MED, V81, P2, DOI 10.1016/0002-9343(86)90787-4; MESSERLI FH, 1991, LANCET, V338, P881, DOI 10.1016/0140-6736(91)91530-8; Mohanan P P, 1987, J Assoc Physicians India, V35, P222; NOBILEORAZIO E, 1981, BRIT MED J, V283, P948, DOI 10.1136/bmj.283.6297.948; Oliver S, 1994, Aust Crit Care, V7, P12, DOI 10.1016/S1036-7314(94)70197-1; OMAILIA JJ, 1987, ANN INTERN MED, V107, P185, DOI 10.7326/0003-4819-107-2-185; OPIE LH, 1985, LANCET, V2, P555; OPIE LH, 1991, LANCET, V338, P1203, DOI 10.1016/0140-6736(91)92064-9; PURI GD, 1987, INDIAN J MED RES, V86, P624; SCHENK CH, 1989, ANN EMERG MED, V18, P114, DOI 10.1016/S0196-0644(89)80347-6; SCHILLINGER D, 1987, Journal of Emergency Medicine, V5, P463, DOI 10.1016/0736-4679(87)90208-3; Schumann D, 1991, Dimens Crit Care Nurs, V10, P314, DOI 10.1097/00003465-199111000-00004; SCHWARTZ M, 1990, ARCH INTERN MED, V150, P686, DOI 10.1001/archinte.150.3.686; SHETTIGAR UR, 1989, CRIT CARE MED, V17, P196, DOI 10.1097/00003246-198902000-00020; Singh N K, 1987, J Assoc Physicians India, V35, P465; SPAH F, 1988, J CARDIOVASC PHARM, V12, pS154; TABURET AM, 1983, HYPERTENSION, V5, P29; VANHARTEN J, 1987, LANCET, V2, P1363; WACHTER RM, 1987, ARCH INTERN MED, V147, P556, DOI 10.1001/archinte.147.3.556; WELLS DG, 1989, ANAESTH INTENS CARE, V17, P31, DOI 10.1177/0310057X8901700107; WU SG, 1993, NEPHRON, V65, P284, DOI 10.1159/000187489; ZANGERLE KF, 1985, ANN EMERG MED, V14, P1005, DOI 10.1016/S0196-0644(85)80250-X; 1979, BRIT MED J, V2, P228; 1991, LANCET, V338, P220	65	306	325	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1328	1331		10.1001/jama.276.16.1328	http://dx.doi.org/10.1001/jama.276.16.1328			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM825	8861992				2022-12-28	WOS:A1996VM82500036
J	Hirth, RA; Turenne, MN; Woods, JD; Young, EW; Port, FK; Pauly, MV; Held, PJ				Hirth, RA; Turenne, MN; Woods, JD; Young, EW; Port, FK; Pauly, MV; Held, PJ			Predictors of type of vascular access in hemodialysis patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AREA VARIATIONS; UNITED-STATES; POLYTETRAFLUOROETHYLENE; COMPLICATIONS; SURVIVAL; FISTULA; GRAFTS; MORBIDITY; THERAPY; VEIN	Objective.-Complications from vascular access account for 15% of hospital admissions among US hemodialysis patients, Complications are less frequent with arteriovenous fistulas than with synthetic grafts, We assessed clinical and nonclinical predictors of whether patients with end-stage renal disease (ESRD) starting hemodialysis receive a fistula or graft, We also investigated changes in practice between 1986-1987 and 1990, Design.-Cross-sectional study. Setting.-United States hemodialysis population, Patients.-Random, national samples of ESRD patients who started hemodialysis in 1986-1987 (n=2741) or 1990 (n=1409) from United States Renal Data System Special Studies, Main Outcome Measure.-Type of permanent vascular access (arteriovenous fistula vs synthetic graft), analyzed using multivariate logistic regression, Results.-Clinical and demographic factors as well as socioeconomic status, region of residence, and year starting hemodialysis predicted the type of vascular access, Overall, 56% of patients had grafts 30 days after starting dialysis, but graft use increased from 51% in 1986-1987 to 65% in 1990 (adjusted odds ratio [AOR], 1.67 for 1990 vs 1986-1987; 95% confidence interval [CI], 1.43-1.95; P<.001), Graft use (relative to fistula) varied by region of residence (ranging from AOR, 0.20; 95% CI, 0.14-0.28; P<.001 [New England], to AOR, 2.69; 95% CI, 2.03-3.58; P<.001 [East South Central]; both relative to the national average), Conclusions.-This national study documents large variations in the relative use of fistulas and grafts and a trend away from fistulas, The prevalence of comorbid conditions fails to explain these findings, Presentation and referral of patients early in the process of their ESRD, teaching surgeons to place fistulas, and training dialysis nurses to access fistulas may increase their use.	UNIV MICHIGAN, DEPT ECON, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA; VET AFFAIRS MED CTR, ANN ARBOR, MI USA; UNIV PENN, DEPT HLTH CARE SYST, PHILADELPHIA, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania	Hirth, RA (corresponding author), UNIV MICHIGAN, SCH PUBL HLTH, DEPT HLTH MANAGEMENT & POLICY, 109 S OBSERV, ANN ARBOR, MI 48109 USA.				NIDDK NIH HHS [N01-DK-3-2202] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK032202] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albers F J, 1994, Adv Ren Replace Ther, V1, P107; BAKER LD, 1976, T AM SOC ART INT ORG, V22, P382; BENNION RS, 1993, VASCULAR SURG COMPRE, P606; BLEYER AJ, 1995, J AM SOC NEPHROL, V6, P483; BRESCIA MJ, 1966, NEW ENGL J MED, V275, P1089, DOI 10.1056/NEJM196611172752002; BROTMAN DN, 1994, J AM COLL SURGEONS, V178, P431; CHAZAN JA, 1995, NEPHRON, V69, P228, DOI 10.1159/000188461; CHURCHILL DN, 1992, AM J KIDNEY DIS, V19, P214, DOI 10.1016/S0272-6386(13)80002-9; COBURN MC, 1994, J VASC SURG, V20, P896, DOI 10.1016/0741-5214(94)90226-7; CONNALL TP, 1995, VASCULAR SURG, P1233; CONNOLLY JE, 1984, ARCH SURG-CHICAGO, V119, P1325; FAN PY, 1992, J AM SOC NEPHROL, V3, P1; FELDMAN HI, 1993, KIDNEY INT, V43, P1091, DOI 10.1038/ki.1993.153; GOLDWASSER P, 1994, AM J KIDNEY DIS, V24, P785, DOI 10.1016/S0272-6386(12)80672-X; Greene, 2003, ECONOMETRIC ANAL, P1241; HELD PJ, 1994, AM J KIDNEY DIS, V24, P974, DOI 10.1016/S0272-6386(12)81108-5; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; HOLAHAN J, 1990, HEALTH AFFAIR, V9, P166, DOI 10.1377/hlthaff.9.4.166; HURT AV, 1983, AM J SURG, V146, P844, DOI 10.1016/0002-9610(83)90356-2; JENKINS AM, 1980, SURGERY, V88, P667; JENSEN B V, 1990, Ugeskrift for Laeger, V152, P2169; KHERLAKIAN GM, 1986, AM J SURG, V152, P238, DOI 10.1016/0002-9610(86)90249-7; LUNDIN AP, 1989, REPLACEMENT RENAL FU, P1133; McEwen D R, 1994, AORN J, V59, P225; MCLAUGHLIN CG, 1989, MED CARE, V27, P507, DOI 10.1097/00005650-198905000-00006; MCMAHON LF, 1989, MED CARE, V27, P623, DOI 10.1097/00005650-198906000-00005; MILLER ME, 1995, MED CARE RES REV, V52, P252, DOI 10.1177/107755879505200205; MUNDA R, 1983, JAMA-J AM MED ASSOC, V249, P219, DOI 10.1001/jama.249.2.219; PALDER SB, 1985, ANN SURG, V202, P235, DOI 10.1097/00000658-198508000-00015; PHELPS CE, 1992, J ECON PERSPECT, V6, P23, DOI 10.1257/jep.6.3.23; PHELPS CE, 1990, MED CARE, V28, P703, DOI 10.1097/00005650-199008000-00004; Prischl FC, 1995, J AM SOC NEPHROL, V6, P1613; RIORDAN S, 1994, AUST NZ J SURG, V64, P763, DOI 10.1111/j.1445-2197.1994.tb04535.x; SANDS JJ, 1995, J AM SOC NEPHROL, V6, P501; Sommer B G, 1992, ASAIO J, V38, P743; SWEDBERG SH, 1989, CIRCULATION, V80, P1726, DOI 10.1161/01.CIR.80.6.1726; TURENNE MN, 1995, J AM SOC NEPHROL, V6, P504; *US REN DAT SYST, 1992, 1992 USRDS NIH NAT I; *US REN DAT SYST, 1996, 1996 USRDS NIH NAT I; *US REN DAT SYST, 1995, 1995 USRDS NIH NAT I; WEHRLI H, 1989, HELV CHIR ACTA, V56, P621; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; Windus D W, 1994, Adv Ren Replace Ther, V1, P148; WINDUS DW, 1993, AM J KIDNEY DIS, V21, P457, DOI 10.1016/S0272-6386(12)80391-X; WINDUS DW, 1992, AM J KIDNEY DIS, V19, P448, DOI 10.1016/S0272-6386(12)80953-X; WINSETT OE, 1985, SOUTHERN MED J, V78, P513, DOI 10.1097/00007611-198505000-00004; YOUNG EW, 1995, J AM SOC NEPHROL, V6, P569; ZIBARI GB, 1988, SURGERY, V104, P681	49	182	184	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1303	1308						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM825	8861988				2022-12-28	WOS:A1996VM82500032
J	Smith, DS; Catalona, WJ; Herschman, JD				Smith, DS; Catalona, WJ; Herschman, JD			Longitudinal screening for prostate cancer with prostate-specific antigen	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARCINOMA; SERUM; COST; MEN	Objective.-To determine for the first 4 years of serial prostate-specific antigen (PSA)-based screening trends in compliance, prevalence of abnormal screening test results, cancer detection rates, and stage and grade of cancers detected. Design.-A community-based study of serial screening for prostate cancer with serum PSA measurements. Setting.-University medical center. Subjects.-A total of 10 248 male volunteers at least 50 years old who were screened at 6-month intervals for a minimum of 48 months. Main Outcome Measures.-The proportion of men who returned for serial screening, the proportion with elevated PSA levels, the proportion with newly elevated PSA levels, prostate cancer detection rates, and the distribution of tumor stages and grades at diagnosis. Results.-At 48 months, 79% of volunteers returned for screening. During this interval there was a decrease in the proportion of volunteers with serum PSA levels higher than 4.0 ng/mL (from 10% to 6%-7%), in cancer detection rates (from 3% to <1%), and in the proportion with clinically advanced cancer (from 6% to 2%). In men who underwent surgery, the proportion with high-grade cancer decreased (from 11% to 6%), and the proportion with pathologically advanced cancer was proportionately reduced but not significantly reduced (from 33% to 27%). Conclusions.-With serial PSA-based screening, the proportion of men with abnormal test results decreased, and the prostate cancer detection rate decreased to near the reported population-based incidence rate, There was also a shift to detection of cancers at an earlier clinical stage and detection of lower-grade cancers. If PSA screening is ultimately shown to be beneficial, then appropriate cost-benefit analyses will be required to determine how the shifts in cancer detection rate and cancer stage will affect the economics of serial PSA-based screening.			Smith, DS (corresponding author), WASHINGTON UNIV,SCH MED,DEPT SURG,DIV UROL SURG,4960 CHILDRENS PL,ST LOUIS,MO 63110, USA.				NATIONAL CANCER INSTITUTE [P20CA058193] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA58193] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAWER MK, 1993, J UROLOGY, V150, P106, DOI 10.1016/S0022-5347(17)35409-5; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; COLBERG JW, 1993, J UROLOGY, V149, P507, DOI 10.1016/S0022-5347(17)36130-X; DEMARKWAHNEFRIED W, 1995, UROLOGY, V46, P346, DOI 10.1016/S0090-4295(99)80218-0; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; GILLILAND F, 1994, CANCER EPIDEM BIOMAR, V3, P105; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; HUMPHREY PA, 1996, J UROLOGY, V156, P816; JACOBSEN SJ, 1995, JAMA-J AM MED ASSOC, V274, P1445, DOI 10.1001/jama.274.18.1445; LITTRUP PJ, 1993, CA-CANCER J CLIN, V43, P134, DOI 10.3322/canjclin.43.3.134; LUBKE WL, 1994, J NATL CANCER I, V86, P1790, DOI 10.1093/jnci/86.23.1790; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; METTLIN C, 1994, J UROLOGY, V152, P1737, DOI 10.1016/S0022-5347(17)32373-X; MILLER BA, 1992, NIH PUBLICATION; MONTIE JE, 1995, CANCER, V75, P1814, DOI 10.1002/1097-0142(19950401)75:7+<1814::AID-CNCR2820751610>3.0.CO;2-B; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; SMITH DS, 1994, J UROLOGY, V152, P1732, DOI 10.1016/S0022-5347(17)32372-8; THOMPSON IM, 1995, ONCOLOGY S, V11, P141; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107	24	160	167	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1996	276	16					1309	1315		10.1001/jama.276.16.1309	http://dx.doi.org/10.1001/jama.276.16.1309			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM825	8861989				2022-12-28	WOS:A1996VM82500033
J	Zerangue, N; Kavanaugh, MP				Zerangue, N; Kavanaugh, MP			Flux coupling in a neuronal glutamate transporter	NATURE			English	Article							ARACHIDONIC-ACID; GLIAL-CELLS; RAT-BRAIN; ASPARTATE; SYNAPTOSOMES; INHIBITION; SUBTYPES; ISCHEMIA; RELEASE; CORTEX	SYNAPTIC transmission is commonly terminated by diffusion and reuptake of neurotransmitter from the synaptic cleft. Glutamate reuptake prevents neurotoxicity and sets the lower limit for the concentration of extracellular glutamate, so it is important to understand the thermodynamics of this process. Here we use voltage clamping with a pH-sensitive fluorescent dye to monitor electrical currents and pH changes associated with flux of glutamate mediated by the human neuronal glutamate transporter EAAT3. In contrast to a previous model(1), we find that three sodium ions and one proton are cotransported viith each glutamate ion into the cell, while one potassium ion is transported out of the cell. This coupling can support a transmembrane glutamate concentration gradient ([Glu](In)/[Glu](out)) exceeding 10(6) under equilibrium conditions, and would allow the transporter to continue removing glutamate over a wide range of ionic conditions.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University								ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Billups B, 1996, NATURE, V379, P171, DOI 10.1038/379171a0; BILLUPS B, IN PRESS J NEUROSCI; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; CHAN PH, 1983, J NEUROCHEM, V40, P309, DOI 10.1111/j.1471-4159.1983.tb11284.x; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; NELSON PJ, 1983, BIOCHEMISTRY-US, V22, P5459, DOI 10.1021/bi00292a030; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SAUGSTAD JA, 1995, EXCITATORY AMINO ACI, P77; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WEBB DJ, 1981, J CELL BIOL, V91, P562, DOI 10.1083/jcb.91.2.562; ZERANGUE N, 1995, J BIOL CHEM, V270, P6433, DOI 10.1074/jbc.270.12.6433; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393	30	664	676	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					634	637		10.1038/383634a0	http://dx.doi.org/10.1038/383634a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857541				2022-12-28	WOS:A1996VM75500057
J	Kim, U; Qin, XF; Gong, SC; Stevens, S; Luo, Y; Nussenzweig, M; Roeder, RG				Kim, U; Qin, XF; Gong, SC; Stevens, S; Luo, Y; Nussenzweig, M; Roeder, RG			The B-cell-specific transcription coactivator OCA-B/OBF-1/Bob-1 is essential for normal production of immunoglobulin isotypes	NATURE			English	Article							BINDING PROTEINS; REGION GENES; ACTIVATION; EXPRESSION; MOUSE; PROMOTERS; MECHANISM	OCA-B was initially identified as a B-cell-restricted coactivator that functions with octamer binding transcription factors (Oct-1 and Oct-2) to mediate efficient cell type-specific transcription of immunoglobulin promoters in vitro(1-3). Subsequent cloning studies led to identification of the coactivator as a single polypeptide, designated either as OCA-B (ref. 3), OBF-1 (ref. 4) or Bob-1 (ref. 5). OCA-B itself does not bind to DNA directly, but interacts with either Oct-1 or Oct-2 to potentiate transcriptional activation(1-5). To determine the biological role of OCA-B, we generated OCA-B-deficient mice by gene targeting. Mice lacking OCA-B undergo normal antigen-independent, B-cell differentiation, including appropriate expression of both immunoglobulin genes and other early B-cell-restricted genes. However, antigen-dependent maturation of B cells is greatly affected. The proliferative response to surface IgM crosslinking is impaired, and there is a severe deficiency in the production of secondary immunoglobulin isotypes including IgG1, IgG2a, IgG2b, IgG3, IgA and IgE in BCA-B-deficient B cells. This defect is not due to a failure of the isotype switching process, but rather to reduced levels of transcription from normally switched immunoglobulin heavy-chain loci. In accord dth the defective isotype production, germinal centre formation is absent in these mutant mice.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,LAB MOL IMMUNOL,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University			Nussenzweig, Michel/AAE-7292-2019	QIN, FRANK XIAOFENG/0000-0002-5395-0304				BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; GOLD MR, 1994, ADV IMMUNOL, V55, P221; Gong SC, 1996, SCIENCE, V272, P411, DOI 10.1126/science.272.5260.411; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; LI SC, 1994, INT IMMUNOL, V6, P491, DOI 10.1093/intimm/6.4.491; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; LUTZKER S, 1988, MOL CELL BIOL, V8, P1849, DOI 10.1128/MCB.8.4.1849; MCLENNAN IC, 1994, ANNU REV IMMUNOL, V12, P117; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.iy.11.040193.001555; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; QIN XF, 1994, EMBO J, V13, P5967, DOI 10.1002/j.1460-2075.1994.tb06942.x; RAJEWSKY K, 1992, CURR OPIN IMMUNOL, V4, P171, DOI 10.1016/0952-7915(92)90008-3; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	27	205	212	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					542	547		10.1038/383542a0	http://dx.doi.org/10.1038/383542a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849728				2022-12-28	WOS:A1996VL75500055
J	Nasir, J; Walton, C				Nasir, J; Walton, C			Lesson of the week - Adrenal mass with virilisation: Importance of endocrine investigation	BRITISH MEDICAL JOURNAL			English	Article							21-HYDROXYLASE DEFICIENCY; ADRENOCORTICAL TUMOR; HYPERPLASIA; INCIDENTALOMA; PATIENT		ROYAL HULL HOSP,MICHAEL WHITE DIABET & ENDOCRINOL CTR,KINGSTON HULL HU3 2RW,N HUMBERSIDE,ENGLAND									FALKE THM, 1986, CLIN RADIOL, V37, P155, DOI 10.1016/S0009-9260(86)80389-0; GUERRERO LA, 1985, UROLOGY, V26, P435, DOI 10.1016/0090-4295(85)90149-9; JARESCH S, 1992, J CLIN ENDOCR METAB, V74, P685, DOI 10.1210/jcem.74.3.1311000; LIGHTNER ES, 1993, AM J DIS CHILD, V147, P1274, DOI 10.1001/archpedi.1993.02160360016002; NEW MI, 1995, AM J MED, V98, pS2, DOI 10.1016/S0002-9343(99)80052-7; PANG S, 1981, PEDIATRICS, V68, P242; ROSS NS, 1990, NEW ENGL J MED, V323, P1401; SEDDON JM, 1985, UROLOGY, V25, P1, DOI 10.1016/0090-4295(85)90552-7; SHIMSHI M, 1992, AM J MED, V93, P338, DOI 10.1016/0002-9343(92)90243-5	9	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1996	313	7061					872	873						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL559	8870581				2022-12-28	WOS:A1996VL55900033
J	Tanabe, Y; Jessell, TM				Tanabe, Y; Jessell, TM			Diversity and pattern in the developing spinal cord	SCIENCE			English	Review							CENTRAL-NERVOUS-SYSTEM; MOTOR-NEURON INDUCTION; MOTONEURON PROJECTION PATTERNS; FLOOR PLATE DIFFERENTIATION; TERMINAL CLEAVAGE PRODUCT; RETINOIC ACID CAUSES; SONIC-HEDGEHOG; XENOPUS-EMBRYOS; DROSOPHILA-MELANOGASTER; MOUSE EMBRYO	The generation of distinct neuronal cell types in appropriate numbers and at precise positions underlies the assembly of neural circuits that encode animal behavior. Despite the complexity of the vertebrate central nervous system, advances have been made in defining the principles that control the diversification and patterning of its component cells. A combination of molecular genetic, biochemical, and embryological assays has begun to reveal the identity and mechanism of action of molecules that induce and pattern neural tissue and the role of transcription factors in establishing generic and specific neuronal fates. Some of these advances are discussed here, focusing on the spinal cord as a model system for analyzing the molecular control of central nervous system development in vertebrates.			Tanabe, Y (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA.							AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; ALBANO RM, 1994, DEVELOPMENT, V120, P803; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; Amthor H, 1996, DEV BIOL, V178, P343, DOI 10.1006/dbio.1996.0223; ANDERSON DJ, IN PRESS NEURONAL DE; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; [Anonymous], 1977, HDB PHYSL NERVOUS SY; AONO A, 1996, BIOCHEM BIOPH RES CO, V85, P947; Appel B, 1995, DEVELOPMENT, V121, P4117; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bang AG, 1996, CURR OPIN NEUROBIOL, V6, P25, DOI 10.1016/S0959-4388(96)80005-5; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; Brown AG, 1981, ORG SPINAL CORD; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; CAMPOSORTEGA JA, 1995, MOL NEUROBIOL, V10, P75, DOI 10.1007/BF02740668; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; Concordet JP, 1996, DEVELOPMENT, V122, P2835; Cox WG, 1995, DEVELOPMENT, V121, P4349; DAVIDSON DR, 1991, SEM DEV BIOL, V2, P405; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; EISEN JS, 1994, ANNU REV NEUROSCI, V17, P1; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; ENSINI M, UNPUB; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; ERICSON J, IN PRESS CELL; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FORBES AJ, 1993, DEVELOPMENT, P115; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GODSAVE SF, 1989, DEV BIOL, V134, P486, DOI 10.1016/0012-1606(89)90122-X; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GROVES AK, 1995, DEVELOPMENT, V121, P887; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; Halpern ME, 1995, DEVELOPMENT, V121, P4257; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HARLAND RM, IN PRESS NEURONAL DE; HARTENSTEIN V, 1989, NEURON, V3, P399, DOI 10.1016/0896-6273(89)90200-6; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HILL J, 1995, MECH DEVELOP, V50, P3, DOI 10.1016/0925-4773(94)00321-D; HIRANO S, 1991, SCIENCE, V251, P310, DOI 10.1126/science.1987648; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HORTON C, 1995, DEV DYNAM, V202, P312, DOI 10.1002/aja.1002020310; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; ISAACS HV, 1992, DEVELOPMENT, V114, P711; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JAN YN, 1994, ANNU REV GENET, V28, P373, DOI 10.1146/annurev.ge.28.120194.002105; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAMB TM, 1995, DEVELOPMENT, V121, P3627; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; Lance-Jones C., 1996, Society for Neuroscience Abstracts, V22, P1216; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P559; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LEBER SM, 1990, J NEUROSCI, V10, P2451; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LIEM K, UNPUB; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Lumsden A, 1995, CURR BIOL, V5, P1347, DOI 10.1016/S0960-9822(95)00266-1; Ma Q., UNPUB; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; Mansouri A, 1996, DEVELOPMENT, V122, P831; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; MARTI E, 1995, DEVELOPMENT, V121, P2537; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Matise MP, 1996, DEVELOPMENT, V122, P659; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MCCONNELL SK, 1995, J NEUROSCI, V15, P6987; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; Miller RH, 1996, TRENDS NEUROSCI, V19, P92, DOI 10.1016/S0166-2236(96)80036-1; MOURY JD, 1990, DEV BIOL, V141, P243, DOI 10.1016/0012-1606(90)90380-2; Myat A, 1996, DEV BIOL, V174, P233, DOI 10.1006/dbio.1996.0069; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; Papalopulu N, 1996, DEVELOPMENT, V122, P3409; PARR BA, 1993, DEVELOPMENT, V119, P247; Patel K, 1996, DEV BIOL, V178, P327, DOI 10.1006/dbio.1996.0222; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Pringle NP, 1996, DEV BIOL, V177, P30, DOI 10.1006/dbio.1996.0142; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; Reilly KM, 1996, CELL, V86, P743, DOI 10.1016/S0092-8674(00)80149-X; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SATO SM, 1989, DEV BIOL, V134, P263, DOI 10.1016/0012-1606(89)90096-1; SCHMIDT JE, 1995, DEV BIOL, V169, P37, DOI 10.1006/dbio.1995.1124; SELLECK MAJ, 1995, DEVELOPMENT, V121, P525; SHIEH P, 1951, J EXP ZOOL, V117, P359, DOI 10.1002/jez.1401170207; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SIMON H, 1995, CURR BIOL, V5, P205, DOI 10.1016/S0960-9822(95)00041-8; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; Skeath JB, 1996, CURR BIOL, V6, P1146, DOI 10.1016/S0960-9822(02)70681-7; SLUSARSKI DC, 1995, GENETICS, V139, P229; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STUART ET, 1994, ANNU REV GENET, V28, P219, DOI 10.1146/annurev.ge.28.120194.001251; TAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P10237, DOI 10.1073/pnas.89.21.10237; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TOKUMOTO M, 1995, DEV BIOL, V171, P578, DOI 10.1006/dbio.1995.1306; TOSNEY KW, 1995, BIOESSAYS, V17, P379, DOI 10.1002/bies.950170503; Tremblay P, 1996, DEVELOPMENT, V122, P2555; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; WAWNG MZ, 1995, NAT MED, V1, P1184; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; YARNADA T, 1991, CELL, V64, P635; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	187	617	630	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1996	274	5290					1115	1123		10.1126/science.274.5290.1115	http://dx.doi.org/10.1126/science.274.5290.1115			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8895454				2022-12-28	WOS:A1996VT33500030
J	Levy, JA				Levy, JA			Infection by human immunodeficiency virus CD4 is not enough	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Levy, JA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143, USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; ENDRES MJ, IN PRESS CELL; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Levy JA, 1994, HIV PATHOGENESIS AID; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0	15	28	45	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1996	335	20					1528	1530		10.1056/NEJM199611143352011	http://dx.doi.org/10.1056/NEJM199611143352011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT340	8890107				2022-12-28	WOS:A1996VT34000011
J	Wu, LJ; Gerard, NP; Wyatt, R; Choe, H; Parolin, C; Ruffing, N; Borsetti, A; Cardoso, AA; Desjardin, E; Newman, W; Gerard, C; Sodroski, J				Wu, LJ; Gerard, NP; Wyatt, R; Choe, H; Parolin, C; Ruffing, N; Borsetti, A; Cardoso, AA; Desjardin, E; Newman, W; Gerard, C; Sodroski, J			CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; ENVELOPE GLYCOPROTEINS; T-CELL; BINDING; CD4; INFECTION; IDENTIFICATION; EPITOPES; FUSION	FOR efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and CXCR-4, respectively, as well as the primary receptor CD4 (refs 1-6). Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1 alpha and MLP-1 beta (refs 7, 8). The apparent affinity of the interaction between gp120 and CCR-5 was dramatically lower in the absence of soluble CD4. Additionally, in the absence of gp120, an interaction between a two-domain CD4 fragment and CCR-5 was observed. A gp120 fragment retaining the CD4-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice(2,9-11), was also present on the molecule. Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp120-CD4 complexes with CCR-5. These results suggest that HIV-1 attachment to CD4 creates a high-affinity binding site for CCR-5, leading to membrane fusion and virus entry.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PATHOL,DIV HUMAN RETROVIOROL,BOSTON,MA 02115; LEUKOSITE INC,CAMBRIDGE,MA 02142; CHILDRENS HOSP,INA SUE PERLMUTTER LAB,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT PEDIAT,BOSTON,MA 02115; UNIV PADUA,INST MICROBIOL,I-35121 PADUA,ITALY; DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of Padua; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health			borsetti, alessandra/K-4103-2016	borsetti, alessandra/0000-0002-5401-135X				Akhatib G., 1996, SCIENCE, V272, P1955; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BACHELDER RE, 1995, J VIROL, V69, P5734, DOI 10.1128/JVI.69.9.5734-5742.1995; BURKLY LC, 1992, J IMMUNOL, V149, P1779; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHESEBRO B, 1991, J VIROL, V65, P5782, DOI 10.1128/JVI.65.11.5782-5789.1991; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CULP JS, 1991, BIO-TECHNOL, V9, P173, DOI 10.1038/nbt0291-173; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GERSHONI JM, 1993, FASEB J, V7, P1185, DOI 10.1096/fasebj.7.12.7690724; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MOORE JP, 1995, J VIROL, V69, P122, DOI 10.1128/JVI.69.1.122-130.1995; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POSNER MR, 1991, J IMMUNOL, V146, P4325; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995	29	1059	1131	3	55	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1996	384	6605					179	183		10.1038/384179a0	http://dx.doi.org/10.1038/384179a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT336	8906795				2022-12-28	WOS:A1996VT33600069
J	Kussie, PH; Gorina, S; Marechal, V; Elenbaas, B; Moreau, J; Levine, AJ; Pavletich, NP				Kussie, PH; Gorina, S; Marechal, V; Elenbaas, B; Moreau, J; Levine, AJ; Pavletich, NP			Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain	SCIENCE			English	Article							WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION DOMAIN; SOFT-TISSUE SARCOMAS; HISTOCOMPATIBILITY ANTIGEN; P53-DEPENDENT APOPTOSIS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; GENE AMPLIFICATION; CRYSTAL-STRUCTURE; BINDING PROTEIN	The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain bf p53 and downregulate its ability to activate transcription. In certain cancers, MDM2 amplification is a common event and contributes to the inactivation of p53. The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix. The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe(19), Trp(23), and Leu(26)-which insert deep into the MDM2 cleft. these same p53 residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain. The structure also suggests that the amphipathic alpha helix may be a common structural motif in the binding of a diverse family of transactivation factors to the TATA-binding protein-associated factors.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; HOP ROTHSCHILD,CERVICE MICROBIOL,F-75571 PARIS 12,FRANCE; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544; INST JACQUES MONOD,EQUIPE EMBRYOL,F-75251 PARIS,FRANCE	Memorial Sloan Kettering Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; Princeton University; UDICE-French Research Universities; Universite Paris Cite			marechal, vincent/P-7719-2017		NCI NIH HHS [CA65698] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065698] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLAIR WS, 1994, J VIROL, V68, P3803, DOI 10.1128/JVI.68.6.3803-3808.1994; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CORDONCARDO C, 1994, CANCER RES, V54, P794; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOOODRICH JA, 1994, CURR OPIN CELL BIOL, V6, P403; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEACH FS, 1993, CANCER RES, V53, P2231; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; MARECHAL V, UNPUB; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Massari ME, 1996, MOL CELL BIOL, V16, P121; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; REIFENBERGER G, 1993, CANCER RES, V53, P2736; REIGER JL, 1993, P NATL ACAD SCI USA, V90, P883; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shibagaki I, 1995, CLIN CANCER RES, V1, P769; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILSON IA, 1994, RES IMMUNOL, V145, P73, DOI 10.1016/S0923-2494(94)80049-9; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIALOING X, 1996, NATURE, V380, P316; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	74	1728	1827	4	249	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					948	953		10.1126/science.274.5289.948	http://dx.doi.org/10.1126/science.274.5289.948			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8875929				2022-12-28	WOS:A1996VR79200038
J	Barhanin, J; Lesage, F; Guillemare, E; Fink, M; Lazdunski, M; Romey, G				Barhanin, J; Lesage, F; Guillemare, E; Fink, M; Lazdunski, M; Romey, G			K(v)LQT1 and IsK (minK) proteins associate to form the I-Ks cardiac potassium current	NATURE			English	Article							RECTIFIER K+ CHANNEL; XENOPUS-OOCYTES; SK PROTEIN; EXPRESSION; CLONING; MEMBRANE; HEART; HERG; SENSITIVITY; ARRHYTHMIA	IN mammalian cardiac cells, a varlets of transient or sustained K+ currents contribute to the repolarization of action potentials(1). There are two main components of the delayed-rectifier sustained K+ current, I-Kr (rapid) and I-Ks (slow)(2). I-Kr is the product of the gene HERG(3,4), which is altered in the long-QT syndrome, LQT2 (ref. 5). A channel with properties similar to those of the I-Ks channel is produced when the cardiac protein IsK is expressed in Xenopus oocytes(6-8). However, it is a small protein with a very unusual structure for a cation channel(9-15). The LQT1 gene is another gene associated with the LQT syndrome, a disorder that causes sudden death from ventricular arrhythmias(16). Here we report the cloning of the full-length mouse K(v)LQT1 complementary DNA and show that K(v)LQT1 associates with IsK to form the channel underlying the I-Ks cardiac current, which is a target of class-III anti-arrhythmic drugs and is involved in the LQT(1) syndrome.	CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Lesage, Florian/P-9780-2019; Lesage, Florian/D-5097-2011	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106				ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; ATTALI B, 1993, J BIOL CHEM, V268, P24283; BenEfraim I, 1996, J BIOL CHEM, V271, P8768, DOI 10.1074/jbc.271.15.8768; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; Fink M, 1996, J BIOL CHEM, V271, P26341, DOI 10.1074/jbc.271.42.26341; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; FREEMAN LC, 1993, CIRC RES, V73, P968, DOI 10.1161/01.RES.73.5.968; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HICE RE, 1994, PFLUG ARCH EUR J PHY, V426, P139, DOI 10.1007/BF00374681; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; HONORE E, 1992, BIOCHEM BIOPH RES CO, V184, P1135, DOI 10.1016/S0006-291X(05)80001-4; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; NUSS HB, 1994, J PHYSIOL-LONDON, V479, P265, DOI 10.1113/jphysiol.1994.sp020294; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; TZOUNOPOULOS T, 1995, P NATL ACAD SCI USA, V92, P9593, DOI 10.1073/pnas.92.21.9593; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; ZHANG ZJ, 1994, P NATL ACAD SCI USA, V91, P1766, DOI 10.1073/pnas.91.5.1766	24	1287	1324	2	36	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					78	80		10.1038/384078a0	http://dx.doi.org/10.1038/384078a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900282				2022-12-28	WOS:A1996VR21900058
J	Mojzsis, SJ; Arrhenius, G; McKeegan, KD; Harrison, TM; Nutman, AP; Friend, CRL				Mojzsis, SJ; Arrhenius, G; McKeegan, KD; Harrison, TM; Nutman, AP; Friend, CRL			Evidence for life on Earth before 3,800 million years ago	NATURE			English	Article							ISUA SUPRACRUSTAL BELT; SEDIMENTARY-ROCKS; WESTERN-AUSTRALIA; PILBARA BLOCK; CARBON; ENVIRONMENT; GREENLAND; ORIGIN; IRON	IT is unknown when life first appeared on Earth. The earliest known microfossils (similar to 3,500 Myr before present) are structurally complex, and if it is assumed that the associated organisms required a long time to develop this degree of complexity, then the existence of life much earlier than this can be argued(1,2). But the known examples of crustal rocks older than similar to 3,500 Myr have experienced intense metamorphism, which would have obliterated any fragile microfossils contained therein. It is therefore necessary to search for geochemical evidence of past biotic activity that has been preserved within minerals that are resistant to metamorphism. Here we report ion-microprobe measurements of the carbon-isotope composition of carbonaceous inclusions within grains of apatite (basic calcium phosphate) from the oldest known sediment sequences-a similar to 3,800-Myr-old banded iron formation from the Isua supracrustal belt, West Greenland(35), and a similar formation from the nearby Akilia island that is possibly older than 3,850 Myr (ref, 3). The carbon in the carbonaceous inclusions is isotopically light, indicative of biological activity; no known abiotic process can explain the data. Unless some unknown abiotic process exists which is able both to create such isotopically light carbon and then selectively incorporate it into apatite grains, our results provide evidence for the emergence of life on Earth by at least 3,800 Myr before present.	WM KECK FDN CTR ISOTOPE GEOCHEM,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90095; AUSTRALIAN NATL UNIV,RES SCH EARTH SCI,CANBERRA,ACT 0200,AUSTRALIA; OXFORD BROOKES UNIV,DEPT GEOL & CARTOG,OXFORD OX3 0BP,ENGLAND	Australian National University; Oxford Brookes University	Mojzsis, SJ (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093, USA.		MOJZSIS, STEPHEN/AAU-9527-2020; Harrison, Timothy M/E-7443-2012; McKeegan, Kevin D/A-4107-2008	MOJZSIS, STEPHEN/0000-0003-0000-125X; McKeegan, Kevin D/0000-0002-1827-729X; Nutman, Allen/0000-0002-8393-9456				Cayeux L, 1936, CR HEBD ACAD SCI, V203, P1198; CHACKO T, 1991, GEOCHIM COSMOCHIM AC, V55, P2867, DOI 10.1016/0016-7037(91)90452-B; Chang S., 1983, EARTHS EARLIEST BIOS, P53; CHYBA CF, 1993, GEOCHIM COSMOCHIM AC, V57, P3351, DOI 10.1016/0016-7037(93)90543-6; DESMARAIS DJ, 1984, EARTH PLANET SC LETT, V69, P43, DOI 10.1016/0012-821X(84)90073-6; Driessens F. C. M., 1990, BIOMINERALS, P85; DYMEK RF, 1988, PRECAMBRIAN RES, V39, P247, DOI 10.1016/0301-9268(88)90022-8; Elliot J. C., 1994, STRUCTURE CHEM APATI; Filippelli GM, 1996, GEOCHIM COSMOCHIM AC, V60, P1479, DOI 10.1016/0016-7037(96)00042-7; GEDULIN B, 1993, NOBEL S, V84, P91; Hayes JM., 1983, EARTHS EARLIEST BIOS, P291; HICKMAN AH, 1981, SPEC PUBL GEOL SOC A, V7, P57; HIRSCHLER A, 1990, GEOMICROBIOL J, V7, P47; IRELAND RR, 1995, ADV ANAL GEOCHEM, V2, P1; James H.L., 1954, ECON GEOL, V49, P235, DOI DOI 10.2113/GSECONGEO.49.3.235; KRAJEWSKI KP, 1994, ECLOGAE GEOL HELV, V87, P701; LUCAS J, 1989, SCI GEOL B, V42, P237; MCGREGOR VR, 1977, AM MINERAL, V62, P887; MCKEEGAN KD, 1985, GEOCHIM COSMOCHIM AC, V49, P1971, DOI 10.1016/0016-7037(85)90091-2; MOORBATH S, 1986, CHEM GEOL, V57, P63, DOI 10.1016/0009-2541(86)90094-X; MOORBATH S, 1973, NATURE, V245, P138, DOI 10.1038/245138a0; NUTMAN AP, 1984, PRECAMBRIAN RES, V25, P365, DOI 10.1016/0301-9268(84)90010-X; Nutman AP, 1996, PRECAMBRIAN RES, V78, P1, DOI 10.1016/0301-9268(95)00066-6; NUTMAN AP, 1991, GEOLOGY, V19, P791, DOI 10.1130/0091-7613(1991)019<0791:VEACAC>2.3.CO;2; Ohmoto H, 1979, GEOCHEMISTRY HYDROTH, V10, P509; PIDGEON RT, 1978, EARTH PLANET SC LETT, V37, P421, DOI 10.1016/0012-821X(78)90057-2; Schidlowski M., 1983, P149; SCHIDLOWSKI M, 1988, NATURE, V333, P313, DOI 10.1038/333313a0; SCHOEMAKER JF, 1992, PEOPLING OF THE AMERICAS - PROCEEDINGS, VOL 3, P41; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; Strauss H., 1992, PROTEROZOIC BIOSPHER, P709; SUGITANI K, 1992, PRECAMBRIAN RES, V57, P21, DOI 10.1016/0301-9268(92)90093-4; VALLEY JW, 1986, STABLE ISOTOPES HIGH, P445; VERBEECK RMH, 1986, B SOC CHIM BELG, V95, P455; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; [No title captured]	37	812	857	6	282	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					55	59		10.1038/384055a0	http://dx.doi.org/10.1038/384055a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900275	Green Submitted			2022-12-28	WOS:A1996VR21900051
J	Simon, R; Igeno, MI; Coupland, G				Simon, R; Igeno, MI; Coupland, G			Activation of floral meristem identity genes in Arabidopsis	NATURE			English	Article							CELL FATE; INITIATION; APETALA1; THALIANA	THE Arabidopsis floral meristem identity genes APETALA1 (AP1) and LEAFY (LFY) confer floral identity on developing floral primordia(1-4), whereas TERMINAL FLOWER (TFL) is required to repress their expression within shoot and inflorescence meristems(1,5). LFY and AP1 are expressed in floral primordia in response to environmental conditions, such as day length, which regulate the onset of flowering, and presumably also in response to the action of genes that influence flowering time. However, the relationship between these flowering-time genes and the floral meristem-identity genes has been difficult to assess because flowering time is determined by several interacting genetic pathways(6,7). Here we describe a method to regulate expression of the flowering-time gene CONSTANS (CO) and demonstrate that CO expression is sufficient to trigger flowering, irrespective of day length. In response to CO expression, transcription of LFY and TFL is initiated rapidly, whereas transcription of AP1 occurs much later. We propose that CO acts within a genetic pathway that is sufficient to activate LFY and TFL transcription, but that rapid activation of AP1 requires an additional pathway.	JOHN INNES CTR PLANT SCI RES,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Coupland, George/AAP-8609-2020; Simon, Rudiger/T-6755-2018	Coupland, George/0000-0001-6988-4172; Simon, Rudiger/0000-0002-1317-7716; Igeno, M. Isabel/0000-0003-4745-3827				AOYAMA T, 1995, PLANT CELL, V7, P1773, DOI 10.1105/tpc.7.11.1773; Bradley D, 1996, NATURE, V379, P791, DOI 10.1038/379791a0; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; COUPLAND G, 1995, TRENDS GENET, V11, P393, DOI 10.1016/S0168-9525(00)89122-2; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; HEMPEL FD, 1994, PLANTA, V192, P276, DOI 10.1007/BF01089045; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; MCDANIEL CN, 1992, DEV BIOL, V153, P59, DOI 10.1016/0012-1606(92)90091-T; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; REDEI GP, 1962, GENETICS, V47, P443; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0	17	257	280	1	33	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1996	384	6604					59	62		10.1038/384059a0	http://dx.doi.org/10.1038/384059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR219	8900276				2022-12-28	WOS:A1996VR21900052
J	Higgins, RM; Bevan, DJ; Carey, BS; Lea, CK; Fallon, M; Buhler, R; Vaughan, RW; ODonnell, PJ; Snowden, SA; Bewick, M; Hendry, BM				Higgins, RM; Bevan, DJ; Carey, BS; Lea, CK; Fallon, M; Buhler, R; Vaughan, RW; ODonnell, PJ; Snowden, SA; Bewick, M; Hendry, BM			Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation	LANCET			English	Article							LYMPHOCYTOTOXIC ANTIBODIES; IMMUNOADSORPTION; RECIPIENTS; CROSSMATCH; ALLOGRAFTS; EPISODES	Background Many patients with circulating antibodies to human leucocyte antigens (anti-HLA) are highly sensitised against renal transplantation and are liable to immediate graft loss through hyperacute rejection. Our aim was to find out whether removal of anti-HLA immediately before renal transplantation prevented hyperacute graft rejection. Methods 13 highly sensitised patients underwent cadaveric renal transplants immediately after immunoadsorption (IA) treatment to remove anti-HLA. Before IA, 12 patients had a positive crossmatch against donor cells either by cytotoxic or flow-cytometric assay; results for one patient were equivocal. Findings Renal biopsy samples were obtained 20 min after removal of the Vascular clamps in nine patients. There was no evidence of hyperacute rejection in six of the nine patients; the other three patients showed glomerular thrombosis but no other evidence of hyperacute rejection. Two of these three grafts were functioning at 31 months of follow-up. Six episodes of acute rejection occurred in five patients during the first month after transplantation and overall there were 13 rejection episodes in nine patients. At latest follow-up (median 26 months, range 9-42), 12 of 13 patients were alive and seven of 13 grafts were surviving with a median plasma creatinine concentration of 185 mu mol/L (range 106-296) in the functioning grafts. No graft was lost as a result of classic hyperacute rejection. Interpretation Immediate pretransplant IA can prevent hyperacute rejection and provide an opportunity for successful transplantation in highly sensitised patients.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,RENAL GRP,LONDON SE5 9PJ,ENGLAND; GUYS HOSP,S THAMES REG TISSUE TYPING LAB,LONDON SE1 9RT,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT HISTOPATHOL,LONDON,ENGLAND; UNIV LONDON KINGS COLL HOSP,RENAL UNIT,LONDON,ENGLAND	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London								ALMOND PS, 1991, TRANSPLANTATION, V52, P253, DOI 10.1097/00007890-199108000-00013; Bevan DJ, 1996, TRANSPLANT INT, V9, P155, DOI 10.1111/j.1432-2277.1996.tb00871.x; BEVAN DJ, 1995, NEPHROL DIAL TRANSPL, V10, P744; BEVAN DJ, 1996, IN PRESS TRANSPL S1, V9; ESNAULT V, 1990, TRANSPLANTATION, V50, P449, DOI 10.1097/00007890-199009000-00018; GASTON RS, 1994, TRANSPLANTATION, V57, P47, DOI 10.1097/00007890-199401000-00010; GJORSTRUP P, 1991, TRANSPLANT P, V23, P392; HEISSE C, 1992, NEPHROL DIAL TRANSPL, V7, P944; Higgins RM, 1996, NEPHRON, V74, P53, DOI 10.1159/000189281; KARUPPAN SS, 1992, TRANSPLANTATION, V53, P666, DOI 10.1097/00007890-199203000-00033; KUPIN WL, 1991, TRANSPLANTATION, V51, P324, DOI 10.1097/00007890-199102000-00010; LAZDA VA, 1988, TRANSPLANTATION, V45, P562, DOI 10.1097/00007890-198803000-00012; PALMER A, 1989, LANCET, V1, P10; PATEL R, 1969, NEW ENGL J MED, V280, P735, DOI 10.1056/NEJM196904032801401; PORTER KA, 1992, PATHOLOGY KIDNEY, P1799; REISAETER AV, 1995, TRANSPLANTATION, V60, P242, DOI 10.1097/00007890-199508000-00006; ROSS CN, 1993, TRANSPLANTATION, V55, P785, DOI 10.1097/00007890-199304000-00019; TAUBE DH, 1984, LANCET, V1, P824; TAYLOR CJ, 1989, TRANSPLANTATION, V48, P953, DOI 10.1097/00007890-198912000-00011; THOROGOOD J, 1991, TRANSPLANTATION, V52, P831, DOI 10.1097/00007890-199111000-00015; WELSH KI, 1988, TRANSPLANT INT, V1, P190, DOI 10.1111/j.1432-2277.1988.tb01814.x	21	98	117	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1996	348	9036					1208	1211		10.1016/S0140-6736(96)03452-6	http://dx.doi.org/10.1016/S0140-6736(96)03452-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ467	8898038				2022-12-28	WOS:A1996VQ46700012
J	Powner, DJ; Ackerman, BM; Grenvik, A				Powner, DJ; Ackerman, BM; Grenvik, A			Medical diagnosis of death in adults: Historical contributions to current controversies	LANCET			English	Article							BRAIN-DEATH; DEFINITION		UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Powner, DJ (corresponding author), UNIV PITTSBURGH, SCH MED, DEPT ANESTHESIOL & CRIT CARE MED, ROOM 612C SCAIFE HALL, PITTSBURGH, PA 15261 USA.							ALEXANDER M, 1980, HASTINGS CENT REP, V10, P25, DOI 10.2307/3560926; ALEXANDRE GPJ, 1991, HIST TRANSPLANTATION; [Anonymous], 1968, JAMA, V205, P337; ARITA K, 1993, ACTA NEUROCHIR, V123, P64, DOI 10.1007/BF01476288; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; BERNAT JL, 1989, NEUROL CLIN, V7, P715, DOI 10.1016/S0733-8619(18)30385-2; BOYD K, 1977, J MED ETHICS, V3, P124, DOI 10.1136/jme.3.3.124; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHURCHILL LR, 1990, MILBANK Q, V68, P147, DOI 10.2307/3350093; DUCACHET HW, 1822, AM M RECORDER, V5, P39; DUNGLISON R, 1895, DICT MED SCI, V309, P631; GERVAIS KG, 1986, REDEFINING DEATH, P183; GOULD GM, 1895, ILLUSTRATED DICT MED, P354; HALEVY M, 1933, ANN INTERN MED, V119, P519; HANTSON P, 1993, EUR NEUROL, V33, P212, DOI 10.1159/000116939; KEATING J, 1892, NEW PRONOUNCING DICT, P430; LIZZA JP, 1993, J MED PHILOS, V18, P351, DOI 10.1093/jmp/18.4.351; Lofstedt S, 1956, OPUSC MED, V8, P199; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARTIMASSO JF, 1993, J NEUROL SCI, V120, P115, DOI 10.1016/0022-510X(93)90034-V; MOLLARET P., 1959, REV NEUROL [PARIS], V101, P3; Pernick M., 2011, DEATH WHOLE BRAIN CR, P17, DOI [10.1007/978-94-009-2707-0_2, DOI 10.1007/978-94-009-2707-0_2]; POWNER DJ, 1987, J INTENSIVE CARE MED, V2, P181; *PRES COMM STUD ET, 1981, DEF DEATH REP MED ET; QUAIN R, 1884, DICT MED, P327; QUINCY J, 1787, LEXICON PHYSICO MED, V263, P488; THOMSON E H, 1963, Bull Hist Med, V37, P43; TRUOG RD, 1992, CRIT CARE MED, V20, P1705, DOI 10.1097/00003246-199212000-00018; VEATCH RM, 1993, HASTINGS CENT REP, V23, P18, DOI 10.2307/3562586; 1994, DORLANDS MED DICT, P430	31	40	40	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 2	1996	348	9036					1219	1223		10.1016/S0140-6736(96)04015-9	http://dx.doi.org/10.1016/S0140-6736(96)04015-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VQ467	8898042				2022-12-28	WOS:A1996VQ46700016
J	Lamarche, N; Tapon, N; Stowers, L; Burbelo, PD; Aspenstrom, P; Bridges, T; Chant, J; Hall, A				Lamarche, N; Tapon, N; Stowers, L; Burbelo, PD; Aspenstrom, P; Bridges, T; Chant, J; Hall, A			Rac and Cdc42 induce actin polymerization and G1 cell cycle progression independently of p65(PAK) and the JNK/SAPK MAP kinase cascade	CELL			English	Article							GTP-BINDING-PROTEIN; ADP-RIBOSYLATION; TARGET PROTEINS; NADPH OXIDASE; STRESS FIBERS; SMALL GTPASES; RHO; ACTIVATION; TRANSFORMATION; PURIFICATION	Rac and Cdc42 regulate a variety of responses in mammalian cells including formation of lamellipodia and filopodia, activation of the JNK MAP kinase cascade, and induction of G1 cell cycle progression. Pac is also one of the downstream targets required for Ras-induced malignant transformation. Pac and Cdc42 containing a Y40C effector site substitution no longer intact with the Ser/Thr kinase p65(PAK) and are unable to activate the JNK MAP kinase pathway. However, they still induce cytoskeletal changes and G1 cell cycle progression. Rac containing an F37A effector site substitution, on the other hand, no longer interacts with the Ser/Thr kinase p160(ROCK) and is unable to induce lamellipodia or G1 progression. We conclude that Pac and Cdc42 control MAP kinase pathways and actin cytoskeleton organization independently through distinct downstream targets.	UNIV LONDON UNIV COLL,DEPT BIOCHEM,CRC ONCOGENE & SIGNAL TRANSDUCT GRP,MRC LAB MOL CELL BIOL,LONDON WC1E 6BT,ENGLAND; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	MRC Laboratory Molecular Biology; University of London; University College London; Harvard University			Burbelo, Peter D./B-1027-2009; Stowers, Lisa/K-6137-2015	Stowers, Lisa/0000-0002-4403-1269; Tapon, Nicolas/0000-0001-5267-6510	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Foster R, 1996, MOL CELL BIOL, V16, P2689; GILLMORE AP, 1996, NATURE, V381, P531; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWIG JH, 1995, CELL, V82, P843; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORII N, 1992, J BIOL CHEM, V267, P20921; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; REID T, 1996, IN PRESS J BIOL CHEM; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; UEDA T, 1990, J BIOL CHEM, V265, P9373; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YAMAMOTO M, 1993, J BIOL CHEM, V268, P21509; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	56	534	536	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					519	529		10.1016/S0092-8674(00)81371-9	http://dx.doi.org/10.1016/S0092-8674(00)81371-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898204	hybrid			2022-12-28	WOS:A1996VQ46600017
J	Liu, ZG; Hsu, HL; Goeddel, DV; Karin, M				Liu, ZG; Hsu, HL; Goeddel, DV; Karin, M			Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappa B activation prevents cell death	CELL			English	Article							TUMOR-NECROSIS-FACTOR; MANGANOUS SUPEROXIDE-DISMUTASE; RAS SIGNALING PATHWAY; PROTEIN-KINASES; FACTOR-ALPHA; DOMAIN; JUN; FAS; PHOSPHORYLATION; INTERLEUKIN-1	Through its type 1 receptor (TNFR1), the cytokine TNF elicits an unusually wide range of biological responses, including inflammation, tumor necrosis, cell proliferation, differentiation, and apoptosis. We investigated how TNFR1 activates different effector functions; the protein kinase JNK, transcription factor NF-kappa B, and apoptosis. We found that the three responses are mediated through separate pathways. Recruitment of the signal transducer FADD to the TNFR1 complex mediates apoptosis but not NF-kappa B or JNK activation. Two other signal transducers, RIP and TRAF2, mediate both JNK and NF-kappa B activation. These two responses, however, diverge downstream to TRAF2. Most importantly, JNK activation is not involved in induction of apoptosis, while activation of NF-kappa B protects against TNF-induced apoptosis.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093; TULARIK INC,S SAN FRANCISCO,CA 94080	University of California System; University of California San Diego								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU MH, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENCZOWSKI JM, 1996, IN PRESS MOL CELL BI; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAY CA, 1992, CELL, V69, P587; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WU, 1996, EMBO J, V15, P4682	64	1764	1810	3	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1996	87	3					565	576		10.1016/S0092-8674(00)81375-6	http://dx.doi.org/10.1016/S0092-8674(00)81375-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VQ466	8898208	Green Published, Bronze			2022-12-28	WOS:A1996VQ46600021
J	Smith, AW; Hatcher, J; Mackenzie, IJ; Thompson, S; Bal, I; Macharia, I; Mugwe, P; OkothOlende, C; Oburra, H; Wanjohi, Z				Smith, AW; Hatcher, J; Mackenzie, IJ; Thompson, S; Bal, I; Macharia, I; Mugwe, P; OkothOlende, C; Oburra, H; Wanjohi, Z			Randomised controlled trial of treatment of chronic suppurative otitis media in Kenyan schoolchildren	LANCET			English	Article							CHILDREN; CIPROFLOXACIN; MANAGEMENT; EAR	Background The outcomes of treatment of chronic suppurative otitis media (CSOM) are disappointing and uncertain, especially in developing countries. Because CSOM is the commonest cause of hearing impairment in children in these countries, an effective method of management that can be implemented on a wide scale is needed. We report a randomised, controlled trial of treatment of CSOM among children in Kenya; unaffected schoolchildren were taught to administer the interventions. Methods We enrolled 524 children with CSOM, aged 5-15 years, from 145 primary schools in Kiambu district of Kenya. The schools were randomly assigned treatments in clusters of five in a ratio of two to dry mopping alone (201 children), two to dry mopping with topical and systemic antibiotics and topical steroids (221 children), and one to no specific treatment (102 children). Schools were matched on factors thought to be related to their socioeconomic status. The primary outcome measures were resolution of otorrhoea and healing of tympanic membranes on otoscopy by 8, 12, and 16 weeks after induction. Absence of perforation was confirmed by tympanometry, and hearing levels were assessed by audiometry. 29 children were withdrawn from the trial because they took non-trial antibiotics. There was no evidence of differences in timing of withdrawals between the groups. Findings By the 16-week follow-up visit, otorrhoea had resolved in a weighted mean proportion of 51% (95% CI 42-59) of children who received dry mopping with antibiotics, compared with 22% (14-31) of those who received dry mopping alone and 22% (9-35) of controls. Similar differences were recorded by the 8-week and 12-week visits. The weighted mean proportions of children with healing of the tympanic membranes by 16 weeks were 15% (10-21) in the dry-mopping plus antibiotics group, 13% (5-20) in the dry-mopping alone group, and 13% (3-23) in the control group. The proportion with resolution in the dry-mopping alone group did not differ significantly from that in the control group at any time. Hearing thresholds were significantly better for children with no otorrhoea at 16 weeks than for those who had otorrhoea, and were also significantly better for those whose ears had healed than for those with otorrhoea at all times. Interpretation Our finding that dry mopping plus topical and systemic antibiotics is superior to dry mopping alone contrasts with that of the only previous community-based trial in a developing country, though it accords with findings of most other trials in developed countries. The potential role of antibiotics needs further investigation. Further, similar trials are needed to identify the most cost-effective and appropriate treatment regimen for CSOM in children in developing countries.	UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,HEARING IMPAIRMENT RES GRP,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND; UNIV NAIROBI,DEPT EAR NOSE & THROAT DIS,NAIROBI,KENYA; UNIV MANCHESTER,CTR AUDIOL EDUC DEAF & SPEECH PATHOL,MANCHESTER,LANCS,ENGLAND; AFRICAN MED & RES FDN,NAIROBI,KENYA	Liverpool School of Tropical Medicine; University of Liverpool; University of Nairobi; University of Manchester; African Medical & Research Foundation (AMREF)								BROWNING GG, 1988, J LARYNGOL OTOL, V102, P491, DOI 10.1017/S0022215100105444; DONNER A, 1982, INT J EPIDEMIOL, V11, P283, DOI 10.1093/ije/11.3.283; EASON RJ, 1986, NEW ZEAL MED J, V99, P812; ESPOSITO S, 1990, ARCH OTOLARYNGOL, V116, P557; ESPOSITO S, 1992, ARCH OTOLARYNGOL, V118, P842; FLISS DM, 1990, J PEDIATR-US, V116, P991, DOI 10.1016/S0022-3476(05)80666-3; GAIL MH, 1992, CONTROL CLIN TRIALS, V13, P6, DOI 10.1016/0197-2456(92)90026-V; GHOSH L M, 1991, Auris Nasus Larynx, V18, P209; HATCHER J, 1995, INT J PEDIATR OTORHI, V33, P197, DOI 10.1016/0165-5876(95)01209-5; HOLBOROW C, 1985, TROP DOCT, V15, P39, DOI 10.1177/004947558501500123; JOHNSON RL, 1967, LARYNGOSCOPE, V77, P1990, DOI 10.1288/00005537-196711000-00004; KANGSANARAK J, 1993, J LARYNGOL OTOL, V107, P999, DOI 10.1017/S0022215100125095; KAPLAN GJ, 1973, PEDIATRICS, V52, P577; KENNA MA, 1988, ANN OTO RHINOL LARYN, V97, P8; LEWIS N, 1976, ARCH OTOLARYNGOL, V102, P387; LILDHOLDT T, 1986, ARCH OTO-RHINO-LARYN, V243, P167, DOI 10.1007/BF00470613; LISBYSUTCH SM, 1990, CLIN PHARM, V9, P18; MACKENZIE I, 1995, TROP DOCT, V25, P25, DOI 10.1177/004947559502500108; Meyerhoff WL, 1988, ANN OTOL RHINOL S131, V97, P21; OKAFOR BC, 1984, J LARYNGOL OTOL, V98, P113, DOI 10.1017/S0022215100146298; PAPASTAVROS T, 1989, LARYNGOSCOPE, V99, P655; PECKHAM CS, 1972, DEV MED CHILD NEUROL, V14, P592; REED D, 1967, AM J PUBLIC HEALTH N, V57, P1657, DOI 10.2105/AJPH.57.9.1657; Rotimi V O, 1990, West Afr J Med, V9, P89; SHENOI PM, 1988, SCOTTBROWNS OTOLOGY; SUGIYAMA M, 1981, ACTA OTO-LARYNGOL, V92, P285, DOI 10.3109/00016488109133264; WANJOHI ZW, 1991, AFYA J MED HLTH WORK, V25, P60; *WHO, 1995, WHOCDR9514AL DIV DIA; World Health Organization, 1986, A3914 WHO; YUEN PW, 1994, AM J OTOL, V15, P670	30	48	48	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1996	348	9035					1128	1133		10.1016/S0140-6736(96)09388-9	http://dx.doi.org/10.1016/S0140-6736(96)09388-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP106	8888166				2022-12-28	WOS:A1996VP10600010
J	Chee, M; Yang, R; Hubbell, E; Berno, A; Huang, XC; Stern, D; Winkler, J; Lockhart, DJ; Morris, MS; Fodor, SPA				Chee, M; Yang, R; Hubbell, E; Berno, A; Huang, XC; Stern, D; Winkler, J; Lockhart, DJ; Morris, MS; Fodor, SPA			Accessing genetic information with high-density DNA arrays	SCIENCE			English	Article							HUMAN MITOCHONDRIAL-DNA; ENZYMATIC AMPLIFICATION; SEQUENCE; HYBRIDIZATION; EVOLUTION; GENOME; DISEASE; ORIGIN	Rapid access to genetic information is central to the revolution taking place in molecular genetics. The simultaneous analysis of the entire human mitochondrial genome is described here, DNA arrays containing up to 135,000 probes complementary to the 16.6-kilobase human mitochondrial genome were generated by light-directed chemical synthesis, A two-color labeling scheme was developed that allows simultaneous comparison of a polymorphic target to a reference DNA or RNA. Complete hybridization patterns were revealed in a matter of minutes. Sequence polymorphisms were detected with single-base resolution and unprecedented efficiency, The methods described are generic and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability.			Chee, M (corresponding author), AFFYMETRIX, 3380 CENT EXPRESSWAY, SANTA CLARA, CA 95051 USA.			Hubbell, Earl/0000-0001-7301-3759	NHGRI NIH HHS [5RO1HG00813] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000813] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; AQUADRO CF, 1983, GENETICS, V103, P287; BAINS W, 1988, J THEOR BIOL, V135, P303, DOI 10.1016/S0022-5193(88)80246-7; BROWN MD, 1992, FASEB J, V6, P2791, DOI 10.1096/fasebj.6.10.1634041; BUTZOW JJ, 1965, BIOPOLYMERS, V3, P95, DOI 10.1002/bip.360030110; CANN RL, 1984, GENETICS, V106, P479; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CHENG S, 1994, NAT GENET, V7, P350, DOI 10.1038/ng0794-350; DRMANAC R, 1989, GENOMICS, V4, P114; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GILL P, 1985, NATURE, V318, P577, DOI 10.1038/318577a0; GREENBERG BD, 1983, GENE, V21, P33, DOI 10.1016/0378-1119(83)90145-2; HACIA J, UNPUB; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; HUFF JW, 1964, BIOCHEMISTRY-US, V3, P501, DOI 10.1021/bi00892a006; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; LOCKHART D, IN PRESS NATURE BIOT; LYSOV YP, 1988, DOKL AKAD NAUK SSSR, V303, P1508; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MELCHIOR WB, 1973, P NATL ACAD SCI USA, V70, P298, DOI 10.1073/pnas.70.2.298; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1992, GENOMICS, V13, P1008, DOI 10.1016/0888-7543(92)90014-J; STONEKING M, 1991, AM J HUM GENET, V48, P370; TRULSON MO, UNPUB; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WODICKA L, COMMUNICATION; ZEVIANI M, 1990, AM J HUM GENET, V47, P904	31	1213	1670	2	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					610	614		10.1126/science.274.5287.610	http://dx.doi.org/10.1126/science.274.5287.610			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8849452				2022-12-28	WOS:A1996VN91900050
J	Kinzler, KW; Vogelstein, B				Kinzler, KW; Vogelstein, B			Lessons from hereditary colorectal cancer	CELL			English	Review							FAMILIAL ADENOMATOUS POLYPOSIS; MISMATCH REPAIR DEFICIENCY; APC GENE-PRODUCT; NONPOLYPOSIS COLON-CANCER; TUMOR-SUPPRESSOR PROTEIN; MICROSATELLITE INSTABILITY; INTESTINAL NEOPLASIA; BETA-CATENIN; GENOMIC INSTABILITY; REPEATED SEQUENCES		HOWARD HUGHES MED INST,BALTIMORE,MD 21231	Howard Hughes Medical Institute	Kinzler, KW (corresponding author), JOHNS HOPKINS ONCOL CTR,424 N BOND ST,BALTIMORE,MD 21231, USA.				NATIONAL CANCER INSTITUTE [P50CA062924, R37CA043460, R37CA057345, R01CA057345, R01CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA 62924, CA 57345, CA 43460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BAKER SJ, 1990, CANCER RES, V50, P7717; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOCKER M, 1996, J PATHOL, V179, P15; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Boolbol SK, 1996, CANCER RES, V56, P2556; BRANCH P, 1995, NAT GENET, V9, P231, DOI 10.1038/ng0395-231; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; DAMS E, 1995, CANCER RES, V55, P1547; DAVIES DR, 1995, AM J HUM GENET, V57, P1151; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GARBER JE, 1991, CANCER RES, V51, P6094; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Giardiello Francis M., 1995, P367; GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; HOULSTON RS, 1992, ANN HUM GENET, V56, P99, DOI 10.1111/j.1469-1809.1992.tb01136.x; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JEN J, 1994, CANCER RES, V54, P5523; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOI M, 1994, CANCER RES, V54, P4308; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEVY DB, 1994, CANCER RES, V54, P5953; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOEB LA, 1991, CANCER RES, V51, P3075; LUONGO C, 1994, CANCER RES, V54, P5947; Lynch HT, 1996, INT J CANCER, V69, P38, DOI 10.1002/(SICI)1097-0215(19960220)69:1<38::AID-IJC9>3.0.CO;2-X; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MODRICH P, 1995, PHILOS T ROY SOC B, V347, P89, DOI 10.1098/rstb.1995.0014; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OLSCHWANG S, 1993, CELL, V75, P959, DOI 10.1016/0092-8674(93)90539-3; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; PRETLOW TP, 1993, J NATL CANCER I, V85, P2004, DOI 10.1093/jnci/85.24.2004; Reitmair AH, 1996, CANCER RES, V56, P2922; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHIBATA D, 1993, J NATL CANCER I, V85, P1058, DOI 10.1093/jnci/85.13.1058; Shpitz B, 1996, DIS COLON RECTUM, V39, P763, DOI 10.1007/BF02054441; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	96	4021	4163	4	340	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1996	87	2					159	170		10.1016/S0092-8674(00)81333-1	http://dx.doi.org/10.1016/S0092-8674(00)81333-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VN403	8861899	hybrid			2022-12-28	WOS:A1996VN40300003
J	Luck, SJ; Vogel, EK; Shapiro, KL				Luck, SJ; Vogel, EK; Shapiro, KL			Word meanings can be accessed but not reported during the attentional blink	NATURE			English	Article							SERIAL VISUAL PRESENTATION; SENTENCES	AFTER the detection of a target item in a rapid stream of visual stimuli, there is a period of 400-600 ms during which subsequent targets are missed. This impairment has been labelled the 'attentional blink'(1). It has been suggested that, unlike an eye blink, the additional blink does not reflect a suppression of perceptual processing, but instead reflects a loss of information at a postperceptual stage, such as visual short-term memory(2-4). Here we provide electrophysiological evidence that words presented during the attentional blink period are analysed to the point of meaning extraction, even though these extracted meanings cannot be reported 1-2 s later. This shows that the attentional blink does indeed reflect a loss of information at a postperceptual stage of processing, and provides a demonstration of the modularity of human brain function.	UNIV WALES, SCH PSYCHOL, BANGOR LL57 2DG, GWYNEDD, WALES	Bangor University	Luck, SJ (corresponding author), UNIV IOWA, DEPT PSYCHOL, IOWA CITY, IA 52242 USA.		Vogel, Edward K/AAW-9466-2021; Shapiro, Kimron/AAC-9685-2019	Shapiro, Kimron/0000-0002-0419-1460				BESSON M, 1992, J COGNITIVE NEUROSCI, V4, P132, DOI 10.1162/jocn.1992.4.2.132; CHUN MM, 1995, J EXP PSYCHOL HUMAN, V21, P109; ELMER M, 1994, PERCEPT PSYCHOPHYS, V55, P667; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; KUTAS M, 1988, ELECTROEN CLIN NEURO, V69, P218, DOI 10.1016/0013-4694(88)90131-9; LUCK SJ, 1994, J EXP PSYCHOL HUMAN, V20, P887, DOI 10.1037/0096-1523.20.4.887; MANGUN GR, 1993, ATTENTION PERFORM, V14, P219; MCCARTHY G, 1993, ELECTROEN CLIN NEURO, V88, P210, DOI 10.1016/0168-5597(93)90005-A; Osterhout L, 1995, ELECTROPHYSIOLOGY MI; POTTER MC, 1976, J EXP PSYCHOL-HUM L, V2, P509, DOI 10.1037/0278-7393.2.5.509; RAYMOND JE, 1992, J EXP PSYCHOL HUMAN, V18, P849, DOI 10.1037/0096-1523.18.3.849; SHAPIRO K, IN PRESS PSYCHOL SCI; SHAPIRO KL, 1994, J EXP PSYCHOL HUMAN, V20, P357, DOI 10.1037/0096-1523.20.2.357	13	371	380	3	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	1996	383	6601					616	618		10.1038/383616a0	http://dx.doi.org/10.1038/383616a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VM755	8857535				2022-12-28	WOS:A1996VM75500051
J	Traub, RD; Whittington, MA; Stanford, IM; Jefferys, JGR				Traub, RD; Whittington, MA; Stanford, IM; Jefferys, JGR			A mechanism for generation of long-range synchronous fast oscillations in the cortex	NATURE			English	Article							CAT VISUAL-CORTEX; NEURONAL RESPONSES; RAT HIPPOCAMPUS; SYNCHRONIZATION; CELLS; AREAS; FIELD	SYNCHRONOUS neuronal oscillations in the 30-70 Hz range, known as gamma oscillations, occur in the cortex of many species(1-6). This synchronization can occur over large distances, and in some cases over multiple cortical areas(7,8) and in both hemispheres(2); it has been proposed to underlie the binding of Several features into a single perceptual entity(4). The mechanism by which coherent oscillations are generated remains unclear, because they often show zero or near-zero phase lags over long distances, whereas much greater phase lags would be expected from the slow speed of axonal conduction. We have previously shown that interneuron networks alone can generate gamma oscillations(9,10); here we propose a simple model to explain how an interconnected chain of such networks can generate coherent oscillations. The model incorporates known properties of excitatory pyramidal tells and inhibitory interneurons; it predicts that when excitation of interneurons reaches a level sufficient to induce pairs of spikes in rapid succession (spike doublets), the network will generate gamma oscillations that are synchronized on a millisecond timescale from one end of the chain to the other. We show that in rat hippocampal slices interneurons do indeed fire spike doublets under conditions in which gamma oscillations are synchronized over several millimetres, whereas they fire single spikes under other conditions. Thus, known properties of neurons and local synaptic circuits can account for tightly synchronized oscillations in large neuronal ensembles.	COLUMBIA UNIV,DEPT NEUROL,NEW YORK,NY 10032; ST MARYS HOSP,IMPERIAL COLL,SCH MED,DEPT PHYSIOL & BIOPHYS,LONDON W2 1PG,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT PHYSIOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	Columbia University; Imperial College London; University of Birmingham	Traub, RD (corresponding author), IBM CORP,DIV RES,TJ WATSON RES CTR,YORKTOWN HTS,NY 10598, USA.		Jefferys, John/E-6132-2012; Jefferys, John G R/AAF-1164-2021	Jefferys, John/0000-0003-0106-4412; Jefferys, John G R/0000-0003-0106-4412; Whittington, Miles Adrian/0000-0002-0247-1362	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSEN P, 1978, BRAIN RES, V144, P11, DOI 10.1016/0006-8993(78)90431-6; BAUER R, 1995, BRAIN RES, V669, P291, DOI 10.1016/0006-8993(94)01273-K; BRAGIN A, 1995, J NEUROSCI, V15, P47; BUHL EH, 1994, J NEUROPHYSIOL, V71, P1289, DOI 10.1152/jn.1994.71.4.1289; Bush P, 1996, J COMPUT NEUROSCI, V3, P91, DOI 10.1007/BF00160806; EECKMAN FH, 1990, BRAIN RES, V528, P238, DOI 10.1016/0006-8993(90)91663-2; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; FRIEN A, 1994, NEUROREPORT, V5, P2273, DOI 10.1097/00001756-199411000-00017; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; INNOCENTI GM, 1980, ARCH ITAL BIOL, V118, P124; KISVARDAY ZF, 1993, J COMP NEUROL, V327, P398, DOI 10.1002/cne.903270307; Konig P, 1991, NEURAL COMPUT, V3, P155, DOI 10.1162/neco.1991.3.2.155; MURAKOSHI T, 1993, NEUROSCI LETT, V163, P211, DOI 10.1016/0304-3940(93)90385-X; RIBARY U, 1991, P NATL ACAD SCI USA, V88, P11037, DOI 10.1073/pnas.88.24.11037; Salin PA, 1996, J NEUROPHYSIOL, V75, P1589, DOI 10.1152/jn.1996.75.4.1589; SIK A, 1995, J NEUROSCI, V15, P6651; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; Traub RD, 1995, J COMPUT NEUROSCI, V2, P291, DOI 10.1007/BF00961441; TRAUB RD, 1994, J PHYSIOL-LONDON, V481, P79, DOI 10.1113/jphysiol.1994.sp020420; Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397; ULNAS RR, 1991, P NATL ACAD SCI USA, V88, P897; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Wilson MA, 1991, NEURAL COMPUT, V3, P498, DOI 10.1162/neco.1991.3.4.498; WONG RKS, 1981, J NEUROPHYSIOL, V45, P86, DOI 10.1152/jn.1981.45.1.86	27	515	523	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1996	383	6601					621	624		10.1038/383621a0	http://dx.doi.org/10.1038/383621a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM755	8857537				2022-12-28	WOS:A1996VM75500053
J	Duncan, R				Duncan, R			Application of image-based brain analysis to research and clinical problems	LANCET			English	Editorial Material											Duncan, R (corresponding author), SO GEN HOSP,INST NEUROL SCI,GLASGOW G51 4TF,LANARK,SCOTLAND.							COOK MJ, 1992, BRAIN, V115, P1001, DOI 10.1093/brain/115.4.1001; COWELL PE, 1994, J NEUROSCI, V14, P4748; DAVIS PC, 1994, AM J ROENTGENOL, V162, P1267, DOI 10.2214/ajr.162.6.8191980; Murphy DGM, 1996, ARCH GEN PSYCHIAT, V53, P585; MURPHY DGM, 1993, LANCET, V342, P1197, DOI 10.1016/0140-6736(93)92184-U; Wang GJ, 1996, J COMPUT ASSIST TOMO, V20, P423, DOI 10.1097/00004728-199605000-00020; Zijdenbos Alex P., 1994, Critical Reviews in Biomedical Engineering, V22, P401	7	2	2	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1996	348	9033					974	975		10.1016/S0140-6736(05)64921-5	http://dx.doi.org/10.1016/S0140-6736(05)64921-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VM027	8855849				2022-12-28	WOS:A1996VM02700005
J	Goedert, M; Jakes, R; Spillantini, MG; Hasegawa, M; Smith, MJ; Crowther, RA				Goedert, M; Jakes, R; Spillantini, MG; Hasegawa, M; Smith, MJ; Crowther, RA			Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans	NATURE			English	Article							PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; HEPARAN-SULFATE; AMYLOID PROTEIN; DISEASE BRAIN; PHOSPHORYLATION; ISOFORMS; BINDING; IDENTIFICATION; CYTOSKELETON	THE paired helical filament (PHF) is the major component of the neurofibrillary deposits that form a defining neuropathological characteristic of Alzheimer's disease (reviewed in refs 1,2). PHFs are composed of microtubule-associated protein fan, in a hyperphosphorylated state(3-8). Hyperphosphorylation of tau results in its inability to bind to microtubules(9,10) and is believed to precede PHF assembly(11). However, it is unclear whether hyperphosphorylation of tau is either necessary or sufficient for PHF formation. Here we show that non-phosphorylated recombinant tau isoforms with three microtubule-binding repeats form paired helical-like filaments under physiological conditions in vitro, when incubated with sulphated glycosaminoglycans such as heparin or heparan sulphate. Furthermore, heparin prevents tau from binding to microtubules and promotes microtubule disassembly. Finally, we show that heparan sulphate and hyperphosphorylated Lau coexist in nerve cells of the Alzheimer's disease brain at the earliest known stages of neurofibrillary pathology. These findings, with previous studies which show that heparin stimulates tau phosphorylation by a number of protein kinases(12-14), indicate that sulphated glycosaminoglycans may be a key factor in the formation of the neurofibrillary lesions of Alzheimer's disease.			Goedert, M (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRANDT R, 1994, J BIOL CHEM, V269, P11176; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Hasegawa M, 1996, FEBS LETT, V384, P25, DOI 10.1016/0014-5793(96)00271-2; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; KATO T, 1991, NEUROSCI LETT, V122, P33, DOI 10.1016/0304-3940(91)90186-W; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; LEE VMY, 1995, CURR OPIN NEUROBIOL, V5, P663, DOI 10.1016/0959-4388(95)80073-5; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P265, DOI 10.1007/BF00227819; PERRY G, 1991, J NEUROSCI, V11, P3679; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SNOW AD, 1989, ACTA NEUROPATHOL, V78, P113, DOI 10.1007/BF00688198; SNOW AD, 1990, AM J PATHOL, V137, P1253; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3947, DOI 10.1073/pnas.87.10.3947; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; YANG SD, 1994, J NEUROCHEM, V63, P1416; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	33	828	842	5	50	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					550	553		10.1038/383550a0	http://dx.doi.org/10.1038/383550a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849730				2022-12-28	WOS:A1996VL75500057
J	Kanyo, ZF; Scolnick, LR; Ash, DE; Christianson, DW				Kanyo, ZF; Scolnick, LR; Ash, DE; Christianson, DW			Structure of a unique binuclear manganese cluster in arginase	NATURE			English	Article							RAT-LIVER ARGINASE; NITRIC-OXIDE BIOSYNTHESIS; HYDROXY-L-ARGININE; INTERMEDIATE; MACROPHAGES; INDUCTION; PROGRAM	EACH individual excretes roughly 10 kg of urea per year, as a result of the hydrolysis of arginine in the final cytosolic step of the urea cycle(1). This reaction allows the disposal of nitrogenous waste from protein catabolism, and is catalysed by the liver arginase enzyme(2). In other tissues that lack a complete urea cycle, arginase regulates cellular arginine and ornithine concentrations for biosynthetic reactions(3), including nitric oxide synthesis: in the macrophage, arginase activity is reciprocally coordinated with that of NO synthase to modulate NO-dependent cytotoxicity(4-9). The bioinorganic chemistry of arginase is particularly rich because this enzyme is one of very few that specifically requires a spin-coupled Mn2+-Mn2+ cluster for catalytic activity in vitro and in vivo(10). The 2.1 Angstrom-resolution crystal structure of trimeric(11) rat liver arginase reveals that this unique metal cluster resides at the bottom of an active-site cleft that is 15 Angstrom deep. Analysis of the structure indicates that arginine hydrolysis is achieved by a metal-activated solvent molecule which symmetrically bridges the two Mn2+ ions.	UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NIGMS NIH HHS [R01 GM067788] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067788] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBINA JE, 1995, J IMMUNOL, V155, P4391; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAVALLI RC, 1994, BIOCHEMISTRY-US, V33, P10652, DOI 10.1021/bi00201a012; CHENAIS B, 1993, BIOCHEM BIOPH RES CO, V196, P1558, DOI 10.1006/bbrc.1993.2429; Christianson DW, 1996, ACCOUNTS CHEM RES, V29, P331, DOI 10.1021/ar9501232; CHRISTIANSON DW, 1989, J AM CHEM SOC, V111, P6412, DOI 10.1021/ja00198a065; CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094; DAGHIGH F, 1994, BIOCHEM BIOPH RES CO, V202, P174, DOI 10.1006/bbrc.1994.1909; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HERZFELD A, 1976, BIOCHEM J, V153, P469, DOI 10.1042/bj1530469; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANYO ZF, 1992, J MOL BIOL, V224, P1175, DOI 10.1016/0022-2836(92)90479-4; KELLER R, 1991, CELL IMMUNOL, V134, P249, DOI 10.1016/0008-8749(91)90348-F; KLATT P, 1993, J BIOL CHEM, V268, P14781; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krebs HA, 1932, H-S Z PHYSIOL CHEM, V210, P33, DOI 10.1515/bchm2.1932.210.1-2.33; KUHN NJ, 1991, ARCH BIOCHEM BIOPHYS, V286, P217, DOI 10.1016/0003-9861(91)90031-D; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nyborg J., 1977, ROTATION METHOD CRYS, P139; Park IS, 1996, BIOCHEMISTRY-US, V35, P5345, DOI 10.1021/bi952894j; RARDIN RL, 1991, NEW J CHEM, V15, P417; RECZKOWSKI RS, 1992, J AM CHEM SOC, V114, P10992, DOI 10.1021/ja00053a064; RECZKOWSKI RS, 1994, ARCH BIOCHEM BIOPHYS, V312, P31, DOI 10.1006/abbi.1994.1276; YIP MCM, 1972, BIOCHEM J, V127, P893, DOI 10.1042/bj1270893	27	376	380	6	71	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1996	383	6600					554	557		10.1038/383554a0	http://dx.doi.org/10.1038/383554a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL755	8849731				2022-12-28	WOS:A1996VL75500058
J	Bauer, MF; Sirrenberg, C; Neupert, W; Brunner, M				Bauer, MF; Sirrenberg, C; Neupert, W; Brunner, M			Role of Tim23 as voltage sensor and presequence receptor in protein import into mitochondria	CELL			English	Article							INNER MEMBRANE; YEAST MITOCHONDRIA; DYNAMIC INTERACTION; CRYSTAL-STRUCTURE; TRANSLOCATION; HSP70; PRECURSOR; SUPPRESSOR; MACHINERY; TRANSPORT	Tim23, an essential component of the protein import machinery of the inner membrane of mitochondria (TIM complex), forms dimers that display a dynamic behavior. Dimer formation is promoted by the membrane potential Delta psi. Binding of a matrix targeting sequence to Tim23 triggers dimer dissociation. Monomeric Tim23 is present when a preprotein chain is in transit across the TIM complex. Dimerization of Tim23 is dependent on the second half of its N-terminal hydrophilic domain, which is exposed to the intermembrane space. This segment contains a heptad leucine repeat motif with a predicted capacity for dimer formation. We propose that Tim23 exerts a key function in protein import: Tim23 dimers formed in response to Delta psi act as receptors for matrix targeting sequences on the surface of the inner membrane. The ensuing dissociation of Tim23 dimer triggers opening of the TIM channel and insertion of the preprotein.			Bauer, MF (corresponding author), UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,D-80336 MUNICH,GERMANY.			Brunner, Michael/0000-0001-9798-3047				BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOM J, 1996, EUR J BIOCHEM, V232, P309; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SCHLEYER M, 1984, J BIOL CHEM, V259, P3487; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0	35	237	238	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					33	41		10.1016/S0092-8674(00)81320-3	http://dx.doi.org/10.1016/S0092-8674(00)81320-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858146	Bronze			2022-12-28	WOS:A1996VL69500006
J	Umar, A; Buermeyer, AB; Simon, JA; Thomas, DC; Clark, AB; Liskay, RM; Kunkel, TA				Umar, A; Buermeyer, AB; Simon, JA; Thomas, DC; Clark, AB; Liskay, RM; Kunkel, TA			Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis	CELL			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; PROTEIN-PROTEIN INTERACTIONS; SIMPLE REPETITIVE DNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; REPLICATION FORK; 2-HYBRID SYSTEM; SHUTTLE VECTORS; TUMOR-CELLS	A two-hybrid system was used to screen yeast and human expression libraries for proteins that interact with mismatch repair proteins. PCNA was recovered from both libraries and shown in the case of yeast to interact with both MLH1 and MSH2. A yeast strain containing a mutation in the PCNA gene had a strongly elevated mutation rate in a dinucleotide repeat, and the rate was not further elevated in a strain also containing a mutation in MLH1. Mismatch repair activity was examined in human cell extracts using an assay that does not require DNA repair synthesis. Activity was inhibited by p21WAF1 or a p21 peptide, both of which bind to PCNA, and activity was restored to inhibited reactions by addition of PCNA. The data suggest a PCNA requirement in mismatch repair at a step preceding DNA resynthesis. The ability of PCNA to bind to MLH1 and MSH2 may reflect linkage between mismatch repair and replication and may be relevant to the roles of mismatch repair proteins in other DNA transactions.	OREGON HLTH SCI UNIV,DEPT MOL & MED GENET,PORTLAND,OR 97201	Oregon Health & Science University	Umar, A (corresponding author), NIEHS,MOL GENET LAB,RES TRIANGLE PK,NC 27709, USA.		Kunkel, Thomas A./D-5088-2019; Umar, Asad/AAI-4560-2020; Buermeyer, Andrew/AAW-4099-2020	Kunkel, Thomas A./0000-0002-9900-1788; Umar, Asad/0000-0002-6239-8494; Buermeyer, Andrew/0000-0003-4502-4666	NIGMS NIH HHS [GM45413-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOYER JC, 1995, CANCER RES, V55, P6063; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FANG WH, 1993, J BIOL CHEM, V268, P11838; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; HALL PA, 1995, ONCOGENE, V10, P2427; HAWN MT, 1995, CANCER RES, V55, P3721; HEALE SM, 1995, CELL, V83, P539, DOI 10.1016/0092-8674(95)90093-4; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOLODNER R, 1996, IN PRESS GENES DEV; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; ROBERTS JD, 1993, GENETICS, V2, P295; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH M, 1994, SCIENCE, V226, P1376; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319	51	486	501	9	114	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1996	87	1					65	73		10.1016/S0092-8674(00)81323-9	http://dx.doi.org/10.1016/S0092-8674(00)81323-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VL695	8858149	Bronze			2022-12-28	WOS:A1996VL69500009
J	Danielian, PS; McMahon, AP				Danielian, PS; McMahon, AP			Engrailed-1 as a target of the Wnt-1 signalling pathway in vertebrate midbrain development	NATURE			English	Article							INT-1 PROTOONCOGENE; MOUSE DEVELOPMENT; EXPRESSION; MICE; DELETION; PHENOTYPE; OUTGROWTH; EMBRYOS; DOMAINS; FAMILY	A SECRETED Signalling molecule encoded by the Wnt-1 gene is required for development of the central nervous system. In mouse embryos homozygous for a Wnt-1-null allele, the midbrain and anterior hindbrain fail to develop(1,2). This corresponds to the region where two transcription factors encoded by the mouse engrailed genes (En-1 and En-2) are normally expressed(3,4). Studies of the Drosophila orthologue of Wnt-1, wingless, indicate that Wingless signal is required to maintain engrailed expression in neighbouring cells of the developing epidermis(5-7). Here we report that expression of En-1 in the developing midbrain of Wnt-1 null embryos is sufficient to rescue early midbrain and anterior hindbrain development. This suggests that a key role of Wnt-1 signalling is to maintain En expression and that this aspect of the Wnt-1/engrailed interaction has been conserved from flies to mice.	HARVARD UNIV, BIOL LABS, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University			McMahon, Andrew P/ABE-7520-2020	Danielian, Paul/0000-0003-2651-0386				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ASANO M, 1992, MECH DEVELOP, V39, P29, DOI 10.1016/0925-4773(92)90023-D; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FRITZSCH B, 1995, J NEUROBIOL, V27, P457, DOI 10.1002/neu.480270403; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KLINGENSMITH J, 1995, REV BIOL, V170, P636; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MASTICK GS, IN PRESS J COMP NEUR; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; PARR BA, 1993, DEVELOPMENT, V119, P247; ROWITCH DH, 1995, MECH DEVELOP, V52, P3, DOI 10.1016/0925-4773(95)00380-J; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; WURST W, 1994, DEVELOPMENT, V120, P2065	23	238	240	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 26	1996	383	6598					332	334		10.1038/383332a0	http://dx.doi.org/10.1038/383332a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848044				2022-12-28	WOS:A1996VJ43900043
